{"b6712d936f1a90d87c92d5806d5b8dd0ba43e723": [["As of January 28, 2020, there have been 106 deaths-all in China (5).", [["deaths", "DISEASE", 44, 50]]], ["On January 30, 2020, the China coronavirus was declared as a global health emergency by the WHO.", [["coronavirus", "DISEASE", 31, 42], ["coronavirus", "ORGANISM", 31, 42], ["China coronavirus", "SPECIES", 25, 42]]], ["An initial prospective analysis of the clinical features of 41 of the initially admitted patients in Wuhan with laboratory-confirmed 2019-nCoV demonstrated that 2019-nCoV caused a severe illness similar clinically to SARS and sometimes resulted in admission to the intensive care unit (13 of 41 patients [32%]) and death (six of 41 patients [15%]).", [["illness", "DISEASE", 187, 194], ["SARS", "DISEASE", 217, 221], ["death", "DISEASE", 315, 320], ["patients", "ORGANISM", 89, 97], ["patients", "ORGANISM", 295, 303], ["patients", "ORGANISM", 332, 340], ["patients", "SPECIES", 89, 97], ["patients", "SPECIES", 295, 303], ["patients", "SPECIES", 332, 340], ["An initial prospective analysis", "TEST", 0, 31], ["a severe illness", "PROBLEM", 178, 194], ["SARS", "PROBLEM", 217, 221], ["death", "PROBLEM", 315, 320], ["severe", "OBSERVATION_MODIFIER", 180, 186], ["illness", "OBSERVATION", 187, 194]]], ["All 41 patients with pneumonia in that study had abnormal findings on chest CT scans, with preliminary reports indicating bilateral abnormal lung opacities in each patient (6) .", [["lung", "ANATOMY", 141, 145], ["pneumonia", "DISEASE", 21, 30], ["abnormal lung opacities", "DISEASE", 132, 155], ["patients", "ORGANISM", 7, 15], ["lung", "ORGAN", 141, 145], ["patient", "ORGANISM", 164, 171], ["patients", "SPECIES", 7, 15], ["patient", "SPECIES", 164, 171], ["pneumonia", "PROBLEM", 21, 30], ["that study", "TEST", 34, 44], ["abnormal findings", "PROBLEM", 49, 66], ["chest CT scans", "TEST", 70, 84], ["bilateral abnormal lung opacities", "PROBLEM", 122, 155], ["pneumonia", "OBSERVATION", 21, 30], ["chest", "ANATOMY", 70, 75], ["bilateral", "ANATOMY_MODIFIER", 122, 131], ["abnormal", "OBSERVATION_MODIFIER", 132, 140], ["lung", "ANATOMY", 141, 145], ["opacities", "OBSERVATION", 146, 155]]]], "b4da4ff0d2d40c002ea40eb0e610f4949ffaa28a": [["Children with severe acute kidney injury (AKI)Children with AKI need supportive therapy to optimize their general recovery, and recovery of their kidney function.", [["kidney", "ANATOMY", 27, 33], ["kidney", "ANATOMY", 146, 152], ["acute kidney injury", "DISEASE", 21, 40], ["AKI", "DISEASE", 42, 45], ["AKI", "DISEASE", 60, 63], ["Children", "ORGANISM", 0, 8], ["kidney", "ORGAN", 27, 33], ["kidney", "ORGAN", 146, 152], ["Children", "SPECIES", 0, 8], ["Children", "SPECIES", 46, 54], ["severe acute kidney injury", "PROBLEM", 14, 40], ["AKI", "PROBLEM", 60, 63], ["supportive therapy", "TREATMENT", 69, 87], ["severe", "OBSERVATION_MODIFIER", 14, 20], ["acute", "OBSERVATION_MODIFIER", 21, 26], ["kidney", "ANATOMY", 27, 33], ["injury", "OBSERVATION", 34, 40], ["kidney", "ANATOMY", 146, 152]]], ["In some severe cases, KRT is also required.", [["some severe cases", "PROBLEM", 3, 20], ["KRT", "TREATMENT", 22, 25], ["severe", "OBSERVATION_MODIFIER", 8, 14], ["cases", "OBSERVATION", 15, 20]]], ["Patients with very little or no urine output are most at risk of complications such as lifethreatening hyperkalaemia or fluid overload; where it is available, early initiation of KRT should be considered for these patients.Children with severe acute kidney injury (AKI)Healthy kidneys maintain the balance of children's fluid status and blood pressure, electrolytes, acid-base balance.", [["urine", "ANATOMY", 32, 37], ["fluid", "ANATOMY", 120, 125], ["kidney", "ANATOMY", 250, 256], ["kidneys", "ANATOMY", 277, 284], ["fluid", "ANATOMY", 320, 325], ["blood", "ANATOMY", 337, 342], ["hyperkalaemia", "DISEASE", 103, 116], ["fluid overload", "DISEASE", 120, 134], ["acute kidney injury", "DISEASE", 244, 263], ["AKI", "DISEASE", 265, 268], ["Patients", "ORGANISM", 0, 8], ["urine", "ORGANISM_SUBSTANCE", 32, 37], ["fluid", "ORGANISM_SUBSTANCE", 120, 125], ["KRT", "SIMPLE_CHEMICAL", 179, 182], ["patients", "ORGANISM", 214, 222], ["Children", "ORGANISM", 223, 231], ["kidney", "ORGAN", 250, 256], ["kidneys", "ORGAN", 277, 284], ["children", "ORGANISM", 309, 317], ["fluid", "ORGANISM_SUBSTANCE", 320, 325], ["blood", "ORGANISM_SUBSTANCE", 337, 342], ["electrolytes", "SIMPLE_CHEMICAL", 353, 365], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 214, 222], ["Children", "SPECIES", 223, 231], ["children", "SPECIES", 309, 317], ["urine output", "PROBLEM", 32, 44], ["complications", "PROBLEM", 65, 78], ["lifethreatening hyperkalaemia", "PROBLEM", 87, 116], ["fluid overload", "PROBLEM", 120, 134], ["KRT", "TREATMENT", 179, 182], ["severe acute kidney injury", "PROBLEM", 237, 263], ["fluid status", "TEST", 320, 332], ["blood pressure", "TEST", 337, 351], ["electrolytes", "TEST", 353, 365], ["acid-base balance", "TEST", 367, 384], ["complications", "OBSERVATION", 65, 78], ["hyperkalaemia", "OBSERVATION", 103, 116], ["fluid overload", "OBSERVATION", 120, 134], ["severe", "OBSERVATION_MODIFIER", 237, 243], ["acute", "OBSERVATION_MODIFIER", 244, 249], ["kidney", "ANATOMY", 250, 256], ["injury", "OBSERVATION", 257, 263], ["AKI", "OBSERVATION", 265, 268], ["kidneys", "ANATOMY", 277, 284]]], ["Absolute indications for kidney replacement therapy include hyperkalaemia, intravascular volume overload/systemic hypertension, metabolic acidosis and severe symptomatic uraemia which do not improve with medical management.", [["kidney", "ANATOMY", 25, 31], ["intravascular", "ANATOMY", 75, 88], ["hyperkalaemia", "DISEASE", 60, 73], ["intravascular volume overload", "DISEASE", 75, 104], ["hypertension", "DISEASE", 114, 126], ["metabolic acidosis", "DISEASE", 128, 146], ["uraemia", "DISEASE", 170, 177], ["kidney", "ORGAN", 25, 31], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 75, 88], ["Absolute indications", "TREATMENT", 0, 20], ["kidney replacement therapy", "TREATMENT", 25, 51], ["hyperkalaemia", "PROBLEM", 60, 73], ["intravascular volume overload", "PROBLEM", 75, 104], ["systemic hypertension", "PROBLEM", 105, 126], ["metabolic acidosis", "PROBLEM", 128, 146], ["severe symptomatic uraemia", "PROBLEM", 151, 177], ["medical management", "TREATMENT", 204, 222], ["kidney", "ANATOMY", 25, 31], ["replacement", "OBSERVATION", 32, 43], ["hyperkalaemia", "OBSERVATION", 60, 73], ["intravascular volume overload", "OBSERVATION", 75, 104], ["systemic", "OBSERVATION_MODIFIER", 105, 113], ["hypertension", "OBSERVATION", 114, 126], ["metabolic acidosis", "OBSERVATION", 128, 146], ["severe", "OBSERVATION_MODIFIER", 151, 157], ["symptomatic", "OBSERVATION_MODIFIER", 158, 169], ["uraemia", "OBSERVATION", 170, 177]]], ["This is most likely to be the case for a child passing little or no urine (see Box 1) .Infants with severe symptomatic hyperammonaemiaChildren with metabolic disorders such urea cycle defects can present with life threatening encephalopathy secondary to hyperammonaemia.", [["urine", "ANATOMY", 68, 73], ["hyperammonaemiaChildren", "DISEASE", 119, 142], ["metabolic disorders", "DISEASE", 148, 167], ["urea", "CHEMICAL", 173, 177], ["encephalopathy", "DISEASE", 226, 240], ["hyperammonaemia", "DISEASE", 254, 269], ["urea", "CHEMICAL", 173, 177], ["urine", "ORGANISM_SUBSTANCE", 68, 73], ["Infants", "SPECIES", 87, 94], ["severe symptomatic hyperammonaemiaChildren", "PROBLEM", 100, 142], ["metabolic disorders", "PROBLEM", 148, 167], ["such urea cycle defects", "PROBLEM", 168, 191], ["life threatening encephalopathy", "PROBLEM", 209, 240], ["hyperammonaemia", "PROBLEM", 254, 269], ["most likely", "UNCERTAINTY", 8, 19], ["severe", "OBSERVATION_MODIFIER", 100, 106], ["symptomatic", "OBSERVATION_MODIFIER", 107, 118], ["hyperammonaemiaChildren", "OBSERVATION", 119, 142], ["metabolic disorders", "OBSERVATION", 148, 167], ["hyperammonaemia", "OBSERVATION", 254, 269]]], ["Recent international guidelines recommend kidney replacement therapy in the most severely affected patients.", [["kidney", "ANATOMY", 42, 48], ["kidney", "ORGAN", 42, 48], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["Recent international guidelines", "TREATMENT", 0, 31], ["kidney replacement therapy", "TREATMENT", 42, 68], ["kidney", "ANATOMY", 42, 48], ["replacement", "OBSERVATION", 49, 60]]], ["Hyperammonaemia and certain toxins can also be managed with high clearance dialysis to ameliorate initial toxicity before maintenance therapies are established.Infants with severe symptomatic hyperammonaemiaWhen should acute kidney replacement therapy be started?Infants with severe symptomatic hyperammonaemiaAside from the immediate life-threatening consequences of metabolic disturbance (e.g. hyperkalaemia resulting in cardiac arrhythmia and non-resolving acidosis), there are other considerations when deciding if a child should receive acute KRT.Infants with severe symptomatic hyperammonaemiaIn adult patients requiring intensive care, early proactive initiation of KRT is associated with lower patient mortality and better recovery of kidney function.", [["kidney", "ANATOMY", 225, 231], ["cardiac", "ANATOMY", 423, 430], ["kidney", "ANATOMY", 743, 749], ["Hyperammonaemia", "DISEASE", 0, 15], ["toxicity", "DISEASE", 106, 114], ["hyperammonaemiaWhen", "DISEASE", 192, 211], ["hyperammonaemiaAside", "DISEASE", 295, 315], ["metabolic disturbance", "DISEASE", 368, 389], ["hyperkalaemia", "DISEASE", 396, 409], ["cardiac arrhythmia", "DISEASE", 423, 441], ["acidosis", "DISEASE", 460, 468], ["Infants", "ORGANISM", 160, 167], ["kidney", "ORGAN", 225, 231], ["Infants", "ORGANISM", 263, 270], ["cardiac", "ORGAN", 423, 430], ["patients", "ORGANISM", 608, 616], ["patient", "ORGANISM", 702, 709], ["kidney", "ORGAN", 743, 749], ["Infants", "SPECIES", 160, 167], ["Infants", "SPECIES", 263, 270], ["Infants", "SPECIES", 552, 559], ["patients", "SPECIES", 608, 616], ["patient", "SPECIES", 702, 709], ["Hyperammonaemia", "PROBLEM", 0, 15], ["certain toxins", "PROBLEM", 20, 34], ["high clearance dialysis", "TREATMENT", 60, 83], ["initial toxicity", "PROBLEM", 98, 114], ["maintenance therapies", "TREATMENT", 122, 143], ["severe symptomatic hyperammonaemiaWhen", "PROBLEM", 173, 211], ["acute kidney replacement therapy", "TREATMENT", 219, 251], ["severe symptomatic hyperammonaemiaAside", "PROBLEM", 276, 315], ["metabolic disturbance", "PROBLEM", 368, 389], ["hyperkalaemia", "PROBLEM", 396, 409], ["cardiac arrhythmia", "PROBLEM", 423, 441], ["non-resolving acidosis", "PROBLEM", 446, 468], ["acute KRT", "TREATMENT", 542, 551], ["severe symptomatic hyperammonaemiaIn adult", "PROBLEM", 565, 607], ["intensive care", "TREATMENT", 627, 641], ["KRT", "TREATMENT", 673, 676], ["lower patient mortality", "PROBLEM", 696, 719], ["severe", "OBSERVATION_MODIFIER", 173, 179], ["symptomatic", "OBSERVATION_MODIFIER", 180, 191], ["kidney", "ANATOMY", 225, 231], ["replacement", "OBSERVATION", 232, 243], ["severe", "OBSERVATION_MODIFIER", 276, 282], ["symptomatic", "OBSERVATION_MODIFIER", 283, 294], ["hyperammonaemiaAside", "OBSERVATION", 295, 315], ["metabolic disturbance", "OBSERVATION", 368, 389], ["cardiac", "ANATOMY", 423, 430], ["arrhythmia", "OBSERVATION", 431, 441], ["acidosis", "OBSERVATION", 460, 468], ["severe", "OBSERVATION_MODIFIER", 565, 571], ["symptomatic", "OBSERVATION_MODIFIER", 572, 583], ["kidney", "ANATOMY", 743, 749]]], ["Evidence is also emerging to support proactive kidney replacement therapy in children with severe AKI, in particular those with significant fluid overload.", [["kidney", "ANATOMY", 47, 53], ["fluid", "ANATOMY", 140, 145], ["AKI", "DISEASE", 98, 101], ["fluid overload", "DISEASE", 140, 154], ["kidney", "ORGAN", 47, 53], ["children", "ORGANISM", 77, 85], ["fluid", "ORGANISM_SUBSTANCE", 140, 145], ["children", "SPECIES", 77, 85], ["support proactive kidney replacement therapy", "TREATMENT", 29, 73], ["severe AKI", "PROBLEM", 91, 101], ["significant fluid overload", "PROBLEM", 128, 154], ["kidney", "ANATOMY", 47, 53], ["replacement", "OBSERVATION", 54, 65], ["severe", "OBSERVATION_MODIFIER", 91, 97], ["AKI", "OBSERVATION", 98, 101], ["significant", "OBSERVATION_MODIFIER", 128, 139], ["fluid overload", "OBSERVATION", 140, 154]]], ["Retrospective studies support early initiation of kidney replacement therapy to aid recovery of both the child, and their kidney function.", [["kidney", "ANATOMY", 50, 56], ["kidney", "ANATOMY", 122, 128], ["kidney", "ORGAN", 50, 56], ["child", "ORGANISM", 105, 110], ["kidney", "ORGAN", 122, 128], ["child", "SPECIES", 105, 110], ["Retrospective studies", "TEST", 0, 21], ["kidney replacement therapy", "TREATMENT", 50, 76], ["kidney", "ANATOMY", 50, 56], ["replacement", "OBSERVATION", 57, 68], ["kidney", "ANATOMY", 122, 128]]], ["Any child for whom kidney replacement therapy may be required warrants early discussion with a paediatric nephrology team.Infants with severe symptomatic hyperammonaemiaWhich modalities of kidney replacement therapy are used to manage AKI?Infants with severe symptomatic hyperammonaemiaContinuous kidney replacement therapy for AKI Continuous kidney replacement therapy is generally used in paediatric intensive care (see Box 3 for another example).", [["kidney", "ANATOMY", 19, 25], ["kidney", "ANATOMY", 189, 195], ["kidney", "ANATOMY", 297, 303], ["kidney", "ANATOMY", 343, 349], ["AKI", "DISEASE", 235, 238], ["AKI", "DISEASE", 328, 331], ["kidney", "ORGAN", 19, 25], ["Infants", "ORGANISM", 122, 129], ["kidney", "ORGAN", 189, 195], ["Infants", "ORGANISM", 239, 246], ["kidney", "ORGAN", 297, 303], ["kidney", "ORGAN", 343, 349], ["Infants", "SPECIES", 122, 129], ["Infants", "SPECIES", 239, 246], ["whom kidney replacement therapy", "TREATMENT", 14, 45], ["severe symptomatic hyperammonaemiaWhich", "PROBLEM", 135, 174], ["kidney replacement therapy", "TREATMENT", 189, 215], ["AKI", "PROBLEM", 235, 238], ["severe symptomatic hyperammonaemiaContinuous kidney replacement therapy", "TREATMENT", 252, 323], ["AKI", "PROBLEM", 328, 331], ["Continuous kidney replacement therapy", "TREATMENT", 332, 369], ["kidney", "ANATOMY", 19, 25], ["replacement", "OBSERVATION", 26, 37], ["severe", "OBSERVATION_MODIFIER", 135, 141], ["symptomatic", "OBSERVATION_MODIFIER", 142, 153], ["hyperammonaemiaWhich", "OBSERVATION", 154, 174], ["kidney", "ANATOMY", 189, 195], ["replacement therapy", "OBSERVATION", 196, 215], ["severe", "OBSERVATION_MODIFIER", 252, 258], ["symptomatic", "OBSERVATION_MODIFIER", 259, 270], ["hyperammonaemiaContinuous", "OBSERVATION", 271, 296], ["kidney", "ANATOMY", 297, 303], ["replacement therapy", "OBSERVATION", 304, 323], ["kidney", "ANATOMY", 343, 349], ["replacement", "OBSERVATION", 350, 361]]], ["Because treatment runs continuously, it mimics continuous kidney function and is therefore more physiological than intermittent dialysis.", [["kidney", "ANATOMY", 58, 64], ["kidney", "ORGAN", 58, 64], ["intermittent dialysis", "TREATMENT", 115, 136], ["kidney", "ANATOMY", 58, 64]]], ["Various continuous kidney replacement modalities are used; the most common in UK PICUs is continuous veno-venous haemofiltration (CVVH).", [["kidney", "ANATOMY", 19, 25], ["kidney", "ORGAN", 19, 25], ["Various continuous kidney replacement modalities", "TREATMENT", 0, 48], ["continuous veno-venous haemofiltration", "TREATMENT", 90, 128], ["CVVH", "TREATMENT", 130, 134], ["kidney", "ANATOMY", 19, 25], ["replacement", "OBSERVATION", 26, 37], ["veno-venous haemofiltration", "OBSERVATION", 101, 128]]], ["Figure 1 shows a typical continuous kidney replacement therapy machine.Infants with severe symptomatic hyperammonaemiaCVVH uses convection to clear solutes such as urea from the circulation.", [["kidney", "ANATOMY", 36, 42], ["hyperammonaemiaCVVH", "DISEASE", 103, 122], ["urea", "CHEMICAL", 164, 168], ["urea", "CHEMICAL", 164, 168], ["kidney", "ORGAN", 36, 42], ["Infants", "ORGANISM", 71, 78], ["urea", "SIMPLE_CHEMICAL", 164, 168], ["Infants", "SPECIES", 71, 78], ["a typical continuous kidney replacement therapy machine", "TREATMENT", 15, 70], ["severe symptomatic hyperammonaemiaCVVH", "PROBLEM", 84, 122], ["kidney", "ANATOMY", 36, 42], ["replacement", "OBSERVATION", 43, 54], ["severe", "OBSERVATION_MODIFIER", 84, 90], ["symptomatic", "OBSERVATION_MODIFIER", 91, 102], ["hyperammonaemiaCVVH", "OBSERVATION", 103, 122], ["circulation", "ANATOMY", 178, 189]]], ["Aqueous fluid with low molecular weight solutes is filtered from plasma through the dialyser membrane, with larger molecular weight molecules such as albumin retained in the circuit.", [["Aqueous fluid", "ANATOMY", 0, 13], ["plasma", "ANATOMY", 65, 71], ["dialyser membrane", "ANATOMY", 84, 101], ["Aqueous fluid", "ORGANISM_SUBSTANCE", 0, 13], ["plasma", "ORGANISM_SUBSTANCE", 65, 71], ["dialyser membrane", "CELLULAR_COMPONENT", 84, 101], ["albumin", "GENE_OR_GENE_PRODUCT", 150, 157], ["albumin", "PROTEIN", 150, 157], ["Aqueous fluid", "TEST", 0, 13], ["low molecular weight solutes", "PROBLEM", 19, 47], ["plasma through the dialyser membrane", "TREATMENT", 65, 101], ["larger molecular weight molecules", "PROBLEM", 108, 141], ["albumin", "TEST", 150, 157], ["fluid", "OBSERVATION", 8, 13], ["low molecular", "OBSERVATION_MODIFIER", 19, 32], ["dialyser membrane", "OBSERVATION", 84, 101], ["larger", "OBSERVATION_MODIFIER", 108, 114], ["weight molecules", "OBSERVATION", 125, 141], ["circuit", "ANATOMY_MODIFIER", 174, 181]]], ["Filtered fluid is discarded and substituted with crystalloid replacement fluid.", [["Filtered fluid", "TREATMENT", 0, 14], ["crystalloid replacement fluid", "TREATMENT", 49, 78], ["fluid", "OBSERVATION", 9, 14], ["replacement fluid", "OBSERVATION", 61, 78]]], ["The composition of replacement fluid can be tailored according to the patient's electrolyte levels.", [["fluid", "ORGANISM_SUBSTANCE", 31, 36], ["patient", "ORGANISM", 70, 77], ["electrolyte", "SIMPLE_CHEMICAL", 80, 91], ["patient", "SPECIES", 70, 77], ["replacement fluid", "TREATMENT", 19, 36], ["the patient's electrolyte levels", "TEST", 66, 98], ["replacement fluid", "OBSERVATION", 19, 36]]], ["The rate of replacement fluid is adjusted to achieve a desired net fluid balance for the patient.", [["fluid", "ORGANISM_SUBSTANCE", 24, 29], ["fluid", "ORGANISM_SUBSTANCE", 67, 72], ["patient", "ORGANISM", 89, 96], ["patient", "SPECIES", 89, 96], ["The rate of replacement fluid", "TREATMENT", 0, 29]]], ["To remove fluid from the patient, the rate of replacement is lower than the filtration rate.Infants with severe symptomatic hyperammonaemiaIf high solute clearance rates are needed, for example to establish rapid control of severe hyperammonaemia, diffusive clearance can be used together with convective clearance.", [["fluid", "ANATOMY", 10, 15], ["hyperammonaemia", "DISEASE", 231, 246], ["fluid", "ORGANISM_SUBSTANCE", 10, 15], ["patient", "ORGANISM", 25, 32], ["patient", "SPECIES", 25, 32], ["Infants", "SPECIES", 92, 99], ["fluid", "TREATMENT", 10, 15], ["the rate of replacement", "TREATMENT", 34, 57], ["the filtration rate", "TEST", 72, 91], ["severe symptomatic hyperammonaemiaIf high solute clearance rates", "PROBLEM", 105, 169], ["severe hyperammonaemia", "PROBLEM", 224, 246], ["diffusive clearance", "TREATMENT", 248, 267], ["convective clearance", "TREATMENT", 294, 314], ["fluid", "OBSERVATION", 10, 15], ["replacement", "OBSERVATION", 46, 57], ["lower", "OBSERVATION_MODIFIER", 61, 66], ["severe", "OBSERVATION_MODIFIER", 105, 111], ["symptomatic", "OBSERVATION_MODIFIER", 112, 123], ["severe", "OBSERVATION_MODIFIER", 224, 230], ["hyperammonaemia", "OBSERVATION", 231, 246]]], ["The combination of diffusive clearance (dialysis) and convective clearance (filtration) is known as continuous veno-venohaemodiafiltration (CVVHDF).", [["diffusive clearance (dialysis", "TREATMENT", 19, 48], ["convective clearance (filtration", "TREATMENT", 54, 86], ["continuous veno-venohaemodiafiltration (CVVHDF", "TREATMENT", 100, 146], ["diffusive", "OBSERVATION_MODIFIER", 19, 28], ["clearance", "OBSERVATION_MODIFIER", 29, 38]]], ["Vascular access is needed with a large (typically minimum 10 Fr) central venous catheter to allow sufficient blood flow through the circuit and dialyser (typically 100e500 mL/minute).Infants with severe symptomatic hyperammonaemiaExtracorporeal circuits are anticoagulated to reduce clotting, particularly in the filter membrane.", [["Vascular", "ANATOMY", 0, 8], ["venous", "ANATOMY", 73, 79], ["blood", "ANATOMY", 109, 114], ["filter membrane", "ANATOMY", 313, 328], ["Vascular", "MULTI-TISSUE_STRUCTURE", 0, 8], ["venous", "MULTI-TISSUE_STRUCTURE", 73, 79], ["blood", "ORGANISM_SUBSTANCE", 109, 114], ["membrane", "CELLULAR_COMPONENT", 320, 328], ["Infants", "SPECIES", 183, 190], ["a large (typically minimum 10 Fr) central venous catheter", "TREATMENT", 31, 88], ["the circuit", "TREATMENT", 128, 139], ["dialyser", "TREATMENT", 144, 152], ["severe symptomatic hyperammonaemiaExtracorporeal circuits", "TREATMENT", 196, 253], ["clotting", "PROBLEM", 283, 291], ["the filter membrane", "TREATMENT", 309, 328], ["large", "OBSERVATION_MODIFIER", 33, 38], ["central", "ANATOMY_MODIFIER", 65, 72], ["venous", "ANATOMY", 73, 79], ["catheter", "OBSERVATION", 80, 88], ["severe", "OBSERVATION_MODIFIER", 196, 202], ["symptomatic", "OBSERVATION_MODIFIER", 203, 214], ["hyperammonaemiaExtracorporeal circuits", "OBSERVATION", 215, 253], ["clotting", "OBSERVATION", 283, 291], ["filter membrane", "OBSERVATION", 313, 328]]], ["Heparin can be used, although the patient will receive some heparin and therefore a degree of systemic anticoagulation.", [["Heparin", "CHEMICAL", 0, 7], ["heparin", "CHEMICAL", 60, 67], ["Heparin", "SIMPLE_CHEMICAL", 0, 7], ["patient", "ORGANISM", 34, 41], ["heparin", "SIMPLE_CHEMICAL", 60, 67], ["patient", "SPECIES", 34, 41], ["Heparin", "TREATMENT", 0, 7], ["some heparin", "TREATMENT", 55, 67], ["systemic anticoagulation", "TREATMENT", 94, 118], ["systemic", "OBSERVATION_MODIFIER", 94, 102], ["anticoagulation", "OBSERVATION", 103, 118]]], ["Citrate is an alternative which allows anticoagulation of the extracorporeal circuit, but not the patient.", [["extracorporeal", "ANATOMY", 62, 76], ["Citrate", "CHEMICAL", 0, 7], ["Citrate", "CHEMICAL", 0, 7], ["Citrate", "SIMPLE_CHEMICAL", 0, 7], ["patient", "ORGANISM", 98, 105], ["patient", "SPECIES", 98, 105], ["Citrate", "TREATMENT", 0, 7], ["an alternative", "TREATMENT", 11, 25], ["anticoagulation of the extracorporeal circuit", "TREATMENT", 39, 84], ["extracorporeal circuit", "OBSERVATION", 62, 84]]], ["Citrate works by complexing with calcium and thereby inactivating the clotting cascade in the extracorporeal circuit.", [["extracorporeal", "ANATOMY", 94, 108], ["Citrate", "CHEMICAL", 0, 7], ["calcium", "CHEMICAL", 33, 40], ["Citrate", "CHEMICAL", 0, 7], ["calcium", "CHEMICAL", 33, 40], ["Citrate", "SIMPLE_CHEMICAL", 0, 7], ["calcium", "SIMPLE_CHEMICAL", 33, 40], ["Citrate", "TREATMENT", 0, 7], ["calcium", "TREATMENT", 33, 40], ["the clotting cascade", "TREATMENT", 66, 86], ["the extracorporeal circuit", "TREATMENT", 90, 116], ["clotting cascade", "OBSERVATION", 70, 86], ["extracorporeal circuit", "OBSERVATION", 94, 116]]], ["During treatment, exogenous calcium is then infused back into blood as it re-enters the patient, thereby restoring functional coagulation in the patient.", [["blood", "ANATOMY", 62, 67], ["calcium", "CHEMICAL", 28, 35], ["calcium", "CHEMICAL", 28, 35], ["calcium", "SIMPLE_CHEMICAL", 28, 35], ["blood", "ORGANISM_SUBSTANCE", 62, 67], ["patient", "ORGANISM", 88, 95], ["patient", "ORGANISM", 145, 152], ["patient", "SPECIES", 88, 95], ["patient", "SPECIES", 145, 152], ["treatment", "TREATMENT", 7, 16], ["exogenous calcium", "TREATMENT", 18, 35], ["functional coagulation", "OBSERVATION", 115, 137]]], ["The balance of citrate levels in the extracorporeal circuit, and calcium infusion to the patient must be carefully managed to avoid complications such as symptomatic hypocalcaemia and citrate toxicity, although these are rare in children with normal liver function.Continuous kidney replacement therapy in neonatesFor infants and neonates, extracorporeal therapies carry additional risks because the extracorporeal circuit volume represents a greater proportion of the small child's circulating blood volume than for larger children.", [["extracorporeal", "ANATOMY", 37, 51], ["liver", "ANATOMY", 250, 255], ["kidney", "ANATOMY", 276, 282], ["extracorporeal", "ANATOMY", 400, 414], ["blood", "ANATOMY", 495, 500], ["citrate", "CHEMICAL", 15, 22], ["calcium", "CHEMICAL", 65, 72], ["hypocalcaemia", "DISEASE", 166, 179], ["citrate", "CHEMICAL", 184, 191], ["toxicity", "DISEASE", 192, 200], ["citrate", "CHEMICAL", 15, 22], ["calcium", "CHEMICAL", 65, 72], ["citrate", "CHEMICAL", 184, 191], ["citrate", "SIMPLE_CHEMICAL", 15, 22], ["calcium", "SIMPLE_CHEMICAL", 65, 72], ["patient", "ORGANISM", 89, 96], ["citrate", "SIMPLE_CHEMICAL", 184, 191], ["children", "ORGANISM", 229, 237], ["liver", "ORGAN", 250, 255], ["kidney", "ORGAN", 276, 282], ["infants", "ORGANISM", 318, 325], ["extracorporeal circuit", "MULTI-TISSUE_STRUCTURE", 400, 422], ["blood", "ORGANISM_SUBSTANCE", 495, 500], ["children", "ORGANISM", 524, 532], ["patient", "SPECIES", 89, 96], ["children", "SPECIES", 229, 237], ["infants", "SPECIES", 318, 325], ["children", "SPECIES", 524, 532], ["citrate levels", "TREATMENT", 15, 29], ["the extracorporeal circuit", "TREATMENT", 33, 59], ["calcium infusion", "TREATMENT", 65, 81], ["complications", "PROBLEM", 132, 145], ["symptomatic hypocalcaemia", "PROBLEM", 154, 179], ["citrate toxicity", "PROBLEM", 184, 200], ["Continuous kidney replacement therapy", "TREATMENT", 265, 302], ["extracorporeal therapies", "TREATMENT", 340, 364], ["the extracorporeal circuit volume", "TREATMENT", 396, 429], ["extracorporeal circuit", "ANATOMY", 37, 59], ["symptomatic", "OBSERVATION_MODIFIER", 154, 165], ["hypocalcaemia", "OBSERVATION", 166, 179], ["liver", "ANATOMY", 250, 255], ["kidney", "ANATOMY", 276, 282], ["replacement", "OBSERVATION", 283, 294], ["extracorporeal circuit", "OBSERVATION", 400, 422], ["greater", "OBSERVATION_MODIFIER", 443, 450], ["small", "OBSERVATION_MODIFIER", 469, 474]]], ["Traditionally, peritoneal dialysis was the only option for babies weighing less than approximately 2.5 kg, however in recent years two novel systems have been developed for infants and are currently undergoing evaluation in clinical trials.", [["peritoneal", "ANATOMY", 15, 25], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 15, 25], ["babies", "ORGANISM", 59, 65], ["infants", "ORGANISM", 173, 180], ["infants", "SPECIES", 173, 180], ["peritoneal dialysis", "TREATMENT", 15, 34], ["evaluation", "TEST", 210, 220], ["peritoneal", "ANATOMY", 15, 25], ["dialysis", "OBSERVATION", 26, 34]]], ["The Newcastle Infant Dialysis and Ultrafiltration System (NIDUS) uses a simple but novel system to achieve clearance and fluid removal.", [["fluid", "ANATOMY", 121, 126], ["The Newcastle Infant Dialysis", "TREATMENT", 0, 29], ["Ultrafiltration System", "TREATMENT", 34, 56], ["a simple but novel system", "TREATMENT", 70, 95], ["fluid removal", "TREATMENT", 121, 134]]], ["It uses a similar principle as an exchange blood transfusion: an aliquot of blood is removed from the patient, dialysed, and then returned to the patient.", [["blood", "ANATOMY", 43, 48], ["blood", "ANATOMY", 76, 81], ["blood", "ORGANISM_SUBSTANCE", 43, 48], ["blood", "ORGANISM_SUBSTANCE", 76, 81], ["patient", "ORGANISM", 102, 109], ["patient", "ORGANISM", 146, 153], ["patient", "SPECIES", 102, 109], ["patient", "SPECIES", 146, 153], ["an exchange blood transfusion", "TREATMENT", 31, 60], ["an aliquot of blood", "TREATMENT", 62, 81]]], ["Because the NIDUSKRT in acute kidney injuryA 4 year old girl presents to the emergency department with a 2 day history of bloody diarrhoea and worsening lethargy following a school trip to a petting farm.", [["kidney", "ANATOMY", 30, 36], ["acute kidney injuryA", "DISEASE", 24, 44], ["diarrhoea", "DISEASE", 129, 138], ["lethargy", "DISEASE", 153, 161], ["kidney", "ORGAN", 30, 36], ["NIDUSKRT", "DNA", 12, 20], ["girl", "SPECIES", 56, 60], ["acute kidney injuryA", "PROBLEM", 24, 44], ["bloody diarrhoea", "PROBLEM", 122, 138], ["worsening lethargy", "PROBLEM", 143, 161], ["acute", "OBSERVATION_MODIFIER", 24, 29], ["kidney", "ANATOMY", 30, 36], ["worsening", "OBSERVATION_MODIFIER", 143, 152], ["lethargy", "OBSERVATION", 153, 161]]], ["She is pale and lethargic, but warm peripherally and well perfused with systolic blood pressure 118 mmHg measured manually.", [["blood", "ANATOMY", 81, 86], ["blood", "ORGANISM_SUBSTANCE", 81, 86], ["lethargic", "PROBLEM", 16, 25], ["systolic blood pressure", "TEST", 72, 95], ["pale", "OBSERVATION", 7, 11], ["lethargic", "OBSERVATION", 16, 25], ["warm", "OBSERVATION", 31, 35], ["perfused", "OBSERVATION", 58, 66]]], ["Initial blood results show Hb 46 g/L, platelets 14, WBC 21, Na 134 mmol/L, K 7.3 mmol/L, urea 46 mmol/L, bicarbonate 12 mmol/L, creatinine 456 mmol/L. She is unable to pass urine for urinalysis.", [["blood", "ANATOMY", 8, 13], ["platelets", "ANATOMY", 38, 47], ["urine", "ANATOMY", 173, 178], ["Na", "CHEMICAL", 60, 62], ["urea", "CHEMICAL", 89, 93], ["bicarbonate", "CHEMICAL", 105, 116], ["creatinine", "CHEMICAL", 128, 138], ["Na", "CHEMICAL", 60, 62], ["urea", "CHEMICAL", 89, 93], ["bicarbonate", "CHEMICAL", 105, 116], ["creatinine", "CHEMICAL", 128, 138], ["blood", "ORGANISM_SUBSTANCE", 8, 13], ["Hb", "GENE_OR_GENE_PRODUCT", 27, 29], ["platelets", "CELL", 38, 47], ["urea", "SIMPLE_CHEMICAL", 89, 93], ["bicarbonate", "SIMPLE_CHEMICAL", 105, 116], ["creatinine", "SIMPLE_CHEMICAL", 128, 138], ["urine", "ORGANISM_SUBSTANCE", 173, 178], ["Hb", "PROTEIN", 27, 29], ["platelets", "CELL_TYPE", 38, 47], ["Hb", "TEST", 27, 29], ["platelets", "TEST", 38, 47], ["WBC", "TEST", 52, 55], ["Na", "TEST", 60, 62], ["mmol", "TEST", 67, 71], ["L", "TEST", 72, 73], ["K", "TEST", 75, 76], ["mmol", "TEST", 81, 85], ["L", "TEST", 86, 87], ["urea", "TEST", 89, 93], ["mmol", "TEST", 97, 101], ["bicarbonate", "TEST", 105, 116], ["creatinine", "TEST", 128, 138], ["urinalysis", "TEST", 183, 193]]], ["You suspect Shiga toxin associated haemolytic Uraemic Syndrome.", [["Shiga toxin", "CHEMICAL", 12, 23], ["haemolytic Uraemic Syndrome", "DISEASE", 35, 62], ["Shiga toxin", "GENE_OR_GENE_PRODUCT", 12, 23], ["Shiga toxin", "PROTEIN", 12, 23], ["Shiga toxin", "PROBLEM", 12, 23], ["haemolytic Uraemic Syndrome", "PROBLEM", 35, 62], ["Shiga", "OBSERVATION_MODIFIER", 12, 17], ["toxin associated", "OBSERVATION_MODIFIER", 18, 34], ["haemolytic", "OBSERVATION_MODIFIER", 35, 45], ["Uraemic Syndrome", "OBSERVATION", 46, 62]]], ["After medical management of hyperkalaemia with calcium gluconate, sodium bicarbonate, intravenous fluid bolus and furosemide, she does not pass urine over the subsequent 4 hours.", [["intravenous", "ANATOMY", 86, 97], ["urine", "ANATOMY", 144, 149], ["hyperkalaemia", "DISEASE", 28, 41], ["calcium gluconate", "CHEMICAL", 47, 64], ["sodium bicarbonate", "CHEMICAL", 66, 84], ["furosemide", "CHEMICAL", 114, 124], ["calcium gluconate", "CHEMICAL", 47, 64], ["sodium bicarbonate", "CHEMICAL", 66, 84], ["furosemide", "CHEMICAL", 114, 124], ["calcium gluconate", "SIMPLE_CHEMICAL", 47, 64], ["sodium bicarbonate", "SIMPLE_CHEMICAL", 66, 84], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 86, 97], ["fluid", "ORGANISM_SUBSTANCE", 98, 103], ["furosemide", "SIMPLE_CHEMICAL", 114, 124], ["urine", "ORGANISM_SUBSTANCE", 144, 149], ["medical management", "TREATMENT", 6, 24], ["hyperkalaemia", "PROBLEM", 28, 41], ["calcium gluconate", "TREATMENT", 47, 64], ["sodium bicarbonate", "TREATMENT", 66, 84], ["intravenous fluid bolus", "TREATMENT", 86, 109], ["furosemide", "TREATMENT", 114, 124], ["hyperkalaemia", "OBSERVATION", 28, 41]]], ["Her bladder appears empty on ultrasound.", [["bladder", "ANATOMY", 4, 11], ["bladder", "ORGAN", 4, 11], ["ultrasound", "TEST", 29, 39], ["bladder", "ANATOMY", 4, 11], ["empty", "OBSERVATION", 20, 25]]], ["After discussion with the tertiary paediatric nephrology unit, she is transferred for kidney replacement therapy.", [["kidney", "ANATOMY", 86, 92], ["kidney", "ORGAN", 86, 92], ["kidney replacement therapy", "TREATMENT", 86, 112], ["kidney", "ANATOMY", 86, 92], ["replacement", "OBSERVATION", 93, 104]]], ["A peritoneal dialysis catheter is placed on the emergency theatre list, and acute peritoneal dialysis commenced that night.", [["peritoneal", "ANATOMY", 2, 12], ["peritoneal", "ANATOMY", 82, 92], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 2, 12], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 82, 92], ["A peritoneal dialysis catheter", "TREATMENT", 0, 30], ["acute peritoneal dialysis", "TREATMENT", 76, 101], ["peritoneal", "ANATOMY", 2, 12], ["dialysis catheter", "OBSERVATION", 13, 30], ["acute", "OBSERVATION_MODIFIER", 76, 81], ["peritoneal", "ANATOMY", 82, 92], ["dialysis", "OBSERVATION", 93, 101]]], ["Within 4 hours, her plasma potassium concentration has reduced to 4.3 mmol/L with urea 37 mmol/L. She receives peritoneal dialysis for 5 days until her urine output returns and kidney function recovers.Box 1 KRT in hyperammonaemiaA 5-day-old boy with a history of worsening irritability and vomiting presented with cyanosis, gasping and no spontaneous movement.", [["plasma", "ANATOMY", 20, 26], ["peritoneal", "ANATOMY", 111, 121], ["urine", "ANATOMY", 152, 157], ["kidney", "ANATOMY", 177, 183], ["potassium", "CHEMICAL", 27, 36], ["urea", "CHEMICAL", 82, 86], ["irritability", "DISEASE", 274, 286], ["vomiting", "DISEASE", 291, 299], ["cyanosis", "DISEASE", 315, 323], ["potassium", "CHEMICAL", 27, 36], ["urea", "CHEMICAL", 82, 86], ["plasma", "ORGANISM_SUBSTANCE", 20, 26], ["potassium", "SIMPLE_CHEMICAL", 27, 36], ["urea", "SIMPLE_CHEMICAL", 82, 86], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 111, 121], ["urine", "ORGANISM_SUBSTANCE", 152, 157], ["kidney", "ORGAN", 177, 183], ["Box 1 KRT", "GENE_OR_GENE_PRODUCT", 202, 211], ["boy", "ORGANISM", 242, 245], ["Box 1 KRT", "DNA", 202, 211], ["boy", "SPECIES", 242, 245], ["her plasma potassium concentration", "TEST", 16, 50], ["urea", "TEST", 82, 86], ["peritoneal dialysis", "TREATMENT", 111, 130], ["her urine output", "TEST", 148, 164], ["kidney function", "TEST", 177, 192], ["worsening irritability", "PROBLEM", 264, 286], ["vomiting", "PROBLEM", 291, 299], ["cyanosis", "PROBLEM", 315, 323], ["gasping", "PROBLEM", 325, 332], ["spontaneous movement", "PROBLEM", 340, 360], ["peritoneal", "ANATOMY", 111, 121], ["dialysis", "OBSERVATION", 122, 130], ["kidney", "ANATOMY", 177, 183], ["worsening", "OBSERVATION_MODIFIER", 264, 273], ["irritability", "OBSERVATION", 274, 286], ["cyanosis", "OBSERVATION", 315, 323], ["no", "UNCERTAINTY", 337, 339], ["spontaneous movement", "OBSERVATION", 340, 360]]], ["He was haemodynamically unstable.", [["haemodynamically unstable", "PROBLEM", 7, 32], ["haemodynamically", "OBSERVATION_MODIFIER", 7, 23], ["unstable", "OBSERVATION", 24, 32]]], ["Initial investigations showed plasma ammonia concentration 857 mmol/L, and a urea cycle disorder was suspected.", [["plasma", "ANATOMY", 30, 36], ["ammonia", "CHEMICAL", 37, 44], ["urea", "CHEMICAL", 77, 81], ["ammonia", "CHEMICAL", 37, 44], ["urea", "CHEMICAL", 77, 81], ["plasma", "ORGANISM_SUBSTANCE", 30, 36], ["ammonia", "SIMPLE_CHEMICAL", 37, 44], ["urea", "SIMPLE_CHEMICAL", 77, 81], ["Initial investigations", "TEST", 0, 22], ["plasma ammonia concentration", "TEST", 30, 58], ["a urea cycle disorder", "PROBLEM", 75, 96]]], ["He was ventilated.", [["He", "ORGANISM", 0, 2], ["ventilated", "TREATMENT", 7, 17], ["ventilated", "OBSERVATION", 7, 17]]], ["Because of his haemodynamic instability and very high ammonia level causing encephalopathy, a double lumen central venous catheter was inserted and continuous kidney replacement therapy (CVVHDF) was started.", [["lumen", "ANATOMY", 101, 106], ["venous", "ANATOMY", 115, 121], ["kidney", "ANATOMY", 159, 165], ["ammonia", "CHEMICAL", 54, 61], ["encephalopathy", "DISEASE", 76, 90], ["ammonia", "CHEMICAL", 54, 61], ["ammonia", "SIMPLE_CHEMICAL", 54, 61], ["venous", "MULTI-TISSUE_STRUCTURE", 115, 121], ["kidney", "ORGAN", 159, 165], ["his haemodynamic instability", "PROBLEM", 11, 39], ["very high ammonia level", "PROBLEM", 44, 67], ["encephalopathy", "PROBLEM", 76, 90], ["a double lumen central venous catheter", "TREATMENT", 92, 130], ["continuous kidney replacement therapy", "TREATMENT", 148, 185], ["CVVHDF", "TREATMENT", 187, 193], ["haemodynamic instability", "OBSERVATION", 15, 39], ["very", "OBSERVATION_MODIFIER", 44, 48], ["high ammonia", "OBSERVATION", 49, 61], ["encephalopathy", "OBSERVATION", 76, 90], ["lumen", "ANATOMY_MODIFIER", 101, 106], ["central", "ANATOMY_MODIFIER", 107, 114], ["venous", "ANATOMY", 115, 121], ["catheter", "OBSERVATION", 122, 130], ["kidney", "ANATOMY", 159, 165], ["replacement", "OBSERVATION", 166, 177]]], ["After one hour of CVVHDF he began moving spontaneously.", [["CVVHDF", "TREATMENT", 18, 24]]], ["After 2 hours, plasma ammonia concentration had decreased to 342 mmol/L. A diagnosis of OTC deficiency was subsequently made, and he went on to receive a successful liver transplant.", [["plasma", "ANATOMY", 15, 21], ["liver", "ANATOMY", 165, 170], ["ammonia", "CHEMICAL", 22, 29], ["OTC deficiency", "DISEASE", 88, 102], ["ammonia", "CHEMICAL", 22, 29], ["plasma", "ORGANISM_SUBSTANCE", 15, 21], ["ammonia", "SIMPLE_CHEMICAL", 22, 29], ["OTC", "CANCER", 88, 91], ["liver", "ORGAN", 165, 170], ["plasma ammonia concentration", "TEST", 15, 43], ["OTC deficiency", "PROBLEM", 88, 102], ["a successful liver transplant", "TREATMENT", 152, 181], ["OTC deficiency", "OBSERVATION", 88, 102], ["liver", "ANATOMY", 165, 170], ["transplant", "OBSERVATION", 171, 181]]], ["Possible indications for KRT in treatment of hyperammonaemia 1 : C Rapidly deteriorating neurological status, coma, or cerebral oedema C Persistently high blood ammonia levels >400 mmol/L (681 mg/dL) refractory to non-kidney replacement therapy (NKRT) medical measures C Rapid rise in ammonia levels >300 mmol/L (511 mg/dL) within a few hours that cannot be controlled via NKRT medical measures Box 2Short-term CVVH as a bridge to recovery in PIMS-TSA 6 year old boy presents to the emergency department with fever, sore throat, lethargy, erythematous rash, cracked lips, neck pain and diarrhoea.", [["neurological", "ANATOMY", 89, 101], ["cerebral", "ANATOMY", 119, 127], ["blood", "ANATOMY", 155, 160], ["non-kidney", "ANATOMY", 214, 224], ["lips", "ANATOMY", 566, 570], ["neck", "ANATOMY", 572, 576], ["KRT", "CHEMICAL", 25, 28], ["hyperammonaemia", "DISEASE", 45, 60], ["coma", "DISEASE", 110, 114], ["cerebral oedema", "DISEASE", 119, 134], ["ammonia", "CHEMICAL", 161, 168], ["ammonia", "CHEMICAL", 285, 292], ["fever", "DISEASE", 509, 514], ["sore throat", "DISEASE", 516, 527], ["lethargy", "DISEASE", 529, 537], ["rash", "DISEASE", 552, 556], ["cracked lips", "DISEASE", 558, 570], ["neck pain", "DISEASE", 572, 581], ["diarrhoea", "DISEASE", 586, 595], ["ammonia", "CHEMICAL", 161, 168], ["ammonia", "CHEMICAL", 285, 292], ["blood", "ORGANISM_SUBSTANCE", 155, 160], ["ammonia", "SIMPLE_CHEMICAL", 161, 168], ["ammonia", "SIMPLE_CHEMICAL", 285, 292], ["boy", "ORGANISM", 463, 466], ["lips", "ORGANISM_SUBDIVISION", 566, 570], ["neck", "ORGANISM_SUBDIVISION", 572, 576], ["boy", "SPECIES", 463, 466], ["KRT", "TREATMENT", 25, 28], ["hyperammonaemia", "PROBLEM", 45, 60], ["Rapidly deteriorating neurological status", "PROBLEM", 67, 108], ["coma", "PROBLEM", 110, 114], ["cerebral oedema", "PROBLEM", 119, 134], ["Persistently high blood ammonia levels", "PROBLEM", 137, 175], ["non-kidney replacement therapy", "TREATMENT", 214, 244], ["medical measures", "TREATMENT", 252, 268], ["Rapid rise", "PROBLEM", 271, 281], ["ammonia levels", "TEST", 285, 299], ["CVVH", "TREATMENT", 411, 415], ["fever", "PROBLEM", 509, 514], ["sore throat", "PROBLEM", 516, 527], ["lethargy", "PROBLEM", 529, 537], ["erythematous rash", "PROBLEM", 539, 556], ["cracked lips", "PROBLEM", 558, 570], ["neck pain", "PROBLEM", 572, 581], ["diarrhoea", "PROBLEM", 586, 595], ["hyperammonaemia", "OBSERVATION", 45, 60], ["cerebral", "ANATOMY", 119, 127], ["oedema", "OBSERVATION", 128, 134], ["fever", "OBSERVATION", 509, 514], ["sore throat", "ANATOMY", 516, 527], ["erythematous", "OBSERVATION_MODIFIER", 539, 551], ["rash", "OBSERVATION", 552, 556], ["lips", "ANATOMY", 566, 570], ["neck", "ANATOMY", 572, 576], ["pain", "OBSERVATION", 577, 581], ["diarrhoea", "OBSERVATION", 586, 595]]], ["He has not passed urine for 24 hours.", [["urine", "ANATOMY", 18, 23], ["He", "ORGANISM", 0, 2], ["urine", "ORGANISM_SUBSTANCE", 18, 23]]], ["He is breathing in air but hypotensive and shocked with systolic blood pressure 68 mmHg.", [["blood", "ANATOMY", 65, 70], ["hypotensive", "DISEASE", 27, 38], ["blood", "ORGANISM_SUBSTANCE", 65, 70], ["hypotensive", "PROBLEM", 27, 38], ["systolic blood pressure", "TEST", 56, 79], ["breathing", "OBSERVATION", 6, 15], ["air", "OBSERVATION", 19, 22], ["hypotensive", "OBSERVATION", 27, 38]]], ["On examination, he has an erythematous rash, bleeding cracked lips, conjunctival injection, and lymphadenopathy.", [["erythematous", "ANATOMY", 26, 38], ["lips", "ANATOMY", 62, 66], ["conjunctival", "ANATOMY", 68, 80], ["rash", "DISEASE", 39, 43], ["bleeding", "DISEASE", 45, 53], ["lymphadenopathy", "DISEASE", 96, 111], ["lips", "ORGANISM_SUBDIVISION", 62, 66], ["conjunctival", "MULTI-TISSUE_STRUCTURE", 68, 80], ["examination", "TEST", 3, 14], ["an erythematous rash", "PROBLEM", 23, 43], ["bleeding cracked lips", "PROBLEM", 45, 66], ["conjunctival injection", "PROBLEM", 68, 90], ["lymphadenopathy", "PROBLEM", 96, 111], ["erythematous", "OBSERVATION_MODIFIER", 26, 38], ["rash", "OBSERVATION", 39, 43], ["bleeding", "OBSERVATION", 45, 53], ["lips", "ANATOMY", 62, 66], ["conjunctival", "ANATOMY", 68, 80], ["lymphadenopathy", "OBSERVATION", 96, 111]]], ["Investigations show pH 7.28, 22.5 HCO3, Lactate 2.2, WBC 18.2, Hb 94, plt 36, Troponin 109, Ferritin: 6698, potassium 7.4 mmol/L, urea: 42.9 mmol/L, creatinine 321 mmol/l.", [["Lactate", "CHEMICAL", 40, 47], ["potassium", "CHEMICAL", 108, 117], ["urea", "CHEMICAL", 130, 134], ["creatinine", "CHEMICAL", 149, 159], ["HCO3", "CHEMICAL", 34, 38], ["Lactate", "CHEMICAL", 40, 47], ["potassium", "CHEMICAL", 108, 117], ["urea", "CHEMICAL", 130, 134], ["creatinine", "CHEMICAL", 149, 159], ["Lactate", "SIMPLE_CHEMICAL", 40, 47], ["Troponin 109", "GENE_OR_GENE_PRODUCT", 78, 90], ["Ferritin", "GENE_OR_GENE_PRODUCT", 92, 100], ["potassium", "SIMPLE_CHEMICAL", 108, 117], ["urea", "SIMPLE_CHEMICAL", 130, 134], ["creatinine", "SIMPLE_CHEMICAL", 149, 159], ["Investigations", "TEST", 0, 14], ["pH", "TEST", 20, 22], ["HCO3", "TEST", 34, 38], ["Lactate", "TEST", 40, 47], ["WBC", "TEST", 53, 56], ["Hb", "TEST", 63, 65], ["plt", "TEST", 70, 73], ["Troponin", "TEST", 78, 86], ["Ferritin", "TEST", 92, 100], ["potassium", "TEST", 108, 117], ["mmol", "TEST", 122, 126], ["urea", "TEST", 130, 134], ["mmol", "TEST", 141, 145], ["creatinine", "TEST", 149, 159]]], ["Chest X-ray shows bilateral infiltrates.", [["Chest X-ray", "TEST", 0, 11], ["bilateral infiltrates", "PROBLEM", 18, 39], ["bilateral", "ANATOMY_MODIFIER", 18, 27], ["infiltrates", "OBSERVATION", 28, 39]]], ["Following fluid resuscitation with 40 ml/kg isotonic fluid, blood pressure and perfusion improve however he passes no urine.", [["fluid", "ANATOMY", 10, 15], ["blood", "ANATOMY", 60, 65], ["urine", "ANATOMY", 118, 123], ["fluid", "ORGANISM_SUBSTANCE", 10, 15], ["blood", "ORGANISM_SUBSTANCE", 60, 65], ["urine", "ORGANISM_SUBSTANCE", 118, 123], ["fluid resuscitation", "TREATMENT", 10, 29], ["isotonic fluid", "TREATMENT", 44, 58], ["blood pressure", "TEST", 60, 74]]], ["Plasma potassium concentration remains elevated at 7.2 mmol/L. After discussion with the paediatric intensive care and paediatric nephrology units, he is transferred for kidney replacement therapy.", [["kidney", "ANATOMY", 170, 176], ["potassium", "CHEMICAL", 7, 16], ["potassium", "CHEMICAL", 7, 16], ["Plasma", "ORGANISM_SUBSTANCE", 0, 6], ["potassium", "SIMPLE_CHEMICAL", 7, 16], ["kidney", "ORGAN", 170, 176], ["Plasma potassium concentration", "TEST", 0, 30], ["elevated", "PROBLEM", 39, 47], ["kidney replacement therapy", "TREATMENT", 170, 196], ["kidney", "ANATOMY", 170, 176], ["replacement", "OBSERVATION", 177, 188]]], ["Following transfer to PICU, a temporary central venous catheter (Vascath) is inserted under anaesthetic, and continus venovenohaemofiltraton started.", [["venous", "ANATOMY", 48, 54], ["venovenohaemofiltraton", "CHEMICAL", 118, 140], ["venous catheter", "MULTI-TISSUE_STRUCTURE", 48, 63], ["venovenohaemofiltraton", "SIMPLE_CHEMICAL", 118, 140], ["a temporary central venous catheter (Vascath)", "TREATMENT", 28, 73], ["anaesthetic", "TREATMENT", 92, 103], ["continus venovenohaemofiltraton", "TREATMENT", 109, 140], ["central", "ANATOMY_MODIFIER", 40, 47], ["venous", "ANATOMY", 48, 54], ["catheter", "OBSERVATION", 55, 63]]], ["After 24 hours, plasma electrolyte and acid-base status normalized.", [["plasma", "ANATOMY", 16, 22], ["plasma", "ORGANISM_SUBSTANCE", 16, 22], ["electrolyte", "SIMPLE_CHEMICAL", 23, 34], ["acid", "SIMPLE_CHEMICAL", 39, 43], ["plasma electrolyte", "TEST", 16, 34], ["acid-base status", "TEST", 39, 55], ["base", "ANATOMY_MODIFIER", 44, 48]]], ["After 48 hours of supportive care, he begins to pass urine and CVVH is discontinued.", [["urine", "ANATOMY", 53, 58], ["urine", "ORGANISM_SUBSTANCE", 53, 58], ["supportive care", "TREATMENT", 18, 33], ["CVVH", "TREATMENT", 63, 67]]], ["Nasopharyngeal aspirate for respiratory viral pCR is positive for Covid-19.", [["Nasopharyngeal aspirate", "ANATOMY", 0, 23], ["respiratory", "ANATOMY", 28, 39], ["respiratory viral pCR", "DISEASE", 28, 49], ["Nasopharyngeal aspirate", "MULTI-TISSUE_STRUCTURE", 0, 23], ["Nasopharyngeal aspirate", "TEST", 0, 23], ["respiratory viral pCR", "TEST", 28, 49], ["Covid", "TEST", 66, 71], ["aspirate", "OBSERVATION", 15, 23]]], ["A diagnosis of Paediatric Inflammatory Multisystem Syndrome Temporally related to SARS-CoV-2 infection (PIMS-TS) is made.Box 3SYMPOSIUM: NEPHROLOGY PAEDIATRICS AND CHILD HEALTH xxx:xxx does not use a continuous circuit, vascular access requirements are less stringent than other therapies, and infants as small as 800 g bodyweight can be dialysed via a 22 gauge cannula.", [["vascular", "ANATOMY", 220, 228], ["Inflammatory Multisystem Syndrome", "DISEASE", 26, 59], ["SARS-CoV-2 infection", "DISEASE", 82, 102], ["vascular", "MULTI-TISSUE_STRUCTURE", 220, 228], ["infants", "ORGANISM", 294, 301], ["infants", "SPECIES", 294, 301], ["SARS-CoV-2", "SPECIES", 82, 92], ["Paediatric Inflammatory Multisystem Syndrome", "PROBLEM", 15, 59], ["SARS", "PROBLEM", 82, 86], ["CoV-2 infection", "PROBLEM", 87, 102], ["a continuous circuit", "TREATMENT", 198, 218], ["vascular access requirements", "TREATMENT", 220, 248], ["other therapies", "TREATMENT", 273, 288], ["a 22 gauge cannula", "TREATMENT", 351, 369], ["Paediatric", "OBSERVATION_MODIFIER", 15, 25], ["Inflammatory", "OBSERVATION_MODIFIER", 26, 38], ["Multisystem Syndrome", "OBSERVATION", 39, 59], ["infection", "OBSERVATION", 93, 102], ["vascular", "ANATOMY", 220, 228]]], ["2 The CARdiorenal PEDIatric EMergency (CARPEDIEM) machine has also been developed to allow continuous kidney replacement therapy in infants.", [["kidney", "ANATOMY", 102, 108], ["kidney", "ORGAN", 102, 108], ["infants", "ORGANISM", 132, 139], ["infants", "SPECIES", 132, 139], ["continuous kidney replacement therapy", "TREATMENT", 91, 128], ["CARdiorenal", "ANATOMY", 6, 17], ["kidney", "ANATOMY", 102, 108], ["replacement", "OBSERVATION", 109, 120]]], ["This is a continuous circuit therapy that requires double lumen vascular access which has been used to dialyse small infants with success.", [["lumen vascular", "ANATOMY", 58, 72], ["vascular", "MULTI-TISSUE_STRUCTURE", 64, 72], ["infants", "ORGANISM", 117, 124], ["infants", "SPECIES", 117, 124], ["a continuous circuit therapy", "TREATMENT", 8, 36], ["double lumen vascular access", "TREATMENT", 51, 79], ["lumen", "ANATOMY_MODIFIER", 58, 63], ["vascular", "ANATOMY", 64, 72]]], ["3 Intermittent kidney replacement therapy for AKI Whilst continuous kidney replacement therapy allows superior physiological control of fluid and solute removal, it is generally only used in intensive care.", [["kidney", "ANATOMY", 15, 21], ["kidney", "ANATOMY", 68, 74], ["AKI", "DISEASE", 46, 49], ["kidney", "ORGAN", 15, 21], ["kidney", "ORGAN", 68, 74], ["fluid", "ORGANISM_SUBSTANCE", 136, 141], ["solute", "SIMPLE_CHEMICAL", 146, 152], ["Intermittent kidney replacement therapy", "TREATMENT", 2, 41], ["AKI", "PROBLEM", 46, 49], ["continuous kidney replacement therapy", "TREATMENT", 57, 94], ["fluid and solute removal", "TREATMENT", 136, 160], ["kidney", "ANATOMY", 15, 21], ["replacement", "OBSERVATION", 22, 33], ["AKI", "OBSERVATION", 46, 49], ["kidney", "ANATOMY", 68, 74], ["replacement", "OBSERVATION", 75, 86], ["fluid", "OBSERVATION", 136, 141]]], ["Some children with AKI require kidney replacement for several days or weeks before sufficient recovery of their kidney function allows kidney support to be discontinued.", [["kidney", "ANATOMY", 31, 37], ["kidney", "ANATOMY", 112, 118], ["kidney", "ANATOMY", 135, 141], ["AKI", "DISEASE", 19, 22], ["children", "ORGANISM", 5, 13], ["kidney", "ORGAN", 31, 37], ["kidney", "ORGAN", 112, 118], ["kidney", "ORGAN", 135, 141], ["children", "SPECIES", 5, 13], ["AKI", "PROBLEM", 19, 22], ["kidney replacement", "TREATMENT", 31, 49], ["kidney support", "TREATMENT", 135, 149], ["AKI", "OBSERVATION", 19, 22], ["kidney", "ANATOMY", 31, 37], ["replacement", "OBSERVATION", 38, 49], ["kidney", "ANATOMY", 112, 118], ["kidney", "ANATOMY", 135, 141]]], ["For children not requiring respiratory or circulatory support on PICU, intermittent dialysis on a paediatric nephrology ward is used.", [["respiratory", "ANATOMY", 27, 38], ["children", "ORGANISM", 4, 12], ["children", "SPECIES", 4, 12], ["circulatory support", "TREATMENT", 42, 61], ["intermittent dialysis", "TREATMENT", 71, 92]]], ["Options include both acute peritoneal dialysis and haemodialysis; choice of modality depends on the needs of the individual child and paediatric nephrology unit practices.Children with end-stage kidney disease (ESKD)Most children with ESKD receive KRT.", [["peritoneal", "ANATOMY", 27, 37], ["kidney", "ANATOMY", 195, 201], ["end-stage kidney disease", "DISEASE", 185, 209], ["ESKD", "DISEASE", 211, 215], ["ESKD", "DISEASE", 235, 239], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 27, 37], ["Children", "ORGANISM", 171, 179], ["kidney", "ORGAN", 195, 201], ["children", "ORGANISM", 221, 229], ["Children", "SPECIES", 171, 179], ["children", "SPECIES", 221, 229], ["both acute peritoneal dialysis", "TREATMENT", 16, 46], ["haemodialysis", "TREATMENT", 51, 64], ["end-stage kidney disease", "PROBLEM", 185, 209], ["ESKD", "PROBLEM", 235, 239], ["KRT", "TREATMENT", 248, 251], ["acute", "OBSERVATION_MODIFIER", 21, 26], ["peritoneal", "ANATOMY", 27, 37], ["dialysis", "OBSERVATION", 38, 46], ["-stage", "OBSERVATION_MODIFIER", 188, 194], ["kidney", "ANATOMY", 195, 201], ["disease", "OBSERVATION", 202, 209]]], ["The choice of KRT modality depends on factors such as size of the child, timing of the child's presentation to nephrology services, family factors that influence suitability for home dialysis therapies, medical comorbidities which may preclude certain modalities for individual patients, and practice patterns of the treating paediatric nephrology unit.", [["patients", "ORGANISM", 278, 286], ["patients", "SPECIES", 278, 286], ["KRT modality", "TREATMENT", 14, 26], ["home dialysis therapies", "TREATMENT", 178, 201], ["medical comorbidities", "PROBLEM", 203, 224]]], ["For example, haemodialysis is technically challenging in small infants because the volume of blood circulating in the extracorporeal dialysis circuit represents a relatively large proportion of the child's total blood volume.", [["blood", "ANATOMY", 93, 98], ["extracorporeal", "ANATOMY", 118, 132], ["blood", "ANATOMY", 212, 217], ["infants", "ORGANISM", 63, 70], ["blood", "ORGANISM_SUBSTANCE", 93, 98], ["blood", "ORGANISM_SUBSTANCE", 212, 217], ["infants", "SPECIES", 63, 70], ["haemodialysis", "TREATMENT", 13, 26], ["the extracorporeal dialysis circuit", "TREATMENT", 114, 149], ["haemodialysis", "OBSERVATION", 13, 26], ["small", "OBSERVATION_MODIFIER", 57, 62], ["extracorporeal", "OBSERVATION_MODIFIER", 118, 132], ["dialysis circuit", "OBSERVATION", 133, 149], ["relatively", "OBSERVATION_MODIFIER", 163, 173], ["large", "OBSERVATION_MODIFIER", 174, 179], ["proportion", "OBSERVATION_MODIFIER", 180, 190]]], ["Peritoneal dialysis is generally preferred in infants but may not be feasible for those who have had previous abdominal surgery with a stoma.", [["Peritoneal", "ANATOMY", 0, 10], ["abdominal", "ANATOMY", 110, 119], ["Peritoneal", "MULTI-TISSUE_STRUCTURE", 0, 10], ["infants", "ORGANISM", 46, 53], ["abdominal", "ORGANISM_SUBDIVISION", 110, 119], ["infants", "SPECIES", 46, 53], ["Peritoneal dialysis", "TREATMENT", 0, 19], ["previous abdominal surgery", "TREATMENT", 101, 127], ["a stoma", "TREATMENT", 133, 140], ["dialysis", "OBSERVATION", 11, 19], ["abdominal", "ANATOMY", 110, 119], ["surgery", "OBSERVATION", 120, 127], ["stoma", "OBSERVATION", 135, 140]]], ["Pre-emptive transplantation is preferred for children with ESKD; this may not be feasible for children who present at a late stage as workup for kidney transplantation typically takes several months.Children with end-stage kidney disease (ESKD)For children with ESKD, dialysis is generally used as a bridge to kidney transplantation.", [["kidney", "ANATOMY", 145, 151], ["kidney", "ANATOMY", 223, 229], ["kidney", "ANATOMY", 310, 316], ["ESKD", "DISEASE", 59, 63], ["end-stage kidney disease", "DISEASE", 213, 237], ["ESKD", "DISEASE", 239, 243], ["ESKD", "DISEASE", 262, 266], ["children", "ORGANISM", 45, 53], ["children", "ORGANISM", 94, 102], ["kidney", "ORGAN", 145, 151], ["Children", "ORGANISM", 199, 207], ["kidney", "ORGAN", 223, 229], ["children", "ORGANISM", 248, 256], ["kidney", "ORGAN", 310, 316], ["children", "SPECIES", 45, 53], ["children", "SPECIES", 94, 102], ["Children", "SPECIES", 199, 207], ["children", "SPECIES", 248, 256], ["Pre-emptive transplantation", "TREATMENT", 0, 27], ["workup", "TEST", 134, 140], ["kidney transplantation", "TREATMENT", 145, 167], ["end-stage kidney disease", "PROBLEM", 213, 237], ["ESKD", "PROBLEM", 262, 266], ["dialysis", "TREATMENT", 268, 276], ["a bridge to kidney transplantation", "TREATMENT", 298, 332], ["kidney", "ANATOMY", 145, 151], ["transplantation", "OBSERVATION", 152, 167], ["-stage", "OBSERVATION_MODIFIER", 216, 222], ["kidney", "ANATOMY", 223, 229], ["disease", "OBSERVATION", 230, 237], ["kidney", "ANATOMY", 310, 316], ["transplantation", "OBSERVATION", 317, 332]]], ["Home therapies (peritoneal dialysis or home haemodialysis) are usually preferable however the family situation may not be suitable to safely undertake dialysis at home.", [["peritoneal", "ANATOMY", 16, 26], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 16, 26], ["Home therapies", "TREATMENT", 0, 14], ["peritoneal dialysis", "TREATMENT", 16, 35], ["home haemodialysis", "TREATMENT", 39, 57], ["dialysis", "TREATMENT", 151, 159], ["peritoneal", "ANATOMY", 16, 26]]], ["Decisions about KRT are made in partnership with the family with support of a kidney multi-professional team including specialist nurses, family support workers, dieticians, social workers, psychologists, play therapists and doctors.Children with end-stage kidney disease (ESKD)For some children with extensive co-morbidites, the burdens of KRT may be considered greater than its benefits for the individual child.", [["kidney", "ANATOMY", 78, 84], ["kidney", "ANATOMY", 257, 263], ["end-stage kidney disease", "DISEASE", 247, 271], ["ESKD", "DISEASE", 273, 277], ["KRT", "CANCER", 16, 19], ["kidney", "ORGAN", 78, 84], ["Children", "ORGANISM", 233, 241], ["kidney", "ORGAN", 257, 263], ["children", "ORGANISM", 287, 295], ["Children", "SPECIES", 233, 241], ["children", "SPECIES", 287, 295], ["KRT", "TREATMENT", 16, 19], ["end-stage kidney disease", "PROBLEM", 247, 271], ["extensive co-morbidites", "PROBLEM", 301, 324], ["KRT", "TREATMENT", 341, 344], ["kidney", "ANATOMY", 78, 84], ["-stage", "OBSERVATION_MODIFIER", 250, 256], ["kidney", "ANATOMY", 257, 263], ["disease", "OBSERVATION", 264, 271]]], ["In such situations, the child's family may opt for a conservative pathway with a focus on symptom control.Pre-emptive kidney transplantFirst-choice kidney replacement therapy for children with ESKD is a pre-emptive kidney transplant, i.e. transplant before dialysis is required.", [["kidney", "ANATOMY", 118, 124], ["kidney", "ANATOMY", 148, 154], ["kidney", "ANATOMY", 215, 221], ["ESKD", "DISEASE", 193, 197], ["child", "ORGANISM", 24, 29], ["kidney", "ORGAN", 118, 124], ["kidney", "ORGAN", 148, 154], ["children", "ORGANISM", 179, 187], ["kidney", "ORGAN", 215, 221], ["children", "SPECIES", 179, 187], ["a conservative pathway", "TREATMENT", 51, 73], ["symptom control", "TREATMENT", 90, 105], ["Pre-emptive kidney transplant", "TREATMENT", 106, 135], ["First-choice kidney replacement therapy", "TREATMENT", 135, 174], ["ESKD", "TREATMENT", 193, 197], ["a pre-emptive kidney transplant", "TREATMENT", 201, 232], ["transplant", "TREATMENT", 239, 249], ["dialysis", "TREATMENT", 257, 265], ["kidney", "ANATOMY", 118, 124], ["transplant", "OBSERVATION", 125, 135], ["kidney", "ANATOMY", 148, 154], ["replacement", "OBSERVATION", 155, 166], ["kidney", "ANATOMY", 215, 221], ["transplant", "OBSERVATION", 222, 232]]], ["A living related donor transplant is preferable to deceased donor transplant and has favourable transplant longevity.", [["A living related donor transplant", "TREATMENT", 0, 33], ["donor transplant", "TREATMENT", 60, 76], ["transplant", "OBSERVATION", 23, 33], ["transplant", "OBSERVATION", 66, 76], ["favourable", "OBSERVATION_MODIFIER", 85, 95], ["transplant longevity", "OBSERVATION", 96, 116]]], ["For many children with ESKD, pre-emptive living donor transplant is achieved, however it is not always feasible for various reasons including size of the child, availability of a suitable living donor and timing of presentation with ESKD.Pre-emptive kidney transplantChildren must be at least 10 kg bodyweight for kidney transplantation.", [["kidney", "ANATOMY", 250, 256], ["kidney", "ANATOMY", 314, 320], ["ESKD", "DISEASE", 23, 27], ["ESKD", "DISEASE", 233, 237], ["children", "ORGANISM", 9, 17], ["kidney", "ORGAN", 250, 256], ["Children", "ORGANISM", 267, 275], ["kidney", "ORGAN", 314, 320], ["children", "SPECIES", 9, 17], ["Children", "SPECIES", 267, 275], ["ESKD", "PROBLEM", 23, 27], ["pre-emptive living donor transplant", "TREATMENT", 29, 64], ["a suitable living donor", "TREATMENT", 177, 200], ["ESKD", "PROBLEM", 233, 237], ["Pre-emptive kidney transplant", "TREATMENT", 238, 267], ["kidney transplantation", "TREATMENT", 314, 336], ["kidney", "ANATOMY", 250, 256], ["transplant", "OBSERVATION", 257, 267], ["kidney", "ANATOMY", 314, 320], ["transplantation", "OBSERVATION", 321, 336]]], ["Extensive preparation for both the recipient and donor is essential.", [["Extensive preparation", "TREATMENT", 0, 21]]], ["Donor and recipient blood group and HLA tissue typing bloods are used to assess compatibly.", [["blood", "ANATOMY", 20, 25], ["tissue", "ANATOMY", 40, 46], ["bloods", "ANATOMY", 54, 60], ["Donor", "CELL", 0, 5], ["blood", "ORGANISM_SUBSTANCE", 20, 25], ["HLA tissue", "TISSUE", 36, 46], ["bloods", "ORGANISM_SUBSTANCE", 54, 60], ["Donor", "TREATMENT", 0, 5], ["recipient blood group", "TEST", 10, 31], ["HLA tissue typing bloods", "TEST", 36, 60]]], ["Vascular imaging is performed to ensure patency of vessels for the transplant operation (iliac vessels or aorta/inferior vena cava in small children).", [["Vascular", "ANATOMY", 0, 8], ["vessels", "ANATOMY", 51, 58], ["iliac vessels", "ANATOMY", 89, 102], ["aorta", "ANATOMY", 106, 111], ["inferior vena cava", "ANATOMY", 112, 130], ["Vascular", "MULTI-TISSUE_STRUCTURE", 0, 8], ["vessels", "MULTI-TISSUE_STRUCTURE", 51, 58], ["iliac vessels", "MULTI-TISSUE_STRUCTURE", 89, 102], ["aorta", "MULTI-TISSUE_STRUCTURE", 106, 111], ["inferior vena cava", "MULTI-TISSUE_STRUCTURE", 112, 130], ["children", "ORGANISM", 140, 148], ["children", "SPECIES", 140, 148], ["Vascular imaging", "TEST", 0, 16], ["the transplant operation", "TREATMENT", 63, 87], ["aorta/inferior vena cava", "TREATMENT", 106, 130], ["patency", "OBSERVATION", 40, 47], ["vessels", "ANATOMY", 51, 58], ["transplant", "OBSERVATION", 67, 77], ["iliac vessels", "ANATOMY", 89, 102], ["aorta", "ANATOMY", 106, 111], ["inferior vena cava", "ANATOMY", 112, 130], ["small", "OBSERVATION_MODIFIER", 134, 139]]], ["A recent echocardiogram is needed to ensure that the child's heart will support the fluid loading required at the time of transplant operation.", [["heart", "ANATOMY", 61, 66], ["fluid", "ANATOMY", 84, 89], ["child", "ORGANISM", 53, 58], ["heart", "ORGAN", 61, 66], ["fluid", "ORGANISM_SUBSTANCE", 84, 89], ["A recent echocardiogram", "TEST", 0, 23], ["the fluid loading", "TREATMENT", 80, 97], ["transplant operation", "TREATMENT", 122, 142], ["heart", "ANATOMY", 61, 66], ["fluid loading", "OBSERVATION", 84, 97]]], ["Additional vaccinations are needed prior to receiving transplant immunosuppressive medications.", [["Additional vaccinations", "TREATMENT", 0, 23], ["transplant immunosuppressive medications", "TREATMENT", 54, 94]]], ["Bladder function must be assessed to ensure that urinary drainage from the transplant can be established.", [["Bladder", "ANATOMY", 0, 7], ["urinary", "ANATOMY", 49, 56], ["Bladder", "ORGAN", 0, 7], ["urinary", "ORGANISM_SUBDIVISION", 49, 56], ["urinary drainage", "TREATMENT", 49, 65], ["the transplant", "TREATMENT", 71, 85], ["urinary", "ANATOMY", 49, 56], ["drainage", "OBSERVATION", 57, 65]]], ["A detailed psychosocial assessment with play therapy preparation for the child is needed so that they are fully prepared for the operation and post-transplant care.", [["child", "ORGANISM", 73, 78], ["A detailed psychosocial assessment", "TEST", 0, 34], ["therapy preparation", "TREATMENT", 45, 64], ["the operation", "TREATMENT", 125, 138], ["post-transplant care", "TREATMENT", 143, 163]]], ["This preparation takes several months, and is vital to ensure the safety and optimisation of the transplant for the child.Pre-emptive kidney transplantWhen successfully transplanted, children's appetite, growth, energy levels and overall wellbeing improve.", [["kidney", "ANATOMY", 134, 140], ["child", "ORGANISM", 116, 121], ["kidney", "ORGAN", 134, 140], ["children", "ORGANISM", 183, 191], ["children", "SPECIES", 183, 191], ["the transplant", "TREATMENT", 93, 107], ["Pre-emptive kidney transplant", "TREATMENT", 122, 151], ["energy levels", "TEST", 212, 225], ["transplant", "OBSERVATION", 97, 107], ["kidney", "ANATOMY", 134, 140], ["transplant", "OBSERVATION", 141, 151]]], ["The duration for which a kidney transplant provides sufficient function varies.", [["kidney", "ANATOMY", 25, 31], ["kidney", "ORGAN", 25, 31], ["a kidney transplant", "TREATMENT", 23, 42], ["kidney", "ANATOMY", 25, 31], ["transplant", "OBSERVATION", 32, 42]]], ["The most significant factor influencing this is concordance with immunosuppressive medication.", [["immunosuppressive medication", "TREATMENT", 65, 93], ["most significant", "OBSERVATION_MODIFIER", 4, 20]]], ["Transplants typically last somewhere in the region of 15 years, although this varies considerably according to quality of the donor organ, concordance with immunosuppressive medication, native kidney disease, bladder drainage and other factors.", [["organ", "ANATOMY", 132, 137], ["kidney", "ANATOMY", 193, 199], ["bladder", "ANATOMY", 209, 216], ["kidney disease", "DISEASE", 193, 207], ["organ", "ORGAN", 132, 137], ["kidney", "ORGAN", 193, 199], ["bladder", "ORGAN", 209, 216], ["Transplants", "TREATMENT", 0, 11], ["immunosuppressive medication", "TREATMENT", 156, 184], ["native kidney disease", "PROBLEM", 186, 207], ["bladder drainage", "TREATMENT", 209, 225], ["other factors", "PROBLEM", 230, 243], ["kidney", "ANATOMY", 193, 199], ["disease", "OBSERVATION", 200, 207], ["bladder", "ANATOMY", 209, 216], ["drainage", "OBSERVATION", 217, 225]]], ["See Box 4.Peritoneal dialysis (PD)In PD, the peritoneal membrane is utilized to exchange solutes and water.", [["Peritoneal", "ANATOMY", 10, 20], ["peritoneal membrane", "ANATOMY", 45, 64], ["PD", "DISEASE", 37, 39], ["Peritoneal", "MULTI-TISSUE_STRUCTURE", 10, 20], ["peritoneal membrane", "MULTI-TISSUE_STRUCTURE", 45, 64], ["water", "SIMPLE_CHEMICAL", 101, 106], ["Box 4", "DNA", 4, 9], ["Peritoneal dialysis (PD)", "TREATMENT", 10, 34], ["PD", "TREATMENT", 37, 39], ["the peritoneal membrane", "TREATMENT", 41, 64], ["dialysis", "OBSERVATION", 21, 29], ["peritoneal membrane", "ANATOMY", 45, 64]]], ["Solutes such as urea, phosphate, potassium and sodium diffuse out of peritoneal capillaries into dialysate solution which is instilled into the abdomen via a peritoneal dialysis catheter.", [["peritoneal capillaries", "ANATOMY", 69, 91], ["abdomen", "ANATOMY", 144, 151], ["peritoneal", "ANATOMY", 158, 168], ["urea", "CHEMICAL", 16, 20], ["phosphate", "CHEMICAL", 22, 31], ["potassium", "CHEMICAL", 33, 42], ["sodium", "CHEMICAL", 47, 53], ["urea", "CHEMICAL", 16, 20], ["phosphate", "CHEMICAL", 22, 31], ["potassium", "CHEMICAL", 33, 42], ["sodium", "CHEMICAL", 47, 53], ["urea", "SIMPLE_CHEMICAL", 16, 20], ["phosphate", "SIMPLE_CHEMICAL", 22, 31], ["potassium", "SIMPLE_CHEMICAL", 33, 42], ["sodium", "SIMPLE_CHEMICAL", 47, 53], ["peritoneal capillaries", "MULTI-TISSUE_STRUCTURE", 69, 91], ["abdomen", "ORGAN", 144, 151], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 158, 168], ["urea, phosphate, potassium", "TEST", 16, 42], ["sodium diffuse out of peritoneal capillaries", "PROBLEM", 47, 91], ["dialysate solution", "TREATMENT", 97, 115], ["a peritoneal dialysis catheter", "TREATMENT", 156, 186], ["diffuse", "OBSERVATION_MODIFIER", 54, 61], ["peritoneal capillaries", "ANATOMY", 69, 91], ["abdomen", "ANATOMY", 144, 151], ["peritoneal", "ANATOMY", 158, 168], ["dialysis catheter", "OBSERVATION", 169, 186]]], ["Excess intravascular fluid is drawn from peritoneal capillaries by the osmotic load of the dialysate fluid.", [["intravascular fluid", "ANATOMY", 7, 26], ["peritoneal capillaries", "ANATOMY", 41, 63], ["dialysate fluid", "ANATOMY", 91, 106], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 7, 20], ["fluid", "ORGANISM_SUBSTANCE", 21, 26], ["peritoneal capillaries", "MULTI-TISSUE_STRUCTURE", 41, 63], ["dialysate fluid", "ORGANISM_SUBSTANCE", 91, 106], ["Excess intravascular fluid", "PROBLEM", 0, 26], ["peritoneal capillaries", "TEST", 41, 63], ["the dialysate fluid", "TREATMENT", 87, 106], ["intravascular fluid", "OBSERVATION", 7, 26], ["peritoneal", "ANATOMY", 41, 51], ["capillaries", "ANATOMY_MODIFIER", 52, 63], ["dialysate fluid", "OBSERVATION", 91, 106]]], ["Spent dialysate fluid is then drained to an effluent bag.Peritoneal dialysis (PD)PD access comprises an intra-abdominal catheter.", [["Peritoneal", "ANATOMY", 57, 67], ["intra-abdominal", "ANATOMY", 104, 119], ["dialysate", "ORGANISM_SUBSTANCE", 6, 15], ["fluid", "ORGANISM_SUBSTANCE", 16, 21], ["Peritoneal", "MULTI-TISSUE_STRUCTURE", 57, 67], ["Spent dialysate fluid", "TREATMENT", 0, 21], ["an effluent bag", "TREATMENT", 41, 56], ["Peritoneal dialysis (PD)PD access", "TREATMENT", 57, 90], ["an intra-abdominal catheter", "TREATMENT", 101, 128], ["fluid", "OBSERVATION", 16, 21], ["effluent bag", "OBSERVATION", 44, 56], ["dialysis", "OBSERVATION", 68, 76], ["intra-abdominal", "ANATOMY", 104, 119], ["catheter", "OBSERVATION", 120, 128]]], ["During surgical catheter placement, the catheter is tunnelled through the abdominal wall; two cuffs minimise infection risk.", [["catheter", "ANATOMY", 16, 24], ["abdominal wall", "ANATOMY", 74, 88], ["infection", "DISEASE", 109, 118], ["abdominal wall", "MULTI-TISSUE_STRUCTURE", 74, 88], ["surgical catheter placement", "TREATMENT", 7, 34], ["the catheter", "TREATMENT", 36, 48], ["two cuffs minimise infection risk", "PROBLEM", 90, 123], ["catheter placement", "OBSERVATION", 16, 34], ["catheter", "OBSERVATION", 40, 48], ["tunnelled", "OBSERVATION", 52, 61], ["abdominal wall", "ANATOMY", 74, 88], ["two", "OBSERVATION_MODIFIER", 90, 93], ["cuffs", "OBSERVATION_MODIFIER", 94, 99], ["minimise", "OBSERVATION_MODIFIER", 100, 108], ["infection", "OBSERVATION", 109, 118]]], ["The tip of the catheter is usually coiled in the pelvis.", [["pelvis", "ANATOMY", 49, 55], ["pelvis", "ORGAN", 49, 55], ["the catheter", "TREATMENT", 11, 23], ["tip", "OBSERVATION_MODIFIER", 4, 7], ["catheter", "OBSERVATION", 15, 23], ["usually", "OBSERVATION_MODIFIER", 27, 34], ["coiled", "OBSERVATION", 35, 41], ["pelvis", "ANATOMY", 49, 55]]], ["Constipation can affect catheter position and function.Peritoneal dialysis (PD)For most children on PD, automated peritoneal dialysis (APD) is performed overnight during sleep.", [["catheter", "ANATOMY", 24, 32], ["Peritoneal", "ANATOMY", 55, 65], ["peritoneal", "ANATOMY", 114, 124], ["Constipation", "DISEASE", 0, 12], ["PD", "DISEASE", 100, 102], ["Peritoneal", "MULTI-TISSUE_STRUCTURE", 55, 65], ["children", "ORGANISM", 88, 96], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 114, 124], ["children", "SPECIES", 88, 96], ["Constipation", "PROBLEM", 0, 12], ["Peritoneal dialysis (PD)", "TREATMENT", 55, 79], ["PD", "TREATMENT", 100, 102], ["automated peritoneal dialysis", "TREATMENT", 104, 133], ["catheter", "OBSERVATION", 24, 32], ["dialysis", "OBSERVATION", 66, 74], ["peritoneal", "ANATOMY", 114, 124], ["dialysis", "OBSERVATION", 125, 133]]], ["An APD machine cycles heated dialysate fluid from sterile bags into the patient's abdomen, leaves it to dwell within the abdomen for a specified time, then drains spent fluid to an effluent bag.", [["abdomen", "ANATOMY", 82, 89], ["abdomen", "ANATOMY", 121, 128], ["patient", "ORGANISM", 72, 79], ["abdomen", "ORGANISM_SUBDIVISION", 82, 89], ["abdomen", "ORGAN", 121, 128], ["patient", "SPECIES", 72, 79], ["An APD machine cycles heated dialysate fluid", "TREATMENT", 0, 44], ["sterile bags", "TREATMENT", 50, 62], ["an effluent bag", "TREATMENT", 178, 193], ["abdomen", "ANATOMY", 82, 89], ["abdomen", "ANATOMY", 121, 128], ["drains", "OBSERVATION", 156, 162], ["effluent bag", "OBSERVATION", 181, 193]]], ["This automated cycle is repeated approximately 6e12 times, depending on the dialysis prescription.Life after kidney transplantationA 5 year old boy has been under the care of the paediatric nephrology team since birth following antenatal detection of dysplastic kidneys.", [["kidney", "ANATOMY", 109, 115], ["dysplastic kidneys", "ANATOMY", 251, 269], ["kidney", "ORGAN", 109, 115], ["boy", "ORGANISM", 144, 147], ["kidneys", "ORGAN", 262, 269], ["boy", "SPECIES", 144, 147], ["the dialysis prescription", "TREATMENT", 72, 97], ["dysplastic kidneys", "PROBLEM", 251, 269], ["kidney", "ANATOMY", 109, 115], ["dysplastic", "OBSERVATION", 251, 261], ["kidneys", "ANATOMY", 262, 269]]], ["For the first 5 years of life he had advanced chronic kidney disease with polyuria.", [["kidney", "ANATOMY", 54, 60], ["chronic kidney disease", "DISEASE", 46, 68], ["polyuria", "DISEASE", 74, 82], ["kidney", "ORGAN", 54, 60], ["advanced chronic kidney disease", "PROBLEM", 37, 68], ["polyuria", "PROBLEM", 74, 82], ["chronic", "OBSERVATION_MODIFIER", 46, 53], ["kidney", "ANATOMY", 54, 60], ["disease", "OBSERVATION", 61, 68], ["polyuria", "OBSERVATION", 74, 82]]], ["With regular input from paediatric renal dieticians, specialist nurses and a paediatric nephrologist he grew along the ninth centile and maintained acceptable blood count (on darbepoietin and iron supplements), bone chemistry (on vitamin D and phosphate binders) and acid-base status (on sodium bicarbonate supplementation).", [["renal", "ANATOMY", 35, 40], ["blood", "ANATOMY", 159, 164], ["bone", "ANATOMY", 211, 215], ["darbepoietin", "CHEMICAL", 175, 187], ["iron", "CHEMICAL", 192, 196], ["vitamin D", "CHEMICAL", 230, 239], ["phosphate", "CHEMICAL", 244, 253], ["sodium bicarbonate", "CHEMICAL", 288, 306], ["darbepoietin", "CHEMICAL", 175, 187], ["iron", "CHEMICAL", 192, 196], ["vitamin D", "CHEMICAL", 230, 239], ["phosphate", "CHEMICAL", 244, 253], ["sodium bicarbonate", "CHEMICAL", 288, 306], ["renal", "ORGAN", 35, 40], ["blood", "ORGANISM_SUBSTANCE", 159, 164], ["darbepoietin", "SIMPLE_CHEMICAL", 175, 187], ["iron", "SIMPLE_CHEMICAL", 192, 196], ["bone", "TISSUE", 211, 215], ["vitamin D", "SIMPLE_CHEMICAL", 230, 239], ["phosphate binders", "SIMPLE_CHEMICAL", 244, 261], ["sodium", "SIMPLE_CHEMICAL", 288, 294], ["bicarbonate", "SIMPLE_CHEMICAL", 295, 306], ["blood count", "TEST", 159, 170], ["darbepoietin", "TREATMENT", 175, 187], ["iron supplements", "TREATMENT", 192, 208], ["bone chemistry", "TEST", 211, 225], ["vitamin D and phosphate binders", "TREATMENT", 230, 261], ["acid-base status", "TEST", 267, 283], ["sodium bicarbonate supplementation", "TREATMENT", 288, 322], ["renal", "ANATOMY", 35, 40], ["base", "ANATOMY_MODIFIER", 272, 276]]], ["When he reached 3 years of age, his father underwent living kidney donor workup in preparation for transplant when required.", [["kidney", "ANATOMY", 60, 66], ["kidney", "ORGAN", 60, 66], ["living kidney donor workup", "TEST", 53, 79], ["transplant", "TREATMENT", 99, 109], ["kidney", "ANATOMY", 60, 66]]], ["At 5 years of age, the child began to experience worsening symptoms of reduced appetite and vomiting and high blood pressure.", [["blood", "ANATOMY", 110, 115], ["vomiting", "DISEASE", 92, 100], ["child", "ORGANISM", 23, 28], ["blood", "ORGANISM_SUBSTANCE", 110, 115], ["child", "SPECIES", 23, 28], ["worsening symptoms", "PROBLEM", 49, 67], ["reduced appetite", "PROBLEM", 71, 87], ["vomiting", "PROBLEM", 92, 100], ["high blood pressure", "PROBLEM", 105, 124]]], ["A decision was taken to proceed with preemptive living related donor transplant.", [["preemptive living related donor transplant", "TREATMENT", 37, 79], ["transplant", "OBSERVATION", 69, 79]]], ["Three months following transplant he had normal kidney function, blood count and blood pressure taking regular immunosuppressive medication.", [["kidney", "ANATOMY", 48, 54], ["blood", "ANATOMY", 65, 70], ["blood", "ANATOMY", 81, 86], ["kidney", "ORGAN", 48, 54], ["blood", "ORGANISM_SUBSTANCE", 65, 70], ["blood", "ORGANISM_SUBSTANCE", 81, 86], ["transplant", "TREATMENT", 23, 33], ["blood count", "TEST", 65, 76], ["blood pressure", "TEST", 81, 95], ["regular immunosuppressive medication", "TREATMENT", 103, 139], ["kidney", "ANATOMY", 48, 54]]], ["His energy levels had markedly improved, as had his appetite and growth.", [["His energy levels", "TEST", 0, 17], ["markedly", "OBSERVATION_MODIFIER", 22, 30], ["improved", "OBSERVATION_MODIFIER", 31, 39]]], ["Later that year, he won a silver medal for swimming at the annual national transplant games.", [["silver medal", "CHEMICAL", 26, 38], ["silver", "CHEMICAL", 26, 32]]], ["Continuous ambulatory peritoneal dialysis (CAPD) can be used as an alternative but is generally preferred for adults.", [["peritoneal", "ANATOMY", 22, 32], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 22, 32], ["Continuous ambulatory peritoneal dialysis (CAPD)", "TREATMENT", 0, 48], ["peritoneal", "ANATOMY", 22, 32]]], ["CAPD involves the patient or parents undertaking manual exchanges of dialysate fluid several times in a 24-hour period without the need for a machine.Life after kidney transplantationPeritoneal dialysis is a home therapy which can be successfully undertaken even in very small and young babies (See Box 5).", [["kidney", "ANATOMY", 161, 167], ["Peritoneal", "ANATOMY", 183, 193], ["patient", "ORGANISM", 18, 25], ["kidney", "ORGAN", 161, 167], ["Peritoneal", "MULTI-TISSUE_STRUCTURE", 183, 193], ["patient", "SPECIES", 18, 25], ["CAPD", "TREATMENT", 0, 4], ["manual exchanges of dialysate fluid", "TREATMENT", 49, 84], ["a machine", "TREATMENT", 140, 149], ["kidney transplantation", "TREATMENT", 161, 183], ["Peritoneal dialysis", "TREATMENT", 183, 202], ["a home therapy", "TREATMENT", 206, 220], ["kidney", "ANATOMY", 161, 167], ["transplantation", "OBSERVATION", 168, 183], ["dialysis", "OBSERVATION", 194, 202]]], ["Prior to embarking on peritoneal dialysis, specialist nurses usually undertake a home visit to ensure suitability of the child's home to accommodate dialysis fluid supplies and the machine.", [["peritoneal", "ANATOMY", 22, 32], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 22, 32], ["peritoneal dialysis", "TREATMENT", 22, 41], ["dialysis fluid supplies", "TREATMENT", 149, 172], ["the machine", "TREATMENT", 177, 188], ["peritoneal", "ANATOMY", 22, 32]]], ["Parents or carers are trained to undertake peritoneal dialysis for the child at home.Life after kidney transplantationPeritonitis is a common complication of peritoneal dialysis.", [["peritoneal", "ANATOMY", 43, 53], ["kidney", "ANATOMY", 96, 102], ["peritoneal", "ANATOMY", 158, 168], ["Peritonitis", "DISEASE", 118, 129], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 43, 53], ["kidney", "ORGAN", 96, 102], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 158, 168], ["peritoneal dialysis", "TREATMENT", 43, 62], ["kidney transplantation", "TREATMENT", 96, 118], ["Peritonitis", "PROBLEM", 118, 129], ["a common complication", "PROBLEM", 133, 154], ["peritoneal dialysis", "TREATMENT", 158, 177], ["peritoneal", "ANATOMY", 43, 53], ["kidney", "ANATOMY", 96, 102], ["transplantation", "OBSERVATION", 103, 118], ["peritoneal", "ANATOMY", 158, 168], ["dialysis", "OBSERVATION", 169, 177]]], ["If a child experiences fever, vomiting, abdominal pain or cloudy peritoneal dialysis effluent fluid then urgent medical assessment is needed with advice from the paediatric nephrology team.", [["abdominal", "ANATOMY", 40, 49], ["peritoneal", "ANATOMY", 65, 75], ["fever", "DISEASE", 23, 28], ["vomiting", "DISEASE", 30, 38], ["abdominal pain", "DISEASE", 40, 54], ["abdominal", "ORGANISM_SUBDIVISION", 40, 49], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 65, 75], ["fever", "PROBLEM", 23, 28], ["vomiting", "PROBLEM", 30, 38], ["abdominal pain", "PROBLEM", 40, 54], ["cloudy peritoneal dialysis effluent fluid", "PROBLEM", 58, 99], ["urgent medical assessment", "TEST", 105, 130], ["abdominal", "ANATOMY", 40, 49], ["cloudy", "OBSERVATION_MODIFIER", 58, 64], ["peritoneal", "ANATOMY", 65, 75]]], ["A sample of peritoneal dialysis fluid should be sent urgently for microscopy, and treatment started with intraperitoneal antibiotics if microscopy is suggestive of infection.", [["sample", "ANATOMY", 2, 8], ["peritoneal", "ANATOMY", 12, 22], ["intraperitoneal", "ANATOMY", 105, 120], ["infection", "DISEASE", 164, 173], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 12, 22], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 105, 120], ["peritoneal dialysis fluid", "TREATMENT", 12, 37], ["microscopy", "TEST", 66, 76], ["treatment", "TREATMENT", 82, 91], ["intraperitoneal antibiotics", "TREATMENT", 105, 132], ["microscopy", "TEST", 136, 146], ["infection", "PROBLEM", 164, 173], ["peritoneal", "ANATOMY", 12, 22], ["dialysis fluid", "OBSERVATION", 23, 37], ["suggestive of", "UNCERTAINTY", 150, 163], ["infection", "OBSERVATION", 164, 173]]], ["Intravenous antibiotics should be given if the child has signs of sepsis in discussion with the paediatric nephrology team.HaemodialysisHaemodialysis uses diffusion to clear solutes such as urea and potassium from the patient.", [["sepsis", "DISEASE", 66, 72], ["Haemodialysis", "DISEASE", 136, 149], ["urea", "CHEMICAL", 190, 194], ["potassium", "CHEMICAL", 199, 208], ["urea", "CHEMICAL", 190, 194], ["potassium", "CHEMICAL", 199, 208], ["child", "ORGANISM", 47, 52], ["urea", "SIMPLE_CHEMICAL", 190, 194], ["potassium", "SIMPLE_CHEMICAL", 199, 208], ["patient", "ORGANISM", 218, 225], ["patient", "SPECIES", 218, 225], ["Intravenous antibiotics", "TREATMENT", 0, 23], ["sepsis", "PROBLEM", 66, 72], ["HaemodialysisHaemodialysis", "TREATMENT", 123, 149], ["urea and potassium", "TEST", 190, 208], ["sepsis", "OBSERVATION", 66, 72]]], ["In addition, excess fluid is removed from the patient by ultrafiltration generated by a pressure difference across the dialysis membrane between the patient blood side (higher pressure) and the dialysate fluid side of the membrane.HaemodialysisA typical haemodialysis treatment regimen for children dialysed in a paediatric nephrology unit comprises three sessions per week, each session lasting between three and five hours.", [["membrane", "ANATOMY", 128, 136], ["blood", "ANATOMY", 157, 162], ["dialysate fluid", "ANATOMY", 194, 209], ["membrane", "ANATOMY", 222, 230], ["fluid", "ORGANISM_SUBSTANCE", 20, 25], ["patient", "ORGANISM", 46, 53], ["membrane", "CELLULAR_COMPONENT", 128, 136], ["patient", "ORGANISM", 149, 156], ["blood", "ORGANISM_SUBSTANCE", 157, 162], ["membrane", "CELLULAR_COMPONENT", 222, 230], ["children", "ORGANISM", 290, 298], ["patient", "SPECIES", 46, 53], ["patient", "SPECIES", 149, 156], ["children", "SPECIES", 290, 298], ["excess fluid", "PROBLEM", 13, 25], ["ultrafiltration", "TREATMENT", 57, 72], ["a pressure difference", "PROBLEM", 86, 107], ["the dialysis membrane", "TREATMENT", 115, 136], ["the dialysate fluid", "TEST", 190, 209], ["Haemodialysis", "TREATMENT", 231, 244], ["A typical haemodialysis treatment regimen", "TREATMENT", 244, 285], ["excess", "OBSERVATION_MODIFIER", 13, 19], ["fluid", "OBSERVATION", 20, 25], ["dialysis membrane", "OBSERVATION", 119, 136], ["dialysate fluid", "OBSERVATION", 194, 209], ["membrane", "ANATOMY_MODIFIER", 222, 230]]], ["More frequent dialysis sessions are needed for infants because it is rarely possible to achieve adequate control of fluid status when receiving liquid feeds with three dialysis sessions per week.", [["fluid", "ANATOMY", 116, 121], ["infants", "ORGANISM", 47, 54], ["fluid", "ORGANISM_SUBSTANCE", 116, 121], ["infants", "SPECIES", 47, 54], ["frequent dialysis sessions", "TREATMENT", 5, 31], ["liquid feeds", "TREATMENT", 144, 156], ["three dialysis sessions", "TREATMENT", 162, 185], ["fluid", "OBSERVATION", 116, 121]]], ["This is because a limited volume of fluid can be safely removed from the child each session.HaemodialysisVascular access for haemodialysis must support high blood flows, typically up to 300 mL/minute.", [["fluid", "ANATOMY", 36, 41], ["blood", "ANATOMY", 157, 162], ["fluid", "ORGANISM_SUBSTANCE", 36, 41], ["blood", "ORGANISM_SUBSTANCE", 157, 162], ["a limited volume of fluid", "TREATMENT", 16, 41], ["HaemodialysisVascular access", "TREATMENT", 92, 120], ["haemodialysis", "TREATMENT", 125, 138], ["high blood flows", "PROBLEM", 152, 168], ["fluid", "OBSERVATION", 36, 41]]], ["Arteriovenous fistulae are the preferred form of access with lower rates of infection and malfunction than central venous dialysis catheters.", [["Arteriovenous fistulae", "ANATOMY", 0, 22], ["venous", "ANATOMY", 115, 121], ["Arteriovenous fistulae", "DISEASE", 0, 22], ["infection", "DISEASE", 76, 85], ["Arteriovenous fistulae", "PATHOLOGICAL_FORMATION", 0, 22], ["venous", "MULTI-TISSUE_STRUCTURE", 115, 121], ["Arteriovenous fistulae", "PROBLEM", 0, 22], ["infection", "PROBLEM", 76, 85], ["central venous dialysis catheters", "TREATMENT", 107, 140], ["fistulae", "OBSERVATION", 14, 22], ["infection", "OBSERVATION", 76, 85], ["central", "ANATOMY_MODIFIER", 107, 114], ["venous", "ANATOMY", 115, 121], ["dialysis catheters", "OBSERVATION", 122, 140]]], ["4 With support from specialist dialysis nurses and play therapists, many children can successfully needle their own arteriovenous fistulae.HaemodialysisAttending the paediatric nephrology unit three days per week impacts children's education, social interaction and quality of life.", [["arteriovenous fistulae", "ANATOMY", 116, 138], ["arteriovenous fistulae", "DISEASE", 116, 138], ["Haemodialysis", "DISEASE", 139, 152], ["children", "ORGANISM", 73, 81], ["arteriovenous fistulae", "PATHOLOGICAL_FORMATION", 116, 138], ["children", "ORGANISM", 221, 229], ["children", "SPECIES", 73, 81], ["children", "SPECIES", 221, 229], ["arteriovenous fistulae", "PROBLEM", 116, 138], ["arteriovenous", "ANATOMY", 116, 129], ["fistulae", "OBSERVATION", 130, 138]]], ["Teachers provide education during dialysis, and play therapists work with children to engage them in activities and games.", [["children", "ORGANISM", 74, 82], ["children", "SPECIES", 74, 82], ["dialysis", "TREATMENT", 34, 42]]], ["Home dialysis therapies are preferred when feasible for the family (see Boxes 5 and 6).HaemodiafiltrationHaemodiafiltration uses both diffusion and convection to clear solutes from the patient.", [["patient", "ORGANISM", 185, 192], ["patient", "SPECIES", 185, 192], ["Home dialysis therapies", "TREATMENT", 0, 23], ["HaemodiafiltrationHaemodiafiltration", "TREATMENT", 87, 123]]], ["Convective clearance allows molecules with larger molecular weight known as \"middle molecules\" to be removed.", [["Convective clearance", "PROBLEM", 0, 20]]], ["Beta 2 microglobulin is an example of a middle molecule cleared by haemodiafiltration; by comparison urea is considered a small molecule and albumin a relatively large molecule.HaemodiafiltrationClinical trials comparing outcomes of adult patients treated with conventional haemodialysis to haemodiafiltration have shown variable results.", [["urea", "CHEMICAL", 101, 105], ["urea", "CHEMICAL", 101, 105], ["Beta 2 microglobulin", "GENE_OR_GENE_PRODUCT", 0, 20], ["urea", "SIMPLE_CHEMICAL", 101, 105], ["albumin", "GENE_OR_GENE_PRODUCT", 141, 148], ["patients", "ORGANISM", 239, 247], ["Beta 2 microglobulin", "PROTEIN", 0, 20], ["albumin", "PROTEIN", 141, 148], ["patients", "SPECIES", 239, 247], ["Beta 2 microglobulin", "TEST", 0, 20], ["a middle molecule", "PROBLEM", 38, 55], ["haemodiafiltration", "TREATMENT", 67, 85], ["comparison urea", "TEST", 90, 105], ["a small molecule and albumin a relatively large molecule", "PROBLEM", 120, 176], ["Haemodiafiltration", "TREATMENT", 177, 195], ["conventional haemodialysis", "TREATMENT", 261, 287], ["haemodiafiltration", "TREATMENT", 291, 309], ["middle", "ANATOMY_MODIFIER", 40, 46], ["haemodiafiltration", "OBSERVATION", 67, 85], ["small molecule", "OBSERVATION", 122, 136], ["relatively", "OBSERVATION_MODIFIER", 151, 161], ["large", "OBSERVATION_MODIFIER", 162, 167], ["molecule", "OBSERVATION", 168, 176]]], ["An international trial in children suggested a potential cardiovascuar benefit from haemodiafiltration over conventional haemodialysis treatment.", [["children", "ORGANISM", 26, 34], ["children", "SPECIES", 26, 34], ["haemodiafiltration", "TREATMENT", 84, 102], ["conventional haemodialysis treatment", "TREATMENT", 108, 144]]], ["5 Home haemodialysis Some families are capable of training to undertake haemodialysis for their child at home.", [["Home haemodialysis", "TREATMENT", 2, 20], ["haemodialysis", "TREATMENT", 72, 85]]], ["Parents are trained by specialist paediatric dialysis nurses to deliver dialysis care, with telephone support from a home haemodialysis team.HaemodiafiltrationVarious equipment set ups are available for home haemodialysis.", [["dialysis care", "TREATMENT", 72, 85], ["Haemodiafiltration", "TREATMENT", 141, 159], ["home haemodialysis", "TREATMENT", 203, 221]]], ["In children, the NxStage system is common comprizing a simplified dialysis machine and sterile bags of dialysate fluid delivered to the patient's home.", [["children", "ORGANISM", 3, 11], ["dialysate fluid", "ORGANISM_SUBSTANCE", 103, 118], ["patient", "ORGANISM", 136, 143], ["children", "SPECIES", 3, 11], ["patient", "SPECIES", 136, 143], ["a simplified dialysis machine", "TREATMENT", 53, 82], ["sterile bags of dialysate fluid", "TREATMENT", 87, 118]]], ["For adult patients, home adaptations for water purification with standard dialysis machines can be used.SummaryKidney replacement therapy can provide lifesaving support for children with severely impaired kidney function.", [["kidney", "ANATOMY", 205, 211], ["impaired kidney function", "DISEASE", 196, 220], ["patients", "ORGANISM", 10, 18], ["children", "ORGANISM", 173, 181], ["kidney", "ORGAN", 205, 211], ["patients", "SPECIES", 10, 18], ["children", "SPECIES", 173, 181], ["home adaptations", "TREATMENT", 20, 36], ["water purification", "TREATMENT", 41, 59], ["standard dialysis machines", "TREATMENT", 65, 91], ["SummaryKidney replacement therapy", "TREATMENT", 104, 137], ["lifesaving support", "TREATMENT", 150, 168], ["severely impaired kidney function", "PROBLEM", 187, 220], ["kidney", "ANATOMY", 205, 211]]], ["Children with anuric AKI can be supported until they recover sufficient kidney function; children with ESKD can be stabilized until they can receive a kidney transplant.", [["kidney", "ANATOMY", 72, 78], ["kidney", "ANATOMY", 151, 157], ["AKI", "DISEASE", 21, 24], ["ESKD", "DISEASE", 103, 107], ["Children", "ORGANISM", 0, 8], ["kidney", "ORGAN", 72, 78], ["children", "ORGANISM", 89, 97], ["kidney", "ORGAN", 151, 157], ["Children", "SPECIES", 0, 8], ["children", "SPECIES", 89, 97], ["anuric AKI", "PROBLEM", 14, 24], ["ESKD", "PROBLEM", 103, 107], ["a kidney transplant", "TREATMENT", 149, 168], ["AKI", "OBSERVATION", 21, 24], ["kidney", "ANATOMY", 151, 157], ["transplant", "OBSERVATION", 158, 168]]], ["Acute life threateningPD in a low-birthweight babyA boy is found to have bilateral hydronephrosis and small dysplastic kidneys on antenatal ultrasound.", [["kidneys", "ANATOMY", 119, 126], ["PD", "DISEASE", 22, 24], ["hydronephrosis", "DISEASE", 83, 97], ["boy", "ORGANISM", 52, 55], ["kidneys", "ORGAN", 119, 126], ["boy", "SPECIES", 52, 55], ["Acute life threateningPD", "PROBLEM", 0, 24], ["bilateral hydronephrosis", "PROBLEM", 73, 97], ["small dysplastic kidneys", "PROBLEM", 102, 126], ["antenatal ultrasound", "TEST", 130, 150], ["bilateral", "ANATOMY_MODIFIER", 73, 82], ["hydronephrosis", "OBSERVATION", 83, 97], ["small", "OBSERVATION_MODIFIER", 102, 107], ["dysplastic", "OBSERVATION", 108, 118], ["kidneys", "ANATOMY", 119, 126]]], ["He is born at 36 weeks gestation with birthweight 2.1 kg.", [["He", "ORGANISM", 0, 2], ["birthweight", "TEST", 38, 49]]], ["He passes very little urine and develops metabolic acidosis, electrolyte disturbance with hyperkalaemia (7.6 mmol/L) and progressive uraemia (26 mmol/L) by day 5.", [["urine", "ANATOMY", 22, 27], ["metabolic acidosis", "DISEASE", 41, 59], ["electrolyte disturbance", "DISEASE", 61, 84], ["hyperkalaemia", "DISEASE", 90, 103], ["uraemia", "DISEASE", 133, 140], ["urine", "ORGANISM_SUBSTANCE", 22, 27], ["very little urine", "PROBLEM", 10, 27], ["metabolic acidosis", "PROBLEM", 41, 59], ["electrolyte disturbance", "PROBLEM", 61, 84], ["hyperkalaemia", "PROBLEM", 90, 103], ["progressive uraemia", "PROBLEM", 121, 140], ["metabolic acidosis", "OBSERVATION", 41, 59], ["progressive", "OBSERVATION_MODIFIER", 121, 132], ["uraemia", "OBSERVATION", 133, 140]]], ["A peritoneal dialysis catheter is inserted, and dialysis commenced on day 5.", [["peritoneal", "ANATOMY", 2, 12], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 2, 12], ["A peritoneal dialysis catheter", "TREATMENT", 0, 30], ["dialysis", "TREATMENT", 48, 56], ["peritoneal", "ANATOMY", 2, 12], ["dialysis catheter", "OBSERVATION", 13, 30]]], ["Plasma potassium concentration improves to 4.3 mmol/L within 3 hours of commencing peritoneal dialysis.", [["peritoneal", "ANATOMY", 83, 93], ["potassium", "CHEMICAL", 7, 16], ["potassium", "CHEMICAL", 7, 16], ["Plasma", "ORGANISM_SUBSTANCE", 0, 6], ["potassium", "SIMPLE_CHEMICAL", 7, 16], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 83, 93], ["Plasma potassium concentration", "TEST", 0, 30], ["peritoneal dialysis", "TREATMENT", 83, 102], ["peritoneal", "ANATOMY", 83, 93], ["dialysis", "OBSERVATION", 94, 102]]], ["The peritoneal dialysis prescription is progressively optimized over the subsequent four weeks.", [["peritoneal", "ANATOMY", 4, 14], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 4, 14], ["The peritoneal dialysis prescription", "TREATMENT", 0, 36], ["peritoneal", "ANATOMY", 4, 14], ["dialysis", "OBSERVATION", 15, 23]]], ["With input from the paediatric renal dietician the nutritional prescription is optimized and he starts to gain nutritional weight.", [["renal", "ANATOMY", 31, 36], ["renal", "ORGAN", 31, 36], ["renal", "ANATOMY", 31, 36]]], ["Specialist peritoneal dialysis nurses train parents to undertake dialysis at home, and he is discharged home after 8 weeks.", [["peritoneal", "ANATOMY", 11, 21], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 11, 21], ["Specialist peritoneal dialysis nurses", "TREATMENT", 0, 37], ["dialysis", "TREATMENT", 65, 73], ["peritoneal", "ANATOMY", 11, 21]]], ["He is initially reviewed weekly in the infant dialysis clinic by a specialist dialysis nurse, dietician and paediatric nephrologist.Box 5Shifting between different dialysis modalities A 4-year-old boy receiving PD for ESKD secondary to kidney dysplasia experiences recurrent Pseudomonas peritonitis.", [["kidney dysplasia", "ANATOMY", 236, 252], ["PD", "DISEASE", 211, 213], ["ESKD", "DISEASE", 218, 222], ["kidney dysplasia", "DISEASE", 236, 252], ["Pseudomonas peritonitis", "DISEASE", 275, 298], ["boy", "ORGANISM", 197, 200], ["kidney", "ORGAN", 236, 242], ["boy", "SPECIES", 197, 200], ["different dialysis modalities", "TREATMENT", 154, 183], ["PD", "TREATMENT", 211, 213], ["ESKD", "PROBLEM", 218, 222], ["kidney dysplasia", "PROBLEM", 236, 252], ["recurrent Pseudomonas peritonitis", "PROBLEM", 265, 298], ["kidney", "ANATOMY", 236, 242], ["dysplasia", "OBSERVATION", 243, 252], ["Pseudomonas", "OBSERVATION_MODIFIER", 275, 286], ["peritonitis", "OBSERVATION", 287, 298]]], ["His PD catheter is removed, and a central venous catheter inserted to establish haemodialysis.", [["venous", "ANATOMY", 42, 48], ["PD", "DISEASE", 4, 6], ["venous catheter", "MULTI-TISSUE_STRUCTURE", 42, 57], ["His PD catheter", "TREATMENT", 0, 15], ["a central venous catheter", "TREATMENT", 32, 57], ["haemodialysis", "TREATMENT", 80, 93], ["PD", "OBSERVATION_MODIFIER", 4, 6], ["catheter", "OBSERVATION", 7, 15], ["central", "ANATOMY_MODIFIER", 34, 41], ["venous", "ANATOMY", 42, 48], ["catheter", "OBSERVATION", 49, 57], ["haemodialysis", "OBSERVATION", 80, 93]]], ["His mother finds haemodialysis in the paediatric nephrology unit challenging, because this involves three four-hour sessions for three days every week, which take the entire day including travel.", [["haemodialysis", "TREATMENT", 17, 30], ["haemodialysis", "OBSERVATION", 17, 30]]], ["After discussion with the paediatric nephrologist and dialysis specialist nurses, the patient's mother is trained to undertake haemodialysis at home using a NxStage machine.", [["patient", "ORGANISM", 86, 93], ["patient", "SPECIES", 86, 93], ["haemodialysis", "TREATMENT", 127, 140], ["a NxStage machine", "TREATMENT", 155, 172]]], ["After 1 month of training, the boy is established on a home dialysis regimen of 5 sessions per week.", [["boy", "ORGANISM", 31, 34], ["training", "TREATMENT", 17, 25], ["a home dialysis regimen", "TREATMENT", 53, 76]]], ["This gives the family more time at home and allows relaxation of some dietary restrictions.Box 6SYMPOSIUM: NEPHROLOGY PAEDIATRICS AND CHILD HEALTH xxx:xxx hyperammonaemia can be rapidly controlled.", [["hyperammonaemia", "DISEASE", 155, 170], ["xxx hyperammonaemia", "PROBLEM", 151, 170], ["hyperammonaemia", "OBSERVATION", 155, 170]]], ["Kidney transplantation is the best long-term kidney replacement therapy to improve the symptoms, growth and wellbeing of children with ESKD.", [["Kidney", "ANATOMY", 0, 6], ["kidney", "ANATOMY", 45, 51], ["ESKD", "DISEASE", 135, 139], ["Kidney", "ORGAN", 0, 6], ["kidney", "ORGAN", 45, 51], ["children", "ORGANISM", 121, 129], ["children", "SPECIES", 121, 129], ["Kidney transplantation", "TREATMENT", 0, 22], ["long-term kidney replacement therapy", "TREATMENT", 35, 71], ["the symptoms", "PROBLEM", 83, 95], ["ESKD", "PROBLEM", 135, 139], ["transplantation", "OBSERVATION", 7, 22], ["long-term", "OBSERVATION_MODIFIER", 35, 44], ["kidney", "ANATOMY", 45, 51], ["replacement", "OBSERVATION", 52, 63]]], ["Early discussion with a paediatric nephrology team is advised for any child who may need kidney replacement therapy.Box 6Practice points C Kidney replacement therapy (KRT) is indicated in children whose renal function cannot adequately eliminate the byproducts of metabolism C Judicious early use of KRT may also improve the outcomes for individuals with AKI", [["kidney", "ANATOMY", 89, 95], ["renal", "ANATOMY", 203, 208], ["KRT", "CHEMICAL", 300, 303], ["AKI", "DISEASE", 355, 358], ["child", "ORGANISM", 70, 75], ["kidney", "ORGAN", 89, 95], ["children", "ORGANISM", 188, 196], ["renal", "ORGAN", 203, 208], ["KRT", "SIMPLE_CHEMICAL", 300, 303], ["children", "SPECIES", 188, 196], ["kidney replacement therapy", "TREATMENT", 89, 115], ["Box 6Practice", "TREATMENT", 116, 129], ["Kidney replacement therapy", "TREATMENT", 139, 165], ["KRT", "TREATMENT", 167, 170], ["KRT", "TREATMENT", 300, 303], ["AKI", "PROBLEM", 355, 358], ["kidney", "ANATOMY", 89, 95], ["replacement", "OBSERVATION", 96, 107], ["Kidney", "ANATOMY", 139, 145], ["replacement", "OBSERVATION", 146, 157], ["renal", "ANATOMY", 203, 208], ["AKI", "OBSERVATION", 355, 358]]]], "e3200c0afb814f23b81e5e827d5640f034533eb7": [["IntroductionCryptosporidium parvum is a ubiquitous intestinal protozoan parasite that commonly infects dairy calves in the first month of life.", [["intestinal", "ANATOMY", 51, 61], ["IntroductionCryptosporidium parvum", "DISEASE", 0, 34], ["protozoan parasite", "DISEASE", 62, 80], ["IntroductionCryptosporidium parvum", "ORGANISM", 0, 34], ["intestinal", "ORGAN", 51, 61], ["calves", "ORGANISM", 109, 115], ["IntroductionCryptosporidium parvum", "SPECIES", 0, 34], ["calves", "SPECIES", 109, 115], ["IntroductionCryptosporidium parvum", "SPECIES", 0, 34], ["IntroductionCryptosporidium parvum", "PROBLEM", 0, 34], ["a ubiquitous intestinal protozoan parasite", "PROBLEM", 38, 80], ["parvum", "OBSERVATION", 28, 34], ["intestinal", "ANATOMY", 51, 61], ["protozoan parasite", "OBSERVATION", 62, 80]]], ["Mortality may occur in severely affected animals, but, more often, a self-limiting secretory diarrhea results in morbidity and increased labour and veterinary costs (de Graaf et al., 1999) .", [["diarrhea", "DISEASE", 93, 101], ["severely affected animals", "PROBLEM", 23, 48], ["a self-limiting secretory diarrhea", "PROBLEM", 67, 101], ["morbidity", "PROBLEM", 113, 122], ["increased labour and veterinary costs", "PROBLEM", 127, 164], ["severely", "OBSERVATION_MODIFIER", 23, 31], ["increased", "OBSERVATION_MODIFIER", 127, 136], ["labour", "OBSERVATION_MODIFIER", 137, 143]]], ["Infected animals usually shed large numbers of infective oocysts in the feces (Nydam et al., 2001) .", [["feces", "ANATOMY", 72, 77], ["infective oocysts", "DISEASE", 47, 64], ["feces", "ORGANISM_SUBSTANCE", 72, 77], ["Infected animals", "PROBLEM", 0, 16], ["infective oocysts", "PROBLEM", 47, 64], ["large", "OBSERVATION_MODIFIER", 30, 35], ["numbers", "OBSERVATION_MODIFIER", 36, 43], ["infective", "OBSERVATION_MODIFIER", 47, 56], ["oocysts", "OBSERVATION", 57, 64], ["feces", "ANATOMY", 72, 77]]], ["Detection of these oocysts, or of C. parvum antigen in feces, is the usual means of diagnosis.", [["feces", "ANATOMY", 55, 60], ["C. parvum", "ORGANISM", 34, 43], ["antigen", "GENE_OR_GENE_PRODUCT", 44, 51], ["feces", "ORGANISM_SUBSTANCE", 55, 60], ["C. parvum", "SPECIES", 34, 43], ["C. parvum", "SPECIES", 34, 43], ["these oocysts", "PROBLEM", 13, 26], ["C. parvum antigen in feces", "PROBLEM", 34, 60], ["oocysts", "OBSERVATION", 19, 26]]], ["In dairy calves, the prevalence of shedding has been reported to be highest among animals 7-21 days of age, with a pre-patent period of 3-6 days (de Graaf et al., 1999) .", [["calves", "ORGANISM", 9, 15], ["calves", "SPECIES", 9, 15], ["dairy calves", "OBSERVATION", 3, 15]]], ["Studies in Canada have reported the prevalence of shedding among dairy calves 0-24 weeks of age to be 15-59% (Olson et al., 1997a,b) .", [["calves", "SPECIES", 71, 77]]], ["In another study, O'Handley et al. (1999) reported a period prevalence of shedding of 100% among dairy calves from birth to 4 months old on a farm in Alberta, Canada.", [["calves", "ORGANISM", 103, 109], ["calves", "SPECIES", 103, 109]]], ["In 2002, 40 .6% of 500 calves aged 7-21 days on 51 dairy farms in south-western Ontario were found to be shedding oocysts (Trotz-Williams et al., 2005a) .IntroductionSeveral management factors have been found to be associated with an increased risk of C. parvum shedding in dairy calves.", [["C. parvum shedding", "DISEASE", 252, 270], ["calves", "ORGANISM", 23, 29], ["C. parvum", "ORGANISM", 252, 261], ["calves", "ORGANISM_SUBDIVISION", 280, 286], ["calves", "SPECIES", 23, 29], ["C. parvum", "SPECIES", 252, 261], ["calves", "SPECIES", 280, 286], ["C. parvum", "SPECIES", 252, 261], ["C. parvum shedding in dairy calves", "PROBLEM", 252, 286], ["increased", "OBSERVATION_MODIFIER", 234, 243], ["C.", "OBSERVATION_MODIFIER", 252, 254], ["parvum shedding", "OBSERVATION", 255, 270], ["dairy calves", "OBSERVATION", 274, 286]]], ["A longitudinal study conducted in the United States (USA) found that infected calves were more likely to be found on farms using multi-cow maternity facilities than on those using single-cow facilities (Garber et al., 1994) .", [["calves", "ORGANISM", 78, 84], ["calves", "SPECIES", 78, 84], ["cow", "SPECIES", 135, 138], ["cow", "SPECIES", 135, 138], ["cow", "SPECIES", 187, 190], ["A longitudinal study", "TEST", 0, 20], ["infected calves", "PROBLEM", 69, 84], ["infected", "OBSERVATION", 69, 77]]], ["Frequent bedding changes in the calf housing area, and increased contact between calves, have also been identified as factors associated with an increased risk of C. parvum shedding in dairy calves in the USA (Sischo et al., 2000) .", [["C. parvum shedding", "DISEASE", 163, 181], ["calf", "ORGANISM_SUBDIVISION", 32, 36], ["calves", "ORGANISM", 81, 87], ["C. parvum", "ORGANISM", 163, 172], ["calves", "ORGANISM_SUBDIVISION", 191, 197], ["calf", "SPECIES", 32, 36], ["calves", "SPECIES", 81, 87], ["C. parvum", "SPECIES", 163, 172], ["calves", "SPECIES", 191, 197], ["C. parvum", "SPECIES", 163, 172], ["Frequent bedding changes", "PROBLEM", 0, 24], ["C. parvum shedding", "PROBLEM", 163, 181], ["bedding", "OBSERVATION", 9, 16], ["calf", "ANATOMY", 32, 36], ["housing", "ANATOMY_MODIFIER", 37, 44], ["increased", "OBSERVATION_MODIFIER", 55, 64], ["contact", "OBSERVATION", 65, 72], ["increased", "OBSERVATION_MODIFIER", 145, 154], ["parvum shedding", "OBSERVATION", 166, 181]]], ["Using a cross-sectional study design, Mohammed et al. (1999) found that feeding milk replacer, use of antibiotics and use of fan or exhaust ventilation in calf rearing areas were all associated with a decreased risk of shedding on dairy farms in New York State, USA.", [["milk", "ORGANISM_SUBSTANCE", 80, 84], ["calf", "ORGANISM_SUBDIVISION", 155, 159], ["calf", "SPECIES", 155, 159], ["a cross-sectional study", "TEST", 6, 29], ["feeding milk replacer", "TREATMENT", 72, 93], ["antibiotics", "TREATMENT", 102, 113], ["fan", "TREATMENT", 125, 128], ["exhaust ventilation", "TREATMENT", 132, 151], ["calf", "ANATOMY", 155, 159]]], ["In a cross-sectional study conducted in Mexico, use of hay bedding in the maternity area, sweeping the maternity area and feeding starter grain to dairy calves were identified as practices associated with increased shedding of C. parvum (Maldonado-Camargo et al., 1998) .IntroductionAlthough shedding of C. parvum, and cryptosporidiosis, are known to be common in dairy calves in Canada (Trotz-Williams et al., 2005a) , little has been published on potential risk factors for infection and neonatal diarrhea (including C. parvum-related diarrhea) in dairy calves in Canada.", [["C. parvum", "DISEASE", 304, 313], ["cryptosporidiosis", "DISEASE", 319, 336], ["infection", "DISEASE", 476, 485], ["neonatal diarrhea", "DISEASE", 490, 507], ["C. parvum", "DISEASE", 519, 528], ["diarrhea", "DISEASE", 537, 545], ["calves", "ORGANISM", 153, 159], ["C. parvum", "ORGANISM", 227, 236], ["C. parvum", "ORGANISM", 304, 313], ["calves", "ORGANISM", 370, 376], ["C. parvum", "ORGANISM", 519, 528], ["calves", "ORGANISM_SUBDIVISION", 556, 562], ["calves", "SPECIES", 153, 159], ["C. parvum", "SPECIES", 227, 236], ["C. parvum", "SPECIES", 304, 313], ["calves", "SPECIES", 370, 376], ["C. parvum", "SPECIES", 519, 528], ["calves", "SPECIES", 556, 562], ["C. parvum", "SPECIES", 227, 236], ["C. parvum", "SPECIES", 304, 313], ["C. parvum", "SPECIES", 519, 528], ["a cross-sectional study", "TEST", 3, 26], ["C. parvum", "PROBLEM", 304, 313], ["cryptosporidiosis", "PROBLEM", 319, 336], ["infection", "PROBLEM", 476, 485], ["neonatal diarrhea", "PROBLEM", 490, 507], ["C. parvum", "PROBLEM", 519, 528], ["diarrhea", "PROBLEM", 537, 545], ["C. parvum", "OBSERVATION_MODIFIER", 304, 313], ["cryptosporidiosis", "OBSERVATION", 319, 336], ["infection", "OBSERVATION", 476, 485]]], ["Moreover, it is unknown whether risk factors for C. parvum shedding and calf diarrhea identified by previous work done in Ontario or elsewhere, are associated with the risk of infection and diarrhea on Ontario dairy farms.", [["C. parvum shedding", "DISEASE", 49, 67], ["diarrhea", "DISEASE", 77, 85], ["infection", "DISEASE", 176, 185], ["diarrhea", "DISEASE", 190, 198], ["C. parvum", "ORGANISM", 49, 58], ["calf", "ORGANISM_SUBDIVISION", 72, 76], ["C. parvum", "SPECIES", 49, 58], ["calf", "SPECIES", 72, 76], ["C. parvum", "SPECIES", 49, 58], ["C. parvum shedding", "PROBLEM", 49, 67], ["calf diarrhea", "PROBLEM", 72, 85], ["infection", "PROBLEM", 176, 185], ["diarrhea", "PROBLEM", 190, 198], ["parvum", "OBSERVATION", 52, 58], ["calf", "ANATOMY", 72, 76], ["diarrhea", "OBSERVATION", 77, 85], ["infection", "OBSERVATION", 176, 185]]], ["This study was carried out with the objective of identifying potential calf-level risk factors for neonatal diarrhea and C. parvum shedding among pre-weaned dairy calves on purposively selected farms with histories of calf diarrhea or cryptosporidiosis in south-western Ontario.Sampling frame and sample size estimationThe implied sampling frame consisted of all dairy herds with a history of neonatal calf diarrhea and/or cryptosporidiosis in south-western Ontario, within 250 km of the Ontario Veterinary College, University of Guelph.Sampling frame and sample size estimationStatistical computer software (Stata 1 8.0, College Station, TX) was used to estimate the number of study units (calves) required for the comparison of two proportions reflecting exposure to risk factors.", [["diarrhea", "DISEASE", 108, 116], ["C. parvum", "DISEASE", 121, 130], ["diarrhea", "DISEASE", 223, 231], ["cryptosporidiosis", "DISEASE", 235, 252], ["calf diarrhea", "DISEASE", 402, 415], ["cryptosporidiosis", "DISEASE", 423, 440], ["calf", "ORGANISM_SUBDIVISION", 71, 75], ["C. parvum", "ORGANISM", 121, 130], ["calves", "ORGANISM", 163, 169], ["calf", "ORGANISM_SUBDIVISION", 218, 222], ["calf", "ORGANISM_SUBDIVISION", 402, 406], ["calves", "ORGANISM", 691, 697], ["calf", "SPECIES", 71, 75], ["C. parvum", "SPECIES", 121, 130], ["calves", "SPECIES", 163, 169], ["calf", "SPECIES", 218, 222], ["calf", "SPECIES", 402, 406], ["calves", "SPECIES", 691, 697], ["C. parvum", "SPECIES", 121, 130], ["This study", "TEST", 0, 10], ["neonatal diarrhea", "PROBLEM", 99, 116], ["C. parvum shedding", "PROBLEM", 121, 139], ["calf diarrhea", "PROBLEM", 218, 231], ["cryptosporidiosis", "PROBLEM", 235, 252], ["Sampling frame", "TEST", 278, 292], ["sample size estimation", "TEST", 297, 319], ["neonatal calf diarrhea", "PROBLEM", 393, 415], ["cryptosporidiosis", "PROBLEM", 423, 440], ["Sampling frame", "TEST", 537, 551], ["Stata", "TEST", 609, 614], ["TX)", "TREATMENT", 639, 642], ["risk factors", "PROBLEM", 769, 781], ["calf", "ANATOMY", 218, 222], ["diarrhea", "OBSERVATION", 223, 231], ["cryptosporidiosis", "OBSERVATION", 235, 252], ["size", "OBSERVATION_MODIFIER", 304, 308], ["calf", "ANATOMY", 402, 406], ["diarrhea", "OBSERVATION", 407, 415], ["cryptosporidiosis", "OBSERVATION", 423, 440], ["size", "OBSERVATION_MODIFIER", 563, 567]]], ["These proportions were set at 0.6 for infected calves and 0.25 in non-infected calves, respectively.", [["calves", "ORGANISM", 47, 53], ["calves", "ORGANISM", 79, 85], ["calves", "SPECIES", 47, 53], ["calves", "SPECIES", 79, 85], ["infected calves", "TREATMENT", 38, 53], ["non-infected calves", "ANATOMY", 66, 85]]], ["The estimated sample size (36 calves per group) was adjusted for a cluster size of 30 with an intra-herd correlation of 0.3, and for 10 covariates with an estimated average correlation with infection of 0.2.", [["sample", "ANATOMY", 14, 20], ["infection", "DISEASE", 190, 199], ["calves", "SPECIES", 30, 36], ["The estimated sample size", "TEST", 0, 25], ["a cluster size", "TEST", 65, 79], ["an intra-herd correlation", "TEST", 91, 116], ["infection", "PROBLEM", 190, 199], ["sample", "OBSERVATION_MODIFIER", 14, 20], ["size", "OBSERVATION_MODIFIER", 21, 25], ["size", "OBSERVATION_MODIFIER", 75, 79], ["infection", "OBSERVATION", 190, 199]]], ["This gave an estimated sample size of 990 calves (495 per group).Sampling frame and sample size estimationEstimates of the two proportions, the ratio of controls to cases, and the intra-herd correlation coefficient were based on data collected in a previous prevalence study conducted in southern Ontario in 2002 (Trotz-Williams et al., 2005a .AnimalsCalves from 0 to 30 days of age on 11 dairy farms in south-western Ontario were sampled.", [["calves", "ORGANISM", 42, 48], ["calves", "SPECIES", 42, 48], ["Calves", "SPECIES", 351, 357], ["Sampling frame", "TEST", 65, 79], ["sample size estimationEstimates", "TEST", 84, 115], ["a previous prevalence study", "TEST", 247, 274], ["size", "OBSERVATION_MODIFIER", 30, 34], ["size", "OBSERVATION_MODIFIER", 91, 95]]], ["Farms were recruited using purposive sampling, with the assistance of dairy practitioners in the area.", [["purposive sampling", "TREATMENT", 27, 45]]], ["Clients' farms with histories of calf diarrhea and or cryptosporidiosis within the previous 2 years, milking at least 60 cows and situated within 250 km of the Ontario Veterinary College (OVC), were encouraged to participate.", [["diarrhea", "DISEASE", 38, 46], ["cryptosporidiosis", "DISEASE", 54, 71], ["calf", "ORGANISM_SUBDIVISION", 33, 37], ["calf", "SPECIES", 33, 37], ["calf diarrhea", "PROBLEM", 33, 46], ["cryptosporidiosis", "PROBLEM", 54, 71], ["calf", "ANATOMY", 33, 37], ["diarrhea", "OBSERVATION", 38, 46], ["cryptosporidiosis", "OBSERVATION", 54, 71]]], ["Attempts were made to enrol all calves born on the farms during the sampling periods, up to a weekly maximum of 50 calves per farm.SamplingFrom June to October 2003 and from January to April 2004, inclusive, each farm was visited weekly by trained research technicians.", [["calves", "ORGANISM", 32, 38], ["calves", "SPECIES", 32, 38], ["calves", "SPECIES", 115, 121]]], ["At each visit, calves born since the previous visit were enrolled in the study.", [["calves", "ORGANISM", 15, 21], ["calves", "SPECIES", 15, 21], ["the study", "TEST", 69, 78]]], ["A 10 mL sample of blood was drawn from each newly enrolled calf by venepuncture: 5 mL into a sterile vacutainer containing ethylene diamine tetra-acetic acid (EDTA) and 5 mL into a vacutainer without anticoagulant (Becton Dickinson, Mississauga, Ont., Canada).", [["sample", "ANATOMY", 8, 14], ["blood", "ANATOMY", 18, 23], ["ethylene diamine tetra-acetic acid", "CHEMICAL", 123, 157], ["EDTA", "CHEMICAL", 159, 163], ["ethylene diamine tetra-acetic acid", "CHEMICAL", 123, 157], ["EDTA", "CHEMICAL", 159, 163], ["blood", "ORGANISM_SUBSTANCE", 18, 23], ["calf", "ORGANISM", 59, 63], ["ethylene diamine tetra-acetic acid", "SIMPLE_CHEMICAL", 123, 157], ["EDTA", "SIMPLE_CHEMICAL", 159, 163], ["calf", "SPECIES", 59, 63], ["A 10 mL sample of blood", "TEST", 0, 23], ["a sterile vacutainer containing ethylene diamine tetra-acetic acid (EDTA)", "TREATMENT", 91, 164], ["a vacutainer", "TREATMENT", 179, 191], ["anticoagulant", "TREATMENT", 200, 213], ["calf", "ANATOMY", 59, 63]]], ["Approximately 5 g of fresh feces were collected per rectum in a clean screw-topped vial.", [["feces", "ANATOMY", 27, 32], ["rectum", "ANATOMY", 52, 58], ["feces", "ORGANISM_SUBSTANCE", 27, 32], ["rectum", "ORGAN", 52, 58], ["fresh feces", "PROBLEM", 21, 32], ["a clean screw", "TREATMENT", 62, 75], ["rectum", "ANATOMY", 52, 58], ["clean screw", "OBSERVATION", 64, 75]]], ["Fecal samples were collected weekly on subsequent visits, to a total of four samples per calf.", [["Fecal samples", "ANATOMY", 0, 13], ["Fecal samples", "ORGANISM_SUBSTANCE", 0, 13], ["calf", "ORGANISM_SUBDIVISION", 89, 93], ["calf", "SPECIES", 89, 93], ["Fecal samples", "TEST", 0, 13], ["calf", "ANATOMY", 89, 93]]], ["The consistency of each fecal sample was recorded at the time of collection by the research technicians, using the scoring system of 1-4 described by Larson et al. (1977) .", [["fecal sample", "ANATOMY", 24, 36], ["each fecal sample", "TEST", 19, 36], ["the scoring system", "TEST", 111, 129], ["consistency", "OBSERVATION_MODIFIER", 4, 15]]], ["Scores of 3 and 4 were regarded as being indicative of diarrhea, while scores of 1 and 2 reflected normal fecal consistency.", [["fecal", "ANATOMY", 106, 111], ["diarrhea", "DISEASE", 55, 63], ["fecal", "ORGANISM_SUBSTANCE", 106, 111], ["Scores", "TEST", 0, 6], ["diarrhea", "PROBLEM", 55, 63], ["diarrhea", "OBSERVATION", 55, 63], ["fecal consistency", "OBSERVATION", 106, 123]]], ["If an attempt to collect feces per rectum was unsuccessful and calves were housed individually, a fresh sample was taken from the ground where available.Testing of samplesBlood and fecal samples were transported to the OVC in coolers, and were then refrigerated at 4 8C until processed.", [["rectum", "ANATOMY", 35, 41], ["sample", "ANATOMY", 104, 110], ["samples", "ANATOMY", 164, 171], ["Blood", "ANATOMY", 171, 176], ["fecal samples", "ANATOMY", 181, 194], ["OVC", "ANATOMY", 219, 222], ["feces", "ORGANISM_SUBDIVISION", 25, 30], ["rectum", "ORGAN", 35, 41], ["calves", "ORGANISM", 63, 69], ["samples", "ORGANISM_SUBSTANCE", 164, 171], ["Blood", "ORGANISM_SUBSTANCE", 171, 176], ["fecal samples", "ORGANISM_SUBSTANCE", 181, 194], ["calves", "SPECIES", 63, 69], ["calves", "SPECIES", 63, 69], ["a fresh sample", "TEST", 96, 110], ["Testing of samples", "TEST", 153, 171], ["Blood", "TEST", 171, 176], ["fecal samples", "TEST", 181, 194], ["rectum", "ANATOMY", 35, 41], ["fecal", "ANATOMY", 181, 186]]], ["Serum was separated from each blood sample within 24 h of collection, and was used to assess passive transfer of maternal immunity by total serum protein refractometry (Calloway et al., 2002) as well as by using an automated serum analyzer (Hitachi Ltd., Hitachinaka, Japan).", [["Serum", "ANATOMY", 0, 5], ["blood sample", "ANATOMY", 30, 42], ["serum", "ANATOMY", 140, 145], ["serum", "ANATOMY", 225, 230], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["blood", "ORGANISM_SUBSTANCE", 30, 35], ["serum", "ORGANISM_SUBSTANCE", 140, 145], ["serum", "ORGANISM_SUBSTANCE", 225, 230], ["Serum", "TEST", 0, 5], ["blood sample", "TEST", 30, 42], ["total serum protein refractometry", "TEST", 134, 167], ["an automated serum analyzer", "TEST", 212, 239], ["Hitachi Ltd.", "TEST", 241, 253]]], ["One milliliter aliquots of blood from the EDTA vacutainers were frozen at \u00c070 8C and were subsequently tested for persistent bovine viral diarrhea virus (BVDV) infection by polymerase chain reaction (PCR), using the protocol described by Deregt et al. (2002) .Testing of samplesFecal samples were examined for the presence of C. parvum oocysts using a standardized sucrose wet mount method.", [["blood", "ANATOMY", 27, 32], ["Fecal samples", "ANATOMY", 278, 291], ["bovine viral diarrhea virus (BVDV) infection", "DISEASE", 125, 169], ["sucrose", "CHEMICAL", 365, 372], ["EDTA", "CHEMICAL", 42, 46], ["sucrose", "CHEMICAL", 365, 372], ["blood", "ORGANISM_SUBSTANCE", 27, 32], ["bovine viral diarrhea virus", "ORGANISM", 125, 152], ["BVDV", "ORGANISM", 154, 158], ["Fecal samples", "ORGANISM_SUBSTANCE", 278, 291], ["parvum", "ORGANISM", 329, 335], ["bovine", "SPECIES", 125, 131], ["viral diarrhea virus", "SPECIES", 132, 152], ["C. parvum", "SPECIES", 326, 335], ["bovine viral diarrhea virus", "SPECIES", 125, 152], ["BVDV", "SPECIES", 154, 158], ["C. parvum", "SPECIES", 326, 335], ["the EDTA vacutainers", "TREATMENT", 38, 58], ["persistent bovine viral diarrhea virus", "PROBLEM", 114, 152], ["BVDV) infection", "PROBLEM", 154, 169], ["polymerase chain reaction", "PROBLEM", 173, 198], ["PCR", "TEST", 200, 203], ["the protocol", "TREATMENT", 212, 224], ["Testing of samplesFecal samples", "TEST", 260, 291], ["C. parvum oocysts", "PROBLEM", 326, 343], ["a standardized sucrose wet mount method", "TREATMENT", 350, 389], ["persistent", "OBSERVATION_MODIFIER", 114, 124], ["bovine viral", "OBSERVATION", 125, 137], ["diarrhea virus", "OBSERVATION", 138, 152], ["parvum oocysts", "OBSERVATION", 329, 343]]], ["Using polymerase chain reaction-restriction fragment length polymorphism of the Cryptosporidium oocyst wall protein as a gold standard, this test showed a sensitivity of 88.6% (95% confidence interval (CI) 80.1%, 94.4%) and a specificity of 93.8% (95% CI 86.0%, 97.9%) when used on 168 calf fecal specimens (Trotz-Williams et al., 2005b) .", [["fecal specimens", "ANATOMY", 291, 306], ["calf", "ORGANISM", 286, 290], ["fecal specimens", "ORGANISM_SUBSTANCE", 291, 306], ["Cryptosporidium oocyst wall protein", "PROTEIN", 80, 115], ["calf", "SPECIES", 286, 290], ["polymerase chain reaction", "PROBLEM", 6, 31], ["restriction fragment length polymorphism", "PROBLEM", 32, 72], ["the Cryptosporidium oocyst wall protein", "PROBLEM", 76, 115], ["this test", "TEST", 136, 145], ["a sensitivity", "TEST", 153, 166], ["CI", "TEST", 202, 204], ["a specificity", "TEST", 224, 237], ["CI", "TEST", 252, 254], ["calf fecal specimens", "TEST", 286, 306], ["fragment", "OBSERVATION_MODIFIER", 44, 52], ["length", "OBSERVATION_MODIFIER", 53, 59], ["Cryptosporidium", "OBSERVATION_MODIFIER", 80, 95], ["oocyst", "OBSERVATION_MODIFIER", 96, 102], ["wall", "ANATOMY_MODIFIER", 103, 107]]], ["Briefly, 1 g of feces was mixed with 3 mL of sucrose solution of specific gravity 1.32.", [["feces", "ANATOMY", 16, 21], ["sucrose", "CHEMICAL", 45, 52], ["sucrose", "CHEMICAL", 45, 52], ["feces", "ORGANISM_SUBSTANCE", 16, 21], ["sucrose solution", "TREATMENT", 45, 61], ["specific gravity", "TEST", 65, 81]]], ["One drop of the resulting fecal suspension was placed on a slide, covered with a 22 mm \u00c2 22 mm coverslip, and examined at \u00c2400 magnification using bright field optical microscopy.", [["fecal", "ANATOMY", 26, 31], ["fecal", "ORGANISM_SUBSTANCE", 26, 31], ["the resulting fecal suspension", "TREATMENT", 12, 42], ["a 22 mm \u00c2 22 mm coverslip", "TREATMENT", 79, 104], ["bright field optical microscopy", "TEST", 147, 178], ["drop", "OBSERVATION_MODIFIER", 4, 8], ["fecal suspension", "OBSERVATION", 26, 42]]], ["C. parvum oocysts were identified as pink, refractile, spherical structures 3-6 mm in diameter situated just beneath the coverslip.", [["oocysts", "ANATOMY", 10, 17], ["C. parvum", "ORGANISM", 0, 9], ["oocysts", "ORGANISM", 10, 17], ["C. parvum", "SPECIES", 0, 9], ["C. parvum", "SPECIES", 0, 9], ["C. parvum oocysts", "PROBLEM", 0, 17], ["parvum oocysts", "OBSERVATION", 3, 17], ["pink", "OBSERVATION_MODIFIER", 37, 41], ["refractile", "OBSERVATION_MODIFIER", 43, 53], ["spherical", "OBSERVATION_MODIFIER", 55, 64], ["structures", "OBSERVATION_MODIFIER", 65, 75], ["3-6 mm", "OBSERVATION_MODIFIER", 76, 82], ["diameter", "OBSERVATION_MODIFIER", 86, 94], ["coverslip", "ANATOMY_MODIFIER", 121, 130]]], ["The average number of oocysts per microscope field was used to estimate the number of oocysts per gram of feces (Trotz-Williams et al., 2005b) .Testing of samplesFecal samples from a specific subset of calves were tested at the University of Guelph Animal Health Laboratory (AHL) for infection with enterotoxigenic Escherichia coli (ETEC), Salmonella spp., bovine rotavirus (BRV) group A and bovine coronavirus (BCV).", [["Fecal samples", "ANATOMY", 162, 175], ["infection", "DISEASE", 284, 293], ["enterotoxigenic Escherichia coli", "DISEASE", 299, 331], ["bovine rotavirus (BRV) group A", "DISEASE", 357, 387], ["feces", "ORGANISM_SUBSTANCE", 106, 111], ["Fecal samples", "CANCER", 162, 175], ["calves", "ORGANISM", 202, 208], ["enterotoxigenic Escherichia coli", "ORGANISM", 299, 331], ["ETEC", "ORGANISM", 333, 337], ["Salmonella spp.", "ORGANISM", 340, 355], ["bovine rotavirus", "ORGANISM", 357, 373], ["bovine coronavirus", "ORGANISM", 392, 410], ["BCV", "ORGANISM", 412, 415], ["calves", "SPECIES", 202, 208], ["Escherichia coli", "SPECIES", 315, 331], ["Salmonella spp.", "SPECIES", 340, 355], ["bovine", "SPECIES", 357, 363], ["rotavirus", "SPECIES", 364, 373], ["bovine", "SPECIES", 392, 398], ["coronavirus", "SPECIES", 399, 410], ["Escherichia coli", "SPECIES", 315, 331], ["ETEC", "SPECIES", 333, 337], ["Salmonella spp.", "SPECIES", 340, 355], ["bovine", "SPECIES", 357, 363], ["BRV", "SPECIES", 375, 378], ["bovine coronavirus", "SPECIES", 392, 410], ["BCV", "SPECIES", 412, 415], ["Testing of samples", "TEST", 144, 162], ["Fecal samples", "TEST", 162, 175], ["infection", "PROBLEM", 284, 293], ["enterotoxigenic Escherichia coli", "PROBLEM", 299, 331], ["Salmonella spp.", "PROBLEM", 340, 355], ["bovine rotavirus (BRV) group A and bovine coronavirus", "PROBLEM", 357, 410], ["average", "OBSERVATION_MODIFIER", 4, 11], ["number", "OBSERVATION_MODIFIER", 12, 18], ["oocysts", "OBSERVATION", 22, 29], ["oocysts", "OBSERVATION", 86, 93], ["Escherichia coli", "OBSERVATION", 315, 331]]], ["Calves were selected for these tests using the two-stage sampling procedure described by Schaubel et al. (1997) .", [["Calves", "ORGANISM", 0, 6], ["Calves", "SPECIES", 0, 6], ["these tests", "TEST", 25, 36], ["the two-stage sampling procedure", "TREATMENT", 43, 75]]], ["Briefly, data from an earlier prevalence study (Trotz-Williams et al., 2005a) were used to assess the relationship between C. parvum shedding and diarrhea.", [["C. parvum shedding", "DISEASE", 123, 141], ["diarrhea", "DISEASE", 146, 154], ["C. parvum", "ORGANISM", 123, 132], ["C. parvum", "SPECIES", 123, 132], ["C. parvum", "SPECIES", 123, 132], ["an earlier prevalence study", "TEST", 19, 46], ["C. parvum shedding", "PROBLEM", 123, 141], ["diarrhea", "PROBLEM", 146, 154], ["parvum", "OBSERVATION", 126, 132]]], ["This information was used to determine the proportion of exposed (C. parvum infected) and diseased (diarrheic) calves that would be selected for bacteriological and virology testing.", [["C. parvum infected", "DISEASE", 66, 84], ["C. parvum", "ORGANISM", 66, 75], ["calves", "ORGANISM", 111, 117], ["C. parvum", "SPECIES", 66, 75], ["calves", "SPECIES", 111, 117], ["C. parvum", "SPECIES", 66, 75], ["diseased (diarrheic) calves", "PROBLEM", 90, 117], ["bacteriological and virology testing", "TEST", 145, 181]]], ["Random systematic sampling was then used to select fecal samples taken in the first week of life for ETEC and Salmonella tests, and specimens from calves 7 to 14 days old for BRV and BCV tests.Testing of samplesTesting for ETEC and Salmonella was performed at the AHL by standard culture methods, with bacterial isolates being identified using a semi-automated bacterial identification system (Replianalyzer, Oxoid, Nepean, Ont., Canada).Testing of samplesTesting for bovine rotavirus was carried out at the AHL using a latex agglutination test (Rotascreen 1 , Microgen Bioproducts, Surrey, UK).", [["fecal samples", "ANATOMY", 51, 64], ["specimens", "ANATOMY", 132, 141], ["samples", "ANATOMY", 204, 211], ["samples", "ANATOMY", 449, 456], ["calves", "ORGANISM", 147, 153], ["ETEC", "GENE_OR_GENE_PRODUCT", 223, 227], ["bovine", "ORGANISM", 468, 474], ["rotavirus", "ORGANISM", 475, 484], ["calves", "SPECIES", 147, 153], ["bovine", "SPECIES", 468, 474], ["ETEC", "SPECIES", 101, 105], ["Salmonella", "SPECIES", 110, 120], ["BRV", "SPECIES", 175, 178], ["BCV", "SPECIES", 183, 186], ["ETEC", "SPECIES", 223, 227], ["Salmonella", "SPECIES", 232, 242], ["bovine", "SPECIES", 468, 474], ["rotavirus", "SPECIES", 475, 484], ["Random systematic sampling", "TEST", 0, 26], ["fecal samples", "TEST", 51, 64], ["ETEC", "PROBLEM", 101, 105], ["Salmonella tests", "TEST", 110, 126], ["specimens", "TEST", 132, 141], ["BRV and BCV tests", "TEST", 175, 192], ["Testing of samples", "TEST", 193, 211], ["ETEC", "PROBLEM", 223, 227], ["Salmonella", "PROBLEM", 232, 242], ["standard culture methods", "TEST", 271, 295], ["bacterial isolates", "PROBLEM", 302, 320], ["Oxoid", "TREATMENT", 409, 414], ["Nepean", "TREATMENT", 416, 422], ["Testing of samples", "TEST", 438, 456], ["Testing", "TEST", 456, 463], ["bovine rotavirus", "PROBLEM", 468, 484], ["a latex agglutination test", "TEST", 518, 544], ["Rotascreen", "TEST", 546, 556]]], ["An antigen detection ELISA (Syracuse Bioanalytical, Syracuse, New York) was employed for detection of bovine coronavirus.QuestionnaireA pre-tested questionnaire was administered to collect information on the management of each calf immediately after birth and for the first 4 weeks thereafter.", [["bovine coronavirus", "DISEASE", 102, 120], ["bovine", "ORGANISM", 102, 108], ["coronavirus", "ORGANISM", 109, 120], ["calf", "ORGANISM_SUBDIVISION", 227, 231], ["bovine", "SPECIES", 102, 108], ["calf", "SPECIES", 227, 231], ["bovine coronavirus", "SPECIES", 102, 120], ["bovine coronavirus", "PROBLEM", 102, 120], ["bovine coronavirus", "OBSERVATION", 102, 120], ["calf", "ANATOMY", 227, 231]]], ["Copies of questionnaires were distributed by research technicians and were completed on farm by producers, one following the birth of each calf.", [["calf", "ORGANISM_SUBDIVISION", 139, 143], ["calf", "SPECIES", 139, 143], ["calf", "ANATOMY", 139, 143]]], ["At the time of completion of each questionnaire, producers were blind to the status (shedding or non-shedding) of the calf for which information was being recorded.", [["calf", "ORGANISM_SUBDIVISION", 118, 122], ["calf", "SPECIES", 118, 122], ["calf", "ANATOMY", 118, 122]]], ["Questions were designed to gather information on management practices reported in the literature as significantly associated with the risk of C. parvum shedding, as well as other factors considered by the authors to be potential predictors of the risk of shedding or calf diarrhea.", [["C. parvum shedding", "DISEASE", 142, 160], ["diarrhea", "DISEASE", 272, 280], ["C. parvum", "ORGANISM", 142, 151], ["calf", "ORGANISM_SUBDIVISION", 267, 271], ["C. parvum", "SPECIES", 142, 151], ["calf", "SPECIES", 267, 271], ["C. parvum", "SPECIES", 142, 151], ["management practices", "TREATMENT", 49, 69], ["C. parvum shedding", "PROBLEM", 142, 160], ["shedding", "PROBLEM", 255, 263], ["calf diarrhea", "PROBLEM", 267, 280], ["parvum", "OBSERVATION", 145, 151], ["calf", "ANATOMY", 267, 271], ["diarrhea", "OBSERVATION", 272, 280]]], ["Examples of factors investigated were ease of birth, amount of time for which the calf had remained with its dam after birth, calving area hygiene, quantity and source of colostrum fed, preventive procedures performed on the neonatal calf such as vaccination and navel-dipping, and type of housing in which the calf was kept for the first 4 weeks of life.", [["calf", "ORGANISM", 82, 86], ["colostrum", "ORGANISM", 171, 180], ["calf", "ORGANISM_SUBDIVISION", 234, 238], ["navel", "ORGANISM_SUBDIVISION", 263, 268], ["calf", "ORGANISM", 311, 315], ["calf", "SPECIES", 82, 86], ["calf", "SPECIES", 234, 238], ["calf", "SPECIES", 311, 315], ["colostrum fed", "TREATMENT", 171, 184], ["preventive procedures", "TREATMENT", 186, 207], ["the neonatal calf", "TREATMENT", 221, 238], ["vaccination", "TREATMENT", 247, 258], ["navel", "TREATMENT", 263, 268], ["calf", "ANATOMY", 82, 86], ["neonatal calf", "ANATOMY", 225, 238], ["calf", "ANATOMY", 311, 315]]], ["A copy of the questionnaire used for this study is available from the authors in English.Statistical analysisData were entered in EpiData 3.02 (EpiData Association, Odense, Denmark) and were exported from EpiData into Stata 9.0 (Stata Corporation, College Station, TX) for screening of variables and analysis.", [["this study", "TEST", 37, 47], ["Statistical analysisData", "TEST", 89, 113], ["screening of variables", "TEST", 273, 295], ["analysis", "TEST", 300, 308]]], ["Variables were screened for associations with C. parvum shedding and diarrhea by unvariable multilevel generalized linear mixed modelling, using the ''GLLAMM'' function in Stata 9.0 with a liberal P-value (0.25).", [["C. parvum shedding", "DISEASE", 46, 64], ["diarrhea", "DISEASE", 69, 77], ["C. parvum", "ORGANISM", 46, 55], ["C. parvum", "SPECIES", 46, 55], ["C. parvum", "SPECIES", 46, 55], ["C. parvum shedding", "PROBLEM", 46, 64], ["diarrhea", "PROBLEM", 69, 77], ["unvariable multilevel generalized linear mixed modelling", "PROBLEM", 81, 137], ["Stata", "TEST", 172, 177], ["a liberal P-value", "TEST", 187, 204], ["linear", "OBSERVATION_MODIFIER", 115, 121], ["mixed", "OBSERVATION_MODIFIER", 122, 127]]], ["This approach was employed to control for clustering at the herd-level, and repeated observations at the calf-level.", [["calf", "ORGANISM_SUBDIVISION", 105, 109], ["calf", "SPECIES", 105, 109], ["This approach", "TREATMENT", 0, 13], ["calf", "ANATOMY", 105, 109]]], ["During screening, the dependent (outcome) variable used to represent the risk of C. parvum shedding was a dichotomous variable representing the positive or negative status of each fecal specimen.", [["fecal specimen", "ANATOMY", 180, 194], ["C. parvum", "ORGANISM", 81, 90], ["fecal specimen", "MULTI-TISSUE_STRUCTURE", 180, 194], ["C. parvum", "SPECIES", 81, 90], ["C. parvum", "SPECIES", 81, 90], ["screening", "TEST", 7, 16], ["C. parvum shedding", "PROBLEM", 81, 99], ["each fecal specimen", "TEST", 175, 194], ["parvum shedding", "OBSERVATION", 84, 99]]], ["Similarly, the dependent variable used to represent the risk of diarrhea was the diarrheic or nondiarrheic status of individual fecal specimens, with specimens having consistency scores of 3 or 4 classified as diarrheic.", [["fecal specimens", "ANATOMY", 128, 143], ["specimens", "ANATOMY", 150, 159], ["diarrhea", "DISEASE", 64, 72], ["diarrheic", "DISEASE", 81, 90], ["diarrheic", "DISEASE", 210, 219], ["fecal specimens", "ORGANISM_SUBSTANCE", 128, 143], ["diarrhea", "PROBLEM", 64, 72], ["the diarrheic", "PROBLEM", 77, 90], ["individual fecal specimens", "TEST", 117, 143], ["consistency scores", "TEST", 167, 185], ["diarrheic", "PROBLEM", 210, 219], ["diarrhea", "OBSERVATION", 64, 72]]], ["The intra-class correlation of C. parvum shedding was estimated using a one-way analysis of variance approach with the 'loneway' command in Stata 9.0.", [["C. parvum", "ORGANISM", 31, 40], ["C. parvum", "SPECIES", 31, 40], ["C. parvum", "SPECIES", 31, 40], ["C. parvum shedding", "PROBLEM", 31, 49], ["Stata", "TEST", 140, 145], ["parvum", "OBSERVATION_MODIFIER", 34, 40]]], ["Collinearity between variables was investigated by examination of covariance matrices, and where necessary by cross-tabulations, comprising groups of variables.Statistical analysisVariables that were significant at the 25% level in univariable screening were used to build multivariable multilevel generalized linear mixed models using the ''GLLAMM'' command in Stata 9.0.", [["Collinearity between variables", "PROBLEM", 0, 30], ["examination of covariance matrices", "TEST", 51, 85], ["Statistical analysisVariables", "TEST", 160, 189], ["univariable screening", "TEST", 232, 253], ["multivariable multilevel generalized linear mixed models", "PROBLEM", 273, 329], ["Stata", "TEST", 362, 367], ["significant", "OBSERVATION_MODIFIER", 200, 211], ["multilevel", "OBSERVATION_MODIFIER", 287, 297], ["generalized", "OBSERVATION_MODIFIER", 298, 309], ["linear", "OBSERVATION_MODIFIER", 310, 316]]], ["As in univariable modelling, C. parvum shedding status, and diarrhea status of calves at individual weekly sampling times, were used as response variables in modelling risk of shedding and risk of diarrhea, respectively.", [["diarrhea", "DISEASE", 60, 68], ["diarrhea", "DISEASE", 197, 205], ["C. parvum", "ORGANISM", 29, 38], ["calves", "ORGANISM", 79, 85], ["C. parvum", "SPECIES", 29, 38], ["calves", "SPECIES", 79, 85], ["C. parvum", "SPECIES", 29, 38], ["C. parvum shedding status", "PROBLEM", 29, 54], ["diarrhea", "PROBLEM", 60, 68], ["shedding", "PROBLEM", 176, 184], ["diarrhea", "PROBLEM", 197, 205], ["parvum", "OBSERVATION_MODIFIER", 32, 38]]], ["Where variables were not mutually exclusive and were highly correlated, only one of the related variables was included in model-building, the decision of which to include being made on the basis of distribution and biological plausibility.", [["biological plausibility", "OBSERVATION", 215, 238]]], ["Models were built by the manual backwards elimination procedure described by Dohoo et al. (2003) with a significance level of P > 0.05 as the criterion for removal of a variable from the model.", [["the manual backwards elimination procedure", "TREATMENT", 21, 63], ["P", "TEST", 126, 127], ["removal", "TREATMENT", 156, 163]]], ["The statistical significance of continuous and dichotomous variables in each model was assessed using Wald's test, and the likelihood ratio test was used to determine the significance of multilevel categorical predictors.", [["continuous and dichotomous variables", "PROBLEM", 32, 68], ["Wald's test", "TEST", 102, 113], ["the likelihood ratio test", "TEST", 119, 144], ["multilevel categorical predictors", "PROBLEM", 187, 220]]], ["During the model-building process, whether or not a predictor was a confounder was determined by removing the variable and observing the effect on the coefficients of the remaining significant variables; a change of more than 25% in one or more coefficients was regarded as evidence of confounding (Dohoo et al., 2003) .", [["significant", "OBSERVATION_MODIFIER", 181, 192]]], ["A P-value of less than 0.05 associated with an interaction term was considered evidence of interaction.Statistical analysisModel diagnostics were performed by generating and examining expected values (probabilities) of the outcome, Pearson residuals, deviance residuals and Cook's distance values.Statistical analysisTo explore whether calves born in the summer may have been managed differently from those born in the winter, management variables were regressed on season of calf's birth using logistic modelling, with farm included as a random effect.", [["calves", "ORGANISM", 336, 342], ["calf", "ORGANISM_SUBDIVISION", 476, 480], ["calves", "SPECIES", 336, 342], ["calf", "SPECIES", 476, 480], ["A P-value", "TEST", 0, 9], ["Statistical analysisModel diagnostics", "TEST", 103, 140], ["Pearson residuals", "TEST", 232, 249], ["deviance residuals", "TEST", 251, 269], ["Cook's distance values", "TEST", 274, 296], ["Statistical analysis", "TEST", 297, 317], ["logistic modelling", "TREATMENT", 495, 513]]], ["This showed that differences significant at the 5% level existed between summer and winter born calves with reference to several management practices.", [["calves", "ORGANISM", 96, 102], ["calves", "SPECIES", 96, 102], ["several management practices", "TREATMENT", 121, 149], ["differences", "OBSERVATION_MODIFIER", 17, 28], ["significant", "OBSERVATION_MODIFIER", 29, 40]]], ["To control for these differences, season of birth was forced into the multilevel models previously described.Statistical analysisIn order to extrapolate the data on bacterial and viral enteropatogens recorded for a subset of the calves, the method described by Cain and Breslow (1988) was used to adjust the regression coefficient representing the relationship between the overall C. parvum shedding status of calves and diarrhea, in a logistic model including all enteropathogens as fixed effects and farm as a random effect.", [["diarrhea", "DISEASE", 421, 429], ["calves", "ORGANISM", 229, 235], ["C. parvum", "ORGANISM", 381, 390], ["calves", "ORGANISM", 410, 416], ["calves", "SPECIES", 229, 235], ["C. parvum", "SPECIES", 381, 390], ["calves", "SPECIES", 410, 416], ["C. parvum", "SPECIES", 381, 390], ["bacterial and viral enteropatogens", "PROBLEM", 165, 199], ["diarrhea", "PROBLEM", 421, 429], ["a logistic model", "TREATMENT", 434, 450], ["calves", "ANATOMY", 229, 235], ["parvum", "OBSERVATION", 384, 390]]], ["The same method was used to adjust the standard error of that coefficient.", [["The same method", "TREATMENT", 0, 15]]], ["Briefly, the unadjusted coefficient was adjusted using the formula:Statistical analysiswhere N 01 , N 11 , N 02 , N 12 , n 01 , n 11 , n 02 and n 12 refer to the numbers of calves in subsets of the first (N) and second (n) stage of the study population, respectively.", [["calves", "ORGANISM", 173, 179], ["calves", "SPECIES", 173, 179], ["N", "TEST", 100, 101], ["N", "TEST", 107, 108], ["N", "TEST", 114, 115], ["n", "TEST", 121, 122], ["n", "TEST", 128, 129], ["n 02", "TEST", 135, 139], ["the study population", "TEST", 232, 252]]], ["Subsets were defined by C. parvum (i) and diarrhea (j) status.ResultsFecal samples were collected from 1045 calves on the 11 farms.", [["ResultsFecal samples", "ANATOMY", 62, 82], ["diarrhea", "DISEASE", 42, 50], ["C. parvum", "ORGANISM", 24, 33], ["ResultsFecal samples", "CANCER", 62, 82], ["calves", "ORGANISM", 108, 114], ["C. parvum", "SPECIES", 24, 33], ["calves", "SPECIES", 108, 114], ["C. parvum", "SPECIES", 24, 33], ["diarrhea", "PROBLEM", 42, 50], ["ResultsFecal samples", "TEST", 62, 82]]], ["The number of calves per farm enrolled in the study ranged from 4 to 521 (median 32).ResultsFor 126 calves, data on C. parvum status were missing for one or more of the 4 weeks.", [["calves", "ORGANISM", 14, 20], ["calves", "ORGANISM", 100, 106], ["C. parvum", "ORGANISM", 116, 125], ["calves", "SPECIES", 14, 20], ["calves", "SPECIES", 100, 106], ["C. parvum", "SPECIES", 116, 125], ["C. parvum", "SPECIES", 116, 125], ["the study", "TEST", 42, 51], ["C. parvum status", "PROBLEM", 116, 132], ["number", "OBSERVATION_MODIFIER", 4, 10], ["calves", "OBSERVATION", 14, 20]]], ["Reasons for missing data included difficulties locating calves during a farm visit, removal of calves from farms (sale or transfer) and death of calves.", [["death", "DISEASE", 136, 141], ["calves", "ORGANISM", 56, 62], ["calves", "ORGANISM_SUBDIVISION", 95, 101], ["calves", "ORGANISM", 145, 151], ["calves", "SPECIES", 56, 62], ["calves", "SPECIES", 95, 101], ["calves", "SPECIES", 145, 151], ["missing data", "PROBLEM", 12, 24], ["difficulties locating calves", "PROBLEM", 34, 62], ["removal of calves", "TREATMENT", 84, 101], ["calves", "ANATOMY", 145, 151]]], ["There was no significant difference in the risk of shedding or diarrhea between these calves and the calves for which data was available for all 4 weeks.", [["diarrhea", "DISEASE", 63, 71], ["calves", "ORGANISM", 86, 92], ["calves", "ORGANISM", 101, 107], ["calves", "SPECIES", 86, 92], ["calves", "SPECIES", 101, 107], ["shedding", "PROBLEM", 51, 59], ["diarrhea between these calves and the calves", "PROBLEM", 63, 107], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35], ["diarrhea", "OBSERVATION", 63, 71], ["calves", "ANATOMY", 86, 92], ["calves", "ANATOMY", 101, 107]]], ["In addition, examination of the data showed no significant difference in management for the two sets of calves.", [["calves", "ORGANISM", 104, 110], ["calves", "SPECIES", 104, 110], ["examination of the data", "TEST", 13, 36], ["significant difference in management", "PROBLEM", 47, 83], ["no", "UNCERTAINTY", 44, 46], ["significant", "OBSERVATION_MODIFIER", 47, 58], ["difference", "OBSERVATION", 59, 69], ["calves", "ANATOMY", 104, 110]]], ["Of the 919 calves for which no data were missing, 721 (78%) tested positive for C. parvum at one or more sampling times.", [["calves", "ORGANISM", 11, 17], ["C. parvum", "ORGANISM", 80, 89], ["calves", "SPECIES", 11, 17], ["C. parvum", "SPECIES", 80, 89], ["C. parvum", "SPECIES", 80, 89], ["C. parvum", "PROBLEM", 80, 89], ["parvum", "OBSERVATION", 83, 89]]], ["Oocysts were detected in fecal samples of calves from all of the 11 farms.", [["Oocysts", "ANATOMY", 0, 7], ["fecal samples", "ANATOMY", 25, 38], ["Oocysts", "GENE_OR_GENE_PRODUCT", 0, 7], ["fecal samples", "ORGANISM_SUBSTANCE", 25, 38], ["calves", "ORGANISM", 42, 48], ["calves", "SPECIES", 42, 48], ["Oocysts", "PROBLEM", 0, 7]]], ["Within-herd prevalence of shedding ranged from 35% to 100%.", [["shedding", "PROBLEM", 26, 34]]], ["Calves under 1 week old were least likely to be shedding C. parvum oocysts (prevalence = 5%), while calves aged 7-14 days had the highest prevalence (53%) of shedding.", [["C. parvum oocysts", "DISEASE", 57, 74], ["Calves", "ORGANISM", 0, 6], ["C. parvum", "ORGANISM", 57, 66], ["oocysts", "ORGANISM", 67, 74], ["calves", "ORGANISM", 100, 106], ["Calves", "SPECIES", 0, 6], ["C. parvum", "SPECIES", 57, 66], ["calves", "SPECIES", 100, 106], ["C. parvum", "SPECIES", 57, 66], ["shedding C. parvum oocysts", "PROBLEM", 48, 74], ["likely to be", "UNCERTAINTY", 35, 47], ["parvum oocysts", "OBSERVATION", 60, 74]]], ["Shedding of oocysts was moderately clustered within herds; the intra-class correlation coefficient (rho) for shedding was 0.4.ResultsFor 199 calves, data on consistency of one or more fecal sample were missing.", [["oocysts", "ANATOMY", 12, 19], ["fecal sample", "ANATOMY", 184, 196], ["calves", "ORGANISM", 141, 147], ["calves", "SPECIES", 141, 147], ["oocysts", "PROBLEM", 12, 19], ["shedding", "PROBLEM", 109, 117], ["oocysts", "OBSERVATION", 12, 19], ["moderately", "OBSERVATION_MODIFIER", 24, 34]]], ["Reasons for this were similar to those stated for missing C. parvum data.", [["C. parvum", "SPECIES", 58, 67], ["C. parvum", "SPECIES", 58, 67], ["missing C. parvum data", "PROBLEM", 50, 72]]], ["Of the remaining 846 animals, 619 (73%) were diarrheic at the time of collection of at least one sample.", [["diarrheic", "DISEASE", 45, 54], ["diarrheic", "PROBLEM", 45, 54]]], ["Scouring was most prevalent in calves at the time of the second sampling (aged 7-14 days) and was least prevalent in calves less than 1 week old; samples from 47% of calves aged 7-14 days were scored as 3 or 4, while only 15% of calves under 1 week old were diarrheic at the time of sampling.ResultsThe prevalence of bacterial and viral enteropathogens is summarized in Table 1 .", [["samples", "ANATOMY", 146, 153], ["diarrheic", "DISEASE", 258, 267], ["bacterial and viral enteropathogens", "DISEASE", 317, 352], ["calves", "ORGANISM", 31, 37], ["calves", "ORGANISM", 117, 123], ["calves", "ORGANISM", 166, 172], ["calves", "ORGANISM", 229, 235], ["calves", "SPECIES", 31, 37], ["calves", "SPECIES", 117, 123], ["calves", "SPECIES", 166, 172], ["calves", "SPECIES", 229, 235], ["the second sampling", "TEST", 53, 72], ["samples", "TEST", 146, 153], ["calves", "TEST", 166, 172], ["diarrheic", "PROBLEM", 258, 267], ["sampling", "TEST", 283, 291], ["bacterial and viral enteropathogens", "PROBLEM", 317, 352], ["most prevalent", "OBSERVATION_MODIFIER", 13, 27], ["bacterial", "OBSERVATION_MODIFIER", 317, 326], ["viral enteropathogens", "OBSERVATION", 331, 352]]], ["Table 2a shows the results of unconditional screening of predictor variables for association with C. parvum shedding.Predictor variables associated with C. parvum sheddingDuring multivariable model-building, the variables representing the quantity of colostrum fed to calves in the first 24 h following birth, and whether calves had been born in a multi-cow calving area, were identified as confounders.", [["C. parvum", "ORGANISM", 98, 107], ["C. parvum", "ORGANISM", 153, 162], ["colostrum", "ORGANISM", 251, 260], ["calves", "ORGANISM", 268, 274], ["calves", "ORGANISM", 322, 328], ["C. parvum", "SPECIES", 98, 107], ["C. parvum", "SPECIES", 153, 162], ["calves", "SPECIES", 268, 274], ["calves", "SPECIES", 322, 328], ["cow", "SPECIES", 354, 357], ["C. parvum", "SPECIES", 98, 107], ["C. parvum", "SPECIES", 153, 162], ["calves", "SPECIES", 322, 328], ["cow", "SPECIES", 354, 357], ["unconditional screening", "TEST", 30, 53], ["C. parvum shedding", "PROBLEM", 98, 116], ["Predictor variables", "PROBLEM", 117, 136], ["C. parvum shedding", "PROBLEM", 153, 171], ["parvum", "OBSERVATION", 101, 107], ["parvum", "OBSERVATION", 156, 162], ["colostrum", "OBSERVATION", 251, 260]]], ["Because several management variables had been found to be statistically associated with season, season of calf's birth was also forced into the model.", [["calf", "ORGANISM_SUBDIVISION", 106, 110], ["calf", "SPECIES", 106, 110], ["calf's birth", "TREATMENT", 106, 118], ["calf", "ANATOMY", 106, 110]]], ["In addition, the quantity of colostrum fed to calves in the first 24 h after birth, and whether calves had been born in a multi-cow calving pen, appeared to be confounders and were therefore forced into the model.", [["colostrum", "ANATOMY", 29, 38], ["colostrum", "ORGANISM", 29, 38], ["calves", "ORGANISM", 46, 52], ["calves", "ORGANISM", 96, 102], ["calves", "SPECIES", 46, 52], ["calves", "SPECIES", 96, 102], ["cow", "SPECIES", 128, 131], ["a multi-cow calving pen", "TREATMENT", 120, 143], ["quantity", "OBSERVATION_MODIFIER", 17, 25], ["colostrum", "OBSERVATION", 29, 38]]], ["There was no statistical evidence of interaction between variables in this model.", [["interaction between variables", "PROBLEM", 37, 66], ["no statistical evidence of", "UNCERTAINTY", 10, 36], ["interaction", "OBSERVATION", 37, 48]]], ["Predicted probabilities, Pearson and deviance residuals and Cook's distance values indicated that the model fit the data moderately well.", [["deviance residuals", "TEST", 37, 55], ["Cook's distance values", "TEST", 60, 82]]], ["Fig. 1 illustrates the relationship between the probability of calves shedding C. parvum oocysts and age of the calves, as represented by the model in Table 3 .", [["calves", "ORGANISM", 63, 69], ["C. parvum", "ORGANISM", 79, 88], ["calves", "ORGANISM", 112, 118], ["calves", "SPECIES", 63, 69], ["C. parvum", "SPECIES", 79, 88], ["calves", "SPECIES", 112, 118], ["C. parvum", "SPECIES", 79, 88], ["calves shedding C. parvum oocysts", "PROBLEM", 63, 96], ["parvum oocysts", "OBSERVATION", 82, 96], ["calves", "ANATOMY", 112, 118]]], ["This relationship reflects the previously mentioned finding that shedding of oocysts was most prevalent in the second and third weeks of life, with the risk of shedding being lowest in calves under 1 week of age.Predictor variables associated with diarrheaVariables significantly associated with diarrhea at the 25% level in unconditional analysis are shown in Table 2b .Predictor variables associated with diarrheaThe multivariable model constructed with diarrhea as the response variable is summarized in Table 4 .", [["diarrhea", "DISEASE", 296, 304], ["diarrhea", "DISEASE", 407, 415], ["diarrhea", "DISEASE", 456, 464], ["calves", "ORGANISM", 185, 191], ["calves", "SPECIES", 185, 191], ["oocysts", "PROBLEM", 77, 84], ["Predictor variables", "PROBLEM", 212, 231], ["diarrheaVariables", "PROBLEM", 248, 265], ["diarrhea", "PROBLEM", 296, 304], ["unconditional analysis", "TEST", 325, 347], ["Predictor variables", "PROBLEM", 371, 390], ["diarrhea", "PROBLEM", 407, 415], ["diarrhea", "PROBLEM", 456, 464], ["oocysts", "OBSERVATION", 77, 84], ["most prevalent", "OBSERVATION_MODIFIER", 89, 103], ["diarrhea", "OBSERVATION", 407, 415], ["diarrhea", "OBSERVATION", 456, 464]]], ["No other confounders were identified, and there was no statistical evidence of interaction between variables in this model.", [["no statistical evidence of", "UNCERTAINTY", 52, 78], ["interaction", "OBSERVATION", 79, 90]]], ["Predicted probabilities, Pearson and deviance residuals and Cook's distance values indicated that this model fit the data moderately well.Predictor variables associated with diarrheaThe relationship between the probability of diarrhea in C. parvum negative calves and age of the calves as represented by the model in Table 4 is shown in Fig. 2 .", [["diarrhea", "DISEASE", 174, 182], ["diarrhea", "DISEASE", 226, 234], ["C. parvum", "ORGANISM", 238, 247], ["calves", "ORGANISM", 257, 263], ["calves", "ORGANISM", 279, 285], ["C. parvum", "SPECIES", 238, 247], ["calves", "SPECIES", 257, 263], ["calves", "SPECIES", 279, 285], ["C. parvum", "SPECIES", 238, 247], ["deviance residuals", "TEST", 37, 55], ["Cook's distance values", "TEST", 60, 82], ["Predictor variables", "PROBLEM", 138, 157], ["diarrhea", "PROBLEM", 174, 182], ["diarrhea", "PROBLEM", 226, 234], ["diarrhea", "OBSERVATION", 174, 182], ["diarrhea", "OBSERVATION", 226, 234], ["parvum negative calves", "OBSERVATION", 241, 263], ["calves", "ANATOMY", 279, 285]]], ["The relationship illustrated pertains to calves for which all covariates listed in Table 3 were at their referent levels (see Table 2a ).", [["calves", "ORGANISM", 41, 47], ["calves", "SPECIES", 41, 47]]], ["Table 2c lists variables significantly associated (P < 0.25) with diarrhea in univariable analysis for calves shedding C. parvum oocysts.", [["diarrhea", "DISEASE", 66, 74], ["C. parvum oocysts", "DISEASE", 119, 136], ["calves", "ORGANISM", 103, 109], ["C. parvum", "ORGANISM", 119, 128], ["oocysts", "ORGANISM", 129, 136], ["calves", "SPECIES", 103, 109], ["C. parvum", "SPECIES", 119, 128], ["calves", "SPECIES", 103, 109], ["C. parvum", "SPECIES", 119, 128], ["diarrhea", "PROBLEM", 66, 74], ["univariable analysis", "TEST", 78, 98], ["calves shedding C. parvum oocysts", "PROBLEM", 103, 136], ["parvum oocysts", "OBSERVATION", 122, 136]]], ["Multivariable modelling of these variables, with presence or absence of diarrhea as the response variable, yielded the final model summarized in Table 5 .", [["diarrhea", "DISEASE", 72, 80], ["diarrhea", "PROBLEM", 72, 80], ["diarrhea", "OBSERVATION", 72, 80]]], ["As in the models described in Sections 3.1 and 3.2, season of birth was forced into the model.", [["Sections", "TEST", 30, 38]]], ["No other confounders were identified, and there was no statistical evidence of interaction a For continuous variables, regression coefficients are reported instead of odds ratios, and quartiles are provided to reflect the distribution of each variable. b High = More than 2.2 \u00c2 10 5 oocysts per gram of feces.", [["feces", "ANATOMY", 303, 308], ["feces", "ORGANISM_SUBDIVISION", 303, 308], ["High", "OBSERVATION_MODIFIER", 255, 259]]], ["Categorization based on grouping of number of oocysts using the 'lintrend' option in Stata 9.0, with number of oocysts grouped into 6 groups of similar sample size. c Sample-level frequencies provided for levels of oocyst shedding.", [["oocyst", "ANATOMY", 215, 221], ["Categorization", "TREATMENT", 0, 14], ["oocysts", "PROBLEM", 46, 53], ["the 'lintrend' option", "TREATMENT", 60, 81], ["Stata", "TEST", 85, 90], ["Sample-level frequencies", "TEST", 167, 191], ["oocyst shedding", "PROBLEM", 215, 230], ["oocysts", "OBSERVATION", 111, 118], ["size", "OBSERVATION_MODIFIER", 159, 163], ["oocyst", "OBSERVATION", 215, 221]]], ["Probability of diarrhea in Ontario dairy calves 0 to 30 days old, by age of calf, as represented by model shown in Table 4 .", [["diarrhea", "DISEASE", 15, 23], ["calf", "ORGANISM_SUBDIVISION", 76, 80], ["calves", "SPECIES", 41, 47], ["calf", "SPECIES", 76, 80], ["diarrhea", "PROBLEM", 15, 23], ["diarrhea", "OBSERVATION", 15, 23], ["calf", "ANATOMY", 76, 80]]], ["The relationship illustrated pertains to calves for which all covariates listed in Table 4 were at their referent levels (see Table 2b ). between variables in this model.", [["calves", "ORGANISM", 41, 47], ["calves", "SPECIES", 41, 47]]], ["Examination of the predicted probabilities, Pearson and deviance residuals, and Cook's distance values associated with this model indicated that this model fit the data well.Two-stage adjustment of logistic coefficientsIn multivariable generalized mixed modelling, none of the enteropathogens for which the calves were tested were significantly associated with diarrhea at the 5% level.", [["diarrhea", "DISEASE", 361, 369], ["calves", "ORGANISM", 307, 313], ["calves", "SPECIES", 307, 313], ["calves", "SPECIES", 307, 313], ["Examination", "TEST", 0, 11], ["deviance residuals", "TEST", 56, 74], ["Cook's distance values", "TEST", 80, 102], ["logistic coefficients", "TEST", 198, 219], ["multivariable generalized mixed modelling", "PROBLEM", 222, 263], ["the enteropathogens", "PROBLEM", 273, 292], ["diarrhea", "PROBLEM", 361, 369], ["generalized", "OBSERVATION_MODIFIER", 236, 247], ["mixed modelling", "OBSERVATION", 248, 263], ["enteropathogens", "OBSERVATION", 277, 292], ["calves", "ANATOMY", 307, 313]]], ["This may have been partly due to low power, as only 25% of the calves were tested for these agents.", [["calves", "ORGANISM", 63, 69], ["calves", "SPECIES", 63, 69], ["these agents", "TREATMENT", 86, 98], ["calves", "ANATOMY", 63, 69]]], ["Nonetheless, the regression coefficient for the overall C. parvum shedding status of calves (produced by the construction of a logistic model for diarrhea that included data on all of the enteropathogens obtained from the second-stage as fixed effects, as well as herd as a random effect) was adjusted using the method previously described.", [["diarrhea", "DISEASE", 146, 154], ["C. parvum", "ORGANISM", 56, 65], ["calves", "ORGANISM", 85, 91], ["C. parvum", "SPECIES", 56, 65], ["calves", "SPECIES", 85, 91], ["C. parvum", "SPECIES", 56, 65], ["a logistic model", "TREATMENT", 125, 141], ["diarrhea", "PROBLEM", 146, 154], ["the enteropathogens", "PROBLEM", 184, 203], ["the method", "TREATMENT", 308, 318], ["parvum", "OBSERVATION", 59, 65]]], ["In comparison with the unadjusted coefficient and standard error for C. parvum (1.06 and 0.34, respectively), the adjusted values were farther from the null: 1.47 and 0.27, respectively.", [["C. parvum", "ORGANISM", 69, 78], ["C. parvum", "SPECIES", 69, 78], ["C. parvum", "SPECIES", 69, 78], ["C. parvum", "PROBLEM", 69, 78], ["the adjusted values", "TEST", 110, 129], ["the null", "TEST", 148, 156]]], ["Corresponding unadjusted and adjusted odds ratios were 2.89 (95% CI 1.48, 5.70) and 4.35 (95% CI 2.22, 8.52), respectively.DiscussionThe prevalence of C. parvum shedding among the calves in this study was higher than figures published in other reports from areas within North America (Garber et al., 1994; Olson et al., 1997a,b; O'Handley et al., 1999; Sischo et al., 2000) .", [["C. parvum shedding", "DISEASE", 151, 169], ["C. parvum", "ORGANISM", 151, 160], ["calves", "ORGANISM", 180, 186], ["C. parvum", "SPECIES", 151, 160], ["calves", "SPECIES", 180, 186], ["C. parvum", "SPECIES", 151, 160], ["odds ratios", "TEST", 38, 49], ["CI", "TEST", 65, 67], ["CI", "TEST", 94, 96], ["C. parvum shedding", "TREATMENT", 151, 169], ["this study", "TEST", 190, 200], ["parvum", "OBSERVATION", 154, 160]]], ["Probable reasons for this apparent discrepancy include the fact that 4 weekly samples were taken from each animal instead of the single sample used in most other studies.", [["samples", "ANATOMY", 78, 85], ["this apparent discrepancy", "PROBLEM", 21, 46]]], ["Furthermore, farms were selected based on the criterion of a previous history of calf diarrhea.", [["diarrhea", "DISEASE", 86, 94], ["calf", "ORGANISM_SUBDIVISION", 81, 85], ["calf", "SPECIES", 81, 85], ["calf diarrhea", "PROBLEM", 81, 94], ["calf", "ANATOMY", 81, 85], ["diarrhea", "OBSERVATION", 86, 94]]], ["In addition, calves in our study were all under 1 month of age, and were therefore within the age group known to show the highest prevalence of C. parvum infection and diarrhea.", [["C. parvum infection", "DISEASE", 144, 163], ["diarrhea", "DISEASE", 168, 176], ["calves", "ORGANISM", 13, 19], ["C. parvum", "ORGANISM", 144, 153], ["calves", "SPECIES", 13, 19], ["C. parvum", "SPECIES", 144, 153], ["C. parvum", "SPECIES", 144, 153], ["our study", "TEST", 23, 32], ["C. parvum infection", "PROBLEM", 144, 163], ["diarrhea", "PROBLEM", 168, 176], ["calves", "OBSERVATION", 13, 19], ["C. parvum infection", "OBSERVATION", 144, 163]]], ["Moreover, of the 1045 calves enrolled in this study, 584 were from a single large herd with a high prevalence of C. parvum shedding (91%) and diarrhea (79%); the overall prevalence of C. parvum shedding on the other 10 farms was 62%.DiscussionMultivariable modelling of C. parvum shedding (Table 3) showed that calves born in the summer months were more likely to shed C. parvum.", [["C. parvum shedding", "DISEASE", 113, 131], ["diarrhea", "DISEASE", 142, 150], ["C. parvum", "DISEASE", 184, 193], ["calves", "ORGANISM", 22, 28], ["C. parvum", "ORGANISM", 113, 122], ["C. parvum", "ORGANISM", 184, 193], ["C. parvum", "ORGANISM", 270, 279], ["calves", "ORGANISM", 311, 317], ["C. parvum", "ORGANISM", 369, 378], ["calves", "SPECIES", 22, 28], ["C. parvum", "SPECIES", 113, 122], ["C. parvum", "SPECIES", 184, 193], ["C. parvum", "SPECIES", 270, 279], ["calves", "SPECIES", 311, 317], ["C. parvum", "SPECIES", 369, 378], ["C. parvum", "SPECIES", 113, 122], ["C. parvum", "SPECIES", 184, 193], ["C. parvum", "SPECIES", 270, 279], ["calves", "SPECIES", 311, 317], ["C. parvum", "SPECIES", 369, 378], ["this study", "TEST", 41, 51], ["C. parvum shedding", "PROBLEM", 113, 131], ["diarrhea", "PROBLEM", 142, 150], ["C. parvum shedding", "PROBLEM", 184, 202], ["C. parvum shedding", "PROBLEM", 270, 288], ["parvum", "OBSERVATION_MODIFIER", 116, 122], ["parvum shedding", "OBSERVATION", 187, 202], ["parvum", "OBSERVATION", 372, 378]]], ["The quantity of colostrum fed to calves in the first 24 h after birth was also positively associated with the risk of C. parvum shedding.", [["colostrum", "ANATOMY", 16, 25], ["colostrum", "ORGANISM", 16, 25], ["calves", "ORGANISM", 33, 39], ["C. parvum", "ORGANISM", 118, 127], ["calves", "SPECIES", 33, 39], ["C. parvum", "SPECIES", 118, 127], ["C. parvum", "SPECIES", 118, 127], ["C. parvum shedding", "PROBLEM", 118, 136], ["quantity", "OBSERVATION_MODIFIER", 4, 12], ["colostrum", "OBSERVATION", 16, 25], ["parvum shedding", "OBSERVATION", 121, 136]]], ["On the other hand, calves that received feed containing coccidiostats, and those born to dams that had been treated with calf-scour prophylactic medications (ScourGuard [Novartis, Ontario] or Ecostar [Pfizer, Ontario]) were significantly less likely to shed C. parvum.", [["coccidiostats", "CHEMICAL", 56, 69], ["calves", "ORGANISM", 19, 25], ["coccidiostats", "SIMPLE_CHEMICAL", 56, 69], ["dams", "ORGANISM", 89, 93], ["calf", "ORGANISM_SUBDIVISION", 121, 125], ["C. parvum", "ORGANISM", 258, 267], ["calves", "SPECIES", 19, 25], ["calf", "SPECIES", 121, 125], ["C. parvum", "SPECIES", 258, 267], ["C. parvum", "SPECIES", 258, 267], ["coccidiostats", "TREATMENT", 56, 69], ["calf-scour prophylactic medications", "TREATMENT", 121, 156], ["calves", "ANATOMY", 19, 25], ["parvum", "OBSERVATION", 261, 267]]], ["Those born in multicow calving pens also showed a slightly lower risk of shedding, though this variable appeared to be a confounder and was not significantly associated with shedding at the 5% level (P = 0.800).", [["multicow calving pens", "TREATMENT", 14, 35], ["a slightly lower risk of shedding", "PROBLEM", 48, 81], ["slightly", "OBSERVATION_MODIFIER", 50, 58], ["lower risk", "OBSERVATION_MODIFIER", 59, 69], ["shedding", "OBSERVATION", 73, 81]]], ["In a previous study, Frank and Kaneene (1993) found that the use of individual maternity stalls was significantly associated with an increased incidence of calf diarrhea in dairy herds with more than 200 cows in Michigan, USA.", [["diarrhea", "DISEASE", 161, 169], ["calf", "ORGANISM_SUBDIVISION", 156, 160], ["calf", "SPECIES", 156, 160], ["a previous study", "TEST", 3, 19], ["calf diarrhea", "PROBLEM", 156, 169], ["increased", "OBSERVATION_MODIFIER", 133, 142], ["calf", "ANATOMY", 156, 160], ["diarrhea", "OBSERVATION", 161, 169]]], ["As is often the case with predictors found to be significantly associated with a response variable in a statistical model, the associations observed in our study may not reflect actual causal or protective relationships.", [["our study", "TEST", 152, 161]]], ["Instead, the predictors included in the model may merely be indicators of other unknown management factors that are directly related to the risk of C. parvum infection and shedding in calves.", [["C. parvum infection", "DISEASE", 148, 167], ["C. parvum", "ORGANISM", 148, 157], ["calves", "ORGANISM", 184, 190], ["C. parvum", "SPECIES", 148, 157], ["calves", "SPECIES", 184, 190], ["C. parvum", "SPECIES", 148, 157], ["C. parvum infection", "PROBLEM", 148, 167], ["C.", "OBSERVATION_MODIFIER", 148, 150], ["parvum", "OBSERVATION_MODIFIER", 151, 157], ["infection", "OBSERVATION", 158, 167]]], ["For example, the negative association between use of calf-scour prophylactic medications in pregnant cows and the risk of shedding may reflect the impact of a generally higher standard of herd management in some herds on the risk of shedding, rather than a direct protective effect, as neither of the medications used is known to provide any protection against C. parvum in calves.", [["C. parvum", "DISEASE", 361, 370], ["calf", "ORGANISM_SUBDIVISION", 53, 57], ["cows", "ORGANISM", 101, 105], ["C. parvum", "ORGANISM", 361, 370], ["calves", "ORGANISM", 374, 380], ["calf", "SPECIES", 53, 57], ["cows", "SPECIES", 101, 105], ["C. parvum", "SPECIES", 361, 370], ["calves", "SPECIES", 374, 380], ["C. parvum", "SPECIES", 361, 370], ["calf-scour prophylactic medications", "TREATMENT", 53, 88], ["pregnant cows", "PROBLEM", 92, 105], ["shedding", "PROBLEM", 122, 130], ["herd management", "TREATMENT", 188, 203], ["shedding", "PROBLEM", 233, 241], ["the medications", "TREATMENT", 297, 312], ["C. parvum in calves", "PROBLEM", 361, 380], ["negative", "OBSERVATION", 17, 25], ["parvum", "OBSERVATION", 364, 370]]], ["Further, it is often difficult to distinguish between calf-and herd-level exposure factors.", [["calf", "ORGANISM_SUBDIVISION", 54, 58], ["calf", "SPECIES", 54, 58], ["calf", "TEST", 54, 58], ["calf", "ANATOMY", 54, 58]]], ["Indeed, the small number of herds used in this study increases the likelihood that the observed associations may be reflections of individual herd effects instead of true causal associations.", [["this study", "TEST", 42, 52], ["individual herd effects", "PROBLEM", 131, 154], ["small", "OBSERVATION_MODIFIER", 12, 17], ["number", "OBSERVATION_MODIFIER", 18, 24], ["herds", "OBSERVATION", 28, 33]]], ["Having said that, we believe that our findings will add to the current knowledge of potential risk factors for C. parvum shedding and diarrhea.DiscussionControlling for other variables included in the model shown in Table 4 , the odds of diarrhea in calves born in the summer months were 69% higher than in those born during the winter, and this association was highly significant.", [["C. parvum shedding", "DISEASE", 111, 129], ["diarrhea", "DISEASE", 134, 142], ["diarrhea", "DISEASE", 238, 246], ["C. parvum", "ORGANISM", 111, 120], ["calves", "ORGANISM", 250, 256], ["C. parvum", "SPECIES", 111, 120], ["calves", "SPECIES", 250, 256], ["C. parvum", "SPECIES", 111, 120], ["C. parvum shedding", "PROBLEM", 111, 129], ["diarrhea", "PROBLEM", 134, 142], ["diarrhea", "PROBLEM", 238, 246], ["parvum shedding", "OBSERVATION", 114, 129], ["diarrhea", "OBSERVATION", 238, 246], ["significant", "OBSERVATION_MODIFIER", 369, 380]]], ["This finding is in contrast to results published by Waltner-Toews et al. (1986) , Curtis et al. (1988) and Frank and Kaneene (1993) , who found higher incidences of calf diarrhea in the winter in New York, Ontario and Michigan dairies, respectively.", [["diarrhea", "DISEASE", 170, 178], ["calf", "ORGANISM_SUBDIVISION", 165, 169], ["calf", "SPECIES", 165, 169], ["calf diarrhea", "PROBLEM", 165, 178], ["calf", "ANATOMY", 165, 169], ["diarrhea", "OBSERVATION", 170, 178]]], ["However, none of these studies investigated the association between C. parvum shedding and calf diarrhea.", [["C. parvum shedding", "DISEASE", 68, 86], ["diarrhea", "DISEASE", 96, 104], ["C. parvum", "ORGANISM", 68, 77], ["calf", "ORGANISM_SUBDIVISION", 91, 95], ["C. parvum", "SPECIES", 68, 77], ["calf", "SPECIES", 91, 95], ["C. parvum", "SPECIES", 68, 77], ["these studies", "TEST", 17, 30], ["C. parvum shedding", "PROBLEM", 68, 86], ["calf diarrhea", "PROBLEM", 91, 104], ["parvum", "OBSERVATION_MODIFIER", 71, 77], ["calf", "ANATOMY", 91, 95], ["diarrhea", "OBSERVATION", 96, 104]]], ["Our study demonstrated a strong association between C. parvum shedding and diarrhea, with shedding calves having more than five times the odds of diarrhea than non-shedding calves.DiscussionNo such association was found between the risk of diarrhea and any of the other enteropathogens investigated.", [["C. parvum shedding", "DISEASE", 52, 70], ["diarrhea", "DISEASE", 75, 83], ["diarrhea", "DISEASE", 146, 154], ["diarrhea", "DISEASE", 240, 248], ["C. parvum", "ORGANISM", 52, 61], ["calves", "ORGANISM", 99, 105], ["calves", "ORGANISM", 173, 179], ["C. parvum", "SPECIES", 52, 61], ["calves", "SPECIES", 99, 105], ["calves", "SPECIES", 173, 179], ["C. parvum", "SPECIES", 52, 61], ["Our study", "TEST", 0, 9], ["C. parvum shedding", "PROBLEM", 52, 70], ["diarrhea", "PROBLEM", 75, 83], ["shedding calves", "PROBLEM", 90, 105], ["diarrhea than non-shedding calves", "PROBLEM", 146, 179], ["diarrhea", "PROBLEM", 240, 248], ["the other enteropathogens", "PROBLEM", 260, 285], ["strong", "OBSERVATION_MODIFIER", 25, 31], ["parvum", "OBSERVATION_MODIFIER", 55, 61], ["diarrhea", "OBSERVATION", 75, 83], ["diarrhea", "OBSERVATION", 146, 154], ["diarrhea", "OBSERVATION", 240, 248]]], ["Indeed, the adjustment of the coefficient for overall C. parvum status of calves using the method described by Cain and Breslow (1988) and the data collected on other enteropathogens for the second stage sample, resulted in an increased value (farther from the null) for the coefficient.", [["C. parvum", "ORGANISM", 54, 63], ["calves", "ORGANISM", 74, 80], ["C. parvum", "SPECIES", 54, 63], ["calves", "SPECIES", 74, 80], ["C. parvum", "SPECIES", 54, 63], ["the data", "TEST", 139, 147], ["the second stage sample", "TEST", 187, 210], ["an increased value", "PROBLEM", 224, 242], ["increased", "OBSERVATION_MODIFIER", 227, 236]]], ["It appears, therefore, that C. parvum was the enteropathogen most strongly associated with diarrhea, as well as, perhaps, the most common cause of calf diarrhea, within our study population.", [["diarrhea", "DISEASE", 91, 99], ["diarrhea", "DISEASE", 152, 160], ["C. parvum", "ORGANISM", 28, 37], ["calf", "ORGANISM_SUBDIVISION", 147, 151], ["C. parvum", "SPECIES", 28, 37], ["calf", "SPECIES", 147, 151], ["C. parvum", "SPECIES", 28, 37], ["C. parvum", "PROBLEM", 28, 37], ["the enteropathogen", "PROBLEM", 42, 60], ["diarrhea", "PROBLEM", 91, 99], ["calf diarrhea", "PROBLEM", 147, 160], ["our study population", "TEST", 169, 189], ["parvum", "OBSERVATION", 31, 37], ["diarrhea", "OBSERVATION", 91, 99], ["calf", "ANATOMY", 147, 151], ["diarrhea", "OBSERVATION", 152, 160]]], ["The low predicted probabilities of diarrhea in C. parvum negative calves (Fig. 2) , computed from coefficients of the model in Table 4 , highlight the importance of the parasite as a cause of scouring, since the overall prevalence of diarrhea in the calves was much higher than the predicted probabilities of scouring in non-shedding calves shown in the graph.DiscussionThe association between C. parvum and diarrhea in calves in Ontario has previously been reported (Trotz-Williams et al., 2005a) , and the results of the present study confirm the importance of the parasite as a cause of calf scours in this region.", [["diarrhea", "DISEASE", 35, 43], ["diarrhea", "DISEASE", 234, 242], ["C. parvum and diarrhea", "DISEASE", 394, 416], ["C. parvum", "ORGANISM", 47, 56], ["calves", "ORGANISM", 66, 72], ["calves", "ORGANISM", 250, 256], ["calves", "ORGANISM", 334, 340], ["C. parvum", "ORGANISM", 394, 403], ["calves", "ORGANISM", 420, 426], ["calf", "ORGANISM_SUBDIVISION", 590, 594], ["C. parvum", "SPECIES", 47, 56], ["calves", "SPECIES", 66, 72], ["calves", "SPECIES", 250, 256], ["calves", "SPECIES", 334, 340], ["C. parvum", "SPECIES", 394, 403], ["calves", "SPECIES", 420, 426], ["calf", "SPECIES", 590, 594], ["C. parvum", "SPECIES", 47, 56], ["C. parvum", "SPECIES", 394, 403], ["diarrhea", "PROBLEM", 35, 43], ["the parasite", "PROBLEM", 165, 177], ["diarrhea in the calves", "PROBLEM", 234, 256], ["C. parvum", "PROBLEM", 394, 403], ["diarrhea", "PROBLEM", 408, 416], ["the present study", "TEST", 519, 536], ["the parasite", "PROBLEM", 563, 575], ["calf scours in this region", "PROBLEM", 590, 616], ["low predicted", "OBSERVATION_MODIFIER", 4, 17], ["diarrhea", "OBSERVATION", 35, 43], ["parvum", "OBSERVATION_MODIFIER", 50, 56], ["negative calves", "OBSERVATION", 57, 72], ["diarrhea", "OBSERVATION", 234, 242], ["calves", "ANATOMY", 250, 256], ["parvum", "OBSERVATION", 397, 403], ["diarrhea", "OBSERVATION", 408, 416], ["parasite", "OBSERVATION", 567, 575], ["calf", "ANATOMY", 590, 594], ["scours", "OBSERVATION", 595, 601]]], ["As the risk of C. parvum shedding was significantly higher in the summer months, it follows that the risk of C. parvumassociated diarrhea would also be higher in these calves at that time of the year.", [["diarrhea", "DISEASE", 129, 137], ["C. parvum", "ORGANISM", 15, 24], ["calves", "ORGANISM", 168, 174], ["C. parvum", "SPECIES", 15, 24], ["calves", "SPECIES", 168, 174], ["C. parvum", "SPECIES", 15, 24], ["C. parvumassociated", "SPECIES", 109, 128], ["C. parvum shedding", "PROBLEM", 15, 33], ["C. parvumassociated diarrhea", "PROBLEM", 109, 137], ["C.", "OBSERVATION_MODIFIER", 15, 17], ["parvum", "OBSERVATION", 18, 24], ["parvumassociated diarrhea", "OBSERVATION", 112, 137], ["higher", "OBSERVATION_MODIFIER", 152, 158]]], ["It is possible that the cases of diarrhea observed in the calves used in previous studies (Waltner-Toews et al., 1986; Curtis et al., 1988; Frank and Kaneene, 1993) were predominantly caused by enteropathogens other than C. parvum.", [["diarrhea", "DISEASE", 33, 41], ["calves", "ORGANISM", 58, 64], ["C. parvum", "ORGANISM", 221, 230], ["calves", "SPECIES", 58, 64], ["C. parvum", "SPECIES", 221, 230], ["C. parvum", "SPECIES", 221, 230], ["diarrhea", "PROBLEM", 33, 41], ["previous studies", "TEST", 73, 89], ["enteropathogens", "PROBLEM", 194, 209], ["diarrhea", "OBSERVATION", 33, 41], ["calves", "ANATOMY", 58, 64], ["parvum", "OBSERVATION", 224, 230]]], ["Furthermore, the fact that the farms used in our study were selected based on a history of calf diarrhea or cryptosporidiosis may have contributed to some of the differences between the findings reported here and those of other researchers.", [["diarrhea", "DISEASE", 96, 104], ["cryptosporidiosis", "DISEASE", 108, 125], ["calf", "ORGANISM_SUBDIVISION", 91, 95], ["calf", "SPECIES", 91, 95], ["our study", "TEST", 45, 54], ["calf diarrhea", "PROBLEM", 91, 104], ["cryptosporidiosis", "PROBLEM", 108, 125], ["calf", "ANATOMY", 91, 95], ["diarrhea", "OBSERVATION", 96, 104], ["cryptosporidiosis", "OBSERVATION", 108, 125]]], ["The length of time for which calves remained with their dams after birth was significantly associated with diarrhea; the odds of diarrhea in calves remaining with their mothers for more than 1 h were 39% higher than the odds of diarrhea in those separated from the dam within an hour of birth (Table 4 ).", [["diarrhea", "DISEASE", 107, 115], ["diarrhea", "DISEASE", 129, 137], ["diarrhea", "DISEASE", 228, 236], ["calves", "ORGANISM", 29, 35], ["dams", "ORGANISM", 56, 60], ["calves", "ORGANISM", 141, 147], ["calves", "SPECIES", 29, 35], ["calves", "SPECIES", 141, 147], ["calves", "SPECIES", 141, 147], ["diarrhea", "PROBLEM", 107, 115], ["diarrhea", "PROBLEM", 129, 137], ["diarrhea", "PROBLEM", 228, 236], ["length", "OBSERVATION_MODIFIER", 4, 10], ["diarrhea", "OBSERVATION", 129, 137], ["diarrhea", "OBSERVATION", 228, 236]]], ["Using an experimental approach, Quigley et al. (1994) found that, in a study population of 96 Jersey calves, the prevalence of Cryptosporidium was significantly higher in calves 1 week of age that had been allowed to nurse their dams, than in calves of the same age that had been separated from their dams before they could nurse, and fed colostrum by bottle.", [["colostrum", "ANATOMY", 339, 348], ["calves", "ORGANISM", 101, 107], ["Cryptosporidium", "ORGANISM", 127, 142], ["dams", "ORGANISM", 229, 233], ["calves", "ORGANISM", 243, 249], ["dams", "ORGANISM", 301, 305], ["colostrum", "ORGANISM_SUBSTANCE", 339, 348], ["calves", "SPECIES", 101, 107], ["calves", "SPECIES", 171, 177], ["calves", "SPECIES", 243, 249], ["Cryptosporidium", "PROBLEM", 127, 142], ["Cryptosporidium", "OBSERVATION", 127, 142]]], ["However, in our study, no statistically significant association was observed between the risk of shedding and length of time with the dam, either in univariable or in multivariable analysis.", [["our study", "TEST", 12, 21], ["multivariable analysis", "TEST", 167, 189]]], ["The reason for the apparent association between length of stay with dam and the risk of diarrhea in our study may therefore be related to factors other than infection with C. parvum.DiscussionControlling for other variables included in the model summarized in Table 5 , the odds of diarrhea in calves shedding C. parvum that were raised in the summer months were 64% higher than the odds of diarrhea in the shedding calves that were raised in the winter.", [["diarrhea", "DISEASE", 88, 96], ["infection", "DISEASE", 157, 166], ["diarrhea", "DISEASE", 282, 290], ["diarrhea", "DISEASE", 391, 399], ["C. parvum", "ORGANISM", 172, 181], ["calves", "ORGANISM", 294, 300], ["C. parvum", "ORGANISM", 310, 319], ["calves", "ORGANISM", 416, 422], ["C. parvum", "SPECIES", 172, 181], ["calves", "SPECIES", 294, 300], ["C. parvum", "SPECIES", 310, 319], ["calves", "SPECIES", 416, 422], ["C. parvum", "SPECIES", 172, 181], ["C. parvum", "SPECIES", 310, 319], ["dam", "TREATMENT", 68, 71], ["diarrhea", "PROBLEM", 88, 96], ["our study", "TEST", 100, 109], ["infection", "PROBLEM", 157, 166], ["C. parvum", "PROBLEM", 172, 181], ["diarrhea", "PROBLEM", 282, 290], ["calves shedding C. parvum", "PROBLEM", 294, 319], ["diarrhea in the shedding calves", "PROBLEM", 391, 422], ["diarrhea", "OBSERVATION", 88, 96], ["diarrhea", "OBSERVATION", 282, 290], ["parvum", "OBSERVATION_MODIFIER", 313, 319], ["diarrhea", "OBSERVATION", 391, 399]]], ["This finding may have been due to better survival of oocysts in the environmental conditions that existed in the summer months, resulting in greater levels of challenge for the animals.", [["oocysts", "PROBLEM", 53, 60], ["may have been due to", "UNCERTAINTY", 13, 33], ["better", "OBSERVATION_MODIFIER", 34, 40], ["survival", "OBSERVATION_MODIFIER", 41, 49], ["oocysts", "OBSERVATION", 53, 60], ["greater", "OBSERVATION_MODIFIER", 141, 148]]], ["Alternatively, other unknown and unmeasured factors that predisposed C. parvum-infected animals to the development of diarrhea may have been more prevalent in the warmer months of the year, either directly or indirectly because of seasonal conditions.", [["C. parvum-infected", "DISEASE", 69, 87], ["diarrhea", "DISEASE", 118, 126], ["C. parvum", "ORGANISM", 69, 78], ["animals", "ORGANISM", 88, 95], ["C. parvum", "SPECIES", 69, 78], ["C. parvum", "SPECIES", 69, 78], ["unmeasured factors", "PROBLEM", 33, 51], ["C. parvum", "PROBLEM", 69, 78], ["diarrhea", "PROBLEM", 118, 126], ["seasonal conditions", "PROBLEM", 231, 250], ["parvum", "OBSERVATION_MODIFIER", 72, 78], ["infected", "OBSERVATION_MODIFIER", 79, 87], ["diarrhea", "OBSERVATION", 118, 126]]], ["Not surprisingly, among the C. parvumpositive calves, the odds of diarrhea in animals shedding more than 2.2 \u00c2 10 5 oocysts per gram of feces were more than six times the odds in calves shedding fewer than 2.2 \u00c2 10 5 oocysts per gram of feces.", [["feces", "ANATOMY", 136, 141], ["feces", "ANATOMY", 237, 242], ["diarrhea", "DISEASE", 66, 74], ["C. parvumpositive calves", "ORGANISM", 28, 52], ["feces", "ORGANISM_SUBSTANCE", 136, 141], ["calves", "ORGANISM", 179, 185], ["feces", "ORGANISM_SUBDIVISION", 237, 242], ["calves", "SPECIES", 46, 52], ["calves", "SPECIES", 179, 185], ["C. parvumpositive", "SPECIES", 28, 45], ["diarrhea", "PROBLEM", 66, 74], ["diarrhea", "OBSERVATION", 66, 74]]], ["This finding implies that the number of oocysts shed in the feces of infected calves may be a reliable indicator of the intensity of infection.DiscussionInterestingly, failure of passive transfer (FPT) was not significantly associated with the risk of diarrhea in the population of calves used in this study.", [["feces", "ANATOMY", 60, 65], ["calves", "ANATOMY", 78, 84], ["infection", "DISEASE", 133, 142], ["diarrhea", "DISEASE", 252, 260], ["feces", "ORGANISM_SUBDIVISION", 60, 65], ["calves", "ORGANISM", 78, 84], ["calves", "ORGANISM", 282, 288], ["calves", "SPECIES", 78, 84], ["calves", "SPECIES", 282, 288], ["oocysts", "PROBLEM", 40, 47], ["infected calves", "PROBLEM", 69, 84], ["infection", "PROBLEM", 133, 142], ["diarrhea", "PROBLEM", 252, 260], ["this study", "TEST", 297, 307], ["number", "OBSERVATION_MODIFIER", 30, 36], ["oocysts", "OBSERVATION", 40, 47], ["feces", "OBSERVATION_MODIFIER", 60, 65], ["infected calves", "OBSERVATION", 69, 84], ["infection", "OBSERVATION", 133, 142], ["diarrhea", "OBSERVATION", 252, 260]]], ["As passive immunity has not been proven important in imparting resistance to the parasite in calves, the lack of an association with C. parvum shedding in multivariable analysis was not surprising.", [["calves", "ORGANISM", 93, 99], ["C. parvum", "ORGANISM", 133, 142], ["calves", "SPECIES", 93, 99], ["C. parvum", "SPECIES", 133, 142], ["C. parvum", "SPECIES", 133, 142], ["C. parvum shedding", "PROBLEM", 133, 151], ["multivariable analysis", "TEST", 155, 177], ["resistance", "OBSERVATION", 63, 73], ["parasite", "OBSERVATION", 81, 89]]], ["However, it is generally accepted that FPT has an impact on calf morbidity and mortality.", [["FPT", "SIMPLE_CHEMICAL", 39, 42], ["calf", "ORGANISM_SUBDIVISION", 60, 64], ["calf", "SPECIES", 60, 64], ["calf morbidity", "PROBLEM", 60, 74], ["calf", "ANATOMY", 60, 64], ["morbidity", "OBSERVATION", 65, 74]]], ["It should be noted that the lack of association in our study may not be reflective of the relationship between FPT and diarrhea in the wider population of dairy calves in the region.", [["diarrhea", "DISEASE", 119, 127], ["calves", "ORGANISM_SUBDIVISION", 161, 167], ["calves", "SPECIES", 161, 167], ["our study", "TEST", 51, 60], ["FPT", "PROBLEM", 111, 114], ["diarrhea", "PROBLEM", 119, 127], ["diarrhea", "OBSERVATION", 119, 127], ["wider", "OBSERVATION_MODIFIER", 135, 140], ["population", "OBSERVATION_MODIFIER", 141, 151], ["dairy calves", "OBSERVATION", 155, 167], ["region", "ANATOMY_MODIFIER", 175, 181]]], ["Table 5 Multivariable generalized linear mixed model of diarrhea in calves 0-30 days in south-western Ontario shedding Cryptosporidium parvum, regressed on management factors significant at the 25% level in univariable analysisVariableOdds ratio (or regression coefficient) a 95% Confidence interval a P Generally, associations reported here between predictor variables and C. parvum oocyst shedding or diarrhea, though in many instances biologically plausible as discussed above, should be interpreted with caution.", [["diarrhea", "DISEASE", 56, 64], ["Cryptosporidium parvum", "DISEASE", 119, 141], ["diarrhea", "DISEASE", 403, 411], ["calves", "ORGANISM", 68, 74], ["Cryptosporidium parvum", "ORGANISM", 119, 141], ["C. parvum", "ORGANISM", 374, 383], ["calves", "SPECIES", 68, 74], ["Cryptosporidium parvum", "SPECIES", 119, 141], ["C. parvum", "SPECIES", 374, 383], ["Cryptosporidium parvum", "SPECIES", 119, 141], ["C. parvum", "SPECIES", 374, 383], ["diarrhea", "PROBLEM", 56, 64], ["Cryptosporidium parvum", "PROBLEM", 119, 141], ["management factors", "TREATMENT", 156, 174], ["univariable analysis", "TEST", 207, 227], ["Odds ratio", "TEST", 235, 245], ["C. parvum oocyst shedding", "PROBLEM", 374, 399], ["diarrhea", "PROBLEM", 403, 411], ["linear", "OBSERVATION_MODIFIER", 34, 40], ["mixed", "OBSERVATION_MODIFIER", 41, 46], ["diarrhea", "OBSERVATION", 56, 64], ["parvum", "OBSERVATION_MODIFIER", 135, 141], ["parvum oocyst", "OBSERVATION", 377, 390]]], ["This would be prudent especially because this is the first published study of its kind conducted in Ontario, and because a large number of potential risk factors were investigated, increasing the likelihood of identifying spurious relationships between variables.", [["potential risk factors", "PROBLEM", 139, 161], ["spurious relationships between variables", "PROBLEM", 222, 262], ["large", "OBSERVATION_MODIFIER", 123, 128], ["spurious", "OBSERVATION", 222, 230]]], ["Predictors that were significant only at the 25% level but not at the 5% level are particularly likely to be variables that have no true causal association with the outcomes.", [["Predictors", "TEST", 0, 10], ["significant", "OBSERVATION_MODIFIER", 21, 32], ["particularly likely", "UNCERTAINTY", 83, 102]]], ["In addition, many of the variables investigated in this study showed little variation among calves within herds, that is, they were essentially herd-level variables.", [["calves", "ORGANISM", 92, 98], ["calves", "SPECIES", 92, 98], ["this study", "TEST", 51, 61], ["little", "OBSERVATION_MODIFIER", 69, 75], ["variation", "OBSERVATION_MODIFIER", 76, 85]]], ["In view of the fact that only 11 purposively selected farms were used in the study, these variables were therefore less suitable for the identification of calf-level risk factors than the 'true' calf-level variables.", [["calf", "ORGANISM_SUBDIVISION", 155, 159], ["calf", "ORGANISM_SUBDIVISION", 195, 199], ["calf", "SPECIES", 155, 159], ["calf", "SPECIES", 195, 199], ["the study", "TEST", 73, 82], ["calf-level risk factors", "PROBLEM", 155, 178], ["calf", "ANATOMY", 155, 159], ["calf", "ANATOMY", 195, 199]]], ["As mentioned previously, most of the variation in the risk of infection was between herds, as opposed to within herds.", [["infection", "DISEASE", 62, 71], ["infection", "PROBLEM", 62, 71], ["infection", "OBSERVATION", 62, 71]]], ["With this in mind, and since many management factors were common to most calves within farms, a separate study specifically designed for the investigation of herd-level factors, and including herds with and without histories of calf diarrhea and cryptosporidiosis, would more effectively disclose any associations that may exist between such factors and the outcomes.ConclusionThe results of this study show that C. parvum is common among calves under 1 month of age in south-western Ontario dairy herds experiencing problems with calf diarrhea.", [["diarrhea", "DISEASE", 233, 241], ["cryptosporidiosis", "DISEASE", 246, 263], ["C. parvum", "DISEASE", 413, 422], ["diarrhea", "DISEASE", 536, 544], ["calves", "ORGANISM", 73, 79], ["calf", "ORGANISM_SUBDIVISION", 228, 232], ["C. parvum", "ORGANISM", 413, 422], ["calves", "ORGANISM", 439, 445], ["calf", "ORGANISM_SUBDIVISION", 531, 535], ["calves", "SPECIES", 73, 79], ["calf", "SPECIES", 228, 232], ["C. parvum", "SPECIES", 413, 422], ["calves", "SPECIES", 439, 445], ["calf", "SPECIES", 531, 535], ["C. parvum", "SPECIES", 413, 422], ["a separate study", "TEST", 94, 110], ["calf diarrhea", "PROBLEM", 228, 241], ["cryptosporidiosis", "PROBLEM", 246, 263], ["this study", "TEST", 392, 402], ["C. parvum", "PROBLEM", 413, 422], ["calf diarrhea", "PROBLEM", 531, 544], ["calf", "ANATOMY", 228, 232], ["diarrhea", "OBSERVATION", 233, 241], ["cryptosporidiosis", "OBSERVATION", 246, 263], ["parvum", "OBSERVATION", 416, 422], ["calf", "ANATOMY", 531, 535], ["diarrhea", "OBSERVATION", 536, 544]]], ["In addition, the parasite appears to be a primary cause of diarrhea among calves under 1 month of age group in the herds used in this study.", [["diarrhea", "DISEASE", 59, 67], ["calves", "ORGANISM", 74, 80], ["calves", "SPECIES", 74, 80], ["the parasite", "PROBLEM", 13, 25], ["diarrhea", "PROBLEM", 59, 67], ["this study", "TEST", 129, 139], ["parasite", "OBSERVATION", 17, 25], ["appears to be", "UNCERTAINTY", 26, 39], ["diarrhea", "OBSERVATION", 59, 67]]], ["The work described here has identified some calf-level, as well as a few herd-level, management practices that are potential predictors of the risk of C. parvum shedding and diarrhea among dairy calves in herds experiencing calf diarrhea problems.", [["C. parvum shedding", "DISEASE", 151, 169], ["diarrhea", "DISEASE", 174, 182], ["diarrhea", "DISEASE", 229, 237], ["calf", "ORGANISM_SUBDIVISION", 44, 48], ["C. parvum", "ORGANISM", 151, 160], ["calves", "ORGANISM_SUBDIVISION", 195, 201], ["calf", "ORGANISM_SUBDIVISION", 224, 228], ["calf", "SPECIES", 44, 48], ["C. parvum", "SPECIES", 151, 160], ["calves", "SPECIES", 195, 201], ["calf", "SPECIES", 224, 228], ["C. parvum", "SPECIES", 151, 160], ["management practices", "TREATMENT", 85, 105], ["C. parvum shedding", "PROBLEM", 151, 169], ["diarrhea", "PROBLEM", 174, 182], ["calf diarrhea problems", "PROBLEM", 224, 246], ["calf", "ANATOMY", 44, 48], ["parvum shedding", "OBSERVATION", 154, 169], ["calf", "ANATOMY", 224, 228], ["diarrhea", "OBSERVATION", 229, 237]]], ["Further investigation of management practices identified here as predictors of C. parvum shedding and diarrhea in Ontario is warranted, and may be of benefit to producers and practitioners involved in the control of this parasite.", [["C. parvum shedding", "DISEASE", 79, 97], ["diarrhea", "DISEASE", 102, 110], ["C. parvum", "ORGANISM", 79, 88], ["C. parvum", "SPECIES", 79, 88], ["C. parvum", "SPECIES", 79, 88], ["management practices", "TREATMENT", 25, 45], ["C. parvum shedding", "PROBLEM", 79, 97], ["diarrhea", "PROBLEM", 102, 110], ["this parasite", "PROBLEM", 216, 229], ["parvum", "OBSERVATION", 82, 88]]]], "PMC7172206": [["Hantaviruses, responsible for hantavirus cardiopulmonary syndrome (HCPS) in the Americas and hemorrhagic fever with renal syndrome (HFRS) in Asia and Europe, are major life-threatening pathogens in human (Schmaljohn and Nichol, 2007).", [["renal", "ANATOMY", 116, 121], ["Hantaviruses", "DISEASE", 0, 12], ["hantavirus cardiopulmonary syndrome", "DISEASE", 30, 65], ["HCPS", "DISEASE", 67, 71], ["hemorrhagic fever", "DISEASE", 93, 110], ["renal syndrome", "DISEASE", 116, 130], ["HFRS", "DISEASE", 132, 136], ["renal", "ORGAN", 116, 121], ["human", "ORGANISM", 198, 203], ["human", "SPECIES", 198, 203], ["human", "SPECIES", 198, 203], ["Hantaviruses", "PROBLEM", 0, 12], ["hantavirus cardiopulmonary syndrome", "PROBLEM", 30, 65], ["hemorrhagic fever", "PROBLEM", 93, 110], ["renal syndrome", "PROBLEM", 116, 130], ["responsible for", "UNCERTAINTY", 14, 29], ["hantavirus", "OBSERVATION", 30, 40], ["syndrome", "OBSERVATION", 57, 65], ["hemorrhagic", "OBSERVATION_MODIFIER", 93, 104], ["fever", "OBSERVATION", 105, 110], ["renal", "ANATOMY", 116, 121], ["syndrome", "OBSERVATION", 122, 130]]], ["About 60,000\u2013150,000 cases of HFRS are reported yearly worldwide with more than 90% in Asia, mostly in China with 29 of its 31 provinces being affected (Jonsson et al., 2010, Zhang et al., 2010, Kariwa et al., 2007).", [["HFRS", "DISEASE", 30, 34], ["HFRS", "PROBLEM", 30, 34]]]], "PMC7127557": [["IntroductionPorcine epidemic diarrhea virus (PEDV) is a positive-sense single stranded RNA virus belonging to the alphacoronavirus genus in the subfamily Coronavirinae of the family Coronaviridae (Pensaert and de Bouck, 1978, Song and Park, 2012).", [["IntroductionPorcine epidemic diarrhea", "DISEASE", 0, 37], ["IntroductionPorcine epidemic diarrhea virus", "ORGANISM", 0, 43], ["alphacoronavirus genus", "ORGANISM", 114, 136], ["epidemic diarrhea virus", "SPECIES", 20, 43], ["IntroductionPorcine epidemic diarrhea virus", "SPECIES", 0, 43], ["PEDV", "SPECIES", 45, 49], ["IntroductionPorcine epidemic diarrhea virus (PEDV", "PROBLEM", 0, 49], ["a positive-sense single stranded RNA virus", "PROBLEM", 54, 96]]], ["PEDV causes acute enteric disease in swine, characterized by acute vomiting and watery diarrhea, which has high mortality rates in newborn piglets (Huang et al., 2013, Pan et al., 2012).", [["PEDV", "CHEMICAL", 0, 4], ["enteric disease", "DISEASE", 18, 33], ["vomiting", "DISEASE", 67, 75], ["watery diarrhea", "DISEASE", 80, 95], ["swine", "ORGANISM", 37, 42], ["piglets", "ORGANISM", 139, 146], ["swine", "SPECIES", 37, 42], ["piglets", "SPECIES", 139, 146], ["PEDV", "SPECIES", 0, 4], ["swine", "SPECIES", 37, 42], ["PEDV", "PROBLEM", 0, 4], ["acute enteric disease in swine", "PROBLEM", 12, 42], ["acute vomiting", "PROBLEM", 61, 75], ["watery diarrhea", "PROBLEM", 80, 95], ["acute", "OBSERVATION_MODIFIER", 12, 17], ["enteric disease", "OBSERVATION", 18, 33], ["acute", "OBSERVATION_MODIFIER", 61, 66], ["vomiting", "OBSERVATION", 67, 75], ["watery", "OBSERVATION_MODIFIER", 80, 86], ["diarrhea", "OBSERVATION", 87, 95], ["high", "OBSERVATION_MODIFIER", 107, 111], ["mortality", "OBSERVATION_MODIFIER", 112, 121]]], ["PEDV was discovered in the United Kingdom in early 1970s and was subsequently identified in many European and Asian countries (Lee et al., 2010, Li et al., 2012, Pensaert and Callebaut, 1974).", [["PEDV", "CHEMICAL", 0, 4], ["PEDV", "SPECIES", 0, 4], ["PEDV", "PROBLEM", 0, 4]]], ["PEDV field strains isolated before 2010 and the derived vaccine strains belong to genogroup 1 (G1) (Kocherhans et al., 2001).", [["PEDV", "SPECIES", 0, 4], ["PEDV field strains", "PROBLEM", 0, 18], ["the derived vaccine strains", "TREATMENT", 44, 71]]], ["Since late 2010, variant PEDV strains (genogroup 2 [G2]) have emerged in China and Southeast Asia that were fatal to young pigs (Huang et al., 2013, Li et al., 2012).", [["pigs", "ORGANISM", 123, 127], ["pigs", "SPECIES", 123, 127], ["pigs", "SPECIES", 123, 127], ["variant PEDV strains", "PROBLEM", 17, 37]]], ["In May 2013, PEDV G2 strains suddenly emerged in the United States, wiping out more than 10% of America's pig population in one year (Huang et al., 2013, Tian et al., 2014).", [["PEDV G2 strains", "CELL", 13, 28], ["pig", "ORGANISM", 106, 109], ["pig", "SPECIES", 106, 109], ["pig", "SPECIES", 106, 109]]], ["PEDV, together with the other newly emerged swine enteric coronaviruses such as porcine deltacoronavirus (PDCoV) and swine enteric alphacoronavirus (SeACoV), are considered serious threats to the pork industry in Asia currently (Jung et al., 2016, Pan et al., 2017).IntroductionAminopeptidase N (APN or CD13) is a type II zinc metalloprotease that mediates various cellular processes, including antigen presentation, cell differentiation, cell motility and coronavirus entry (Luan and Xu, 2007).", [["cellular", "ANATOMY", 365, 373], ["cell", "ANATOMY", 417, 421], ["cell", "ANATOMY", 439, 443], ["PEDV", "CHEMICAL", 0, 4], ["enteric coronaviruses", "DISEASE", 50, 71], ["enteric alphacoronavirus", "DISEASE", 123, 147], ["zinc", "CHEMICAL", 322, 326], ["PEDV", "GENE_OR_GENE_PRODUCT", 0, 4], ["swine", "ORGANISM", 44, 49], ["enteric coronaviruses", "ORGANISM", 50, 71], ["porcine deltacoronavirus", "ORGANISM", 80, 104], ["PDCoV", "ORGANISM", 106, 111], ["swine enteric alphacoronavirus", "ORGANISM", 117, 147], ["Aminopeptidase N", "GENE_OR_GENE_PRODUCT", 278, 294], ["APN", "GENE_OR_GENE_PRODUCT", 296, 299], ["CD13", "GENE_OR_GENE_PRODUCT", 303, 307], ["type II zinc metalloprotease", "GENE_OR_GENE_PRODUCT", 314, 342], ["cellular", "CELL", 365, 373], ["antigen", "GENE_OR_GENE_PRODUCT", 395, 402], ["cell", "CELL", 417, 421], ["cell", "CELL", 439, 443], ["Aminopeptidase N", "PROTEIN", 278, 294], ["APN", "PROTEIN", 296, 299], ["CD13", "PROTEIN", 303, 307], ["type II zinc metalloprotease", "PROTEIN", 314, 342], ["swine", "SPECIES", 44, 49], ["porcine", "SPECIES", 80, 87], ["swine enteric alphacoronavirus", "SPECIES", 117, 147], ["PEDV", "SPECIES", 0, 4], ["swine enteric coronaviruses", "SPECIES", 44, 71], ["porcine deltacoronavirus", "SPECIES", 80, 104], ["PDCoV", "SPECIES", 106, 111], ["swine", "SPECIES", 117, 122], ["SeACoV", "SPECIES", 149, 155], ["pork", "SPECIES", 196, 200], ["PEDV", "PROBLEM", 0, 4], ["the other newly emerged swine enteric coronaviruses", "PROBLEM", 20, 71], ["porcine deltacoronavirus (PDCoV)", "TREATMENT", 80, 112], ["IntroductionAminopeptidase N (APN or CD13)", "TREATMENT", 266, 308], ["a type II zinc metalloprotease", "TREATMENT", 312, 342], ["various cellular processes", "PROBLEM", 357, 383], ["coronaviruses", "OBSERVATION", 58, 71], ["cellular processes", "OBSERVATION", 365, 383], ["cell differentiation", "OBSERVATION", 417, 437], ["cell motility", "OBSERVATION", 439, 452]]], ["Porcine APN (pAPN) was first identified as a major receptor for a porcine enteropathogenic alphacoronavirus, transmissible gastroenteritis virus (TGEV) (Delmas et al., 1992).", [["enteropathogenic alphacoronavirus", "DISEASE", 74, 107], ["transmissible gastroenteritis", "DISEASE", 109, 138], ["Porcine", "ORGANISM", 0, 7], ["APN", "GENE_OR_GENE_PRODUCT", 8, 11], ["pAPN", "GENE_OR_GENE_PRODUCT", 13, 17], ["porcine enteropathogenic alphacoronavirus", "ORGANISM", 66, 107], ["transmissible gastroenteritis virus", "ORGANISM", 109, 144], ["TGEV", "ORGANISM", 146, 150], ["Porcine APN", "PROTEIN", 0, 11], ["pAPN", "PROTEIN", 13, 17], ["Porcine", "SPECIES", 0, 7], ["porcine", "SPECIES", 66, 73], ["transmissible gastroenteritis virus", "SPECIES", 109, 144], ["Porcine", "SPECIES", 0, 7], ["transmissible gastroenteritis virus", "SPECIES", 109, 144], ["TGEV", "SPECIES", 146, 150], ["Porcine APN (pAPN", "TREATMENT", 0, 17], ["a major receptor", "TREATMENT", 43, 59], ["a porcine enteropathogenic alphacoronavirus", "PROBLEM", 64, 107], ["transmissible gastroenteritis virus", "PROBLEM", 109, 144], ["enteropathogenic alphacoronavirus", "OBSERVATION", 74, 107]]], ["A related human alphacoronavirus, HCoV-229E, utilizes the human APN (hAPN) to enter host cells (Yeager et al., 1992).", [["cells", "ANATOMY", 89, 94], ["human", "ORGANISM", 10, 15], ["alphacoronavirus", "CANCER", 16, 32], ["HCoV-229E", "CELL", 34, 43], ["human", "ORGANISM", 58, 63], ["APN", "GENE_OR_GENE_PRODUCT", 64, 67], ["hAPN", "GENE_OR_GENE_PRODUCT", 69, 73], ["host cells", "CELL", 84, 94], ["HCoV-229E", "DNA", 34, 43], ["human APN", "PROTEIN", 58, 67], ["hAPN", "PROTEIN", 69, 73], ["host cells", "CELL_TYPE", 84, 94], ["human", "SPECIES", 10, 15], ["human", "SPECIES", 58, 63], ["human", "SPECIES", 10, 15], ["HCoV-229E", "SPECIES", 34, 43], ["human", "SPECIES", 58, 63], ["A related human alphacoronavirus", "PROBLEM", 0, 32], ["HCoV", "TEST", 34, 38], ["the human APN", "TREATMENT", 54, 67]]], ["The interactions between TGEV/HCoV-229E and pAPN/hAPN are highly natural host specific, in which TGEV can use pAPN but not hAPN as its cellular receptor, and HCoV-229E can use hAPN but not pAPN (Kolb et al., 1996).", [["cellular", "ANATOMY", 135, 143], ["HCoV-229E", "CHEMICAL", 158, 167], ["TGEV", "ORGANISM", 25, 29], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 30, 39], ["pAPN", "GENE_OR_GENE_PRODUCT", 44, 48], ["hAPN", "GENE_OR_GENE_PRODUCT", 49, 53], ["TGEV", "ORGANISM", 97, 101], ["pAPN", "GENE_OR_GENE_PRODUCT", 110, 114], ["hAPN", "GENE_OR_GENE_PRODUCT", 123, 127], ["cellular", "CELL", 135, 143], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 158, 167], ["hAPN", "SIMPLE_CHEMICAL", 176, 180], ["HCoV", "PROTEIN", 30, 34], ["229E", "PROTEIN", 35, 39], ["pAPN", "PROTEIN", 44, 48], ["hAPN", "PROTEIN", 49, 53], ["pAPN", "PROTEIN", 110, 114], ["hAPN", "PROTEIN", 123, 127], ["cellular receptor", "PROTEIN", 135, 152], ["HCoV", "PROTEIN", 158, 162], ["hAPN", "PROTEIN", 176, 180], ["TGEV/HCoV-229E", "SPECIES", 25, 39], ["TGEV", "SPECIES", 97, 101], ["HCoV-229E", "SPECIES", 158, 167], ["TGEV/HCoV", "TEST", 25, 34]]], ["It was reported that transfection and expression of pAPN was sufficient to confer PEDV infection to a non-permissive canine kidney MDCK cell line, indicating pAPN is likely a functional receptor for PEDV as well (Li et al., 2007).", [["kidney MDCK cell line", "ANATOMY", 124, 145], ["infection", "DISEASE", 87, 96], ["pAPN", "GENE_OR_GENE_PRODUCT", 52, 56], ["PEDV", "GENE_OR_GENE_PRODUCT", 82, 86], ["canine", "ORGANISM", 117, 123], ["kidney MDCK cell line", "CELL", 124, 145], ["pAPN", "GENE_OR_GENE_PRODUCT", 158, 162], ["PEDV", "GENE_OR_GENE_PRODUCT", 199, 203], ["pAPN", "PROTEIN", 52, 56], ["non-permissive canine kidney MDCK cell line", "CELL_LINE", 102, 145], ["pAPN", "PROTEIN", 158, 162], ["canine", "SPECIES", 117, 123], ["PEDV", "SPECIES", 82, 86], ["canine", "SPECIES", 117, 123], ["PEDV", "SPECIES", 199, 203], ["expression of pAPN", "PROBLEM", 38, 56], ["PEDV infection", "PROBLEM", 82, 96], ["a non-permissive canine kidney MDCK cell line", "TREATMENT", 100, 145], ["PEDV", "PROBLEM", 199, 203], ["infection", "OBSERVATION", 87, 96], ["kidney", "ANATOMY", 124, 130], ["MDCK cell line", "OBSERVATION", 131, 145]]], ["Moreover, transgenic mice expressing pAPN confer susceptibility to PEDV (Park et al., 2015).", [["pAPN", "CHEMICAL", 37, 41], ["mice", "ORGANISM", 21, 25], ["pAPN", "GENE_OR_GENE_PRODUCT", 37, 41], ["pAPN", "PROTEIN", 37, 41], ["mice", "SPECIES", 21, 25], ["mice", "SPECIES", 21, 25], ["PEDV", "SPECIES", 67, 71]]], ["It was also reported that, unlike TGEV or HCoV-229E, PEDV spike protein-mediated pseudovirus was able to enter non-permissive canine kidney MDCK cells exogenously expressing either hAPN or pAPN, suggesting that the PEDV-APN interaction is not species specific (Liu et al., 2015).", [["kidney MDCK cells", "ANATOMY", 133, 150], ["HCoV-229E", "CHEMICAL", 42, 51], ["TGEV", "ORGANISM", 34, 38], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 42, 51], ["PEDV spike protein", "GENE_OR_GENE_PRODUCT", 53, 71], ["pseudovirus", "ORGANISM", 81, 92], ["canine", "ORGANISM", 126, 132], ["kidney MDCK cells", "CELL", 133, 150], ["hAPN", "GENE_OR_GENE_PRODUCT", 181, 185], ["pAPN", "GENE_OR_GENE_PRODUCT", 189, 193], ["PEDV", "GENE_OR_GENE_PRODUCT", 215, 219], ["APN", "GENE_OR_GENE_PRODUCT", 220, 223], ["PEDV spike protein", "PROTEIN", 53, 71], ["non-permissive canine kidney MDCK cells", "CELL_LINE", 111, 150], ["hAPN", "PROTEIN", 181, 185], ["pAPN", "PROTEIN", 189, 193], ["PEDV", "PROTEIN", 215, 219], ["APN", "PROTEIN", 220, 223], ["canine", "SPECIES", 126, 132], ["TGEV", "SPECIES", 34, 38], ["HCoV-229E", "SPECIES", 42, 51], ["canine", "SPECIES", 126, 132], ["HCoV", "TEST", 42, 46], ["PEDV spike protein-mediated pseudovirus", "PROBLEM", 53, 92], ["pAPN", "PROBLEM", 189, 193], ["the PEDV", "PROBLEM", 211, 219], ["kidney", "ANATOMY", 133, 139]]], ["Correspondingly, PEDV can infect various cell lines from human, monkey, pig and bat species (Liu et al., 2015), but whether species-specific APN functions as the PEDV entry receptor on the respective cell line has not been investigated.", [["cell lines", "ANATOMY", 41, 51], ["cell line", "ANATOMY", 200, 209], ["PEDV", "CHEMICAL", 17, 21], ["PEDV", "GENE_OR_GENE_PRODUCT", 17, 21], ["cell lines", "CELL", 41, 51], ["human", "ORGANISM", 57, 62], ["monkey", "ORGANISM", 64, 70], ["pig", "ORGANISM", 72, 75], ["bat", "ORGANISM", 80, 83], ["APN", "GENE_OR_GENE_PRODUCT", 141, 144], ["PEDV entry receptor", "GENE_OR_GENE_PRODUCT", 162, 181], ["cell line", "CELL", 200, 209], ["PEDV", "PROTEIN", 17, 21], ["cell lines", "CELL_LINE", 41, 51], ["APN", "PROTEIN", 141, 144], ["PEDV entry receptor", "PROTEIN", 162, 181], ["human", "SPECIES", 57, 62], ["monkey", "SPECIES", 64, 70], ["pig", "SPECIES", 72, 75], ["PEDV", "SPECIES", 17, 21], ["human", "SPECIES", 57, 62], ["pig", "SPECIES", 72, 75], ["PEDV", "PROBLEM", 17, 21], ["the respective cell line", "TREATMENT", 185, 209], ["various cell lines", "OBSERVATION", 33, 51], ["cell line", "OBSERVATION", 200, 209]]], ["However, most recently, two groups independently demonstrated that neither hAPN nor pAPN is the functional receptor for PEDV by using more comprehensive analyses, including knockout of endogenous expression of hAPN or pAPN in human or porcine cell lines by the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein-9 nuclease (Cas9) system (Li et al., 2017, Shirato et al., 2016).IntroductionAn African green monkey (Chlorocebus sabaeus) kidney cell line, Vero (ATCC CCL-81), is commonly used for PEDV adaption and culture in the presence of trypsin in vitro for research or vaccine production (Hofmann and Wyler, 1988, Pan et al., 2012).", [["cell lines", "ANATOMY", 243, 253], ["kidney cell line", "ANATOMY", 477, 493], ["Vero", "ANATOMY", 495, 499], ["ATCC CCL-81", "ANATOMY", 501, 512], ["CCL-81", "CHEMICAL", 506, 512], ["hAPN", "GENE_OR_GENE_PRODUCT", 75, 79], ["pAPN", "GENE_OR_GENE_PRODUCT", 84, 88], ["PEDV", "GENE_OR_GENE_PRODUCT", 120, 124], ["hAPN", "GENE_OR_GENE_PRODUCT", 210, 214], ["pAPN", "GENE_OR_GENE_PRODUCT", 218, 222], ["human", "ORGANISM", 226, 231], ["porcine cell lines", "CELL", 235, 253], ["CRISPR-associated protein-9 nuclease", "GENE_OR_GENE_PRODUCT", 328, 364], ["Cas9", "GENE_OR_GENE_PRODUCT", 366, 370], ["green monkey", "ORGANISM", 442, 454], ["Chlorocebus sabaeus", "ORGANISM", 456, 475], ["kidney cell line", "CELL", 477, 493], ["Vero", "CELL", 495, 499], ["ATCC CCL-81", "CELL", 501, 512], ["trypsin", "GENE_OR_GENE_PRODUCT", 581, 588], ["hAPN", "PROTEIN", 75, 79], ["pAPN", "PROTEIN", 84, 88], ["PEDV", "PROTEIN", 120, 124], ["hAPN", "PROTEIN", 210, 214], ["pAPN", "PROTEIN", 218, 222], ["human or porcine cell lines", "CELL_LINE", 226, 253], ["Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein-9 nuclease", "DNA", 261, 364], ["Cas9", "PROTEIN", 366, 370], ["African green monkey (Chlorocebus sabaeus) kidney cell line", "CELL_LINE", 434, 493], ["ATCC CCL-81", "CELL_LINE", 501, 512], ["trypsin", "PROTEIN", 581, 588], ["human", "SPECIES", 226, 231], ["green monkey", "SPECIES", 442, 454], ["Chlorocebus sabaeus", "SPECIES", 456, 475], ["human", "SPECIES", 226, 231], ["African green monkey", "SPECIES", 434, 454], ["Chlorocebus sabaeus", "SPECIES", 456, 475], ["ATCC CCL-81", "SPECIES", 501, 512], ["PEDV", "SPECIES", 536, 540], ["PEDV", "PROBLEM", 120, 124], ["hAPN", "TREATMENT", 210, 214], ["porcine cell lines", "TREATMENT", 235, 253], ["CRISPR", "TEST", 328, 334], ["protein", "TEST", 346, 353], ["IntroductionAn African green monkey (Chlorocebus sabaeus)", "TREATMENT", 419, 476], ["kidney cell line", "TREATMENT", 477, 493], ["Vero (ATCC CCL", "TREATMENT", 495, 509], ["PEDV adaption", "TREATMENT", 536, 549], ["culture", "TEST", 554, 561], ["trypsin", "PROBLEM", 581, 588], ["cell lines", "OBSERVATION", 243, 253], ["kidney", "ANATOMY", 477, 483], ["cell line", "OBSERVATION", 484, 493]]], ["Green monkey specific APN expressed on Vero cells (Vero-APN/vAPN) may serve as the entry receptor for PEDV (Li et al., 2007).", [["Vero cells", "ANATOMY", 39, 49], ["Green monkey", "ORGANISM", 0, 12], ["APN", "GENE_OR_GENE_PRODUCT", 22, 25], ["Vero cells", "CELL", 39, 49], ["Vero-APN", "GENE_OR_GENE_PRODUCT", 51, 59], ["vAPN", "GENE_OR_GENE_PRODUCT", 60, 64], ["APN", "PROTEIN", 22, 25], ["Vero cells", "CELL_LINE", 39, 49], ["APN", "PROTEIN", 56, 59], ["vAPN", "PROTEIN", 60, 64], ["Vero cells", "TREATMENT", 39, 49], ["Vero-APN/vAPN", "TREATMENT", 51, 64], ["PEDV", "PROBLEM", 102, 106], ["Vero cells", "OBSERVATION_MODIFIER", 39, 49]]], ["However, a few studies remarked Vero cells without APN expression, but no experimental evidences were provided in these publications (Li et al., 2016, Nam and Lee, 2010).", [["Vero cells", "ANATOMY", 32, 42], ["Vero cells", "CELL", 32, 42], ["APN", "GENE_OR_GENE_PRODUCT", 51, 54], ["Vero cells", "CELL_LINE", 32, 42], ["APN", "PROTEIN", 51, 54], ["a few studies", "TEST", 9, 22], ["Vero cells", "PROBLEM", 32, 42], ["APN expression", "PROBLEM", 51, 65], ["Vero cells", "OBSERVATION", 32, 42]]], ["Therefore, the aim of this study was to clarify the argument, investigating whether Vero-APN is indeed responsible for PEDV entry into Vero cells.", [["Vero cells", "ANATOMY", 135, 145], ["Vero-APN", "GENE_OR_GENE_PRODUCT", 84, 92], ["PEDV", "SIMPLE_CHEMICAL", 119, 123], ["Vero cells", "CELL", 135, 145], ["APN", "PROTEIN", 89, 92], ["PEDV", "PROTEIN", 119, 123], ["Vero cells", "CELL_LINE", 135, 145], ["PEDV", "SPECIES", 119, 123], ["this study", "TEST", 22, 32], ["PEDV", "PROBLEM", 119, 123], ["Vero cells", "OBSERVATION", 135, 145]]], ["Furthermore, we sought to test whether knockdown of pAPN expression on porcine small intestinal epithelial cell line, IPEC-J2, is correlated with PEDV infection in comparison with TGEV.Results and discussionWe first aimed to confirm if the putative green monkey APN (vAPN) gene exists in Vero cellular genome DNA.", [["small intestinal epithelial cell line", "ANATOMY", 79, 116], ["IPEC-J2", "ANATOMY", 118, 125], ["cellular", "ANATOMY", 293, 301], ["infection", "DISEASE", 151, 160], ["pAPN", "GENE_OR_GENE_PRODUCT", 52, 56], ["porcine", "ORGANISM", 71, 78], ["small intestinal epithelial cell line", "CELL", 79, 116], ["IPEC-J2", "CELL", 118, 125], ["PEDV", "GENE_OR_GENE_PRODUCT", 146, 150], ["TGEV", "ORGANISM", 180, 184], ["green monkey", "ORGANISM", 249, 261], ["APN", "GENE_OR_GENE_PRODUCT", 262, 265], ["vAPN", "GENE_OR_GENE_PRODUCT", 267, 271], ["Vero cellular", "CELL", 288, 301], ["DNA", "CELLULAR_COMPONENT", 309, 312], ["pAPN", "PROTEIN", 52, 56], ["porcine small intestinal epithelial cell line", "CELL_LINE", 71, 116], ["IPEC-J2", "CELL_LINE", 118, 125], ["putative green monkey APN (vAPN) gene", "DNA", 240, 277], ["Vero cellular genome DNA", "DNA", 288, 312], ["porcine", "SPECIES", 71, 78], ["PEDV", "SPECIES", 146, 150], ["TGEV", "SPECIES", 180, 184], ["green monkey", "SPECIES", 249, 261], ["pAPN expression", "PROBLEM", 52, 67], ["porcine small intestinal epithelial cell line", "TREATMENT", 71, 116], ["PEDV infection", "PROBLEM", 146, 160], ["the putative green monkey APN (vAPN)", "TREATMENT", 236, 272], ["Vero cellular genome DNA", "PROBLEM", 288, 312], ["small", "OBSERVATION_MODIFIER", 79, 84], ["intestinal", "ANATOMY", 85, 95], ["epithelial cell line", "OBSERVATION", 96, 116], ["J2", "ANATOMY", 123, 125], ["PEDV", "OBSERVATION_MODIFIER", 146, 150], ["infection", "OBSERVATION", 151, 160], ["genome DNA", "OBSERVATION", 302, 312]]], ["The 5\u2019-part of the vAPN gene (3,340 bp), which was not available on the public genome database, was cloned by genomic PCR from extracted Vero genomic DNA with a pair of PCR primers shared significant sequence homology with human, chimpanzee, rhesus monkey and pig APNs.", [["APNs", "ANATOMY", 264, 268], ["vAPN", "GENE_OR_GENE_PRODUCT", 19, 23], ["DNA", "CELLULAR_COMPONENT", 150, 153], ["human", "ORGANISM", 223, 228], ["chimpanzee", "ORGANISM", 230, 240], ["rhesus monkey", "ORGANISM", 242, 255], ["pig", "ORGANISM", 260, 263], ["APNs", "ORGANISM", 264, 268], ["5\u2019-part", "DNA", 4, 11], ["vAPN gene", "DNA", 19, 28], ["public genome database", "DNA", 72, 94], ["Vero genomic DNA", "DNA", 137, 153], ["PCR primers", "DNA", 169, 180], ["human", "SPECIES", 223, 228], ["chimpanzee", "SPECIES", 230, 240], ["rhesus monkey", "SPECIES", 242, 255], ["pig", "SPECIES", 260, 263], ["human", "SPECIES", 223, 228], ["rhesus monkey", "SPECIES", 242, 255], ["pig", "SPECIES", 260, 263], ["the vAPN gene", "TREATMENT", 15, 28], ["bp", "TEST", 36, 38], ["genomic PCR", "TEST", 110, 121], ["extracted Vero genomic DNA", "PROBLEM", 127, 153], ["a pair of PCR primers", "TREATMENT", 159, 180], ["human, chimpanzee, rhesus monkey", "TREATMENT", 223, 255], ["pig APNs", "TREATMENT", 260, 268]]], ["As illustrated inFig.", [["Fig", "OBSERVATION_MODIFIER", 17, 20]]], ["1, the partial cloned vAPN gene contains nine exons or coding DNA sequence (CDS).", [["vAPN", "GENE_OR_GENE_PRODUCT", 22, 26], ["DNA", "CELLULAR_COMPONENT", 62, 65], ["vAPN gene", "DNA", 22, 31], ["exons", "DNA", 46, 51], ["coding DNA sequence", "DNA", 55, 74], ["CDS", "DNA", 76, 79], ["the partial cloned vAPN gene", "TREATMENT", 3, 31], ["coding DNA sequence", "TEST", 55, 74]]], ["The start codon ATG is located at CDS1 having 617 base pair (bp), whereas the sizes of the other eight CDS (CDS2\u20139) vary from 66 to 155 bp (Fig. 1).", [["ATG", "AMINO_ACID", 16, 19], ["CDS1", "GENE_OR_GENE_PRODUCT", 34, 38], ["start codon ATG", "DNA", 4, 19], ["CDS1", "DNA", 34, 38], ["617 base pair", "DNA", 46, 59], ["CDS", "DNA", 103, 106], ["CDS2\u20139", "DNA", 108, 114], ["The start codon ATG", "TREATMENT", 0, 19], ["bp", "TEST", 61, 63], ["bp", "TEST", 136, 138], ["sizes", "OBSERVATION_MODIFIER", 78, 83]]], ["The partial cloned vAPN gene and its encoding cDNA (1,572 bp in size) share 97.9% and 98.9% sequence homology with the available rhesus monkey APN gene and cDNA, respectively.", [["vAPN", "GENE_OR_GENE_PRODUCT", 19, 23], ["rhesus", "ORGANISM", 129, 135], ["monkey", "ORGANISM", 136, 142], ["APN", "GENE_OR_GENE_PRODUCT", 143, 146], ["vAPN gene", "DNA", 19, 28], ["cDNA", "DNA", 46, 50], ["rhesus monkey APN gene", "DNA", 129, 151], ["cDNA", "DNA", 156, 160], ["rhesus monkey", "SPECIES", 129, 142], ["rhesus monkey", "SPECIES", 129, 142], ["The partial cloned vAPN gene", "TREATMENT", 0, 28], ["its encoding cDNA", "TEST", 33, 50], ["bp", "TEST", 58, 60]]], ["Attempts to amplification of the entire or the 5\u2019-partial vAPN mRNA by RT-PCR were failed.", [["vAPN", "GENE_OR_GENE_PRODUCT", 58, 62], ["5\u2019-partial vAPN mRNA", "RNA", 47, 67], ["partial vAPN mRNA", "TREATMENT", 50, 67], ["RT-PCR", "TEST", 71, 77]]], ["Therefore, we performed a quantitative real-time PCR (qRT-PCR) analysis to detect if vAPN mRNA is expressed endogenously in Vero cells.", [["Vero cells", "ANATOMY", 124, 134], ["vAPN", "GENE_OR_GENE_PRODUCT", 85, 89], ["Vero cells", "CELL", 124, 134], ["vAPN mRNA", "RNA", 85, 94], ["Vero cells", "CELL_LINE", 124, 134], ["time PCR", "TEST", 44, 52], ["qRT", "TEST", 54, 57], ["analysis", "TEST", 63, 71], ["vAPN mRNA", "PROBLEM", 85, 94], ["Vero cells", "OBSERVATION", 124, 134]]], ["As a control we examined hAPN mRNA expression in Huh-7 cells.", [["Huh-7 cells", "ANATOMY", 49, 60], ["hAPN", "GENE_OR_GENE_PRODUCT", 25, 29], ["Huh-7 cells", "CELL", 49, 60], ["hAPN mRNA", "RNA", 25, 34], ["Huh-7 cells", "CELL_LINE", 49, 60], ["Huh-7", "SPECIES", 49, 54], ["Huh", "TEST", 49, 52]]], ["When we confirmed endogenous hAPN mRNA expression, which was in line with the previously publications (Li et al., 2017, Liu et al., 2015), relative quantification of vAPN mRNA level to the green monkey \u03b2-actin control in Vero cells did not give a convincingly positive value in a cell-culture period of 3 days (data not shown).", [["Vero cells", "ANATOMY", 221, 231], ["cell", "ANATOMY", 280, 284], ["hAPN", "GENE_OR_GENE_PRODUCT", 29, 33], ["vAPN", "GENE_OR_GENE_PRODUCT", 166, 170], ["green monkey", "ORGANISM", 189, 201], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 202, 209], ["Vero cells", "CELL", 221, 231], ["cell", "CELL", 280, 284], ["hAPN mRNA", "RNA", 29, 38], ["vAPN mRNA", "RNA", 166, 175], ["Vero cells", "CELL_LINE", 221, 231], ["green monkey", "SPECIES", 189, 201], ["endogenous hAPN mRNA expression", "PROBLEM", 18, 49], ["vAPN mRNA level", "PROBLEM", 166, 181], ["Vero cells", "PROBLEM", 221, 231], ["a convincingly positive value", "PROBLEM", 245, 274]]], ["The result indicated that vAPN mRNA was expressed under the detection limit or was deficient in expression.Results and discussionWe further examined endogenous and exogenous expression of APN in the protein level using a broadly reactive anti-APN antibody by immunofluorescence assay (IFA) and western blot (WB) analysis.", [["vAPN", "GENE_OR_GENE_PRODUCT", 26, 30], ["APN", "GENE_OR_GENE_PRODUCT", 188, 191], ["anti-APN", "SIMPLE_CHEMICAL", 238, 246], ["vAPN mRNA", "RNA", 26, 35], ["APN", "PROTEIN", 188, 191], ["anti-APN antibody", "PROTEIN", 238, 255], ["vAPN mRNA", "PROBLEM", 26, 35], ["APN in the protein level", "PROBLEM", 188, 212], ["a broadly reactive anti-APN antibody", "TEST", 219, 255], ["immunofluorescence assay", "TEST", 259, 283], ["western blot (WB) analysis", "TEST", 294, 320]]], ["For comparison, two recombinant APN expression plasmids were constructed.", [["APN", "GENE_OR_GENE_PRODUCT", 32, 35], ["recombinant APN expression plasmids", "DNA", 20, 55], ["two recombinant APN expression plasmids", "TREATMENT", 16, 55]]], ["Plasmid pCI-pAPN harbored the full-length porcine APN cDNA (2,892 bp) whereas plasmid pRK-vAPN contained the nine CDS of vAPN without introns followed by a stop codon (1,575 bp) that were fused sequentially by overlapping PCR.", [["pCI-pAPN", "GENE_OR_GENE_PRODUCT", 8, 16], ["porcine", "ORGANISM", 42, 49], ["APN", "GENE_OR_GENE_PRODUCT", 50, 53], ["pRK-vAPN", "GENE_OR_GENE_PRODUCT", 86, 94], ["vAPN", "GENE_OR_GENE_PRODUCT", 121, 125], ["pCI", "DNA", 8, 11], ["pAPN", "DNA", 12, 16], ["APN cDNA", "DNA", 50, 58], ["2,892 bp", "DNA", 60, 68], ["pRK", "DNA", 86, 89], ["vAPN", "DNA", 90, 94], ["CDS", "DNA", 114, 117], ["vAPN", "DNA", 121, 125], ["introns", "DNA", 134, 141], ["stop codon", "DNA", 156, 166], ["Plasmid pCI", "TREATMENT", 0, 11], ["the full-length porcine APN cDNA", "TREATMENT", 26, 58], ["bp", "TEST", 66, 68], ["plasmid pRK", "TREATMENT", 78, 89], ["vAPN", "TREATMENT", 90, 94], ["vAPN", "TREATMENT", 121, 125], ["introns", "TREATMENT", 134, 141], ["a stop codon", "TREATMENT", 154, 166], ["bp", "TEST", 174, 176], ["overlapping PCR", "TEST", 210, 225], ["pCI", "OBSERVATION", 8, 11]]], ["Vero or Huh-7 cells were transfected with either of the two plasmids.", [["Vero", "ANATOMY", 0, 4], ["Huh-7 cells", "ANATOMY", 8, 19], ["plasmids", "ANATOMY", 60, 68], ["Vero", "CELL", 0, 4], ["Huh-7 cells", "CELL", 8, 19], ["Huh-7 cells", "CELL_LINE", 8, 19], ["plasmids", "DNA", 60, 68], ["Vero", "TEST", 0, 4], ["Huh", "TEST", 8, 11], ["the two plasmids", "TREATMENT", 52, 68]]], ["At 48 hour post-transfection, transfected or untransfected cells were subjected to IFA or WB.", [["cells", "ANATOMY", 59, 64], ["WB", "ANATOMY", 90, 92], ["cells", "CELL", 59, 64], ["untransfected cells", "CELL_LINE", 45, 64], ["transfected or untransfected cells", "PROBLEM", 30, 64], ["IFA", "TEST", 83, 86]]], ["Specific anti-APN fluorescence signal was detected in transfected Vero or Huh-7 cells as well as untransfected Huh-7 cells (though the intensity was weak), but not observed in untransfected Vero cells (Fig. 2A).", [["Vero", "ANATOMY", 66, 70], ["Huh-7 cells", "ANATOMY", 74, 85], ["Huh-7 cells", "ANATOMY", 111, 122], ["Vero cells", "ANATOMY", 190, 200], ["anti-APN", "GENE_OR_GENE_PRODUCT", 9, 17], ["Vero", "CELL", 66, 70], ["Huh-7 cells", "CELL", 74, 85], ["Huh-7 cells", "CELL", 111, 122], ["Vero cells", "CELL", 190, 200], ["Fig. 2A", "CELL", 202, 209], ["anti-APN", "PROTEIN", 9, 17], ["Huh-7 cells", "CELL_LINE", 74, 85], ["untransfected Huh-7 cells", "CELL_LINE", 97, 122], ["untransfected Vero cells", "CELL_LINE", 176, 200], ["Specific anti-APN fluorescence signal", "TEST", 0, 37], ["transfected Vero", "TEST", 54, 70], ["Huh", "TEST", 74, 77], ["untransfected Huh", "TEST", 97, 114], ["Vero cells", "OBSERVATION", 190, 200]]], ["The WB analysis was consistent with the IFA result, showing individual bands of distinct sizes representing the full-length APN (APN-FL) or the partial APN (vAPN-CDS1\u20139) in pCI-pAPN- or pRK-vAPN-transfected Vero cells, whereas no bands were detected in untransfected Vero cells (Fig. 2B).", [["WB", "ANATOMY", 4, 6], ["Vero cells", "ANATOMY", 207, 217], ["Vero cells", "ANATOMY", 267, 277], ["APN", "GENE_OR_GENE_PRODUCT", 124, 127], ["APN-FL", "GENE_OR_GENE_PRODUCT", 129, 135], ["APN", "GENE_OR_GENE_PRODUCT", 152, 155], ["vAPN-CDS1\u20139", "GENE_OR_GENE_PRODUCT", 157, 168], ["pCI-pAPN", "GENE_OR_GENE_PRODUCT", 173, 181], ["pRK-vAPN", "GENE_OR_GENE_PRODUCT", 186, 194], ["Vero cells", "CELL", 207, 217], ["Vero cells", "CELL", 267, 277], ["Fig. 2B", "CELL", 279, 286], ["APN", "PROTEIN", 124, 127], ["APN", "PROTEIN", 129, 132], ["FL", "PROTEIN", 133, 135], ["APN", "PROTEIN", 152, 155], ["vAPN", "PROTEIN", 157, 161], ["CDS1\u20139", "PROTEIN", 162, 168], ["pCI-pAPN- or pRK-vAPN-transfected Vero cells", "CELL_LINE", 173, 217], ["untransfected Vero cells", "CELL_LINE", 253, 277], ["The WB analysis", "TEST", 0, 15], ["the IFA result", "TEST", 36, 50], ["individual bands of distinct sizes", "PROBLEM", 60, 94], ["APN", "TEST", 129, 132], ["the partial APN", "PROBLEM", 140, 155], ["vAPN", "TEST", 157, 161], ["pCI", "TEST", 173, 176], ["pAPN", "TEST", 177, 181], ["pRK", "TEST", 186, 189], ["vAPN", "TEST", 190, 194], ["transfected Vero cells", "PROBLEM", 195, 217], ["bands", "PROBLEM", 230, 235], ["consistent with", "UNCERTAINTY", 20, 35], ["distinct", "OBSERVATION_MODIFIER", 80, 88], ["sizes", "OBSERVATION_MODIFIER", 89, 94], ["Vero cells", "OBSERVATION", 207, 217], ["Vero cells", "OBSERVATION", 267, 277]]], ["In contrast, Huh-7 cells displayed a band corresponding to APN-FL regardless whether transfection with pCI-pAPN- or pRK-vAPN or not (Fig. 2B).", [["Huh-7 cells", "ANATOMY", 13, 24], ["Huh-7 cells", "CELL", 13, 24], ["APN-FL", "GENE_OR_GENE_PRODUCT", 59, 65], ["pCI-pAPN", "GENE_OR_GENE_PRODUCT", 103, 111], ["pRK-vAPN", "GENE_OR_GENE_PRODUCT", 116, 124], ["Huh-7 cells", "CELL_LINE", 13, 24], ["APN", "PROTEIN", 59, 62], ["pCI", "PROTEIN", 103, 106], ["pAPN", "PROTEIN", 107, 111], ["pRK", "PROTEIN", 116, 119], ["vAPN", "PROTEIN", 120, 124], ["Huh", "TEST", 13, 16], ["a band", "PROBLEM", 35, 41], ["APN", "TEST", 59, 62], ["pCI", "TEST", 103, 106], ["pAPN", "TEST", 107, 111], ["pRK", "TREATMENT", 116, 119], ["vAPN", "TREATMENT", 120, 124]]], ["Theses results indicated that Huh-7 cells express hAPN endogenously while Vero cells probably do not express vAPN inherently.Results and discussionTo further examine the effects of anti-APN antibody on PEDV entry into these two cell lines, we carried out quantitative PEDV infection analysis with a recombinant PEDV-GFP (see \u201cMaterials and methods\u201d).", [["Huh-7 cells", "ANATOMY", 30, 41], ["Vero cells", "ANATOMY", 74, 84], ["cell lines", "ANATOMY", 228, 238], ["infection", "DISEASE", 273, 282], ["Huh-7 cells", "CELL", 30, 41], ["hAPN", "GENE_OR_GENE_PRODUCT", 50, 54], ["Vero cells", "CELL", 74, 84], ["vAPN", "GENE_OR_GENE_PRODUCT", 109, 113], ["anti-APN antibody", "GENE_OR_GENE_PRODUCT", 181, 198], ["PEDV", "SIMPLE_CHEMICAL", 202, 206], ["cell lines", "CELL", 228, 238], ["GFP", "GENE_OR_GENE_PRODUCT", 316, 319], ["Huh-7 cells", "CELL_LINE", 30, 41], ["hAPN", "PROTEIN", 50, 54], ["Vero cells", "CELL_LINE", 74, 84], ["vAPN", "PROTEIN", 109, 113], ["anti-APN antibody", "PROTEIN", 181, 198], ["cell lines", "CELL_LINE", 228, 238], ["PEDV", "PROTEIN", 311, 315], ["GFP", "PROTEIN", 316, 319], ["PEDV", "SPECIES", 202, 206], ["PEDV", "SPECIES", 311, 315], ["Huh", "TEST", 30, 33], ["Vero cells", "PROBLEM", 74, 84], ["anti-APN antibody", "TREATMENT", 181, 198], ["PEDV entry", "TREATMENT", 202, 212], ["quantitative PEDV infection analysis", "PROBLEM", 255, 291], ["a recombinant PEDV", "TEST", 297, 315], ["two cell lines", "OBSERVATION", 224, 238]]], ["Either Vero or Huh-7 cells were infected efficiently by PEDV-GFP, showing clear GFP fluorescence co-localized with cytopathic effects (CPE), which could be assessed by counting the numbers of GFP-positive cell clusters (Fig. 3A).", [["Vero", "ANATOMY", 7, 11], ["Huh-7 cells", "ANATOMY", 15, 26], ["cell", "ANATOMY", 205, 209], ["Vero", "CELL", 7, 11], ["Huh-7 cells", "CELL", 15, 26], ["PEDV-GFP", "GENE_OR_GENE_PRODUCT", 56, 64], ["GFP", "GENE_OR_GENE_PRODUCT", 80, 83], ["GFP", "GENE_OR_GENE_PRODUCT", 192, 195], ["Vero or Huh-7 cells", "CELL_LINE", 7, 26], ["PEDV", "PROTEIN", 56, 60], ["GFP", "PROTEIN", 61, 64], ["GFP", "PROTEIN", 192, 195], ["PEDV", "SPECIES", 56, 60], ["Huh", "TEST", 15, 18], ["PEDV-GFP", "TEST", 56, 64], ["clear GFP fluorescence", "PROBLEM", 74, 96], ["cytopathic effects (CPE", "PROBLEM", 115, 138], ["GFP", "TEST", 192, 195], ["cytopathic", "OBSERVATION_MODIFIER", 115, 125], ["positive cell clusters", "OBSERVATION", 196, 218]]], ["Moreover, PEDV-GFP infection of two cell lines could be neutralized by anti-PEDV-S IgM or IgG in a dose-dependent manner (Fig. 3B), indicating that it is an appropriate in vitro model for quantification of PEDV infection.", [["cell lines", "ANATOMY", 36, 46], ["PEDV", "CHEMICAL", 10, 14], ["infection", "DISEASE", 19, 28], ["infection", "DISEASE", 211, 220], ["PEDV-GFP", "GENE_OR_GENE_PRODUCT", 10, 18], ["cell lines", "CELL", 36, 46], ["anti-PEDV-S IgM", "GENE_OR_GENE_PRODUCT", 71, 86], ["IgG", "GENE_OR_GENE_PRODUCT", 90, 93], ["PEDV", "ORGANISM", 206, 210], ["PEDV", "PROTEIN", 10, 14], ["cell lines", "CELL_LINE", 36, 46], ["anti-PEDV", "PROTEIN", 71, 80], ["S IgM", "PROTEIN", 81, 86], ["IgG", "PROTEIN", 90, 93], ["anti-PEDV", "SPECIES", 71, 80], ["PEDV", "SPECIES", 206, 210], ["PEDV", "PROBLEM", 10, 14], ["GFP infection", "PROBLEM", 15, 28], ["two cell lines", "TREATMENT", 32, 46], ["anti-PEDV", "TEST", 71, 80], ["S IgM", "TEST", 81, 86], ["IgG", "TREATMENT", 90, 93], ["PEDV infection", "PROBLEM", 206, 220], ["GFP infection", "OBSERVATION", 15, 28], ["two cell lines", "OBSERVATION", 32, 46], ["PEDV", "OBSERVATION_MODIFIER", 206, 210], ["infection", "OBSERVATION", 211, 220]]], ["When anti-APN antibody at 2 \u03bcg/ml or 20 mg/ml was incubated with the cells prior to PEDV-GFP infection, it did not block PEDV-GFP entry or infection in Vero cells at 12 or 24 hour post-infection (hpi; Fig. 3C).", [["cells", "ANATOMY", 69, 74], ["Vero cells", "ANATOMY", 152, 162], ["PEDV", "CHEMICAL", 84, 88], ["infection", "DISEASE", 93, 102], ["infection", "DISEASE", 139, 148], ["infection", "DISEASE", 185, 194], ["anti-APN antibody", "GENE_OR_GENE_PRODUCT", 5, 22], ["cells", "CELL", 69, 74], ["PEDV-GFP", "GENE_OR_GENE_PRODUCT", 84, 92], ["PEDV-GFP", "GENE_OR_GENE_PRODUCT", 121, 129], ["Vero cells", "CELL", 152, 162], ["anti-APN antibody", "PROTEIN", 5, 22], ["PEDV", "PROTEIN", 121, 125], ["Vero cells", "CELL_LINE", 152, 162], ["PEDV", "SPECIES", 84, 88], ["anti-APN antibody", "TREATMENT", 5, 22], ["the cells", "PROBLEM", 65, 74], ["PEDV", "PROBLEM", 84, 88], ["GFP infection", "PROBLEM", 89, 102], ["PEDV", "PROBLEM", 121, 125], ["GFP entry", "PROBLEM", 126, 135], ["infection in Vero cells", "PROBLEM", 139, 162], ["infection", "PROBLEM", 185, 194], ["infection", "OBSERVATION", 93, 102], ["infection", "OBSERVATION", 139, 148], ["infection", "OBSERVATION", 185, 194]]], ["For Huh-7 cells, it was observed that pretreatment with the antibody significantly decreased GFP-positive cell cluster numbers at 12 hpi; however, there was no differences in comparison with untreated cells at 24 hpi (Fig. 3C).", [["Huh-7 cells", "ANATOMY", 4, 15], ["cell", "ANATOMY", 106, 110], ["cells", "ANATOMY", 201, 206], ["Huh-7 cells", "CELL", 4, 15], ["GFP", "GENE_OR_GENE_PRODUCT", 93, 96], ["cell", "CELL", 106, 110], ["cells", "CELL", 201, 206], ["Huh-7 cells", "CELL_LINE", 4, 15], ["GFP", "PROTEIN", 93, 96], ["untreated cells", "CELL_TYPE", 191, 206], ["Huh-7 cells", "PROBLEM", 4, 15], ["the antibody", "TEST", 56, 68], ["GFP", "TEST", 93, 96], ["positive cell cluster numbers", "PROBLEM", 97, 126], ["untreated cells", "PROBLEM", 191, 206], ["7 cells", "OBSERVATION_MODIFIER", 8, 15], ["positive cell", "OBSERVATION", 97, 110]]], ["Shirato and his colleagues reported that pAPN promotes PEDV infection through its protease activity rather than its proposed receptor function (Shirato et al., 2016).", [["pAPN", "CHEMICAL", 41, 45], ["PEDV", "CHEMICAL", 55, 59], ["infection", "DISEASE", 60, 69], ["pAPN", "GENE_OR_GENE_PRODUCT", 41, 45], ["PEDV", "GENE_OR_GENE_PRODUCT", 55, 59], ["protease", "PROTEIN", 82, 90], ["PEDV", "SPECIES", 55, 59], ["PEDV infection", "PROBLEM", 55, 69], ["its protease activity", "TREATMENT", 78, 99], ["PEDV", "OBSERVATION_MODIFIER", 55, 59], ["infection", "OBSERVATION", 60, 69]]], ["Since the protease active sites are highly conserved between hAPN and pAPN (Delmas et al., 1994), it is hypothesized that the anti-APN antibody blocked PEDV infection by targeting the enzymatically catalytic sites of hAPN on Huh-7 cells in the early stage (0\u201312 hpi).", [["Huh-7 cells", "ANATOMY", 225, 236], ["PEDV", "CHEMICAL", 152, 156], ["infection", "DISEASE", 157, 166], ["hAPN", "GENE_OR_GENE_PRODUCT", 61, 65], ["anti-APN antibody", "GENE_OR_GENE_PRODUCT", 126, 143], ["PEDV", "SIMPLE_CHEMICAL", 152, 156], ["hAPN", "GENE_OR_GENE_PRODUCT", 217, 221], ["Huh-7 cells", "CELL", 225, 236], ["protease active sites", "PROTEIN", 10, 31], ["anti-APN antibody", "PROTEIN", 126, 143], ["enzymatically catalytic sites", "DNA", 184, 213], ["hAPN", "PROTEIN", 217, 221], ["Huh-7 cells", "CELL_LINE", 225, 236], ["PEDV", "SPECIES", 152, 156], ["the protease active sites", "PROBLEM", 6, 31], ["the anti-APN antibody", "PROBLEM", 122, 143], ["PEDV infection", "PROBLEM", 152, 166], ["Huh", "TEST", 225, 228], ["infection", "OBSERVATION", 157, 166], ["early stage", "OBSERVATION_MODIFIER", 244, 255]]], ["The inhibited effect was likely diminished when PEDV continued to propagate and spread thereafter.", [["PEDV", "CHEMICAL", 48, 52], ["PEDV", "CHEMICAL", 48, 52], ["PEDV", "PROTEIN", 48, 52], ["PEDV", "SPECIES", 48, 52], ["diminished", "PROBLEM", 32, 42], ["PEDV", "PROBLEM", 48, 52], ["likely", "UNCERTAINTY", 25, 31], ["diminished", "OBSERVATION_MODIFIER", 32, 42]]], ["These results demonstrated that anti-APN antibody had no effects on PEDV entry into Vero cells, probably due to the absence of vAPN expression.Results and discussionIn order to completely rule out the potential vAPN production in Vero cells that may be under the detection limit, we set out to generate vAPN-knockout cells using CRISPR/Cas9 system.", [["Vero cells", "ANATOMY", 84, 94], ["Vero cells", "ANATOMY", 230, 240], ["cells", "ANATOMY", 317, 322], ["anti-APN antibody", "GENE_OR_GENE_PRODUCT", 32, 49], ["PEDV", "SIMPLE_CHEMICAL", 68, 72], ["Vero cells", "CELL", 84, 94], ["vAPN", "GENE_OR_GENE_PRODUCT", 127, 131], ["vAPN", "SIMPLE_CHEMICAL", 211, 215], ["Vero cells", "CELL", 230, 240], ["vAPN", "GENE_OR_GENE_PRODUCT", 303, 307], ["cells", "CELL", 317, 322], ["CRISPR/Cas9", "GENE_OR_GENE_PRODUCT", 329, 340], ["anti-APN antibody", "PROTEIN", 32, 49], ["Vero cells", "CELL_LINE", 84, 94], ["vAPN", "PROTEIN", 127, 131], ["Vero cells", "CELL_LINE", 230, 240], ["vAPN-knockout cells", "CELL_LINE", 303, 322], ["CRISPR", "DNA", 329, 335], ["PEDV", "SPECIES", 68, 72], ["anti-APN antibody", "TEST", 32, 49], ["PEDV entry into Vero cells", "PROBLEM", 68, 94], ["vAPN expression", "PROBLEM", 127, 142], ["the potential vAPN production in Vero cells", "PROBLEM", 197, 240], ["vAPN-knockout cells", "TREATMENT", 303, 322], ["CRISPR/Cas9 system", "TREATMENT", 329, 347], ["Vero cells", "OBSERVATION", 84, 94]]], ["A single-plasmid CRISPR/Cas9 approach was developed, in which two guide RNA (gRNA) molecules and the Cas9 enzyme followed by a puromycin resistance gene are simultaneously expressed (Fig. 4A).", [["puromycin", "CHEMICAL", 127, 136], ["puromycin", "CHEMICAL", 127, 136], ["Cas9", "GENE_OR_GENE_PRODUCT", 101, 105], ["puromycin", "SIMPLE_CHEMICAL", 127, 136], ["Cas9", "DNA", 24, 28], ["guide RNA (gRNA) molecules", "PROTEIN", 66, 92], ["Cas9 enzyme", "PROTEIN", 101, 112], ["puromycin resistance gene", "DNA", 127, 152], ["A single-plasmid CRISPR/Cas9 approach", "TREATMENT", 0, 37], ["the Cas9 enzyme", "TEST", 97, 112], ["a puromycin resistance gene", "TREATMENT", 125, 152], ["puromycin resistance", "OBSERVATION", 127, 147]]], ["We designed a knockout strategy using an engineered pX480-vAPNKO plasmid by targeting the vAPN CDS1 with two gRNA/Cas9 complexes to delete a 160-bp fragment between nucleotides 290\u2013449 downstream of the translation initiation site (Fig. 1).", [["nucleotides 290\u2013449", "CHEMICAL", 165, 184], ["nucleotides", "CHEMICAL", 165, 176], ["pX480", "GENE_OR_GENE_PRODUCT", 52, 57], ["vAPN CDS1", "GENE_OR_GENE_PRODUCT", 90, 99], ["Cas9", "GENE_OR_GENE_PRODUCT", 114, 118], ["pX480-vAPNKO plasmid", "DNA", 52, 72], ["vAPN CDS1", "PROTEIN", 90, 99], ["gRNA/Cas9 complexes", "PROTEIN", 109, 128], ["160-bp fragment", "DNA", 141, 156], ["nucleotides 290\u2013449 downstream", "DNA", 165, 195], ["translation initiation site", "DNA", 203, 230], ["a knockout strategy", "TREATMENT", 12, 31], ["an engineered pX480-vAPNKO plasmid", "TREATMENT", 38, 72], ["the vAPN CDS1", "TREATMENT", 86, 99], ["two gRNA/Cas9 complexes", "TREATMENT", 105, 128], ["bp fragment between nucleotides", "TREATMENT", 145, 176]]], ["At 3 days post-transfection with the pX480-vAPNKO plasmid plus puromycin selection, the genomic DNA was isolated and tested for vAPN gene integrity by PCR.", [["puromycin", "CHEMICAL", 63, 72], ["puromycin", "CHEMICAL", 63, 72], ["pX480", "GENE_OR_GENE_PRODUCT", 37, 42], ["puromycin", "SIMPLE_CHEMICAL", 63, 72], ["DNA", "CELLULAR_COMPONENT", 96, 99], ["vAPN", "GENE_OR_GENE_PRODUCT", 128, 132], ["pX480", "DNA", 37, 42], ["vAPNKO plasmid", "DNA", 43, 57], ["genomic DNA", "DNA", 88, 99], ["vAPN gene", "DNA", 128, 137], ["the pX480-vAPNKO plasmid", "TREATMENT", 33, 57], ["puromycin selection", "TREATMENT", 63, 82], ["the genomic DNA", "PROBLEM", 84, 99], ["vAPN gene integrity", "TREATMENT", 128, 147]]], ["It was shown that two different cell pools (using the same approach in two batches) possessed the intended vAPN deletion fragment, displaying weak bands smaller than the intact CDS1 (Fig. 4B).", [["cell", "ANATOMY", 32, 36], ["cell", "CELL", 32, 36], ["vAPN", "GENE_OR_GENE_PRODUCT", 107, 111], ["vAPN deletion fragment", "DNA", 107, 129], ["CDS1", "PROTEIN", 177, 181], ["Fig. 4B", "PROTEIN", 183, 190], ["two different cell pools", "PROBLEM", 18, 42], ["the same approach in two batches", "TREATMENT", 50, 82], ["the intended vAPN deletion fragment", "PROBLEM", 94, 129], ["weak bands", "PROBLEM", 142, 152], ["different", "OBSERVATION_MODIFIER", 22, 31], ["cell pools", "OBSERVATION", 32, 42], ["vAPN deletion", "OBSERVATION", 107, 120], ["fragment", "OBSERVATION_MODIFIER", 121, 129], ["weak", "OBSERVATION_MODIFIER", 142, 146], ["bands", "OBSERVATION_MODIFIER", 147, 152], ["smaller", "OBSERVATION_MODIFIER", 153, 160]]], ["From these cell pools, we generated single cell clones, designated as vAPNKO1 and vAPNKO2, by limiting dilution with puromycin selection again.", [["cell", "ANATOMY", 11, 15], ["cell clones", "ANATOMY", 43, 54], ["puromycin", "CHEMICAL", 117, 126], ["puromycin", "CHEMICAL", 117, 126], ["cell", "CELL", 11, 15], ["single cell clones", "CELL", 36, 54], ["vAPNKO1", "GENE_OR_GENE_PRODUCT", 70, 77], ["vAPNKO2", "GENE_OR_GENE_PRODUCT", 82, 89], ["puromycin", "SIMPLE_CHEMICAL", 117, 126], ["single cell clones", "CELL_LINE", 36, 54], ["vAPNKO1", "CELL_LINE", 70, 77], ["vAPNKO2", "CELL_LINE", 82, 89], ["single cell clones", "TREATMENT", 36, 54], ["vAPNKO1", "TREATMENT", 70, 77], ["vAPNKO2", "TREATMENT", 82, 89], ["puromycin selection", "TREATMENT", 117, 136], ["cell pools", "OBSERVATION", 11, 21], ["cell clones", "OBSERVATION", 43, 54]]], ["However, the intended vAPN deletion fragment was not visible in the clone vAPNKO1 (Fig. 4C).", [["vAPN", "GENE_OR_GENE_PRODUCT", 22, 26], ["vAPN deletion fragment", "DNA", 22, 44], ["clone vAPNKO1", "CELL_LINE", 68, 81], ["the intended vAPN deletion fragment", "PROBLEM", 9, 44], ["fragment", "OBSERVATION_MODIFIER", 36, 44], ["not", "UNCERTAINTY", 49, 52], ["visible", "OBSERVATION_MODIFIER", 53, 60]]], ["Sequence analysis of the PCR products of the clone vAPNKO1 revealed that there was only a 5-bp deletion (nt 290\u2013294) downstream of the fist Cas9 cleavage site (Fig. 4D).", [["vAPNKO1", "GENE_OR_GENE_PRODUCT", 51, 58], ["Cas9", "GENE_OR_GENE_PRODUCT", 140, 144], ["clone vAPNKO1", "DNA", 45, 58], ["5-bp deletion", "DNA", 90, 103], ["nt 290\u2013294", "DNA", 105, 115], ["fist Cas9 cleavage site", "DNA", 135, 158], ["Sequence analysis", "TEST", 0, 17], ["the PCR", "TEST", 21, 28], ["the clone vAPNKO1", "TEST", 41, 58], ["a 5-bp deletion", "PROBLEM", 88, 103], ["fist Cas9", "ANATOMY", 135, 144]]], ["The single cell clone vAPNKO2 displayed the intended vAPN deletion fragment that was subsequently confirmed to have the expected 160-bp deletion by sequencing (Fig. 4C and D).", [["cell clone", "ANATOMY", 11, 21], ["single cell clone", "CELL", 4, 21], ["vAPN", "GENE_OR_GENE_PRODUCT", 53, 57], ["vAPN deletion fragment", "DNA", 53, 75], ["160-bp deletion", "DNA", 129, 144], ["The single cell clone vAPNKO2", "TREATMENT", 0, 29], ["the intended vAPN deletion fragment", "PROBLEM", 40, 75], ["vAPN deletion", "OBSERVATION", 53, 66]]], ["Nevertheless, either of the deletions in vAPNKO1 or vAPNKO2 would result in a frameshift of vAPN allele.Results and discussionWe next confirmed that these knockout cells, Vero-vAPNKO1 and Vero-vAPNKO2, were deficient in vAPN expression by IFA (Fig. 5A).", [["cells", "ANATOMY", 164, 169], ["vAPNKO1", "GENE_OR_GENE_PRODUCT", 41, 48], ["vAPNKO2", "GENE_OR_GENE_PRODUCT", 52, 59], ["vAPN", "GENE_OR_GENE_PRODUCT", 92, 96], ["cells", "CELL", 164, 169], ["Vero-vAPNKO1", "GENE_OR_GENE_PRODUCT", 171, 183], ["Vero-vAPNKO2", "GENE_OR_GENE_PRODUCT", 188, 200], ["vAPN", "GENE_OR_GENE_PRODUCT", 220, 224], ["vAPNKO1", "DNA", 41, 48], ["vAPNKO2", "DNA", 52, 59], ["vAPN allele", "DNA", 92, 103], ["knockout cells", "CELL_TYPE", 155, 169], ["Vero-vAPNKO1", "PROTEIN", 171, 183], ["Vero-vAPNKO2", "CELL_LINE", 188, 200], ["vAPN", "PROTEIN", 220, 224], ["the deletions in vAPNKO1", "PROBLEM", 24, 48], ["vAPNKO2", "TREATMENT", 52, 59], ["a frameshift of vAPN allele", "PROBLEM", 76, 103], ["these knockout cells", "PROBLEM", 149, 169], ["Vero-vAPNKO1", "TREATMENT", 171, 183], ["Vero-vAPNKO2", "TREATMENT", 188, 200]]], ["Upon PEDV-GFP infection, both Vero-vAPNKO1 and Vero-vAPNKO2 cells exhibited consequent CPE and GFP expression similar to normal Vero cells, indicating that vAPN knockout had no effects on PEDV entry and infection (Fig. 5B).", [["Vero-vAPNKO2 cells", "ANATOMY", 47, 65], ["Vero cells", "ANATOMY", 128, 138], ["infection", "DISEASE", 203, 212], ["PEDV", "GENE_OR_GENE_PRODUCT", 5, 9], ["GFP", "GENE_OR_GENE_PRODUCT", 10, 13], ["Vero-vAPNKO1", "GENE_OR_GENE_PRODUCT", 30, 42], ["Vero-vAPNKO2 cells", "CELL", 47, 65], ["GFP", "GENE_OR_GENE_PRODUCT", 95, 98], ["Vero cells", "CELL", 128, 138], ["vAPN", "GENE_OR_GENE_PRODUCT", 156, 160], ["PEDV", "SIMPLE_CHEMICAL", 188, 192], ["Vero-vAPNKO1", "CELL_LINE", 30, 42], ["Vero-vAPNKO2 cells", "CELL_LINE", 47, 65], ["normal Vero cells", "CELL_LINE", 121, 138], ["vAPN", "PROTEIN", 156, 160], ["PEDV", "SPECIES", 188, 192], ["PEDV", "PROBLEM", 5, 9], ["GFP infection", "PROBLEM", 10, 23], ["Vero-vAPNKO1 and Vero-vAPNKO2 cells", "TREATMENT", 30, 65], ["consequent CPE", "PROBLEM", 76, 90], ["GFP expression", "PROBLEM", 95, 109], ["vAPN knockout", "PROBLEM", 156, 169], ["PEDV entry", "PROBLEM", 188, 198], ["infection", "PROBLEM", 203, 212], ["GFP infection", "OBSERVATION", 10, 23], ["Vero cells", "OBSERVATION", 128, 138], ["infection", "OBSERVATION", 203, 212]]], ["Sialic acids such as Neu5Ac have been shown to be involved in PEDV entry as the co-receptor (Liu et al., 2015); therefore we examined whether there may be any interplay between sialic acids and APN for PEDV entry.", [["Sialic acids", "CHEMICAL", 0, 12], ["Neu5Ac", "CHEMICAL", 21, 27], ["sialic acids", "CHEMICAL", 177, 189], ["Sialic acids", "CHEMICAL", 0, 12], ["Neu5Ac", "CHEMICAL", 21, 27], ["sialic acids", "CHEMICAL", 177, 189], ["Sialic acids", "SIMPLE_CHEMICAL", 0, 12], ["Neu5Ac", "GENE_OR_GENE_PRODUCT", 21, 27], ["PEDV", "GENE_OR_GENE_PRODUCT", 62, 66], ["sialic acids", "SIMPLE_CHEMICAL", 177, 189], ["APN", "GENE_OR_GENE_PRODUCT", 194, 197], ["PEDV", "GENE_OR_GENE_PRODUCT", 202, 206], ["Neu5Ac", "PROTEIN", 21, 27], ["PEDV", "PROTEIN", 62, 66], ["APN", "PROTEIN", 194, 197], ["PEDV", "SPECIES", 62, 66], ["PEDV", "SPECIES", 202, 206], ["Sialic acids", "TREATMENT", 0, 12], ["Neu5Ac", "TREATMENT", 21, 27], ["sialic acids", "TREATMENT", 177, 189], ["PEDV entry", "PROBLEM", 202, 212]]], ["Vero, Vero-vAPNKO1 and Vero-vAPNKO2 cells were infected with PEDV-GFP, respectively, in the presence of distinct concentrations of neuraminidase, which would cleave sialic acids on the cell surface.", [["Vero", "ANATOMY", 0, 4], ["Vero-vAPNKO2 cells", "ANATOMY", 23, 41], ["cell surface", "ANATOMY", 185, 197], ["sialic acids", "CHEMICAL", 165, 177], ["sialic acids", "CHEMICAL", 165, 177], ["Vero", "CELL", 0, 4], ["Vero-vAPNKO1", "CELL", 6, 18], ["Vero-vAPNKO2 cells", "CELL", 23, 41], ["PEDV-GFP", "GENE_OR_GENE_PRODUCT", 61, 69], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 131, 144], ["sialic acids", "SIMPLE_CHEMICAL", 165, 177], ["cell surface", "CELLULAR_COMPONENT", 185, 197], ["Vero-vAPNKO1", "CELL_LINE", 6, 18], ["Vero-vAPNKO2 cells", "CELL_LINE", 23, 41], ["PEDV", "PROTEIN", 61, 65], ["GFP", "PROTEIN", 66, 69], ["neuraminidase", "PROTEIN", 131, 144], ["Vero, Vero-vAPNKO1 and Vero-vAPNKO2 cells", "TREATMENT", 0, 41], ["distinct concentrations of neuraminidase", "PROBLEM", 104, 144], ["distinct concentrations", "OBSERVATION", 104, 127], ["neuraminidase", "OBSERVATION", 131, 144]]], ["PEDV-GFP infection was inhibited slightly by neuraminidase treatment in a dose-dependent manner (Fig. 5C).", [["PEDV", "CHEMICAL", 0, 4], ["infection", "DISEASE", 9, 18], ["PEDV", "GENE_OR_GENE_PRODUCT", 0, 4], ["GFP", "GENE_OR_GENE_PRODUCT", 5, 8], ["neuraminidase", "SIMPLE_CHEMICAL", 45, 58], ["neuraminidase", "PROTEIN", 45, 58], ["PEDV", "SPECIES", 0, 4], ["PEDV", "PROBLEM", 0, 4], ["GFP infection", "PROBLEM", 5, 18], ["neuraminidase treatment", "TREATMENT", 45, 68], ["GFP infection", "OBSERVATION", 5, 18]]], ["However, there were no significant differences of overall effect of neuraminidase treatment on PEDV-GFP infection between normal Vero cells and knockout cells (Fig. 5C).", [["Vero cells", "ANATOMY", 129, 139], ["cells", "ANATOMY", 153, 158], ["PEDV", "CHEMICAL", 95, 99], ["infection", "DISEASE", 104, 113], ["neuraminidase", "SIMPLE_CHEMICAL", 68, 81], ["PEDV-GFP", "GENE_OR_GENE_PRODUCT", 95, 103], ["Vero cells", "CELL", 129, 139], ["knockout cells", "CELL", 144, 158], ["neuraminidase", "PROTEIN", 68, 81], ["normal Vero cells", "CELL_LINE", 122, 139], ["knockout cells", "CELL_TYPE", 144, 158], ["neuraminidase treatment", "TREATMENT", 68, 91], ["PEDV", "PROBLEM", 95, 99], ["GFP infection", "PROBLEM", 100, 113], ["knockout cells", "PROBLEM", 144, 158], ["no", "UNCERTAINTY", 20, 22], ["significant", "OBSERVATION_MODIFIER", 23, 34], ["infection", "OBSERVATION", 104, 113], ["Vero cells", "OBSERVATION", 129, 139], ["knockout cells", "OBSERVATION", 144, 158]]], ["These results indicated that vAPN knockout had no effects on potential association with sialic acids mediating PEDV entry.Results and discussionIt is reported that overexpression of pAPN in porcine kidney or testis cells slightly increased the production of PEDV, suggesting the role of pAPN in promoting PEDV replication (Nam and Lee, 2010, Shirato et al., 2016).", [["kidney", "ANATOMY", 198, 204], ["testis cells", "ANATOMY", 208, 220], ["vAPN", "CHEMICAL", 29, 33], ["sialic acids", "CHEMICAL", 88, 100], ["PEDV", "CHEMICAL", 111, 115], ["sialic acids", "CHEMICAL", 88, 100], ["vAPN", "GENE_OR_GENE_PRODUCT", 29, 33], ["sialic acids", "SIMPLE_CHEMICAL", 88, 100], ["PEDV", "SIMPLE_CHEMICAL", 111, 115], ["pAPN", "GENE_OR_GENE_PRODUCT", 182, 186], ["porcine", "ORGANISM", 190, 197], ["kidney", "ORGAN", 198, 204], ["testis cells", "CELL", 208, 220], ["PEDV", "GENE_OR_GENE_PRODUCT", 258, 262], ["pAPN", "GENE_OR_GENE_PRODUCT", 287, 291], ["PEDV", "GENE_OR_GENE_PRODUCT", 305, 309], ["vAPN", "PROTEIN", 29, 33], ["PEDV", "PROTEIN", 111, 115], ["pAPN", "PROTEIN", 182, 186], ["testis cells", "CELL_TYPE", 208, 220], ["PEDV", "PROTEIN", 258, 262], ["pAPN", "PROTEIN", 287, 291], ["porcine", "SPECIES", 190, 197], ["porcine", "SPECIES", 190, 197], ["PEDV", "SPECIES", 305, 309], ["vAPN knockout", "PROBLEM", 29, 42], ["sialic acids", "TREATMENT", 88, 100], ["overexpression of pAPN in porcine kidney", "PROBLEM", 164, 204], ["testis cells", "PROBLEM", 208, 220], ["PEDV", "PROBLEM", 258, 262], ["kidney", "ANATOMY", 198, 204], ["testis", "ANATOMY", 208, 214], ["slightly", "OBSERVATION_MODIFIER", 221, 229], ["increased", "OBSERVATION_MODIFIER", 230, 239], ["PEDV replication", "OBSERVATION", 305, 321]]], ["We developed a stable Vero cell line expressing pAPN (Vero-pAPN; (Wang et al., 2018), and then determined whether Vero-pAPN cells could support PEDV-GFP propagation more efficiently in comparison with Vero cells.", [["Vero cell line", "ANATOMY", 22, 36], ["Vero-pAPN cells", "ANATOMY", 114, 129], ["Vero cells", "ANATOMY", 201, 211], ["Vero cell line", "CELL", 22, 36], ["pAPN", "CELL", 48, 52], ["Vero-pAPN cells", "CELL", 114, 129], ["PEDV", "GENE_OR_GENE_PRODUCT", 144, 148], ["GFP", "GENE_OR_GENE_PRODUCT", 149, 152], ["Vero cells", "CELL", 201, 211], ["Vero cell line", "CELL_LINE", 22, 36], ["pAPN", "PROTEIN", 48, 52], ["Vero-pAPN", "PROTEIN", 54, 63], ["Vero-pAPN cells", "CELL_LINE", 114, 129], ["PEDV", "PROTEIN", 144, 148], ["Vero cells", "CELL_LINE", 201, 211], ["Vero-pAPN cells", "PROBLEM", 114, 129], ["PEDV", "PROBLEM", 144, 148], ["GFP propagation", "PROBLEM", 149, 164], ["stable", "OBSERVATION_MODIFIER", 15, 21], ["Vero cell line", "OBSERVATION", 22, 36]]], ["In agree with the previous findings, PEDV-GFP infectious titers increased during the early infection stage (0\u201324 hpi;Fig. 6).", [["infection", "DISEASE", 91, 100], ["PEDV", "GENE_OR_GENE_PRODUCT", 37, 41], ["GFP", "GENE_OR_GENE_PRODUCT", 42, 45], ["PEDV", "PROTEIN", 37, 41], ["the previous findings", "TEST", 14, 35], ["PEDV", "TEST", 37, 41], ["GFP infectious titers", "PROBLEM", 42, 63], ["the early infection stage", "PROBLEM", 81, 106], ["infectious", "OBSERVATION_MODIFIER", 46, 56]]], ["However, the peak virus titers were comparable between two cell lines (36\u201348 hpi; Fig. 6).", [["cell lines", "ANATOMY", 59, 69], ["cell lines", "CELL", 59, 69], ["cell lines", "CELL_LINE", 59, 69], ["the peak virus titers", "TEST", 9, 30], ["cell lines", "OBSERVATION", 59, 69]]], ["The result indicated that although pAPN slightly facilitated PEDV replication in the early stage, it had limited effects on PEDV infection in Vero cells, probably due to the presence of an unidentified bona fide receptor.Results and discussionPEDV infects pigs by targeting porcine small intestinal epithelial cells.", [["Vero cells", "ANATOMY", 142, 152], ["small intestinal epithelial cells", "ANATOMY", 282, 315], ["pAPN", "CHEMICAL", 35, 39], ["PEDV", "CHEMICAL", 61, 65], ["infection", "DISEASE", 129, 138], ["pAPN", "CHEMICAL", 35, 39], ["pAPN", "SIMPLE_CHEMICAL", 35, 39], ["PEDV", "CANCER", 61, 65], ["PEDV", "SIMPLE_CHEMICAL", 124, 128], ["Vero cells", "CELL", 142, 152], ["pigs", "ORGANISM", 256, 260], ["porcine", "ORGANISM", 274, 281], ["small intestinal epithelial cells", "CELL", 282, 315], ["pAPN", "PROTEIN", 35, 39], ["Vero cells", "CELL_LINE", 142, 152], ["bona fide receptor", "PROTEIN", 202, 220], ["porcine small intestinal epithelial cells", "CELL_TYPE", 274, 315], ["pigs", "SPECIES", 256, 260], ["porcine", "SPECIES", 274, 281], ["PEDV", "SPECIES", 61, 65], ["PEDV", "SPECIES", 124, 128], ["pigs", "SPECIES", 256, 260], ["porcine", "SPECIES", 274, 281], ["PEDV replication", "TREATMENT", 61, 77], ["PEDV infection in Vero cells", "PROBLEM", 124, 152], ["targeting porcine small intestinal epithelial cells", "PROBLEM", 264, 315], ["PEDV", "OBSERVATION", 61, 65], ["early stage", "OBSERVATION_MODIFIER", 85, 96], ["PEDV", "OBSERVATION_MODIFIER", 124, 128], ["infection", "OBSERVATION", 129, 138], ["Vero cells", "OBSERVATION", 142, 152], ["probably due to", "UNCERTAINTY", 154, 169], ["bona fide receptor", "OBSERVATION", 202, 220], ["small", "OBSERVATION_MODIFIER", 282, 287], ["intestinal epithelial cells", "OBSERVATION", 288, 315]]], ["Recently, a non-transformed, non-tumorigenic cell line named IPEC-J2, from jejunum epithelium isolated from a neonatal piglet, was characterized and used for studying porcine enteric virus-host interactions (Liu et al., 2010).", [["non-tumorigenic cell line", "ANATOMY", 29, 54], ["IPEC-J2", "ANATOMY", 61, 68], ["jejunum epithelium", "ANATOMY", 75, 93], ["piglet", "ANATOMY", 119, 125], ["IPEC-J2", "CHEMICAL", 61, 68], ["non-tumorigenic cell line", "CELL", 29, 54], ["IPEC-J2", "CELL", 61, 68], ["jejunum epithelium", "TISSUE", 75, 93], ["piglet", "ORGANISM", 119, 125], ["porcine", "ORGANISM", 167, 174], ["enteric virus", "ORGANISM", 175, 188], ["non-transformed, non-tumorigenic cell line", "CELL_LINE", 12, 54], ["IPEC-J2", "CELL_LINE", 61, 68], ["piglet", "SPECIES", 119, 125], ["a non-transformed, non-tumorigenic cell line", "PROBLEM", 10, 54], ["jejunum epithelium", "PROBLEM", 75, 93], ["studying porcine enteric virus", "TREATMENT", 158, 188], ["non-tumorigenic cell line", "OBSERVATION", 29, 54], ["J2", "ANATOMY", 66, 68], ["jejunum", "ANATOMY", 75, 82], ["epithelium", "ANATOMY_MODIFIER", 83, 93], ["neonatal piglet", "ANATOMY", 110, 125]]], ["Efficient PEDV-GFP or TGEV infection of IPEC-J2 cells was confirmed by optimizing the multiplicity of infection even treated with a small interfering RNA (siRNA) negative control (Fig. 7A and B), allowing us to use this cell line to study PEDV-pAPN interplay.", [["IPEC-J2 cells", "ANATOMY", 40, 53], ["cell line", "ANATOMY", 220, 229], ["infection", "DISEASE", 27, 36], ["infection", "DISEASE", 102, 111], ["PEDV-GFP", "GENE_OR_GENE_PRODUCT", 10, 18], ["TGEV", "ORGANISM", 22, 26], ["IPEC-J2 cells", "CELL", 40, 53], ["B", "CELL", 192, 193], ["cell line", "CELL", 220, 229], ["PEDV", "GENE_OR_GENE_PRODUCT", 239, 243], ["pAPN", "GENE_OR_GENE_PRODUCT", 244, 248], ["IPEC-J2 cells", "CELL_LINE", 40, 53], ["PEDV", "PROTEIN", 239, 243], ["pAPN", "PROTEIN", 244, 248], ["TGEV", "SPECIES", 22, 26], ["TGEV", "SPECIES", 22, 26], ["Efficient PEDV", "PROBLEM", 0, 14], ["GFP", "PROBLEM", 15, 18], ["TGEV infection of IPEC", "PROBLEM", 22, 44], ["J2 cells", "PROBLEM", 45, 53], ["infection", "PROBLEM", 102, 111], ["a small interfering RNA (siRNA", "TREATMENT", 130, 160], ["this cell line", "TREATMENT", 215, 229], ["PEDV", "OBSERVATION", 10, 14], ["J2 cells", "OBSERVATION_MODIFIER", 45, 53], ["infection", "OBSERVATION", 102, 111], ["small", "OBSERVATION_MODIFIER", 132, 137]]], ["However, our many attempts to knockout the pAPN in IPEC-J2 cells by CRISPR/Cas9 were failed, probably due to sensitivity of the cells to puromycin in the course of selection of single-cell clones (data not shown).", [["IPEC-J2 cells", "ANATOMY", 51, 64], ["cells", "ANATOMY", 128, 133], ["single-cell clones", "ANATOMY", 177, 195], ["puromycin", "CHEMICAL", 137, 146], ["puromycin", "CHEMICAL", 137, 146], ["pAPN", "GENE_OR_GENE_PRODUCT", 43, 47], ["IPEC-J2 cells", "CELL", 51, 64], ["CRISPR/Cas9", "GENE_OR_GENE_PRODUCT", 68, 79], ["cells", "CELL", 128, 133], ["puromycin", "SIMPLE_CHEMICAL", 137, 146], ["single-cell clones", "CELL", 177, 195], ["pAPN", "PROTEIN", 43, 47], ["IPEC-J2 cells", "CELL_LINE", 51, 64], ["CRISPR", "DNA", 68, 74], ["Cas9", "DNA", 75, 79], ["single-cell clones", "CELL_LINE", 177, 195], ["the pAPN in IPEC-J2 cells", "TREATMENT", 39, 64], ["CRISPR/Cas9", "TREATMENT", 68, 79], ["the cells", "PROBLEM", 124, 133], ["puromycin", "TREATMENT", 137, 146], ["single-cell clones", "TEST", 177, 195], ["J2 cells", "OBSERVATION", 56, 64], ["cell clones", "OBSERVATION", 184, 195]]], ["We hence depleted pAPN expression by siRNA treatment (sipAPN) in IPEC-J2 cells that were subsequently (24 hours post-siRNA transfection) infected with PEDV-GFP or TGEV.", [["IPEC-J2 cells", "ANATOMY", 65, 78], ["pAPN", "GENE_OR_GENE_PRODUCT", 18, 22], ["sipAPN", "SIMPLE_CHEMICAL", 54, 60], ["IPEC-J2 cells", "CELL", 65, 78], ["PEDV-GFP", "GENE_OR_GENE_PRODUCT", 151, 159], ["TGEV", "ORGANISM", 163, 167], ["pAPN", "PROTEIN", 18, 22], ["IPEC-J2 cells", "CELL_LINE", 65, 78], ["PEDV", "PROTEIN", 151, 155], ["GFP", "PROTEIN", 156, 159], ["PEDV", "SPECIES", 151, 155], ["TGEV", "SPECIES", 163, 167], ["depleted pAPN expression", "TREATMENT", 9, 33], ["siRNA treatment (sipAPN", "TREATMENT", 37, 60], ["IPEC-J2 cells", "TREATMENT", 65, 78], ["PEDV", "PROBLEM", 151, 155], ["TGEV", "PROBLEM", 163, 167], ["depleted", "OBSERVATION_MODIFIER", 9, 17], ["pAPN expression", "OBSERVATION", 18, 33], ["J2 cells", "ANATOMY", 70, 78]]], ["Immunoblot analysis of cell extracts harvested at 24 hpi verified that knockdown of the TGEV functional receptor, pAPN, reduced the abundance of the TGEV N protein relative to its level in cells treated with siNC (Fig. 7C).", [["cell extracts", "ANATOMY", 23, 36], ["cells", "ANATOMY", 189, 194], ["cell extracts", "ORGANISM_SUBSTANCE", 23, 36], ["TGEV", "ORGANISM", 88, 92], ["pAPN", "GENE_OR_GENE_PRODUCT", 114, 118], ["TGEV N", "GENE_OR_GENE_PRODUCT", 149, 155], ["cells", "CELL", 189, 194], ["TGEV functional receptor", "PROTEIN", 88, 112], ["pAPN", "PROTEIN", 114, 118], ["TGEV N protein", "PROTEIN", 149, 163], ["TGEV", "SPECIES", 88, 92], ["TGEV", "SPECIES", 149, 153], ["Immunoblot analysis", "TEST", 0, 19], ["cell extracts", "TREATMENT", 23, 36], ["the TGEV functional receptor", "TREATMENT", 84, 112], ["the TGEV N protein", "TEST", 145, 163], ["siNC (Fig. 7C", "TREATMENT", 208, 221]]], ["In accord with this, TGEV infection level decreased significantly as shown by IFA staining (Fig. 7A) and by measurement of the TGEV-positive cell clusters (Fig. 7B).", [["cell", "ANATOMY", 141, 145], ["infection", "DISEASE", 26, 35], ["TGEV", "ORGANISM", 21, 25], ["TGEV", "ORGANISM", 127, 131], ["TGEV", "SPECIES", 21, 25], ["TGEV", "SPECIES", 127, 131], ["TGEV infection level", "PROBLEM", 21, 41], ["IFA staining", "TEST", 78, 90], ["the TGEV", "TEST", 123, 131], ["infection", "OBSERVATION", 26, 35], ["positive cell clusters", "OBSERVATION", 132, 154]]], ["In contrast, sipAPN knockdown did not affect PEDV-GFP infection as well as PEDV-N protein expression compared to the control (Fig. 7A-C), indicating that pAPN is the TGEV receptor but may not serve as the entry receptor for PEDV.Results and discussionDuring the time of our study in progress, two independent studies described that neither hAPN nor pAPN is required for PEDV entry (Li et al., 2017, Shirato et al., 2016).", [["infection", "DISEASE", 54, 63], ["hAPN", "CHEMICAL", 340, 344], ["pAPN", "CHEMICAL", 349, 353], ["sipAPN", "GENE_OR_GENE_PRODUCT", 13, 19], ["PEDV-GFP", "GENE_OR_GENE_PRODUCT", 45, 53], ["PEDV-N", "GENE_OR_GENE_PRODUCT", 75, 81], ["pAPN", "GENE_OR_GENE_PRODUCT", 154, 158], ["TGEV", "ORGANISM", 166, 170], ["PEDV", "GENE_OR_GENE_PRODUCT", 224, 228], ["hAPN", "GENE_OR_GENE_PRODUCT", 340, 344], ["pAPN", "GENE_OR_GENE_PRODUCT", 349, 353], ["sipAPN", "PROTEIN", 13, 19], ["PEDV", "PROTEIN", 45, 49], ["PEDV", "PROTEIN", 75, 79], ["N protein", "PROTEIN", 80, 89], ["pAPN", "PROTEIN", 154, 158], ["TGEV receptor", "PROTEIN", 166, 179], ["PEDV", "PROTEIN", 224, 228], ["hAPN", "PROTEIN", 340, 344], ["pAPN", "PROTEIN", 349, 353], ["TGEV", "SPECIES", 166, 170], ["PEDV", "SPECIES", 224, 228], ["PEDV", "SPECIES", 370, 374], ["PEDV", "PROBLEM", 45, 49], ["GFP infection", "PROBLEM", 50, 63], ["PEDV", "PROBLEM", 75, 79], ["N protein expression", "TREATMENT", 80, 100], ["the TGEV receptor", "TREATMENT", 162, 179], ["PEDV", "PROBLEM", 224, 228], ["our study", "TEST", 270, 279], ["two independent studies", "TEST", 293, 316], ["infection", "OBSERVATION", 54, 63]]], ["In particular, Li et al. employed CRISPR/Cas9 technique to knockout either hAPN in Huh-7 cells or pAPN in ST cells, still resulting in efficient infection of PEDV in knockout cells, which convincingly demonstrated that PEDV infection does not utilize them as functional receptors (Li et al., 2017).", [["Huh-7 cells", "ANATOMY", 83, 94], ["ST cells", "ANATOMY", 106, 114], ["cells", "ANATOMY", 175, 180], ["Li", "CHEMICAL", 15, 17], ["infection", "DISEASE", 145, 154], ["PEDV", "CHEMICAL", 219, 223], ["infection", "DISEASE", 224, 233], ["CRISPR/Cas9", "GENE_OR_GENE_PRODUCT", 34, 45], ["Huh-7 cells", "CELL", 83, 94], ["pAPN", "CELL", 98, 102], ["ST cells", "CELL", 106, 114], ["PEDV", "GENE_OR_GENE_PRODUCT", 158, 162], ["cells", "CELL", 175, 180], ["PEDV", "SIMPLE_CHEMICAL", 219, 223], ["CRISPR", "DNA", 34, 40], ["hAPN", "PROTEIN", 75, 79], ["Huh-7 cells", "CELL_LINE", 83, 94], ["pAPN", "PROTEIN", 98, 102], ["ST cells", "CELL_TYPE", 106, 114], ["PEDV", "PROTEIN", 158, 162], ["knockout cells", "CELL_TYPE", 166, 180], ["PEDV", "SPECIES", 158, 162], ["PEDV", "SPECIES", 219, 223], ["CRISPR/Cas9 technique", "TREATMENT", 34, 55], ["Huh", "TEST", 83, 86], ["pAPN in ST cells", "PROBLEM", 98, 114], ["efficient infection of PEDV in knockout cells", "PROBLEM", 135, 180], ["PEDV infection", "PROBLEM", 219, 233], ["efficient", "OBSERVATION_MODIFIER", 135, 144], ["infection", "OBSERVATION", 145, 154], ["infection", "OBSERVATION", 224, 233]]], ["Our study is in line with these results, providing additional evidences that the Vero cell line of green monkey origin does not express vAPN for PEDV entry and propagation, and that PEDV infection of the small intestinal epithelial cells is likely not associated with pAPN.", [["Vero cell line", "ANATOMY", 81, 95], ["small intestinal epithelial cells", "ANATOMY", 204, 237], ["infection", "DISEASE", 187, 196], ["Vero cell line", "CELL", 81, 95], ["green monkey", "ORGANISM", 99, 111], ["vAPN", "GENE_OR_GENE_PRODUCT", 136, 140], ["PEDV", "GENE_OR_GENE_PRODUCT", 145, 149], ["PEDV", "GENE_OR_GENE_PRODUCT", 182, 186], ["intestinal epithelial cells", "CELL", 210, 237], ["pAPN", "GENE_OR_GENE_PRODUCT", 268, 272], ["Vero cell line", "CELL_LINE", 81, 95], ["vAPN", "PROTEIN", 136, 140], ["small intestinal epithelial cells", "CELL_TYPE", 204, 237], ["pAPN", "PROTEIN", 268, 272], ["green monkey", "SPECIES", 99, 111], ["PEDV", "SPECIES", 145, 149], ["PEDV", "SPECIES", 182, 186], ["Our study", "TEST", 0, 9], ["the Vero cell line", "TREATMENT", 77, 95], ["PEDV entry", "PROBLEM", 145, 155], ["PEDV infection", "PROBLEM", 182, 196], ["the small intestinal epithelial cells", "PROBLEM", 200, 237], ["Vero cell line", "OBSERVATION", 81, 95], ["green monkey", "OBSERVATION", 99, 111], ["infection", "OBSERVATION", 187, 196], ["small", "OBSERVATION_MODIFIER", 204, 209], ["intestinal epithelial cells", "OBSERVATION", 210, 237], ["likely not associated with", "UNCERTAINTY", 241, 267]]], ["The present study should have broad biological significance, since the Vero cell is commonly used for PEDV propagation and vaccine production in vitro, and the porcine small intestine epithelial cells is the PEDV target in vivo.", [["Vero cell", "ANATOMY", 71, 80], ["small intestine epithelial cells", "ANATOMY", 168, 200], ["Vero cell", "CELL", 71, 80], ["porcine", "ORGANISM", 160, 167], ["small intestine epithelial cells", "CELL", 168, 200], ["Vero cell", "CELL_LINE", 71, 80], ["porcine small intestine epithelial cells", "CELL_TYPE", 160, 200], ["porcine", "SPECIES", 160, 167], ["PEDV", "SPECIES", 102, 106], ["The present study", "TEST", 0, 17], ["the Vero cell", "PROBLEM", 67, 80], ["PEDV propagation", "TREATMENT", 102, 118], ["vaccine production", "TREATMENT", 123, 141], ["vitro", "TREATMENT", 145, 150], ["the porcine small intestine epithelial cells", "PROBLEM", 156, 200], ["intestine", "ANATOMY", 174, 183], ["epithelial cells", "OBSERVATION", 184, 200]]], ["Furthermore, in our experiment using the PEDV non-susceptible BHK-21 or NIH-3T3 cells, we found that overexpression of pAPN did not confer PEDV-GFP entry or infection as well (data not shown).", [["BHK-21", "ANATOMY", 62, 68], ["NIH-3T3 cells", "ANATOMY", 72, 85], ["infection", "DISEASE", 157, 166], ["BHK-21", "CELL", 62, 68], ["NIH-3T3 cells", "CELL", 72, 85], ["pAPN", "GENE_OR_GENE_PRODUCT", 119, 123], ["PEDV-GFP", "GENE_OR_GENE_PRODUCT", 139, 147], ["PEDV non-susceptible BHK-21", "CELL_LINE", 41, 68], ["NIH-3T3 cells", "CELL_LINE", 72, 85], ["pAPN", "PROTEIN", 119, 123], ["PEDV", "PROTEIN", 139, 143], ["BHK-21", "SPECIES", 62, 68], ["the PEDV non-susceptible BHK", "TEST", 37, 65], ["overexpression of pAPN", "PROBLEM", 101, 123], ["PEDV", "PROBLEM", 139, 143], ["infection", "PROBLEM", 157, 166], ["infection", "OBSERVATION", 157, 166]]], ["Therefore, these data collectively suggest that there exist additional cellular receptors independent of human, green monkey, and porcine APN for PEDV entry.", [["cellular", "ANATOMY", 71, 79], ["cellular", "CELL", 71, 79], ["human", "ORGANISM", 105, 110], ["green monkey", "ORGANISM", 112, 124], ["porcine", "ORGANISM", 130, 137], ["APN", "GENE_OR_GENE_PRODUCT", 138, 141], ["PEDV", "GENE_OR_GENE_PRODUCT", 146, 150], ["cellular receptors", "PROTEIN", 71, 89], ["human", "SPECIES", 105, 110], ["porcine", "SPECIES", 130, 137], ["human", "SPECIES", 105, 110], ["green monkey", "SPECIES", 112, 124], ["porcine", "SPECIES", 130, 137], ["PEDV", "SPECIES", 146, 150], ["these data", "TEST", 11, 21]]], ["Moreover, although PEDV is able to infect various cell lines of distinct species origin (Liu et al., 2015), even in duck species (Khatri, 2015), the other non-porcine and non-primate species-specific APNs (such as bat or duck APN) likely not functions as the PEDV entry receptor.", [["cell lines", "ANATOMY", 50, 60], ["PEDV", "CHEMICAL", 19, 23], ["PEDV", "GENE_OR_GENE_PRODUCT", 19, 23], ["cell lines", "CELL", 50, 60], ["duck", "ORGANISM", 116, 120], ["APNs", "GENE_OR_GENE_PRODUCT", 200, 204], ["bat", "ORGANISM", 214, 217], ["duck", "ORGANISM", 221, 225], ["APN", "GENE_OR_GENE_PRODUCT", 226, 229], ["PEDV entry receptor", "GENE_OR_GENE_PRODUCT", 259, 278], ["PEDV", "PROTEIN", 19, 23], ["cell lines", "CELL_LINE", 50, 60], ["APNs", "PROTEIN", 200, 204], ["duck APN", "PROTEIN", 221, 229], ["PEDV entry receptor", "PROTEIN", 259, 278], ["duck", "SPECIES", 116, 120], ["duck", "SPECIES", 221, 225], ["PEDV", "SPECIES", 19, 23], ["PEDV", "PROBLEM", 19, 23], ["the other non-porcine and non-primate species", "PROBLEM", 145, 190], ["cell lines", "OBSERVATION", 50, 60], ["distinct", "OBSERVATION_MODIFIER", 64, 72], ["species", "OBSERVATION_MODIFIER", 73, 80]]], ["Searching for the unknown PEDV functional receptor is still ongoing and should answer this enigma in the future.Cell lines and virus stocks ::: Materials and methodsA monkey kidney cell line Vero (ATCC CCL-81), human hepatoma cell line Huh-7 and a swine testis cell line ST (ATCC CRL-1746) were grown in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% antibiotics at a 37\u00b0C incubator, respectively.", [["Cell lines", "ANATOMY", 112, 122], ["kidney cell line Vero", "ANATOMY", 174, 195], ["ATCC CCL-81", "ANATOMY", 197, 208], ["hepatoma cell line Huh-7", "ANATOMY", 217, 241], ["testis cell line ST", "ANATOMY", 254, 273], ["ATCC CRL-1746", "ANATOMY", 275, 288], ["fetal bovine serum", "ANATOMY", 366, 384], ["FBS", "ANATOMY", 386, 389], ["CRL-1746", "CHEMICAL", 280, 288], ["PEDV", "GENE_OR_GENE_PRODUCT", 26, 30], ["Cell lines", "CELL", 112, 122], ["monkey", "ORGANISM", 167, 173], ["kidney cell line Vero", "CELL", 174, 195], ["ATCC CCL-81", "CELL", 197, 208], ["human", "ORGANISM", 211, 216], ["hepatoma cell line Huh-7", "CELL", 217, 241], ["swine", "ORGANISM", 248, 253], ["testis cell line ST", "CELL", 254, 273], ["ATCC CRL-1746", "CELL", 275, 288], ["bovine", "ORGANISM", 372, 378], ["serum", "ORGANISM_SUBSTANCE", 379, 384], ["FBS", "ORGANISM_SUBSTANCE", 386, 389], ["PEDV functional receptor", "PROTEIN", 26, 50], ["monkey kidney cell line Vero", "CELL_LINE", 167, 195], ["ATCC CCL-81", "CELL_LINE", 197, 208], ["human hepatoma cell line Huh-7", "CELL_LINE", 211, 241], ["swine testis cell line ST", "CELL_LINE", 248, 273], ["ATCC CRL-1746", "CELL_LINE", 275, 288], ["human", "SPECIES", 211, 216], ["swine", "SPECIES", 248, 253], ["bovine", "SPECIES", 372, 378], ["ATCC CCL-81", "SPECIES", 197, 208], ["human", "SPECIES", 211, 216], ["Huh-7", "SPECIES", 236, 241], ["swine", "SPECIES", 248, 253], ["ATCC CRL-1746)", "SPECIES", 275, 289], ["methods", "TEST", 158, 165], ["Vero (ATCC CCL", "TEST", 191, 205], ["human hepatoma cell line", "TEST", 211, 235], ["Huh", "TEST", 236, 239], ["a swine testis", "TEST", 246, 260], ["ST (ATCC CRL", "TEST", 271, 283], ["10% fetal bovine serum (FBS)", "TREATMENT", 362, 390], ["1% antibiotics", "TREATMENT", 395, 409], ["virus stocks", "OBSERVATION", 127, 139], ["kidney", "ANATOMY", 174, 180], ["cell line", "OBSERVATION", 181, 190], ["hepatoma", "ANATOMY", 217, 225], ["cell line", "OBSERVATION", 226, 235], ["testis", "ANATOMY", 254, 260], ["cell line", "OBSERVATION", 261, 270]]], ["A Vero cell line stably expressing the pAPN coding region (Vero-pAPN) was cultured in DMEM supplemented with 10 \u03bcg/ml puromycin and antibiotics (Wang et al., 2018).", [["Vero cell line", "ANATOMY", 2, 16], ["puromycin", "CHEMICAL", 118, 127], ["puromycin", "CHEMICAL", 118, 127], ["Vero cell line", "CELL", 2, 16], ["pAPN", "GENE_OR_GENE_PRODUCT", 39, 43], ["puromycin", "SIMPLE_CHEMICAL", 118, 127], ["Vero cell line", "CELL_LINE", 2, 16], ["pAPN coding region", "DNA", 39, 57], ["Vero-pAPN", "DNA", 59, 68], ["A Vero cell line", "TREATMENT", 0, 16], ["the pAPN coding region", "TREATMENT", 35, 57], ["Vero-pAPN", "TREATMENT", 59, 68], ["puromycin", "TREATMENT", 118, 127], ["antibiotics", "TREATMENT", 132, 143], ["Vero cell line", "OBSERVATION", 2, 16]]], ["The IPEC-J2 cell line, from jejunum epithelium isolated from a neonatal piglet, was a generous gift from Dr. Lijuan Yuan at Virginia Tech, Blacksburg, VA (Liu et al., 2010).", [["IPEC-J2 cell line", "ANATOMY", 4, 21], ["jejunum epithelium", "ANATOMY", 28, 46], ["piglet", "ANATOMY", 72, 78], ["IPEC-J2 cell line", "CELL", 4, 21], ["jejunum epithelium", "TISSUE", 28, 46], ["piglet", "ORGANISM", 72, 78], ["IPEC-J2 cell line", "CELL_LINE", 4, 21], ["piglet", "SPECIES", 72, 78], ["The IPEC-J2 cell line", "TREATMENT", 0, 21], ["jejunum epithelium", "PROBLEM", 28, 46], ["J2 cell line", "OBSERVATION", 9, 21], ["jejunum", "ANATOMY", 28, 35], ["epithelium", "ANATOMY_MODIFIER", 36, 46], ["neonatal piglet", "OBSERVATION", 63, 78]]], ["The IPEC-J2 cells were grown in DMEM supplemented with 5% FBS and 1% antibiotics.Cell lines and virus stocks ::: Materials and methodsA G2 PEDV Chinese strain, ZJU/G2/2013 (GenBank accession no. KU558701), was used in this study (Qin et al., 2017).", [["IPEC-J2 cells", "ANATOMY", 4, 17], ["Cell lines", "ANATOMY", 81, 91], ["IPEC-J2 cells", "CELL", 4, 17], ["FBS", "ORGANISM_SUBSTANCE", 58, 61], ["Cell lines", "CELL", 81, 91], ["IPEC-J2 cells", "CELL_LINE", 4, 17], ["ZJU/G2/2013 (GenBank accession no. KU558701", "SPECIES", 160, 203], ["The IPEC-J2 cells", "TREATMENT", 0, 17], ["5% FBS", "TREATMENT", 55, 61], ["1% antibiotics", "TREATMENT", 66, 80], ["this study", "TEST", 218, 228], ["J2 cells", "OBSERVATION_MODIFIER", 9, 17], ["virus stocks", "OBSERVATION", 96, 108]]], ["The virus stocks of recombinant ZJU/G2/2013 expressing enhanced green fluorescent protein (GFP), designated PEDV-GFP, was generated by transfection of Vero cells with a DNA-launched PEDV infectious cDNA clone (Zhao et al., 2018), followed by two serial passages on Vero cells supplemented with 5 \u03bcg/ml trypsin (Sigma, Cat#T7186-50TAB, St Louis, MO, USA) and without FBS.", [["Vero cells", "ANATOMY", 151, 161], ["Vero cells", "ANATOMY", 265, 275], ["FBS", "ANATOMY", 366, 369], ["ZJU/G2/2013", "ORGANISM", 32, 43], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 64, 89], ["GFP", "GENE_OR_GENE_PRODUCT", 91, 94], ["PEDV-GFP", "GENE_OR_GENE_PRODUCT", 108, 116], ["Vero cells", "CELL", 151, 161], ["DNA", "CELLULAR_COMPONENT", 169, 172], ["clone", "CELL", 203, 208], ["Vero cells", "CELL", 265, 275], ["trypsin", "GENE_OR_GENE_PRODUCT", 302, 309], ["St Louis", "ORGANISM", 335, 343], ["FBS", "ORGANISM_SUBSTANCE", 366, 369], ["ZJU", "PROTEIN", 32, 35], ["G2", "PROTEIN", 36, 38], ["2013", "PROTEIN", 39, 43], ["enhanced green fluorescent protein", "PROTEIN", 55, 89], ["GFP", "PROTEIN", 91, 94], ["PEDV", "PROTEIN", 108, 112], ["GFP", "PROTEIN", 113, 116], ["Vero cells", "CELL_LINE", 151, 161], ["PEDV infectious cDNA clone", "DNA", 182, 208], ["Vero cells", "CELL_LINE", 265, 275], ["trypsin", "PROTEIN", 302, 309], ["green fluorescent protein", "TEST", 64, 89], ["designated PEDV-GFP", "TEST", 97, 116], ["Vero cells", "PROBLEM", 151, 161], ["a DNA", "PROBLEM", 167, 172], ["launched PEDV infectious cDNA clone", "PROBLEM", 173, 208], ["Vero cells", "TREATMENT", 265, 275], ["FBS", "TEST", 366, 369], ["virus stocks", "OBSERVATION", 4, 16]]], ["The virus stocks were PEDV-GFP-containing supernatants without cell debris that were removed by centrifugation.", [["supernatants", "ANATOMY", 42, 54], ["cell", "ANATOMY", 63, 67], ["GFP", "GENE_OR_GENE_PRODUCT", 27, 30], ["cell", "CELL", 63, 67], ["GFP", "PROTEIN", 27, 30], ["The virus stocks", "TREATMENT", 0, 16], ["PEDV", "PROBLEM", 22, 26], ["cell debris", "PROBLEM", 63, 74], ["virus stocks", "OBSERVATION", 4, 16], ["without", "UNCERTAINTY", 55, 62], ["cell debris", "OBSERVATION", 63, 74]]], ["The virus titers of PEDV-GFP were determined by endpoint dilutions as 50% tissue culture infective dose (TCID50) on Vero cells.", [["tissue", "ANATOMY", 74, 80], ["Vero cells", "ANATOMY", 116, 126], ["PEDV-GFP", "GENE_OR_GENE_PRODUCT", 20, 28], ["tissue", "TISSUE", 74, 80], ["Vero cells", "CELL", 116, 126], ["PEDV", "PROTEIN", 20, 24], ["GFP", "PROTEIN", 25, 28], ["Vero cells", "CELL_LINE", 116, 126], ["PEDV", "SPECIES", 20, 24], ["The virus titers", "TEST", 0, 16], ["PEDV-GFP", "TEST", 20, 28], ["endpoint dilutions", "TEST", 48, 66], ["Vero cells", "TREATMENT", 116, 126], ["Vero cells", "OBSERVATION", 116, 126]]], ["Virus stocks were stored at \u221280 \u00b0C until use.", [["Virus", "ORGANISM", 0, 5], ["Virus stocks", "TREATMENT", 0, 12]]], ["The PEDV-GFP infection efficiency in Vero, IPEC-J2, or Huh-7 cells was assessed by counting the numbers of GFP-positive cell clusters (quantified as fluorescent focus-forming unit [FFU]).", [["Vero", "ANATOMY", 37, 41], ["IPEC-J2", "ANATOMY", 43, 50], ["Huh-7 cells", "ANATOMY", 55, 66], ["cell", "ANATOMY", 120, 124], ["infection", "DISEASE", 13, 22], ["PEDV", "GENE_OR_GENE_PRODUCT", 4, 8], ["GFP", "GENE_OR_GENE_PRODUCT", 9, 12], ["Vero", "CELL", 37, 41], ["IPEC-J2", "CELL", 43, 50], ["Huh-7 cells", "CELL", 55, 66], ["GFP", "GENE_OR_GENE_PRODUCT", 107, 110], ["PEDV", "PROTEIN", 4, 8], ["Vero", "CELL_LINE", 37, 41], ["IPEC", "CELL_LINE", 43, 47], ["J2", "CELL_LINE", 48, 50], ["Huh-7 cells", "CELL_LINE", 55, 66], ["GFP", "PROTEIN", 107, 110], ["The PEDV", "TEST", 0, 8], ["GFP infection efficiency", "PROBLEM", 9, 33], ["Vero", "TEST", 37, 41], ["IPEC", "TEST", 43, 47], ["Huh", "TEST", 55, 58], ["GFP", "TEST", 107, 110], ["positive cell clusters", "PROBLEM", 111, 133], ["fluorescent focus", "TEST", 149, 166], ["GFP", "OBSERVATION", 9, 12], ["infection efficiency", "OBSERVATION", 13, 33], ["J2", "ANATOMY", 48, 50], ["positive cell clusters", "OBSERVATION", 111, 133]]], ["TGEV Purdue strain was kindly provided by Dr. Rong Ye at Shanghai Medical College of Fudan University, which was propagated on ST cells (Pan et al., 2017).", [["ST cells", "ANATOMY", 127, 135], ["TGEV", "ORGANISM", 0, 4], ["ST cells", "CELL", 127, 135], ["ST cells", "CELL_TYPE", 127, 135], ["TGEV", "SPECIES", 0, 4], ["TGEV", "SPECIES", 0, 4]]], ["The TGEV infection efficiency in TGEV-infected-IPEC-J2 cells was also evaluated by counting the FFU numbers following immunofluorescence assay with a TGEV-specific antibody.Genomic PCR and sequence analysis ::: Materials and methodsA pairs of primers, vAPN-CDS1-F (5\u2019- ATGGCCAAGGGCTTCTACATTTCCAAG-3\u2019) and vAPN-CDS9-R (5\u2019- CTCCTGCAGGTGGTCCCACAGGTTC-3\u2019), were designed for amplification of the 5\u2019-end region of the putative green monkey APN gene in Vero cells by one-step genomic PCR, based upon four published APN gene sequences from different species: Homo sapiens (human; Gene ID: 290), Pan troglodytes (chimpanzee; Gene ID: 467758), Macaca mulatta (rhesus monkey; Gene ID: 701117) and Sus scrofa (pig; Gene ID: 397520).", [["IPEC-J2 cells", "ANATOMY", 47, 60], ["Vero cells", "ANATOMY", 447, 457], ["infection", "DISEASE", 9, 18], ["TGEV", "ORGANISM", 4, 8], ["TGEV", "ORGANISM", 33, 37], ["IPEC-J2 cells", "CELL", 47, 60], ["TGEV", "ORGANISM", 150, 154], ["vAPN-CDS9-R", "GENE_OR_GENE_PRODUCT", 305, 316], ["green monkey", "ORGANISM", 422, 434], ["APN", "GENE_OR_GENE_PRODUCT", 435, 438], ["Vero cells", "CELL", 447, 457], ["APN", "GENE_OR_GENE_PRODUCT", 509, 512], ["Homo sapiens", "ORGANISM", 552, 564], ["human", "ORGANISM", 566, 571], ["Pan troglodytes", "ORGANISM", 588, 603], ["chimpanzee", "ORGANISM", 605, 615], ["Gene ID: 467758", "ORGANISM", 617, 632], ["Macaca mulatta", "ORGANISM", 635, 649], ["rhesus monkey", "ORGANISM", 651, 664], ["Gene ID: 701117", "ORGANISM", 666, 681], ["Sus scrofa", "ORGANISM", 687, 697], ["pig", "ORGANISM", 699, 702], ["TGEV-infected-IPEC-J2 cells", "CELL_LINE", 33, 60], ["TGEV-specific antibody", "PROTEIN", 150, 172], ["vAPN", "DNA", 252, 256], ["CDS1", "DNA", 257, 261], ["vAPN", "DNA", 305, 309], ["CDS9", "DNA", 310, 314], ["5\u2019-end region", "DNA", 392, 405], ["putative green monkey APN gene", "DNA", 413, 443], ["Vero cells", "CELL_LINE", 447, 457], ["APN gene sequences", "DNA", 509, 527], ["TGEV", "SPECIES", 33, 37], ["Homo sapiens", "SPECIES", 552, 564], ["human", "SPECIES", 566, 571], ["Pan troglodytes", "SPECIES", 588, 603], ["Macaca mulatta", "SPECIES", 635, 649], ["rhesus monkey", "SPECIES", 651, 664], ["Sus scrofa", "SPECIES", 687, 697], ["pig", "SPECIES", 699, 702], ["TGEV", "SPECIES", 4, 8], ["TGEV", "SPECIES", 33, 37], ["TGEV", "SPECIES", 150, 154], ["green monkey", "SPECIES", 422, 434], ["Homo sapiens", "SPECIES", 552, 564], ["human", "SPECIES", 566, 571], ["Pan troglodytes", "SPECIES", 588, 603], ["Macaca mulatta", "SPECIES", 635, 649], ["rhesus monkey; Gene ID: 701117)", "SPECIES", 651, 682], ["Sus scrofa", "SPECIES", 687, 697], ["pig", "SPECIES", 699, 702], ["The TGEV infection efficiency", "PROBLEM", 0, 29], ["TGEV", "PROBLEM", 33, 37], ["J2 cells", "PROBLEM", 52, 60], ["immunofluorescence assay", "TEST", 118, 142], ["a TGEV", "TEST", 148, 154], ["Genomic PCR", "TEST", 173, 184], ["sequence analysis", "TEST", 189, 206], ["primers", "TEST", 243, 250], ["vAPN", "TEST", 252, 256], ["CDS1", "TEST", 257, 261], ["ATGGCCAAGGGCTTCTACATTTCCAAG", "TEST", 269, 296], ["vAPN", "TEST", 305, 309], ["CDS9", "TEST", 310, 314], ["CTCCTGCAGGTGGTCCCACAGGTTC", "TEST", 322, 347], ["step genomic PCR", "PROBLEM", 465, 481], ["TGEV", "OBSERVATION_MODIFIER", 4, 8], ["infection efficiency", "OBSERVATION", 9, 29], ["infected", "OBSERVATION_MODIFIER", 38, 46], ["J2 cells", "OBSERVATION_MODIFIER", 52, 60], ["green monkey", "OBSERVATION", 422, 434], ["Vero cells", "OBSERVATION", 447, 457], ["Homo sapiens", "OBSERVATION", 552, 564]]], ["The forward primer vAPN-CDS1-F contains the start codon ATG while the reverse primer vAPN-CDS9-R is complementary to the sequence at the 3\u2019-end of the exon-9 of the rhesus monkey APN gene.", [["vAPN-CDS1-F", "GENE_OR_GENE_PRODUCT", 19, 30], ["vAPN-CDS9-R", "GENE_OR_GENE_PRODUCT", 85, 96], ["rhesus", "ORGANISM", 165, 171], ["monkey", "ORGANISM", 172, 178], ["APN", "GENE_OR_GENE_PRODUCT", 179, 182], ["forward primer vAPN-CDS1-F", "DNA", 4, 30], ["start codon ATG", "DNA", 44, 59], ["reverse primer vAPN-CDS9-R", "DNA", 70, 96], ["3\u2019-end", "DNA", 137, 143], ["exon-9", "DNA", 151, 157], ["rhesus monkey APN gene", "DNA", 165, 187], ["rhesus monkey", "SPECIES", 165, 178], ["rhesus monkey", "SPECIES", 165, 178], ["codon ATG", "TREATMENT", 50, 59], ["the reverse primer vAPN-CDS9", "TEST", 66, 94]]], ["Genomic PCR was performed with a KOD DNA polymerase (Toyobo, Japan) using 100 ng of extracted genomic DNA from Vero cells in a total volume of 50 \u03bcl.", [["Vero cells", "ANATOMY", 111, 121], ["DNA", "CELLULAR_COMPONENT", 37, 40], ["DNA", "CELLULAR_COMPONENT", 102, 105], ["Vero cells", "CELL", 111, 121], ["KOD DNA polymerase", "PROTEIN", 33, 51], ["genomic DNA", "DNA", 94, 105], ["Vero cells", "CELL_LINE", 111, 121], ["Genomic PCR", "TEST", 0, 11], ["a KOD DNA polymerase", "TEST", 31, 51], ["extracted genomic DNA", "PROBLEM", 84, 105], ["Vero cells", "TEST", 111, 121], ["a total volume", "TEST", 125, 139], ["Vero cells", "OBSERVATION", 111, 121]]], ["The PCR condition was 30 cycles of 98\u00b0C for 30 sec, 58\u00b0C for 30 sec, 68\u00b0C for 4 min with an initial denaturing of the template DNA at 94\u00b0C for 3 min and a final extension at 68\u00b0C for 7 min.", [["DNA", "CELLULAR_COMPONENT", 127, 130], ["template DNA", "DNA", 118, 130], ["The PCR condition", "TEST", 0, 17], ["an initial denaturing", "TREATMENT", 89, 110], ["the template DNA", "PROBLEM", 114, 130]]], ["The resulting fragment was cloned into a Zero pCR-Blunt vector (Thermo Fisher Scientific) by blunt-end cloning strategy followed by Sanger sequencing.", [["Zero pCR-Blunt vector", "DNA", 41, 62], ["The resulting fragment", "PROBLEM", 0, 22], ["a Zero pCR", "TEST", 39, 49], ["blunt-end cloning strategy", "TREATMENT", 93, 119], ["fragment", "OBSERVATION", 14, 22]]], ["Analysis and alignment of DNA and amino acid sequences were performed using Lasergene Package (DNASTAR Inc., Madison, WI).Construction of the recombinant vectors expressing pAPN or Vero-APN and in vitro expression ::: Materials and methodsThe complete coding region of pAPN was amplified by one-step RT-PCR with primers PCI-APN-F (aggctagctACCATGGCCAAGGGATTCTACATTTCCAA) and PCI-APN-R (TTGTCGACTCAGCTGTGCTCTATGAACCAATTCAACA) using total RNAs extracted from porcine small intestine, and subsequently cloned into a pCI-neo vector (Promega) downstream of the CMV immediate-early enhancer/promoter using NheI and SalI restriction sites.", [["small intestine", "ANATOMY", 465, 480], ["amino acid", "CHEMICAL", 34, 44], ["amino acid", "CHEMICAL", 34, 44], ["DNA", "CELLULAR_COMPONENT", 26, 29], ["amino acid", "AMINO_ACID", 34, 44], ["pAPN", "GENE_OR_GENE_PRODUCT", 173, 177], ["Vero-APN", "GENE_OR_GENE_PRODUCT", 181, 189], ["pAPN", "GENE_OR_GENE_PRODUCT", 269, 273], ["PCI-APN-R", "GENE_OR_GENE_PRODUCT", 375, 384], ["porcine", "ORGANISM", 457, 464], ["small intestine", "ORGAN", 465, 480], ["Promega", "GENE_OR_GENE_PRODUCT", 529, 536], ["CMV", "ORGANISM", 556, 559], ["NheI", "GENE_OR_GENE_PRODUCT", 600, 604], ["SalI", "GENE_OR_GENE_PRODUCT", 609, 613], ["pAPN", "PROTEIN", 173, 177], ["APN", "PROTEIN", 186, 189], ["pAPN", "DNA", 269, 273], ["APN", "DNA", 324, 327], ["F", "DNA", 328, 329], ["aggctagctACCATGGCCAAGGGATTCTACATTTCCAA", "DNA", 331, 369], ["PCI", "DNA", 375, 378], ["APN", "DNA", 379, 382], ["pCI-neo vector", "DNA", 513, 527], ["Promega", "DNA", 529, 536], ["CMV immediate-early enhancer", "DNA", 556, 584], ["promoter", "DNA", 585, 593], ["NheI and SalI restriction sites", "DNA", 600, 631], ["porcine", "SPECIES", 457, 464], ["Analysis", "TEST", 0, 8], ["alignment of DNA and amino acid sequences", "TEST", 13, 54], ["Lasergene Package", "TREATMENT", 76, 93], ["the recombinant vectors", "TREATMENT", 138, 161], ["primers PCI", "TREATMENT", 312, 323], ["APN", "TEST", 324, 327], ["PCI", "TEST", 375, 378], ["APN", "TEST", 379, 382], ["R (TTGTCGACTCAGCTGTGCTCTATGAACCAATTCAACA)", "TREATMENT", 383, 424], ["total RNAs", "TREATMENT", 431, 441], ["a pCI", "TREATMENT", 511, 516], ["neo vector (Promega)", "TREATMENT", 517, 537], ["the CMV immediate", "TREATMENT", 552, 569], ["early enhancer/promoter", "TREATMENT", 570, 593], ["NheI and SalI restriction sites", "TREATMENT", 600, 631], ["small intestine", "ANATOMY", 465, 480], ["CMV", "OBSERVATION", 556, 559]]], ["The construct was sequenced to verify the identity and designated as pCI-pAPN.", [["pCI-pAPN", "GENE_OR_GENE_PRODUCT", 69, 77], ["pCI", "DNA", 69, 72], ["pAPN", "DNA", 73, 77]]], ["The nine exons, encoding the first 1572-bp of Vero-APN mRNA from the Vero-APN gene, were fused sequentially by overlapping PCR, and inserted into a pRK5 vector, to construct an expression vector, pRK-vAPN.", [["Vero-APN", "GENE_OR_GENE_PRODUCT", 46, 54], ["Vero-APN", "GENE_OR_GENE_PRODUCT", 69, 77], ["pRK5", "GENE_OR_GENE_PRODUCT", 148, 152], ["pRK-vAPN", "GENE_OR_GENE_PRODUCT", 196, 204], ["exons", "DNA", 9, 14], ["Vero-APN mRNA", "RNA", 46, 59], ["Vero-APN gene", "DNA", 69, 82], ["pRK5 vector", "DNA", 148, 159], ["expression vector", "DNA", 177, 194], ["pRK", "DNA", 196, 199], ["vAPN", "DNA", 200, 204], ["Vero-APN mRNA", "TREATMENT", 46, 59], ["the Vero-APN gene", "TREATMENT", 65, 82], ["overlapping PCR", "TEST", 111, 126], ["a pRK5 vector", "TREATMENT", 146, 159], ["an expression vector", "TREATMENT", 174, 194]]], ["Plasmids pCI-pAPN or pRK-vAPN were transiently transfected into Vero cells using Lipofectamine 3000 (Thermo Fisher Scientific) according to the manufacturer's protocol.", [["Vero cells", "ANATOMY", 64, 74], ["pCI-pAPN", "GENE_OR_GENE_PRODUCT", 9, 17], ["pRK-vAPN", "GENE_OR_GENE_PRODUCT", 21, 29], ["Vero cells", "CELL", 64, 74], ["pCI", "PROTEIN", 9, 12], ["pAPN", "PROTEIN", 13, 17], ["pRK", "DNA", 21, 24], ["vAPN", "DNA", 25, 29], ["Vero cells", "CELL_LINE", 64, 74], ["Plasmids pCI", "TREATMENT", 0, 12], ["pAPN", "TREATMENT", 13, 17], ["pRK", "TREATMENT", 21, 24], ["vAPN", "TREATMENT", 25, 29], ["Lipofectamine", "TREATMENT", 81, 94], ["the manufacturer's protocol", "TREATMENT", 140, 167]]], ["Cells were cultured for 48 to 72 hours, and then applied to immunofluorescence assay or western blot to detect the expression of APN.siRNA and siRNA transfections ::: Materials and methodsThe siRNA directed against pAPN (sipAPN: 5\u2019-AACAAGCCCAGCUGGUAAA-3\u2019) or the negative control (siNC: 5\u2019-UUCUCCGAACGUGUCACGU-3\u2019) was purchased from RiboBio (Guangzhou, China).", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["APN", "GENE_OR_GENE_PRODUCT", 129, 132], ["pAPN", "GENE_OR_GENE_PRODUCT", 215, 219], ["APN", "PROTEIN", 129, 132], ["pAPN", "PROTEIN", 215, 219], ["Cells", "TEST", 0, 5], ["immunofluorescence assay", "TEST", 60, 84], ["western blot", "TEST", 88, 100], ["APN", "PROBLEM", 129, 132], ["siRNA and siRNA transfections", "TREATMENT", 133, 162], ["The siRNA", "TREATMENT", 188, 197], ["pAPN", "TEST", 215, 219], ["AACAAGCCCAGCUGGUAAA", "TEST", 232, 251], ["siRNA transfections", "OBSERVATION", 143, 162]]], ["The siRNA transfections in IPEC-J2 cells were performed using the Lipofectamine RNAiMAX transfection reagent (Thermo Fisher Scientific, USA) according to manufacturer's instructions.", [["IPEC-J2 cells", "ANATOMY", 27, 40], ["IPEC-J2 cells", "CELL", 27, 40], ["IPEC-J2 cells", "CELL_LINE", 27, 40], ["The siRNA transfections", "TREATMENT", 0, 23], ["IPEC-J2 cells", "TREATMENT", 27, 40], ["the Lipofectamine RNAiMAX transfection reagent", "TREATMENT", 62, 108], ["siRNA transfections", "OBSERVATION", 4, 23]]], ["At 24 hour post-transfection, IPEC-J2 cells were infected with PEDV-GFP at an MOI (multiplicity of infection) of 5 or with TGEV (MOI=1).Immunofluorescence assay, western blot and quantitative real-time PCR ::: Materials and methodsTransfected cells or APN-knockout Vero cells were washed 2 times with PBS, fixed with 4% paraformaldehyde in PBS for 20 min and then permeabilized with 0.5% Triton X-100 for 10 min.", [["IPEC-J2 cells", "ANATOMY", 30, 43], ["cells", "ANATOMY", 243, 248], ["Vero cells", "ANATOMY", 265, 275], ["infection", "DISEASE", 99, 108], ["paraformaldehyde", "CHEMICAL", 320, 336], ["Triton X-100", "CHEMICAL", 388, 400], ["paraformaldehyde", "CHEMICAL", 320, 336], ["IPEC-J2 cells", "CELL", 30, 43], ["PEDV-GFP", "GENE_OR_GENE_PRODUCT", 63, 71], ["TGEV", "ORGANISM", 123, 127], ["cells", "CELL", 243, 248], ["APN", "GENE_OR_GENE_PRODUCT", 252, 255], ["Vero cells", "CELL", 265, 275], ["paraformaldehyde", "SIMPLE_CHEMICAL", 320, 336], ["Triton X-100", "SIMPLE_CHEMICAL", 388, 400], ["IPEC-J2 cells", "CELL_LINE", 30, 43], ["PEDV", "PROTEIN", 63, 67], ["APN-knockout Vero cells", "CELL_LINE", 252, 275], ["PEDV", "SPECIES", 63, 67], ["TGEV", "SPECIES", 123, 127], ["IPEC", "TEST", 30, 34], ["J2 cells", "PROBLEM", 35, 43], ["PEDV", "PROBLEM", 63, 67], ["infection", "PROBLEM", 99, 108], ["TGEV (MOI", "TEST", 123, 132], ["Immunofluorescence assay", "TEST", 136, 160], ["western blot", "TEST", 162, 174], ["methodsTransfected cells", "TREATMENT", 224, 248], ["APN", "TEST", 252, 255], ["knockout Vero cells", "PROBLEM", 256, 275], ["PBS", "TREATMENT", 301, 304], ["4% paraformaldehyde in PBS", "TREATMENT", 317, 343], ["infection", "OBSERVATION", 99, 108]]], ["One hundred microliters of the polyclonal anti-APN antibody (abcam #93897), at a 1:100 dilution in PBS, was added over the cells and incubated for 1 hour at 37\u00b0C. Cells were washed trice with PBS and 100 \u03bcl FITC-labeled goat anti-rabbit IgG (Thermo Fisher Scientific) at a 1:100 dilution was then added.", [["cells", "ANATOMY", 123, 128], ["Cells", "ANATOMY", 163, 168], ["abcam #93897", "CHEMICAL", 61, 73], ["FITC", "CHEMICAL", 207, 211], ["anti-APN", "GENE_OR_GENE_PRODUCT", 42, 50], ["cells", "CELL", 123, 128], ["Cells", "CELL", 163, 168], ["trice", "SIMPLE_CHEMICAL", 181, 186], ["FITC", "SIMPLE_CHEMICAL", 207, 211], ["goat", "ORGANISM", 220, 224], ["polyclonal anti-APN antibody", "PROTEIN", 31, 59], ["abcam #93897", "PROTEIN", 61, 73], ["goat anti-rabbit IgG", "PROTEIN", 220, 240], ["goat", "SPECIES", 220, 224], ["anti-rabbit", "SPECIES", 225, 236], ["goat", "SPECIES", 220, 224], ["anti-rabbit", "SPECIES", 225, 236], ["the polyclonal anti-APN antibody", "TEST", 27, 59], ["a 1:100 dilution in PBS", "TREATMENT", 79, 102], ["PBS", "TEST", 192, 195], ["\u03bcl FITC-labeled goat anti-rabbit IgG", "TREATMENT", 204, 240]]], ["After 30 min incubation at 37\u00b0C, the cells were washed trice with PBS followed by 4',6-diamidino-2-phenylindole (DAPI) staining, and were visualized under a fluorescence microscope.", [["cells", "ANATOMY", 37, 42], ["4',6-diamidino-2-phenylindole", "CHEMICAL", 82, 111], ["4',6-diamidino-2-phenylindole", "CHEMICAL", 82, 111], ["DAPI", "CHEMICAL", 113, 117], ["cells", "CELL", 37, 42], ["trice", "SIMPLE_CHEMICAL", 55, 60], ["4',6-diamidino-2-phenylindole", "SIMPLE_CHEMICAL", 82, 111], ["DAPI", "SIMPLE_CHEMICAL", 113, 117], ["PBS", "TREATMENT", 66, 69], ["diamidino", "TREATMENT", 87, 96], ["a fluorescence microscope", "TEST", 155, 180]]], ["For detection of TGEV infection in ST cells, at 24 hpi, TGEV-infected ST cells were stained with a rabbit anti-TGEV-nucleocapsid protein (N) polyclonal antibody (made in-house) as the primary antibody, and an Alexa Fluor 488-conjugated goat anti-rabbit IgG (Thermo Fisher Scientific, USA) as the secondary antibody followed by DAPI staining.Immunofluorescence assay, western blot and quantitative real-time PCR ::: Materials and methodsFor western blot analysis of APN expression, pCI-pAPN or pRK-vAPN transfected cells, PEDV- or TGEV-infected IPEC-J2 cells were lysed in 125 \u03bcl CelLytic M lysis buffer (Sigma) per 106 cells, respectively.", [["ST cells", "ANATOMY", 35, 43], ["ST cells", "ANATOMY", 70, 78], ["cells", "ANATOMY", 514, 519], ["IPEC-J2 cells", "ANATOMY", 544, 557], ["cells", "ANATOMY", 619, 624], ["TGEV infection", "DISEASE", 17, 31], ["Alexa Fluor 488", "CHEMICAL", 209, 224], ["DAPI", "CHEMICAL", 327, 331], ["TGEV", "ORGANISM", 17, 21], ["ST cells", "CELL", 35, 43], ["TGEV", "ORGANISM", 56, 60], ["ST cells", "CELL", 70, 78], ["rabbit", "ORGANISM", 99, 105], ["Alexa Fluor 488", "SIMPLE_CHEMICAL", 209, 224], ["goat", "ORGANISM", 236, 240], ["DAPI", "SIMPLE_CHEMICAL", 327, 331], ["APN", "GENE_OR_GENE_PRODUCT", 465, 468], ["pCI-pAPN", "GENE_OR_GENE_PRODUCT", 481, 489], ["pRK-vAPN", "GENE_OR_GENE_PRODUCT", 493, 501], ["cells", "CELL", 514, 519], ["PEDV", "CELL", 521, 525], ["TGEV", "ORGANISM", 530, 534], ["IPEC-J2 cells", "CELL", 544, 557], ["cells", "CELL", 619, 624], ["ST cells", "CELL_TYPE", 35, 43], ["ST cells", "CELL_TYPE", 70, 78], ["rabbit anti-TGEV-nucleocapsid protein (N) polyclonal antibody", "PROTEIN", 99, 160], ["primary antibody", "PROTEIN", 184, 200], ["Alexa Fluor 488-conjugated goat anti-rabbit IgG", "PROTEIN", 209, 256], ["APN", "PROTEIN", 465, 468], ["pCI", "PROTEIN", 481, 484], ["pAPN", "PROTEIN", 485, 489], ["pRK-vAPN transfected cells", "CELL_LINE", 493, 519], ["PEDV- or TGEV-infected IPEC-J2 cells", "CELL_LINE", 521, 557], ["rabbit", "SPECIES", 99, 105], ["goat", "SPECIES", 236, 240], ["anti-rabbit", "SPECIES", 241, 252], ["TGEV", "SPECIES", 17, 21], ["TGEV", "SPECIES", 56, 60], ["rabbit", "SPECIES", 99, 105], ["goat", "SPECIES", 236, 240], ["anti-rabbit", "SPECIES", 241, 252], ["TGEV", "SPECIES", 530, 534], ["TGEV infection in ST cells", "PROBLEM", 17, 43], ["TGEV", "TEST", 56, 60], ["infected ST cells", "PROBLEM", 61, 78], ["a rabbit anti-TGEV", "TEST", 97, 115], ["nucleocapsid protein", "TEST", 116, 136], ["polyclonal antibody", "TEST", 141, 160], ["the primary antibody", "TEST", 180, 200], ["an Alexa Fluor", "TEST", 206, 220], ["the secondary antibody", "PROBLEM", 292, 314], ["DAPI staining", "PROBLEM", 327, 340], ["Immunofluorescence assay", "TEST", 341, 365], ["western blot", "TEST", 367, 379], ["blot analysis", "TEST", 448, 461], ["APN expression", "TEST", 465, 479], ["pCI", "TEST", 481, 484], ["pAPN", "TEST", 485, 489], ["pRK", "TEST", 493, 496], ["vAPN transfected cells", "PROBLEM", 497, 519], ["PEDV", "PROBLEM", 521, 525], ["TGEV", "PROBLEM", 530, 534], ["infected IPEC", "TREATMENT", 535, 548], ["J2 cells", "TREATMENT", 549, 557], ["CelLytic M lysis buffer", "TREATMENT", 579, 602], ["TGEV", "OBSERVATION_MODIFIER", 17, 21], ["infection", "OBSERVATION", 22, 31], ["DAPI staining", "OBSERVATION", 327, 340]]], ["Protein extracts were collected, aliquated and frozen at \u221220\u00b0C. Samples were resolved on SDS-PAGE and transferred onto polyvinylidene difluoride (PVDF) membrane that was subsequently blocked with Tris-buffered saline (TBS) containing 3% bovine serum albumin (BSA) overnight at 4\u00b0C. Proteins were detected using the anti-APN antibody at a 1:200 dilution followed by incubation with horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (Thermo Fisher Scientific).", [["extracts", "ANATOMY", 8, 16], ["Samples", "ANATOMY", 64, 71], ["serum", "ANATOMY", 244, 249], ["Tris-buffered", "CHEMICAL", 196, 209], ["polyvinylidene difluoride", "CHEMICAL", 119, 144], ["PVDF", "CHEMICAL", 146, 150], ["Tris", "CHEMICAL", 196, 200], ["extracts", "ORGANISM_SUBSTANCE", 8, 16], ["Tris-buffered saline", "SIMPLE_CHEMICAL", 196, 216], ["TBS", "SIMPLE_CHEMICAL", 218, 221], ["bovine", "ORGANISM", 237, 243], ["serum", "ORGANISM_SUBSTANCE", 244, 249], ["albumin", "SIMPLE_CHEMICAL", 250, 257], ["BSA", "SIMPLE_CHEMICAL", 259, 262], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 381, 403], ["HRP", "SIMPLE_CHEMICAL", 405, 408], ["anti-APN antibody", "PROTEIN", 315, 332], ["horseradish peroxidase (HRP)-conjugated anti-rabbit IgG", "PROTEIN", 381, 436], ["bovine", "SPECIES", 237, 243], ["horseradish", "SPECIES", 381, 392], ["anti-rabbit", "SPECIES", 421, 432], ["Protein extracts", "TEST", 0, 16], ["Samples", "TEST", 64, 71], ["SDS", "TEST", 89, 92], ["polyvinylidene difluoride (PVDF) membrane", "TREATMENT", 119, 160], ["Tris-buffered saline (TBS)", "TREATMENT", 196, 222], ["3% bovine serum albumin", "TREATMENT", 234, 257], ["Proteins", "TEST", 282, 290], ["the anti-APN antibody", "TREATMENT", 311, 332], ["horseradish peroxidase", "TREATMENT", 381, 403], ["conjugated anti-rabbit IgG", "TREATMENT", 410, 436]]], ["Detection of the N protein expression of PEDV or TGEV in infected IPEC-J2 cells were conducted by using the anti-PEDV-N monoclonal antibody (purchased from Medgene Labs, Brookings, SD, USA) or the anti-TGEV-N polyclonal antibody.Immunofluorescence assay, western blot and quantitative real-time PCR ::: Materials and methodsFor qRT-PCR analysis, total RNA was extracted from cell lysis using an AxyPrep Multisource Total RNA Miniprep Kit (Axygen).", [["IPEC-J2 cells", "ANATOMY", 66, 79], ["cell", "ANATOMY", 375, 379], ["PEDV", "GENE_OR_GENE_PRODUCT", 41, 45], ["TGEV", "ORGANISM", 49, 53], ["IPEC-J2 cells", "CELL", 66, 79], ["cell", "CELL", 375, 379], ["Axygen", "SIMPLE_CHEMICAL", 439, 445], ["N protein", "PROTEIN", 17, 26], ["PEDV", "PROTEIN", 41, 45], ["IPEC-J2 cells", "CELL_LINE", 66, 79], ["anti-PEDV", "PROTEIN", 108, 117], ["N monoclonal antibody", "PROTEIN", 118, 139], ["anti-TGEV-N polyclonal antibody", "PROTEIN", 197, 228], ["TGEV", "SPECIES", 49, 53], ["PEDV", "SPECIES", 41, 45], ["TGEV", "SPECIES", 49, 53], ["the N protein expression", "PROBLEM", 13, 37], ["PEDV", "PROBLEM", 41, 45], ["TGEV", "PROBLEM", 49, 53], ["J2 cells", "PROBLEM", 71, 79], ["the anti-PEDV", "TEST", 104, 117], ["N monoclonal antibody", "TEST", 118, 139], ["Medgene Labs", "TEST", 156, 168], ["Brookings", "TEST", 170, 179], ["the anti-TGEV", "TEST", 193, 206], ["Immunofluorescence assay", "TEST", 229, 253], ["western blot", "TEST", 255, 267], ["methods", "TEST", 317, 324], ["qRT-PCR analysis", "TEST", 328, 344], ["total RNA", "PROBLEM", 346, 355], ["cell lysis", "TREATMENT", 375, 385], ["an AxyPrep Multisource Total RNA Miniprep Kit (Axygen)", "TREATMENT", 392, 446], ["polyclonal antibody", "OBSERVATION", 209, 228], ["cell lysis", "OBSERVATION", 375, 385]]], ["Detection of mRNA expression levels of hAPN in Huh-7 cells or vAPN in Vero cells by qRT-PCR was performed using TransScript Green One-Step qRT-PCR SuperMix (Transbionovo, Beijing, China) with primers hAPN-qPCR-F (5\u2019-GGACAGCCAGTATGAGAT-3\u2019) and hAPN-qPCR-R (5\u2019-GGATAAGCGTGATGTTGAA-3\u2019), or primers vAPN-qPCR-F (5\u2019-TGAGATGGACAGTGAGTTC-3\u2019) and vAPN-qPCR-R (5\u2019-GTGGATAAGCGTGATGTTG-3\u2019).", [["Huh-7 cells", "ANATOMY", 47, 58], ["vAPN", "ANATOMY", 62, 66], ["Vero cells", "ANATOMY", 70, 80], ["hAPN", "GENE_OR_GENE_PRODUCT", 39, 43], ["Huh-7 cells", "CELL", 47, 58], ["vAPN", "CELL", 62, 66], ["Vero cells", "CELL", 70, 80], ["hAPN-qPCR-R", "GENE_OR_GENE_PRODUCT", 243, 254], ["hAPN", "PROTEIN", 39, 43], ["Huh-7 cells", "CELL_LINE", 47, 58], ["vAPN", "CELL_LINE", 62, 66], ["Vero cells", "CELL_LINE", 70, 80], ["hAPN", "DNA", 243, 247], ["vAPN", "DNA", 295, 299], ["vAPN", "DNA", 339, 343], ["mRNA expression levels", "TEST", 13, 35], ["hAPN", "TEST", 39, 43], ["Huh", "TEST", 47, 50], ["vAPN", "TEST", 62, 66], ["Vero cells", "TEST", 70, 80], ["qRT", "TEST", 84, 87], ["PCR", "TEST", 88, 91], ["SuperMix (Transbionovo", "TREATMENT", 147, 169], ["primers hAPN", "TREATMENT", 192, 204], ["GGACAGCCAGTATGAGAT", "TEST", 216, 234], ["hAPN", "TEST", 243, 247], ["qPCR", "TEST", 248, 252], ["GGATAAGCGTGATGTTGAA", "TEST", 259, 278], ["vAPN", "TEST", 295, 299], ["TGAGATGGACAGTGAGTTC", "TEST", 311, 330], ["vAPN", "TEST", 339, 343]]], ["Relative quantification was expressed as 2-\u0394Ct, where Ct is the difference between the main Ct value of the sample in triplicate and that of an endogenous human \u03b2-actin (primers 5\u2019-ATGACCAACAAGTGTCTCCTCC-3\u2019 and 5\u2019-GGAATCCAAGCAAGTTGTAGCTC-3\u2019) or green monkey \u03b2-actin control (primers 5\u2019-CCTGGCACCCAGCACAAT-3\u2019 and 5\u2019-GGGCCGGACTCGTCATAC-3\u2019).Treatment with anti-PEDV spike (S) protein antibodies, anti-APN antibody or neuraminidase ::: Materials and methodsCells were incubated with the anti-APN antibody at 2 \u03bcg/ml or 20 mg/ml or neuraminidase (Sigma) at concentrations of 5, 10, 20, 30 or 50 mU in DMEM for 1 h at 37\u00b0C prior to PEDV-GFP infection.", [["sample", "ANATOMY", 108, 114], ["Cells", "ANATOMY", 453, 458], ["PEDV", "CHEMICAL", 626, 630], ["infection", "DISEASE", 635, 644], ["human", "ORGANISM", 155, 160], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 161, 168], ["anti-PEDV spike (S)", "GENE_OR_GENE_PRODUCT", 353, 372], ["anti-APN antibody", "GENE_OR_GENE_PRODUCT", 393, 410], ["Cells", "CELL", 453, 458], ["neuraminidase", "SIMPLE_CHEMICAL", 527, 540], ["Sigma", "SIMPLE_CHEMICAL", 542, 547], ["GFP", "GENE_OR_GENE_PRODUCT", 631, 634], ["endogenous human \u03b2-actin", "PROTEIN", 144, 168], ["green monkey \u03b2-actin control", "DNA", 245, 273], ["anti-PEDV spike (S) protein antibodies", "PROTEIN", 353, 391], ["anti-APN antibody", "PROTEIN", 393, 410], ["neuraminidase", "PROTEIN", 414, 427], ["anti-APN antibody", "PROTEIN", 483, 500], ["neuraminidase", "PROTEIN", 527, 540], ["human", "SPECIES", 155, 160], ["human", "SPECIES", 155, 160], ["green monkey", "SPECIES", 245, 257], ["PEDV", "SPECIES", 626, 630], ["Ct", "TEST", 54, 56], ["Ct value", "TEST", 92, 100], ["the sample", "TEST", 104, 114], ["an endogenous human \u03b2-actin (primers", "TEST", 141, 177], ["ATGACCAACAAGTGTCTCCTCC", "TEST", 181, 203], ["GGAATCCAAGCAAGTTGTAGCTC", "TEST", 214, 237], ["green monkey \u03b2-actin control (primers", "TREATMENT", 245, 282], ["CCTGGCACCCAGCACAAT", "TEST", 286, 304], ["GGGCCGGACTCGTCATAC", "TEST", 315, 333], ["anti-PEDV spike", "TEST", 353, 368], ["protein antibodies", "TEST", 373, 391], ["anti-APN antibody", "TEST", 393, 410], ["the anti-APN antibody", "TREATMENT", 479, 500], ["neuraminidase", "TREATMENT", 527, 540], ["PEDV", "PROBLEM", 626, 630], ["GFP infection", "PROBLEM", 631, 644], ["main", "OBSERVATION_MODIFIER", 87, 91], ["infection", "OBSERVATION", 635, 644]]], ["For neutralizing test, serial dilutions (1:50, 1:100, 1:500 or 1:1000) of anti-PEDV-S IgM (Medgene Labs, Brookings, SD, USA) or anti-PEDV-S IgG (JBT, Korea) were each mixed with 100 FFU of PEDV-GFP, incubated at 37 \u00b0C for 1 h to form virus-antibody complexes, and added to Vero cells.", [["Vero cells", "ANATOMY", 273, 283], ["anti-PEDV-S IgM", "SIMPLE_CHEMICAL", 74, 89], ["anti-PEDV-S IgG", "GENE_OR_GENE_PRODUCT", 128, 143], ["GFP", "GENE_OR_GENE_PRODUCT", 194, 197], ["Vero cells", "CELL", 273, 283], ["anti-PEDV", "PROTEIN", 74, 83], ["S IgM", "PROTEIN", 84, 89], ["anti-PEDV", "PROTEIN", 128, 137], ["S IgG", "PROTEIN", 138, 143], ["JBT", "PROTEIN", 145, 148], ["PEDV", "PROTEIN", 189, 193], ["GFP", "PROTEIN", 194, 197], ["virus-antibody complexes", "PROTEIN", 234, 258], ["Vero cells", "CELL_LINE", 273, 283], ["anti-PEDV", "SPECIES", 128, 137], ["PEDV", "SPECIES", 189, 193], ["neutralizing test", "TEST", 4, 21], ["serial dilutions", "TEST", 23, 39], ["anti-PEDV", "TEST", 74, 83], ["S IgM", "TEST", 84, 89], ["Medgene Labs", "TEST", 91, 103], ["Brookings", "TEST", 105, 114], ["anti-PEDV", "TEST", 128, 137], ["S IgG", "TEST", 138, 143], ["PEDV", "PROBLEM", 189, 193], ["virus-antibody complexes", "TEST", 234, 258], ["Vero cells", "TREATMENT", 273, 283], ["Vero cells", "OBSERVATION", 273, 283]]], ["Cells were fixed in 4% paraformaldehyde at appropriate time points, and GFP-positive cells were counted.Generation of APN knockout (KO) cell lines by using CRISPR/Cas9 system ::: Materials and methodsWe first constructed a Cas9 backbone cloning vector, named pX480, harboring two guide RNA (gRNA) expression cassettes as well as a 2A-puromycin resistance gene inserted following the human Cas9 gene based upon the pX330 vector (Addgene) (Ran et al., 2013).", [["Cells", "ANATOMY", 0, 5], ["GFP-positive cells", "ANATOMY", 72, 90], ["APN knockout (KO) cell lines", "ANATOMY", 118, 146], ["puromycin", "CHEMICAL", 334, 343], ["paraformaldehyde", "CHEMICAL", 23, 39], ["Cells", "CELL", 0, 5], ["paraformaldehyde", "SIMPLE_CHEMICAL", 23, 39], ["GFP", "GENE_OR_GENE_PRODUCT", 72, 75], ["cells", "CELL", 85, 90], ["APN", "GENE_OR_GENE_PRODUCT", 118, 121], ["Cas9", "GENE_OR_GENE_PRODUCT", 223, 227], ["pX480", "GENE_OR_GENE_PRODUCT", 259, 264], ["puromycin", "GENE_OR_GENE_PRODUCT", 334, 343], ["human", "ORGANISM", 383, 388], ["Cas9", "GENE_OR_GENE_PRODUCT", 389, 393], ["pX330", "GENE_OR_GENE_PRODUCT", 414, 419], ["Addgene", "GENE_OR_GENE_PRODUCT", 428, 435], ["GFP-positive cells", "CELL_LINE", 72, 90], ["APN knockout (KO) cell lines", "CELL_LINE", 118, 146], ["CRISPR", "DNA", 156, 162], ["Cas9 backbone cloning vector", "DNA", 223, 251], ["pX480", "DNA", 259, 264], ["guide RNA (gRNA) expression cassettes", "DNA", 280, 317], ["2A-puromycin resistance gene", "DNA", 331, 359], ["human Cas9 gene", "DNA", 383, 398], ["pX330 vector", "DNA", 414, 426], ["Addgene", "DNA", 428, 435], ["human", "SPECIES", 383, 388], ["human", "SPECIES", 383, 388], ["Cells", "TEST", 0, 5], ["GFP", "TEST", 72, 75], ["a Cas9 backbone cloning vector", "TREATMENT", 221, 251], ["harboring two guide RNA (gRNA) expression cassettes", "TREATMENT", 266, 317], ["a 2A-puromycin resistance gene", "TREATMENT", 329, 359], ["the human Cas9 gene", "TREATMENT", 379, 398], ["positive cells", "OBSERVATION", 76, 90]]], ["The pX480 vector was digested with BbsI and BsaI sequentially and ligated with annealed protospacer oligoDNAs (nucleotides 284\u2013306, 5\u2019-CCGATGACAGGGGCCTATAC-3\u2019 and nucleotides 444\u2013466, 5\u2019-CGACATCGACAGAACCGAGC-3\u2019) specific for the vAPN CDS1 sequences to obtain a single-plasmid pX480-vAPNKO.", [["nucleotides", "CHEMICAL", 111, 122], ["nucleotides", "CHEMICAL", 163, 174], ["pX480", "GENE_OR_GENE_PRODUCT", 4, 9], ["BbsI", "GENE_OR_GENE_PRODUCT", 35, 39], ["BsaI", "GENE_OR_GENE_PRODUCT", 44, 48], ["pX480 vector", "DNA", 4, 16], ["BbsI", "PROTEIN", 35, 39], ["BsaI", "PROTEIN", 44, 48], ["annealed protospacer oligoDNAs", "DNA", 79, 109], ["vAPN CDS1 sequences", "DNA", 229, 248], ["pX480", "DNA", 276, 281], ["vAPNKO", "DNA", 282, 288], ["The pX480 vector", "TREATMENT", 0, 16], ["nucleotides", "TEST", 111, 122], ["CCGATGACAGGGGCCTATAC", "TEST", 135, 155], ["nucleotides", "TEST", 163, 174], ["CGACATCGACAGAACCGAGC", "TEST", 187, 207], ["the vAPN CDS1 sequences", "TEST", 225, 248], ["a single-plasmid pX480-vAPNKO", "TREATMENT", 259, 288]]], ["Vero-APN knockout cells were generated by CRISPR/Cas9 gene editing as described (Ran et al., 2013).", [["cells", "ANATOMY", 18, 23], ["APN", "GENE_OR_GENE_PRODUCT", 5, 8], ["Cas9", "GENE_OR_GENE_PRODUCT", 49, 53], ["Vero-APN knockout cells", "CELL_LINE", 0, 23], ["CRISPR", "DNA", 42, 48], ["Vero-APN knockout cells", "PROBLEM", 0, 23], ["CRISPR/Cas9 gene editing", "PROBLEM", 42, 66], ["knockout cells", "OBSERVATION", 9, 23]]], ["Single cell clones of vAPN knockout cells were obtained by limiting dilution and genotyped by PCR and DNA sequencing.Nucleotide sequence accession numbers ::: Materials and methodsThe sequences of the pAPN cDNA and the partial Vero-APN gene determined in this study have been deposited in GenBank under accession nos.", [["cell clones", "ANATOMY", 7, 18], ["vAPN knockout cells", "ANATOMY", 22, 41], ["Single cell clones", "CELL", 0, 18], ["vAPN knockout cells", "CELL", 22, 41], ["DNA", "CELLULAR_COMPONENT", 102, 105], ["pAPN", "GENE_OR_GENE_PRODUCT", 201, 205], ["Vero-APN", "GENE_OR_GENE_PRODUCT", 227, 235], ["vAPN knockout cells", "CELL_LINE", 22, 41], ["pAPN cDNA", "DNA", 201, 210], ["partial Vero-APN gene", "DNA", 219, 240], ["Single cell clones", "TEST", 0, 18], ["vAPN knockout cells", "PROBLEM", 22, 41], ["PCR", "TEST", 94, 97], ["DNA sequencing", "TEST", 102, 116], ["the pAPN cDNA", "TREATMENT", 197, 210], ["this study", "TEST", 255, 265], ["cell clones", "OBSERVATION", 7, 18]]], ["KX342854 and KX342855, respectively.", [["KX342854", "CHEMICAL", 0, 8], ["KX342855", "CHEMICAL", 13, 21], ["KX342854", "CHEMICAL", 0, 8], ["KX342855", "CHEMICAL", 13, 21], ["KX342854", "SIMPLE_CHEMICAL", 0, 8], ["KX342855", "SIMPLE_CHEMICAL", 13, 21]]]], "PMC7469729": [["COVID-19 Is Clinically RelevantThe clinical presentation of COVID-19 ranges from asymptomatic or mild symptoms to severe illness and death.", [["illness", "DISEASE", 121, 128], ["death", "DISEASE", 133, 138], ["COVID", "TEST", 0, 5], ["COVID", "TEST", 60, 65], ["asymptomatic", "PROBLEM", 81, 93], ["mild symptoms", "PROBLEM", 97, 110], ["severe illness", "PROBLEM", 114, 128], ["death", "PROBLEM", 133, 138], ["mild", "OBSERVATION_MODIFIER", 97, 101], ["severe", "OBSERVATION_MODIFIER", 114, 120], ["illness", "OBSERVATION", 121, 128]]], ["The most common symptoms are fever and coughing, with severe illness occurring in 16% of the patients after hospital admission.6 In a study of 72,314 cases reported in China, 81% of cases were mild (absent or mild pneumonia); 14%, severe (hypoxia, dyspnea, >50% lung involvement within 24-48 hours); and 5%, critical (shock, respiratory failure, multiorgan dysfunction).", [["lung", "ANATOMY", 262, 266], ["respiratory", "ANATOMY", 325, 336], ["multiorgan", "ANATOMY", 346, 356], ["fever", "DISEASE", 29, 34], ["coughing", "DISEASE", 39, 47], ["illness", "DISEASE", 61, 68], ["pneumonia", "DISEASE", 214, 223], ["hypoxia", "DISEASE", 239, 246], ["dyspnea", "DISEASE", 248, 255], ["shock", "DISEASE", 318, 323], ["respiratory failure", "DISEASE", 325, 344], ["multiorgan dysfunction", "DISEASE", 346, 368], ["patients", "ORGANISM", 93, 101], ["lung", "ORGAN", 262, 266], ["multiorgan", "ORGAN", 346, 356], ["patients", "SPECIES", 93, 101], ["The most common symptoms", "PROBLEM", 0, 24], ["fever", "PROBLEM", 29, 34], ["coughing", "PROBLEM", 39, 47], ["severe illness", "PROBLEM", 54, 68], ["a study", "TEST", 132, 139], ["mild (absent or mild pneumonia)", "PROBLEM", 193, 224], ["severe (hypoxia", "PROBLEM", 231, 246], ["dyspnea", "PROBLEM", 248, 255], ["critical (shock", "PROBLEM", 308, 323], ["respiratory failure", "PROBLEM", 325, 344], ["multiorgan dysfunction", "PROBLEM", 346, 368], ["fever", "OBSERVATION", 29, 34], ["severe", "OBSERVATION_MODIFIER", 54, 60], ["illness", "OBSERVATION", 61, 68], ["mild", "OBSERVATION_MODIFIER", 193, 197], ["mild", "OBSERVATION_MODIFIER", 209, 213], ["pneumonia", "OBSERVATION", 214, 223], ["severe", "OBSERVATION_MODIFIER", 231, 237], ["hypoxia", "OBSERVATION_MODIFIER", 239, 246], ["lung", "ANATOMY", 262, 266], ["respiratory failure", "OBSERVATION", 325, 344], ["multiorgan dysfunction", "OBSERVATION", 346, 368]]], ["Of all confirmed cases in this series, 2.3% resulted in death.20", [["death", "DISEASE", 56, 61], ["death", "PROBLEM", 56, 61], ["cases", "OBSERVATION", 17, 22]]]], "ebb14ba99afe3b4c57ff7bebbfa2d021458feba0": [["INTRODUCTIONThe rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection to pandemic level has posed an unprecedented challenge to the health services at different levels requiring a global response to adapt rapidly to a fast-changing situation.", [["acute respiratory syndrome coronavirus", "DISEASE", 42, 80], ["infection", "DISEASE", 96, 105], ["SARS-CoV-2", "ORGANISM", 84, 94], ["severe acute respiratory syndrome coronavirus", "SPECIES", 35, 80], ["SARS-CoV-2", "SPECIES", 84, 94], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 35, 80], ["SARS", "PROBLEM", 84, 88], ["CoV", "TEST", 89, 92], ["infection", "PROBLEM", 96, 105], ["severe", "OBSERVATION_MODIFIER", 35, 41], ["acute", "OBSERVATION_MODIFIER", 42, 47], ["respiratory syndrome", "OBSERVATION", 48, 68]]], ["1 The spread of the COVID-19 requires mitigation policies at political and social levels to contain the diffusion of the virus.", [["COVID-19", "DNA", 20, 28], ["the COVID", "TEST", 16, 25], ["mitigation policies", "TREATMENT", 38, 57], ["the diffusion of the virus", "PROBLEM", 100, 126], ["spread", "OBSERVATION_MODIFIER", 6, 12]]], ["While healthcare facilities (outpatient and inpatient based) have responded quickly to guarantee the adequate acute care of patients with COVID-19 related complications, management of non-COVID-19 diseases needs to be redefined to guarantee continuum of care according to the highest gold standards, evidenced-based knowledge and value-based priorities.", [["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 124, 132], ["COVID-19 related complications", "PROBLEM", 138, 168], ["non-COVID-19 diseases", "PROBLEM", 184, 205]]], ["2 3 Vulnerable populations with chronic diseases are at significant risk of acquiring COVID-19 infection, with the frequent development of complications causing a disruption in their care plan.", [["chronic diseases", "DISEASE", 32, 48], ["infection", "DISEASE", 95, 104], ["chronic diseases", "PROBLEM", 32, 48], ["acquiring COVID-19 infection", "PROBLEM", 76, 104], ["complications", "PROBLEM", 139, 152], ["Vulnerable", "OBSERVATION_MODIFIER", 4, 14], ["populations", "OBSERVATION_MODIFIER", 15, 26], ["chronic", "OBSERVATION_MODIFIER", 32, 39], ["diseases", "OBSERVATION", 40, 48], ["significant", "OBSERVATION_MODIFIER", 56, 67], ["infection", "OBSERVATION", 95, 104], ["complications", "OBSERVATION", 139, 152], ["disruption", "OBSERVATION", 163, 173]]], ["4 Patients with cancer are at higher risk of severe complications due to their immunosuppressive status and the high prevalence of comorbidities.", [["cancer", "ANATOMY", 16, 22], ["cancer", "DISEASE", 16, 22], ["Patients", "ORGANISM", 2, 10], ["cancer", "CANCER", 16, 22], ["Patients", "SPECIES", 2, 10], ["cancer", "PROBLEM", 16, 22], ["severe complications", "PROBLEM", 45, 65], ["their immunosuppressive status", "PROBLEM", 73, 103], ["comorbidities", "PROBLEM", 131, 144], ["cancer", "OBSERVATION", 16, 22], ["severe", "OBSERVATION_MODIFIER", 45, 51], ["complications", "OBSERVATION", 52, 65]]], ["5 6 Thus, the oncology community has had to reshape the organisation of daily standard activities and care facilities to protect patients and healthcare providers from the spread of the infection while maintaining access to oncological care through a framework-defined prioritisation of resources.", [["infection", "DISEASE", 186, 195], ["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 129, 137], ["care facilities", "TREATMENT", 102, 117], ["the infection", "PROBLEM", 182, 195], ["oncological care", "TREATMENT", 224, 240], ["infection", "OBSERVATION", 186, 195]]], ["Strategies to minimise risks have been broadly endorsed: establishment of checkpoints to triage patients for COVID-19 symptoms, frequent handwashing and use of protective masks, a reduction of the outpatient visits or replacement by telemedicine, engagement of primary healthcare sectors, patient education, reorganisation of outpatient clinics to guarantee social distancing and more frequent remote support especially when visits and assessments are cancelled or postponed.", [["patients", "ORGANISM", 96, 104], ["patient", "ORGANISM", 289, 296], ["patients", "SPECIES", 96, 104], ["patient", "SPECIES", 289, 296], ["COVID", "TEST", 109, 114], ["symptoms", "PROBLEM", 118, 126], ["protective masks", "TREATMENT", 160, 176], ["replacement", "TREATMENT", 218, 229]]], ["3 7-10 National and international guidelines are followed to prioritise oncological interventions, focusing on a continuous risk/benefit ratio assessment to select the best treatment option available.", [["oncological interventions", "TREATMENT", 72, 97], ["ratio assessment", "TEST", 137, 153], ["the best treatment option", "TREATMENT", 164, 189]]], ["While some strategies and definition of priorities might be similar across tumour types (eg, treatment with curative intent, management of symptoms, acute complications of surgery or medical or radiation interventions), specific considerations are needed for each disease entity to define which treatment can be delayed, and for how long.", [["tumour", "ANATOMY", 75, 81], ["tumour", "DISEASE", 75, 81], ["tumour", "CANCER", 75, 81], ["treatment", "TREATMENT", 93, 102], ["curative intent", "TREATMENT", 108, 123], ["symptoms", "PROBLEM", 139, 147], ["acute complications", "PROBLEM", 149, 168], ["surgery", "TREATMENT", 172, 179], ["medical or radiation interventions", "TREATMENT", 183, 217], ["each disease entity", "PROBLEM", 259, 278]]], ["Gynaecological malignancies are commonly associated with risk factors and cancer-related complications (eg, median age at diagnosis >60 years, comorbidities, thromboembolic events) that overlap with those observed during COVID-19 infection.", [["Gynaecological malignancies", "ANATOMY", 0, 27], ["cancer", "ANATOMY", 74, 80], ["Gynaecological malignancies", "DISEASE", 0, 27], ["cancer", "DISEASE", 74, 80], ["thromboembolic", "DISEASE", 158, 172], ["infection", "DISEASE", 230, 239], ["malignancies", "CANCER", 15, 27], ["cancer", "CANCER", 74, 80], ["Gynaecological malignancies", "PROBLEM", 0, 27], ["risk factors", "PROBLEM", 57, 69], ["cancer", "PROBLEM", 74, 80], ["comorbidities", "PROBLEM", 143, 156], ["thromboembolic events", "PROBLEM", 158, 179], ["COVID-19 infection", "PROBLEM", 221, 239], ["malignancies", "OBSERVATION", 15, 27], ["thromboembolic", "OBSERVATION", 158, 172], ["infection", "OBSERVATION", 230, 239]]], ["11 12 The management of gynaecological cancers is based on a multidisciplinary approach in which surgery plays a primary role.", [["gynaecological cancers", "ANATOMY", 24, 46], ["cancers", "DISEASE", 39, 46], ["gynaecological cancers", "CANCER", 24, 46], ["gynaecological cancers", "PROBLEM", 24, 46], ["a multidisciplinary approach", "TREATMENT", 59, 87], ["surgery", "TREATMENT", 97, 104], ["gynaecological cancers", "OBSERVATION", 24, 46]]], ["For patients with a new diagnosis of an apparent early stage cancer, a delay in surgery could be considered as there is no immediate risk to life.", [["early stage cancer", "ANATOMY", 49, 67], ["cancer", "DISEASE", 61, 67], ["patients", "ORGANISM", 4, 12], ["early stage cancer", "CANCER", 49, 67], ["patients", "SPECIES", 4, 12], ["an apparent early stage cancer", "PROBLEM", 37, 67], ["surgery", "TREATMENT", 80, 87], ["early", "OBSERVATION_MODIFIER", 49, 54], ["stage", "OBSERVATION_MODIFIER", 55, 60], ["cancer", "OBSERVATION", 61, 67], ["no", "UNCERTAINTY", 120, 122]]], ["However, when surgical intent is curative, any delay must be balanced against the effect this might have on patients' overall survival (OS).", [["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116], ["any delay", "PROBLEM", 43, 52]]], ["In advanced stage cancer, where the intent of surgery may not be curative, any delay in surgery needs to take account of the consequence this might have on disease-related complications and improvements in progression-free and OS and quality of life (QoL).", [["cancer", "ANATOMY", 18, 24], ["cancer", "DISEASE", 18, 24], ["advanced stage cancer", "CANCER", 3, 24], ["advanced stage cancer", "PROBLEM", 3, 24], ["surgery", "TREATMENT", 46, 53], ["surgery", "TREATMENT", 88, 95], ["disease", "PROBLEM", 156, 163], ["complications", "PROBLEM", 172, 185], ["advanced stage", "OBSERVATION_MODIFIER", 3, 17], ["cancer", "OBSERVATION", 18, 24]]], ["The high complexity of some surgical interventions for gynaecological cancers requires the availability of intensive care units facilities which can be overwhelmed during the infective emergency.", [["gynaecological cancers", "ANATOMY", 55, 77], ["cancers", "DISEASE", 70, 77], ["gynaecological cancers", "CANCER", 55, 77], ["some surgical interventions", "TREATMENT", 23, 50], ["gynaecological cancers", "PROBLEM", 55, 77], ["high", "OBSERVATION_MODIFIER", 4, 8], ["complexity", "OBSERVATION_MODIFIER", 9, 19], ["some", "OBSERVATION_MODIFIER", 23, 27], ["surgical", "OBSERVATION", 28, 36], ["cancers", "OBSERVATION", 70, 77]]], ["Moreover, a nasopharyngeal swab for COVID-19 diagnosis should be carried out in all patients undergoing surgery.", [["nasopharyngeal swab", "ANATOMY", 12, 31], ["nasopharyngeal swab", "CANCER", 12, 31], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["a nasopharyngeal swab", "TEST", 10, 31], ["COVID", "TEST", 36, 41], ["surgery", "TREATMENT", 104, 111], ["nasopharyngeal", "ANATOMY", 12, 26]]], ["A careful identification of the requirements to support patients in the postsurgical recovery is also relevant, given the higher susceptibility to infections and complications during this time.", [["infections", "DISEASE", 147, 157], ["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["the higher susceptibility to infections", "PROBLEM", 118, 157], ["complications", "PROBLEM", 162, 175], ["infections", "OBSERVATION", 147, 157]]], ["When it is not possible to guarantee adequate surgical or medical care access, referral to a COVID-19 free comprehensive cancer centre (Oncological Hub) highly specialised for the treatment of gynaecological malignancies should be discussed.", [["cancer", "ANATOMY", 121, 127], ["gynaecological malignancies", "ANATOMY", 193, 220], ["cancer", "DISEASE", 121, 127], ["malignancies", "DISEASE", 208, 220], ["cancer", "CANCER", 121, 127], ["gynaecological malignancies", "CANCER", 193, 220], ["gynaecological malignancies", "PROBLEM", 193, 220], ["not possible", "UNCERTAINTY", 11, 23]]], ["Chemotherapy is a key component of the multidisciplinary treatment of gynaecological malignancies.", [["gynaecological malignancies", "ANATOMY", 70, 97], ["malignancies", "DISEASE", 85, 97], ["gynaecological malignancies", "CANCER", 70, 97], ["Chemotherapy", "TREATMENT", 0, 12], ["the multidisciplinary treatment", "TREATMENT", 35, 66], ["gynaecological malignancies", "PROBLEM", 70, 97], ["gynaecological malignancies", "OBSERVATION", 70, 97]]], ["During this extraordinary pandemic, it is important to evaluate the potential risks of immunosuppression or adverse events, which might require hospital admission or more frequent outpatient visits.", [["immunosuppression", "TREATMENT", 87, 104], ["adverse events", "PROBLEM", 108, 122]]], ["Adjustments to the dose of drugs or schedule of administration should be considered to mitigate this risk.", [["drugs", "TREATMENT", 27, 32], ["administration", "TREATMENT", 48, 62]]], ["Thus, different aspects have to be sought and a careful discussion with patients and their families on the expected benefits and potential additional risks in this particular situation is necessary.", [["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80]]], ["In addition, testing of patients for SARS-CoV-2 before starting chemotherapy may be considered according to local practice and institutional directives, taking into account that infected patients are more contagious during the first days when no symptoms have occurred in the greater majority of cases.INTRODUCTIONClinical research is a key element in the care of patients, many of whom are receiving treatment within a clinical trial.", [["SARS", "DISEASE", 37, 41], ["patients", "ORGANISM", 24, 32], ["SARS-CoV-2", "ORGANISM", 37, 47], ["patients", "ORGANISM", 187, 195], ["patients", "ORGANISM", 364, 372], ["patients", "SPECIES", 24, 32], ["patients", "SPECIES", 187, 195], ["patients", "SPECIES", 364, 372], ["SARS-CoV", "SPECIES", 37, 45], ["testing", "TEST", 13, 20], ["SARS", "PROBLEM", 37, 41], ["CoV", "TEST", 42, 45], ["chemotherapy", "TREATMENT", 64, 76], ["symptoms", "PROBLEM", 246, 254], ["treatment", "TREATMENT", 401, 410], ["a clinical trial", "TREATMENT", 418, 434], ["infected", "OBSERVATION", 178, 186]]], ["Regulatory agencies (eg, European Medicines Agency; Food and Drug Administration) have provided guidance on extraordinary measures to adjust clinical trials in order to protect patients safety and trial conduct.", [["patients", "ORGANISM", 177, 185], ["patients", "SPECIES", 177, 185], ["European Medicines", "TREATMENT", 25, 43], ["extraordinary measures", "TREATMENT", 108, 130], ["clinical trials", "TREATMENT", 141, 156]]], ["Patients in a clinical trial should continue to receive treatment if it does not pose safety concerns.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["treatment", "TREATMENT", 56, 65]]], ["Accrual of new patients to a clinical trial depends on local resources, the patients' social conditions and geographical considerations; it should only occur if compliance to the protocol can be guaranteed and when data collection, particularly safety reporting can be assured.", [["patients", "ORGANISM", 15, 23], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 15, 23], ["patients", "SPECIES", 76, 84], ["the protocol", "TREATMENT", 175, 187], ["data collection", "TEST", 215, 230], ["new", "OBSERVATION_MODIFIER", 11, 14]]], ["Priority should be given to clinical trials where there is a high likelihood of benefit of the trial treatment.", [["the trial treatment", "TREATMENT", 91, 110]]], ["The impact of protocol deviations on the subsequent clinical data and trial primary endpoints should also be considered.INTRODUCTIONIn the coordinated effort to deliver high-level oncological care while facing COVID-19 pandemics, the European Society of Medical Oncology (ESMO) defined a tiered approach across three levels of priorities, namely: tier 1 (high priority intervention), 2 (medium priority) and 3 (low priority)-defined with the criteria of the Ontario Health Cancer Care Ontario, Huntsman Cancer Institute and Magnitude of Clinical Benefit Scale (MCBS), incorporating the information on the value-based prioritisation and clinical cogency of the interventions.", [["Cancer", "DISEASE", 473, 479], ["Cancer", "DISEASE", 503, 509], ["protocol deviations", "TREATMENT", 14, 33], ["high-level oncological care", "TREATMENT", 169, 196], ["high priority intervention", "TREATMENT", 355, 381], ["the value", "TEST", 601, 610], ["the interventions", "TREATMENT", 656, 673]]], ["15 16 \u25ba Tier 1 (high priority): patient's condition is immediately life threatening, clinically unstable and/or the magnitude of benefit qualifies the intervention as high priority (eg, significant OS gain and/or substantial improvement of the QoL). \u25ba Tier 2 (medium priority): patient situation is non-critical but delay beyond 6-8 weeks could potentially impact overall outcome and/or the magnitude of benefit qualifies for intermediate priority. \u25ba Tier 3 (low priority): patient condition is stable enough that services can be delayed for the duration of the COVID-19 pandemic and/or the intervention is nonpriority based on the magnitude of benefit (eg, no survival gain with no change to or reduced QoL).", [["patient", "ORGANISM", 32, 39], ["patient", "ORGANISM", 278, 285], ["patient", "ORGANISM", 474, 481], ["patient", "SPECIES", 32, 39], ["patient", "SPECIES", 278, 285], ["patient", "SPECIES", 474, 481], ["the intervention", "TREATMENT", 147, 163], ["significant OS gain", "PROBLEM", 186, 205], ["the COVID", "TEST", 558, 567], ["the intervention", "TREATMENT", 587, 603], ["survival gain", "PROBLEM", 661, 674]]], ["Reassessment of deferrable interventions is advisable to confirm the level of priority remains unchanged overtime.", [["deferrable interventions", "TREATMENT", 16, 40], ["unchanged", "OBSERVATION", 95, 104]]], ["The peculiarities of gynaecological malignancies previously described have been considered along with the national and international guidelines to define COVID-19 adapted recommendations.", [["gynaecological malignancies", "ANATOMY", 21, 48], ["gynaecological malignancies", "DISEASE", 21, 48], ["gynaecological malignancies", "CANCER", 21, 48], ["gynaecological malignancies", "PROBLEM", 21, 48], ["gynaecological malignancies", "OBSERVATION", 21, 48]]], ["3 15 17-19 These recommendations provide a guide for physicians managing ovarian, endometrial and cervical cancer while facing the COVID-19 pandemic, without replacing the current ESMO Clinical Practice Guidelines [20] [21] [22] and have adapted them in the context of value-based priorities similarly to what has been implemented in the ESMO MCBS.", [["ovarian", "ANATOMY", 73, 80], ["endometrial", "ANATOMY", 82, 93], ["cervical cancer", "ANATOMY", 98, 113], ["ovarian, endometrial and cervical cancer", "DISEASE", 73, 113], ["ovarian", "CANCER", 73, 80], ["endometrial", "CANCER", 82, 93], ["cervical cancer", "CANCER", 98, 113], ["ovarian, endometrial and cervical cancer", "PROBLEM", 73, 113], ["the COVID", "TEST", 127, 136], ["endometrial", "ANATOMY", 82, 93], ["cervical", "ANATOMY", 98, 106], ["cancer", "OBSERVATION", 107, 113]]], ["16 These recommendations do not substitute the adoption of broader national health and social strategies to protect patients and communities, but they can be integrated to mitigate the negative impact of COVID-19 and guarantee a coordinated global response.INTRODUCTIONThe present manuscript has been developed according the ESMO guidelines for patients' management during the COVID-19 pandemic, available at https://www. esmo. org/ guidelines/ cancer-patient-management-during-thecovid-19-pandemic/.INTRODUCTIONIn addition, the pandemic is evolving and these recommendations could be reassessed and adapted to the current status of the SARS-CoV-2 infection and the local and national resources availability.MANAGEMENT OF EPITHELIAL OVARIAN CANCEROvarian cancer (OC) represents the leading cause of death from gynaecological cancer in developed countries.", [["cancer", "ANATOMY", 445, 451], ["CANCEROvarian cancer", "ANATOMY", 741, 761], ["OC", "ANATOMY", 763, 765], ["gynaecological cancer", "ANATOMY", 810, 831], ["cancer", "DISEASE", 445, 451], ["SARS", "DISEASE", 637, 641], ["infection", "DISEASE", 648, 657], ["CANCEROvarian cancer", "DISEASE", 741, 761], ["OC", "CHEMICAL", 763, 765], ["death", "DISEASE", 799, 804], ["gynaecological cancer", "DISEASE", 810, 831], ["COVID-19", "CHEMICAL", 204, 212], ["patients", "ORGANISM", 116, 124], ["patients", "ORGANISM", 345, 353], ["cancer", "CANCER", 445, 451], ["patient", "ORGANISM", 452, 459], ["SARS-CoV-2", "ORGANISM", 637, 647], ["CANCEROvarian cancer", "CANCER", 741, 761], ["OC", "CANCER", 763, 765], ["gynaecological cancer", "CANCER", 810, 831], ["patients", "SPECIES", 116, 124], ["patients", "SPECIES", 345, 353], ["patient", "SPECIES", 452, 459], ["social strategies", "TREATMENT", 87, 104], ["COVID", "TEST", 204, 209], ["patients' management", "TREATMENT", 345, 365], ["cancer", "PROBLEM", 445, 451], ["management", "TREATMENT", 460, 470], ["the SARS", "PROBLEM", 633, 641], ["CoV-2 infection", "PROBLEM", 642, 657], ["EPITHELIAL OVARIAN CANCEROvarian cancer", "PROBLEM", 722, 761], ["death", "PROBLEM", 799, 804], ["gynaecological cancer", "PROBLEM", 810, 831], ["EPITHELIAL", "ANATOMY_MODIFIER", 722, 732], ["OVARIAN", "ANATOMY", 733, 740], ["CANCEROvarian cancer", "OBSERVATION", 741, 761], ["gynaecological", "ANATOMY", 810, 824], ["cancer", "OBSERVATION", 825, 831]]], ["The disease spread at the diagnosis and the residual tumour at the end of the surgery are the most important prognostic factors for OS.", [["tumour", "ANATOMY", 53, 59], ["tumour", "DISEASE", 53, 59], ["tumour", "CANCER", 53, 59], ["The disease spread", "PROBLEM", 0, 18], ["the residual tumour", "PROBLEM", 40, 59], ["the surgery", "TREATMENT", 74, 85], ["disease", "OBSERVATION", 4, 11], ["residual", "OBSERVATION_MODIFIER", 44, 52], ["tumour", "OBSERVATION", 53, 59]]], ["According to the 2018 ESMO-ESGO consensus conference recommendations, the standard surgical staging of apparently early stage epithelial OC (International Federation of Gynaecology and Obstetrics 'FIGO' stages I and II tumours) includes total hysterectomy, bilateral salpingo-oophorectomy (BSO), peritoneal and lymph node sampling and omentectomy.", [["epithelial OC", "ANATOMY", 126, 139], ["tumours", "ANATOMY", 219, 226], ["peritoneal", "ANATOMY", 296, 306], ["lymph node", "ANATOMY", 311, 321], ["OC", "CHEMICAL", 137, 139], ["BSO", "CHEMICAL", 290, 293], ["epithelial OC", "CANCER", 126, 139], ["tumours", "CANCER", 219, 226], ["BSO", "SIMPLE_CHEMICAL", 290, 293], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 296, 306], ["lymph node", "MULTI-TISSUE_STRUCTURE", 311, 321], ["the standard surgical staging", "TEST", 70, 99], ["early stage epithelial OC", "PROBLEM", 114, 139], ["Obstetrics 'FIGO' stages I and II tumours", "TREATMENT", 185, 226], ["total hysterectomy", "TREATMENT", 237, 255], ["bilateral salpingo-oophorectomy (BSO", "TREATMENT", 257, 293], ["peritoneal and lymph node sampling", "TREATMENT", 296, 330], ["omentectomy", "TREATMENT", 335, 346], ["early stage", "OBSERVATION_MODIFIER", 114, 125], ["epithelial OC", "OBSERVATION_MODIFIER", 126, 139], ["hysterectomy", "OBSERVATION", 243, 255], ["bilateral", "ANATOMY_MODIFIER", 257, 266], ["salpingo", "ANATOMY", 267, 275], ["oophorectomy", "OBSERVATION", 276, 288], ["peritoneal", "ANATOMY", 296, 306], ["lymph node", "OBSERVATION", 311, 321], ["omentectomy", "OBSERVATION", 335, 346]]], ["20 In advanced stages, primary cytoreductive surgery followed by platinum-based combination chemotherapy is the standard treatment.", [["platinum", "CHEMICAL", 65, 73], ["platinum", "CHEMICAL", 65, 73], ["platinum", "SIMPLE_CHEMICAL", 65, 73], ["primary cytoreductive surgery", "TREATMENT", 23, 52], ["platinum-based combination chemotherapy", "TREATMENT", 65, 104], ["the standard treatment", "TREATMENT", 108, 130], ["cytoreductive surgery", "OBSERVATION", 31, 52]]], ["However, a patient's clinical condition and frailty score should be carefully considered since extensive surgery has a non-negligible incidence of surgically-related complications.", [["patient", "ORGANISM", 11, 18], ["patient", "SPECIES", 11, 18], ["a patient's clinical condition", "PROBLEM", 9, 39], ["frailty score", "PROBLEM", 44, 57], ["extensive surgery", "TREATMENT", 95, 112], ["surgically-related complications", "PROBLEM", 147, 179], ["surgically", "OBSERVATION", 147, 157], ["complications", "OBSERVATION", 166, 179]]], ["This underscores the importance of managing patients with OC in highly specialised gynaecological oncology centres by a multidisciplinary team (MDT).", [["OC", "CHEMICAL", 58, 60], ["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52]]], ["Besides patients' status, surgical resection may not always be possible due to tumour extension; neoadjuvant chemotherapy (NACT) followed by interval debulking surgery may be an alternative option.", [["tumour", "ANATOMY", 79, 85], ["tumour", "DISEASE", 79, 85], ["patients", "ORGANISM", 8, 16], ["tumour", "CANCER", 79, 85], ["patients", "SPECIES", 8, 16], ["surgical resection", "TREATMENT", 26, 44], ["tumour extension", "PROBLEM", 79, 95], ["neoadjuvant chemotherapy (NACT)", "TREATMENT", 97, 128], ["interval debulking surgery", "TREATMENT", 141, 167], ["an alternative option", "TREATMENT", 175, 196], ["resection", "OBSERVATION", 35, 44], ["tumour", "OBSERVATION", 79, 85]]], ["20 Maintenance therapies, such as bevacizumab and poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi), significantly improve the progression-free survival following platinum-based chemotherapy and are part of the standard of care.", [["bevacizumab", "CHEMICAL", 34, 45], ["poly (ADP-ribose", "CHEMICAL", 50, 66], ["platinum", "CHEMICAL", 168, 176], ["bevacizumab", "CHEMICAL", 34, 45], ["poly (ADP-ribose)", "CHEMICAL", 50, 67], ["platinum", "CHEMICAL", 168, 176], ["bevacizumab", "SIMPLE_CHEMICAL", 34, 45], ["poly (ADP-ribose) polymerase", "GENE_OR_GENE_PRODUCT", 50, 78], ["PARP", "GENE_OR_GENE_PRODUCT", 80, 84], ["PARPi", "SIMPLE_CHEMICAL", 98, 103], ["poly (ADP-ribose) polymerase", "PROTEIN", 50, 78], ["PARP", "PROTEIN", 80, 84], ["Maintenance therapies", "TREATMENT", 3, 24], ["bevacizumab and poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi", "TREATMENT", 34, 103], ["platinum-based chemotherapy", "TREATMENT", 168, 195]]], ["Particularly, PARPi are completely changing the therapeutic algorithm of primary and recurrent disease.Outpatient visitsDuring the COVID-19 pandemic, reorganisation of outpatient activities is necessary to reduce hospital visits and maintain the recommended preventive measures in the outpatient setting.", [["PARPi", "SIMPLE_CHEMICAL", 14, 19], ["PARPi", "PROTEIN", 14, 19], ["PARPi", "PROBLEM", 14, 19], ["primary and recurrent disease", "PROBLEM", 73, 102], ["preventive measures", "TREATMENT", 258, 277], ["PARPi", "OBSERVATION", 14, 19], ["therapeutic", "OBSERVATION_MODIFIER", 48, 59], ["recurrent", "OBSERVATION_MODIFIER", 85, 94], ["disease", "OBSERVATION", 95, 102]]], ["Priority should be given to treating conditions for which a delay could compromise outcome and QoL (eg, symptomatic ascites or pleural effusion in newly diagnosed OC, acute abdominal pain or intestinal obstruction or postsurgical complications).", [["ascites", "ANATOMY", 116, 123], ["pleural", "ANATOMY", 127, 134], ["abdominal", "ANATOMY", 173, 182], ["intestinal", "ANATOMY", 191, 201], ["ascites", "DISEASE", 116, 123], ["pleural effusion", "DISEASE", 127, 143], ["OC", "DISEASE", 163, 165], ["abdominal pain", "DISEASE", 173, 187], ["intestinal obstruction", "DISEASE", 191, 213], ["pleural", "ORGAN", 127, 134], ["abdominal", "ORGANISM_SUBDIVISION", 173, 182], ["intestinal", "ORGAN", 191, 201], ["QoL (eg, symptomatic ascites", "PROBLEM", 95, 123], ["pleural effusion", "PROBLEM", 127, 143], ["newly diagnosed OC", "PROBLEM", 147, 165], ["acute abdominal pain", "PROBLEM", 167, 187], ["intestinal obstruction", "PROBLEM", 191, 213], ["postsurgical complications", "PROBLEM", 217, 243], ["symptomatic", "OBSERVATION_MODIFIER", 104, 115], ["ascites", "OBSERVATION", 116, 123], ["pleural", "ANATOMY", 127, 134], ["effusion", "OBSERVATION", 135, 143], ["acute", "OBSERVATION_MODIFIER", 167, 172], ["abdominal", "ANATOMY", 173, 182], ["intestinal", "ANATOMY", 191, 201], ["obstruction", "OBSERVATION", 202, 213]]], ["Hospital visits may be postponed up to 6 weeks for newly diagnosed patients who do not exhibit critical symptoms and those with planned postoperative follow-up.", [["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["critical symptoms", "PROBLEM", 95, 112]]], ["These situations should be considered as medium priority but should nevertheless be managed in a reasonable timeframe.Outpatient visitsTo reduce the number and the duration of the visits, alternative approaches (eg, telemedicine or phone consultations) should be put in place to assess patients on treatment the day before an infusion, and to address new problems or symptoms resulting from treatment.", [["patients", "ORGANISM", 286, 294], ["patients", "SPECIES", 286, 294], ["treatment", "TREATMENT", 298, 307], ["an infusion", "TREATMENT", 323, 334], ["new problems", "PROBLEM", 351, 363], ["symptoms", "PROBLEM", 367, 375], ["treatment", "TREATMENT", 391, 400]]], ["4 The safety monitoring of patients receiving oral treatments (eg, hormonal therapy, PARPi maintenance) should be organised through a system of telemedicine, with scheduled blood tests and imaging done close to home, and the postal delivery of oral medications.", [["oral", "ANATOMY", 46, 50], ["blood", "ANATOMY", 173, 178], ["oral", "ANATOMY", 244, 248], ["patients", "ORGANISM", 27, 35], ["oral", "ORGANISM_SUBDIVISION", 46, 50], ["blood", "ORGANISM_SUBSTANCE", 173, 178], ["oral", "ORGANISM_SUBDIVISION", 244, 248], ["patients", "SPECIES", 27, 35], ["oral treatments (eg", "TREATMENT", 46, 65], ["hormonal therapy", "TREATMENT", 67, 83], ["PARPi maintenance", "TREATMENT", 85, 102], ["scheduled blood tests", "TEST", 163, 184], ["imaging", "TEST", 189, 196], ["oral medications", "TREATMENT", 244, 260]]], ["A regular remote contact with patients is recommended to identify changes promptly as the clinical situation might modify the level of priority.Outpatient visitsFollow-up visits could be postponed up to a maximum of 6 months and eventually managed through telemedicine.", [["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38]]], ["Imaging should be guided based on clinical symptoms and/or Ca125 value (table 1) .ImagingImaging continues to have an important diagnostic role for symptomatic patients with advanced OC to identify intestinal obstruction or abdominal perforation, as these are considered a high priority for intervention.", [["intestinal", "ANATOMY", 198, 208], ["abdominal", "ANATOMY", 224, 233], ["OC", "CHEMICAL", 183, 185], ["intestinal obstruction", "DISEASE", 198, 220], ["abdominal perforation", "DISEASE", 224, 245], ["patients", "ORGANISM", 160, 168], ["intestinal", "ORGAN", 198, 208], ["abdominal", "ORGANISM_SUBDIVISION", 224, 233], ["patients", "SPECIES", 160, 168], ["Imaging", "TEST", 0, 7], ["clinical symptoms", "PROBLEM", 34, 51], ["Ca125 value", "TEST", 59, 70], ["advanced OC", "TREATMENT", 174, 185], ["intestinal obstruction", "PROBLEM", 198, 220], ["abdominal perforation", "PROBLEM", 224, 245], ["intervention", "TREATMENT", 291, 303], ["intestinal", "ANATOMY", 198, 208], ["obstruction", "OBSERVATION", 209, 220], ["abdominal", "ANATOMY", 224, 233], ["perforation", "OBSERVATION", 234, 245]]], ["It remains an important investigation for patients with symptoms typically associated with a diagnosis of advanced OC (eg, ascites, bowel obstruction, abdominal swelling).", [["ascites", "ANATOMY", 123, 130], ["bowel", "ANATOMY", 132, 137], ["abdominal", "ANATOMY", 151, 160], ["OC", "DISEASE", 115, 117], ["ascites", "DISEASE", 123, 130], ["bowel obstruction", "DISEASE", 132, 149], ["abdominal swelling", "DISEASE", 151, 169], ["patients", "ORGANISM", 42, 50], ["OC", "CANCER", 115, 117], ["bowel", "ORGAN", 132, 137], ["abdominal", "ORGANISM_SUBDIVISION", 151, 160], ["patients", "SPECIES", 42, 50], ["symptoms", "PROBLEM", 56, 64], ["advanced OC (eg", "PROBLEM", 106, 121], ["ascites", "PROBLEM", 123, 130], ["bowel obstruction", "PROBLEM", 132, 149], ["abdominal swelling", "PROBLEM", 151, 169], ["ascites", "OBSERVATION", 123, 130], ["bowel", "ANATOMY", 132, 137], ["obstruction", "OBSERVATION", 138, 149], ["abdominal", "ANATOMY", 151, 160], ["swelling", "OBSERVATION", 161, 169]]], ["Accurate preoperative imaging can guide the surgical approach and select patients who could benefit from primary debulking surgery.", [["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["Accurate preoperative imaging", "TEST", 0, 29], ["the surgical approach", "TREATMENT", 40, 61], ["primary debulking surgery", "TREATMENT", 105, 130]]], ["However, some sites will not be able to prioritise the CT scans during the COVID-19 crisis and may base their evaluation on clinical or ultrasound examination or ask the patients to perform the CT scan in another facility closer to their home.ImagingThe radiological assessment of the response to treatment, usually carried out by CT scan and evaluated according to the Response Evaluation Criteria in Solid Tumours (RECIST) tool 23 is a critical component of the primary endpoint for the majority of clinical trials as well as a fundamental instrument used in clinical practice.", [["patients", "ORGANISM", 170, 178], ["Solid Tumours", "CANCER", 402, 415], ["patients", "SPECIES", 170, 178], ["the CT scans", "TEST", 51, 63], ["the COVID", "TEST", 71, 80], ["base their evaluation", "TEST", 99, 120], ["clinical or ultrasound examination", "TEST", 124, 158], ["the CT scan", "TEST", 190, 201], ["Imaging", "TEST", 243, 250], ["The radiological assessment", "TEST", 250, 277], ["treatment", "TREATMENT", 297, 306], ["CT scan", "TEST", 331, 338], ["the Response Evaluation", "TEST", 366, 389], ["a fundamental instrument", "TREATMENT", 528, 552]]], ["For imaging within clinical trials, it is strongly recommended to perform the CT scan according to the schedule of the study if possible (table 1) .Surgical oncologyDuring an infectious disease pandemic, patients with cancer may face difficulties, such as access to hospital and deferred surgery.", [["cancer", "ANATOMY", 218, 224], ["infectious disease pandemic", "DISEASE", 175, 202], ["cancer", "DISEASE", 218, 224], ["patients", "ORGANISM", 204, 212], ["cancer", "CANCER", 218, 224], ["patients", "SPECIES", 204, 212], ["imaging", "TEST", 4, 11], ["the CT scan", "TEST", 74, 85], ["the study", "TEST", 115, 124], ["cancer", "PROBLEM", 218, 224], ["face difficulties", "PROBLEM", 229, 246], ["surgery", "TREATMENT", 288, 295], ["infectious", "OBSERVATION_MODIFIER", 175, 185]]], ["Different patients' characteristic and tumour prognostic factors should be taken into consideration when deciding how long surgery could be delayed.", [["tumour", "ANATOMY", 39, 45], ["tumour", "DISEASE", 39, 45], ["patients", "ORGANISM", 10, 18], ["tumour", "CANCER", 39, 45], ["patients", "SPECIES", 10, 18], ["Different patients' characteristic and tumour prognostic factors", "PROBLEM", 0, 64], ["long surgery", "TREATMENT", 118, 130]]], ["Life-threatening clinical conditions related to tumour spread, such as intestinal obstruction, bowel perforation, peritonitis, postsurgical complications, torsion of a pelvic mass or urinary obstruction should be considered as high priorities for surgery.", [["tumour", "ANATOMY", 48, 54], ["intestinal", "ANATOMY", 71, 81], ["bowel", "ANATOMY", 95, 100], ["pelvic mass", "ANATOMY", 168, 179], ["urinary", "ANATOMY", 183, 190], ["tumour", "DISEASE", 48, 54], ["intestinal obstruction", "DISEASE", 71, 93], ["bowel perforation", "DISEASE", 95, 112], ["peritonitis", "DISEASE", 114, 125], ["urinary obstruction", "DISEASE", 183, 202], ["tumour", "CANCER", 48, 54], ["intestinal", "ORGAN", 71, 81], ["bowel", "ORGAN", 95, 100], ["pelvic", "ORGAN", 168, 174], ["urinary", "ORGANISM_SUBDIVISION", 183, 190], ["Life-threatening clinical conditions", "PROBLEM", 0, 36], ["tumour spread", "PROBLEM", 48, 61], ["intestinal obstruction", "PROBLEM", 71, 93], ["bowel perforation", "PROBLEM", 95, 112], ["peritonitis", "PROBLEM", 114, 125], ["postsurgical complications", "PROBLEM", 127, 153], ["torsion", "PROBLEM", 155, 162], ["a pelvic mass", "PROBLEM", 166, 179], ["urinary obstruction", "PROBLEM", 183, 202], ["surgery", "TREATMENT", 247, 254], ["tumour spread", "OBSERVATION", 48, 61], ["intestinal", "ANATOMY", 71, 81], ["obstruction", "OBSERVATION", 82, 93], ["bowel", "ANATOMY", 95, 100], ["perforation", "OBSERVATION", 101, 112], ["peritonitis", "OBSERVATION", 114, 125], ["postsurgical", "OBSERVATION_MODIFIER", 127, 139], ["complications", "OBSERVATION", 140, 153], ["pelvic", "ANATOMY", 168, 174], ["mass", "OBSERVATION", 175, 179], ["urinary", "ANATOMY", 183, 190], ["obstruction", "OBSERVATION", 191, 202]]], ["Residual disease is the most important prognostic determinant following surgery, so primary cytoreduction should not be deferred beyond 6 weeks during the COVID-19 outbreak.", [["Residual disease", "PROBLEM", 0, 16], ["surgery", "TREATMENT", 72, 79], ["primary cytoreduction", "TREATMENT", 84, 105], ["the COVID", "TEST", 151, 160], ["disease", "OBSERVATION", 9, 16]]], ["NACT may be considered in frail patients or in those for whom complete cytoreduction is not achievable.", [["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["NACT", "TREATMENT", 0, 4], ["complete cytoreduction", "TREATMENT", 62, 84], ["may be considered", "UNCERTAINTY", 5, 22]]], ["Interval debulking surgery should ideally be performed after 3-4 cycles.", [["Interval debulking surgery", "TREATMENT", 0, 26], ["debulking", "OBSERVATION", 9, 18]]], ["However, in cases where there is a suboptimal response to chemotherapy and/or persisting poor general condition of the patient or when is not considered safe to perform a major surgical procedure due to the pandemic situation, surgery could be deferred and chemotherapy continued.", [["patient", "ORGANISM", 119, 126], ["patient", "SPECIES", 119, 126], ["chemotherapy", "TREATMENT", 58, 70], ["a major surgical procedure", "TREATMENT", 169, 195], ["the pandemic situation", "PROBLEM", 203, 225], ["surgery", "TREATMENT", 227, 234], ["chemotherapy", "TREATMENT", 257, 269]]], ["For all these reasons, consideration should be given to identify highly specialised COVID-19-free centres that could undertake these complex treatments, while minimising infection risk (table 2) .Medical oncologyIt is important to underline that the potential benefits of chemotherapy are unchanged, but the risk of harm is increased during COVID-19 to a level that is difficult to quantify.", [["infection", "DISEASE", 170, 179], ["COVID-19", "CHEMICAL", 341, 349], ["these complex treatments", "TREATMENT", 127, 151], ["minimising infection risk", "PROBLEM", 159, 184], ["chemotherapy", "TREATMENT", 272, 284], ["COVID", "TEST", 341, 346], ["unchanged", "OBSERVATION_MODIFIER", 289, 298], ["increased", "OBSERVATION_MODIFIER", 324, 333]]], ["Health prioritisation during this time should take into consideration the most effective treatment approaches.Medical oncologyPostoperative chemotherapy for early stage OC should be considered as a high priority for patients with highgrade serous or endometrioid histological subtypes, since an improvement in OS has been demonstrated.", [["serous", "ANATOMY", 240, 246], ["endometrioid", "ANATOMY", 250, 262], ["OC", "CHEMICAL", 169, 171], ["patients", "ORGANISM", 216, 224], ["highgrade serous", "CANCER", 230, 246], ["patients", "SPECIES", 216, 224], ["Postoperative chemotherapy", "TREATMENT", 126, 152], ["early stage OC", "PROBLEM", 157, 171], ["highgrade serous", "PROBLEM", 230, 246], ["endometrioid histological subtypes", "PROBLEM", 250, 284], ["OS", "PROBLEM", 310, 312], ["endometrioid", "OBSERVATION", 250, 262], ["improvement", "OBSERVATION_MODIFIER", 295, 306], ["OS", "OBSERVATION", 310, 312]]], ["20 Adjuvant chemotherapy in low-grade serous or endometrioid early-stage OC is low priority because of limited benefit and hormonal therapy alone could be considered in selected cases.Medical oncologyIn advanced stages, first-line postoperative chemotherapy in high-grade serous and endometrioid subtypes is high priority, while chemotherapy for clear cell or mucinous tumours can be postponed because of lower benefit (medium priority).", [["low-grade serous", "ANATOMY", 28, 44], ["endometrioid early-stage OC", "ANATOMY", 48, 75], ["high-grade serous", "ANATOMY", 261, 278], ["endometrioid subtypes", "ANATOMY", 283, 304], ["clear cell", "ANATOMY", 346, 356], ["mucinous tumours", "ANATOMY", 360, 376], ["OC", "CHEMICAL", 73, 75], ["clear cell or mucinous tumours", "DISEASE", 346, 376], ["low-grade serous", "CANCER", 28, 44], ["high-grade serous", "CANCER", 261, 278], ["endometrioid", "CANCER", 283, 295], ["cell", "CELL", 352, 356], ["mucinous tumours", "CANCER", 360, 376], ["Adjuvant chemotherapy", "TREATMENT", 3, 24], ["low-grade serous", "PROBLEM", 28, 44], ["endometrioid early", "PROBLEM", 48, 66], ["stage OC", "PROBLEM", 67, 75], ["hormonal therapy", "TREATMENT", 123, 139], ["first-line postoperative chemotherapy", "TREATMENT", 220, 257], ["high-grade serous and endometrioid subtypes", "PROBLEM", 261, 304], ["chemotherapy", "TREATMENT", 329, 341], ["clear cell", "PROBLEM", 346, 356], ["mucinous tumours", "PROBLEM", 360, 376], ["endometrioid", "OBSERVATION", 48, 60], ["stage OC", "OBSERVATION_MODIFIER", 67, 75], ["low priority", "OBSERVATION_MODIFIER", 79, 91], ["advanced", "OBSERVATION_MODIFIER", 203, 211], ["stages", "OBSERVATION_MODIFIER", 212, 218], ["high-grade", "OBSERVATION_MODIFIER", 261, 271], ["serous", "OBSERVATION_MODIFIER", 272, 278], ["endometrioid subtypes", "OBSERVATION", 283, 304], ["high priority", "OBSERVATION_MODIFIER", 308, 321], ["mucinous tumours", "OBSERVATION", 360, 376]]], ["Also in advanced low-grade serous or endometrioid cases, postoperative chemotherapy is low priority.Medical oncologyWhen chemotherapy is indicated, standard combination with carboplatin and paclitaxel should be administered, if deemed safe.", [["low-grade serous", "ANATOMY", 17, 33], ["endometrioid", "ANATOMY", 37, 49], ["carboplatin", "CHEMICAL", 174, 185], ["paclitaxel", "CHEMICAL", 190, 200], ["carboplatin", "CHEMICAL", 174, 185], ["paclitaxel", "CHEMICAL", 190, 200], ["low-grade serous", "CANCER", 17, 33], ["endometrioid", "CANCER", 37, 49], ["carboplatin", "SIMPLE_CHEMICAL", 174, 185], ["paclitaxel", "SIMPLE_CHEMICAL", 190, 200], ["advanced low-grade serous or endometrioid cases", "PROBLEM", 8, 55], ["postoperative chemotherapy", "TREATMENT", 57, 83], ["chemotherapy", "TREATMENT", 121, 133], ["carboplatin", "TREATMENT", 174, 185], ["paclitaxel", "TREATMENT", 190, 200], ["advanced", "OBSERVATION_MODIFIER", 8, 16], ["low-grade", "OBSERVATION_MODIFIER", 17, 26], ["serous", "OBSERVATION_MODIFIER", 27, 33], ["endometrioid cases", "OBSERVATION", 37, 55], ["postoperative chemotherapy", "OBSERVATION", 57, 83], ["low priority", "OBSERVATION_MODIFIER", 87, 99]]], ["Granulocyte growth factors in selected cases or other strategies, such as adopting a 4-weekly schedule of treatment, could be considered to reduce hospital visits and the risk of myelotoxicity.", [["myelotoxicity", "DISEASE", 179, 192], ["Granulocyte growth factors", "GENE_OR_GENE_PRODUCT", 0, 26], ["Granulocyte growth factors", "PROTEIN", 0, 26], ["Granulocyte growth factors", "PROBLEM", 0, 26], ["treatment", "TREATMENT", 106, 115], ["myelotoxicity", "PROBLEM", 179, 192], ["myelotoxicity", "OBSERVATION", 179, 192]]], ["Ongoing treatments should be completed, particularly in the context of clinical studies, as any compromise in dose intensity may adversely impact prognosis.Medical oncologyBevacizumab should be used with caution because of the increased risk of arterial hypertension and thromboembolic events that may worsen COVID-19 outcome.", [["arterial", "ANATOMY", 245, 253], ["Bevacizumab", "CHEMICAL", 172, 183], ["hypertension", "DISEASE", 254, 266], ["thromboembolic", "DISEASE", 271, 285], ["Bevacizumab", "CHEMICAL", 172, 183], ["Bevacizumab", "SIMPLE_CHEMICAL", 172, 183], ["arterial", "MULTI-TISSUE_STRUCTURE", 245, 253], ["Ongoing treatments", "TREATMENT", 0, 18], ["clinical studies", "TEST", 71, 87], ["Bevacizumab", "TREATMENT", 172, 183], ["arterial hypertension", "PROBLEM", 245, 266], ["thromboembolic events", "PROBLEM", 271, 292], ["COVID", "TEST", 309, 314], ["arterial", "ANATOMY", 245, 253], ["hypertension", "OBSERVATION", 254, 266], ["thromboembolic", "OBSERVATION", 271, 285]]], ["11 12 The benefit of maintenance PARPi, particularly for patients with breast cancer gene (BRCA)-mutated OC in the recurrent and front-line setting, has been clearly demonstrated.", [["breast cancer", "ANATOMY", 71, 84], ["PARPi", "CHEMICAL", 33, 38], ["breast cancer", "DISEASE", 71, 84], ["OC", "CHEMICAL", 105, 107], ["PARPi", "GENE_OR_GENE_PRODUCT", 33, 38], ["patients", "ORGANISM", 57, 65], ["breast cancer", "CANCER", 71, 84], ["BRCA", "GENE_OR_GENE_PRODUCT", 91, 95], ["patients", "SPECIES", 57, 65], ["maintenance PARPi", "TREATMENT", 21, 38], ["breast cancer gene (BRCA", "PROBLEM", 71, 95], ["mutated OC", "PROBLEM", 97, 107], ["breast", "ANATOMY", 71, 77], ["cancer", "OBSERVATION", 78, 84]]], ["24 25 Moreover, significant benefit of PARPi maintenance has been proven in BRCA wild-type platinum-sensitive recurrent OC.", [["OC", "ANATOMY", 120, 122], ["PARPi", "CHEMICAL", 39, 44], ["platinum", "CHEMICAL", 91, 99], ["OC", "CHEMICAL", 120, 122], ["platinum", "CHEMICAL", 91, 99], ["PARPi", "SIMPLE_CHEMICAL", 39, 44], ["BRCA wild-type platinum", "CANCER", 76, 99], ["OC", "CANCER", 120, 122], ["PARPi", "PROTEIN", 39, 44], ["PARPi maintenance", "TREATMENT", 39, 56], ["BRCA", "PROBLEM", 76, 80], ["type platinum", "TREATMENT", 86, 99]]], ["26 Shortening the duration of chemotherapy to 4-5 cycles in responding patients before starting the maintenance treatment could be considered, especially in the setting of recurrent disease.Medical oncologyChemotherapy for platinum-sensitive relapse should be delivered within a maximum of 6 weeks, and earlier in symptomatic patients, given the chance to obtain a longlasting clinical benefit.Medical oncologyAfter failure of platinum-based treatment, patients' outcome is commonly poor and chemotherapy provides limited benefit.", [["platinum", "CHEMICAL", 223, 231], ["platinum", "CHEMICAL", 427, 435], ["platinum", "CHEMICAL", 223, 231], ["platinum", "CHEMICAL", 427, 435], ["patients", "ORGANISM", 71, 79], ["patients", "ORGANISM", 326, 334], ["platinum", "SIMPLE_CHEMICAL", 427, 435], ["patients", "ORGANISM", 453, 461], ["patients", "SPECIES", 71, 79], ["patients", "SPECIES", 326, 334], ["patients", "SPECIES", 453, 461], ["chemotherapy", "TREATMENT", 30, 42], ["the maintenance treatment", "TREATMENT", 96, 121], ["recurrent disease", "PROBLEM", 172, 189], ["Chemotherapy", "TREATMENT", 206, 218], ["platinum", "TREATMENT", 223, 231], ["sensitive relapse", "PROBLEM", 232, 249], ["platinum-based treatment", "TREATMENT", 427, 451], ["chemotherapy", "TREATMENT", 492, 504], ["recurrent", "OBSERVATION_MODIFIER", 172, 181], ["disease", "OBSERVATION", 182, 189]]], ["However, some patients may derive an improvement in QoL and disease-related symptoms: a careful evaluation is therefore warranted, taking into consideration patients' performance status, expectations and the likelihood of response.", [["patients", "ORGANISM", 14, 22], ["patients", "ORGANISM", 157, 165], ["patients", "SPECIES", 14, 22], ["patients", "SPECIES", 157, 165], ["QoL and disease-related symptoms", "PROBLEM", 52, 84], ["a careful evaluation", "TEST", 86, 106]]], ["A thorough discussion with patients and families should influence the decision to start a non-platinum regimen or to adopt alternative palliative strategies to manage symptoms (table 2) .MANAGEMENT OF ENDOMETRIAL CANCERThe management of patients with endometrial cancer during the COVID-19 pandemic is particularly challenging due to the vulnerability of this patient population.", [["endometrial cancer", "ANATOMY", 251, 269], ["endometrial cancer", "DISEASE", 251, 269], ["patients", "ORGANISM", 27, 35], ["patients", "ORGANISM", 237, 245], ["endometrial cancer", "CANCER", 251, 269], ["patient", "ORGANISM", 360, 367], ["patients", "SPECIES", 27, 35], ["patients", "SPECIES", 237, 245], ["patient", "SPECIES", 360, 367], ["a non-platinum regimen", "TREATMENT", 88, 110], ["alternative palliative strategies", "TREATMENT", 123, 156], ["symptoms", "PROBLEM", 167, 175], ["ENDOMETRIAL CANCER", "PROBLEM", 201, 219], ["endometrial cancer", "PROBLEM", 251, 269], ["the COVID", "TEST", 277, 286], ["ENDOMETRIAL", "ANATOMY", 201, 212], ["CANCER", "OBSERVATION", 213, 219], ["endometrial", "ANATOMY", 251, 262], ["cancer", "OBSERVATION", 263, 269]]], ["Age at diagnosis >60 years, obesity, uncontrolled diabetes, high prevalence of cardiovascular and respiratory comorbidities are common features of women diagnosed with endometrial cancer and lead to a significant increased risk for severe complications and fatal outcome following SAR-CoV-2 infection.", [["cardiovascular", "ANATOMY", 79, 93], ["respiratory", "ANATOMY", 98, 109], ["endometrial cancer", "ANATOMY", 168, 186], ["obesity", "DISEASE", 28, 35], ["diabetes", "DISEASE", 50, 58], ["cardiovascular and respiratory comorbidities", "DISEASE", 79, 123], ["endometrial cancer", "DISEASE", 168, 186], ["infection", "DISEASE", 291, 300], ["cardiovascular", "ANATOMICAL_SYSTEM", 79, 93], ["women", "ORGANISM", 147, 152], ["endometrial cancer", "CANCER", 168, 186], ["CoV-2", "ORGANISM", 285, 290], ["women", "SPECIES", 147, 152], ["obesity", "PROBLEM", 28, 35], ["uncontrolled diabetes", "PROBLEM", 37, 58], ["cardiovascular and respiratory comorbidities", "PROBLEM", 79, 123], ["endometrial cancer", "PROBLEM", 168, 186], ["severe complications", "PROBLEM", 232, 252], ["fatal outcome", "PROBLEM", 257, 270], ["SAR-CoV-2 infection", "PROBLEM", 281, 300], ["obesity", "OBSERVATION", 28, 35], ["uncontrolled", "OBSERVATION_MODIFIER", 37, 49], ["diabetes", "OBSERVATION", 50, 58], ["high", "OBSERVATION_MODIFIER", 60, 64], ["cardiovascular", "ANATOMY", 79, 93], ["respiratory", "ANATOMY", 98, 109], ["comorbidities", "OBSERVATION", 110, 123], ["endometrial", "ANATOMY", 168, 179], ["cancer", "OBSERVATION", 180, 186], ["significant", "OBSERVATION_MODIFIER", 201, 212], ["increased", "OBSERVATION_MODIFIER", 213, 222], ["severe", "OBSERVATION_MODIFIER", 232, 238], ["complications", "OBSERVATION", 239, 252], ["infection", "OBSERVATION", 291, 300]]], ["11 The prioritisation of the interventions for the investigation and treatment of this disease should take account of these factors and be discussed within an MDT.", [["the interventions", "TREATMENT", 25, 42], ["the investigation", "TEST", 47, 64], ["treatment", "TREATMENT", 69, 78], ["this disease", "PROBLEM", 82, 94]]], ["Radical and curative treatment delay could be reasonably foreseen for low-grade cases apparently confined to the uterus, while those with highgrade or advanced uterine cancer, commonly associated with cancer-related symptoms, require rapid access to medical care.", [["uterus", "ANATOMY", 113, 119], ["uterine cancer", "ANATOMY", 160, 174], ["cancer", "ANATOMY", 201, 207], ["uterine cancer", "DISEASE", 160, 174], ["cancer", "DISEASE", 201, 207], ["uterus", "ORGAN", 113, 119], ["uterine cancer", "CANCER", 160, 174], ["cancer", "CANCER", 201, 207], ["Radical", "TREATMENT", 0, 7], ["curative treatment delay", "TREATMENT", 12, 36], ["low-grade cases", "PROBLEM", 70, 85], ["highgrade or advanced uterine cancer", "PROBLEM", 138, 174], ["cancer", "PROBLEM", 201, 207], ["related symptoms", "PROBLEM", 208, 224], ["medical care", "TREATMENT", 250, 262], ["curative", "OBSERVATION_MODIFIER", 12, 20], ["uterus", "ANATOMY", 113, 119], ["advanced", "OBSERVATION_MODIFIER", 151, 159], ["uterine", "ANATOMY", 160, 167], ["cancer", "OBSERVATION", 168, 174]]], ["The identification of conditions in which a delay might compromise patients' outcome is of utmost relevance.Outpatient visitsIn the outpatient setting, acute or severe tumour-related symptoms such as persistent severe vaginal bleeding, acute abdominal pain, anuria, symptoms of deep vein thrombosis or pulmonary embolism and symptoms possibly related to a recent surgery or ongoing radiotherapy require immediate assessment and proper interventions.Outpatient visitsThe assessment of patients with non-critical clinical conditions (eg, mild postmenopausal bleeding) and oncological consultations to discuss and plan an adjuvant treatment has to occur in a reasonable timeframe especially when a curative treatment is possible and a delay of more than 6-8 weeks will have a negative impact on patients' outcome.", [["tumour", "ANATOMY", 168, 174], ["vaginal", "ANATOMY", 218, 225], ["abdominal", "ANATOMY", 242, 251], ["deep vein", "ANATOMY", 278, 287], ["pulmonary", "ANATOMY", 302, 311], ["tumour", "DISEASE", 168, 174], ["vaginal bleeding", "DISEASE", 218, 234], ["abdominal pain", "DISEASE", 242, 256], ["anuria", "DISEASE", 258, 264], ["deep vein thrombosis", "DISEASE", 278, 298], ["pulmonary embolism", "DISEASE", 302, 320], ["bleeding", "DISEASE", 556, 564], ["patients", "ORGANISM", 67, 75], ["tumour", "CANCER", 168, 174], ["vaginal", "ORGANISM_SUBDIVISION", 218, 225], ["abdominal", "ORGANISM_SUBDIVISION", 242, 251], ["deep vein", "MULTI-TISSUE_STRUCTURE", 278, 287], ["pulmonary", "ORGAN", 302, 311], ["patients", "ORGANISM", 484, 492], ["patients", "ORGANISM", 792, 800], ["patients", "SPECIES", 67, 75], ["patients", "SPECIES", 484, 492], ["patients", "SPECIES", 792, 800], ["acute or severe tumour-related symptoms", "PROBLEM", 152, 191], ["persistent severe vaginal bleeding", "PROBLEM", 200, 234], ["acute abdominal pain", "PROBLEM", 236, 256], ["anuria", "PROBLEM", 258, 264], ["symptoms", "PROBLEM", 266, 274], ["deep vein thrombosis", "PROBLEM", 278, 298], ["pulmonary embolism", "PROBLEM", 302, 320], ["symptoms", "PROBLEM", 325, 333], ["a recent surgery", "TREATMENT", 354, 370], ["ongoing radiotherapy", "TREATMENT", 374, 394], ["immediate assessment", "TEST", 403, 423], ["proper interventions", "TREATMENT", 428, 448], ["The assessment", "TEST", 466, 480], ["non-critical clinical conditions", "PROBLEM", 498, 530], ["mild postmenopausal bleeding", "PROBLEM", 536, 564], ["oncological consultations", "TREATMENT", 570, 595], ["an adjuvant treatment", "TREATMENT", 616, 637], ["a curative treatment", "TREATMENT", 693, 713], ["acute", "OBSERVATION_MODIFIER", 152, 157], ["severe", "OBSERVATION_MODIFIER", 161, 167], ["tumour", "OBSERVATION", 168, 174], ["persistent", "OBSERVATION_MODIFIER", 200, 210], ["severe", "OBSERVATION_MODIFIER", 211, 217], ["vaginal", "ANATOMY", 218, 225], ["bleeding", "OBSERVATION", 226, 234], ["acute", "OBSERVATION_MODIFIER", 236, 241], ["abdominal", "ANATOMY", 242, 251], ["pain", "OBSERVATION", 252, 256], ["anuria", "OBSERVATION", 258, 264], ["deep", "ANATOMY_MODIFIER", 278, 282], ["vein", "ANATOMY", 283, 287], ["thrombosis", "OBSERVATION", 288, 298], ["pulmonary", "ANATOMY", 302, 311], ["embolism", "OBSERVATION", 312, 320], ["surgery", "OBSERVATION", 363, 370]]], ["Low priority hospital visits should be minimised and alternative approaches (eg, telemedicine or phone consultations) considered if this will not compromise the safety of the patients.", [["patients", "ORGANISM", 175, 183], ["patients", "SPECIES", 175, 183]]], ["Fertility-preserving therapy in premalignant disease (atypical hyperplasia (AH) or endometrial intraepithelial neoplasia (EIN)) and clinical assessment of patients with slow-growing asymptomatic vaginal or pelvic recurrence can be delayed unless potential unstable conditions will occur.", [["premalignant disease", "ANATOMY", 32, 52], ["atypical hyperplasia", "ANATOMY", 54, 74], ["AH", "ANATOMY", 76, 78], ["endometrial intraepithelial neoplasia", "ANATOMY", 83, 120], ["vaginal", "ANATOMY", 195, 202], ["pelvic", "ANATOMY", 206, 212], ["premalignant disease", "DISEASE", 32, 52], ["atypical hyperplasia", "DISEASE", 54, 74], ["AH", "DISEASE", 76, 78], ["endometrial intraepithelial neoplasia", "DISEASE", 83, 120], ["EIN", "DISEASE", 122, 125], ["premalignant disease", "CANCER", 32, 52], ["atypical hyperplasia", "CANCER", 54, 74], ["AH", "CANCER", 76, 78], ["endometrial intraepithelial neoplasia", "CANCER", 83, 120], ["EIN", "CANCER", 122, 125], ["patients", "ORGANISM", 155, 163], ["vaginal", "ORGANISM_SUBDIVISION", 195, 202], ["pelvic", "ORGAN", 206, 212], ["patients", "SPECIES", 155, 163], ["Fertility", "TREATMENT", 0, 9], ["preserving therapy", "TREATMENT", 10, 28], ["premalignant disease", "PROBLEM", 32, 52], ["atypical hyperplasia (AH)", "PROBLEM", 54, 79], ["endometrial intraepithelial neoplasia", "PROBLEM", 83, 120], ["clinical assessment", "TEST", 132, 151], ["slow-growing asymptomatic vaginal or pelvic recurrence", "PROBLEM", 169, 223], ["potential unstable conditions", "PROBLEM", 246, 275], ["premalignant", "OBSERVATION_MODIFIER", 32, 44], ["atypical", "OBSERVATION_MODIFIER", 54, 62], ["hyperplasia", "OBSERVATION", 63, 74], ["endometrial", "ANATOMY", 83, 94], ["intraepithelial neoplasia", "OBSERVATION", 95, 120], ["vaginal", "ANATOMY", 195, 202], ["pelvic", "ANATOMY", 206, 212], ["recurrence", "OBSERVATION", 213, 223]]], ["Follow-up visits with clinical and pelvic examination could be postponed up to a maximum of 6 months in curatively treated asymptomatic high-risk patients and converted to telemedicine for intermediate-low-risk patients (table 3) .ImagingDespite the difficulties to categorise the different possible clinical scenarios, the priority of the diagnostic workup should be adapted to the possible impact on patient's outcome and QoL.", [["pelvic", "ANATOMY", 35, 41], ["pelvic", "ORGAN", 35, 41], ["patients", "ORGANISM", 146, 154], ["patients", "ORGANISM", 211, 219], ["patient", "ORGANISM", 402, 409], ["patients", "SPECIES", 146, 154], ["patients", "SPECIES", 211, 219], ["patient", "SPECIES", 402, 409], ["clinical and pelvic examination", "TEST", 22, 53], ["the diagnostic workup", "TEST", 336, 357], ["pelvic", "ANATOMY", 35, 41]]], ["Differential diagnosis of life-threatening conditions related to the underlying malignancy or to postsurgical complications (eg, bowel perforation, peritonitis, anastomotic leak, pulmonary embolism or hydroureteronephrosis) requires immediate imaging.", [["malignancy", "ANATOMY", 80, 90], ["bowel", "ANATOMY", 129, 134], ["anastomotic", "ANATOMY", 161, 172], ["pulmonary", "ANATOMY", 179, 188], ["malignancy", "DISEASE", 80, 90], ["bowel perforation", "DISEASE", 129, 146], ["peritonitis", "DISEASE", 148, 159], ["anastomotic leak", "DISEASE", 161, 177], ["pulmonary embolism", "DISEASE", 179, 197], ["hydroureteronephrosis", "DISEASE", 201, 222], ["malignancy", "CANCER", 80, 90], ["bowel", "ORGAN", 129, 134], ["pulmonary", "ORGAN", 179, 188], ["life-threatening conditions", "PROBLEM", 26, 53], ["the underlying malignancy", "PROBLEM", 65, 90], ["postsurgical complications (eg", "PROBLEM", 97, 127], ["bowel perforation", "PROBLEM", 129, 146], ["peritonitis", "PROBLEM", 148, 159], ["anastomotic leak", "PROBLEM", 161, 177], ["pulmonary embolism", "PROBLEM", 179, 197], ["hydroureteronephrosis", "PROBLEM", 201, 222], ["immediate imaging", "TEST", 233, 250], ["malignancy", "OBSERVATION", 80, 90], ["bowel", "ANATOMY", 129, 134], ["perforation", "OBSERVATION", 135, 146], ["peritonitis", "OBSERVATION", 148, 159], ["anastomotic leak", "OBSERVATION", 161, 177], ["pulmonary", "ANATOMY", 179, 188], ["embolism", "OBSERVATION", 189, 197], ["hydroureteronephrosis", "OBSERVATION", 201, 222]]], ["In patients with newly diagnosed endometrial cancer, staging CT scan is crucial to define the best treatment strategy and needs to be planned with high priority especially when curative treatments are possible.ImagingWhen a tumour recurrence after radical treatment for early disease is suspected, radiological images should be performed in an adequate timeframe within a maximum of 2 months.", [["endometrial cancer", "ANATOMY", 33, 51], ["tumour", "ANATOMY", 224, 230], ["endometrial cancer", "DISEASE", 33, 51], ["tumour", "DISEASE", 224, 230], ["patients", "ORGANISM", 3, 11], ["endometrial cancer", "CANCER", 33, 51], ["tumour", "CANCER", 224, 230], ["patients", "SPECIES", 3, 11], ["newly diagnosed endometrial cancer", "PROBLEM", 17, 51], ["staging CT scan", "TEST", 53, 68], ["curative treatments", "TREATMENT", 177, 196], ["a tumour recurrence", "PROBLEM", 222, 241], ["radical treatment", "TREATMENT", 248, 265], ["early disease", "PROBLEM", 270, 283], ["radiological images", "TEST", 298, 317], ["endometrial", "ANATOMY", 33, 44], ["cancer", "OBSERVATION", 45, 51], ["early", "OBSERVATION_MODIFIER", 270, 275], ["disease", "OBSERVATION", 276, 283]]], ["In the palliative setting, imaging may be delayed in clinically stable patients (medium priority).", [["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["imaging", "TEST", 27, 34]]], ["Outside of a clinical trial, follow-up imaging as well as blood tests can be safely performed closer to patients' home and follow-up visits converted in telemedicine, if feasible (table 3) .Surgical oncologySurgery (hysterectomy\u00b1BSO and sentinel node biopsy (SLN) or lymphadenectomy) is the cornerstone for the management of newly diagnosed endometrial cancer in the cases apparently confined to the uterus and needs to occur as soon as possible.", [["blood", "ANATOMY", 58, 63], ["sentinel node", "ANATOMY", 237, 250], ["SLN", "ANATOMY", 259, 262], ["endometrial cancer", "ANATOMY", 341, 359], ["uterus", "ANATOMY", 400, 406], ["BSO", "CHEMICAL", 229, 232], ["endometrial cancer", "DISEASE", 341, 359], ["BSO", "CHEMICAL", 229, 232], ["blood", "ORGANISM_SUBSTANCE", 58, 63], ["patients", "ORGANISM", 104, 112], ["node biopsy", "MULTI-TISSUE_STRUCTURE", 246, 257], ["endometrial cancer", "CANCER", 341, 359], ["uterus", "ORGAN", 400, 406], ["patients", "SPECIES", 104, 112], ["follow-up imaging", "TEST", 29, 46], ["blood tests", "TEST", 58, 69], ["Surgical oncologySurgery (hysterectomy\u00b1BSO", "TREATMENT", 190, 232], ["sentinel node biopsy", "TEST", 237, 257], ["lymphadenectomy", "TREATMENT", 267, 282], ["the management", "TREATMENT", 307, 321], ["newly diagnosed endometrial cancer", "PROBLEM", 325, 359], ["hysterectomy", "OBSERVATION", 216, 228], ["sentinel node", "OBSERVATION", 237, 250], ["lymphadenectomy", "OBSERVATION", 267, 282], ["endometrial", "ANATOMY", 341, 352], ["cancer", "OBSERVATION", 353, 359], ["uterus", "ANATOMY", 400, 406]]], ["22 Laparoscopy is also a justifiable approach when performed by an expert gynaecology oncologist surgeon because of the reduced postsurgical recovery, complications and costs.", [["Laparoscopy", "TREATMENT", 3, 14], ["the reduced postsurgical recovery", "PROBLEM", 116, 149], ["Laparoscopy", "OBSERVATION", 3, 14], ["reduced", "OBSERVATION_MODIFIER", 120, 127], ["postsurgical", "OBSERVATION", 128, 140]]], ["The priority-based framework for surgical management of endometrial cancer must take into account tumour biology (histological subtype and grade), clinical stage, patients' general conditions and comorbidities and the possible risks from COVID-19 infection to estimate for how long a radical surgery could be safely delayed without compromising the chance of a curative approach.", [["endometrial cancer", "ANATOMY", 56, 74], ["tumour", "ANATOMY", 98, 104], ["endometrial cancer", "DISEASE", 56, 74], ["tumour", "DISEASE", 98, 104], ["infection", "DISEASE", 247, 256], ["endometrial cancer", "CANCER", 56, 74], ["tumour", "CANCER", 98, 104], ["patients", "ORGANISM", 163, 171], ["patients", "SPECIES", 163, 171], ["surgical management", "TREATMENT", 33, 52], ["endometrial cancer", "PROBLEM", 56, 74], ["clinical stage", "PROBLEM", 147, 161], ["patients' general conditions", "PROBLEM", 163, 191], ["comorbidities", "PROBLEM", 196, 209], ["COVID-19 infection", "PROBLEM", 238, 256], ["a radical surgery", "TREATMENT", 282, 299], ["a curative approach", "TREATMENT", 359, 378], ["endometrial", "ANATOMY", 56, 67], ["cancer", "OBSERVATION", 68, 74]]], ["Potential unstable medical conditions like uterine haemorrhage, radiologically confirmed peritonitis, postsurgical (perforation, ureteral dissection, bleeding) or radiotherapy complications (fistulisation, bowel perforation) require a prompt access to surgical theatre.", [["uterine", "ANATOMY", 43, 50], ["ureteral", "ANATOMY", 129, 137], ["bowel", "ANATOMY", 206, 211], ["uterine haemorrhage", "DISEASE", 43, 62], ["peritonitis", "DISEASE", 89, 100], ["perforation, ureteral dissection", "DISEASE", 116, 148], ["bleeding", "DISEASE", 150, 158], ["fistulisation", "DISEASE", 191, 204], ["bowel perforation", "DISEASE", 206, 223], ["uterine", "MULTI-TISSUE_STRUCTURE", 43, 50], ["ureteral", "ORGAN", 129, 137], ["bowel", "ORGAN", 206, 211], ["Potential unstable medical conditions", "PROBLEM", 0, 37], ["uterine haemorrhage", "PROBLEM", 43, 62], ["peritonitis", "PROBLEM", 89, 100], ["postsurgical (perforation", "PROBLEM", 102, 127], ["ureteral dissection", "PROBLEM", 129, 148], ["bleeding", "PROBLEM", 150, 158], ["radiotherapy complications", "PROBLEM", 163, 189], ["fistulisation", "PROBLEM", 191, 204], ["bowel perforation", "PROBLEM", 206, 223], ["surgical theatre", "TREATMENT", 252, 268], ["unstable", "OBSERVATION_MODIFIER", 10, 18], ["uterine", "ANATOMY", 43, 50], ["haemorrhage", "OBSERVATION", 51, 62], ["peritonitis", "OBSERVATION", 89, 100], ["postsurgical", "OBSERVATION_MODIFIER", 102, 114], ["perforation", "OBSERVATION", 116, 127], ["ureteral", "ANATOMY", 129, 137], ["dissection", "OBSERVATION", 138, 148], ["bleeding", "OBSERVATION", 150, 158], ["bowel", "ANATOMY", 206, 211], ["perforation", "OBSERVATION", 212, 223]]], ["Risk-reducing surgery for cancer predisposition and AH/EIN not responding to hormonal treatment is low priority (table 4) .Medical oncologyOngoing medical treatment should continue adjusting doses and schedules, when appropriate.", [["cancer", "ANATOMY", 26, 32], ["cancer", "DISEASE", 26, 32], ["AH", "DISEASE", 52, 54], ["EIN", "DISEASE", 55, 58], ["cancer", "CANCER", 26, 32], ["reducing surgery", "TREATMENT", 5, 21], ["cancer predisposition", "PROBLEM", 26, 47], ["AH/EIN", "TREATMENT", 52, 58], ["hormonal treatment", "TREATMENT", 77, 95], ["Ongoing medical treatment", "TREATMENT", 139, 164], ["adjusting doses and schedules", "TREATMENT", 181, 210]]], ["First-line chemotherapy for symptomatic metastatic or recurrent endometrial cancer not sensitive to hormonal treatment and adjuvant chemotherapy (with/without radiation treatment) in high-risk patients have the highest priority.", [["endometrial cancer", "ANATOMY", 64, 82], ["endometrial cancer", "DISEASE", 64, 82], ["endometrial cancer", "CANCER", 64, 82], ["patients", "ORGANISM", 193, 201], ["patients", "SPECIES", 193, 201], ["First-line chemotherapy", "TREATMENT", 0, 23], ["symptomatic metastatic", "PROBLEM", 28, 50], ["recurrent endometrial cancer", "PROBLEM", 54, 82], ["hormonal treatment", "TREATMENT", 100, 118], ["adjuvant chemotherapy", "TREATMENT", 123, 144], ["radiation treatment", "TREATMENT", 159, 178], ["symptomatic", "OBSERVATION_MODIFIER", 28, 39], ["metastatic", "OBSERVATION", 40, 50], ["recurrent", "OBSERVATION_MODIFIER", 54, 63], ["endometrial", "ANATOMY", 64, 75], ["cancer", "OBSERVATION", 76, 82]]], ["In grade 1-2 metastatic/recurrent endometrial cancer, hormonal treatment could be considered as first-line option.", [["grade 1-2 metastatic/recurrent endometrial cancer", "ANATOMY", 3, 52], ["endometrial cancer", "DISEASE", 34, 52], ["endometrial cancer", "CANCER", 34, 52], ["grade 1-2 metastatic/recurrent endometrial cancer", "PROBLEM", 3, 52], ["hormonal treatment", "TREATMENT", 54, 72], ["first-line option", "TREATMENT", 96, 113], ["grade 1", "OBSERVATION_MODIFIER", 3, 10], ["-2", "OBSERVATION_MODIFIER", 10, 12], ["metastatic", "OBSERVATION_MODIFIER", 13, 23], ["recurrent", "OBSERVATION_MODIFIER", 24, 33], ["endometrial", "ANATOMY", 34, 45], ["cancer", "OBSERVATION", 46, 52]]], ["Patients receiving hormonal treatment should be carefully monitored due to the known thromboembolic risk associated both to the viral infection and the hormonal agent.", [["thromboembolic", "DISEASE", 85, 99], ["viral infection", "DISEASE", 128, 143], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["hormonal treatment", "TREATMENT", 19, 37], ["the known thromboembolic risk", "PROBLEM", 75, 104], ["the viral infection", "PROBLEM", 124, 143], ["the hormonal agent", "TREATMENT", 148, 166], ["thromboembolic", "OBSERVATION", 85, 99], ["viral", "OBSERVATION_MODIFIER", 128, 133], ["infection", "OBSERVATION", 134, 143]]], ["After failure of platinum-based treatment, patients' outcome is commonly poor and second-line chemotherapy options are limited with minimal benefits expected.", [["platinum", "CHEMICAL", 17, 25], ["platinum", "CHEMICAL", 17, 25], ["platinum", "SIMPLE_CHEMICAL", 17, 25], ["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["platinum-based treatment", "TREATMENT", 17, 41], ["second-line chemotherapy options", "TREATMENT", 82, 114], ["platinum", "OBSERVATION_MODIFIER", 17, 25]]], ["In this situation, best supportive care is recommended (table 4) .Radiation oncologyRadiation therapy has a fundamental role in the multidisciplinary management of endometrial cancer and is commonly used with curative intent.", [["endometrial cancer", "ANATOMY", 164, 182], ["endometrial cancer", "DISEASE", 164, 182], ["endometrial cancer", "CANCER", 164, 182], ["Radiation oncology", "TREATMENT", 66, 84], ["Radiation therapy", "TREATMENT", 84, 101], ["the multidisciplinary management", "TREATMENT", 128, 160], ["endometrial cancer", "PROBLEM", 164, 182], ["curative intent", "TREATMENT", 209, 224], ["endometrial", "ANATOMY", 164, 175], ["cancer", "OBSERVATION", 176, 182]]], ["Daily access to radiation oncology departments, risks of cross contamination from equipment and the need to maintain dose intensity can be a real challenge to the management of patients.", [["patients", "ORGANISM", 177, 185], ["patients", "SPECIES", 177, 185], ["cross contamination", "PROBLEM", 57, 76], ["equipment", "TREATMENT", 82, 91], ["dose intensity", "TREATMENT", 117, 131]]], ["Immediate treatment should be offered to the patients with symptomatic primary tumour not suitable for surgery.", [["primary tumour", "ANATOMY", 71, 85], ["tumour", "DISEASE", 79, 85], ["patients", "ORGANISM", 45, 53], ["tumour", "CANCER", 79, 85], ["patients", "SPECIES", 45, 53], ["Immediate treatment", "TREATMENT", 0, 19], ["symptomatic primary tumour", "PROBLEM", 59, 85], ["surgery", "TREATMENT", 103, 110]]], ["Adjuvant external beam radiation treatment in high-risk endometrial cancer (with/without chemotherapy) is also of high priority given the curative role of this approach.", [["high-risk endometrial cancer", "ANATOMY", 46, 74], ["endometrial cancer", "DISEASE", 56, 74], ["high-risk endometrial cancer", "CANCER", 46, 74], ["Adjuvant external beam radiation treatment", "TREATMENT", 0, 42], ["high-risk endometrial cancer", "PROBLEM", 46, 74], ["chemotherapy", "TREATMENT", 89, 101], ["this approach", "TREATMENT", 155, 168], ["beam radiation", "OBSERVATION", 18, 32], ["endometrial", "ANATOMY", 56, 67], ["cancer", "OBSERVATION", 68, 74]]], ["Adjuvant brachytherapy and radiation treatment for vaginal cuff relapse can be planned as medium priority when a curative intent is foreseen, while treatment of asymptomatic vaginal or pelvic relapse can be safely delayed according to type and grade of symptoms (table 4) .", [["vaginal", "ANATOMY", 51, 58], ["vaginal", "ANATOMY", 174, 181], ["pelvic", "ANATOMY", 185, 191], ["vaginal cuff", "MULTI-TISSUE_STRUCTURE", 51, 63], ["vaginal", "ORGANISM_SUBDIVISION", 174, 181], ["pelvic", "ORGAN", 185, 191], ["Adjuvant brachytherapy", "TREATMENT", 0, 22], ["radiation treatment", "TREATMENT", 27, 46], ["vaginal cuff relapse", "TREATMENT", 51, 71], ["asymptomatic vaginal or pelvic relapse", "PROBLEM", 161, 199], ["symptoms", "PROBLEM", 253, 261], ["vaginal", "ANATOMY", 174, 181], ["pelvic", "ANATOMY", 185, 191], ["relapse", "OBSERVATION", 192, 199]]], ["Similarly to other pelvic malignancies, hypofractionated radiotherapy could be considered, even though supportive data are not yet available in gynaecological cancer.MANAGEMENT OF CERVICAL CANCERIn the treatment of patients with cervical cancer, the priority should be given to diagnosis, staging workup and treatment of potentially or already unstable lifethreatening conditions and localised disease suitable for curative treatment.", [["pelvic malignancies", "ANATOMY", 19, 38], ["gynaecological cancer", "ANATOMY", 144, 165], ["cervical cancer", "ANATOMY", 229, 244], ["pelvic malignancies", "DISEASE", 19, 38], ["cancer", "DISEASE", 159, 165], ["cervical cancer", "DISEASE", 229, 244], ["pelvic malignancies", "CANCER", 19, 38], ["gynaecological cancer", "CANCER", 144, 165], ["patients", "ORGANISM", 215, 223], ["cervical cancer", "CANCER", 229, 244], ["patients", "SPECIES", 215, 223], ["other pelvic malignancies", "PROBLEM", 13, 38], ["hypofractionated radiotherapy", "TREATMENT", 40, 69], ["gynaecological cancer", "PROBLEM", 144, 165], ["CERVICAL CANCERIn the treatment", "TREATMENT", 180, 211], ["cervical cancer", "PROBLEM", 229, 244], ["staging workup", "TEST", 289, 303], ["treatment", "TREATMENT", 308, 317], ["already unstable lifethreatening conditions", "PROBLEM", 336, 379], ["localised disease", "PROBLEM", 384, 401], ["curative treatment", "TREATMENT", 415, 433], ["pelvic", "ANATOMY", 19, 25], ["malignancies", "OBSERVATION", 26, 38], ["cancer", "OBSERVATION", 159, 165], ["CERVICAL", "ANATOMY", 180, 188], ["cervical", "ANATOMY", 229, 237], ["cancer", "OBSERVATION", 238, 244]]], ["The combined chemoradiotherapy (CRT) approach is high priority in locally advanced stages.", [["The combined chemoradiotherapy (CRT) approach", "TREATMENT", 0, 45], ["chemoradiotherapy", "OBSERVATION", 13, 30], ["high", "OBSERVATION_MODIFIER", 49, 53]]], ["The MDT discussion is necessary to define the best treatment and the availability of resources for the management of patients with cervical cancer.Outpatient visitsThe aim of high priority outpatient visits is to prevent and identify possible tumour or treatment-related complications and to define the best optimal treatment for newly diagnosed patients.", [["cervical cancer", "ANATOMY", 131, 146], ["tumour", "ANATOMY", 243, 249], ["cervical cancer", "DISEASE", 131, 146], ["tumour", "DISEASE", 243, 249], ["patients", "ORGANISM", 117, 125], ["cervical cancer", "CANCER", 131, 146], ["tumour", "CANCER", 243, 249], ["patients", "ORGANISM", 346, 354], ["patients", "SPECIES", 117, 125], ["patients", "SPECIES", 346, 354], ["the management", "TREATMENT", 99, 113], ["cervical cancer", "PROBLEM", 131, 146], ["tumour", "PROBLEM", 243, 249], ["related complications", "PROBLEM", 263, 284], ["cervical", "ANATOMY", 131, 139], ["cancer", "OBSERVATION", 140, 146]]], ["In the latter case, patients should be scheduled for staging workup (CT scan and blood tests) close to home, if possible, followed by MDT discussion.", [["blood", "ANATOMY", 81, 86], ["patients", "ORGANISM", 20, 28], ["blood", "ORGANISM_SUBSTANCE", 81, 86], ["patients", "SPECIES", 20, 28], ["staging workup", "TEST", 53, 67], ["CT scan and blood tests", "TEST", 69, 92]]], ["Unstable patients with life-threatening conditions as acute abdominal symptoms, bleeding or anuria must be seen as soon as possible.", [["abdominal", "ANATOMY", 60, 69], ["acute abdominal symptoms", "DISEASE", 54, 78], ["bleeding", "DISEASE", 80, 88], ["anuria", "DISEASE", 92, 98], ["patients", "ORGANISM", 9, 17], ["abdominal", "ORGANISM_SUBDIVISION", 60, 69], ["patients", "SPECIES", 9, 17], ["life-threatening conditions", "PROBLEM", 23, 50], ["acute abdominal symptoms", "PROBLEM", 54, 78], ["bleeding", "PROBLEM", 80, 88], ["anuria", "PROBLEM", 92, 98], ["acute", "OBSERVATION_MODIFIER", 54, 59], ["abdominal", "ANATOMY", 60, 69], ["symptoms", "OBSERVATION", 70, 78], ["bleeding", "OBSERVATION", 80, 88], ["anuria", "OBSERVATION", 92, 98]]], ["Patients with symptoms possibly related to previous surgery or ongoing radiotherapy should be seen as high priority.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["symptoms", "PROBLEM", 14, 22], ["previous surgery", "TREATMENT", 43, 59], ["ongoing radiotherapy", "TREATMENT", 63, 83]]], ["For postoperative patients without complications, a visit delay up to 6-8 weeks is acceptable, if no adjuvant treatment is planned.", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["complications", "PROBLEM", 35, 48], ["adjuvant treatment", "TREATMENT", 101, 119]]], ["Assessments of patients after palliative treatment for advanced/recurrent disease can be postponed up to 2 months, if patient remains clinically stable.", [["patients", "ORGANISM", 15, 23], ["patient", "ORGANISM", 118, 125], ["patients", "SPECIES", 15, 23], ["patient", "SPECIES", 118, 125], ["Assessments", "TEST", 0, 11], ["palliative treatment", "TREATMENT", 30, 50], ["advanced/recurrent disease", "PROBLEM", 55, 81], ["disease", "OBSERVATION", 74, 81], ["stable", "OBSERVATION", 145, 151]]], ["Follow-up visits after radical treatment for early disease or survivorship visits after the end of a study can be postponed up to a maximum of 6 months in asymptomatic patients (table 5) .ImagingImaging in patients with acute abdominal symptoms and life-threatening conditions, or complications from surgical or radiotherapy interventions (eg, bowel perforation, peritonitis, anastomotic leak, ureteral compression or hydronephrosis) is high priority.", [["abdominal", "ANATOMY", 226, 235], ["bowel", "ANATOMY", 344, 349], ["anastomotic", "ANATOMY", 376, 387], ["ureteral", "ANATOMY", 394, 402], ["bowel perforation", "DISEASE", 344, 361], ["peritonitis", "DISEASE", 363, 374], ["anastomotic leak", "DISEASE", 376, 392], ["ureteral compression", "DISEASE", 394, 414], ["hydronephrosis", "DISEASE", 418, 432], ["patients", "ORGANISM", 168, 176], ["patients", "ORGANISM", 206, 214], ["abdominal", "ORGANISM_SUBDIVISION", 226, 235], ["bowel", "ORGAN", 344, 349], ["ureteral", "ORGAN", 394, 402], ["patients", "SPECIES", 168, 176], ["patients", "SPECIES", 206, 214], ["radical treatment", "TREATMENT", 23, 40], ["early disease", "PROBLEM", 45, 58], ["a study", "TEST", 99, 106], ["ImagingImaging", "TEST", 188, 202], ["acute abdominal symptoms", "PROBLEM", 220, 244], ["life-threatening conditions", "PROBLEM", 249, 276], ["complications", "PROBLEM", 281, 294], ["surgical or radiotherapy interventions", "TREATMENT", 300, 338], ["bowel perforation", "PROBLEM", 344, 361], ["peritonitis", "PROBLEM", 363, 374], ["anastomotic leak", "PROBLEM", 376, 392], ["ureteral compression", "PROBLEM", 394, 414], ["hydronephrosis", "PROBLEM", 418, 432], ["acute", "OBSERVATION_MODIFIER", 220, 225], ["abdominal", "ANATOMY", 226, 235], ["symptoms", "OBSERVATION", 236, 244], ["bowel", "ANATOMY", 344, 349], ["perforation", "OBSERVATION", 350, 361], ["peritonitis", "OBSERVATION", 363, 374], ["anastomotic leak", "OBSERVATION", 376, 392], ["ureteral", "ANATOMY", 394, 402], ["compression", "OBSERVATION", 403, 414], ["hydronephrosis", "OBSERVATION", 418, 432], ["high", "OBSERVATION_MODIFIER", 437, 441]]], ["Patients with acute rapidly worsening of peripheral neurological symptoms as in case of nerve root compression or spinal involvement must perform CT scan as soon as possible.ImagingThe imaging performed for staging workup is also high priority in patients with a new suspicious or histologically confirmed diagnosis of cervical cancer because of the negative impact of a delay in the selection of the best treatment and on the outcome.", [["neurological", "ANATOMY", 52, 64], ["nerve root", "ANATOMY", 88, 98], ["spinal", "ANATOMY", 114, 120], ["cervical cancer", "ANATOMY", 319, 334], ["peripheral neurological symptoms", "DISEASE", 41, 73], ["nerve root compression", "DISEASE", 88, 110], ["cervical cancer", "DISEASE", 319, 334], ["Patients", "ORGANISM", 0, 8], ["nerve root", "MULTI-TISSUE_STRUCTURE", 88, 98], ["spinal", "ORGAN", 114, 120], ["patients", "ORGANISM", 247, 255], ["cervical cancer", "CANCER", 319, 334], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 247, 255], ["peripheral neurological symptoms", "PROBLEM", 41, 73], ["nerve root compression", "PROBLEM", 88, 110], ["spinal involvement", "PROBLEM", 114, 132], ["CT scan", "TEST", 146, 153], ["Imaging", "TEST", 174, 181], ["The imaging", "TEST", 181, 192], ["staging workup", "TEST", 207, 221], ["a new suspicious or histologically", "PROBLEM", 261, 295], ["cervical cancer", "PROBLEM", 319, 334], ["a delay", "PROBLEM", 369, 376], ["acute", "OBSERVATION_MODIFIER", 14, 19], ["rapidly", "OBSERVATION_MODIFIER", 20, 27], ["worsening", "OBSERVATION_MODIFIER", 28, 37], ["peripheral", "ANATOMY_MODIFIER", 41, 51], ["neurological symptoms", "OBSERVATION", 52, 73], ["nerve root", "ANATOMY", 88, 98], ["compression", "OBSERVATION", 99, 110], ["spinal", "ANATOMY", 114, 120], ["cervical", "ANATOMY", 319, 327], ["cancer", "OBSERVATION", 328, 334]]], ["Imaging for suspicion of tumour recurrence after radical treatment for early stages could be delayed up to a maximum of 2 months because of the prognostic value of an early detection suitable for a localised curative approach.", [["tumour", "ANATOMY", 25, 31], ["tumour", "DISEASE", 25, 31], ["tumour", "CANCER", 25, 31], ["Imaging", "TEST", 0, 7], ["tumour recurrence", "PROBLEM", 25, 42], ["radical treatment", "TREATMENT", 49, 66], ["a localised curative approach", "TREATMENT", 196, 225], ["tumour", "OBSERVATION", 25, 31]]], ["21 Follow-up imaging within clinical trials or after palliative treatment for advance or recurrent disease has a medium priority.", [["Follow-up imaging", "TEST", 3, 20], ["palliative treatment", "TREATMENT", 53, 73], ["recurrent disease", "PROBLEM", 89, 106]]], ["For patients enrolled in clinical trials, schedule of assessments should be maintained as close as possible to the study requirements balancing the need of a safety control and patients' risk of hospital visits (table 5) .Surgical oncologyThe management of a radiologically confirmed bowel perforation, peritonitis or surgery/radiotherapy complications (perforation, ureteral dissection or fistulisation) cannot be delayed.", [["bowel", "ANATOMY", 284, 289], ["ureteral", "ANATOMY", 367, 375], ["bowel perforation", "DISEASE", 284, 301], ["peritonitis", "DISEASE", 303, 314], ["perforation", "DISEASE", 354, 365], ["fistulisation", "DISEASE", 390, 403], ["patients", "ORGANISM", 4, 12], ["patients", "ORGANISM", 177, 185], ["bowel", "ORGAN", 284, 289], ["ureteral", "ORGAN", 367, 375], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 177, 185], ["assessments", "TEST", 54, 65], ["the study requirements", "TEST", 111, 133], ["a safety control", "TREATMENT", 156, 172], ["bowel perforation", "PROBLEM", 284, 301], ["peritonitis", "PROBLEM", 303, 314], ["surgery", "TREATMENT", 318, 325], ["radiotherapy complications", "PROBLEM", 326, 352], ["perforation", "PROBLEM", 354, 365], ["ureteral dissection", "TREATMENT", 367, 386], ["fistulisation", "PROBLEM", 390, 403], ["bowel", "ANATOMY", 284, 289], ["perforation", "OBSERVATION", 290, 301], ["peritonitis", "OBSERVATION", 303, 314], ["perforation", "OBSERVATION", 354, 365], ["ureteral", "ANATOMY", 367, 375], ["dissection", "OBSERVATION", 376, 386]]], ["Surgical curative therapy in cervical cancer depends on the stage.", [["cervical cancer", "ANATOMY", 29, 44], ["cervical cancer", "DISEASE", 29, 44], ["cervical cancer", "CANCER", 29, 44], ["Surgical curative therapy", "TREATMENT", 0, 25], ["cervical cancer", "PROBLEM", 29, 44], ["curative therapy", "OBSERVATION", 9, 25], ["cervical", "ANATOMY", 29, 37], ["cancer", "OBSERVATION", 38, 44]]], ["Microinvasive cervical cancer (stage IA1) has a very slow progression time, and trachelectomy\u00b1SLN sampling could be postponed up to 2 months.", [["cervical cancer", "ANATOMY", 14, 29], ["cervical cancer", "DISEASE", 14, 29], ["trachelectomy", "DISEASE", 80, 93], ["cervical cancer", "CANCER", 14, 29], ["Microinvasive cervical cancer (stage IA1", "PROBLEM", 0, 40], ["trachelectomy", "TREATMENT", 80, 93], ["SLN sampling", "TREATMENT", 94, 106], ["cervical", "ANATOMY", 14, 22], ["cancer", "OBSERVATION", 23, 29], ["very", "OBSERVATION_MODIFIER", 48, 52], ["slow", "OBSERVATION_MODIFIER", 53, 57], ["trachelectomy", "OBSERVATION", 80, 93]]], ["For patients with FIGO stages IA2, IB and IIA, the radical curative surgery can be planned within a maximum of 6-8 weeks.Surgical oncologyTreatment for asymptomatic fistula, slowly growing central recurrence or premalignant disease can be Pelvic exenteration is an invasive extensive surgical procedure with very restricted indications and requires a prolonged and demanding postsurgical management, and thus, it can be postponed when possible (table 6) .Medical oncologyAll the patients with a new diagnosis of cervical cancer stages IB3-IVB or with a symptomatic metastatic recurrence need a systemic treatment.", [["IIA", "ANATOMY", 42, 45], ["fistula", "ANATOMY", 165, 172], ["Pelvic", "ANATOMY", 239, 245], ["cervical cancer", "ANATOMY", 512, 527], ["fistula", "DISEASE", 165, 172], ["cervical cancer", "DISEASE", 512, 527], ["IVB", "DISEASE", 539, 542], ["patients", "ORGANISM", 4, 12], ["IIA", "CANCER", 42, 45], ["fistula", "PATHOLOGICAL_FORMATION", 165, 172], ["patients", "ORGANISM", 479, 487], ["cervical cancer", "CANCER", 512, 527], ["IB3-IVB", "CANCER", 535, 542], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 479, 487], ["FIGO stages IA2", "PROBLEM", 18, 33], ["the radical curative surgery", "TREATMENT", 47, 75], ["Treatment", "TREATMENT", 138, 147], ["asymptomatic fistula", "PROBLEM", 152, 172], ["slowly growing central recurrence", "PROBLEM", 174, 207], ["premalignant disease", "PROBLEM", 211, 231], ["Pelvic exenteration", "TREATMENT", 239, 258], ["an invasive extensive surgical procedure", "TREATMENT", 262, 302], ["a prolonged and demanding postsurgical management", "TREATMENT", 349, 398], ["cervical cancer", "PROBLEM", 512, 527], ["IVB", "TREATMENT", 539, 542], ["a symptomatic metastatic recurrence", "PROBLEM", 551, 586], ["a systemic treatment", "TREATMENT", 592, 612], ["IIA", "ANATOMY", 42, 45], ["radical", "OBSERVATION_MODIFIER", 51, 58], ["asymptomatic", "OBSERVATION_MODIFIER", 152, 164], ["fistula", "OBSERVATION", 165, 172], ["slowly", "OBSERVATION_MODIFIER", 174, 180], ["growing", "OBSERVATION_MODIFIER", 181, 188], ["central", "OBSERVATION_MODIFIER", 189, 196], ["recurrence", "OBSERVATION", 197, 207], ["premalignant disease", "OBSERVATION", 211, 231], ["Pelvic", "ANATOMY", 239, 245], ["exenteration", "OBSERVATION", 246, 258], ["invasive", "OBSERVATION_MODIFIER", 265, 273], ["extensive", "OBSERVATION_MODIFIER", 274, 283], ["surgical", "OBSERVATION", 284, 292], ["cervical", "ANATOMY", 512, 520], ["cancer", "OBSERVATION", 521, 527], ["symptomatic", "OBSERVATION_MODIFIER", 553, 564], ["metastatic", "OBSERVATION_MODIFIER", 565, 575], ["recurrence", "OBSERVATION", 576, 586]]], ["21 Concomitant CRT for locally advanced cervical cancer or first-line chemotherapy with/without bevacizumab in the metastatic setting is high priority.", [["cervical cancer", "ANATOMY", 40, 55], ["cervical cancer", "DISEASE", 40, 55], ["bevacizumab", "CHEMICAL", 96, 107], ["bevacizumab", "CHEMICAL", 96, 107], ["cervical cancer", "CANCER", 40, 55], ["bevacizumab", "SIMPLE_CHEMICAL", 96, 107], ["Concomitant CRT", "TREATMENT", 3, 18], ["locally advanced cervical cancer", "PROBLEM", 23, 55], ["first-line chemotherapy", "TREATMENT", 59, 82], ["bevacizumab", "TREATMENT", 96, 107], ["locally", "OBSERVATION_MODIFIER", 23, 30], ["advanced", "OBSERVATION_MODIFIER", 31, 39], ["cervical", "ANATOMY", 40, 48], ["cancer", "OBSERVATION", 49, 55], ["metastatic", "OBSERVATION", 115, 125]]], ["Also in patients with pelvic/ abdominal recurrence after 12 months from primary CRT, cisplatin and paclitaxel combination with/without bevacizumab is a high priority intervention because of the known improvement in OS reported with the combination.", [["pelvic", "ANATOMY", 22, 28], ["abdominal", "ANATOMY", 30, 39], ["cisplatin", "CHEMICAL", 85, 94], ["paclitaxel", "CHEMICAL", 99, 109], ["bevacizumab", "CHEMICAL", 135, 146], ["cisplatin", "CHEMICAL", 85, 94], ["paclitaxel", "CHEMICAL", 99, 109], ["bevacizumab", "CHEMICAL", 135, 146], ["patients", "ORGANISM", 8, 16], ["pelvic", "ORGAN", 22, 28], ["abdominal", "ORGAN", 30, 39], ["cisplatin", "SIMPLE_CHEMICAL", 85, 94], ["paclitaxel", "SIMPLE_CHEMICAL", 99, 109], ["bevacizumab", "SIMPLE_CHEMICAL", 135, 146], ["patients", "SPECIES", 8, 16], ["pelvic/ abdominal recurrence", "PROBLEM", 22, 50], ["primary CRT", "TREATMENT", 72, 83], ["cisplatin", "TREATMENT", 85, 94], ["paclitaxel combination", "TREATMENT", 99, 121], ["bevacizumab", "TREATMENT", 135, 146], ["a high priority intervention", "TREATMENT", 150, 178], ["pelvic", "ANATOMY", 22, 28], ["abdominal", "ANATOMY", 30, 39], ["recurrence", "OBSERVATION", 40, 50], ["improvement", "OBSERVATION_MODIFIER", 200, 211]]], ["When cisplatin is contraindicated, combination of carboplatin or topotecan with paclitaxel can be considered.", [["cisplatin", "CHEMICAL", 5, 14], ["carboplatin", "CHEMICAL", 50, 61], ["topotecan", "CHEMICAL", 65, 74], ["paclitaxel", "CHEMICAL", 80, 90], ["cisplatin", "CHEMICAL", 5, 14], ["carboplatin", "CHEMICAL", 50, 61], ["topotecan", "CHEMICAL", 65, 74], ["paclitaxel", "CHEMICAL", 80, 90], ["cisplatin", "SIMPLE_CHEMICAL", 5, 14], ["carboplatin", "SIMPLE_CHEMICAL", 50, 61], ["topotecan", "SIMPLE_CHEMICAL", 65, 74], ["paclitaxel", "SIMPLE_CHEMICAL", 80, 90], ["cisplatin", "TREATMENT", 5, 14], ["carboplatin", "TREATMENT", 50, 61], ["topotecan", "TREATMENT", 65, 74], ["paclitaxel", "TREATMENT", 80, 90]]], ["The use of bevacizumab carries the hypertension and thromboembolic side effects which are additional risk factors for a negative outcome of the COVID-19 infection.", [["bevacizumab", "CHEMICAL", 11, 22], ["hypertension", "DISEASE", 35, 47], ["thromboembolic", "DISEASE", 52, 66], ["infection", "DISEASE", 153, 162], ["bevacizumab", "CHEMICAL", 11, 22], ["bevacizumab", "SIMPLE_CHEMICAL", 11, 22], ["COVID-19", "ORGANISM", 144, 152], ["COVID-19", "SPECIES", 144, 152], ["bevacizumab", "TREATMENT", 11, 22], ["the hypertension", "PROBLEM", 31, 47], ["thromboembolic side effects", "PROBLEM", 52, 79], ["the COVID-19 infection", "PROBLEM", 140, 162], ["hypertension", "OBSERVATION", 35, 47], ["thromboembolic", "OBSERVATION", 52, 66], ["infection", "OBSERVATION", 153, 162]]], ["Bevacizumab, however, is the only agent for which an improvement in OS has been reported in this difficult setting and its use should be discussed with patients taking into account the structural resources available and the local and national guidelines.", [["Bevacizumab", "CHEMICAL", 0, 11], ["Bevacizumab", "CHEMICAL", 0, 11], ["Bevacizumab", "SIMPLE_CHEMICAL", 0, 11], ["patients", "ORGANISM", 152, 160], ["patients", "SPECIES", 152, 160], ["Bevacizumab", "TREATMENT", 0, 11]]], ["27 The continuation of treatments started before the COVID-19 period is medium priority and should be continued if a clinical benefit has been reported, possibly adjusting doses and schedules after a case-bycase discussion.", [["treatments", "TREATMENT", 23, 33]]], ["For patients progressing after firstline chemotherapy, there are not effective second-line options and their use should be discussed with patients according to clinical needs, patient's wishes and conditions and available resources 21 (table 6 ).", [["patients", "ORGANISM", 4, 12], ["patients", "ORGANISM", 138, 146], ["patient", "ORGANISM", 176, 183], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 138, 146], ["patient", "SPECIES", 176, 183], ["firstline chemotherapy", "TREATMENT", 31, 53], ["second-line options", "TREATMENT", 79, 98]]], ["The decision on the administration of immune checkpoint inhibitors, where approved, needs to be balanced against the risk of immune-related adverse events, particularly pneumonitis, whose signs and symptoms might overlap with the ones of interstitial pneumonitis commonly observed in patients with COVID-19 infection.Radiation oncologyCurative treatment for locally advanced cervical cancer (stages IB3, IIA-IIB) is of high benefit in terms of overall and disease-free survival and should be offered taking into account the risks associated with daily accesses to hospital.", [["interstitial", "ANATOMY", 238, 250], ["cervical cancer", "ANATOMY", 375, 390], ["stages IB3, IIA-IIB", "ANATOMY", 392, 411], ["pneumonitis", "DISEASE", 169, 180], ["interstitial pneumonitis", "DISEASE", 238, 262], ["COVID-19", "CHEMICAL", 298, 306], ["infection", "DISEASE", 307, 316], ["cervical cancer", "DISEASE", 375, 390], ["interstitial pneumonitis", "PATHOLOGICAL_FORMATION", 238, 262], ["patients", "ORGANISM", 284, 292], ["cervical cancer", "CANCER", 375, 390], ["IIA-IIB", "CANCER", 404, 411], ["patients", "SPECIES", 284, 292], ["immune checkpoint inhibitors", "TREATMENT", 38, 66], ["immune-related adverse events", "PROBLEM", 125, 154], ["pneumonitis", "PROBLEM", 169, 180], ["symptoms", "PROBLEM", 198, 206], ["interstitial pneumonitis", "PROBLEM", 238, 262], ["COVID-19 infection", "PROBLEM", 298, 316], ["Radiation oncologyCurative treatment", "TREATMENT", 317, 353], ["locally advanced cervical cancer", "PROBLEM", 358, 390], ["pneumonitis", "OBSERVATION", 169, 180], ["interstitial", "ANATOMY_MODIFIER", 238, 250], ["pneumonitis", "OBSERVATION", 251, 262], ["infection", "OBSERVATION", 307, 316], ["locally", "OBSERVATION_MODIFIER", 358, 365], ["advanced", "OBSERVATION_MODIFIER", 366, 374], ["cervical", "ANATOMY", 375, 383], ["cancer", "OBSERVATION", 384, 390], ["high benefit", "OBSERVATION_MODIFIER", 419, 431]]], ["Palliative radiotherapy for symptomatic spinal cord compression, brain metastasis or other critical lesions cannot be postponed and should be prioritised over symptomatic localised central or retroperitoneal lymphonodes recurrence.", [["spinal cord", "ANATOMY", 40, 51], ["brain", "ANATOMY", 65, 70], ["lesions", "ANATOMY", 100, 107], ["retroperitoneal lymphonodes", "ANATOMY", 192, 219], ["cord compression", "DISEASE", 47, 63], ["brain metastasis", "DISEASE", 65, 81], ["spinal cord", "ORGAN", 40, 51], ["brain", "ORGAN", 65, 70], ["lesions", "CANCER", 100, 107], ["retroperitoneal lymphonodes", "CANCER", 192, 219], ["Palliative radiotherapy", "TREATMENT", 0, 23], ["symptomatic spinal cord compression", "PROBLEM", 28, 63], ["brain metastasis", "PROBLEM", 65, 81], ["other critical lesions", "PROBLEM", 85, 107], ["symptomatic localised central or retroperitoneal lymphonodes recurrence", "PROBLEM", 159, 230], ["symptomatic", "OBSERVATION_MODIFIER", 28, 39], ["spinal cord", "ANATOMY", 40, 51], ["compression", "OBSERVATION", 52, 63], ["brain", "ANATOMY", 65, 70], ["metastasis", "OBSERVATION", 71, 81], ["critical", "OBSERVATION_MODIFIER", 91, 99], ["lesions", "OBSERVATION", 100, 107], ["symptomatic", "OBSERVATION_MODIFIER", 159, 170], ["localised", "OBSERVATION_MODIFIER", 171, 180], ["central", "OBSERVATION_MODIFIER", 181, 188], ["retroperitoneal", "ANATOMY", 192, 207], ["lymphonodes", "OBSERVATION", 208, 219]]], ["Treatment of asymptomatic pelvic recurrence not amenable to surgery has low priority and can be delayed (table 6) .CONCLUSIONSCOVID-19 pandemic is forcing the healthcare providers to rethink the management of patients with cancer to align with global response plans to contain SARS-CoV-2 spread and, as a consequence, the burden on the healthcare systems.", [["pelvic", "ANATOMY", 26, 32], ["cancer", "ANATOMY", 223, 229], ["cancer", "DISEASE", 223, 229], ["SARS", "DISEASE", 277, 281], ["pelvic", "ORGAN", 26, 32], ["patients", "ORGANISM", 209, 217], ["cancer", "CANCER", 223, 229], ["patients", "SPECIES", 209, 217], ["asymptomatic pelvic recurrence", "PROBLEM", 13, 43], ["surgery", "TREATMENT", 60, 67], ["CONCLUSIONSCOVID", "TEST", 115, 131], ["the management", "TREATMENT", 191, 205], ["cancer", "PROBLEM", 223, 229], ["SARS", "PROBLEM", 277, 281], ["asymptomatic", "OBSERVATION_MODIFIER", 13, 25], ["pelvic", "ANATOMY", 26, 32], ["recurrence", "OBSERVATION", 33, 43], ["cancer", "OBSERVATION", 223, 229]]], ["Despite differences might exist between countries and regions, a coordinated response is essential to define strategic plans to protect vulnerable subjects.CONCLUSIONSIn the oncology setting, a value-based framework to define level of priorities has been developed to provide guidance to surgical, medical and radiation oncology communities within the framework of a multidisciplinary approach.", [["a value", "TEST", 192, 199], ["a multidisciplinary approach", "TREATMENT", 365, 393]]], ["The tiered approach in three different levels of priority (high, medium and low) endorsed by ESMO has leveraged the specific recommendations according to tumour types and ESMO clinical guidelines.CONCLUSIONSFor the management of patients with gynaecological malignancies during the COVID-19 emergency, special consideration has to be given to the frailty of this population, often of older age, with significant comorbidities and high symptomatic tumours.", [["tumour", "ANATOMY", 154, 160], ["gynaecological malignancies", "ANATOMY", 243, 270], ["tumours", "ANATOMY", 447, 454], ["tumour", "DISEASE", 154, 160], ["gynaecological malignancies", "DISEASE", 243, 270], ["tumours", "DISEASE", 447, 454], ["tumour", "CANCER", 154, 160], ["patients", "ORGANISM", 229, 237], ["malignancies", "CANCER", 258, 270], ["tumours", "CANCER", 447, 454], ["patients", "SPECIES", 229, 237], ["The tiered approach", "TREATMENT", 0, 19], ["gynaecological malignancies", "PROBLEM", 243, 270], ["significant comorbidities", "PROBLEM", 400, 425], ["high symptomatic tumours", "PROBLEM", 430, 454], ["high", "OBSERVATION_MODIFIER", 430, 434], ["symptomatic", "OBSERVATION_MODIFIER", 435, 446], ["tumours", "OBSERVATION", 447, 454]]], ["However, high quality standard of care delivered by an MDT is able to favourable impact patients outcome in the majority of cases and this has be considered while defining level of priorities.CONCLUSIONSTwitter Ilaria Betella", [["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["high", "OBSERVATION_MODIFIER", 9, 13]]]], "848f1be60f1026c0fe0c8453bf324e00ba1cbc42": [["BackgroundZika virus (ZIKV) is a member of the Flaviviridae family first isolated in 1947 from a sentinel rhesus macaque in the Zika Forest region in Uganda [1] .", [["BackgroundZika virus", "ORGANISM", 0, 20], ["ZIKV", "GENE_OR_GENE_PRODUCT", 22, 26], ["rhesus", "ORGANISM", 106, 112], ["macaque", "ORGANISM", 113, 120], ["BackgroundZika virus", "SPECIES", 0, 20], ["rhesus macaque", "SPECIES", 106, 120], ["BackgroundZika virus", "SPECIES", 0, 20], ["ZIKV", "SPECIES", 22, 26], ["rhesus macaque", "SPECIES", 106, 120], ["BackgroundZika virus", "PROBLEM", 0, 20], ["a sentinel rhesus macaque", "TREATMENT", 95, 120]]], ["For the following 60 years, only scattered cases were identified in Africa and Asia until 2007, when ZIKV emerged in a series of outbreaks across the Pacific [2] [3] [4] [5] .", [["[2] [3] [4", "SIMPLE_CHEMICAL", 158, 168], ["ZIKV", "SPECIES", 101, 105], ["scattered", "OBSERVATION_MODIFIER", 33, 42]]], ["A large pandemic expanded in 2014 and 2015 when ZIKV exploded into the Americas dramatically [6] [7] [8] .", [["ZIKV", "SPECIES", 48, 52], ["large", "OBSERVATION_MODIFIER", 2, 7], ["pandemic", "OBSERVATION_MODIFIER", 8, 16], ["expanded", "OBSERVATION_MODIFIER", 17, 25]]], ["By now, ZIKV infections have widespread in the Americas and Southeast and South Asia and have become a threat to all tropical and temperate countries.", [["ZIKV infections", "DISEASE", 8, 23], ["ZIKV", "ORGANISM", 8, 12], ["ZIKV", "SPECIES", 8, 12], ["ZIKV infections", "PROBLEM", 8, 23], ["ZIKV", "OBSERVATION", 8, 12]]], ["The World Health Organization declared the clusters of microcephaly and neurological disorders and their association with ZIKV infection to be a global public health emergency, highlighting the significance and severity of this virus in human beings [9] .BackgroundMost flaviviruses are transmitted by mosquitos; however, ZIKV can also spread directly through sexual contact [10] [11] [12] [13] and vertically from mother to fetus [14] [15] [16] .", [["neurological", "ANATOMY", 72, 84], ["microcephaly", "DISEASE", 55, 67], ["neurological disorders", "DISEASE", 72, 94], ["ZIKV infection", "DISEASE", 122, 136], ["ZIKV", "CHEMICAL", 322, 326], ["human", "ORGANISM", 237, 242], ["mosquitos", "GENE_OR_GENE_PRODUCT", 302, 311], ["ZIKV", "GENE_OR_GENE_PRODUCT", 322, 326], ["human", "SPECIES", 237, 242], ["ZIKV", "SPECIES", 122, 126], ["human", "SPECIES", 237, 242], ["ZIKV", "SPECIES", 322, 326], ["microcephaly", "PROBLEM", 55, 67], ["neurological disorders", "PROBLEM", 72, 94], ["ZIKV infection", "PROBLEM", 122, 136], ["this virus", "PROBLEM", 223, 233], ["BackgroundMost flaviviruses", "PROBLEM", 255, 282], ["ZIKV", "PROBLEM", 322, 326], ["microcephaly", "OBSERVATION", 55, 67], ["flaviviruses", "OBSERVATION", 270, 282]]], ["In general, ZIKV infection is mostly asymptomatic, and most symptomatic infections are mild and resemble those observed with dengue viral infection presenting symptoms and signs of rash, fever, arthralgia, conjunctivitis, myalgia, headache, and retro-orbital pain [17] .", [["retro-orbital", "ANATOMY", 245, 258], ["infection", "DISEASE", 17, 26], ["infections", "DISEASE", 72, 82], ["dengue viral infection", "DISEASE", 125, 147], ["rash", "DISEASE", 181, 185], ["fever", "DISEASE", 187, 192], ["arthralgia", "DISEASE", 194, 204], ["conjunctivitis", "DISEASE", 206, 220], ["myalgia", "DISEASE", 222, 229], ["headache", "DISEASE", 231, 239], ["retro-orbital pain", "DISEASE", 245, 263], ["ZIKV", "ORGANISM", 12, 16], ["ZIKV", "SPECIES", 12, 16], ["ZIKV infection", "PROBLEM", 12, 26], ["asymptomatic", "PROBLEM", 37, 49], ["most symptomatic infections", "PROBLEM", 55, 82], ["dengue viral infection presenting symptoms", "PROBLEM", 125, 167], ["rash", "PROBLEM", 181, 185], ["fever", "PROBLEM", 187, 192], ["arthralgia", "PROBLEM", 194, 204], ["conjunctivitis", "PROBLEM", 206, 220], ["myalgia", "PROBLEM", 222, 229], ["headache", "PROBLEM", 231, 239], ["retro-orbital pain", "PROBLEM", 245, 263], ["ZIKV infection", "OBSERVATION", 12, 26], ["symptomatic", "OBSERVATION_MODIFIER", 60, 71], ["infections", "OBSERVATION", 72, 82], ["mild", "OBSERVATION_MODIFIER", 87, 91], ["arthralgia", "OBSERVATION", 194, 204], ["conjunctivitis", "OBSERVATION", 206, 220], ["myalgia", "OBSERVATION", 222, 229], ["retro-orbital", "ANATOMY", 245, 258]]], ["However, infection of ZIKV has been strongly associated with not only neurological sequelae, most commonly Guillain-Barr\u00e9 syndrome (GBS) [18] , but also meningoencephalitis and myelitis [19] .", [["neurological", "ANATOMY", 70, 82], ["infection", "DISEASE", 9, 18], ["ZIKV", "DISEASE", 22, 26], ["neurological sequelae", "DISEASE", 70, 91], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 107, 130], ["GBS", "DISEASE", 132, 135], ["meningoencephalitis", "DISEASE", 153, 172], ["myelitis", "DISEASE", 177, 185], ["ZIKV", "ORGANISM", 22, 26], ["Guillain-Barr\u00e9", "ORGANISM", 107, 121], ["ZIKV", "SPECIES", 22, 26], ["infection", "PROBLEM", 9, 18], ["ZIKV", "PROBLEM", 22, 26], ["neurological sequelae", "PROBLEM", 70, 91], ["Barr\u00e9 syndrome", "PROBLEM", 116, 130], ["GBS", "TEST", 132, 135], ["meningoencephalitis", "PROBLEM", 153, 172], ["myelitis", "PROBLEM", 177, 185], ["infection", "OBSERVATION", 9, 18], ["ZIKV", "OBSERVATION", 22, 26], ["meningoencephalitis", "OBSERVATION", 153, 172], ["myelitis", "OBSERVATION", 177, 185]]], ["Notably, when the infection occurs during pregnancy, severe fetal abnormalities and death maybe the most serious complications of the virus infection, which underscore a particular importance distinct from other pathogenic flaviviruses [20, 21] .BackgroundDespite diversity in pathogenesis, the Flavivirus members have highly similar viral structures and genomic organization.", [["fetal", "ANATOMY", 60, 65], ["infection", "DISEASE", 18, 27], ["fetal abnormalities", "DISEASE", 60, 79], ["death", "DISEASE", 84, 89], ["infection", "DISEASE", 140, 149], ["fetal", "ANATOMICAL_SYSTEM", 60, 65], ["the infection", "PROBLEM", 14, 27], ["pregnancy", "PROBLEM", 42, 51], ["severe fetal abnormalities", "PROBLEM", 53, 79], ["death", "PROBLEM", 84, 89], ["the virus infection", "PROBLEM", 130, 149], ["other pathogenic flaviviruses", "PROBLEM", 206, 235], ["pathogenesis", "PROBLEM", 277, 289], ["infection", "OBSERVATION", 18, 27], ["severe", "OBSERVATION_MODIFIER", 53, 59], ["virus infection", "OBSERVATION", 134, 149], ["diversity", "OBSERVATION_MODIFIER", 264, 273], ["viral structures", "OBSERVATION", 334, 350], ["genomic organization", "OBSERVATION", 355, 375]]], ["Like other flaviviruses, ZIKV is an enveloped virus with a positive-sense, single-stranded RNA genome, which encodes a single open reading frame (ORF).", [["ZIKV", "GENE_OR_GENE_PRODUCT", 25, 29], ["single-stranded RNA genome", "DNA", 75, 101], ["open reading frame", "DNA", 126, 144], ["ORF", "DNA", 146, 149], ["ZIKV", "SPECIES", 25, 29], ["other flaviviruses", "PROBLEM", 5, 23], ["ZIKV", "PROBLEM", 25, 29], ["an enveloped virus", "PROBLEM", 33, 51], ["single-stranded RNA genome", "PROBLEM", 75, 101], ["flaviviruses", "OBSERVATION", 11, 23], ["RNA genome", "OBSERVATION", 91, 101]]], ["Translation of the long ORF produces a large polyprotein which is then cleaved by both viral and host proteases to generate ten individual viral proteins, which include three structural proteins (capsid, prM, and E) and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) [22] .BackgroundIt is noteworthy that effective therapeutics of ZIKV are not currently available [23] .", [["capsid", "GENE_OR_GENE_PRODUCT", 196, 202], ["prM", "GENE_OR_GENE_PRODUCT", 204, 207], ["E", "GENE_OR_GENE_PRODUCT", 213, 214], ["NS1", "GENE_OR_GENE_PRODUCT", 251, 254], ["NS2A", "GENE_OR_GENE_PRODUCT", 256, 260], ["NS2B", "GENE_OR_GENE_PRODUCT", 262, 266], ["NS3", "GENE_OR_GENE_PRODUCT", 268, 271], ["NS4A", "GENE_OR_GENE_PRODUCT", 273, 277], ["NS4B", "GENE_OR_GENE_PRODUCT", 279, 283], ["ZIKV", "ORGANISM", 358, 362], ["long ORF", "DNA", 19, 27], ["viral and host proteases", "PROTEIN", 87, 111], ["viral proteins", "PROTEIN", 139, 153], ["structural proteins", "PROTEIN", 175, 194], ["capsid", "PROTEIN", 196, 202], ["prM", "PROTEIN", 204, 207], ["E", "PROTEIN", 213, 214], ["non-structural proteins", "PROTEIN", 226, 249], ["NS1", "PROTEIN", 251, 254], ["NS2A", "PROTEIN", 256, 260], ["NS2B", "PROTEIN", 262, 266], ["NS3", "PROTEIN", 268, 271], ["NS4A", "PROTEIN", 273, 277], ["NS4B", "PROTEIN", 279, 283], ["NS5", "PROTEIN", 289, 292], ["ZIKV", "SPECIES", 358, 362], ["the long ORF", "PROBLEM", 15, 27], ["a large polyprotein", "PROBLEM", 37, 56], ["ten individual viral proteins", "PROBLEM", 124, 153], ["NS1", "TEST", 251, 254], ["NS2A", "TREATMENT", 256, 260], ["NS2B", "TREATMENT", 262, 266], ["NS3", "TREATMENT", 268, 271], ["NS4A", "TREATMENT", 273, 277], ["NS4B", "TREATMENT", 279, 283], ["NS5", "TREATMENT", 289, 292], ["ZIKV", "PROBLEM", 358, 362], ["large", "OBSERVATION_MODIFIER", 39, 44], ["polyprotein", "OBSERVATION", 45, 56]]], ["Developing drugs targeting viral proteins key to the replication represents a potentially promising strategy for the treatment of ZIKV infection, as it is also pursued in other flaviviridae diseases such as hepatitis C virus (HCV) and dengue virus (DENV) infections [24, 25] .", [["ZIKV infection", "DISEASE", 130, 144], ["hepatitis C virus (HCV) and dengue virus (DENV) infections", "DISEASE", 207, 265], ["ZIKV", "ORGANISM", 130, 134], ["hepatitis C virus", "ORGANISM", 207, 224], ["HCV", "ORGANISM", 226, 229], ["dengue virus", "ORGANISM", 235, 247], ["DENV", "ORGANISM", 249, 253], ["viral proteins", "PROTEIN", 27, 41], ["hepatitis C virus", "SPECIES", 207, 224], ["dengue virus", "SPECIES", 235, 247], ["ZIKV", "SPECIES", 130, 134], ["hepatitis C virus", "SPECIES", 207, 224], ["HCV", "SPECIES", 226, 229], ["dengue virus", "SPECIES", 235, 247], ["DENV", "SPECIES", 249, 253], ["Developing drugs", "TREATMENT", 0, 16], ["viral proteins", "PROBLEM", 27, 41], ["the treatment", "TREATMENT", 113, 126], ["ZIKV infection", "PROBLEM", 130, 144], ["other flaviviridae diseases", "PROBLEM", 171, 198], ["hepatitis C virus (HCV)", "PROBLEM", 207, 230], ["dengue virus (DENV) infections", "PROBLEM", 235, 265], ["ZIKV", "OBSERVATION_MODIFIER", 130, 134], ["infection", "OBSERVATION", 135, 144]]], ["Therefore, efforts in identifying viral target(s) and compounds targeting these targets are urgently needed.BackgroundIn the context of finding ZIKV protein targets for treatment, it is of great interest to note that the RNA-dependent RNA polymerase (RdRp) has been identified as a potentially targetable component for anti-flavivirus drugs [26] .", [["ZIKV", "GENE_OR_GENE_PRODUCT", 144, 148], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 221, 249], ["anti-flavivirus", "SIMPLE_CHEMICAL", 319, 334], ["ZIKV protein", "PROTEIN", 144, 156], ["RNA-dependent RNA polymerase", "PROTEIN", 221, 249], ["RdRp", "PROTEIN", 251, 255], ["ZIKV protein targets", "TREATMENT", 144, 164], ["treatment", "TREATMENT", 169, 178], ["the RNA-dependent RNA polymerase (RdRp", "PROBLEM", 217, 255], ["anti-flavivirus drugs", "TREATMENT", 319, 340]]], ["Specifically, RdRp is known as an enzyme essential for the replication of flaviviral RNA genome, which is key to the multiplication of flaviviruses, whose failure leads to cessation of the viral life cycle [27] .", [["flaviviruses", "DISEASE", 135, 147], ["RdRp", "PROTEIN", 14, 18], ["flaviviral RNA genome", "DNA", 74, 95], ["RdRp", "PROBLEM", 14, 18], ["an enzyme", "TEST", 31, 40], ["flaviviral RNA genome", "PROBLEM", 74, 95], ["flaviviruses", "PROBLEM", 135, 147], ["the viral life cycle", "TREATMENT", 185, 205], ["RdRp", "OBSERVATION", 14, 18], ["flaviviral RNA genome", "OBSERVATION", 74, 95]]], ["Moreover, the catalytic center of RdRp is relatively conserved among flaviviruses but absent in eukaryotic host cells, presumably providing a relatively safety profile for the antivirals in this drug category [28] .", [["cells", "ANATOMY", 112, 117], ["RdRp", "GENE_OR_GENE_PRODUCT", 34, 38], ["eukaryotic host cells", "CELL", 96, 117], ["RdRp", "PROTEIN", 34, 38], ["eukaryotic host cells", "CELL_TYPE", 96, 117], ["RdRp", "PROBLEM", 34, 38], ["flaviviruses", "PROBLEM", 69, 81], ["the antivirals", "TREATMENT", 172, 186], ["RdRp", "OBSERVATION", 34, 38], ["eukaryotic host cells", "OBSERVATION", 96, 117]]], ["In addition, RdRp is a domain of NS5, and the latter catalyzes multiple biochemical reactions and interacts with numerous regulators, such as interferon suppression by targeting the IFN-regulated transcriptional activator STAT2 for degradation [29, 30] , providing potential of targeting ZIKV NS5 for antiviral purposes.", [["RdRp", "GENE_OR_GENE_PRODUCT", 13, 17], ["NS5", "GENE_OR_GENE_PRODUCT", 33, 36], ["interferon", "GENE_OR_GENE_PRODUCT", 142, 152], ["IFN", "GENE_OR_GENE_PRODUCT", 182, 185], ["STAT2", "GENE_OR_GENE_PRODUCT", 222, 227], ["ZIKV NS5", "ORGANISM", 288, 296], ["RdRp", "PROTEIN", 13, 17], ["NS5", "PROTEIN", 33, 36], ["interferon", "PROTEIN", 142, 152], ["IFN-regulated transcriptional activator", "PROTEIN", 182, 221], ["STAT2", "PROTEIN", 222, 227], ["ZIKV NS5", "PROTEIN", 288, 296], ["ZIKV", "SPECIES", 288, 292], ["RdRp", "TREATMENT", 13, 17], ["a domain of NS5", "TREATMENT", 21, 36], ["multiple biochemical reactions", "PROBLEM", 63, 93], ["interferon suppression", "TREATMENT", 142, 164], ["the IFN", "TREATMENT", 178, 185], ["targeting ZIKV NS5", "TREATMENT", 278, 296], ["antiviral purposes", "TREATMENT", 301, 319], ["RdRp", "OBSERVATION", 13, 17], ["multiple", "OBSERVATION_MODIFIER", 63, 71], ["biochemical reactions", "OBSERVATION", 72, 93]]], ["Furthermore, RNA polymerase inhibitors, such as sofosbuvir [31] , ribavirin [32] , beclabuvir [33] , and favipiravir [34] , have been clinically tested with success as antivirals approved for the treatment of viral infections [35] , although no drug has been approved yet for specific antiviral treatment of flaviviral diseases.", [["sofosbuvir", "CHEMICAL", 48, 58], ["ribavirin", "CHEMICAL", 66, 75], ["[32] , beclabuvir [33]", "CHEMICAL", 76, 98], ["favipiravir", "CHEMICAL", 105, 116], ["viral infections", "DISEASE", 209, 225], ["flaviviral diseases", "DISEASE", 308, 327], ["sofosbuvir", "CHEMICAL", 48, 58], ["ribavirin", "CHEMICAL", 66, 75], ["beclabuvir", "CHEMICAL", 83, 93], ["favipiravir", "CHEMICAL", 105, 116], ["sofosbuvir [31]", "SIMPLE_CHEMICAL", 48, 63], ["ribavirin", "SIMPLE_CHEMICAL", 66, 75], ["[32]", "SIMPLE_CHEMICAL", 76, 80], ["beclabuvir [33]", "SIMPLE_CHEMICAL", 83, 98], ["favipiravir", "SIMPLE_CHEMICAL", 105, 116], ["RNA polymerase inhibitors", "TREATMENT", 13, 38], ["sofosbuvir", "TREATMENT", 48, 58], ["ribavirin", "TREATMENT", 66, 75], ["beclabuvir", "TREATMENT", 83, 93], ["favipiravir", "TREATMENT", 105, 116], ["antivirals", "TREATMENT", 168, 178], ["viral infections", "PROBLEM", 209, 225], ["specific antiviral treatment", "TREATMENT", 276, 304], ["flaviviral diseases", "PROBLEM", 308, 327], ["flaviviral diseases", "OBSERVATION", 308, 327]]], ["Taken together, RdRp inhibition might represent a potentially promising anti-ZIKV strategy.BackgroundThe RdRp domain is at the C-terminus of the ZIKV NS5, which also contains a methyltransferase (MTase) domain at the N-terminus.", [["RdRp", "GENE_OR_GENE_PRODUCT", 16, 20], ["anti-ZIKV", "CANCER", 72, 81], ["ZIKV", "GENE_OR_GENE_PRODUCT", 145, 149], ["MTase", "GENE_OR_GENE_PRODUCT", 196, 201], ["RdRp domain", "PROTEIN", 105, 116], ["C-terminus", "PROTEIN", 127, 137], ["ZIKV NS5", "PROTEIN", 145, 153], ["methyltransferase (MTase) domain", "PROTEIN", 177, 209], ["N-terminus", "PROTEIN", 217, 227], ["RdRp inhibition", "TREATMENT", 16, 31], ["The RdRp domain", "PROBLEM", 101, 116], ["the ZIKV NS5", "PROBLEM", 141, 153], ["a methyltransferase (MTase) domain at the N-terminus", "PROBLEM", 175, 227], ["might represent", "UNCERTAINTY", 32, 47], ["RdRp domain", "OBSERVATION", 105, 116], ["ZIKV NS5", "ANATOMY", 145, 153], ["methyltransferase", "OBSERVATION_MODIFIER", 177, 194], ["N-terminus", "OBSERVATION_MODIFIER", 217, 227]]], ["The NS5 protein is the largest ZIKV protein (approximately 100 kDa), and its structure is highly conserved among the members of the Flaviviridae family, including ZIKV, DENV, and Japanese encephalitis virus (JEV) [28, 36] .", [["Japanese encephalitis", "DISEASE", 179, 200], ["JEV", "DISEASE", 208, 211], ["NS5", "GENE_OR_GENE_PRODUCT", 4, 7], ["ZIKV", "GENE_OR_GENE_PRODUCT", 31, 35], ["ZIKV", "GENE_OR_GENE_PRODUCT", 163, 167], ["DENV", "ORGANISM", 169, 173], ["Japanese encephalitis virus", "ORGANISM", 179, 206], ["JEV", "ORGANISM", 208, 211], ["NS5 protein", "PROTEIN", 4, 15], ["ZIKV protein", "PROTEIN", 31, 43], ["Japanese encephalitis virus", "SPECIES", 179, 206], ["ZIKV", "SPECIES", 163, 167], ["DENV", "SPECIES", 169, 173], ["Japanese encephalitis virus", "SPECIES", 179, 206], ["JEV", "SPECIES", 208, 211], ["The NS5 protein", "TEST", 0, 15], ["ZIKV", "PROBLEM", 163, 167], ["DENV", "PROBLEM", 169, 173], ["Japanese encephalitis virus", "PROBLEM", 179, 206], ["NS5 protein", "OBSERVATION", 4, 15], ["largest", "OBSERVATION_MODIFIER", 23, 30]]], ["As previous studies indicate that protein structural conservation might be associated with a functional consistency, multiple alignment of amino acid residues of ZIKV NS5 and its flaviviral homologs may provide a foundation for the uncovering of binding pocket(s) for effective inhibitory binding by inhibitors of RdRp.", [["amino acid", "CHEMICAL", 139, 149], ["amino acid", "CHEMICAL", 139, 149], ["amino acid", "AMINO_ACID", 139, 149], ["ZIKV NS5", "GENE_OR_GENE_PRODUCT", 162, 170], ["RdRp", "GENE_OR_GENE_PRODUCT", 314, 318], ["ZIKV NS5", "PROTEIN", 162, 170], ["flaviviral homologs", "PROTEIN", 179, 198], ["RdRp", "PROTEIN", 314, 318], ["previous studies", "TEST", 3, 19], ["protein structural conservation", "PROBLEM", 34, 65], ["amino acid residues", "TREATMENT", 139, 158], ["ZIKV NS5", "TREATMENT", 162, 170], ["its flaviviral homologs", "TREATMENT", 175, 198], ["binding pocket", "PROBLEM", 246, 260], ["effective inhibitory binding", "PROBLEM", 268, 296], ["RdRp", "PROBLEM", 314, 318]]], ["Moreover, the crystal structures of the ZIKV full-length NS5 protein and RdRp domain have been reported [27, [36] [37] [38] [39] .", [["NS5", "GENE_OR_GENE_PRODUCT", 57, 60], ["[27, [36] [37] [38", "SIMPLE_CHEMICAL", 104, 122], ["ZIKV full-length NS5 protein", "PROTEIN", 40, 68], ["RdRp domain", "PROTEIN", 73, 84], ["length NS5 protein", "TEST", 50, 68], ["RdRp domain", "TEST", 73, 84]]], ["The ZIKV RdRp has a typical viral RdRp structure, which adopts a classic \"right-hand\" structure consisting of the palm, finger, and thumb subdomains.", [["right-hand", "ANATOMY", 74, 84], ["palm", "ANATOMY", 114, 118], ["finger", "ANATOMY", 120, 126], ["thumb subdomains", "ANATOMY", 132, 148], ["ZIKV RdRp", "ORGANISM", 4, 13], ["palm", "ORGANISM_SUBDIVISION", 114, 118], ["finger", "ORGANISM_SUBDIVISION", 120, 126], ["ZIKV RdRp", "PROTEIN", 4, 13], ["viral RdRp structure", "PROTEIN", 28, 48], ["palm, finger, and thumb subdomains", "PROTEIN", 114, 148], ["ZIKV", "SPECIES", 4, 8], ["The ZIKV RdRp", "PROBLEM", 0, 13], ["a typical viral RdRp structure", "PROBLEM", 18, 48], ["ZIKV RdRp", "OBSERVATION", 4, 13], ["typical", "OBSERVATION_MODIFIER", 20, 27], ["viral RdRp structure", "OBSERVATION", 28, 48], ["right", "ANATOMY_MODIFIER", 74, 79], ["hand", "ANATOMY", 80, 84], ["\"", "OBSERVATION", 84, 85], ["palm", "ANATOMY_MODIFIER", 114, 118], ["finger", "ANATOMY", 120, 126], ["thumb", "ANATOMY", 132, 137]]], ["The rich structural details should inform in silico and functional screening of inhibitors against ZIKV RdRp and accelerate the identification of effective anti-ZIKV agents.", [["anti-ZIKV", "ANATOMY", 156, 165], ["ZIKV RdRp", "ORGANISM", 99, 108], ["anti-ZIKV agents", "SIMPLE_CHEMICAL", 156, 172], ["ZIKV RdRp", "PROTEIN", 99, 108], ["ZIKV", "SPECIES", 99, 103], ["anti-ZIKV", "SPECIES", 156, 165], ["inhibitors", "TREATMENT", 80, 90], ["ZIKV RdRp", "PROBLEM", 99, 108], ["effective anti-ZIKV agents", "TREATMENT", 146, 172]]], ["In this paper, we identified a firstin-class macrocyclic antibiotic fidaxomicin, which is being used clinically to treat Clostridium difficile infection (CDI) [40] , as an effective antiviral agent against ZIKV.", [["fidaxomicin", "CHEMICAL", 68, 79], ["Clostridium difficile infection", "DISEASE", 121, 152], ["CDI", "DISEASE", 154, 157], ["fidaxomicin", "CHEMICAL", 68, 79], ["fidaxomicin", "SIMPLE_CHEMICAL", 68, 79], ["Clostridium difficile", "ORGANISM", 121, 142], ["ZIKV", "ORGANISM", 206, 210], ["Clostridium difficile", "SPECIES", 121, 142], ["Clostridium difficile", "SPECIES", 121, 142], ["ZIKV", "SPECIES", 206, 210], ["a firstin-class macrocyclic antibiotic fidaxomicin", "TREATMENT", 29, 79], ["Clostridium difficile infection", "PROBLEM", 121, 152], ["an effective antiviral agent", "TREATMENT", 169, 197], ["ZIKV", "PROBLEM", 206, 210]]], ["Herein, we show that fidaxomicin directly bound ZIKV RdRp, inhibited ZIKV RNA replication in vitro and in vivo, and suppressed ZIKV-induced disease in infected mice. kidney epithelial cell line Vero, human embryonic kidney cell line 293T, and human umbilical vein endothelial cells (HUVECs) were obtain from the Cell Bank of the Chinese Academy of Sciences (CBCAS), Shanghai, China.", [["kidney epithelial cell line Vero", "ANATOMY", 166, 198], ["embryonic kidney cell line 293T", "ANATOMY", 206, 237], ["human umbilical vein endothelial cells", "ANATOMY", 243, 281], ["HUVECs", "ANATOMY", 283, 289], ["Cell", "ANATOMY", 312, 316], ["fidaxomicin", "CHEMICAL", 21, 32], ["ZIKV", "CHEMICAL", 127, 131], ["fidaxomicin", "CHEMICAL", 21, 32], ["fidaxomicin", "SIMPLE_CHEMICAL", 21, 32], ["ZIKV", "GENE_OR_GENE_PRODUCT", 48, 52], ["ZIKV", "GENE_OR_GENE_PRODUCT", 69, 73], ["ZIKV", "GENE_OR_GENE_PRODUCT", 127, 131], ["mice", "ORGANISM", 160, 164], ["kidney epithelial cell line Vero", "CELL", 166, 198], ["human", "ORGANISM", 200, 205], ["embryonic kidney cell line 293T", "CELL", 206, 237], ["human umbilical vein endothelial cells", "CELL", 243, 281], ["HUVECs", "CELL", 283, 289], ["Cell", "CELL", 312, 316], ["ZIKV RdRp", "PROTEIN", 48, 57], ["kidney epithelial cell line Vero", "CELL_LINE", 166, 198], ["human embryonic kidney cell line 293T", "CELL_LINE", 200, 237], ["human umbilical vein endothelial cells", "CELL_LINE", 243, 281], ["HUVECs", "CELL_LINE", 283, 289], ["mice", "SPECIES", 160, 164], ["Vero", "SPECIES", 194, 198], ["human", "SPECIES", 200, 205], ["human", "SPECIES", 243, 248], ["ZIKV", "SPECIES", 48, 52], ["ZIKV", "SPECIES", 69, 73], ["ZIKV", "SPECIES", 127, 131], ["mice", "SPECIES", 160, 164], ["human", "SPECIES", 200, 205], ["human", "SPECIES", 243, 248], ["fidaxomicin", "TREATMENT", 21, 32], ["ZIKV RdRp", "TREATMENT", 48, 57], ["ZIKV RNA replication", "TREATMENT", 69, 89], ["ZIKV", "PROBLEM", 127, 131], ["kidney epithelial cell line Vero", "TREATMENT", 166, 198], ["human embryonic kidney cell line", "TREATMENT", 200, 232], ["human umbilical vein endothelial cells", "TREATMENT", 243, 281], ["ZIKV RdRp", "OBSERVATION", 48, 57], ["infected mice", "OBSERVATION", 151, 164], ["epithelial cell line", "OBSERVATION", 173, 193], ["embryonic kidney cell line", "OBSERVATION", 206, 232], ["293T", "OBSERVATION", 233, 237], ["umbilical vein", "ANATOMY", 249, 263], ["endothelial cells", "OBSERVATION", 264, 281]]], ["Human glioblastoma cell line SNB19 (CRL-2219, ATCC, Manassas, VA, USA) and human glioblastoma cell line A172 (ATCC CCL-1620) were obtained from ATCC.", [["glioblastoma cell line SNB19", "ANATOMY", 6, 34], ["CRL-2219", "ANATOMY", 36, 44], ["ATCC", "ANATOMY", 46, 50], ["Manassas", "ANATOMY", 52, 60], ["VA", "ANATOMY", 62, 64], ["glioblastoma cell line A172", "ANATOMY", 81, 108], ["ATCC CCL-1620", "ANATOMY", 110, 123], ["ATCC", "ANATOMY", 144, 148], ["glioblastoma", "DISEASE", 6, 18], ["CRL-2219", "CHEMICAL", 36, 44], ["glioblastoma", "DISEASE", 81, 93], ["CCL-1620", "CHEMICAL", 115, 123], ["Human", "ORGANISM", 0, 5], ["glioblastoma cell line SNB19", "CELL", 6, 34], ["CRL-2219, ATCC, Manassas", "CELL", 36, 60], ["VA", "CELL", 62, 64], ["USA", "CELL", 66, 69], ["human", "ORGANISM", 75, 80], ["glioblastoma cell line A172", "CELL", 81, 108], ["ATCC CCL-1620", "CELL", 110, 123], ["ATCC", "CELL", 144, 148], ["Human glioblastoma cell line SNB19", "CELL_LINE", 0, 34], ["CRL-2219", "CELL_LINE", 36, 44], ["ATCC", "CELL_LINE", 46, 50], ["VA", "CELL_LINE", 62, 64], ["USA", "CELL_LINE", 66, 69], ["human glioblastoma cell line A172", "CELL_LINE", 75, 108], ["ATCC CCL-1620", "CELL_LINE", 110, 123], ["ATCC", "CELL_LINE", 144, 148], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 75, 80], ["Human", "SPECIES", 0, 5], ["Manassas", "SPECIES", 52, 60], ["human", "SPECIES", 75, 80], ["ATCC CCL-1620", "SPECIES", 110, 123], ["ATCC", "SPECIES", 144, 148], ["Human glioblastoma cell line", "TEST", 0, 28], ["CRL", "TEST", 36, 39], ["ATCC", "TEST", 46, 50], ["Manassas", "TEST", 52, 60], ["human glioblastoma cell line", "TREATMENT", 75, 103], ["ATCC CCL", "TEST", 110, 118], ["glioblastoma cell line", "OBSERVATION", 6, 28], ["glioblastoma cell line", "OBSERVATION", 81, 103]]], ["A549, Huh7, Vero, 293T, SNB19, and A172 cells were cultured in DMEM (Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum (FBS) (GIBCO, Carlsbad, CA, USA), 2 mM L-glutamine, 100 \u03bcg/mL streptomycin, and 100 units/mL penicillin (Invitrogen) at 37\u00b0C under 5% CO 2 .", [["A549", "ANATOMY", 0, 4], ["Huh7", "ANATOMY", 6, 10], ["Vero", "ANATOMY", 12, 16], ["293T", "ANATOMY", 18, 22], ["SNB19", "ANATOMY", 24, 29], ["A172 cells", "ANATOMY", 35, 45], ["fetal bovine serum", "ANATOMY", 115, 133], ["FBS", "ANATOMY", 135, 138], ["L-glutamine", "CHEMICAL", 173, 184], ["streptomycin", "CHEMICAL", 196, 208], ["penicillin", "CHEMICAL", 227, 237], ["L-glutamine", "CHEMICAL", 173, 184], ["streptomycin", "CHEMICAL", 196, 208], ["penicillin", "CHEMICAL", 227, 237], ["CO 2", "CHEMICAL", 268, 272], ["A549", "CELL", 0, 4], ["Huh7", "CELL", 6, 10], ["Vero", "CELL", 12, 16], ["293T", "CELL", 18, 22], ["SNB19", "CELL", 24, 29], ["A172 cells", "CELL", 35, 45], ["bovine", "ORGANISM", 121, 127], ["serum", "ORGANISM_SUBSTANCE", 128, 133], ["FBS", "ORGANISM_SUBSTANCE", 135, 138], ["L-glutamine", "SIMPLE_CHEMICAL", 173, 184], ["streptomycin", "SIMPLE_CHEMICAL", 196, 208], ["penicillin", "SIMPLE_CHEMICAL", 227, 237], ["Invitrogen", "SIMPLE_CHEMICAL", 239, 249], ["A549", "CELL_LINE", 0, 4], ["Huh7", "CELL_LINE", 6, 10], ["Vero", "CELL_LINE", 12, 16], ["293T", "CELL_LINE", 18, 22], ["SNB19", "CELL_LINE", 24, 29], ["A172 cells", "CELL_LINE", 35, 45], ["bovine", "SPECIES", 121, 127], ["bovine", "SPECIES", 121, 127], ["A549", "TEST", 0, 4], ["Huh7", "TEST", 6, 10], ["Vero", "TEST", 12, 16], ["SNB19", "TEST", 24, 29], ["A172 cells", "TEST", 35, 45], ["DMEM", "TEST", 63, 67], ["Invitrogen", "TEST", 69, 79], ["Carlsbad", "TEST", 81, 89], ["CA", "TEST", 91, 93], ["fetal bovine serum", "TEST", 115, 133], ["FBS", "TEST", 135, 138], ["GIBCO", "TEST", 141, 146], ["Carlsbad", "TEST", 148, 156], ["CA", "TEST", 158, 160], ["2 mM L-glutamine", "TREATMENT", 168, 184], ["streptomycin", "TREATMENT", 196, 208], ["penicillin", "TREATMENT", 227, 237]]], ["HUVECs were grown in M199 medium (GIBCO, Carlsbad, CA, USA) supplemented with 15% (vol/vol) FBS, 2 mM L-glutamine, 0.02 mg/mL endothelial cell growth supplement (Corning, NY, USA), and 0.05 mg/mL heparin (Sigma-Aldrich, St. Louis, MO, USA).", [["HUVECs", "ANATOMY", 0, 6], ["endothelial cell", "ANATOMY", 126, 142], ["L-glutamine", "CHEMICAL", 102, 113], ["heparin", "CHEMICAL", 196, 203], ["L-glutamine", "CHEMICAL", 102, 113], ["HUVECs", "CELL", 0, 6], ["FBS", "ORGANISM_SUBSTANCE", 92, 95], ["L-glutamine", "SIMPLE_CHEMICAL", 102, 113], ["endothelial cell", "CELL", 126, 142], ["heparin", "SIMPLE_CHEMICAL", 196, 203], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 205, 218], ["St. Louis", "ORGANISM", 220, 229], ["HUVECs", "CELL_LINE", 0, 6], ["HUVECs", "TEST", 0, 6], ["GIBCO", "TEST", 34, 39], ["Carlsbad", "TEST", 41, 49], ["CA", "TEST", 51, 53], ["FBS", "TEST", 92, 95], ["2 mM L-glutamine", "TREATMENT", 97, 113], ["heparin", "TREATMENT", 196, 203]]], ["Aedes albopictus C6/36 cells (ATCC, CRL-1660) were maintained at 28\u00b0C with 5% CO 2 in DMEM supplemented with 10% FBS.", [["C6/36 cells", "ANATOMY", 17, 28], ["ATCC", "ANATOMY", 30, 34], ["CRL-1660", "ANATOMY", 36, 44], ["FBS", "ANATOMY", 113, 116], ["CRL-1660", "CHEMICAL", 36, 44], ["CO 2", "CHEMICAL", 78, 82], ["Aedes albopictus", "ORGANISM", 0, 16], ["C6/36 cells", "CELL", 17, 28], ["ATCC", "CELL", 30, 34], ["CRL-1660", "CELL", 36, 44], ["FBS", "ORGANISM_SUBSTANCE", 113, 116], ["C6/36 cells", "CELL_LINE", 17, 28], ["Aedes albopictus", "SPECIES", 0, 16], ["Aedes albopictus", "SPECIES", 0, 16], ["ATCC", "TEST", 30, 34], ["CRL", "TEST", 36, 39], ["10% FBS", "TREATMENT", 109, 116]]], ["All cell lines were authenticated by short tandem repeat (STR) DNA profiling and verified to be mycoplasma-free.", [["cell lines", "ANATOMY", 4, 14], ["cell lines", "CELL", 4, 14], ["DNA", "CELLULAR_COMPONENT", 63, 66], ["cell lines", "CELL_LINE", 4, 14], ["All cell lines", "TREATMENT", 0, 14], ["short tandem repeat (STR) DNA profiling", "PROBLEM", 37, 76], ["mycoplasma", "PROBLEM", 96, 106], ["cell lines", "OBSERVATION", 4, 14], ["mycoplasma", "OBSERVATION", 96, 106]]], ["ZIKV ZG-01 strain (China, 2016, GenBank accession number KY379148) and MR766 strain (Uganda, 2016, GenBank accession number MK105975), respectively, were kind gifts from professor Xi Huang and professor Hui Zhang (Sun Yatsen University, Guangzhou, China) [41, 42] .", [["ZIKV ZG-01 strain", "CELL", 0, 17], ["ZIKV ZG-01 strain", "SPECIES", 0, 17]]], ["Both virus stocks were grown in C6/36 cells and quantified by plaque assay.", [["C6/36 cells", "ANATOMY", 32, 43], ["plaque", "ANATOMY", 62, 68], ["C6/36 cells", "CELL", 32, 43], ["C6/36 cells", "CELL_LINE", 32, 43], ["Both virus stocks", "PROBLEM", 0, 17], ["plaque assay", "TEST", 62, 74], ["virus stocks", "OBSERVATION", 5, 17], ["C6", "ANATOMY", 32, 34], ["36 cells", "OBSERVATION", 35, 43], ["plaque", "OBSERVATION", 62, 68]]], ["The Dengue-2 virus New Guinea C strain (GenBank accession number M29095) was provided by Guangzhou Centers for Disease Control and propagated in C6/36 cells [43] .", [["C6/36 cells", "ANATOMY", 145, 156], ["Dengue-2 virus New Guinea C", "ORGANISM", 4, 31], ["C6/36 cells", "CELL", 145, 156], ["C6/36 cells", "CELL_LINE", 145, 156], ["Dengue-2 virus", "SPECIES", 4, 18], ["Dengue-2 virus", "SPECIES", 4, 18], ["The Dengue-2 virus", "PROBLEM", 0, 18], ["New Guinea C strain", "PROBLEM", 19, 38], ["Disease Control", "TREATMENT", 111, 126]]], ["Type-I interferon receptor-deficient (Ifnar1 \u2212/\u2212 ) mice with a C57BL/6 background were provided by professor Gucheng Zeng and bred in specific pathogen-free animal facilities at Sun Yat-sen University [44] .", [["Type-I interferon receptor", "GENE_OR_GENE_PRODUCT", 0, 26], ["Ifnar1", "GENE_OR_GENE_PRODUCT", 38, 44], ["mice", "ORGANISM", 51, 55], ["C57BL/6 background", "ORGANISM", 63, 81], ["Type-I interferon receptor", "PROTEIN", 0, 26], ["Ifnar1", "PROTEIN", 38, 44], ["mice", "SPECIES", 51, 55], ["mice", "SPECIES", 51, 55], ["Type-I interferon receptor", "TREATMENT", 0, 26], ["a C57BL/6 background", "TREATMENT", 61, 81]]], ["Mice approximately 5 weeks of age were used for these experiments.", [["Mice", "ORGANISM", 0, 4], ["Mice", "SPECIES", 0, 4]]], ["For ZIKV infection and antiviral treatment studies, mice were randomly assigned to groups of 10 animals each to ensure the adequate power.Compounds databaseThe compounds database used for in silico screening was supplied by courtesy of Target Molecule Corp. (Tar-getMol, http://targetmol.com/).", [["ZIKV infection", "DISEASE", 4, 18], ["mice", "ORGANISM", 52, 56], ["mice", "SPECIES", 52, 56], ["ZIKV", "SPECIES", 4, 8], ["mice", "SPECIES", 52, 56], ["ZIKV infection", "PROBLEM", 4, 18], ["antiviral treatment", "TREATMENT", 23, 42], ["silico screening", "TEST", 191, 207], ["Target Molecule Corp. (Tar-getMol", "TREATMENT", 236, 269]]], ["The collection consisted of a dataset of 1789 drugs approved by the Food and Drug Administration (FDA) with the information of chemical structure and biological activities.", [["drugs", "TREATMENT", 46, 51], ["collection", "OBSERVATION", 4, 14]]], ["Plasmids cDNAs coding for ZIKV NS5 protein and its RdRp domain (aa271~903), both with N-terminal 8\u00d7 histidine tags, were PCR amplified from ZG-01 strain viral cDNA as a template and cloned into pcDNA3.1 or pET-30amutant vectors. pISRE (IFN-stimulated response element)-luciferase reporter construct (pISRE-Luc) was based on the pGL3-Promoter Vector, according to a previously described method [45] .", [["N", "CHEMICAL", 86, 87], ["histidine", "CHEMICAL", 100, 109], ["ZIKV NS5", "GENE_OR_GENE_PRODUCT", 26, 34], ["ZG-01 strain", "CELL", 140, 152], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 194, 202], ["pET-30amutant", "GENE_OR_GENE_PRODUCT", 206, 219], ["pISRE", "GENE_OR_GENE_PRODUCT", 229, 234], ["IFN-stimulated response element", "GENE_OR_GENE_PRODUCT", 236, 267], ["luciferase", "GENE_OR_GENE_PRODUCT", 269, 279], ["pISRE-Luc", "GENE_OR_GENE_PRODUCT", 300, 309], ["pGL3", "GENE_OR_GENE_PRODUCT", 328, 332], ["cDNAs", "DNA", 9, 14], ["ZIKV NS5 protein", "PROTEIN", 26, 42], ["RdRp domain", "PROTEIN", 51, 62], ["aa271~903", "PROTEIN", 64, 73], ["N-terminal 8\u00d7 histidine tags", "DNA", 86, 114], ["viral cDNA", "DNA", 153, 163], ["pcDNA3.1 or pET-30amutant vectors", "DNA", 194, 227], ["pISRE (IFN-stimulated response element", "DNA", 229, 267], ["luciferase reporter construct", "DNA", 269, 298], ["pISRE", "DNA", 300, 305], ["Luc", "DNA", 306, 309], ["pGL3", "DNA", 328, 332], ["Promoter Vector", "DNA", 333, 348], ["Plasmids cDNAs", "TREATMENT", 0, 14], ["ZIKV NS5 protein", "TEST", 26, 42], ["its RdRp domain", "TEST", 47, 62], ["N", "TEST", 86, 87], ["histidine tags", "TEST", 100, 114], ["PCR", "TEST", 121, 124], ["ZG", "TEST", 140, 142], ["a template", "TREATMENT", 167, 177], ["pET-30amutant vectors", "TREATMENT", 206, 227], ["pISRE (IFN-stimulated response element)", "TREATMENT", 229, 268], ["luciferase reporter construct", "TEST", 269, 298], ["the pGL3-Promoter Vector", "TREATMENT", 324, 348]]], ["All constructs were verified by DNA sequencing.", [["DNA", "CELLULAR_COMPONENT", 32, 35]]], ["All primers used for plasmid construction are listed in Additional file 1: Table S1 .Molecular docking of ZIKV NS5Molecular docking was performed using the Molecular Operating Environment (MOE, 2010.10, Chemical Computing Group Inc., Montreal, QC, Canada) software with default parameters.", [["All primers", "TREATMENT", 0, 11], ["plasmid construction", "TREATMENT", 21, 41], ["ZIKV NS5Molecular docking", "TREATMENT", 106, 131], ["S1", "ANATOMY", 81, 83]]], ["The protein structure of the ZIKV MR766 strain NS5 (PDB: 5TFR) [39] has been used, and the docking site has been defined by the MOE Site Finder functionality.", [["NS5", "PROTEIN", 47, 50], ["ZIKV MR766 strain NS5", "SPECIES", 29, 50], ["the ZIKV", "TEST", 25, 33], ["the docking site", "PROBLEM", 87, 103]]], ["The results of docking were generated with the method of Triangle Matcher (Placement) and ASE (Rescoring).", [["Triangle Matcher (Placement", "TREATMENT", 57, 84]]], ["The optimal geometric conformation of the best result was selected from the Ligand Interactions feature.Molecular docking of ZIKV NS5Expression and purification of ZIKV NS5, RdRp, and DENV NS5 proteinMolecular docking of ZIKV NS5The cDNA fragment of ZIKV (ZG-01 strain) NS5 (amino acids 1 to 903), RdRp (amino acids 272 to 903), or DENV2 NS5 (amino acids 1 to 900) containing an Nterminal His tag sequence was cloned into a pET-30amutant vector.", [["amino acids", "CHEMICAL", 275, 286], ["amino acids", "CHEMICAL", 304, 315], ["amino acids", "CHEMICAL", 343, 354], ["amino acids", "CHEMICAL", 275, 286], ["amino acids", "CHEMICAL", 304, 315], ["amino acids", "CHEMICAL", 343, 354], ["His", "CHEMICAL", 389, 392], ["ZIKV NS5", "GENE_OR_GENE_PRODUCT", 164, 172], ["RdRp", "GENE_OR_GENE_PRODUCT", 174, 178], ["DENV NS5", "ORGANISM", 184, 192], ["ZIKV NS5", "ORGANISM", 221, 229], ["ZG-01 strain", "ORGANISM", 256, 268], ["amino acids", "AMINO_ACID", 275, 286], ["amino acids", "AMINO_ACID", 304, 315], ["amino acids", "AMINO_ACID", 343, 354], ["pET-30amutant", "GENE_OR_GENE_PRODUCT", 424, 437], ["ZIKV NS5Expression", "PROTEIN", 125, 143], ["ZIKV NS5", "PROTEIN", 164, 172], ["RdRp", "PROTEIN", 174, 178], ["DENV NS5", "PROTEIN", 184, 192], ["ZIKV NS5", "PROTEIN", 221, 229], ["cDNA fragment", "DNA", 233, 246], ["ZIKV (ZG-01 strain", "DNA", 250, 268], ["NS5", "PROTEIN", 270, 273], ["amino acids 1 to 903", "PROTEIN", 275, 295], ["RdRp", "PROTEIN", 298, 302], ["amino acids 272 to 903", "PROTEIN", 304, 326], ["DENV2 NS5", "PROTEIN", 332, 341], ["amino acids 1 to 900", "PROTEIN", 343, 363], ["Nterminal His tag sequence", "DNA", 379, 405], ["pET-30amutant vector", "DNA", 424, 444], ["ZIKV", "SPECIES", 164, 168], ["DENV NS5", "SPECIES", 184, 192], ["ZIKV", "SPECIES", 221, 225], ["DENV2 NS5", "SPECIES", 332, 341], ["ZIKV NS5Expression", "TREATMENT", 125, 143], ["purification", "TREATMENT", 148, 160], ["ZIKV NS5", "PROBLEM", 164, 172], ["RdRp", "PROBLEM", 174, 178], ["DENV NS5 proteinMolecular docking", "TREATMENT", 184, 217], ["ZIKV NS5", "TREATMENT", 221, 229], ["The cDNA fragment", "TEST", 229, 246], ["ZIKV", "PROBLEM", 250, 254], ["ZG", "TEST", 256, 258], ["NS5 (amino acids", "TEST", 270, 286], ["RdRp (amino acids", "TEST", 298, 315], ["DENV2 NS5 (amino acids", "TREATMENT", 332, 354], ["an Nterminal His tag sequence", "TREATMENT", 376, 405], ["ZIKV NS5Expression", "OBSERVATION", 125, 143]]], ["For protein expression, the plasmids were transformed into Rosetta\u2122 competent cells (TIANGEN BIOTECH Co., Ltd., Beijing, China), respectively.", [["plasmids", "ANATOMY", 28, 36], ["cells", "ANATOMY", 78, 83], ["cells", "CELL", 78, 83], ["plasmids", "DNA", 28, 36], ["Rosetta\u2122 competent cells", "CELL_LINE", 59, 83], ["protein expression", "PROBLEM", 4, 22], ["the plasmids", "TREATMENT", 24, 36]]], ["Protein expression was induced with IPTG, and cells were harvested for the purification with a Ni-NTA affinity column (His-trap HP, GE Healthcare, China) according to the manufacturer's suggested protocol.", [["cells", "ANATOMY", 46, 51], ["IPTG", "CHEMICAL", 36, 40], ["Ni-NTA", "CHEMICAL", 95, 101], ["IPTG", "CHEMICAL", 36, 40], ["Ni-NTA", "CHEMICAL", 95, 101], ["His", "CHEMICAL", 119, 122], ["IPTG", "SIMPLE_CHEMICAL", 36, 40], ["cells", "CELL", 46, 51], ["Ni-NTA", "SIMPLE_CHEMICAL", 95, 101], ["Protein expression", "PROBLEM", 0, 18], ["IPTG", "TREATMENT", 36, 40], ["the purification", "TEST", 71, 87], ["a Ni-NTA affinity column", "TEST", 93, 117]]], ["Mass spectrometry was performed by Shanghai Applied Protein Technology Co. Ltd.", [["Mass spectrometry", "PROBLEM", 0, 17]]], ["The concentration of a targeted protein was measured by SDS-PAGE using BSA (Sigma, St. Louis, MO) as a standard.BIAcore analysisSurface plasmon resonance (SPR) experiments were performed in a BIAcore T100 device (BIAcore Inc., Uppsala, Sweden) using CM5 sensor chips (General Electric Company, GE) according to the protocol provided by the manufacturer.", [["BSA", "SIMPLE_CHEMICAL", 71, 74], ["a targeted protein", "TEST", 21, 39], ["a BIAcore T100 device", "TREATMENT", 190, 211], ["CM5 sensor chips", "TREATMENT", 250, 266], ["concentration", "OBSERVATION_MODIFIER", 4, 17]]], ["Briefly, recombinant ZIKV NS5 protein, RdRp protein, or DENV2 NS5 protein was immobilized on a CM5 chip, respectively.", [["ZIKV NS5", "GENE_OR_GENE_PRODUCT", 21, 29], ["RdRp", "GENE_OR_GENE_PRODUCT", 39, 43], ["DENV2", "ORGANISM", 56, 61], ["recombinant ZIKV NS5 protein", "PROTEIN", 9, 37], ["RdRp protein", "PROTEIN", 39, 51], ["DENV2 NS5 protein", "PROTEIN", 56, 73], ["ZIKV", "SPECIES", 21, 25], ["DENV2", "SPECIES", 56, 61], ["recombinant ZIKV NS5 protein", "TEST", 9, 37], ["RdRp protein", "TEST", 39, 51], ["DENV2 NS5 protein", "TEST", 56, 73], ["a CM5 chip", "TREATMENT", 93, 103]]], ["Different concentrations of fidaxomicin or ribavirin were injected at a flow rate of 30 \u03bcL/min for 3 min.", [["fidaxomicin", "CHEMICAL", 28, 39], ["ribavirin", "CHEMICAL", 43, 52], ["fidaxomicin", "CHEMICAL", 28, 39], ["ribavirin", "CHEMICAL", 43, 52], ["fidaxomicin", "SIMPLE_CHEMICAL", 28, 39], ["ribavirin", "SIMPLE_CHEMICAL", 43, 52], ["fidaxomicin", "TREATMENT", 28, 39], ["ribavirin", "TREATMENT", 43, 52], ["a flow rate", "TEST", 70, 81]]], ["The chip was regenerated by injecting 10 \u03bcL of 15 mM NaOH for 20 s.", [["NaOH", "CHEMICAL", 53, 57], ["NaOH", "CHEMICAL", 53, 57], ["NaOH", "SIMPLE_CHEMICAL", 53, 57], ["The chip", "TREATMENT", 0, 8]]], ["All procedures were run in 1% DMSO PBS-P20 (GE) as a running buffer.", [["DMSO", "CHEMICAL", 30, 34], ["DMSO", "CHEMICAL", 30, 34], ["PBS-P20", "SIMPLE_CHEMICAL", 35, 42], ["All procedures", "TREATMENT", 0, 14], ["a running buffer", "TREATMENT", 51, 67]]], ["The binding kinetics was analyzed with the software BIAevaluation version 3.1 using a 1:1 Langmuir binding model.", [["the software BIAevaluation version", "TEST", 39, 73], ["a 1:1 Langmuir binding model", "TREATMENT", 84, 112]]], ["The K d was calculated as previously described [43] .BIAcore analysisPolymerase activity assay ZIKV NS5 polymerase activity was determined using a primer extension reaction with a fluorescently labeled RNA primer/RNA template complex (P/T) as described by Lu et al. [46] .", [["K", "CHEMICAL", 4, 5], ["K d", "GENE_OR_GENE_PRODUCT", 4, 7], ["NS5 polymerase", "PROTEIN", 100, 114], ["RNA template complex", "PROTEIN", 213, 233], ["P", "PROTEIN", 235, 236], ["The K d", "TEST", 0, 7], ["BIAcore analysis", "TEST", 53, 69], ["Polymerase activity", "TEST", 69, 88], ["ZIKV NS5 polymerase activity", "PROBLEM", 95, 123], ["a primer extension reaction", "PROBLEM", 145, 172], ["a fluorescently labeled RNA primer/RNA template complex (P/T)", "TREATMENT", 178, 239]]], ["Briefly, fluorescently labeled oligonucleotide primer (Cy5-RNA) and unlabeled RNA template were mixed and then slowly cooled down for annealing.", [["fluorescently labeled oligonucleotide primer", "TREATMENT", 9, 53], ["Cy5-RNA", "TREATMENT", 55, 62], ["unlabeled RNA template", "PROBLEM", 68, 90]]], ["A typical primer extension reaction was performed by ZIKV NS5 polymerase at various concentrations, followed by incubation for 2 h at 37\u00b0C. To determine the inhibitory activity of fidaxomicin, the polymerase reactions were initiated by addition of fidaxomicin at gradient concentrations ranging between 0 and 200 \u03bcM.", [["fidaxomicin", "CHEMICAL", 180, 191], ["fidaxomicin", "CHEMICAL", 248, 259], ["fidaxomicin", "CHEMICAL", 180, 191], ["fidaxomicin", "CHEMICAL", 248, 259], ["fidaxomicin", "SIMPLE_CHEMICAL", 180, 191], ["fidaxomicin", "SIMPLE_CHEMICAL", 248, 259], ["ZIKV NS5 polymerase", "PROTEIN", 53, 72], ["ZIKV", "SPECIES", 53, 57], ["A typical primer extension reaction", "PROBLEM", 0, 35], ["ZIKV NS5 polymerase", "TREATMENT", 53, 72], ["fidaxomicin", "TREATMENT", 180, 191], ["the polymerase reactions", "PROBLEM", 193, 217], ["fidaxomicin at gradient concentrations", "TREATMENT", 248, 286], ["extension reaction", "OBSERVATION", 17, 35]]], ["The products were detected by denaturing polyacrylamide gel electrophoresis (Urea PAGE), and the results were scanned using an Odyssey infrared imaging system (LI-COR Biosciences, Lincoln, NE).", [["polyacrylamide", "CHEMICAL", 41, 55], ["denaturing polyacrylamide gel electrophoresis", "TEST", 30, 75], ["Urea PAGE", "TEST", 77, 86], ["an Odyssey infrared imaging system", "TEST", 124, 158]]], ["The images were analyzed, and proper RNA bands were quantified using Image J software version 1.52a (NIH, Bethesda, MD, USA).Luciferase reporter assays293T cells were cultured in 24-well plates (~1 \u00d7 10 5 cells per well) and co-transfected with pISRE-Luc (100 ng) and the plasmid coding for RIG-I (100 ng) together with the ZIKV NS5 plasmid at indicated concentrations.", [["293T cells", "ANATOMY", 151, 161], ["cells", "ANATOMY", 205, 210], ["plasmid", "ANATOMY", 272, 279], ["293T cells", "CELL", 151, 161], ["cells", "CELL", 205, 210], ["pISRE-Luc", "GENE_OR_GENE_PRODUCT", 245, 254], ["RIG-I", "GENE_OR_GENE_PRODUCT", 291, 296], ["293T cells", "CELL_LINE", 151, 161], ["pISRE", "DNA", 245, 250], ["Luc", "DNA", 251, 254], ["RIG-I", "DNA", 291, 296], ["ZIKV NS5 plasmid", "DNA", 324, 340], ["ZIKV", "SPECIES", 324, 328], ["The images", "TEST", 0, 10], ["Luciferase reporter assays", "TEST", 125, 151], ["cells", "TEST", 156, 161], ["pISRE-Luc", "TREATMENT", 245, 254], ["the plasmid coding", "TREATMENT", 268, 286], ["RIG-I", "TREATMENT", 291, 296], ["the ZIKV NS5 plasmid", "TREATMENT", 320, 340]]], ["Control pcDNA3.1 vector was added to ensure that the same total amount of DNA was used for each transfection.", [["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 8, 16], ["DNA", "CELLULAR_COMPONENT", 74, 77], ["pcDNA3.1 vector", "DNA", 8, 23], ["Control pcDNA3.1 vector", "TREATMENT", 0, 23], ["the same total amount of DNA", "TREATMENT", 49, 77], ["each transfection", "TREATMENT", 91, 108]]], ["To normalize for transfection efficiency, 5 ng of the constitutive Renilla luciferase reporter pRL-TK (Promega, San Luis Obispo, CA, USA) was added to each transfection.", [["luciferase", "GENE_OR_GENE_PRODUCT", 75, 85], ["constitutive Renilla luciferase reporter pRL", "DNA", 54, 98], ["transfection efficiency", "PROBLEM", 17, 40], ["pRL", "TEST", 95, 98], ["CA, USA", "TREATMENT", 129, 136]]], ["Six hours after transfection, cells were treated by fidaxomicin at indicated concentration for 30 h, followed by analysis of cell lysates for luciferase activity using the Dual-Luciferase Reporter Assay System Kit (Promega) according to the manufacturer's protocol.In vitro antiviral assayThe anti-ZIKV activity of fidaxomicin and ribavirin was evaluated in vitro by plaque assay.", [["cells", "ANATOMY", 30, 35], ["cell lysates", "ANATOMY", 125, 137], ["plaque", "ANATOMY", 367, 373], ["fidaxomicin", "CHEMICAL", 52, 63], ["fidaxomicin", "CHEMICAL", 315, 326], ["ribavirin", "CHEMICAL", 331, 340], ["fidaxomicin", "CHEMICAL", 52, 63], ["fidaxomicin", "CHEMICAL", 315, 326], ["ribavirin", "CHEMICAL", 331, 340], ["cells", "CELL", 30, 35], ["fidaxomicin", "SIMPLE_CHEMICAL", 52, 63], ["cell lysates", "ORGANISM_SUBSTANCE", 125, 137], ["luciferase", "GENE_OR_GENE_PRODUCT", 142, 152], ["anti-ZIKV", "CANCER", 293, 302], ["fidaxomicin", "SIMPLE_CHEMICAL", 315, 326], ["ribavirin", "SIMPLE_CHEMICAL", 331, 340], ["luciferase", "PROTEIN", 142, 152], ["fidaxomicin", "TREATMENT", 52, 63], ["cell lysates", "TREATMENT", 125, 137], ["luciferase activity", "TREATMENT", 142, 161], ["the Dual-Luciferase Reporter Assay System Kit (Promega)", "TREATMENT", 168, 223], ["the manufacturer's protocol", "TREATMENT", 237, 264], ["vitro antiviral assay", "TREATMENT", 268, 289], ["The anti-ZIKV activity", "TREATMENT", 289, 311], ["fidaxomicin", "TREATMENT", 315, 326], ["ribavirin", "TREATMENT", 331, 340], ["antiviral assay", "OBSERVATION", 274, 289], ["plaque", "OBSERVATION", 367, 373]]], ["Various cell lines, including SNB19 (6 \u00d7 10 4 /well, 10% FBS DMEM), A172 (7 \u00d7 10 4 /well, 10% FBS DMEM), Vero (6 \u00d7 10 4 /well 10% FBS DMEM), Huh7 (7 \u00d7 10 4 /well, 10% FBS DMEM), HUVECs (7 \u00d7 10 4 /well, 15% FBS M199 medium supplemented with 2 mM L-glutamine, 0.02 mg/mL endothelial cell growth supplement, and 0.05 mg/mL heparin), and A549 (6 \u00d7 10 4 /well, 5% FBS DMEM), were plated in 12well plates and allowed to attach overnight, followed by infection with ZIKV (ZG-01 strain or MR766 strain, respectively, at indicated MOI) in the presence of different concentrations of fidaxomicin, ribavirin, or vehicle control for 1 h, followed by two washes with 1 \u00d7 PBS and incubated with fresh medium (without virus) consisting of corresponding concentrations of the compounds for further 48 h.", [["cell lines", "ANATOMY", 8, 18], ["A172", "ANATOMY", 68, 72], ["Huh7", "ANATOMY", 141, 145], ["HUVECs", "ANATOMY", 178, 184], ["endothelial cell", "ANATOMY", 269, 285], ["A549", "ANATOMY", 334, 338], ["MR766 strain", "ANATOMY", 481, 493], ["L-glutamine", "CHEMICAL", 245, 256], ["heparin", "CHEMICAL", 320, 327], ["infection", "DISEASE", 444, 453], ["fidaxomicin", "CHEMICAL", 574, 585], ["ribavirin", "CHEMICAL", 587, 596], ["L-glutamine", "CHEMICAL", 245, 256], ["fidaxomicin", "CHEMICAL", 574, 585], ["ribavirin", "CHEMICAL", 587, 596], ["cell lines", "CELL", 8, 18], ["A172", "CELL", 68, 72], ["Huh7", "CELL", 141, 145], ["HUVECs", "CELL", 178, 184], ["L-glutamine", "SIMPLE_CHEMICAL", 245, 256], ["endothelial cell", "CELL", 269, 285], ["heparin", "SIMPLE_CHEMICAL", 320, 327], ["A549", "CELL", 334, 338], ["ZG-01 strain", "CELL", 465, 477], ["fidaxomicin", "SIMPLE_CHEMICAL", 574, 585], ["ribavirin", "SIMPLE_CHEMICAL", 587, 596], ["cell lines", "CELL_LINE", 8, 18], ["HUVECs", "CELL_LINE", 178, 184], ["ZIKV", "SPECIES", 459, 463], ["Various cell lines", "TREATMENT", 0, 18], ["SNB19", "TEST", 30, 35], ["FBS DMEM", "TEST", 57, 65], ["A172", "TEST", 68, 72], ["FBS DMEM", "TEST", 94, 102], ["Vero", "TEST", 105, 109], ["FBS DMEM", "TEST", 130, 138], ["Huh7", "TEST", 141, 145], ["FBS DMEM", "TEST", 167, 175], ["HUVECs", "TEST", 178, 184], ["FBS", "TEST", 206, 209], ["2 mM L-glutamine", "TREATMENT", 240, 256], ["endothelial cell growth supplement", "TREATMENT", 269, 303], ["heparin", "TREATMENT", 320, 327], ["A549", "TREATMENT", 334, 338], ["5% FBS DMEM", "TREATMENT", 356, 367], ["infection", "PROBLEM", 444, 453], ["ZIKV", "PROBLEM", 459, 463], ["MR766 strain", "PROBLEM", 481, 493], ["fidaxomicin", "TREATMENT", 574, 585], ["ribavirin", "TREATMENT", 587, 596], ["vehicle control", "TREATMENT", 601, 616], ["1 \u00d7 PBS", "TREATMENT", 654, 661], ["virus", "PROBLEM", 703, 708], ["cell lines", "OBSERVATION", 8, 18], ["infection", "OBSERVATION", 444, 453]]], ["The cell supernatants were collected to quantify ZIKV infection by plaque assay as previously described [47] or by RT-qPCR.", [["cell supernatants", "ANATOMY", 4, 21], ["plaque", "ANATOMY", 67, 73], ["infection", "DISEASE", 54, 63], ["cell supernatants", "CELL", 4, 21], ["ZIKV", "GENE_OR_GENE_PRODUCT", 49, 53], ["ZIKV", "SPECIES", 49, 53], ["The cell supernatants", "TEST", 0, 21], ["ZIKV infection", "PROBLEM", 49, 63], ["plaque assay", "TEST", 67, 79], ["cell supernatants", "OBSERVATION", 4, 21], ["plaque", "OBSERVATION", 67, 73]]], ["The 50% effective concentration (EC 50 ) and 90% effective concentration (EC 90 ) were estimated by plotting values from triplicate independent experiments using GraphPad (non-linear fit, log inhibitor vs normalized response).", [["The 50% effective concentration (EC", "TREATMENT", 0, 35], ["GraphPad (non-linear fit", "TREATMENT", 162, 186], ["log inhibitor", "TREATMENT", 188, 201]]], ["The anti-DENV activity of fidaxomicin was evaluated in vitro by RT-qPCR.Cell viability assayCell viability was detected by the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay according to a previously described method [48] .", [["Cell", "ANATOMY", 72, 76], ["fidaxomicin", "CHEMICAL", 26, 37], ["3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide", "CHEMICAL", 127, 191], ["fidaxomicin", "CHEMICAL", 26, 37], ["3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide", "CHEMICAL", 127, 191], ["MTT", "CHEMICAL", 193, 196], ["anti-DENV", "CANCER", 4, 13], ["fidaxomicin", "SIMPLE_CHEMICAL", 26, 37], ["Cell", "CELL", 72, 76], ["assayCell", "CELL", 87, 96], ["3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide", "SIMPLE_CHEMICAL", 127, 191], ["fidaxomicin", "TREATMENT", 26, 37], ["Cell viability assayCell viability", "TEST", 72, 106], ["dimethyl", "TEST", 134, 142], ["diphenyl", "TREATMENT", 160, 168], ["tetrazolium bromide", "TREATMENT", 172, 191]]], ["Briefly, cells were seeded in 96-well plates at a density of 1 \u00d7 10 4 cells per well and cultured at 37\u00b0C for 24 h, followed by exposure to the serially diluted fidaxomicin or ribavirin separately for 48 h.", [["cells", "ANATOMY", 9, 14], ["cells", "ANATOMY", 70, 75], ["fidaxomicin", "CHEMICAL", 161, 172], ["ribavirin", "CHEMICAL", 176, 185], ["fidaxomicin", "CHEMICAL", 161, 172], ["ribavirin", "CHEMICAL", 176, 185], ["cells", "CELL", 9, 14], ["cells", "CELL", 70, 75], ["fidaxomicin", "SIMPLE_CHEMICAL", 161, 172], ["ribavirin", "SIMPLE_CHEMICAL", 176, 185], ["the serially diluted fidaxomicin", "TREATMENT", 140, 172], ["ribavirin", "TREATMENT", 176, 185]]], ["Cell survival rate was determined by MTT reduction assay according to the manufacturer's protocol (Invitrogen).", [["Cell", "ANATOMY", 0, 4], ["MTT", "CHEMICAL", 37, 40], ["Cell", "CELL", 0, 4], ["Cell survival rate", "TREATMENT", 0, 18], ["MTT reduction assay", "TEST", 37, 56], ["the manufacturer's protocol", "TREATMENT", 70, 97]]], ["The 50% cytotoxic concentration (CC 50 ) was defined as the compound concentration required to inhibit the cell growth by 50% compared with the control assay.", [["cell", "ANATOMY", 107, 111], ["CC", "CHEMICAL", 33, 35], ["cell", "CELL", 107, 111], ["The 50% cytotoxic concentration (CC", "TREATMENT", 0, 35], ["the compound concentration", "PROBLEM", 56, 82], ["the control assay", "TEST", 140, 157], ["cell", "OBSERVATION", 107, 111], ["growth", "OBSERVATION_MODIFIER", 112, 118]]], ["The assay was performed in triplicates in three independent experiments.Cell viability assayRNA extraction, reverse transcription, and real-time PCR RNA from cell supernatants or from mouse tissues (brain and testis) was prepared with RaPure Viral RNA/ DNA Kit (Magen, Guangzhou, China) according to the manufacturer's instructions.", [["Cell", "ANATOMY", 72, 76], ["cell supernatants", "ANATOMY", 158, 175], ["tissues", "ANATOMY", 190, 197], ["brain", "ANATOMY", 199, 204], ["testis", "ANATOMY", 209, 215], ["Cell", "CELL", 72, 76], ["cell", "CELL", 158, 162], ["mouse", "ORGANISM", 184, 189], ["tissues", "TISSUE", 190, 197], ["brain", "ORGAN", 199, 204], ["testis", "ORGAN", 209, 215], ["mouse", "SPECIES", 184, 189], ["mouse", "SPECIES", 184, 189], ["The assay", "TEST", 0, 9], ["Cell viability assayRNA extraction", "TREATMENT", 72, 106], ["reverse transcription", "TREATMENT", 108, 129], ["cell supernatants", "TEST", 158, 175], ["brain", "ANATOMY", 199, 204], ["testis", "ANATOMY", 209, 215]]], ["The first-strand cDNA was synthesized using random hexamer primers with the Revert Aid Reverse Transcription Kit (Thermo Fisher Scientific, Rockford, IL, USA), and real-time PCR was carried out by using LightCycler\u00ae 480 Probes Master (2\u00d7 reaction mix buffer including DNA polymerase) (no. 04887301001, Roche, Basel, Switzerland).", [["DNA", "CELLULAR_COMPONENT", 268, 271], ["first-strand cDNA", "DNA", 4, 21], ["DNA polymerase", "PROTEIN", 268, 282], ["The first-strand cDNA", "TREATMENT", 0, 21], ["random hexamer primers", "TREATMENT", 44, 66], ["real-time PCR", "TEST", 164, 177], ["LightCycler", "TEST", 203, 214], ["DNA polymerase", "TEST", 268, 282]]], ["Virus concentration was determined by interpolation onto an internal standard curve made up of a 7-point dilution series of in vitro transcribed RNA and tissue weight to quantify ZIKV RNA as copies/gram tissue.", [["tissue", "ANATOMY", 153, 159], ["gram tissue", "ANATOMY", 198, 209], ["Virus", "ORGANISM", 0, 5], ["tissue", "TISSUE", 153, 159], ["ZIKV", "GENE_OR_GENE_PRODUCT", 179, 183], ["tissue", "TISSUE", 203, 209], ["in vitro transcribed RNA", "RNA", 124, 148], ["ZIKV RNA", "RNA", 179, 187], ["ZIKV", "SPECIES", 179, 183], ["Virus concentration", "PROBLEM", 0, 19], ["an internal standard curve", "TEST", 57, 83], ["a 7-point dilution series", "TREATMENT", 95, 120], ["vitro transcribed RNA", "TREATMENT", 127, 148], ["tissue weight", "TEST", 153, 166], ["ZIKV RNA", "PROBLEM", 179, 187], ["gram tissue", "OBSERVATION_MODIFIER", 198, 209]]], ["Primer sets used for real-time PCR are shown in Additional file 1: Table S1 .", [["Primer sets", "TEST", 0, 11], ["real-time PCR", "TEST", 21, 34], ["S1", "ANATOMY", 73, 75]]], ["Reverse transcription and real-time PCR were performed for at least three times.Western blotting analysisTissue specimens obtained from mice or cells were lysed with RIPA lysis buffer (Millipore, Bedford, MA) containing a cocktail of protease and phosphatase inhibitors (Sigma-Aldrich, St. Louis, MO, USA).", [["analysisTissue specimens", "ANATOMY", 97, 121], ["cells", "ANATOMY", 144, 149], ["mice", "ORGANISM", 136, 140], ["cells", "CELL", 144, 149], ["St. Louis", "ORGANISM", 286, 295], ["protease", "PROTEIN", 234, 242], ["mice", "SPECIES", 136, 140], ["mice", "SPECIES", 136, 140], ["Reverse transcription", "TREATMENT", 0, 21], ["real-time PCR", "TEST", 26, 39], ["blotting analysisTissue specimens", "TEST", 88, 121], ["mice or cells", "TREATMENT", 136, 149], ["RIPA lysis buffer", "TREATMENT", 166, 183], ["a cocktail of protease", "TREATMENT", 220, 242], ["phosphatase inhibitors", "TREATMENT", 247, 269]]], ["Protein concentrations were measured with a bicinchoninic acid (BCA) protein assay (Thermo Fisher Scientific, Rockford, IL, USA).", [["bicinchoninic acid", "CHEMICAL", 44, 62], ["BCA", "CHEMICAL", 64, 67], ["bicinchoninic acid", "CHEMICAL", 44, 62], ["BCA", "CHEMICAL", 64, 67], ["bicinchoninic acid", "SIMPLE_CHEMICAL", 44, 62], ["BCA", "SIMPLE_CHEMICAL", 64, 67], ["Protein concentrations", "TEST", 0, 22], ["a bicinchoninic acid", "TEST", 42, 62], ["protein assay", "TEST", 69, 82]]], ["Protein samples were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto a polyvinylidene difluoride (PVDF) membrane.", [["samples", "ANATOMY", 8, 15], ["sodium dodecyl sulfate", "CHEMICAL", 34, 56], ["sodium dodecyl sulfate", "CHEMICAL", 34, 56], ["polyacrylamide", "CHEMICAL", 57, 71], ["polyvinylidene difluoride", "CHEMICAL", 126, 151], ["PVDF", "CHEMICAL", 153, 157], ["sodium dodecyl sulfate", "SIMPLE_CHEMICAL", 34, 56], ["membrane", "CELLULAR_COMPONENT", 159, 167], ["Protein samples", "TEST", 0, 15], ["sodium dodecyl sulfate", "TREATMENT", 34, 56], ["polyacrylamide gel electrophoresis", "TREATMENT", 57, 91], ["a polyvinylidene difluoride (PVDF) membrane", "TREATMENT", 124, 167]]], ["Non-specific antibody binding sites were blocked with 5% non-fat milk in Tris- Membranes were incubated with horseradish peroxidaseconjugated secondary antibody, and signals were detected by enhanced chemiluminescence using a commercial kit (Thermo Fisher Scientific) according to the manufacturer's suggested protocols.", [["fat milk", "ANATOMY", 61, 69], ["Membranes", "ANATOMY", 79, 88], ["fat milk", "ORGANISM_SUBSTANCE", 61, 69], ["Tris- Membranes", "SIMPLE_CHEMICAL", 73, 88], ["horseradish peroxidaseconjugated", "SIMPLE_CHEMICAL", 109, 141], ["antibody binding sites", "DNA", 13, 35], ["horseradish peroxidaseconjugated secondary antibody", "PROTEIN", 109, 160], ["horseradish", "SPECIES", 109, 120], ["Non-specific antibody binding sites", "PROBLEM", 0, 35], ["5% non-fat milk in Tris- Membranes", "TREATMENT", 54, 88], ["horseradish peroxidaseconjugated secondary antibody", "TEST", 109, 160]]], ["The relative protein level was quantified by densitometry and normalized to GAPDH or mGAPDH level using Image J software (NIH, Bethesda, MD, USA).Animal experimentsFor ZIKV infection and antiviral treatment studies, mice were randomly assigned to groups (n = 12-13/group).", [["ZIKV infection", "DISEASE", 168, 182], ["GAPDH", "GENE_OR_GENE_PRODUCT", 76, 81], ["mGAPDH", "GENE_OR_GENE_PRODUCT", 85, 91], ["mice", "ORGANISM", 216, 220], ["mGAPDH", "PROTEIN", 85, 91], ["mice", "SPECIES", 216, 220], ["ZIKV", "SPECIES", 168, 172], ["mice", "SPECIES", 216, 220], ["The relative protein level", "TEST", 0, 26], ["densitometry", "TEST", 45, 57], ["GAPDH", "TEST", 76, 81], ["ZIKV infection", "PROBLEM", 168, 182], ["antiviral treatment", "TREATMENT", 187, 206]]], ["Male and female 5-week-old Ifnar1 \u2212/\u2212 mice were infected subcutaneously (s.c.) with ZIKV (ZG-01 strain, 2 \u00d7 10 4 PFU for each mouse) 1 h before administration of treatment agents.", [["subcutaneously", "ANATOMY", 57, 71], ["ZIKV", "CHEMICAL", 84, 88], ["Ifnar1", "ORGANISM", 27, 33], ["\u2212/\u2212 mice", "ORGANISM", 34, 42], ["ZG-01 strain", "CELL", 90, 102], ["mouse", "ORGANISM", 126, 131], ["mice", "SPECIES", 38, 42], ["mouse", "SPECIES", 126, 131], ["mice", "SPECIES", 38, 42], ["ZIKV", "SPECIES", 84, 88], ["mouse", "SPECIES", 126, 131], ["ZIKV (ZG-01 strain", "TREATMENT", 84, 102], ["treatment agents", "TREATMENT", 162, 178]]], ["Compounds were prepared in sterile pharmaceutical dosage form of 1:10:89 (DMSO : Tween80 : 5% glucose solution) less than 4 h prior to administration in mice.", [["DMSO", "CHEMICAL", 74, 78], ["Tween80", "CHEMICAL", 81, 88], ["glucose", "CHEMICAL", 94, 101], ["DMSO", "CHEMICAL", 74, 78], ["Tween80", "CHEMICAL", 81, 88], ["glucose", "CHEMICAL", 94, 101], ["DMSO", "SIMPLE_CHEMICAL", 74, 78], ["Tween80", "SIMPLE_CHEMICAL", 81, 88], ["glucose", "SIMPLE_CHEMICAL", 94, 101], ["mice", "ORGANISM", 153, 157], ["mice", "SPECIES", 153, 157], ["mice", "SPECIES", 153, 157], ["5% glucose solution", "TREATMENT", 91, 110]]], ["Fidaxomicin was administered by tail vein injection daily at 20 or 10 mg/kg for 7 days.", [["tail vein", "ANATOMY", 32, 41], ["Fidaxomicin", "CHEMICAL", 0, 11], ["Fidaxomicin", "CHEMICAL", 0, 11], ["Fidaxomicin", "SIMPLE_CHEMICAL", 0, 11], ["tail vein", "MULTI-TISSUE_STRUCTURE", 32, 41], ["Fidaxomicin", "TREATMENT", 0, 11], ["tail vein", "ANATOMY", 32, 41]]], ["The identity of the treatment groups was blinded to the researcher administering treatments.", [["the treatment groups", "TREATMENT", 16, 36], ["treatments", "TREATMENT", 81, 91]]], ["Survival, disease signs, and the weight of each mouse were recorded on day 0 and then every other day from 1 to 15 days postinfection (dpi).", [["mouse", "ORGANISM", 48, 53], ["mouse", "SPECIES", 48, 53], ["mouse", "SPECIES", 48, 53], ["disease signs", "PROBLEM", 10, 23], ["disease", "OBSERVATION", 10, 17]]], ["Mice were humanely euthanized if they could no longer right themselves or were unresponsive to stimuli.", [["Mice", "ORGANISM", 0, 4], ["Mice", "SPECIES", 0, 4], ["unresponsive", "PROBLEM", 79, 91]]], ["Tissues, including the brains and testes, were collected from each animal.", [["Tissues", "ANATOMY", 0, 7], ["brains", "ANATOMY", 23, 29], ["testes", "ANATOMY", 34, 40], ["Tissues", "CANCER", 0, 7], ["brains", "ORGAN", 23, 29], ["testes", "ORGAN", 34, 40], ["brains", "ANATOMY", 23, 29], ["testes", "ANATOMY", 34, 40]]], ["Part of each tissue was fixed in 4% paraformaldehyde or in PBS for at least 24 h prior to paraffin embedding and sectioning for use in immunohistochemistry analysis, immunofluorescence analysis, or analysis of viral RNA.", [["tissue", "ANATOMY", 13, 19], ["paraformaldehyde", "CHEMICAL", 36, 52], ["paraffin", "CHEMICAL", 90, 98], ["tissue", "TISSUE", 13, 19], ["paraformaldehyde", "SIMPLE_CHEMICAL", 36, 52], ["viral RNA", "RNA", 210, 219], ["4% paraformaldehyde", "TREATMENT", 33, 52], ["PBS", "TREATMENT", 59, 62], ["paraffin embedding", "TREATMENT", 90, 108], ["immunohistochemistry analysis", "TEST", 135, 164], ["immunofluorescence analysis", "TEST", 166, 193], ["viral RNA", "PROBLEM", 210, 219], ["fixed", "OBSERVATION_MODIFIER", 24, 29], ["viral RNA", "OBSERVATION", 210, 219]]], ["Total RNA was extracted from tissues, and ZIKV RNA was quantified as described above.Tissue immunofluorescence and immunohistochemistryImmunofluorescence assay was carried out on paraffinembedded mouse brain and testis tissue slides, incubated with an anti-ZIKV E antibody (1:500, BioFront Technologies, Tallahassee, FL, USA).", [["tissues", "ANATOMY", 29, 36], ["Tissue", "ANATOMY", 85, 91], ["brain", "ANATOMY", 202, 207], ["testis tissue", "ANATOMY", 212, 225], ["tissues", "TISSUE", 29, 36], ["ZIKV", "GENE_OR_GENE_PRODUCT", 42, 46], ["Tissue", "TISSUE", 85, 91], ["mouse", "ORGANISM", 196, 201], ["brain", "ORGAN", 202, 207], ["testis tissue slides", "TISSUE", 212, 232], ["ZIKV RNA", "RNA", 42, 50], ["anti-ZIKV E antibody", "PROTEIN", 252, 272], ["mouse", "SPECIES", 196, 201], ["ZIKV", "SPECIES", 42, 46], ["mouse", "SPECIES", 196, 201], ["anti-ZIKV", "SPECIES", 252, 261], ["Total RNA", "PROBLEM", 0, 9], ["ZIKV RNA", "PROBLEM", 42, 50], ["Tissue immunofluorescence", "TEST", 85, 110], ["immunohistochemistryImmunofluorescence assay", "TEST", 115, 159], ["an anti-ZIKV E antibody", "TEST", 249, 272], ["BioFront Technologies", "TEST", 281, 302], ["RNA", "OBSERVATION", 6, 9], ["ZIKV RNA", "OBSERVATION", 42, 50], ["brain", "ANATOMY", 202, 207], ["testis", "ANATOMY", 212, 218]]], ["The secondary antibody was Rhodamine Red\u2122-X (RRX) AffiniPure F (ab') 2 Fragment Goat Anti-Mouse IgG (1:500, AB_2338781, Jackson Immu-noResearch Laboratories, Inc. West Grove, PA, USA), and 4-,6-diamidino-2-phenylindole (DAPI, 1:1000, Sangon Biotech, Shanghai, China) was used to stain the nuclei.", [["nuclei", "ANATOMY", 289, 295], ["Rhodamine", "CHEMICAL", 27, 36], ["4-,6-diamidino-2-phenylindole", "CHEMICAL", 189, 218], ["Rhodamine", "CHEMICAL", 27, 36], ["4-,6-diamidino-2-phenylindole", "CHEMICAL", 189, 218], ["DAPI", "CHEMICAL", 220, 224], ["Rhodamine Red\u2122-X", "SIMPLE_CHEMICAL", 27, 43], ["RRX", "SIMPLE_CHEMICAL", 45, 48], ["Mouse", "ORGANISM", 90, 95], ["4-,6-diamidino-2-phenylindole", "SIMPLE_CHEMICAL", 189, 218], ["DAPI", "SIMPLE_CHEMICAL", 220, 224], ["nuclei", "CELLULAR_COMPONENT", 289, 295], ["Mouse IgG", "PROTEIN", 90, 99], ["Goat", "SPECIES", 80, 84], ["Mouse", "SPECIES", 90, 95], ["Mouse", "SPECIES", 90, 95], ["The secondary antibody", "TEST", 0, 22], ["Rhodamine", "TEST", 27, 36], ["Fragment Goat Anti-Mouse IgG", "TEST", 71, 99], ["AB", "TEST", 108, 110], ["diamidino", "TEST", 194, 203], ["DAPI", "TREATMENT", 220, 224], ["nuclei", "ANATOMY", 289, 295]]], ["The immunofluorescent images were taken with an inverted microscope (Carl Zeiss, Oberkochen, Germany).", [["The immunofluorescent images", "TEST", 0, 28]]], ["For histologic staining, the fixed tissues were dehydrated, embedded in paraffin, sectioned, rehydrated, and stained with hematoxylin and eosin (H/E).", [["tissues", "ANATOMY", 35, 42], ["paraffin", "CHEMICAL", 72, 80], ["hematoxylin", "CHEMICAL", 122, 133], ["eosin", "CHEMICAL", 138, 143], ["tissues", "TISSUE", 35, 42], ["hematoxylin", "SIMPLE_CHEMICAL", 122, 133], ["histologic staining", "TEST", 4, 23], ["the fixed tissues", "PROBLEM", 25, 42], ["dehydrated", "PROBLEM", 48, 58], ["hematoxylin", "TEST", 122, 133], ["eosin", "TEST", 138, 143], ["staining", "OBSERVATION", 15, 23]]], ["The H/E-stained sections were evaluated for viral-induced neuropathology.", [["sections", "ANATOMY", 16, 24], ["neuropathology", "DISEASE", 58, 72], ["sections", "MULTI-TISSUE_STRUCTURE", 16, 24], ["The H/E-stained sections", "TEST", 0, 24], ["viral-induced neuropathology", "PROBLEM", 44, 72]]], ["Unblinded histological examination was performed by a board-certified veterinary pathologist.", [["Unblinded histological examination", "TEST", 0, 34]]], ["Each slide was auto scanned by Axio Scan Z1 (Carl Zeiss, Oberkochen, Germany).Statistical analysisStatistical analyses were performed on triplicate experiments using a two-tailed Student's t test.", [["Statistical analysisStatistical analyses", "TEST", 78, 118], ["Student's t test", "TEST", 179, 195]]], ["The results are expressed as the mean \u00b1 standard deviation (SD).ResultsFidaxomicin is predicted to bind ZIKV RdRp protein through structure-based virtual screeningResultsIn order to obtain anti-ZIKV candidate compounds targeting RdRp, we applied a computer docking method to simulate RdRp-compound binding and screened the compounds collection consisting of 1789 FDA-approved drugs.", [["ResultsFidaxomicin", "CHEMICAL", 64, 82], ["ResultsFidaxomicin", "SIMPLE_CHEMICAL", 64, 82], ["ZIKV", "GENE_OR_GENE_PRODUCT", 104, 108], ["ResultsFidaxomicin", "PROTEIN", 64, 82], ["ZIKV RdRp protein", "PROTEIN", 104, 121], ["RdRp", "PROTEIN", 229, 233], ["ResultsFidaxomicin", "TREATMENT", 64, 82], ["virtual screening", "TEST", 146, 163], ["RdRp", "TREATMENT", 229, 233], ["a computer docking method", "TREATMENT", 246, 271], ["RdRp", "PROBLEM", 284, 288], ["compound binding", "PROBLEM", 289, 305]]], ["In brief, the crystal structure of ZIKV NS5 protein (PDB: 5tfr) (Fig. 1a) was downloaded from the Protein Data Bank website as a receptor, and the active structure of the RdRp domain was identified by the Site Finder of Molecular Operating Environment (MOE) as the docking site.", [["ZIKV NS5", "GENE_OR_GENE_PRODUCT", 35, 43], ["PDB: 5tfr) (Fig. 1a", "GENE_OR_GENE_PRODUCT", 53, 72], ["ZIKV NS5 protein", "PROTEIN", 35, 51], ["5tfr", "PROTEIN", 58, 62], ["Fig. 1a", "PROTEIN", 65, 72], ["Protein Data Bank website", "PROTEIN", 98, 123], ["RdRp domain", "PROTEIN", 171, 182], ["ZIKV NS5 protein", "TEST", 35, 51], ["PDB", "TEST", 53, 56], ["a receptor", "TREATMENT", 127, 137], ["the RdRp domain", "PROBLEM", 167, 182], ["active", "OBSERVATION_MODIFIER", 147, 153]]], ["Small binding molecules of ZIKV RdRp were screened in the aforementioned compounds collection by employing the ASE Rescoring function and the Triangle Matcher placement method.", [["ZIKV", "GENE_OR_GENE_PRODUCT", 27, 31], ["Small binding molecules", "PROTEIN", 0, 23], ["ZIKV RdRp", "PROTEIN", 27, 36], ["Small binding molecules", "PROBLEM", 0, 23], ["ZIKV RdRp", "PROBLEM", 27, 36], ["the Triangle Matcher placement method", "TREATMENT", 138, 175], ["binding molecules", "OBSERVATION", 6, 23], ["ZIKV RdRp", "OBSERVATION", 27, 36]]], ["In the structurebased virtual screening, fidaxomicin received the highest score and was predicted to bind ZIKV RdRp domain with 5 H-bonds and 1 H-pi-bond (Fig. 1b, c) .", [["fidaxomicin", "CHEMICAL", 41, 52], ["fidaxomicin", "CHEMICAL", 41, 52], ["H", "CHEMICAL", 130, 131], ["fidaxomicin", "SIMPLE_CHEMICAL", 41, 52], ["ZIKV", "GENE_OR_GENE_PRODUCT", 106, 110], ["H-pi-bond", "SIMPLE_CHEMICAL", 144, 153], ["ZIKV RdRp domain", "PROTEIN", 106, 122], ["the structurebased virtual screening", "TEST", 3, 39], ["fidaxomicin", "TREATMENT", 41, 52], ["bonds", "TEST", 132, 137]]], ["Of note, residues putatively essential for fidaxomicin binding (795T and 798S) in the ZIKV NS5 protein are located in the priming loop (residues 787-809), an important stacking platform for the initiation of NTP entry into de novo RNA synthesis [37] .", [["fidaxomicin", "CHEMICAL", 43, 54], ["NTP", "CHEMICAL", 208, 211], ["fidaxomicin", "CHEMICAL", 43, 54], ["NTP", "CHEMICAL", 208, 211], ["fidaxomicin", "GENE_OR_GENE_PRODUCT", 43, 54], ["ZIKV NS5", "GENE_OR_GENE_PRODUCT", 86, 94], ["NTP", "SIMPLE_CHEMICAL", 208, 211], ["ZIKV NS5 protein", "PROTEIN", 86, 102], ["ZIKV", "SPECIES", 86, 90], ["fidaxomicin binding", "TREATMENT", 43, 62], ["the ZIKV NS5 protein", "TREATMENT", 82, 102], ["NTP entry", "TREATMENT", 208, 217]]], ["Taken together, the above results of our docking screening suggest that fidaxomicin might represent a novel inhibitor of ZIKV RdRp and ZIKV replication.Identification of fidaxomicin as an inhibitor of ZIKV RdRp in vitroNext, we performed experiments to investigate the biological activity of fidaxomicin for inhibition of ZIKV replication.", [["fidaxomicin", "CHEMICAL", 72, 83], ["fidaxomicin", "CHEMICAL", 170, 181], ["fidaxomicin", "CHEMICAL", 292, 303], ["fidaxomicin", "CHEMICAL", 72, 83], ["fidaxomicin", "CHEMICAL", 170, 181], ["fidaxomicin", "CHEMICAL", 292, 303], ["fidaxomicin", "SIMPLE_CHEMICAL", 72, 83], ["ZIKV", "GENE_OR_GENE_PRODUCT", 121, 125], ["ZIKV", "GENE_OR_GENE_PRODUCT", 135, 139], ["fidaxomicin", "SIMPLE_CHEMICAL", 170, 181], ["ZIKV RdRp", "ORGANISM", 201, 210], ["fidaxomicin", "SIMPLE_CHEMICAL", 292, 303], ["ZIKV", "GENE_OR_GENE_PRODUCT", 322, 326], ["ZIKV RdRp", "PROTEIN", 201, 210], ["ZIKV", "SPECIES", 121, 125], ["ZIKV", "SPECIES", 135, 139], ["ZIKV", "SPECIES", 201, 205], ["ZIKV", "SPECIES", 322, 326], ["our docking screening", "TEST", 37, 58], ["fidaxomicin", "TREATMENT", 72, 83], ["a novel inhibitor", "TREATMENT", 100, 117], ["ZIKV RdRp", "TREATMENT", 121, 130], ["ZIKV replication", "TREATMENT", 135, 151], ["fidaxomicin", "TREATMENT", 170, 181], ["an inhibitor", "TREATMENT", 185, 197], ["ZIKV RdRp", "TREATMENT", 201, 210], ["fidaxomicin", "TREATMENT", 292, 303], ["ZIKV replication", "TREATMENT", 322, 338]]], ["Firstly, we prepared both full-length NS5 and a truncated NS5 containing only the RdRp domain without the MTase domain (Fig. 2a) .", [["NS5", "GENE_OR_GENE_PRODUCT", 38, 41], ["NS5", "GENE_OR_GENE_PRODUCT", 58, 61], ["NS5", "PROTEIN", 38, 41], ["truncated NS5", "PROTEIN", 48, 61], ["RdRp domain", "PROTEIN", 82, 93], ["MTase domain", "PROTEIN", 106, 118], ["full-length NS5", "TREATMENT", 26, 41], ["a truncated NS5", "TREATMENT", 46, 61], ["the RdRp domain", "TREATMENT", 78, 93]]], ["These two forms of ZIKV RNA polymerase were expressed in and purified from Escherichia coli and were used for subsequent experiments.", [["ZIKV", "GENE_OR_GENE_PRODUCT", 19, 23], ["Escherichia coli", "ORGANISM", 75, 91], ["ZIKV RNA polymerase", "PROTEIN", 19, 38], ["Escherichia coli", "SPECIES", 75, 91], ["ZIKV", "SPECIES", 19, 23], ["Escherichia coli", "SPECIES", 75, 91], ["ZIKV RNA polymerase", "PROBLEM", 19, 38], ["Escherichia coli", "PROBLEM", 75, 91], ["ZIKV", "OBSERVATION", 19, 23], ["Escherichia coli", "OBSERVATION", 75, 91]]], ["Our results of SPR assay using the BIAcore analysis showed that fidaxomicin directly bound ZIKV NS5 full-length protein (K d value = 19 \u03bcM) (Fig. 2b) , in contrast to the very weak interaction shown between ribavirin and the NS5 protein (Fig. 2c) .", [["fidaxomicin", "CHEMICAL", 64, 75], ["ribavirin", "CHEMICAL", 207, 216], ["fidaxomicin", "CHEMICAL", 64, 75], ["ribavirin", "CHEMICAL", 207, 216], ["fidaxomicin", "SIMPLE_CHEMICAL", 64, 75], ["ribavirin", "SIMPLE_CHEMICAL", 207, 216], ["ZIKV NS5 full-length protein", "PROTEIN", 91, 119], ["NS5 protein", "PROTEIN", 225, 236], ["Fig. 2c", "PROTEIN", 238, 245], ["SPR assay", "TEST", 15, 24], ["the BIAcore analysis", "TEST", 31, 51], ["fidaxomicin", "TREATMENT", 64, 75], ["length protein", "TEST", 105, 119], ["K d value", "TEST", 121, 130], ["ribavirin", "TREATMENT", 207, 216], ["the NS5 protein", "TREATMENT", 221, 236]]], ["Moreover, a strong, clear binding was also observed between fidaxomicin and ZIKV RdRp protein (Fig. 2d) , further indicating that the binding was indeed between fidaxomicin b-e SPR assay to examine and characterize the binding of fidaxomicin or ribavirin to either ZIKV NS5 or RdRp, using a BIAcore T100 system.", [["fidaxomicin", "CHEMICAL", 60, 71], ["fidaxomicin", "CHEMICAL", 230, 241], ["ribavirin", "CHEMICAL", 245, 254], ["fidaxomicin", "CHEMICAL", 60, 71], ["fidaxomicin", "CHEMICAL", 161, 172], ["fidaxomicin", "CHEMICAL", 230, 241], ["ribavirin", "CHEMICAL", 245, 254], ["fidaxomicin", "SIMPLE_CHEMICAL", 60, 71], ["ZIKV RdRp", "GENE_OR_GENE_PRODUCT", 76, 85], ["fidaxomicin", "SIMPLE_CHEMICAL", 161, 172], ["fidaxomicin", "SIMPLE_CHEMICAL", 230, 241], ["ribavirin", "SIMPLE_CHEMICAL", 245, 254], ["ZIKV NS5", "ORGANISM", 265, 273], ["fidaxomicin", "PROTEIN", 60, 71], ["ZIKV RdRp protein", "PROTEIN", 76, 93], ["Fig. 2d", "PROTEIN", 95, 102], ["ZIKV NS5", "PROTEIN", 265, 273], ["RdRp", "PROTEIN", 277, 281], ["ZIKV", "SPECIES", 76, 80], ["ZIKV", "SPECIES", 265, 269], ["fidaxomicin", "TREATMENT", 60, 71], ["ZIKV RdRp protein", "TREATMENT", 76, 93], ["the binding", "PROBLEM", 130, 141], ["fidaxomicin", "TREATMENT", 161, 172], ["fidaxomicin", "TREATMENT", 230, 241], ["ribavirin", "TREATMENT", 245, 254], ["ZIKV NS5", "PROBLEM", 265, 273], ["RdRp", "PROBLEM", 277, 281], ["a BIAcore T100 system", "TREATMENT", 289, 310]]], ["ZIKV NS5 or RdRp protein was immobilized on a CM5 chip, respectively.", [["ZIKV", "GENE_OR_GENE_PRODUCT", 0, 4], ["RdRp", "GENE_OR_GENE_PRODUCT", 12, 16], ["ZIKV NS5", "PROTEIN", 0, 8], ["RdRp protein", "PROTEIN", 12, 24], ["ZIKV", "SPECIES", 0, 4], ["ZIKV NS5", "TREATMENT", 0, 8], ["RdRp protein", "TREATMENT", 12, 24], ["a CM5 chip", "TREATMENT", 44, 54]]], ["The analytes were consisting of serial dilutions of fidaxomicin or ribavirin, as indicated.", [["fidaxomicin", "CHEMICAL", 52, 63], ["ribavirin", "CHEMICAL", 67, 76], ["fidaxomicin", "CHEMICAL", 52, 63], ["ribavirin", "CHEMICAL", 67, 76], ["fidaxomicin", "SIMPLE_CHEMICAL", 52, 63], ["ribavirin", "SIMPLE_CHEMICAL", 67, 76], ["The analytes", "TREATMENT", 0, 12], ["serial dilutions", "TREATMENT", 32, 48], ["fidaxomicin", "TREATMENT", 52, 63], ["ribavirin", "TREATMENT", 67, 76]]], ["The K d values presented in b and d were calculated via the BIAcore T100 analysis software (BIAevaluation Version 3.1). f The polymerase activity of NS5 at gradient concentrations ranging between 0 and 20 nM (left) and inhibition of the polymerase activity of NS5 (20 nM) gradient concentrations of fidaxomicin ranging between 0 and 200 \u03bcM (right).", [["fidaxomicin", "CHEMICAL", 299, 310], ["fidaxomicin", "CHEMICAL", 299, 310], ["NS5", "GENE_OR_GENE_PRODUCT", 149, 152], ["fidaxomicin", "SIMPLE_CHEMICAL", 299, 310], ["NS5", "PROTEIN", 149, 152], ["NS5", "PROTEIN", 260, 263], ["The K d values", "TEST", 0, 14], ["the BIAcore", "TEST", 56, 67], ["BIAevaluation Version", "TEST", 92, 113], ["NS5 at gradient concentrations", "TEST", 149, 179], ["NS5", "TEST", 260, 263], ["gradient concentrations", "TEST", 272, 295], ["fidaxomicin", "TREATMENT", 299, 310], ["activity", "OBSERVATION_MODIFIER", 137, 145], ["left", "ANATOMY_MODIFIER", 209, 213], ["right", "ANATOMY_MODIFIER", 341, 346]]], ["Constant concentrations of Primer/Template (10 nM) were used in both assays.", [["Primer/Template (10 nM)", "TREATMENT", 27, 50], ["concentrations", "OBSERVATION_MODIFIER", 9, 23]]], ["The red word \"20 nt\" indicates location of the unextended primer, and \"28 nt\" indicates location of the full-length product. g Quantification of the NS5 activities tested in f (right panel at bottom) using gray scale scanning by Image J. Data are representative of three independent experiments and the RdRp enzyme domain ZIKV NS5.", [["unextended primer", "DNA", 47, 64], ["full-length product", "PROTEIN", 104, 123], ["NS5", "PROTEIN", 149, 152], ["RdRp enzyme domain", "PROTEIN", 303, 321], ["ZIKV NS5", "PROTEIN", 322, 330], ["the NS5 activities", "TEST", 145, 163], ["gray scale scanning", "TEST", 206, 225], ["the RdRp enzyme", "TEST", 299, 314]]], ["Notably, the binding between ribavirin and the RdRp protein was weak (Fig. 2e) , further suggesting a specific interaction between fidaxomicin and RdRp.", [["ribavirin", "CHEMICAL", 29, 38], ["fidaxomicin", "CHEMICAL", 131, 142], ["ribavirin", "CHEMICAL", 29, 38], ["fidaxomicin", "CHEMICAL", 131, 142], ["ribavirin", "SIMPLE_CHEMICAL", 29, 38], ["fidaxomicin", "SIMPLE_CHEMICAL", 131, 142], ["RdRp", "GENE_OR_GENE_PRODUCT", 147, 151], ["RdRp protein", "PROTEIN", 47, 59], ["fidaxomicin", "PROTEIN", 131, 142], ["RdRp", "PROTEIN", 147, 151], ["ribavirin", "TREATMENT", 29, 38], ["the RdRp protein", "TEST", 43, 59], ["fidaxomicin", "TREATMENT", 131, 142], ["RdRp", "TREATMENT", 147, 151]]], ["To investigate whether binding of fidaxomicin to the RdRp alters the biochemical function of NS5 RdRp, we assessed the polymerase activity of NS5 with or without treatment with fidaxomicin using an in vitro non-radioactive primer extension assay [46] .", [["fidaxomicin", "CHEMICAL", 34, 45], ["fidaxomicin", "CHEMICAL", 177, 188], ["fidaxomicin", "CHEMICAL", 34, 45], ["fidaxomicin", "CHEMICAL", 177, 188], ["fidaxomicin", "GENE_OR_GENE_PRODUCT", 34, 45], ["RdRp", "GENE_OR_GENE_PRODUCT", 53, 57], ["NS5", "GENE_OR_GENE_PRODUCT", 93, 96], ["NS5", "GENE_OR_GENE_PRODUCT", 142, 145], ["fidaxomicin", "SIMPLE_CHEMICAL", 177, 188], ["RdRp", "PROTEIN", 53, 57], ["NS5 RdRp", "PROTEIN", 93, 101], ["NS5", "PROTEIN", 142, 145], ["fidaxomicin", "TREATMENT", 34, 45], ["the RdRp", "PROBLEM", 49, 57], ["NS5 RdRp", "TREATMENT", 93, 101], ["NS5", "TREATMENT", 142, 145], ["treatment", "TREATMENT", 162, 171], ["fidaxomicin", "TREATMENT", 177, 188], ["an in vitro non-radioactive primer extension assay", "TEST", 195, 245], ["NS5 RdRp", "OBSERVATION", 93, 101]]], ["As shown in Fig. 2f , g, fidaxomicin was able to inhibit the RNA polymerase activity of NS5, whereas in the absence of fidaxomicin, the NS5 protein was capable of synthesizing the 28-nt viral RNA products in a dose-dependent manner.", [["fidaxomicin", "CHEMICAL", 25, 36], ["fidaxomicin", "CHEMICAL", 119, 130], ["fidaxomicin", "CHEMICAL", 25, 36], ["fidaxomicin", "CHEMICAL", 119, 130], ["fidaxomicin", "SIMPLE_CHEMICAL", 25, 36], ["NS5", "GENE_OR_GENE_PRODUCT", 88, 91], ["fidaxomicin", "SIMPLE_CHEMICAL", 119, 130], ["NS5", "GENE_OR_GENE_PRODUCT", 136, 139], ["RNA polymerase", "PROTEIN", 61, 75], ["NS5", "PROTEIN", 88, 91], ["NS5 protein", "PROTEIN", 136, 147], ["28-nt viral RNA products", "PROTEIN", 180, 204], ["fidaxomicin", "TREATMENT", 25, 36], ["NS5", "PROBLEM", 88, 91], ["fidaxomicin", "TREATMENT", 119, 130], ["the NS5 protein", "TEST", 132, 147], ["nt viral RNA products", "TREATMENT", 183, 204], ["viral RNA", "OBSERVATION", 186, 195]]], ["Consistently, the inhibitory effect of fidaxomicin on ZIKV RdRp-catalyzed RNA synthesis was also dose-dependent (Fig. 2f) , and the IC 50 value was estimated to be 10.9 \u03bcM as quantified by the amount of the RNA products (Fig. 2g) .Identification of fidaxomicin as an inhibitor of ZIKV RdRp in vitroMoreover, as it was reported that ZIKV NS5 targets IFNregulated transcriptional activator STAT2 and mediates STAT2 degradation [30] , we subsequently examined whether fidaxomicin could interrupt STAT2 degradation induced by NS5 and further suppress the antagonism of ZIKV on IFN signaling.", [["fidaxomicin", "CHEMICAL", 39, 50], ["fidaxomicin", "CHEMICAL", 249, 260], ["fidaxomicin", "CHEMICAL", 465, 476], ["fidaxomicin", "CHEMICAL", 39, 50], ["fidaxomicin", "CHEMICAL", 249, 260], ["fidaxomicin", "CHEMICAL", 465, 476], ["fidaxomicin", "SIMPLE_CHEMICAL", 39, 50], ["ZIKV RdRp", "ORGANISM", 54, 63], ["fidaxomicin", "SIMPLE_CHEMICAL", 249, 260], ["ZIKV RdRp", "ORGANISM", 280, 289], ["ZIKV NS5", "ORGANISM", 332, 340], ["STAT2", "GENE_OR_GENE_PRODUCT", 388, 393], ["STAT2", "GENE_OR_GENE_PRODUCT", 407, 412], ["fidaxomicin", "SIMPLE_CHEMICAL", 465, 476], ["STAT2", "GENE_OR_GENE_PRODUCT", 493, 498], ["NS5", "GENE_OR_GENE_PRODUCT", 522, 525], ["ZIKV", "GENE_OR_GENE_PRODUCT", 565, 569], ["IFN", "GENE_OR_GENE_PRODUCT", 573, 576], ["ZIKV RdRp", "PROTEIN", 54, 63], ["RNA products", "PROTEIN", 207, 219], ["ZIKV RdRp", "PROTEIN", 280, 289], ["ZIKV NS5", "PROTEIN", 332, 340], ["IFNregulated transcriptional activator", "PROTEIN", 349, 387], ["STAT2", "PROTEIN", 388, 393], ["STAT2", "PROTEIN", 407, 412], ["STAT2", "PROTEIN", 493, 498], ["NS5", "PROTEIN", 522, 525], ["ZIKV", "PROTEIN", 565, 569], ["IFN", "PROTEIN", 573, 576], ["ZIKV", "SPECIES", 54, 58], ["ZIKV", "SPECIES", 280, 284], ["ZIKV", "SPECIES", 332, 336], ["ZIKV", "SPECIES", 565, 569], ["fidaxomicin", "TREATMENT", 39, 50], ["ZIKV RdRp", "TREATMENT", 54, 63], ["catalyzed RNA synthesis", "TREATMENT", 64, 87], ["the IC 50 value", "TEST", 128, 143], ["the RNA products", "TREATMENT", 203, 219], ["fidaxomicin", "TREATMENT", 249, 260], ["an inhibitor", "TREATMENT", 264, 276], ["ZIKV RdRp", "TREATMENT", 280, 289], ["ZIKV NS5 targets", "TREATMENT", 332, 348], ["transcriptional activator STAT2", "TREATMENT", 362, 393], ["STAT2 degradation", "PROBLEM", 407, 424], ["fidaxomicin", "TREATMENT", 465, 476], ["STAT2 degradation", "PROBLEM", 493, 510], ["NS5", "TREATMENT", 522, 525], ["ZIKV on IFN signaling", "PROBLEM", 565, 586]]], ["We co-transfected 293T cells with the expression vector containing ZIKV NS5 and RIG-I(N), which is well known to activate the signaling pathway for IFN1, together with pISRE-Luc and increasing concentration of fidaxomicin.", [["293T cells", "ANATOMY", 18, 28], ["fidaxomicin", "CHEMICAL", 210, 221], ["fidaxomicin", "CHEMICAL", 210, 221], ["293T cells", "CELL", 18, 28], ["ZIKV NS5", "GENE_OR_GENE_PRODUCT", 67, 75], ["RIG-I", "GENE_OR_GENE_PRODUCT", 80, 85], ["IFN1", "GENE_OR_GENE_PRODUCT", 148, 152], ["pISRE-Luc", "GENE_OR_GENE_PRODUCT", 168, 177], ["fidaxomicin", "SIMPLE_CHEMICAL", 210, 221], ["293T cells", "CELL_LINE", 18, 28], ["expression vector", "DNA", 38, 55], ["ZIKV NS5", "DNA", 67, 75], ["RIG-I(N)", "DNA", 80, 88], ["IFN1", "PROTEIN", 148, 152], ["pISRE", "PROTEIN", 168, 173], ["Luc", "PROTEIN", 174, 177], ["ZIKV", "SPECIES", 67, 71], ["the expression vector", "TREATMENT", 34, 55], ["ZIKV NS5", "TREATMENT", 67, 75], ["IFN1", "TREATMENT", 148, 152], ["pISRE-Luc", "TREATMENT", 168, 177], ["fidaxomicin", "TREATMENT", 210, 221], ["293T cells", "OBSERVATION", 18, 28]]], ["Our results demonstrated that overexpression of ZIKV NS5 inhibited the reporter luciferase activity driven by RIG-I(N), but fidaxomicin did not liberate the suppression of IFN signaling induced by ZIKV NS5 (Additional file 1: Fig. S1a) .", [["fidaxomicin", "CHEMICAL", 124, 135], ["fidaxomicin", "CHEMICAL", 124, 135], ["ZIKV NS5", "GENE_OR_GENE_PRODUCT", 48, 56], ["luciferase", "GENE_OR_GENE_PRODUCT", 80, 90], ["RIG-I", "GENE_OR_GENE_PRODUCT", 110, 115], ["fidaxomicin", "SIMPLE_CHEMICAL", 124, 135], ["IFN", "GENE_OR_GENE_PRODUCT", 172, 175], ["Fig. S1a", "GENE_OR_GENE_PRODUCT", 226, 234], ["ZIKV NS5", "PROTEIN", 48, 56], ["luciferase", "PROTEIN", 80, 90], ["RIG-I(N)", "PROTEIN", 110, 118], ["IFN", "PROTEIN", 172, 175], ["ZIKV NS5", "PROTEIN", 197, 205], ["ZIKV", "SPECIES", 48, 52], ["ZIKV", "SPECIES", 197, 201], ["ZIKV NS5", "TREATMENT", 48, 56], ["fidaxomicin", "TREATMENT", 124, 135], ["IFN signaling", "PROBLEM", 172, 185]]], ["Furthermore, the results of western blotting of the expression of STAT2 showed that fidaxomicin did not prevent the degradation of STAT2 in the presence of NS5 either (Additional file 1: Fig. S1b ).", [["fidaxomicin", "CHEMICAL", 84, 95], ["fidaxomicin", "CHEMICAL", 84, 95], ["STAT2", "GENE_OR_GENE_PRODUCT", 66, 71], ["fidaxomicin", "SIMPLE_CHEMICAL", 84, 95], ["STAT2", "GENE_OR_GENE_PRODUCT", 131, 136], ["STAT2", "PROTEIN", 66, 71], ["STAT2", "PROTEIN", 131, 136], ["NS5", "PROTEIN", 156, 159], ["fidaxomicin", "TREATMENT", 84, 95], ["NS5", "PROBLEM", 156, 159]]], ["Taken together, these data suggest that the inhibition of NS5 by fidaxomicin is mainly achieved through direct binding to the RdRp active site, which is independent of the antagonistic effect of NS5 on IFN signaling.Fidaxomicin suppresses ZIKV infection in vitroNext, we employed plaque reduction assay and RT-qPCR to evaluate the antiviral effects of fidaxomicin on ZIKV (ZG-01 and MR766 strains) infection in a variety of host cell types, including SNB19, A172, A549, Huh7, Vero, and HUVECs.", [["plaque", "ANATOMY", 280, 286], ["strains", "ANATOMY", 389, 396], ["cell", "ANATOMY", 429, 433], ["SNB19", "ANATOMY", 451, 456], ["A172", "ANATOMY", 458, 462], ["A549", "ANATOMY", 464, 468], ["Huh7", "ANATOMY", 470, 474], ["Vero", "ANATOMY", 476, 480], ["HUVECs", "ANATOMY", 486, 492], ["fidaxomicin", "CHEMICAL", 65, 76], ["Fidaxomicin", "CHEMICAL", 216, 227], ["infection", "DISEASE", 244, 253], ["fidaxomicin", "CHEMICAL", 352, 363], ["infection", "DISEASE", 398, 407], ["fidaxomicin", "CHEMICAL", 65, 76], ["Fidaxomicin", "CHEMICAL", 216, 227], ["fidaxomicin", "CHEMICAL", 352, 363], ["NS5", "GENE_OR_GENE_PRODUCT", 58, 61], ["fidaxomicin", "SIMPLE_CHEMICAL", 65, 76], ["NS5", "GENE_OR_GENE_PRODUCT", 195, 198], ["IFN", "GENE_OR_GENE_PRODUCT", 202, 205], ["Fidaxomicin", "SIMPLE_CHEMICAL", 216, 227], ["ZIKV", "GENE_OR_GENE_PRODUCT", 239, 243], ["plaque", "PATHOLOGICAL_FORMATION", 280, 286], ["fidaxomicin", "SIMPLE_CHEMICAL", 352, 363], ["ZIKV", "ORGANISM", 367, 371], ["ZG-01", "CELL", 373, 378], ["MR766 strains", "CELL", 383, 396], ["host cell", "CELL", 424, 433], ["SNB19", "CELL", 451, 456], ["A172", "CELL", 458, 462], ["A549", "CELL", 464, 468], ["Huh7", "CELL", 470, 474], ["Vero", "CELL", 476, 480], ["HUVECs", "CELL", 486, 492], ["NS5", "PROTEIN", 58, 61], ["RdRp active site", "DNA", 126, 142], ["NS5", "PROTEIN", 195, 198], ["IFN", "PROTEIN", 202, 205], ["SNB19", "CELL_LINE", 451, 456], ["A172", "CELL_LINE", 458, 462], ["A549", "CELL_LINE", 464, 468], ["Huh7", "CELL_LINE", 470, 474], ["Vero", "CELL_LINE", 476, 480], ["HUVECs", "CELL_LINE", 486, 492], ["ZIKV", "SPECIES", 239, 243], ["ZIKV", "SPECIES", 367, 371], ["NS5", "TREATMENT", 58, 61], ["fidaxomicin", "TREATMENT", 65, 76], ["NS5 on IFN signaling", "TREATMENT", 195, 215], ["Fidaxomicin", "TREATMENT", 216, 227], ["ZIKV infection", "PROBLEM", 239, 253], ["plaque reduction assay", "TREATMENT", 280, 302], ["RT-qPCR", "TEST", 307, 314], ["fidaxomicin", "TREATMENT", 352, 363], ["ZIKV (ZG", "TREATMENT", 367, 375], ["MR766 strains) infection", "PROBLEM", 383, 407], ["SNB19", "TEST", 451, 456], ["A172", "TEST", 458, 462], ["A549", "TEST", 464, 468], ["Huh7", "TEST", 470, 474], ["Vero", "TEST", 476, 480], ["antiviral", "OBSERVATION", 331, 340], ["infection", "OBSERVATION", 398, 407], ["host cell types", "OBSERVATION", 424, 439], ["HUVECs", "ANATOMY", 486, 492]]], ["The results showed that fidaxomicin was effective against multiple strains of ZIKV, including Asian and African strains in various types of host cells (Table 1 and Additional file 1: Table S2 ).", [["cells", "ANATOMY", 145, 150], ["fidaxomicin", "CHEMICAL", 24, 35], ["fidaxomicin", "CHEMICAL", 24, 35], ["fidaxomicin", "SIMPLE_CHEMICAL", 24, 35], ["ZIKV", "ORGANISM", 78, 82], ["host cells", "CELL", 140, 150], ["host cells", "CELL_TYPE", 140, 150], ["ZIKV", "SPECIES", 78, 82], ["fidaxomicin", "TREATMENT", 24, 35], ["ZIKV", "PROBLEM", 78, 82], ["African strains", "PROBLEM", 104, 119], ["host cells", "PROBLEM", 140, 150], ["host cells", "OBSERVATION", 140, 150]]], ["In the light that neurodegenaration could be involved in ZIKV pathogenesis in the CNS, we tested the antiviral effects of fidaxomicin and ribavirin in CNS cells.", [["CNS", "ANATOMY", 82, 85], ["CNS cells", "ANATOMY", 151, 160], ["fidaxomicin", "CHEMICAL", 122, 133], ["ribavirin", "CHEMICAL", 138, 147], ["fidaxomicin", "CHEMICAL", 122, 133], ["ribavirin", "CHEMICAL", 138, 147], ["ZIKV", "CANCER", 57, 61], ["CNS", "ANATOMICAL_SYSTEM", 82, 85], ["fidaxomicin", "SIMPLE_CHEMICAL", 122, 133], ["ribavirin", "SIMPLE_CHEMICAL", 138, 147], ["CNS cells", "CELL", 151, 160], ["CNS cells", "CELL_TYPE", 151, 160], ["ZIKV", "SPECIES", 57, 61], ["neurodegenaration", "PROBLEM", 18, 35], ["ZIKV pathogenesis", "PROBLEM", 57, 74], ["fidaxomicin", "TREATMENT", 122, 133], ["ribavirin in CNS cells", "TREATMENT", 138, 160], ["ZIKV", "OBSERVATION", 57, 61], ["CNS", "ANATOMY", 82, 85], ["CNS cells", "OBSERVATION", 151, 160]]], ["Notably, compared with that of ribavirin, the EC 50 value of fidaxomicin was lower by 10-fold in SNB19 cells (Table 1 ).", [["EC", "ANATOMY", 46, 48], ["SNB19 cells", "ANATOMY", 97, 108], ["ribavirin", "CHEMICAL", 31, 40], ["fidaxomicin", "CHEMICAL", 61, 72], ["ribavirin", "CHEMICAL", 31, 40], ["fidaxomicin", "CHEMICAL", 61, 72], ["ribavirin", "SIMPLE_CHEMICAL", 31, 40], ["EC", "CELL", 46, 48], ["fidaxomicin", "SIMPLE_CHEMICAL", 61, 72], ["SNB19 cells", "CELL", 97, 108], ["SNB19 cells", "CELL_LINE", 97, 108], ["ribavirin", "TREATMENT", 31, 40], ["the EC", "TEST", 42, 48], ["fidaxomicin", "TEST", 61, 72]]], ["In addition, fidaxomicin also showed low EC 90 value (approximately 9 \u03bcM, shown in Table 1 ), relative to the CC 10 value (about 50 \u03bcM) in SNB19 cells (Fig. 3a) , indicating that fidaxomicin possessed strong anti-ZIKV activity without significant cell cytotoxicity against the host cells.", [["EC", "ANATOMY", 41, 43], ["SNB19 cells", "ANATOMY", 139, 150], ["cell", "ANATOMY", 247, 251], ["cells", "ANATOMY", 282, 287], ["fidaxomicin", "CHEMICAL", 13, 24], ["CC", "CHEMICAL", 110, 112], ["fidaxomicin", "CHEMICAL", 179, 190], ["fidaxomicin", "CHEMICAL", 13, 24], ["fidaxomicin", "CHEMICAL", 179, 190], ["fidaxomicin", "SIMPLE_CHEMICAL", 13, 24], ["EC", "CELL", 41, 43], ["SNB19 cells", "CELL", 139, 150], ["fidaxomicin", "SIMPLE_CHEMICAL", 179, 190], ["anti-ZIKV", "CANCER", 208, 217], ["cell", "CELL", 247, 251], ["cells", "CELL", 282, 287], ["SNB19 cells", "CELL_LINE", 139, 150], ["host cells", "CELL_TYPE", 277, 287], ["fidaxomicin", "TREATMENT", 13, 24], ["low EC 90 value", "PROBLEM", 37, 52], ["fidaxomicin", "TREATMENT", 179, 190], ["significant cell cytotoxicity", "PROBLEM", 235, 264], ["cell cytotoxicity", "OBSERVATION", 247, 264], ["host cells", "OBSERVATION", 277, 287]]], ["By contrast, ribavirin was far less effective against ZIKV infection in SNB19 cells under the non-cytotoxic concentration (Fig. 3b) .", [["SNB19 cells", "ANATOMY", 72, 83], ["ribavirin", "CHEMICAL", 13, 22], ["infection", "DISEASE", 59, 68], ["ribavirin", "CHEMICAL", 13, 22], ["ribavirin", "SIMPLE_CHEMICAL", 13, 22], ["ZIKV", "SIMPLE_CHEMICAL", 54, 58], ["SNB19 cells", "CELL", 72, 83], ["SNB19 cells", "CELL_LINE", 72, 83], ["ZIKV", "SPECIES", 54, 58], ["ribavirin", "TREATMENT", 13, 22], ["ZIKV infection in SNB19 cells", "PROBLEM", 54, 83], ["the non-cytotoxic concentration", "TREATMENT", 90, 121]]], ["Interestingly, as recent studies reported that ribavirin can inhibit ZIKV infection in cell culture [49, 50] , our results showed that compared to ribavirin, fidaxomicin possessed higher anti-ZIKV activity and lower cellular toxicity.", [["cell culture", "ANATOMY", 87, 99], ["cellular", "ANATOMY", 216, 224], ["ribavirin", "CHEMICAL", 47, 56], ["ZIKV", "CHEMICAL", 69, 73], ["infection", "DISEASE", 74, 83], ["ribavirin", "CHEMICAL", 147, 156], ["fidaxomicin", "CHEMICAL", 158, 169], ["toxicity", "DISEASE", 225, 233], ["ribavirin", "CHEMICAL", 47, 56], ["ribavirin", "CHEMICAL", 147, 156], ["fidaxomicin", "CHEMICAL", 158, 169], ["ribavirin", "SIMPLE_CHEMICAL", 47, 56], ["ZIKV", "SIMPLE_CHEMICAL", 69, 73], ["cell", "CELL", 87, 91], ["ribavirin", "SIMPLE_CHEMICAL", 147, 156], ["fidaxomicin", "SIMPLE_CHEMICAL", 158, 169], ["anti-ZIKV", "CANCER", 187, 196], ["cellular", "CELL", 216, 224], ["ZIKV", "SPECIES", 69, 73], ["anti-ZIKV", "SPECIES", 187, 196], ["recent studies", "TEST", 18, 32], ["ribavirin", "TREATMENT", 47, 56], ["ZIKV infection", "PROBLEM", 69, 83], ["cell culture", "TEST", 87, 99], ["ribavirin", "TREATMENT", 147, 156], ["fidaxomicin", "TREATMENT", 158, 169], ["lower cellular toxicity", "PROBLEM", 210, 233], ["anti-ZIKV activity", "OBSERVATION", 187, 205], ["lower", "OBSERVATION_MODIFIER", 210, 215], ["cellular toxicity", "OBSERVATION", 216, 233]]], ["Furthermore, as shown in Fig. 3c , d, the inhibitory effect of fidaxomicin on ZIKV production was dose-dependent, and ZIKV infection was completely undetectable when the concentration of fidaxomicin exceeded 18 \u03bcM, strongly suggesting a dose-dependent suppressive effect of fidaxomicin treatment on ZIKV multiplication.", [["fidaxomicin", "CHEMICAL", 63, 74], ["ZIKV", "CHEMICAL", 78, 82], ["infection", "DISEASE", 123, 132], ["fidaxomicin", "CHEMICAL", 187, 198], ["fidaxomicin", "CHEMICAL", 274, 285], ["fidaxomicin", "CHEMICAL", 63, 74], ["fidaxomicin", "CHEMICAL", 187, 198], ["fidaxomicin", "CHEMICAL", 274, 285], ["fidaxomicin", "SIMPLE_CHEMICAL", 63, 74], ["ZIKV", "SIMPLE_CHEMICAL", 78, 82], ["ZIKV", "ORGANISM", 118, 122], ["fidaxomicin", "SIMPLE_CHEMICAL", 187, 198], ["fidaxomicin", "SIMPLE_CHEMICAL", 274, 285], ["ZIKV", "SIMPLE_CHEMICAL", 299, 303], ["ZIKV", "SPECIES", 78, 82], ["ZIKV", "SPECIES", 118, 122], ["ZIKV", "SPECIES", 299, 303], ["fidaxomicin", "TREATMENT", 63, 74], ["ZIKV production", "TREATMENT", 78, 93], ["ZIKV infection", "PROBLEM", 118, 132], ["fidaxomicin", "TREATMENT", 187, 198], ["fidaxomicin treatment", "TREATMENT", 274, 295], ["ZIKV multiplication", "TREATMENT", 299, 318]]], ["To confirm the antiviral activity at higher MOI of virus, we performed the antiviral assays with MOI 1.0, 2.0, and 4.0 of ZIKV and quantified the viral loads cultured in SNB19 cells by PFU assay and RT-qPCR.", [["SNB19 cells", "ANATOMY", 170, 181], ["ZIKV", "ORGANISM", 122, 126], ["SNB19 cells", "CELL", 170, 181], ["SNB19 cells", "CELL_LINE", 170, 181], ["ZIKV", "SPECIES", 122, 126], ["the antiviral activity", "PROBLEM", 11, 33], ["the antiviral assays", "TEST", 71, 91], ["MOI", "TEST", 97, 100], ["ZIKV", "TREATMENT", 122, 126], ["the viral loads", "TEST", 142, 157], ["PFU assay", "TEST", 185, 194], ["RT", "TEST", 199, 201], ["viral loads", "OBSERVATION", 146, 157]]], ["Our results showed that the obtained EC 50 s (shown in Additional file 1: Fig. S2 a and b) were similar to those shown in Table 1 .", [["EC", "ANATOMY", 37, 39], ["EC", "CELL", 37, 39], ["S2", "PROTEIN", 79, 81]]], ["Moreover, we chose ZIKV NS3, NS5, and E protein to quantify the viral loads The 50% effective concentration, or the concentration necessary to reduce viral yield by 50%, was determined using a plaque assay bFidaxomicin suppresses ZIKV infection in vitroThe 90% effective concentration, or the concentration necessary to reduce viral yield by 90%, was determined using a plaque assay c Concentration required to inhibit the cell growth by 50% in the absence of virus in response to fidaxomicin treatment.", [["plaque", "ANATOMY", 193, 199], ["plaque", "ANATOMY", 370, 376], ["cell", "ANATOMY", 423, 427], ["bFidaxomicin", "CHEMICAL", 206, 218], ["ZIKV", "CHEMICAL", 230, 234], ["infection", "DISEASE", 235, 244], ["fidaxomicin", "CHEMICAL", 481, 492], ["bFidaxomicin", "CHEMICAL", 206, 218], ["fidaxomicin", "CHEMICAL", 481, 492], ["ZIKV NS3", "GENE_OR_GENE_PRODUCT", 19, 27], ["NS5", "GENE_OR_GENE_PRODUCT", 29, 32], ["E", "GENE_OR_GENE_PRODUCT", 38, 39], ["bFidaxomicin", "SIMPLE_CHEMICAL", 206, 218], ["ZIKV", "ORGANISM", 230, 234], ["cell", "CELL", 423, 427], ["fidaxomicin", "SIMPLE_CHEMICAL", 481, 492], ["ZIKV", "PROTEIN", 19, 23], ["NS3", "PROTEIN", 24, 27], ["NS5", "PROTEIN", 29, 32], ["E protein", "PROTEIN", 38, 47], ["ZIKV", "SPECIES", 19, 23], ["ZIKV", "SPECIES", 230, 234], ["ZIKV NS3", "TREATMENT", 19, 27], ["NS5", "TEST", 29, 32], ["the viral loads", "TEST", 60, 75], ["The 50% effective concentration", "TREATMENT", 76, 107], ["a plaque assay bFidaxomicin", "TREATMENT", 191, 218], ["ZIKV infection", "PROBLEM", 230, 244], ["The 90% effective concentration", "TREATMENT", 253, 284], ["a plaque assay", "TREATMENT", 368, 382], ["the cell growth", "PROBLEM", 419, 434], ["virus", "PROBLEM", 460, 465], ["fidaxomicin treatment", "TREATMENT", 481, 502], ["viral loads", "OBSERVATION", 64, 75], ["plaque", "OBSERVATION", 370, 376], ["virus", "OBSERVATION", 460, 465]]], ["As shown in Fig. 3e , the amount of ZIKV NS3 was decreased by fidaxomicin treatment in a time-dependent manner.", [["fidaxomicin", "CHEMICAL", 62, 73], ["fidaxomicin", "CHEMICAL", 62, 73], ["ZIKV", "GENE_OR_GENE_PRODUCT", 36, 40], ["fidaxomicin", "SIMPLE_CHEMICAL", 62, 73], ["ZIKV NS3", "PROTEIN", 36, 44], ["ZIKV", "SPECIES", 36, 40], ["ZIKV NS3", "TREATMENT", 36, 44], ["fidaxomicin treatment", "TREATMENT", 62, 83]]], ["Similar observation that ZIKV NS5 and E proteins were also decreased by fidaxomicin treatment was made via western blotting analysis (Additional file 1: Fig. S2 c and d) .Fidaxomicin inhibits ZIKV replication and prevents ZIKVinfected mice from deathOur in vivo experiments in mice dosed i.v. with fidaxomicin at 200 mg/kg daily for 10 days displayed no detectable adverse effect as the mice showed no significant weight loss, irreversible corneal opacities, blood abnormalities, and movement disorders (Additional file 1: Fig. S3 , Table S3 - (Table 1) , we selected the Asian strain (ZIKV ZG-01) to implement the subsequent animal experiments.", [["corneal", "ANATOMY", 440, 447], ["blood", "ANATOMY", 459, 464], ["fidaxomicin", "CHEMICAL", 72, 83], ["Fidaxomicin", "CHEMICAL", 171, 182], ["fidaxomicin", "CHEMICAL", 298, 309], ["weight loss", "DISEASE", 414, 425], ["corneal opacities", "DISEASE", 440, 457], ["blood abnormalities", "DISEASE", 459, 478], ["movement disorders", "DISEASE", 484, 502], ["fidaxomicin", "CHEMICAL", 72, 83], ["Fidaxomicin", "CHEMICAL", 171, 182], ["fidaxomicin", "CHEMICAL", 298, 309], ["ZIKV NS5", "GENE_OR_GENE_PRODUCT", 25, 33], ["E", "GENE_OR_GENE_PRODUCT", 38, 39], ["fidaxomicin", "SIMPLE_CHEMICAL", 72, 83], ["S2 c", "GENE_OR_GENE_PRODUCT", 158, 162], ["Fidaxomicin", "SIMPLE_CHEMICAL", 171, 182], ["ZIKV", "GENE_OR_GENE_PRODUCT", 192, 196], ["ZIKVinfected mice", "ORGANISM", 222, 239], ["mice", "ORGANISM", 277, 281], ["fidaxomicin", "SIMPLE_CHEMICAL", 298, 309], ["mice", "ORGANISM", 387, 391], ["corneal", "TISSUE", 440, 447], ["blood", "ORGANISM_SUBSTANCE", 459, 464], ["Table S3", "GENE_OR_GENE_PRODUCT", 533, 541], ["ZIKV ZG-01", "CELL", 586, 596], ["ZIKV NS5 and E proteins", "PROTEIN", 25, 48], ["S2 c and d", "PROTEIN", 158, 168], ["mice", "SPECIES", 235, 239], ["mice", "SPECIES", 277, 281], ["mice", "SPECIES", 387, 391], ["ZIKV", "SPECIES", 25, 29], ["ZIKV", "SPECIES", 192, 196], ["mice", "SPECIES", 235, 239], ["mice", "SPECIES", 277, 281], ["mice", "SPECIES", 387, 391], ["ZIKV NS5 and E proteins", "TEST", 25, 48], ["fidaxomicin treatment", "TREATMENT", 72, 93], ["blotting analysis", "TEST", 115, 132], ["Fidaxomicin", "TREATMENT", 171, 182], ["ZIKV replication", "TREATMENT", 192, 208], ["fidaxomicin", "TREATMENT", 298, 309], ["detectable adverse effect", "PROBLEM", 354, 379], ["significant weight loss", "PROBLEM", 402, 425], ["irreversible corneal opacities", "PROBLEM", 427, 457], ["blood abnormalities", "PROBLEM", 459, 478], ["movement disorders", "PROBLEM", 484, 502], ["the Asian strain", "TREATMENT", 568, 584], ["ZIKV ZG", "TREATMENT", 586, 593], ["no", "UNCERTAINTY", 399, 401], ["significant", "OBSERVATION_MODIFIER", 402, 413], ["weight loss", "OBSERVATION", 414, 425], ["irreversible", "OBSERVATION_MODIFIER", 427, 439], ["corneal", "ANATOMY", 440, 447], ["opacities", "OBSERVATION", 448, 457], ["blood", "ANATOMY", 459, 464], ["Table S3", "ANATOMY", 533, 541]]], ["To determine the antiviral efficacy in vivo, two doses of fidaxomicin were given i.v. daily for 7 days (Fig. 4a) .", [["fidaxomicin", "CHEMICAL", 58, 69], ["fidaxomicin", "CHEMICAL", 58, 69], ["fidaxomicin", "SIMPLE_CHEMICAL", 58, 69], ["fidaxomicin", "TREATMENT", 58, 69]]], ["Fidaxomicin improved the survival of ZIKV-infected mice in both treatment groups.", [["Fidaxomicin", "CHEMICAL", 0, 11], ["ZIKV-infected", "DISEASE", 37, 50], ["Fidaxomicin", "CHEMICAL", 0, 11], ["Fidaxomicin", "SIMPLE_CHEMICAL", 0, 11], ["ZIKV", "ORGANISM", 37, 41], ["mice", "ORGANISM", 51, 55], ["mice", "SPECIES", 51, 55], ["ZIKV", "SPECIES", 37, 41], ["mice", "SPECIES", 51, 55], ["Fidaxomicin", "TREATMENT", 0, 11], ["ZIKV", "PROBLEM", 37, 41]]], ["Particularly, in the high-dose group, nine out of 13 mice were protected from mortality (Fig. 4b) .", [["mice", "ORGANISM", 53, 57], ["mice", "SPECIES", 53, 57], ["mice", "SPECIES", 53, 57]]], ["Median survival was significantly prolonged in the fidaxomicin-treated groups, with over 15 days for the 20 mg/kg group and 14 days for the 10 mg/kg group, both of which were significantly longer than 8.5 days exhibited in the vehicle-control group.", [["fidaxomicin", "CHEMICAL", 51, 62], ["fidaxomicin", "CHEMICAL", 51, 62], ["fidaxomicin", "SIMPLE_CHEMICAL", 51, 62], ["the fidaxomicin", "TREATMENT", 47, 62], ["significantly", "OBSERVATION_MODIFIER", 20, 33], ["prolonged", "OBSERVATION_MODIFIER", 34, 43]]], ["Furthermore, fidaxomicin also appeared to be able to reverse the body weight loss of ZIKV-infected mice.", [["body", "ANATOMY", 65, 69], ["fidaxomicin", "CHEMICAL", 13, 24], ["weight loss", "DISEASE", 70, 81], ["ZIKV", "CHEMICAL", 85, 89], ["fidaxomicin", "CHEMICAL", 13, 24], ["fidaxomicin", "SIMPLE_CHEMICAL", 13, 24], ["body", "ORGANISM_SUBDIVISION", 65, 69], ["ZIKV", "GENE_OR_GENE_PRODUCT", 85, 89], ["mice", "ORGANISM", 99, 103], ["mice", "SPECIES", 99, 103], ["ZIKV", "SPECIES", 85, 89], ["mice", "SPECIES", 99, 103], ["fidaxomicin", "TREATMENT", 13, 24], ["ZIKV", "PROBLEM", 85, 89]]], ["While all mice infected with ZIKV showed the same trend of weight loss within 7 days post-infection (dpi), between 8 and 15 dpi, an obvious protection from weight loss was observed in mice treated with 20 mg/kg/day fidaxomicin, as compared with that found in the vehicle-control group (Fig. 4c) .", [["weight loss", "DISEASE", 59, 70], ["infection", "DISEASE", 90, 99], ["weight loss", "DISEASE", 156, 167], ["fidaxomicin", "CHEMICAL", 215, 226], ["fidaxomicin", "CHEMICAL", 215, 226], ["mice", "ORGANISM", 10, 14], ["mice", "ORGANISM", 184, 188], ["fidaxomicin", "SIMPLE_CHEMICAL", 215, 226], ["mice", "SPECIES", 10, 14], ["mice", "SPECIES", 184, 188], ["mice", "SPECIES", 10, 14], ["ZIKV", "SPECIES", 29, 33], ["mice", "SPECIES", 184, 188], ["ZIKV", "PROBLEM", 29, 33], ["weight loss", "PROBLEM", 59, 70], ["post-infection (dpi)", "PROBLEM", 85, 105], ["weight loss", "PROBLEM", 156, 167], ["fidaxomicin", "TREATMENT", 215, 226], ["infection", "OBSERVATION", 90, 99], ["obvious", "OBSERVATION_MODIFIER", 132, 139], ["protection", "OBSERVATION", 140, 150], ["weight loss", "OBSERVATION", 156, 167]]], ["In addition to the improvement in survival rate and weight recovery, viral RNA levels in the brain and testis on 15 dpi were significantly decreased in the two groups treated with fidaxomicin (Fig. 4d, e) .", [["brain", "ANATOMY", 93, 98], ["testis", "ANATOMY", 103, 109], ["fidaxomicin", "CHEMICAL", 180, 191], ["fidaxomicin", "CHEMICAL", 180, 191], ["brain", "ORGAN", 93, 98], ["testis", "ORGAN", 103, 109], ["fidaxomicin", "SIMPLE_CHEMICAL", 180, 191], ["viral RNA", "RNA", 69, 78], ["survival rate", "TEST", 34, 47], ["weight recovery", "TEST", 52, 67], ["viral RNA levels", "TEST", 69, 85], ["fidaxomicin", "TREATMENT", 180, 191], ["improvement", "OBSERVATION_MODIFIER", 19, 30], ["viral RNA", "OBSERVATION", 69, 78], ["brain", "ANATOMY", 93, 98], ["testis", "ANATOMY", 103, 109], ["significantly", "OBSERVATION_MODIFIER", 125, 138], ["decreased", "OBSERVATION_MODIFIER", 139, 148]]], ["A progressive decrease in the number of neurological signs, including paralysis and hunching, was observed in both treatment groups, and the degree of improvement was dose-dependent ( Fig. 4f-h) .", [["neurological", "ANATOMY", 40, 52], ["neurological signs", "DISEASE", 40, 58], ["paralysis", "DISEASE", 70, 79], ["A progressive decrease", "PROBLEM", 0, 22], ["neurological signs", "PROBLEM", 40, 58], ["paralysis", "PROBLEM", 70, 79], ["hunching", "PROBLEM", 84, 92], ["progressive", "OBSERVATION_MODIFIER", 2, 13], ["decrease", "OBSERVATION_MODIFIER", 14, 22], ["number", "OBSERVATION_MODIFIER", 30, 36], ["neurological signs", "OBSERVATION", 40, 58], ["paralysis", "OBSERVATION", 70, 79]]], ["Additionally, oral administration was also tested for its therapeutic efficacy, and our results showed that at the dosage as high as 225 mg/kg, orally administered fidaxomicin did not improve the outcome of ZIKV-infected mice as compared with the vehicle-control group (Additional file 1: Fig. S4) .", [["oral", "ANATOMY", 14, 18], ["fidaxomicin", "CHEMICAL", 164, 175], ["ZIKV-infected", "DISEASE", 207, 220], ["fidaxomicin", "CHEMICAL", 164, 175], ["oral", "ORGANISM_SUBDIVISION", 14, 18], ["fidaxomicin", "SIMPLE_CHEMICAL", 164, 175], ["ZIKV", "SIMPLE_CHEMICAL", 207, 211], ["mice", "ORGANISM", 221, 225], ["mice", "SPECIES", 221, 225], ["ZIKV", "SPECIES", 207, 211], ["mice", "SPECIES", 221, 225], ["oral administration", "TREATMENT", 14, 33], ["fidaxomicin", "TREATMENT", 164, 175], ["ZIKV", "PROBLEM", 207, 211]]], ["Further, the in vivo antiviral efficacy of fidaxomicin was also detected using tissue immunofluorescence assay and western blotting analysis for the viral protein present in the brain and the testes.", [["tissue", "ANATOMY", 79, 85], ["brain", "ANATOMY", 178, 183], ["testes", "ANATOMY", 192, 198], ["fidaxomicin", "CHEMICAL", 43, 54], ["fidaxomicin", "CHEMICAL", 43, 54], ["fidaxomicin", "SIMPLE_CHEMICAL", 43, 54], ["tissue", "TISSUE", 79, 85], ["brain", "ORGAN", 178, 183], ["testes", "ORGAN", 192, 198], ["viral protein", "PROTEIN", 149, 162], ["fidaxomicin", "TREATMENT", 43, 54], ["tissue immunofluorescence assay", "TEST", 79, 110], ["western blotting analysis", "TEST", 115, 140], ["the viral protein", "TEST", 145, 162], ["viral protein", "OBSERVATION", 149, 162], ["brain", "ANATOMY", 178, 183], ["testes", "ANATOMY", 192, 198]]], ["Immunohistochemical staining showed that as compared with the ubiquitous ZIKV-positive cells in the cerebra and testes of vehicle-control mice, fidaxomicin treatment reduced the ZIKV load in the brains and testes clearly as the results of immunostaining showed (Fig. 5a , b, Additional file 1: Fig. S5 ).", [["ZIKV-positive cells", "ANATOMY", 73, 92], ["cerebra", "ANATOMY", 100, 107], ["testes", "ANATOMY", 112, 118], ["ZIKV", "ANATOMY", 178, 182], ["brains", "ANATOMY", 195, 201], ["testes", "ANATOMY", 206, 212], ["fidaxomicin", "CHEMICAL", 144, 155], ["fidaxomicin", "CHEMICAL", 144, 155], ["ZIKV", "GENE_OR_GENE_PRODUCT", 73, 77], ["cells", "CELL", 87, 92], ["cerebra", "MULTI-TISSUE_STRUCTURE", 100, 107], ["testes", "ORGAN", 112, 118], ["mice", "ORGANISM", 138, 142], ["fidaxomicin", "SIMPLE_CHEMICAL", 144, 155], ["ZIKV", "GENE_OR_GENE_PRODUCT", 178, 182], ["brains", "ORGAN", 195, 201], ["testes", "ORGAN", 206, 212], ["ubiquitous ZIKV-positive cells", "CELL_LINE", 62, 92], ["mice", "SPECIES", 138, 142], ["mice", "SPECIES", 138, 142], ["ZIKV", "SPECIES", 178, 182], ["Immunohistochemical staining", "TEST", 0, 28], ["the ubiquitous ZIKV", "TEST", 58, 77], ["fidaxomicin treatment", "TREATMENT", 144, 165], ["the ZIKV load", "PROBLEM", 174, 187], ["immunostaining", "TEST", 239, 253], ["positive cells", "OBSERVATION", 78, 92], ["testes", "ANATOMY", 112, 118], ["ZIKV load", "OBSERVATION", 178, 187], ["brains", "ANATOMY", 195, 201], ["testes", "ANATOMY", 206, 212]]], ["Western blotting analysis of ZIKV E protein in the brain and testis tissues confirmed a significant suppressive effect of fidaxomicin on ZIKV in vivo (Fig. 5c-f ).Fidaxomicin inhibits ZIKV replication and prevents ZIKVinfected mice from deathTo further examine whether ZIKV-induced brain lesions could be protected by fidaxomicin in vivo, histopathological and immunohistochemical analyses were performed using the cerebra specimens obtained from ZIKV-infected mice treated with two dosages of fidaxomicin.", [["brain", "ANATOMY", 51, 56], ["testis tissues", "ANATOMY", 61, 75], ["brain lesions", "ANATOMY", 282, 295], ["cerebra specimens", "ANATOMY", 415, 432], ["fidaxomicin", "CHEMICAL", 122, 133], ["Fidaxomicin", "CHEMICAL", 163, 174], ["death", "DISEASE", 237, 242], ["ZIKV", "CHEMICAL", 269, 273], ["brain lesions", "DISEASE", 282, 295], ["fidaxomicin", "CHEMICAL", 318, 329], ["ZIKV-infected", "DISEASE", 447, 460], ["fidaxomicin", "CHEMICAL", 494, 505], ["fidaxomicin", "CHEMICAL", 122, 133], ["Fidaxomicin", "CHEMICAL", 163, 174], ["fidaxomicin", "CHEMICAL", 318, 329], ["fidaxomicin", "CHEMICAL", 494, 505], ["ZIKV E", "GENE_OR_GENE_PRODUCT", 29, 35], ["brain", "ORGAN", 51, 56], ["testis tissues", "TISSUE", 61, 75], ["fidaxomicin", "SIMPLE_CHEMICAL", 122, 133], ["ZIKV", "SIMPLE_CHEMICAL", 137, 141], ["Fidaxomicin", "SIMPLE_CHEMICAL", 163, 174], ["ZIKV", "CANCER", 184, 188], ["ZIKVinfected mice", "ORGANISM", 214, 231], ["ZIKV", "GENE_OR_GENE_PRODUCT", 269, 273], ["brain lesions", "PATHOLOGICAL_FORMATION", 282, 295], ["fidaxomicin", "SIMPLE_CHEMICAL", 318, 329], ["cerebra specimens", "TISSUE", 415, 432], ["ZIKV", "ORGANISM", 447, 451], ["mice", "ORGANISM", 461, 465], ["fidaxomicin", "SIMPLE_CHEMICAL", 494, 505], ["ZIKV E protein", "PROTEIN", 29, 43], ["mice", "SPECIES", 227, 231], ["mice", "SPECIES", 461, 465], ["ZIKV", "SPECIES", 29, 33], ["ZIKV", "SPECIES", 137, 141], ["ZIKV", "SPECIES", 184, 188], ["mice", "SPECIES", 227, 231], ["ZIKV", "SPECIES", 269, 273], ["ZIKV", "SPECIES", 447, 451], ["mice", "SPECIES", 461, 465], ["Western blotting analysis", "TEST", 0, 25], ["ZIKV E protein in the brain", "TEST", 29, 56], ["fidaxomicin", "TREATMENT", 122, 133], ["ZIKV", "TREATMENT", 137, 141], ["Fidaxomicin", "TREATMENT", 163, 174], ["ZIKV replication", "TREATMENT", 184, 200], ["death", "PROBLEM", 237, 242], ["ZIKV", "PROBLEM", 269, 273], ["brain lesions", "PROBLEM", 282, 295], ["fidaxomicin", "TREATMENT", 318, 329], ["immunohistochemical analyses", "TEST", 361, 389], ["the cerebra specimens", "TEST", 411, 432], ["ZIKV", "PROBLEM", 447, 451], ["fidaxomicin", "TREATMENT", 494, 505], ["brain", "ANATOMY", 51, 56], ["testis", "ANATOMY", 61, 67], ["significant", "OBSERVATION_MODIFIER", 88, 99], ["suppressive", "OBSERVATION", 100, 111], ["brain", "ANATOMY", 282, 287], ["lesions", "OBSERVATION", 288, 295]]], ["As shown in Fig. 6 , multifocal histologic lesions were observed in the cerebra of vehicle-control mice, including scattered perivascular cuffing of vessels with mononuclear cells, diffused gliosis, and neuronal necrosis.", [["lesions", "ANATOMY", 43, 50], ["cerebra", "ANATOMY", 72, 79], ["perivascular", "ANATOMY", 125, 137], ["vessels", "ANATOMY", 149, 156], ["mononuclear cells", "ANATOMY", 162, 179], ["neuronal", "ANATOMY", 203, 211], ["gliosis", "DISEASE", 190, 197], ["neuronal necrosis", "DISEASE", 203, 220], ["histologic lesions", "PATHOLOGICAL_FORMATION", 32, 50], ["cerebra", "CANCER", 72, 79], ["mice", "ORGANISM", 99, 103], ["perivascular", "IMMATERIAL_ANATOMICAL_ENTITY", 125, 137], ["vessels", "MULTI-TISSUE_STRUCTURE", 149, 156], ["mononuclear cells", "CELL", 162, 179], ["neuronal", "CELL", 203, 211], ["mononuclear cells", "CELL_TYPE", 162, 179], ["mice", "SPECIES", 99, 103], ["mice", "SPECIES", 99, 103], ["multifocal histologic lesions", "PROBLEM", 21, 50], ["scattered perivascular cuffing of vessels", "PROBLEM", 115, 156], ["mononuclear cells", "PROBLEM", 162, 179], ["diffused gliosis", "PROBLEM", 181, 197], ["neuronal necrosis", "PROBLEM", 203, 220], ["multifocal", "OBSERVATION_MODIFIER", 21, 31], ["histologic", "OBSERVATION_MODIFIER", 32, 42], ["lesions", "OBSERVATION", 43, 50], ["scattered", "OBSERVATION_MODIFIER", 115, 124], ["perivascular", "ANATOMY_MODIFIER", 125, 137], ["cuffing", "OBSERVATION", 138, 145], ["vessels", "ANATOMY", 149, 156], ["mononuclear cells", "OBSERVATION", 162, 179], ["diffused", "OBSERVATION_MODIFIER", 181, 189], ["gliosis", "OBSERVATION", 190, 197], ["neuronal", "OBSERVATION_MODIFIER", 203, 211], ["necrosis", "OBSERVATION", 212, 220]]], ["In the cerebra of fidaxomicin-treated mice, the pathologic damages caused by ZIKV infection were remarkably alleviated in both treatment groups as compared with the vehicle-control group (Fig. 6a, b) .", [["cerebra", "ANATOMY", 7, 14], ["fidaxomicin", "CHEMICAL", 18, 29], ["ZIKV", "CHEMICAL", 77, 81], ["infection", "DISEASE", 82, 91], ["fidaxomicin", "CHEMICAL", 18, 29], ["cerebra", "CANCER", 7, 14], ["fidaxomicin", "SIMPLE_CHEMICAL", 18, 29], ["mice", "ORGANISM", 38, 42], ["mice", "SPECIES", 38, 42], ["mice", "SPECIES", 38, 42], ["ZIKV", "SPECIES", 77, 81], ["fidaxomicin", "TREATMENT", 18, 29], ["the pathologic damages", "PROBLEM", 44, 66], ["ZIKV infection", "PROBLEM", 77, 91], ["ZIKV infection", "OBSERVATION", 77, 91]]], ["Moreover, fidaxomicin therapy remarkably reduced neuronal necrosis in hippocampal pyramidal cells, as characterized by reduction of hypereosinophilic neurons and pyknosis, karyolysis, and necrotic debris (Fig. 6c) .", [["neuronal", "ANATOMY", 49, 57], ["hippocampal pyramidal cells", "ANATOMY", 70, 97], ["hypereosinophilic neurons", "ANATOMY", 132, 157], ["necrotic debris", "ANATOMY", 188, 203], ["fidaxomicin", "CHEMICAL", 10, 21], ["neuronal necrosis", "DISEASE", 49, 66], ["reduction of hypereosinophilic neurons", "DISEASE", 119, 157], ["pyknosis", "DISEASE", 162, 170], ["karyolysis", "DISEASE", 172, 182], ["necrotic", "DISEASE", 188, 196], ["fidaxomicin", "CHEMICAL", 10, 21], ["fidaxomicin", "SIMPLE_CHEMICAL", 10, 21], ["neuronal", "CELL", 49, 57], ["hippocampal pyramidal cells", "CELL", 70, 97], ["hypereosinophilic neurons", "CELL", 132, 157], ["hippocampal pyramidal cells", "CELL_TYPE", 70, 97], ["hypereosinophilic neurons", "CELL_TYPE", 132, 157], ["fidaxomicin therapy", "TREATMENT", 10, 29], ["reduced neuronal necrosis in hippocampal pyramidal cells", "PROBLEM", 41, 97], ["hypereosinophilic neurons", "PROBLEM", 132, 157], ["pyknosis", "PROBLEM", 162, 170], ["karyolysis", "PROBLEM", 172, 182], ["necrotic debris", "PROBLEM", 188, 203], ["reduced", "OBSERVATION_MODIFIER", 41, 48], ["neuronal", "OBSERVATION_MODIFIER", 49, 57], ["necrosis", "OBSERVATION", 58, 66], ["hippocampal pyramidal cells", "OBSERVATION", 70, 97], ["reduction", "OBSERVATION_MODIFIER", 119, 128], ["hypereosinophilic neurons", "OBSERVATION", 132, 157], ["pyknosis", "OBSERVATION", 162, 170], ["necrotic", "OBSERVATION_MODIFIER", 188, 196], ["debris", "OBSERVATION", 197, 203]]], ["Furthermore, our data of quantitative analysis for perivascular cuffing of vessels also showed a significant decrease in both treatment groups (p = 0.0090 and p < 0.0001, respectively) (Fig. 6d) , further suggesting that fidaxomicin therapy indeed protects the ZIKV-infected brains from ZIKV infection and/ or ZIKV-induced pathologic changes.", [["perivascular", "ANATOMY", 51, 63], ["vessels", "ANATOMY", 75, 82], ["brains", "ANATOMY", 275, 281], ["fidaxomicin", "CHEMICAL", 221, 232], ["ZIKV-infected", "DISEASE", 261, 274], ["infection", "DISEASE", 292, 301], ["ZIKV", "CHEMICAL", 310, 314], ["fidaxomicin", "CHEMICAL", 221, 232], ["perivascular", "IMMATERIAL_ANATOMICAL_ENTITY", 51, 63], ["vessels", "MULTI-TISSUE_STRUCTURE", 75, 82], ["fidaxomicin", "SIMPLE_CHEMICAL", 221, 232], ["ZIKV", "GENE_OR_GENE_PRODUCT", 261, 265], ["brains", "ORGANISM", 275, 281], ["ZIKV", "GENE_OR_GENE_PRODUCT", 287, 291], ["ZIKV", "SPECIES", 261, 265], ["ZIKV", "SPECIES", 287, 291], ["ZIKV", "SPECIES", 310, 314], ["quantitative analysis", "TEST", 25, 46], ["perivascular cuffing of vessels", "PROBLEM", 51, 82], ["a significant decrease", "PROBLEM", 95, 117], ["fidaxomicin therapy", "TREATMENT", 221, 240], ["the ZIKV", "PROBLEM", 257, 265], ["infected brains", "PROBLEM", 266, 281], ["ZIKV infection", "PROBLEM", 287, 301], ["ZIKV", "PROBLEM", 310, 314], ["pathologic changes", "PROBLEM", 323, 341], ["perivascular", "ANATOMY_MODIFIER", 51, 63], ["cuffing", "OBSERVATION", 64, 71], ["vessels", "ANATOMY", 75, 82], ["significant", "OBSERVATION_MODIFIER", 97, 108], ["decrease", "OBSERVATION_MODIFIER", 109, 117], ["both", "OBSERVATION_MODIFIER", 121, 125], ["treatment", "OBSERVATION_MODIFIER", 126, 135], ["ZIKV infection", "OBSERVATION", 287, 301], ["pathologic", "OBSERVATION", 323, 333]]], ["Collectively, our findings demonstrated a potent in vivo therapeutic efficacy of fidaxomicin against ZIKV-induced disease in virusinfected mice.DiscussionThe key finding presented in our present report is that fidaxomicin, a currently clinically used macrocyclic antibacterial agent, is also an effective anti-ZIKV agent.", [["fidaxomicin", "CHEMICAL", 81, 92], ["ZIKV", "CHEMICAL", 101, 105], ["fidaxomicin", "CHEMICAL", 210, 221], ["fidaxomicin", "CHEMICAL", 81, 92], ["fidaxomicin", "CHEMICAL", 210, 221], ["fidaxomicin", "SIMPLE_CHEMICAL", 81, 92], ["ZIKV", "SIMPLE_CHEMICAL", 101, 105], ["mice", "ORGANISM", 139, 143], ["fidaxomicin", "SIMPLE_CHEMICAL", 210, 221], ["anti-ZIKV", "CANCER", 305, 314], ["mice", "SPECIES", 139, 143], ["ZIKV", "SPECIES", 101, 105], ["mice", "SPECIES", 139, 143], ["anti-ZIKV", "SPECIES", 305, 314], ["fidaxomicin", "TREATMENT", 81, 92], ["ZIKV", "PROBLEM", 101, 105], ["induced disease in virusinfected mice", "PROBLEM", 106, 143], ["fidaxomicin", "TREATMENT", 210, 221], ["macrocyclic antibacterial agent", "TREATMENT", 251, 282], ["an effective anti-ZIKV agent", "TREATMENT", 292, 320], ["potent", "OBSERVATION_MODIFIER", 42, 48]]], ["Such a notion is supported by several lines of evidence provided by our study.", [["our study", "TEST", 68, 77]]], ["Firstly, fidaxomicin directly binds ZIKV NS5 protein and inhibits its RdRp activity, which is essential for the replication of ZIKV genome and production of viral particles.", [["fidaxomicin", "CHEMICAL", 9, 20], ["fidaxomicin", "CHEMICAL", 9, 20], ["fidaxomicin", "SIMPLE_CHEMICAL", 9, 20], ["ZIKV NS5", "GENE_OR_GENE_PRODUCT", 36, 44], ["ZIKV", "GENE_OR_GENE_PRODUCT", 127, 131], ["fidaxomicin", "PROTEIN", 9, 20], ["ZIKV NS5 protein", "PROTEIN", 36, 52], ["RdRp", "PROTEIN", 70, 74], ["ZIKV genome", "DNA", 127, 138], ["ZIKV", "SPECIES", 127, 131], ["fidaxomicin", "TREATMENT", 9, 20], ["ZIKV NS5 protein", "TEST", 36, 52], ["its RdRp activity", "PROBLEM", 66, 83], ["ZIKV genome", "PROBLEM", 127, 138], ["viral particles", "PROBLEM", 157, 172], ["RdRp activity", "OBSERVATION", 70, 83], ["ZIKV genome", "OBSERVATION", 127, 138], ["viral particles", "OBSERVATION", 157, 172]]], ["Secondly, fidaxomicin is effective against multiple strains of ZIKV, including Asian and African strains, and potently inhibits ZIKV infection in a wide variety of cell lines of distinct tissue origins.", [["cell lines", "ANATOMY", 164, 174], ["tissue", "ANATOMY", 187, 193], ["fidaxomicin", "CHEMICAL", 10, 21], ["infection", "DISEASE", 133, 142], ["fidaxomicin", "CHEMICAL", 10, 21], ["fidaxomicin", "SIMPLE_CHEMICAL", 10, 21], ["ZIKV", "ORGANISM", 63, 67], ["ZIKV", "GENE_OR_GENE_PRODUCT", 128, 132], ["cell lines", "CELL", 164, 174], ["tissue", "TISSUE", 187, 193], ["cell lines", "CELL_LINE", 164, 174], ["ZIKV", "SPECIES", 63, 67], ["ZIKV", "SPECIES", 128, 132], ["fidaxomicin", "TREATMENT", 10, 21], ["ZIKV", "PROBLEM", 63, 67], ["African strains", "PROBLEM", 89, 104], ["ZIKV infection", "PROBLEM", 128, 142], ["ZIKV infection", "OBSERVATION", 128, 142], ["cell lines", "OBSERVATION", 164, 174], ["distinct tissue origins", "OBSERVATION", 178, 201]]], ["Thirdly, fidaxomicin effectively suppresses ZIKV infection in vivo and alleviates ZIKV-associated pathological damages in infected mice.", [["fidaxomicin", "CHEMICAL", 9, 20], ["infection", "DISEASE", 49, 58], ["ZIKV", "CHEMICAL", 82, 86], ["fidaxomicin", "CHEMICAL", 9, 20], ["fidaxomicin", "SIMPLE_CHEMICAL", 9, 20], ["ZIKV", "GENE_OR_GENE_PRODUCT", 44, 48], ["mice", "ORGANISM", 131, 135], ["mice", "SPECIES", 131, 135], ["ZIKV", "SPECIES", 44, 48], ["ZIKV", "SPECIES", 82, 86], ["mice", "SPECIES", 131, 135], ["fidaxomicin", "TREATMENT", 9, 20], ["ZIKV infection", "PROBLEM", 44, 58], ["ZIKV", "PROBLEM", 82, 86], ["pathological damages in infected mice", "PROBLEM", 98, 135], ["infected mice", "OBSERVATION", 122, 135]]], ["Most notably, fidaxomicin efficaciously inhibits ZIKV replication and robustly improves the survival of ZIKV-infected mice.", [["fidaxomicin", "CHEMICAL", 14, 25], ["fidaxomicin", "CHEMICAL", 14, 25], ["fidaxomicin", "SIMPLE_CHEMICAL", 14, 25], ["ZIKV", "CANCER", 49, 53], ["ZIKV", "GENE_OR_GENE_PRODUCT", 104, 108], ["mice", "ORGANISM", 118, 122], ["mice", "SPECIES", 118, 122], ["ZIKV", "SPECIES", 49, 53], ["ZIKV", "SPECIES", 104, 108], ["mice", "SPECIES", 118, 122], ["fidaxomicin", "TREATMENT", 14, 25], ["ZIKV replication", "PROBLEM", 49, 65], ["ZIKV", "PROBLEM", 104, 108]]], ["Fig. 4 Antiviral efficacy of fidaxomicin in vivo. a Schematic illustration of the animal experimental design for detecting the anti-ZIKV (ZG-01) efficacy of fidaxomicin in vivo (n = 12-13 animals per group).", [["fidaxomicin", "CHEMICAL", 29, 40], ["ZG-01", "CHEMICAL", 138, 143], ["fidaxomicin", "CHEMICAL", 157, 168], ["fidaxomicin", "CHEMICAL", 29, 40], ["fidaxomicin", "CHEMICAL", 157, 168], ["fidaxomicin", "SIMPLE_CHEMICAL", 29, 40], ["ZG-01", "CELL", 138, 143], ["fidaxomicin", "SIMPLE_CHEMICAL", 157, 168], ["fidaxomicin", "TREATMENT", 29, 40], ["the anti-ZIKV (ZG", "TREATMENT", 123, 140], ["fidaxomicin", "TREATMENT", 157, 168]]], ["Each mouse was infected by 2 \u00d7 10 4 PFU of ZIKV. b The Kaplan-Meier survival of ZIKV-infected mice treated with fidaxomicin at the indicated dosages or with control vehicle. c Changes in animal body weight were calculated daily for ZIKV-infected mice treated with fidaxomicin at the indicated dosages or with control vehicle. d, e Tissue viral loads in the brains (d) and testes (e) of ZIKV-infected mice were determined by RT-qPCR (p value, compared to the vehicle-control group). f-h Neurological symptoms of ZIKV-infected mice observed in the vehicle-control group (f) or in the fidaxomicin treatment groups (g, h) were assessed at indicated dpi.", [["body", "ANATOMY", 194, 198], ["Tissue", "ANATOMY", 331, 337], ["brains", "ANATOMY", 357, 363], ["testes", "ANATOMY", 372, 378], ["ZIKV", "CHEMICAL", 43, 47], ["ZIKV-infected", "DISEASE", 80, 93], ["fidaxomicin", "CHEMICAL", 112, 123], ["fidaxomicin", "CHEMICAL", 264, 275], ["ZIKV-infected", "DISEASE", 511, 524], ["fidaxomicin", "CHEMICAL", 582, 593], ["fidaxomicin", "CHEMICAL", 112, 123], ["fidaxomicin", "CHEMICAL", 264, 275], ["fidaxomicin", "CHEMICAL", 582, 593], ["mouse", "ORGANISM", 5, 10], ["ZIKV", "ORGANISM", 43, 47], ["ZIKV", "ORGANISM", 80, 84], ["mice", "ORGANISM", 94, 98], ["fidaxomicin", "SIMPLE_CHEMICAL", 112, 123], ["body", "ORGANISM_SUBDIVISION", 194, 198], ["mice", "ORGANISM", 246, 250], ["fidaxomicin", "SIMPLE_CHEMICAL", 264, 275], ["Tissue viral", "ORGANISM", 331, 343], ["brains", "ORGAN", 357, 363], ["testes", "ORGAN", 372, 378], ["ZIKV", "GENE_OR_GENE_PRODUCT", 386, 390], ["mice", "ORGANISM", 400, 404], ["ZIKV", "ORGANISM", 511, 515], ["mice", "ORGANISM", 525, 529], ["fidaxomicin", "SIMPLE_CHEMICAL", 582, 593], ["mouse", "SPECIES", 5, 10], ["mice", "SPECIES", 94, 98], ["mice", "SPECIES", 246, 250], ["mice", "SPECIES", 400, 404], ["mice", "SPECIES", 525, 529], ["mouse", "SPECIES", 5, 10], ["ZIKV", "SPECIES", 43, 47], ["ZIKV", "SPECIES", 80, 84], ["mice", "SPECIES", 94, 98], ["ZIKV", "SPECIES", 232, 236], ["mice", "SPECIES", 246, 250], ["ZIKV", "SPECIES", 386, 390], ["mice", "SPECIES", 400, 404], ["ZIKV", "SPECIES", 511, 515], ["mice", "SPECIES", 525, 529], ["ZIKV", "PROBLEM", 43, 47], ["ZIKV", "PROBLEM", 80, 84], ["fidaxomicin", "TREATMENT", 112, 123], ["animal body weight", "TEST", 187, 205], ["ZIKV", "PROBLEM", 232, 236], ["fidaxomicin", "TREATMENT", 264, 275], ["e Tissue viral loads", "TEST", 329, 349], ["ZIKV", "PROBLEM", 386, 390], ["infected mice", "PROBLEM", 391, 404], ["qPCR", "TEST", 427, 431], ["p value", "TEST", 433, 440], ["Neurological symptoms", "PROBLEM", 486, 507], ["ZIKV", "PROBLEM", 511, 515], ["infected mice", "PROBLEM", 516, 529], ["the fidaxomicin treatment groups", "TREATMENT", 578, 610], ["infected", "OBSERVATION", 15, 23], ["ZIKV", "OBSERVATION", 43, 47], ["e Tissue", "OBSERVATION_MODIFIER", 329, 337], ["viral loads", "OBSERVATION", 338, 349], ["brains", "ANATOMY", 357, 363], ["testes", "ANATOMY", 372, 378]]], ["Each mouse was assigned with dead (euthanized or dead), paralyzed (dragging rear legs and/or blind), hunched (ruffled coat, hunched, and/or moving slowly), or no disease in the process of experiment.", [["legs", "ANATOMY", 81, 85], ["mouse", "ORGANISM", 5, 10], ["legs", "ORGANISM_SUBDIVISION", 81, 85], ["mouse", "SPECIES", 5, 10], ["mouse", "SPECIES", 5, 10], ["blind", "PROBLEM", 93, 98], ["disease", "PROBLEM", 162, 169], ["no", "UNCERTAINTY", 159, 161], ["disease", "OBSERVATION", 162, 169]]], ["Data represent results from three independent experiments Fig. 5 Fidaxomicin suppresses ZIKV infection in the brains and testes of ZIKV-infected mice. a, b Representative images of immunofluorescence staining for ZIKV protein (ZIKV E; red) and nuclei (with DAPI; blue) on the cerebra (a) and on the testes (b) obtained from ZIKV-infected mice treated with control vehicle or with fidaxomicin at the indicated dosages (scale bar = 200 \u03bcm).", [["brains", "ANATOMY", 110, 116], ["testes", "ANATOMY", 121, 127], ["nuclei", "ANATOMY", 244, 250], ["cerebra", "ANATOMY", 276, 283], ["testes", "ANATOMY", 299, 305], ["Fidaxomicin", "CHEMICAL", 65, 76], ["infection", "DISEASE", 93, 102], ["fidaxomicin", "CHEMICAL", 380, 391], ["Fidaxomicin", "CHEMICAL", 65, 76], ["DAPI", "CHEMICAL", 257, 261], ["fidaxomicin", "CHEMICAL", 380, 391], ["Fidaxomicin", "GENE_OR_GENE_PRODUCT", 65, 76], ["ZIKV", "GENE_OR_GENE_PRODUCT", 88, 92], ["brains", "ORGAN", 110, 116], ["testes", "ORGAN", 121, 127], ["ZIKV", "GENE_OR_GENE_PRODUCT", 131, 135], ["mice", "ORGANISM", 145, 149], ["ZIKV", "GENE_OR_GENE_PRODUCT", 213, 217], ["ZIKV E; red)", "GENE_OR_GENE_PRODUCT", 227, 239], ["nuclei", "CELLULAR_COMPONENT", 244, 250], ["DAPI", "SIMPLE_CHEMICAL", 257, 261], ["cerebra", "CANCER", 276, 283], ["testes", "ORGAN", 299, 305], ["ZIKV", "GENE_OR_GENE_PRODUCT", 324, 328], ["mice", "ORGANISM", 338, 342], ["fidaxomicin", "SIMPLE_CHEMICAL", 380, 391], ["ZIKV protein", "PROTEIN", 213, 225], ["ZIKV E", "PROTEIN", 227, 233], ["red", "PROTEIN", 235, 238], ["mice", "SPECIES", 145, 149], ["mice", "SPECIES", 338, 342], ["ZIKV", "SPECIES", 88, 92], ["ZIKV", "SPECIES", 131, 135], ["mice", "SPECIES", 145, 149], ["ZIKV", "SPECIES", 324, 328], ["mice", "SPECIES", 338, 342], ["Fidaxomicin", "TREATMENT", 65, 76], ["ZIKV infection in the brains", "PROBLEM", 88, 116], ["ZIKV", "PROBLEM", 131, 135], ["immunofluorescence staining", "TEST", 181, 208], ["ZIKV protein", "TEST", 213, 225], ["ZIKV", "PROBLEM", 324, 328], ["control vehicle", "TREATMENT", 356, 371], ["fidaxomicin", "TREATMENT", 380, 391], ["ZIKV infection", "OBSERVATION", 88, 102], ["brains", "ANATOMY", 110, 116], ["testes", "ANATOMY", 121, 127], ["ZIKV", "OBSERVATION", 131, 135], ["infected mice", "OBSERVATION", 136, 149], ["nuclei", "ANATOMY", 244, 250], ["testes", "ANATOMY", 299, 305]]], ["The marks, such as F158 and M159, are the unique numbers to identify each mouse during the experimental process. c, e Western blotting of the expression of ZIKV E protein in brain tissues (c) and in testis tissues (e) from ZIKV-infected mice. d, f Quantification of ZIKV E protein band intensities, normalized with mGAPDH (p value, compared to vehicle control) fidaxomicin treatment of ZIKV-infected mice significantly attenuates the symptoms in the central nervous system (CNS) caused by ZIKV infection, such as paralysis and hunching.", [["brain tissues", "ANATOMY", 174, 187], ["testis tissues", "ANATOMY", 199, 213], ["central nervous system", "ANATOMY", 450, 472], ["CNS", "ANATOMY", 474, 477], ["fidaxomicin", "CHEMICAL", 361, 372], ["ZIKV", "CHEMICAL", 386, 390], ["infection", "DISEASE", 494, 503], ["paralysis", "DISEASE", 513, 522], ["fidaxomicin", "CHEMICAL", 361, 372], ["mouse", "ORGANISM", 74, 79], ["ZIKV E", "GENE_OR_GENE_PRODUCT", 156, 162], ["brain tissues", "TISSUE", 174, 187], ["testis tissues", "TISSUE", 199, 213], ["ZIKV", "GENE_OR_GENE_PRODUCT", 223, 227], ["mice", "ORGANISM", 237, 241], ["ZIKV E", "GENE_OR_GENE_PRODUCT", 266, 272], ["mGAPDH", "SIMPLE_CHEMICAL", 315, 321], ["fidaxomicin", "SIMPLE_CHEMICAL", 361, 372], ["ZIKV", "ORGANISM", 386, 390], ["mice", "ORGANISM", 400, 404], ["central nervous system", "ANATOMICAL_SYSTEM", 450, 472], ["CNS", "ANATOMICAL_SYSTEM", 474, 477], ["F158", "DNA", 19, 23], ["ZIKV E protein", "PROTEIN", 156, 170], ["mGAPDH", "PROTEIN", 315, 321], ["mouse", "SPECIES", 74, 79], ["mice", "SPECIES", 237, 241], ["mice", "SPECIES", 400, 404], ["mouse", "SPECIES", 74, 79], ["ZIKV", "SPECIES", 223, 227], ["mice", "SPECIES", 237, 241], ["ZIKV", "SPECIES", 386, 390], ["mice", "SPECIES", 400, 404], ["ZIKV", "SPECIES", 489, 493], ["ZIKV E protein in brain tissues (c) and in testis tissues", "PROBLEM", 156, 213], ["ZIKV", "PROBLEM", 223, 227], ["ZIKV E protein band intensities", "TEST", 266, 297], ["mGAPDH", "PROBLEM", 315, 321], ["fidaxomicin treatment", "TREATMENT", 361, 382], ["ZIKV", "PROBLEM", 386, 390], ["the symptoms", "PROBLEM", 430, 442], ["ZIKV infection", "PROBLEM", 489, 503], ["paralysis", "PROBLEM", 513, 522], ["hunching", "PROBLEM", 527, 535], ["ZIKV", "OBSERVATION", 156, 160], ["brain tissues", "ANATOMY", 174, 187], ["testis tissues", "ANATOMY", 199, 213], ["central", "ANATOMY_MODIFIER", 450, 457], ["nervous system", "ANATOMY", 458, 472], ["CNS", "ANATOMY", 474, 477], ["ZIKV infection", "OBSERVATION", 489, 503], ["paralysis", "OBSERVATION", 513, 522]]], ["In the light that ZIKV represents a currently serious threat to global health and that fidaxomicin is already an approved clinical drug, our finding may offer a novel strategy for the control of ZIKV infection in involved individuals and the population.DiscussionIt is noteworthy though that as a clinically used therapeutic agent for C. difficile-associated diarrhea approved by the US FDA and counterpart agencies of several other countries [51] , fidaxomicin is an orally administered drug.", [["ZIKV", "CHEMICAL", 18, 22], ["fidaxomicin", "CHEMICAL", 87, 98], ["infection", "DISEASE", 200, 209], ["C. difficile", "DISEASE", 335, 347], ["diarrhea", "DISEASE", 359, 367], ["fidaxomicin", "CHEMICAL", 450, 461], ["fidaxomicin", "CHEMICAL", 87, 98], ["fidaxomicin", "CHEMICAL", 450, 461], ["fidaxomicin", "SIMPLE_CHEMICAL", 87, 98], ["ZIKV", "ORGANISM", 195, 199], ["C. difficile", "ORGANISM", 335, 347], ["fidaxomicin", "SIMPLE_CHEMICAL", 450, 461], ["C. difficile", "SPECIES", 335, 347], ["ZIKV", "SPECIES", 18, 22], ["ZIKV", "SPECIES", 195, 199], ["C. difficile", "SPECIES", 335, 347], ["ZIKV", "PROBLEM", 18, 22], ["fidaxomicin", "TREATMENT", 87, 98], ["a novel strategy", "TREATMENT", 159, 175], ["ZIKV infection", "PROBLEM", 195, 209], ["therapeutic agent", "TREATMENT", 313, 330], ["C. difficile", "PROBLEM", 335, 347], ["diarrhea", "PROBLEM", 359, 367], ["fidaxomicin", "TREATMENT", 450, 461], ["ZIKV", "OBSERVATION", 18, 22]]], ["According to pharmacokinetic studies, it is minimally absorbed through the gastrointestinal (GI) tract upon oral administration, and the resultant plasma concentration ranges within nanogram-per-milliliter scale Fig. 6 Fidaxomicin attenuates ZIKV-induced brain lesions. a Representative H/E staining of the cerebra specimens obtained from the mock infection group, the vehicle-control group, the 10 mg/kg fidaxomicin treatment group, and the 20 mg/kg fidaxomicin treatment group, respectively.", [["gastrointestinal", "ANATOMY", 75, 91], ["GI", "ANATOMY", 93, 95], ["oral", "ANATOMY", 108, 112], ["plasma", "ANATOMY", 147, 153], ["brain lesions", "ANATOMY", 255, 268], ["cerebra specimens", "ANATOMY", 307, 324], ["gastrointestinal (GI) tract", "DISEASE", 75, 102], ["Fidaxomicin", "CHEMICAL", 219, 230], ["ZIKV", "CHEMICAL", 242, 246], ["brain lesions", "DISEASE", 255, 268], ["infection", "DISEASE", 348, 357], ["fidaxomicin", "CHEMICAL", 405, 416], ["fidaxomicin", "CHEMICAL", 451, 462], ["Fidaxomicin", "CHEMICAL", 219, 230], ["fidaxomicin", "CHEMICAL", 405, 416], ["fidaxomicin", "CHEMICAL", 451, 462], ["gastrointestinal", "ORGANISM_SUBDIVISION", 75, 91], ["GI", "ORGANISM_SUBDIVISION", 93, 95], ["tract", "ORGANISM_SUBDIVISION", 97, 102], ["oral", "ORGANISM_SUBDIVISION", 108, 112], ["plasma", "ORGANISM_SUBSTANCE", 147, 153], ["Fidaxomicin", "SIMPLE_CHEMICAL", 219, 230], ["ZIKV", "GENE_OR_GENE_PRODUCT", 242, 246], ["brain lesions", "PATHOLOGICAL_FORMATION", 255, 268], ["cerebra specimens", "CANCER", 307, 324], ["fidaxomicin", "SIMPLE_CHEMICAL", 405, 416], ["fidaxomicin", "SIMPLE_CHEMICAL", 451, 462], ["ZIKV", "SPECIES", 242, 246], ["pharmacokinetic studies", "TEST", 13, 36], ["oral administration", "TREATMENT", 108, 127], ["the resultant plasma concentration", "TEST", 133, 167], ["nanogram", "TEST", 182, 190], ["Fidaxomicin", "TREATMENT", 219, 230], ["induced brain lesions", "PROBLEM", 247, 268], ["a Representative H/E staining", "TEST", 270, 299], ["the cerebra specimens", "TEST", 303, 324], ["fidaxomicin treatment group", "TREATMENT", 405, 432], ["fidaxomicin treatment group", "TREATMENT", 451, 478], ["gastrointestinal", "ANATOMY", 75, 91], ["brain", "ANATOMY", 255, 260], ["lesions", "OBSERVATION", 261, 268], ["infection", "OBSERVATION", 348, 357]]], ["Cerebra specimens were collected on the day of death or at the experimental endpoint.", [["Cerebra specimens", "ANATOMY", 0, 17], ["death", "DISEASE", 47, 52], ["Cerebra specimens", "CANCER", 0, 17], ["Cerebra specimens", "TEST", 0, 17]]], ["The perivascular infiltrates of mononuclear cells (\"perivascular cuffing\") are indicated by black triangles. b Magnified images of the boxed areas in a, respectively.", [["perivascular infiltrates", "ANATOMY", 4, 28], ["mononuclear cells", "ANATOMY", 32, 49], ["perivascular cuffing", "ANATOMY", 52, 72], ["perivascular infiltrates", "CELL", 4, 28], ["mononuclear cells", "CELL", 32, 49], ["mononuclear cells", "CELL_TYPE", 32, 49], ["The perivascular infiltrates of mononuclear cells", "PROBLEM", 0, 49], ["black triangles", "PROBLEM", 92, 107], ["Magnified images", "TEST", 111, 127], ["perivascular", "ANATOMY_MODIFIER", 4, 16], ["infiltrates", "OBSERVATION", 17, 28], ["mononuclear cells", "OBSERVATION", 32, 49], ["perivascular", "ANATOMY_MODIFIER", 52, 64], ["cuffing", "OBSERVATION", 65, 72], ["black triangles", "OBSERVATION", 92, 107]]], ["Black triangles show the perivascular cuffing; scale bar represents 500 \u03bcm. c Magnified images of the boxed areas in b, respectively.", [["perivascular", "ANATOMY", 25, 37], ["the perivascular cuffing", "PROBLEM", 21, 45], ["Magnified images", "TEST", 78, 94], ["perivascular", "ANATOMY_MODIFIER", 25, 37], ["cuffing", "OBSERVATION", 38, 45], ["scale bar", "OBSERVATION", 47, 56], ["500 \u03bcm", "OBSERVATION_MODIFIER", 68, 74]]], ["Red circles show the neuronal necrosis, and black triangles show the perivascular cuffing; scale bar represents 100 \u03bcm. d Quantification of the perivascular cuffing in whole cerebra tissue slices of the vehicle-control group and the fidaxomicin treatment groups (p value, compared to vehicle control) [52] .", [["neuronal", "ANATOMY", 21, 29], ["perivascular", "ANATOMY", 69, 81], ["perivascular", "ANATOMY", 144, 156], ["whole cerebra tissue slices", "ANATOMY", 168, 195], ["neuronal necrosis", "DISEASE", 21, 38], ["fidaxomicin", "CHEMICAL", 233, 244], ["fidaxomicin", "CHEMICAL", 233, 244], ["neuronal", "CELL", 21, 29], ["perivascular", "IMMATERIAL_ANATOMICAL_ENTITY", 144, 156], ["cerebra tissue slices", "TISSUE", 174, 195], ["fidaxomicin", "SIMPLE_CHEMICAL", 233, 244], ["Red circles", "TEST", 0, 11], ["the neuronal necrosis", "PROBLEM", 17, 38], ["black triangles", "PROBLEM", 44, 59], ["the perivascular cuffing", "PROBLEM", 65, 89], ["the perivascular cuffing", "PROBLEM", 140, 164], ["the fidaxomicin treatment groups", "TREATMENT", 229, 261], ["p value", "TEST", 263, 270], ["circles", "OBSERVATION_MODIFIER", 4, 11], ["neuronal", "OBSERVATION_MODIFIER", 21, 29], ["necrosis", "OBSERVATION", 30, 38], ["black triangles", "OBSERVATION", 44, 59], ["perivascular", "ANATOMY_MODIFIER", 69, 81], ["cuffing", "OBSERVATION", 82, 89], ["scale bar", "OBSERVATION", 91, 100], ["100 \u03bcm", "OBSERVATION_MODIFIER", 112, 118], ["perivascular", "ANATOMY_MODIFIER", 144, 156], ["cuffing", "OBSERVATION", 157, 164], ["whole", "ANATOMY_MODIFIER", 168, 173], ["cerebra tissue", "ANATOMY_MODIFIER", 174, 188]]], ["On the other hand, as ZIKV infection is mostly a systemic disease involving multiple organs and systems [19, 53] , antiviral therapy against ZIKV infection requires systematic treatment.", [["organs", "ANATOMY", 85, 91], ["infection", "DISEASE", 27, 36], ["ZIKV infection", "DISEASE", 141, 155], ["organs", "ORGAN", 85, 91], ["ZIKV", "ORGANISM", 141, 145], ["ZIKV", "SPECIES", 22, 26], ["ZIKV", "SPECIES", 141, 145], ["ZIKV infection", "PROBLEM", 22, 36], ["a systemic disease involving multiple organs and systems", "PROBLEM", 47, 103], ["antiviral therapy", "TREATMENT", 115, 132], ["ZIKV infection", "PROBLEM", 141, 155], ["systematic treatment", "TREATMENT", 165, 185], ["infection", "OBSERVATION", 27, 36], ["systemic", "OBSERVATION_MODIFIER", 49, 57], ["disease", "OBSERVATION", 58, 65]]], ["Notably, while our animal experiments showed that orally administered fidaxomicin only weakly antagonizes ZIKV infection, presumably due to the poor GI absorption, intravenous injection of fidaxomicin exhibited potent anti-ZIKV therapeutic effect.", [["GI", "ANATOMY", 149, 151], ["intravenous", "ANATOMY", 164, 175], ["fidaxomicin", "CHEMICAL", 70, 81], ["infection", "DISEASE", 111, 120], ["fidaxomicin", "CHEMICAL", 189, 200], ["fidaxomicin", "CHEMICAL", 70, 81], ["fidaxomicin", "CHEMICAL", 189, 200], ["fidaxomicin", "SIMPLE_CHEMICAL", 70, 81], ["ZIKV", "GENE_OR_GENE_PRODUCT", 106, 110], ["GI", "ORGANISM_SUBDIVISION", 149, 151], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 164, 175], ["fidaxomicin", "SIMPLE_CHEMICAL", 189, 200], ["anti-ZIKV", "CANCER", 218, 227], ["ZIKV", "SPECIES", 106, 110], ["fidaxomicin", "TREATMENT", 70, 81], ["weakly antagonizes ZIKV infection", "PROBLEM", 87, 120], ["the poor GI absorption", "PROBLEM", 140, 162], ["intravenous injection", "TREATMENT", 164, 185], ["fidaxomicin", "TREATMENT", 189, 200], ["potent anti-ZIKV therapeutic effect", "TREATMENT", 211, 246]]], ["Of particular note, the effective therapeutic doses of fidaxomicin against ZIKV (10-20 mg/kg) are much lower than the maximum non-toxic dose (> 200 mg/kg) in mice and the No Observed Adverse Effect Level (NOAEL) of the drug in rats (62.5 mg/kg) [54] , providing a possibly tolerable safety profile for future application of this agent as a clinical anti-ZIKV drug.", [["fidaxomicin", "CHEMICAL", 55, 66], ["ZIKV", "CHEMICAL", 75, 79], ["fidaxomicin", "CHEMICAL", 55, 66], ["ZIKV", "CHEMICAL", 75, 79], ["fidaxomicin", "SIMPLE_CHEMICAL", 55, 66], ["ZIKV", "SIMPLE_CHEMICAL", 75, 79], ["mice", "ORGANISM", 158, 162], ["rats", "ORGANISM", 227, 231], ["anti-ZIKV", "SIMPLE_CHEMICAL", 349, 358], ["mice", "SPECIES", 158, 162], ["rats", "SPECIES", 227, 231], ["ZIKV", "SPECIES", 75, 79], ["mice", "SPECIES", 158, 162], ["anti-ZIKV", "SPECIES", 349, 358], ["fidaxomicin", "TREATMENT", 55, 66], ["ZIKV", "TREATMENT", 75, 79], ["the maximum non-toxic dose", "TREATMENT", 114, 140], ["the drug in rats", "TREATMENT", 215, 231], ["this agent", "TREATMENT", 324, 334], ["a clinical anti-ZIKV drug", "TREATMENT", 338, 363]]], ["In this context, further effort in implementing pre-clinical and human testing for i.v. application of the agent is needed in future investigation.", [["human", "ORGANISM", 65, 70], ["human", "SPECIES", 65, 70], ["human", "SPECIES", 65, 70], ["pre-clinical and human testing", "TEST", 48, 78], ["the agent", "TREATMENT", 103, 112], ["future investigation", "TEST", 126, 146]]], ["Alternatively, it is also of worth investigating whether modification of the oral dosage form of fidaxomicin could improve the intestinal absorption so that oral administration might remain effective against ZIKV infection in humans.", [["oral", "ANATOMY", 77, 81], ["intestinal", "ANATOMY", 127, 137], ["oral", "ANATOMY", 157, 161], ["fidaxomicin", "CHEMICAL", 97, 108], ["infection", "DISEASE", 213, 222], ["fidaxomicin", "CHEMICAL", 97, 108], ["oral", "ORGANISM_SUBDIVISION", 77, 81], ["fidaxomicin", "SIMPLE_CHEMICAL", 97, 108], ["intestinal", "ORGAN", 127, 137], ["oral", "ORGANISM_SUBDIVISION", 157, 161], ["ZIKV", "ORGANISM", 208, 212], ["humans", "ORGANISM", 226, 232], ["humans", "SPECIES", 226, 232], ["ZIKV", "SPECIES", 208, 212], ["humans", "SPECIES", 226, 232], ["the oral dosage", "TREATMENT", 73, 88], ["fidaxomicin", "TREATMENT", 97, 108], ["the intestinal absorption", "PROBLEM", 123, 148], ["oral administration", "TREATMENT", 157, 176], ["ZIKV infection in humans", "PROBLEM", 208, 232], ["intestinal", "ANATOMY", 127, 137]]], ["Moreover, the design of administration employed in our current study was aimed to provide a proof-of-concept basis for future further pre-clinical as well as clinical testing.", [["clinical testing", "TEST", 158, 174]]], ["Considering the clinical characteristics of ZIKV, mostly asymptomatic infection or mild, postponing the beginning of fidaxomicin treatment to a more opportune time is certainly necessary when a more comprehensive pre-clinical trial is implemented.DiscussionThe lack of drugs treating ZIKV infection, particularly those cases giving rise to newborn microencephaly, has prompted active searches for anti-ZIKV candidate compounds.", [["ZIKV", "DISEASE", 44, 48], ["infection", "DISEASE", 70, 79], ["fidaxomicin", "CHEMICAL", 117, 128], ["ZIKV infection", "DISEASE", 284, 298], ["microencephaly", "DISEASE", 348, 362], ["fidaxomicin", "CHEMICAL", 117, 128], ["ZIKV", "ORGANISM", 44, 48], ["fidaxomicin", "SIMPLE_CHEMICAL", 117, 128], ["ZIKV", "ORGANISM", 284, 288], ["ZIKV", "SPECIES", 44, 48], ["ZIKV", "SPECIES", 284, 288], ["anti-ZIKV", "SPECIES", 397, 406], ["ZIKV", "PROBLEM", 44, 48], ["mostly asymptomatic infection", "PROBLEM", 50, 79], ["fidaxomicin treatment", "TREATMENT", 117, 138], ["drugs", "TREATMENT", 269, 274], ["ZIKV infection", "PROBLEM", 284, 298], ["newborn microencephaly", "PROBLEM", 340, 362], ["anti-ZIKV candidate compounds", "TREATMENT", 397, 426], ["ZIKV", "OBSERVATION", 44, 48], ["asymptomatic", "OBSERVATION_MODIFIER", 57, 69], ["infection", "OBSERVATION", 70, 79], ["mild", "OBSERVATION_MODIFIER", 83, 87]]], ["Compounds identified by previous studies to possess anti-ZIKV activities include those that had been shown to be able to suppress the replication of other flaviviruses, such as sofosbuvir [55, 56] , ribavirin [49] , 4-HPR [57] , 7-deaza-2\u2032-C-methyladenosine [58] , and NITD008 [59] .", [["sofosbuvir", "CHEMICAL", 177, 187], ["ribavirin", "CHEMICAL", 199, 208], ["4-HPR [57] , 7-deaza-2\u2032-C-methyladenosine", "CHEMICAL", 216, 257], ["NITD008", "CHEMICAL", 269, 276], ["sofosbuvir", "CHEMICAL", 177, 187], ["ribavirin", "CHEMICAL", 199, 208], ["4-HPR [57] , 7-deaza-2\u2032-C-methyladenosine", "CHEMICAL", 216, 257], ["NITD008", "CHEMICAL", 269, 276], ["anti-ZIKV", "GENE_OR_GENE_PRODUCT", 52, 61], ["sofosbuvir", "SIMPLE_CHEMICAL", 177, 187], ["ribavirin", "SIMPLE_CHEMICAL", 199, 208], ["4-HPR [57] , 7-deaza-2\u2032-C-methyladenosine", "SIMPLE_CHEMICAL", 216, 257], ["previous studies", "TEST", 24, 40], ["other flaviviruses", "PROBLEM", 149, 167], ["sofosbuvir", "TREATMENT", 177, 187], ["ribavirin", "TREATMENT", 199, 208], ["-deaza", "TEST", 230, 236]]], ["In addition, chemicals previously unknown to have any antiviral function were also obtained from anti-ZIKV compound searches, such as niclosamide [60] and daptomycin [23] , whose mechanism and in vivo anti-ZIKV effect remain unclear.", [["niclosamide", "CHEMICAL", 134, 145], ["daptomycin", "CHEMICAL", 155, 165], ["niclosamide", "CHEMICAL", 134, 145], ["daptomycin", "CHEMICAL", 155, 165], ["niclosamide [60]", "SIMPLE_CHEMICAL", 134, 150], ["daptomycin [23]", "SIMPLE_CHEMICAL", 155, 170], ["anti-ZIKV", "SPECIES", 97, 106], ["any antiviral function", "PROBLEM", 50, 72], ["niclosamide", "TREATMENT", 134, 145], ["daptomycin", "TREATMENT", 155, 165], ["vivo anti-ZIKV effect", "TREATMENT", 196, 217]]], ["As a newly found inhibitor of RdRp, the molecular structure of fidaxomicin is remarkably distinct from those of previously identified RdRp inhibitors.", [["fidaxomicin", "CHEMICAL", 63, 74], ["fidaxomicin", "CHEMICAL", 63, 74], ["RdRp", "GENE_OR_GENE_PRODUCT", 30, 34], ["fidaxomicin", "SIMPLE_CHEMICAL", 63, 74], ["RdRp", "PROTEIN", 30, 34], ["a newly found inhibitor of RdRp", "PROBLEM", 3, 34], ["fidaxomicin", "TREATMENT", 63, 74], ["RdRp inhibitors", "TREATMENT", 134, 149], ["fidaxomicin", "OBSERVATION", 63, 74], ["distinct", "OBSERVATION_MODIFIER", 89, 97], ["RdRp inhibitors", "OBSERVATION", 134, 149]]], ["Unlike traditional nucleoside or non-nucleoside RdRp inhibitors, fidaxomicin is a large macrocyclic molecule, and the residues of RdRp key to fidaxomicin binding are putatively located in a crucial functional domain of the enzyme, which might block the initiation of synthesis of ZIKV RNA.", [["nucleoside", "CHEMICAL", 19, 29], ["fidaxomicin", "CHEMICAL", 65, 76], ["fidaxomicin", "CHEMICAL", 142, 153], ["nucleoside", "CHEMICAL", 19, 29], ["fidaxomicin", "CHEMICAL", 65, 76], ["fidaxomicin", "CHEMICAL", 142, 153], ["nucleoside", "SIMPLE_CHEMICAL", 19, 29], ["fidaxomicin", "SIMPLE_CHEMICAL", 65, 76], ["fidaxomicin", "GENE_OR_GENE_PRODUCT", 142, 153], ["ZIKV", "GENE_OR_GENE_PRODUCT", 280, 284], ["RdRp", "PROTEIN", 130, 134], ["enzyme", "PROTEIN", 223, 229], ["ZIKV RNA", "RNA", 280, 288], ["ZIKV", "SPECIES", 280, 284], ["traditional nucleoside", "TREATMENT", 7, 29], ["non-nucleoside RdRp inhibitors", "TREATMENT", 33, 63], ["fidaxomicin", "TREATMENT", 65, 76], ["a large macrocyclic molecule", "PROBLEM", 80, 108], ["RdRp", "TREATMENT", 130, 134], ["fidaxomicin binding", "TREATMENT", 142, 161], ["synthesis of ZIKV RNA", "PROBLEM", 267, 288], ["large", "OBSERVATION_MODIFIER", 82, 87], ["macrocyclic molecule", "OBSERVATION", 88, 108], ["ZIKV RNA", "OBSERVATION", 280, 288]]], ["Interestingly, in the light that RdRp is fairly conserved among members of the Flavivirus genus, it would be worthwhile to test in future studies whether fidaxomicin also has the capacity of suppressing RdRp of other flaviviruses than ZIKV and inhibiting their replication.", [["fidaxomicin", "CHEMICAL", 154, 165], ["fidaxomicin", "CHEMICAL", 154, 165], ["RdRp", "GENE_OR_GENE_PRODUCT", 33, 37], ["Flavivirus genus", "ORGANISM", 79, 95], ["fidaxomicin", "SIMPLE_CHEMICAL", 154, 165], ["RdRp", "PROTEIN", 33, 37], ["RdRp", "PROTEIN", 203, 207], ["ZIKV", "SPECIES", 235, 239], ["the Flavivirus genus", "PROBLEM", 75, 95], ["fidaxomicin", "TREATMENT", 154, 165], ["other flaviviruses", "PROBLEM", 211, 229], ["ZIKV", "PROBLEM", 235, 239]]], ["Indeed, our study also detected an inhibition of dengue virus by fidaxomicin (Additional file 1: Table S6 ) and affinity between fidaxomicin and DENV2 NS5 protein (Additional file 1: Fig. S6 ).", [["dengue", "DISEASE", 49, 55], ["fidaxomicin", "CHEMICAL", 65, 76], ["fidaxomicin", "CHEMICAL", 129, 140], ["fidaxomicin", "CHEMICAL", 65, 76], ["dengue virus", "ORGANISM", 49, 61], ["fidaxomicin", "SIMPLE_CHEMICAL", 65, 76], ["fidaxomicin", "SIMPLE_CHEMICAL", 129, 140], ["DENV2", "ORGANISM", 145, 150], ["S6", "PROTEIN", 103, 105], ["fidaxomicin", "PROTEIN", 129, 140], ["DENV2 NS5 protein", "PROTEIN", 145, 162], ["S6", "PROTEIN", 188, 190], ["dengue virus", "SPECIES", 49, 61], ["DENV2", "SPECIES", 145, 150], ["our study", "TEST", 8, 17], ["dengue virus", "PROBLEM", 49, 61], ["fidaxomicin", "TREATMENT", 65, 76], ["fidaxomicin", "TREATMENT", 129, 140], ["DENV2 NS5 protein", "TREATMENT", 145, 162]]], ["Further investigation in this context is therefore needed to confirm whether the antiviral effects can be translated to other related viruses and to new flaviviruses that may emerge in the future.ConclusionsIn summary, our findings demonstrate that a clinically in-use antibacterial drug, fidaxomicin, potently inhibits ZIKV infection both in vitro and in vivo through directly targeting an essential ZIKV non-structural protein, NS5 RdRp, robustly alleviating neurologic lesions in the CNS caused by ZIKV and preventing infected mice from morbidity.", [["neurologic lesions", "ANATOMY", 461, 479], ["CNS", "ANATOMY", 487, 490], ["flaviviruses", "DISEASE", 153, 165], ["fidaxomicin", "CHEMICAL", 289, 300], ["infection", "DISEASE", 325, 334], ["neurologic lesions", "DISEASE", 461, 479], ["ZIKV", "CHEMICAL", 501, 505], ["fidaxomicin", "CHEMICAL", 289, 300], ["fidaxomicin", "SIMPLE_CHEMICAL", 289, 300], ["ZIKV", "GENE_OR_GENE_PRODUCT", 320, 324], ["ZIKV", "GENE_OR_GENE_PRODUCT", 401, 405], ["NS5", "GENE_OR_GENE_PRODUCT", 430, 433], ["neurologic lesions", "PATHOLOGICAL_FORMATION", 461, 479], ["CNS", "ANATOMICAL_SYSTEM", 487, 490], ["mice", "ORGANISM", 530, 534], ["ZIKV non-structural protein", "PROTEIN", 401, 428], ["NS5 RdRp", "PROTEIN", 430, 438], ["mice", "SPECIES", 530, 534], ["ZIKV", "SPECIES", 320, 324], ["ZIKV", "SPECIES", 401, 405], ["ZIKV", "SPECIES", 501, 505], ["mice", "SPECIES", 530, 534], ["Further investigation", "TEST", 0, 21], ["the antiviral effects", "PROBLEM", 77, 98], ["other related viruses", "PROBLEM", 120, 141], ["new flaviviruses", "PROBLEM", 149, 165], ["antibacterial drug", "TREATMENT", 269, 287], ["fidaxomicin", "TREATMENT", 289, 300], ["ZIKV infection", "PROBLEM", 320, 334], ["an essential ZIKV non-structural protein", "PROBLEM", 388, 428], ["NS5 RdRp", "TREATMENT", 430, 438], ["robustly alleviating neurologic lesions", "PROBLEM", 440, 479], ["the CNS", "PROBLEM", 483, 490], ["ZIKV", "PROBLEM", 501, 505], ["morbidity", "PROBLEM", 540, 549], ["ZIKV infection", "OBSERVATION", 320, 334], ["ZIKV non-structural protein", "OBSERVATION", 401, 428], ["alleviating", "OBSERVATION_MODIFIER", 449, 460], ["neurologic", "OBSERVATION_MODIFIER", 461, 471], ["lesions", "OBSERVATION", 472, 479], ["CNS", "ANATOMY", 487, 490], ["ZIKV", "OBSERVATION", 501, 505]]], ["This study might provide a foundation for development of fidaxomicin as a novel anti-ZIKV drug.Supplementary informationSupplementary information accompanies this paper at https://doi.org/10.", [["fidaxomicin", "CHEMICAL", 57, 68], ["fidaxomicin", "CHEMICAL", 57, 68], ["fidaxomicin", "SIMPLE_CHEMICAL", 57, 68], ["anti-ZIKV", "CANCER", 80, 89], ["anti-ZIKV", "SPECIES", 80, 89], ["This study", "TEST", 0, 10], ["fidaxomicin", "TREATMENT", 57, 68], ["a novel anti-ZIKV drug", "TREATMENT", 72, 94]]], ["1186/s12916-020-01663-1.Supplementary informationAdditional file 1: Fig. S1 .", [["1186/s12916-020-01663", "CHEMICAL", 0, 21], ["S1", "GENE_OR_GENE_PRODUCT", 73, 75], ["S1", "PROTEIN", 73, 75]]], ["Effects of fidaxomicin on ZIKV NS5-mediated interferon suppression and STAT2 degradation.", [["fidaxomicin", "CHEMICAL", 11, 22], ["fidaxomicin", "CHEMICAL", 11, 22], ["fidaxomicin", "SIMPLE_CHEMICAL", 11, 22], ["ZIKV NS5", "ORGANISM", 26, 34], ["interferon", "GENE_OR_GENE_PRODUCT", 44, 54], ["STAT2", "GENE_OR_GENE_PRODUCT", 71, 76], ["NS5", "PROTEIN", 31, 34], ["interferon", "PROTEIN", 44, 54], ["STAT2", "PROTEIN", 71, 76], ["ZIKV", "SPECIES", 26, 30], ["fidaxomicin", "TREATMENT", 11, 22], ["ZIKV NS5-mediated interferon suppression", "TREATMENT", 26, 66], ["STAT2 degradation", "PROBLEM", 71, 88], ["interferon suppression", "OBSERVATION", 44, 66]]], ["Fig. S2 .", [["S2", "ANATOMY", 5, 7]]], ["In vitro effect of fidaxomicin on ZIKV replication at various MOIs.", [["fidaxomicin", "CHEMICAL", 19, 30], ["fidaxomicin", "CHEMICAL", 19, 30], ["fidaxomicin", "SIMPLE_CHEMICAL", 19, 30], ["ZIKV", "ORGANISM", 34, 38], ["ZIKV", "SPECIES", 34, 38], ["fidaxomicin", "TREATMENT", 19, 30], ["ZIKV replication", "TREATMENT", 34, 50]]], ["Fig. S3 .", [["S3", "ANATOMY", 5, 7]]], ["Changes of body weight recorded daily for mice treated i.v. with fidaxomicin at dosage of 200 mg/kg or with control vehicle.", [["body", "ANATOMY", 11, 15], ["fidaxomicin", "CHEMICAL", 65, 76], ["fidaxomicin", "CHEMICAL", 65, 76], ["body", "ORGANISM_SUBDIVISION", 11, 15], ["mice", "ORGANISM", 42, 46], ["fidaxomicin", "SIMPLE_CHEMICAL", 65, 76], ["mice", "SPECIES", 42, 46], ["mice", "SPECIES", 42, 46], ["Changes of body weight", "PROBLEM", 0, 22], ["fidaxomicin", "TREATMENT", 65, 76], ["body", "ANATOMY", 11, 15]]], ["Fig. S4 .", [["S4", "GENE_OR_GENE_PRODUCT", 5, 7]]], ["Oral administration test for the antiviral efficacy of fidaxomicin in vivo.", [["Oral", "ANATOMY", 0, 4], ["fidaxomicin", "CHEMICAL", 55, 66], ["fidaxomicin", "CHEMICAL", 55, 66], ["Oral", "ORGANISM_SUBDIVISION", 0, 4], ["fidaxomicin", "SIMPLE_CHEMICAL", 55, 66], ["Oral administration test", "TEST", 0, 24], ["the antiviral efficacy", "TREATMENT", 29, 51], ["fidaxomicin", "TREATMENT", 55, 66]]], ["Fig. S5 .", [["S5", "ANATOMY", 5, 7]]], ["Fluorescence intensity analysis of immunohistochemical staining for ZIKV E of representative mouse tissues comparing mock and vehicle.", [["tissues", "ANATOMY", 99, 106], ["ZIKV E", "GENE_OR_GENE_PRODUCT", 68, 74], ["mouse", "ORGANISM", 93, 98], ["tissues", "TISSUE", 99, 106], ["ZIKV E", "PROTEIN", 68, 74], ["mouse", "SPECIES", 93, 98], ["mouse", "SPECIES", 93, 98], ["Fluorescence intensity analysis", "TEST", 0, 31], ["immunohistochemical staining", "TEST", 35, 63], ["mouse tissues", "OBSERVATION", 93, 106]]], ["Fig. S6 .", [["S6", "PROTEIN", 5, 7], ["S6", "ANATOMY", 5, 7]]], ["SPR assay to examine and characterize binding of fidaxomicin or ribavirin with DENV2 NS5.", [["fidaxomicin", "CHEMICAL", 49, 60], ["ribavirin", "CHEMICAL", 64, 73], ["fidaxomicin", "CHEMICAL", 49, 60], ["ribavirin", "CHEMICAL", 64, 73], ["fidaxomicin", "SIMPLE_CHEMICAL", 49, 60], ["ribavirin", "SIMPLE_CHEMICAL", 64, 73], ["DENV2", "ORGANISM", 79, 84], ["NS5", "ORGANISM", 85, 88], ["DENV2 NS5", "PROTEIN", 79, 88], ["DENV2 NS5", "SPECIES", 79, 88], ["SPR assay", "TEST", 0, 9], ["fidaxomicin", "TREATMENT", 49, 60], ["ribavirin", "TREATMENT", 64, 73], ["DENV2 NS5", "TREATMENT", 79, 88]]], ["Table S1 .", [["S1", "ANATOMY", 6, 8]]], ["Primer sequences used in this work.", [["Primer sequences", "DNA", 0, 16], ["Primer sequences", "TEST", 0, 16]]], ["Table S2 .", [["S2", "ANATOMY", 6, 8]]], ["In vitro effect of fidaxomicin on ZIKV multiplication assessed by RT-qPCR.", [["fidaxomicin", "CHEMICAL", 19, 30], ["fidaxomicin", "CHEMICAL", 19, 30], ["fidaxomicin", "SIMPLE_CHEMICAL", 19, 30], ["ZIKV", "SIMPLE_CHEMICAL", 34, 38], ["ZIKV", "SPECIES", 34, 38], ["fidaxomicin", "TREATMENT", 19, 30], ["ZIKV multiplication", "TREATMENT", 34, 53]]], ["Hematological parameters of mice following a 10-day treatment with fidaxomicin at dose of 200 mg/kg.", [["fidaxomicin", "CHEMICAL", 67, 78], ["fidaxomicin", "CHEMICAL", 67, 78], ["mice", "ORGANISM", 28, 32], ["fidaxomicin", "SIMPLE_CHEMICAL", 67, 78], ["mice", "SPECIES", 28, 32], ["mice", "SPECIES", 28, 32], ["Hematological parameters", "TEST", 0, 24], ["fidaxomicin", "TREATMENT", 67, 78]]], ["Biochemical parameters of mice following a 10-day treatment with fidaxomicin at dose of 200 mg/ kg.", [["fidaxomicin", "CHEMICAL", 65, 76], ["fidaxomicin", "CHEMICAL", 65, 76], ["mice", "ORGANISM", 26, 30], ["fidaxomicin", "SIMPLE_CHEMICAL", 65, 76], ["mice", "SPECIES", 26, 30], ["mice", "SPECIES", 26, 30], ["fidaxomicin", "TREATMENT", 65, 76]]], ["Relative organ weights (g/100 g of body weight) of mice following a 10-day treatment with fidaxomicin at dose of 200 mg/kg.", [["organ", "ANATOMY", 9, 14], ["body", "ANATOMY", 35, 39], ["fidaxomicin", "CHEMICAL", 90, 101], ["fidaxomicin", "CHEMICAL", 90, 101], ["organ", "ORGAN", 9, 14], ["body", "ORGANISM_SUBDIVISION", 35, 39], ["mice", "ORGANISM", 51, 55], ["fidaxomicin", "SIMPLE_CHEMICAL", 90, 101], ["mice", "SPECIES", 51, 55], ["mice", "SPECIES", 51, 55], ["Relative organ weights", "TEST", 0, 22], ["fidaxomicin", "TREATMENT", 90, 101]]], ["Table S6 .", [["S6", "PROTEIN", 6, 8]]], ["In vitro effect of fidaxomicin on DENV2 multiplication in SNB19 and A549 cells.", [["SNB19", "ANATOMY", 58, 63], ["A549 cells", "ANATOMY", 68, 78], ["fidaxomicin", "CHEMICAL", 19, 30], ["fidaxomicin", "CHEMICAL", 19, 30], ["fidaxomicin", "SIMPLE_CHEMICAL", 19, 30], ["DENV2", "ORGANISM", 34, 39], ["SNB19", "CELL", 58, 63], ["A549 cells", "CELL", 68, 78], ["SNB19", "CELL_LINE", 58, 63], ["A549 cells", "CELL_LINE", 68, 78], ["DENV2", "SPECIES", 34, 39], ["fidaxomicin", "TREATMENT", 19, 30], ["DENV2 multiplication", "TREATMENT", 34, 54], ["A549 cells", "OBSERVATION", 68, 78]]]], "aa9541b15ae667a5f60b94ff2dd4d30a21dce58a": [["A novel human coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in late 2019 in Wuhan, China, resulting in a pandemic [1] .", [["human coronavirus", "DISEASE", 8, 25], ["acute respiratory syndrome coronavirus", "DISEASE", 40, 78], ["human", "ORGANISM", 8, 13], ["coronavirus", "ORGANISM", 14, 25], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 33, 80], ["SARS-CoV-2", "ORGANISM", 82, 92], ["human", "SPECIES", 8, 13], ["coronavirus", "SPECIES", 14, 25], ["human coronavirus", "SPECIES", 8, 25], ["severe acute respiratory syndrome coronavirus", "SPECIES", 33, 78], ["SARS-CoV-2", "SPECIES", 82, 92], ["A novel human coronavirus", "PROBLEM", 0, 25], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 33, 78], ["SARS-CoV", "TEST", 82, 90], ["severe", "OBSERVATION_MODIFIER", 33, 39], ["acute", "OBSERVATION_MODIFIER", 40, 45], ["respiratory syndrome", "OBSERVATION", 46, 66]]], ["Due to the need for physical distancing and isolation, universities closed and most medical clinics were ordered to continue with \"essential\" in-person visits only.", [["physical distancing and isolation", "TREATMENT", 20, 53]]], ["In addition to a wave of medical appointment cancellations, many medical research activities, such as participant recruitment, study visits, and outcomes assessments were halted.", [["outcomes assessments", "TEST", 145, 165]]], ["In light of rapid societal change in response to the pandemic, this paper summarizes our considerations for conducting remote research.", [["rapid societal change", "PROBLEM", 12, 33], ["rapid", "OBSERVATION_MODIFIER", 12, 17], ["societal", "OBSERVATION", 18, 26]]], ["The discussion provided here is not exhaustive, but rather a starting place for a fundamental shift in how research is conducted.Advertisement and RecruitmentEven without a pandemic, over 19% of trials close without meeting target accrual rates [2] , underscoring the need to investigate new methods for research recruitment.", [["a fundamental shift", "TREATMENT", 80, 99], ["trials", "TREATMENT", 195, 201], ["research recruitment", "TREATMENT", 304, 324]]], ["This indicates a wide reach for online advertisement and recruitment for research, with the added potential to recruit populations typically considered hard-to-reach [5] .Advertisement and RecruitmentCompared to traditional recruitment methods (e.g. print and television), studies using advertisements via social media have been shown to be financially feasible, attract large numbers of individuals, and have condensed recruitment periods.", [["traditional recruitment methods", "TREATMENT", 212, 243], ["recruitment periods", "OBSERVATION", 420, 439]]], ["They have also been shown to provide opportunities for connecting with individuals with specific health conditions, living in remote geographic locations, or who may have been difficult to recruit due to stigma or medical mistrust [6, 7] .", [["stigma", "PROBLEM", 204, 210]]], ["Some examples of social media to advertise and recruit participants include: social networks (such as Facebook, Instagram, and Twitter), dating apps (Grindr, Scruff, and Jack'd), and online listservs for various medical societies or health conditions.", [["participants", "SPECIES", 55, 67]]], ["The main disadvantage of using social media for study recruitment is the lack of reach to those with limited or no internet access.", [["social media", "TREATMENT", 31, 43], ["study recruitment", "TREATMENT", 48, 65], ["main", "OBSERVATION_MODIFIER", 4, 8], ["disadvantage", "OBSERVATION_MODIFIER", 9, 21]]], ["This can result in reduced generalizability of research findings [7, 8] .", [["reduced", "OBSERVATION_MODIFIER", 19, 26]]], ["Researchers concerned about generalizability, however, can supplement online advertisement with traditional methods.Advertisement and RecruitmentAnother remote recruitment method involves networkbased online referral strategies.", [["traditional methods", "TREATMENT", 96, 115]]], ["One example is respondentdriven sampling for online research which involves recruiting initial participants (i.e. \"seeds\") who are then asked to recruit friends to enroll in the study, and so on [9] .", [["participants", "SPECIES", 95, 107], ["the study", "TEST", 174, 183]]], ["Finally, a host of specialist 0medical research recruiting agencies now exist that tout increased recruitment efficiency.Screening and EnrollmentScreening (or pre-screening) can be conducted via simple web forms on a study website.", [["increased recruitment efficiency", "PROBLEM", 88, 120], ["a study", "TEST", 215, 222], ["increased", "OBSERVATION_MODIFIER", 88, 97], ["recruitment efficiency", "OBSERVATION", 98, 120]]], ["This can increase web traffic to the study website, decrease the workload for research staff, and increase a potential participant's trust in the legitimacy of the study (e.g. if the webpage is part of a reputable university with an \"edu\" domain).", [["the study", "TEST", 33, 42], ["the study", "TEST", 160, 169]]], ["The main disadvantage of online screening is that it may either deter some to participate (e.g. if the form is too complicated or lengthy) or increase inappropriate participation (e.g. an individual or bot responding repeatedly to be eventually deemed eligible).", [["online screening", "TEST", 25, 41], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["One option to minimize these barriers is to include a simple pre-screening form on the study website and to contact the interested individual by phone call or text message to complete the screening process.Screening and EnrollmentTo ensure certain key study inclusion criteria, participants can be asked to text message photographs of documents.", [["participants", "SPECIES", 278, 290], ["the study", "TEST", 83, 92], ["Screening", "TEST", 206, 215]]], ["For example, an identification card bearing their name and date of birth to verify age or a photograph of a letter of HIV diagnosis or antiretroviral medication vial bearing their name to verify HIV serostatus [10, 11] .", [["HIV serostatus", "DISEASE", 195, 209], ["HIV", "ORGANISM", 118, 121], ["HIV", "ORGANISM", 195, 198], ["HIV", "SPECIES", 118, 121], ["HIV", "SPECIES", 195, 198], ["HIV", "SPECIES", 118, 121], ["HIV", "SPECIES", 195, 198], ["HIV diagnosis", "TREATMENT", 118, 131], ["antiretroviral medication", "TREATMENT", 135, 160], ["HIV serostatus", "PROBLEM", 195, 209]]], ["Detailed review of the consent process is critical to ensure an individual's understanding of the study.Intervention ProvisionThere are numerous ways of providing remote interventions.", [["the study", "TEST", 94, 103], ["remote interventions", "TREATMENT", 163, 183]]], ["Text messaging has been used frequently for motivational messages, reminders, and ecological momentary assessments [12] [13] [14] .", [["ecological momentary assessments", "TEST", 82, 114]]], ["Many text messaging platforms have been developed and evaluated for HIPAA-compliant communication with participants [15] .Intervention ProvisionTelehealth via videochat platforms have also been used for the provision of study interventions [16] .", [["participants", "SPECIES", 103, 115], ["videochat platforms", "TREATMENT", 159, 178], ["study interventions", "TREATMENT", 220, 239]]], ["This modality lends itself well to interventions that do not require physical contact but are enhanced by face-to-face communication, such as interventions for mental health, smoking cessation, and medication adherence counseling.", [["interventions", "TREATMENT", 35, 48], ["smoking cessation", "TREATMENT", 175, 192], ["medication adherence counseling", "TREATMENT", 198, 229]]], ["Participants in prior studies noted high acceptability levels in using videochat for research intervention delivery [17] .", [["videochat", "CHEMICAL", 71, 80], ["Participants", "SPECIES", 0, 12], ["prior studies", "TEST", 16, 29], ["research intervention delivery", "TREATMENT", 85, 115]]], ["Benefits included being able to speak more candidly and being less intimidated, and experiencing reduced barriers for research participation (e.g. financial barriers related to travel expenses or time off from work, stigma associated with research participation, and physical disabilities precluding mobility) [17, 18] .", [["physical disabilities", "DISEASE", 267, 288]]], ["In addition to providing interventions, these platforms can be used for one-on-one qualitative interviews and focus groups.", [["interventions", "TREATMENT", 25, 38]]], ["They allow for video-or audio-recording of the session (with consent from the participant) which can be used later for interview transcription and analysis.", [["analysis", "TEST", 147, 155]]], ["Other remote methods of delivering an intervention include mobile health applications [11] , computers-based programs [19] , and the internet [20] .Monitoring and AssessmentIn addition to self-reported outcomes, which may be subject to recall and social desirability biases [21, 22] , objective monitoring of study outcomes can be conducted remotely in numerous ways.", [["an intervention", "TREATMENT", 35, 50], ["objective monitoring of study", "TEST", 285, 314]]], ["For example medication adherence can be evaluated by drug hair concentrations using mail-in hair samples [23] [24] [25] and text messaged photographs of pill counts or refill dates [23] [24] [25] .", [["hair", "ANATOMY", 58, 62], ["hair samples", "ANATOMY", 92, 104], ["hair", "MULTI-TISSUE_STRUCTURE", 58, 62], ["medication adherence", "TREATMENT", 12, 32], ["mail-in hair samples", "TREATMENT", 84, 104], ["pill counts", "TEST", 153, 164], ["refill dates", "TEST", 168, 180]]], ["Adherence has been monitored using medication event monitoring system (MEMS) caps, ingestion sensors, and \"wise\"-products [26] [27] [28] [29] [30] .Monitoring and AssessmentSome labs provide infectious disease testing services which can examine 4th generation HIV antibody testing using dried blood spot and chlamydia and gonorrhea testing using mail-in swabs, as well as mail-in samples for Hepatitis B and C testing [31] [32] [33] .", [["blood", "ANATOMY", 293, 298], ["gonorrhea", "DISEASE", 322, 331], ["Hepatitis B", "DISEASE", 392, 403], ["[26] [27] [28] [29] [30]", "SIMPLE_CHEMICAL", 122, 146], ["HIV", "ORGANISM", 260, 263], ["blood", "ORGANISM_SUBSTANCE", 293, 298], ["HIV", "SPECIES", 260, 263], ["HIV", "SPECIES", 260, 263], ["Hepatitis B", "SPECIES", 392, 403], ["AssessmentSome labs", "TEST", 163, 182], ["HIV antibody testing", "TEST", 260, 280], ["dried blood spot", "TEST", 287, 303], ["chlamydia", "PROBLEM", 308, 317], ["gonorrhea testing", "TEST", 322, 339], ["Hepatitis B and C testing", "TEST", 392, 417]]], ["Alcohol use can be remotely monitored using Bluetooth-enabled breathalyzers that estimate breath alcohol concentration or wrist-worn alcohol biosensors that continuously measure transdermal alcohol content [34] [35] [36] .Monitoring and AssessmentStudy assessments can be conducted via online surveys which can be emailed or text messaged to participants.", [["Alcohol", "CHEMICAL", 0, 7], ["alcohol", "CHEMICAL", 97, 104], ["alcohol", "CHEMICAL", 133, 140], ["alcohol", "CHEMICAL", 190, 197], ["alcohol", "CHEMICAL", 97, 104], ["alcohol", "CHEMICAL", 133, 140], ["alcohol", "CHEMICAL", 190, 197], ["alcohol", "SIMPLE_CHEMICAL", 97, 104], ["wrist", "ORGANISM_SUBDIVISION", 122, 127], ["alcohol", "SIMPLE_CHEMICAL", 133, 140], ["alcohol", "SIMPLE_CHEMICAL", 190, 197], ["participants", "SPECIES", 342, 354], ["AssessmentStudy assessments", "TEST", 237, 264], ["wrist", "ANATOMY", 122, 127]]], ["In cases of limited literacy, research staff can read questions to study participants or use survey platforms that include the ability to audio-record questions.", [["participants", "SPECIES", 73, 85]]], ["Qualitative research can also be conducted using telephone, videochat, or remote focus group platforms currently typically used for marketing.Participant IncentivesStudy incentives can be provided remotely in numerous ways.", [["Participant", "SPECIES", 142, 153], ["videochat", "TREATMENT", 60, 69]]], ["For longitudinal research, reloadable debit cards are a convenient method of payment and have been shown to be highly feasible and acceptable by research participants [24] .", [["participants", "SPECIES", 154, 166]]], ["These debit cards can be mailed to participants without any funds loaded until confirmation of receipt and funds can be transferred from one card to another in case of lost or stolen cards.", [["participants", "SPECIES", 35, 47]]], ["These are important benefits of reloadable debit cards over mailed gift cards.ConclusionIn the era of pandemics, such SARS-CoV-2, there is a need to continue research activities, while keeping research participants and staff safe.", [["SARS", "DISEASE", 118, 122], ["participants", "SPECIES", 202, 214], ["SARS-CoV", "SPECIES", 118, 126], ["pandemics", "PROBLEM", 102, 111]]], ["Aligning research activities with remotely-conducted research methodology has the potential benefits of reducing time and cost for conducting the study, improving ease of participation for many individuals, enhancing the generalizability of findings, and increasing the speed of publication of study findings, all while preventing potential viral transmissions to research participants or staff.", [["participants", "SPECIES", 373, 385], ["conducting the study", "TEST", 131, 151], ["study findings", "TEST", 294, 308]]]], "PMC7498028": [["IntroductionIn December 2019, the appearance of a novel coronavirus caused an outbreak of respiratory infections originating from the Huanan food market in Wuhan, China [1, 2], which has since developed into a global pandemic.", [["respiratory", "ANATOMY", 90, 101], ["coronavirus", "DISEASE", 56, 67], ["respiratory infections", "DISEASE", 90, 112], ["coronavirus", "ORGANISM", 56, 67], ["a novel coronavirus", "PROBLEM", 48, 67], ["respiratory infections", "PROBLEM", 90, 112], ["a global pandemic", "PROBLEM", 208, 225], ["outbreak", "OBSERVATION_MODIFIER", 78, 86], ["respiratory infections", "OBSERVATION", 90, 112], ["global", "OBSERVATION_MODIFIER", 210, 216], ["pandemic", "OBSERVATION", 217, 225]]], ["The novel coronavirus is referred to as \u201csevere acute respiratory syndrome coronavirus 2\u201d (SARS-CoV-2) potentially resulting in \u201ccoronavirus disease\u201d (COVID-19) [3].", [["acute respiratory syndrome coronavirus", "DISEASE", 48, 86], ["coronavirus disease", "DISEASE", 129, 148], ["coronavirus", "ORGANISM", 10, 21], ["SARS-CoV-2", "ORGANISM", 91, 101], ["\u201csevere acute respiratory syndrome coronavirus", "SPECIES", 40, 86], ["SARS-CoV", "SPECIES", 91, 99], ["The novel coronavirus", "PROBLEM", 0, 21], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 41, 86], ["SARS", "TEST", 91, 95], ["CoV", "TEST", 96, 99], ["\u201ccoronavirus disease", "PROBLEM", 128, 148], ["COVID", "TEST", 151, 156], ["coronavirus", "OBSERVATION", 10, 21], ["severe", "OBSERVATION_MODIFIER", 41, 47], ["acute", "OBSERVATION_MODIFIER", 48, 53], ["respiratory syndrome", "OBSERVATION", 54, 74], ["coronavirus disease", "OBSERVATION", 129, 148]]], ["As of August 8, 2020, 19,497,292 patients have been infected globally, and 723,854 deaths have been recorded [4].", [["deaths", "DISEASE", 83, 89], ["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41], ["infected", "OBSERVATION", 52, 60]]], ["Clinical symptoms of infection with SARS-CoV-2 are heterogeneous and vary in severity; some patients may even be asymptomatic [5, 6].", [["infection", "DISEASE", 21, 30], ["SARS", "DISEASE", 36, 40], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["SARS-CoV", "SPECIES", 36, 44], ["Clinical symptoms", "PROBLEM", 0, 17], ["infection", "PROBLEM", 21, 30], ["SARS", "PROBLEM", 36, 40], ["asymptomatic", "PROBLEM", 113, 125], ["infection", "OBSERVATION", 21, 30], ["heterogeneous", "OBSERVATION_MODIFIER", 51, 64]]], ["In some patients, COVID-19 leads to serious outcomes, such as acute respiratory distress syndrome, coagulation dysfunction and death [5, 7, 8].", [["respiratory", "ANATOMY", 68, 79], ["respiratory distress syndrome", "DISEASE", 68, 97], ["coagulation dysfunction", "DISEASE", 99, 122], ["death", "DISEASE", 127, 132], ["COVID-19", "CHEMICAL", 18, 26], ["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["COVID", "TREATMENT", 18, 23], ["acute respiratory distress syndrome", "PROBLEM", 62, 97], ["coagulation dysfunction", "PROBLEM", 99, 122], ["death", "PROBLEM", 127, 132], ["acute", "OBSERVATION_MODIFIER", 62, 67], ["respiratory distress", "OBSERVATION", 68, 88]]], ["However, many questions about the clinical syndrome of COVID-19 remain unanswered.IntroductionThe evidence base on COVID-19 is rapidly expanding.", [["COVID", "DISEASE", 55, 60], ["COVID-19", "CHEMICAL", 55, 63], ["COVID-19", "CHEMICAL", 115, 123], ["the clinical syndrome", "PROBLEM", 30, 51], ["COVID", "TEST", 55, 60], ["COVID", "TEST", 115, 120], ["base", "OBSERVATION_MODIFIER", 107, 111], ["rapidly", "OBSERVATION_MODIFIER", 127, 134]]], ["The large volume of data and short timeframe challenges clinicians, researchers and policy makers worldwide.", [["large", "OBSERVATION_MODIFIER", 4, 9], ["volume", "OBSERVATION_MODIFIER", 10, 16]]], ["In addition, as would be expected in the early stages of a pandemic involving a novel virus, much of the data is derived from observational case series, providing only limited evidence.", [["a pandemic", "PROBLEM", 57, 67], ["a novel virus", "PROBLEM", 78, 91]]], ["Publication timescales are exceptionally short given the urgency of the situation and balancing the need for rapid dissemination of information with established reporting standards is challenging.", [["the urgency of the situation", "PROBLEM", 53, 81]]], ["Rigorous assessment of study methodology and outcomes is therefore especially important in order to facilitate evidence-based clinical practice and policy.IntroductionOur research group recently performed a scoping review and meta-analysis that analyzed data published up until February 24, 2020 [5].", [["Rigorous assessment", "TEST", 0, 19], ["study methodology", "TEST", 23, 40], ["a scoping review", "TEST", 205, 221], ["meta-analysis", "TEST", 226, 239]]], ["The work reported here substantially builds on this using the same stringent protocol to encompass subsequent studies.", [["the same stringent protocol", "TREATMENT", 58, 85], ["subsequent studies", "TEST", 99, 117]]], ["The aim was to systematically analyze all clinical evidence on the COVID-19 pandemic published in the peer-reviewed literature.", [["the COVID", "TEST", 63, 72]]], ["We aimed to look at the impact of severity of disease on clinical, laboratory and radiological characteristics, and outcomes and specifically investigated differences between the overall COVID-19 patient group and patients with severe disease.Data sources and information searches ::: MethodsThis review follows meta-analysis of observational studies in epidemiology (MOOSE) guidelines [9] and is reported in accordance with the preferred reporting items for systematic reviews and meta-analyses (PRISMA) [10].", [["patient", "ORGANISM", 196, 203], ["patients", "ORGANISM", 214, 222], ["patient", "SPECIES", 196, 203], ["patients", "SPECIES", 214, 222], ["disease", "PROBLEM", 46, 53], ["severe disease", "PROBLEM", 228, 242], ["Methods", "TREATMENT", 285, 292], ["observational studies", "TEST", 329, 350], ["systematic reviews", "TEST", 459, 477], ["disease", "OBSERVATION", 46, 53], ["severe", "OBSERVATION_MODIFIER", 228, 234], ["disease", "OBSERVATION", 235, 242]]], ["We restricted the sample size in eligible studies to at least 10 patients, as the minimum to calculate a valid percentage.", [["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["eligible studies", "TEST", 33, 49], ["size", "OBSERVATION_MODIFIER", 25, 29]]], ["There were two minor deviations from the original protocol: in quantitative synthesis we excluded studies in which all patients or the majority of patients were children, and we introduced subgroup analysis based on disease severity.Data sources and information searches ::: MethodsWe searched the following five databases: MEDLINE, CENTRAL, EMBASE, Scopus, and LILACS from January 1, 2019 to March 22, 2020.", [["patients", "ORGANISM", 119, 127], ["patients", "ORGANISM", 147, 155], ["children", "ORGANISM", 161, 169], ["patients", "SPECIES", 119, 127], ["patients", "SPECIES", 147, 155], ["children", "SPECIES", 161, 169], ["two minor deviations", "PROBLEM", 11, 31], ["subgroup analysis", "TEST", 189, 206], ["disease severity", "PROBLEM", 216, 232], ["two", "OBSERVATION_MODIFIER", 11, 14], ["minor", "OBSERVATION_MODIFIER", 15, 20], ["deviations", "OBSERVATION", 21, 31], ["CENTRAL", "ANATOMY", 333, 340]]], ["Reference lists of relevant studies were screened to identify additional publications.Study selection ::: MethodsStudies eligible for inclusion reported confirmed cases of SARS-CoV-2 in humans, including at least 10 patients in the study sample, and were published in a peer reviewed journal.", [["SARS", "DISEASE", 172, 176], ["SARS-CoV-2", "ORGANISM", 172, 182], ["humans", "ORGANISM", 186, 192], ["patients", "ORGANISM", 216, 224], ["humans", "SPECIES", 186, 192], ["patients", "SPECIES", 216, 224], ["SARS-CoV", "SPECIES", 172, 180], ["humans", "SPECIES", 186, 192], ["relevant studies", "TEST", 19, 35], ["SARS", "PROBLEM", 172, 176], ["CoV", "TEST", 177, 180]]], ["In vitro and mathematical modelling studies were excluded.", [["mathematical modelling studies", "TEST", 13, 43]]], ["Studies were included irrespective of the clinical study design or publication language.", [["the clinical study", "TEST", 38, 56]]], ["COVID-19 was defined as a diagnosis by any specific test such as positive SARS-CoV-2 PCR, genetic sequence analysis or IgM/IgA antibody detected in a serological assay.", [["IgM", "GENE_OR_GENE_PRODUCT", 119, 122], ["IgA", "GENE_OR_GENE_PRODUCT", 123, 126], ["COVID-19", "DNA", 0, 8], ["IgM", "PROTEIN", 119, 122], ["IgA antibody", "PROTEIN", 123, 135], ["COVID", "TEST", 0, 5], ["any specific test", "TEST", 39, 56], ["positive SARS", "PROBLEM", 65, 78], ["CoV", "TEST", 79, 82], ["PCR", "TEST", 85, 88], ["genetic sequence analysis", "TEST", 90, 115], ["IgM", "TEST", 119, 122], ["IgA antibody", "TEST", 123, 135], ["a serological assay", "TEST", 148, 167]]], ["Two independent investigators conducted the title/abstract screening and full-text screening.", [["abstract screening", "TEST", 50, 68], ["text screening", "TEST", 78, 92]]], ["The study selection was performed using the Covidence platform.", [["The study selection", "TEST", 0, 19]]], ["Articles deemed potentially eligible during title/abstract screening were retrieved as full text for further screening.", [["abstract screening", "TEST", 50, 68], ["further screening", "TEST", 101, 118]]], ["In both stages of screening (titles/abstracts and full texts), discrepancies were resolved by a third review author.", [["screening", "TEST", 18, 27]]], ["Articles published in languages other than English were translated by a native/fluent speaker.Data collecting process and quality assessment ::: MethodsTwo investigators independently extracted data using customized tables and were blinded to each other until data extraction was finished.", [["quality assessment", "TEST", 122, 140], ["data extraction", "TREATMENT", 260, 275]]], ["Data were carefully assessed for any overlap of study populations.", [["study populations", "TEST", 48, 65]]], ["If any overlap was suspected, an assessment was made based on hospitals involved and the time frame of the study.", [["an assessment", "TEST", 30, 43], ["the study", "TEST", 103, 112]]], ["In cases of overlapping, the most recent study was included.Data collecting process and quality assessment ::: MethodsThe primary outcomes were all-cause mortality, and prevalence of clinical symptoms, laboratory findings and chest imaging findings in COVID-19.", [["chest", "ANATOMY", 226, 231], ["the most recent study", "TEST", 25, 46], ["quality assessment", "TEST", 88, 106], ["Methods", "TREATMENT", 111, 118], ["mortality", "PROBLEM", 154, 163], ["clinical symptoms", "PROBLEM", 183, 200], ["laboratory findings", "TEST", 202, 221], ["chest imaging findings", "TEST", 226, 248], ["COVID", "TEST", 252, 257], ["chest", "ANATOMY", 226, 231]]], ["Other data analyzed included demographic characteristics, comorbidities, incubation period, treatment provided, pharmacotherapy, admission to the intensive care unit (ICU), length of stay in the ICU and in hospital.", [["treatment", "TREATMENT", 92, 101], ["pharmacotherapy", "TREATMENT", 112, 127]]], ["If studies reported multiple follow-up time points, most recent data was analyzed.", [["studies", "TEST", 3, 10]]], ["Data from severely ill patients were comparable in terms of participant characteristics and outcome measures, and therefore pooled together in a meta-analysis.Data collecting process and quality assessment ::: MethodsTwo researchers independently assessed the risk of bias of case series and epidemiological studies using the \u2018Methodological Quality and Synthesis of Case Series and Case Reports Protocol\u2019 [11], derived from the Newcastle-Ottawa Scale (NOS), and randomized clinical trials were assessed using the Cochrane risk of bias tool for randomized trials (RoB) [12].", [["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["a meta-analysis", "TEST", 143, 158], ["quality assessment", "TEST", 187, 205], ["case series", "TEST", 276, 287], ["epidemiological studies", "TEST", 292, 315]]], ["Disagreements were resolved by consulting a third reviewer.Data analysis ::: MethodsFor dichotomous data, we extracted data for the number of events and total number of patients in order to perform proportion meta-analysis.", [["patients", "ORGANISM", 169, 177], ["patients", "SPECIES", 169, 177], ["Data analysis", "TEST", 59, 72], ["dichotomous data", "TEST", 88, 104], ["proportion meta-analysis", "TEST", 198, 222]]], ["For continuous data we extracted means and standard deviations.", [["standard deviations", "OBSERVATION", 43, 62]]], ["If data were presented as medians, and interquartile ranges or ranges, we estimated means and standard deviations using the method described by Wan et al. [14].Data analysis ::: MethodsMeta-analyses of clinical, radiological and laboratory data, as well as data on clinical management and epidemiological characteristics of included patients were conducted using MetaXL v5.2 (EpiGear International, Sunrise Beach, Australia).", [["patients", "ORGANISM", 333, 341], ["patients", "SPECIES", 333, 341], ["the method", "TREATMENT", 120, 130], ["Data analysis", "TEST", 160, 173], ["laboratory data", "TEST", 229, 244], ["clinical management", "TREATMENT", 265, 284]]], ["Pooled proportions or means and 95% confidence intervals (CI) were calculated using the quality effects model (QE) [16].", [["CI", "TEST", 58, 60]]], ["The method was chosen over the random effects model because of high heterogeneity of the data.", [["The method", "TREATMENT", 0, 10], ["high heterogeneity of the data", "PROBLEM", 63, 93]]], ["QE stabilizes the variance and mitigates the issue of a conventional random effects model underestimating standard errors in presence of high heterogeneity [17, 18].", [["high heterogeneity", "PROBLEM", 137, 155], ["high", "OBSERVATION_MODIFIER", 137, 141], ["heterogeneity", "OBSERVATION_MODIFIER", 142, 155]]], ["The quality effects model also allows incorporation of information on study quality into the analysis.", [["study quality", "TEST", 70, 83], ["the analysis", "TEST", 89, 101]]], ["Heterogeneity was assessed by Cochrane's Q test considering a statistically significant value for p < 0.1, and Higgins I2 [20].Data analysis ::: MethodsStudies were assigned to subgroups based on the study sample.", [["Cochrane's Q test", "TEST", 30, 47], ["Data analysis", "TEST", 127, 140], ["the study sample", "TEST", 196, 212]]], ["Studies enrolling initially asymptomatic patients that were then followed over time were categorized as \u2018initially asymptomatic\u2019.", [["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["Studies", "TEST", 0, 7]]], ["\u2018Early\u2019 subgroup studies monitored onset of early symptoms of the disease in patients mainly identified through epidemiological tracking of close contacts.", [["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["Early\u2019 subgroup studies", "TEST", 1, 24], ["early symptoms", "PROBLEM", 44, 58], ["the disease", "PROBLEM", 62, 73], ["disease", "OBSERVATION", 66, 73]]], ["The study by Han et al. was also assigned to this category since the study investigated early clinical symptoms in patients who were admitted to hospital because of mild pneumonia [21].", [["pneumonia", "DISEASE", 170, 179], ["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123], ["The study", "TEST", 0, 9], ["the study", "TEST", 65, 74], ["early clinical symptoms", "PROBLEM", 88, 111], ["mild pneumonia", "PROBLEM", 165, 179], ["mild", "OBSERVATION_MODIFIER", 165, 169], ["pneumonia", "OBSERVATION", 170, 179]]], ["The \u2018all-comers\u2019 subgroup contained studies enrolling consecutive patients who had a positive PCR test, regardless of symptom presentation.", [["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74], ["a positive PCR test", "PROBLEM", 83, 102], ["symptom presentation", "PROBLEM", 118, 138]]], ["These studies would be expected to be the most representative of COVID-19-positive individuals in the general population in our analysis because they included asymptomatic patients and outpatients as well as hospitalized patients.", [["COVID-19", "GENE_OR_GENE_PRODUCT", 65, 73], ["patients", "ORGANISM", 172, 180], ["patients", "ORGANISM", 221, 229], ["patients", "SPECIES", 172, 180], ["outpatients", "SPECIES", 185, 196], ["patients", "SPECIES", 221, 229], ["These studies", "TEST", 0, 13], ["COVID", "TEST", 65, 70], ["our analysis", "TEST", 124, 136]]], ["We included epidemiological reports that collected data from Centers for Disease Control, hospital laboratories nation/region-wide, and studies that collected data from multi/single-center hospital laboratories that also collected data from outpatients and asymptomatic patients.", [["patients", "ORGANISM", 270, 278], ["outpatients", "SPECIES", 241, 252], ["patients", "SPECIES", 270, 278]]], ["Finally, studies assigned to an \u2018admitted-to-hospital\u2019 subgroup analyzed exclusively patients who were admitted to a hospital.", [["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93]]], ["Data on severely ill patients (defined as patients requiring care in an intensive care unit and/or requiring invasive or non-invasive ventilation) were extracted for further analysis.Data analysis ::: MethodsWe assessed statistical heterogeneity by examining the I2, while also considering magnitude and direction of effects and strength of evidence.", [["patients", "ORGANISM", 21, 29], ["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 21, 29], ["patients", "SPECIES", 42, 50], ["invasive or non-invasive ventilation", "TREATMENT", 109, 145], ["further analysis", "TEST", 166, 182], ["Data analysis", "TEST", 183, 196]]], ["Heterogeneity was defined according to the Cochrane Handbook [22]; it might not be important heterogeneity (0\u201340%), moderate heterogeneity (30\u201360%), substantial heterogeneity (50\u201390%) and considerable heterogeneity (75\u2013100%) [22].", [["moderate heterogeneity", "PROBLEM", 116, 138], ["substantial heterogeneity", "PROBLEM", 149, 174], ["considerable heterogeneity", "PROBLEM", 188, 214], ["moderate", "OBSERVATION_MODIFIER", 116, 124], ["heterogeneity", "OBSERVATION_MODIFIER", 125, 138], ["substantial", "OBSERVATION_MODIFIER", 149, 160], ["heterogeneity", "OBSERVATION_MODIFIER", 161, 174], ["considerable", "OBSERVATION_MODIFIER", 188, 200], ["heterogeneity", "OBSERVATION_MODIFIER", 201, 214]]], ["Pooled point estimates are reported where I2<90% and where we judged that estimates were not methodologically or clinically too diverse to be pooled; otherwise prevalence ranges are reported.", [["I2", "TEST", 42, 44]]], ["Methodological and clinical heterogeneity of studies, in particular sampling bias, was a significant source of heterogeneity.", [["studies", "TEST", 45, 52], ["sampling bias", "TEST", 68, 81], ["heterogeneity", "PROBLEM", 111, 124], ["significant", "OBSERVATION_MODIFIER", 89, 100], ["heterogeneity", "OBSERVATION", 111, 124]]], ["Patients were sampled at different stages of disease progression.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["disease progression", "PROBLEM", 45, 64], ["disease", "OBSERVATION", 45, 52], ["progression", "OBSERVATION_MODIFIER", 53, 64]]], ["In people identified through close contacts/epidemiological tracking usually only initial symptoms were observed (\u2018early\u2019 studies).", [["people", "ORGANISM", 3, 9], ["people", "SPECIES", 3, 9], ["initial symptoms", "PROBLEM", 82, 98]]], ["Some studies identified cases through laboratory testing, therefore including a wide spectrum of disease severities (\u2018all-comer\u2019 studies).", [["Some studies", "TEST", 0, 12], ["laboratory testing", "TEST", 38, 56], ["disease severities", "PROBLEM", 97, 115]]], ["Other studies specifically included initially asymptomatic patients, pregnant women, or patients admitted to hospital (representative of more severe cases).Data analysis ::: MethodsIn order to investigate the association of various clinical, laboratory and radiological characteristics with severity of disease, we categorized hospital-based studies according to the overall disease severity of patients in each study and ordered studies by increasing severity within each category in forest plots.", [["patients", "ORGANISM", 59, 67], ["women", "ORGANISM", 78, 83], ["patients", "ORGANISM", 88, 96], ["patients", "ORGANISM", 395, 403], ["patients", "SPECIES", 59, 67], ["women", "SPECIES", 78, 83], ["patients", "SPECIES", 88, 96], ["patients", "SPECIES", 395, 403], ["Other studies", "TEST", 0, 13], ["Data analysis", "TEST", 156, 169], ["Methods", "TREATMENT", 174, 181], ["disease", "PROBLEM", 303, 310], ["each study", "TEST", 407, 417], ["ordered studies", "TEST", 422, 437], ["increasing severity", "PROBLEM", 441, 460]]], ["The same order of studies was used for all analyses.", [["studies", "TEST", 18, 25], ["all analyses", "TEST", 39, 51]]], ["This severity index was determined according to the number of patients in each study meeting criteria from the \u2018Diagnosis and treatment protocol for novel coronavirus pneumonia\u2019, published by the China National Health Commission [23].", [["coronavirus pneumonia\u2019", "DISEASE", 155, 177], ["patients", "ORGANISM", 62, 70], ["coronavirus", "ORGANISM", 155, 166], ["patients", "SPECIES", 62, 70], ["This severity index", "TEST", 0, 19], ["treatment protocol", "TREATMENT", 126, 144], ["novel coronavirus pneumonia\u2019", "PROBLEM", 149, 177]]], ["\u2018Mild\u2019 was defined as mild clinical symptoms with no sign of pneumonia on imaging; \u2018moderate\u2019 as fever and respiratory symptoms with radiological findings of pneumonia; \u2018severe\u2019 as meeting any of the following criteria: 1) respiratory distress (\u226530 breaths/min); 2) oxygen saturation \u226493% at rest; 3) arterial partial pressure of oxygen/fraction of inspired oxygen \u2264300mmHg (1mmHg = 0.133kPa); \u2018critical\u2019: cases meeting any of the following criteria: a) respiratory failure and requiring mechanical ventilation; b) shock; c) with other organ failure requiring ICU care.", [["respiratory", "ANATOMY", 107, 118], ["respiratory", "ANATOMY", 223, 234], ["arterial", "ANATOMY", 301, 309], ["respiratory", "ANATOMY", 454, 465], ["organ", "ANATOMY", 536, 541], ["pneumonia", "DISEASE", 61, 70], ["fever", "DISEASE", 97, 102], ["respiratory symptoms", "DISEASE", 107, 127], ["pneumonia", "DISEASE", 158, 167], ["respiratory distress", "DISEASE", 223, 243], ["oxygen", "CHEMICAL", 266, 272], ["oxygen", "CHEMICAL", 330, 336], ["oxygen", "CHEMICAL", 358, 364], ["respiratory failure", "DISEASE", 454, 473], ["shock", "DISEASE", 515, 520], ["organ failure", "DISEASE", 536, 549], ["oxygen", "CHEMICAL", 266, 272], ["oxygen", "CHEMICAL", 330, 336], ["oxygen", "CHEMICAL", 358, 364], ["oxygen", "SIMPLE_CHEMICAL", 266, 272], ["arterial", "MULTI-TISSUE_STRUCTURE", 301, 309], ["oxygen", "SIMPLE_CHEMICAL", 330, 336], ["oxygen", "SIMPLE_CHEMICAL", 358, 364], ["organ", "ORGAN", 536, 541], ["Mild\u2019", "PROBLEM", 1, 6], ["mild clinical symptoms", "PROBLEM", 22, 44], ["pneumonia", "PROBLEM", 61, 70], ["imaging", "TEST", 74, 81], ["moderate\u2019", "PROBLEM", 84, 93], ["fever", "PROBLEM", 97, 102], ["respiratory symptoms", "PROBLEM", 107, 127], ["pneumonia", "PROBLEM", 158, 167], ["respiratory distress", "PROBLEM", 223, 243], ["oxygen saturation", "TEST", 266, 283], ["arterial partial pressure of oxygen/fraction", "TREATMENT", 301, 345], ["inspired oxygen", "TEST", 349, 364], ["respiratory failure", "PROBLEM", 454, 473], ["mechanical ventilation", "TREATMENT", 488, 510], ["shock", "PROBLEM", 515, 520], ["other organ failure", "PROBLEM", 530, 549], ["ICU care", "TREATMENT", 560, 568], ["Mild", "OBSERVATION_MODIFIER", 1, 5], ["mild", "OBSERVATION_MODIFIER", 22, 26], ["no sign of", "UNCERTAINTY", 50, 60], ["pneumonia", "OBSERVATION", 61, 70], ["moderate", "OBSERVATION_MODIFIER", 84, 92], ["pneumonia", "OBSERVATION", 158, 167], ["respiratory", "ANATOMY", 223, 234], ["distress", "OBSERVATION", 235, 243], ["pressure", "OBSERVATION_MODIFIER", 318, 326], ["respiratory", "ANATOMY", 454, 465], ["failure", "OBSERVATION", 466, 473], ["organ", "ANATOMY", 536, 541], ["failure", "OBSERVATION", 542, 549]]], ["As the QE model utilizes information on RoB and adjusts for bias, we did not perform sensitivity analysis for high- and low- quality studies.", [["sensitivity analysis", "TEST", 85, 105]]], ["However, we performed one-out sensitivity analyses, where we excluded one study at a time and evaluated the impact of removing each of the studies on the summary results and the between-study heterogeneity.Study characteristics and risk of bias ::: ResultsThe flow of studies through the search and selection process is presented in Fig 1.", [["sensitivity analyses", "TEST", 30, 50], ["one study", "TEST", 70, 79], ["the studies", "TEST", 135, 146], ["The flow of studies", "TEST", 256, 275], ["flow", "OBSERVATION", 260, 264]]], ["Our previously published review included 60 studies [5].", [["60 studies", "TEST", 41, 51]]], ["Of these studies, 43 studies were not included in this update because our revised methodology included only studies with \u226510 patients.", [["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 125, 133], ["these studies", "TEST", 3, 16], ["43 studies", "TEST", 18, 28], ["studies", "TEST", 108, 115]]], ["The main characteristics of the included studies are summarized in S1 Table in S1 File.", [["the included studies", "TEST", 28, 48], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["Studies excluded because of overlapping are summarized in S2 Table in S1 File, and studies excluded for other reasons are shown in S3 Table in S1 File.", [["Studies", "TEST", 0, 7], ["studies", "TEST", 83, 90]]], ["A total of 86 studies were included in the meta-analyses (n = 91,621), and these were 29 case series, 45 consecutive retrospective case series, 2 consecutive prospective case series, a single RCT and 9 epidemiological reports.", [["the meta-analyses", "TEST", 39, 56], ["a single RCT", "TEST", 183, 195]]], ["An additional 4 studies met the inclusion criteria, but the study populations were neonates or children, and these studies were excluded from the meta-analyses to reduce heterogeneity.", [["neonates", "ORGANISM", 83, 91], ["children", "ORGANISM", 95, 103], ["children", "SPECIES", 95, 103], ["An additional 4 studies", "TEST", 0, 23], ["the study populations", "TEST", 56, 77], ["these studies", "TEST", 109, 122], ["heterogeneity", "PROBLEM", 170, 183]]], ["Patients were from 13 countries (China, 92.7%; United States, 2.1%; South Korea, 2.1%; Singapore, 2.1%; and 9 countries across Europe, 1.0%).", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["In most publications, COVID-19 was diagnosed according to the \u2018Diagnosis and treatment protocol for novel coronavirus pneumonia\u2019, published by the China National Health Commission [23].", [["coronavirus pneumonia\u2019", "DISEASE", 106, 128], ["COVID-19", "CELL", 22, 30], ["coronavirus", "ORGANISM", 106, 117], ["COVID", "TEST", 22, 27], ["treatment protocol", "TREATMENT", 77, 95], ["novel coronavirus pneumonia\u2019", "PROBLEM", 100, 128]]], ["Overall, included studies were judged as being of high risk of bias (S3\u2013S5 Tables in S1 File; S1\u2013S2 Figs in S1 File).", [["S1", "PROTEIN", 94, 96], ["studies", "TEST", 18, 25], ["bias", "TEST", 63, 67]]], ["The only included RCT had high risk of performance and detection bias, as the trial was not blinded; the risk of bias in the remaining five domains was low [24].", [["RCT", "TEST", 18, 21], ["bias in the remaining five domains", "PROBLEM", 113, 147]]], ["The majority of the studies were retrospective case series with risk of selection bias and selective reporting.Overall associations ::: ResultsAs summarized in Table 1, we identified five groups of variables: those associated with the presence of disease or worsening clinical status (14 variables), those with borderline associations (4 variables), those showing non-linear association patterns (4 variables), those with no apparent association (1 variable) and those with too few studies/too little data to indicate any association (6 variables).Patient age and sex ::: ResultsFindings from the quality effects models of mean age and prevalence of men among included studies are summarized in Table 2 and forest plots are presented in the Supplementary Appendix in S1 File.", [["men", "ORGANISM", 650, 653], ["Patient", "SPECIES", 548, 555], ["men", "SPECIES", 650, 653], ["the studies", "TEST", 16, 27], ["disease", "PROBLEM", 247, 254], ["worsening clinical status", "PROBLEM", 258, 283], ["non-linear association patterns", "PROBLEM", 364, 395], ["studies", "TEST", 669, 676], ["forest plots", "TEST", 707, 719], ["disease", "OBSERVATION", 247, 254], ["worsening", "OBSERVATION_MODIFIER", 258, 267], ["no apparent", "UNCERTAINTY", 422, 433], ["Supplementary Appendix", "ANATOMY", 741, 763], ["S1", "ANATOMY", 767, 769]]], ["Severity of disease increased with age.", [["Severity of disease", "PROBLEM", 0, 19], ["disease", "OBSERVATION", 12, 19], ["increased", "OBSERVATION_MODIFIER", 20, 29]]], ["Namely, patients admitted to hospital from the moderate/severe group were significantly older than patients from the mild/moderate group: 54 years [95% CI 51\u201357] vs. 42 [95% CI 38\u201346].", [["patients", "ORGANISM", 8, 16], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 8, 16], ["patients", "SPECIES", 99, 107], ["CI", "TEST", 152, 154], ["CI", "TEST", 174, 176]]], ["Moreover, within the moderate/severe group, the older age was associated with worse clinical status (Table 2, Source of heterogeneity).", [["the moderate/severe group", "PROBLEM", 17, 42], ["moderate", "OBSERVATION_MODIFIER", 21, 29], ["severe", "OBSERVATION_MODIFIER", 30, 36]]], ["In severely ill patients, in 4 out of 5 studies the mean age was \u226554 years.Patient age and sex ::: ResultsRegarding the sex distribution, in patients admitted to hospital male sex was associated with worse clinical status.", [["patients", "ORGANISM", 16, 24], ["patients", "ORGANISM", 141, 149], ["patients", "SPECIES", 16, 24], ["Patient", "SPECIES", 75, 82], ["patients", "SPECIES", 141, 149], ["severely", "OBSERVATION_MODIFIER", 3, 11], ["ill", "OBSERVATION_MODIFIER", 12, 15]]], ["In moderate/severe group there were significantly more men than women (pooled prevalence, 56% of men; 95% CI 53\u201360%).", [["men", "ORGANISM", 55, 58], ["women", "ORGANISM", 64, 69], ["men", "ORGANISM", 97, 100], ["men", "SPECIES", 55, 58], ["women", "SPECIES", 64, 69], ["men", "SPECIES", 97, 100], ["CI", "TEST", 106, 108], ["moderate", "OBSERVATION_MODIFIER", 3, 11], ["severe", "OBSERVATION_MODIFIER", 12, 18]]], ["In addition, when we compared studies including more vs those including less severe patients within the moderate/severe group; we found that men were more often severely ill: 61% of men [95% CI 58\u201365%] vs. 53% [49\u201356%].", [["ill", "DISEASE", 170, 173], ["patients", "ORGANISM", 84, 92], ["men", "ORGANISM", 141, 144], ["men", "ORGANISM", 182, 185], ["patients", "SPECIES", 84, 92], ["men", "SPECIES", 141, 144], ["men", "SPECIES", 182, 185], ["studies", "TEST", 30, 37], ["the moderate/severe group", "PROBLEM", 100, 125], ["CI", "TEST", 191, 193], ["\u2013", "TEST", 196, 197], ["moderate", "OBSERVATION_MODIFIER", 104, 112], ["severe", "OBSERVATION_MODIFIER", 113, 119]]], ["In mild/moderate hospitalized patents, the evidence on association of sex with clinical severity of COVID19 stemmed from studies reporting on more severely ill cases in which the prevalence of men increased with increasing COVID19 severity of included patients (Table 2, Source of heterogeneity).", [["COVID19", "GENE_OR_GENE_PRODUCT", 100, 107], ["men", "ORGANISM", 193, 196], ["patients", "ORGANISM", 252, 260], ["men", "SPECIES", 193, 196], ["patients", "SPECIES", 252, 260], ["mild/moderate hospitalized patents", "PROBLEM", 3, 37], ["studies", "TEST", 121, 128], ["increasing COVID19 severity", "PROBLEM", 212, 239], ["mild", "OBSERVATION_MODIFIER", 3, 7], ["moderate", "OBSERVATION_MODIFIER", 8, 16], ["hospitalized", "OBSERVATION_MODIFIER", 17, 29], ["patents", "OBSERVATION", 30, 37]]], ["Contrary to hospitalized patients, \u2018initially asymptomatic\u2019 patients were more likely women: pooled prevalence, 38% of men [95%CI 28\u201349%].", [["patients", "ORGANISM", 25, 33], ["patients", "ORGANISM", 60, 68], ["women", "ORGANISM", 86, 91], ["men", "ORGANISM", 119, 122], ["patients", "SPECIES", 25, 33], ["patients", "SPECIES", 60, 68], ["women", "SPECIES", 86, 91], ["men", "SPECIES", 119, 122], ["asymptomatic", "PROBLEM", 46, 58], ["CI", "TEST", 127, 129]]], ["Similar was found for \u2018early\u2019 studies, but due to considerable heterogeneity between studies, the evidence was uncertain.Symptoms ::: ResultsTable 3 shows the prevalence ranges of the most commonly reported symptoms, along with pooled prevalence estimates where study heterogeneity was acceptable; forest plots for each symptom are presented in the Supplementary Appendix in S1 File.", [["early\u2019 studies", "TEST", 23, 37], ["considerable heterogeneity between studies", "PROBLEM", 50, 92], ["Symptoms", "PROBLEM", 121, 129], ["symptoms", "PROBLEM", 207, 215], ["study heterogeneity", "TEST", 262, 281], ["forest plots", "PROBLEM", 298, 310], ["each symptom", "PROBLEM", 315, 327], ["Supplementary Appendix", "ANATOMY", 349, 371], ["S1", "ANATOMY", 375, 377]]], ["Fever was extremely common among patients admitted to hospital (pooled prevalence 84%; 95% CI 80\u201387%).", [["Fever", "DISEASE", 0, 5], ["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41], ["Fever", "PROBLEM", 0, 5], ["CI", "TEST", 91, 93]]], ["Regardless, it still showed strong association with patient\u2019s clinical status and a good predictive power for COVID19 outcomes.", [["patient", "ORGANISM", 52, 59], ["patient", "SPECIES", 52, 59], ["COVID19 outcomes", "TREATMENT", 110, 126]]], ["Specifically, moderate/severe patients presented with fever more commonly than mild/moderate: 89% [95% CI 86\u201392%] vs. 77% [72\u201382%].", [["fever", "DISEASE", 54, 59], ["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["moderate/severe patients", "PROBLEM", 14, 38], ["fever", "PROBLEM", 54, 59], ["CI", "TEST", 103, 105], ["moderate", "OBSERVATION_MODIFIER", 14, 22], ["severe", "OBSERVATION_MODIFIER", 23, 29], ["moderate", "OBSERVATION_MODIFIER", 84, 92]]], ["Also, in hospitalized as well as in severely ill patents, the prevalence of fever increased with worsening of patients\u2019 clinical status (Table 3, Source of heterogeneity).", [["fever", "DISEASE", 76, 81], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 110, 118], ["fever", "PROBLEM", 76, 81], ["severely", "OBSERVATION_MODIFIER", 36, 44], ["ill", "OBSERVATION", 45, 48], ["fever", "OBSERVATION", 76, 81], ["worsening", "OBSERVATION_MODIFIER", 97, 106]]], ["Among two studies of initially asymptomatic patients, some of whom later became symptomatic, the pooled frequency of fever at some point during the course of infection was 16% (95% CI 6\u201329%) [26, 27].", [["fever", "DISEASE", 117, 122], ["infection", "DISEASE", 158, 167], ["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["symptomatic", "PROBLEM", 80, 91], ["fever", "PROBLEM", 117, 122], ["infection", "PROBLEM", 158, 167], ["CI", "TEST", 181, 183], ["symptomatic", "OBSERVATION_MODIFIER", 80, 91]]], ["Among \u2018early symptom\u2019 studies, the prevalence of fever was very heterogeneous (p<0.01; I2 = 99%).Symptoms ::: ResultsPrevalence of cough appeared to increase from ~35% as estimated in \u2018early\u2019 and \u2018pregnant\u2019 studies to above 50% in patients admitted to hospital.", [["fever", "DISEASE", 49, 54], ["cough", "DISEASE", 131, 136], ["patients", "ORGANISM", 231, 239], ["patients", "SPECIES", 231, 239], ["fever", "PROBLEM", 49, 54], ["very heterogeneous", "PROBLEM", 59, 77], ["I2", "TEST", 87, 89], ["Symptoms", "PROBLEM", 97, 105], ["cough", "PROBLEM", 131, 136], ["heterogeneous", "OBSERVATION_MODIFIER", 64, 77], ["cough", "OBSERVATION", 131, 136], ["increase", "OBSERVATION_MODIFIER", 149, 157]]], ["However, due to high heterogeneity of studies this increasing trend was not statistically significant.", [["high heterogeneity of studies", "PROBLEM", 16, 45]]], ["Even among patients admitted to hospital, prevalence of cough varied considerably (2\u201392%).", [["cough", "DISEASE", 56, 61], ["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["cough", "PROBLEM", 56, 61], ["cough", "OBSERVATION", 56, 61]]], ["Most of this variability was assigned to studies enrolling moderate/severe patients, which formed two distinct groups of studies.", [["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["studies", "TEST", 41, 48], ["moderate/severe patients", "PROBLEM", 59, 83], ["studies", "TEST", 121, 128], ["severe", "OBSERVATION_MODIFIER", 68, 74]]], ["One group included 10 studies tightly clustered together around the pooled prevalence of 79% (95% CI 77\u201382%) and showing no heterogeneity, whereas the second group of 9 studies was widely dispersed (2\u201363%).", [["10 studies", "TEST", 19, 29], ["CI", "TEST", 98, 100], ["heterogeneity", "PROBLEM", 124, 137], ["no", "UNCERTAINTY", 121, 123], ["heterogeneity", "OBSERVATION", 124, 137]]], ["We found that cough was associated with the severity of disease in hospitalized patients, as moderate/severe patients from homogeneous cluster of studies reported cough more frequently than the mild/moderate group: 79%, 95% CI 77\u201382% vs. 54%, 47\u201361.", [["cough", "DISEASE", 14, 19], ["cough", "DISEASE", 163, 168], ["patients", "ORGANISM", 80, 88], ["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 80, 88], ["patients", "SPECIES", 109, 117], ["cough", "PROBLEM", 14, 19], ["disease", "PROBLEM", 56, 63], ["moderate/severe patients", "PROBLEM", 93, 117], ["cough", "PROBLEM", 163, 168], ["CI", "TEST", 224, 226], ["cough", "OBSERVATION", 14, 19], ["disease", "OBSERVATION", 56, 63], ["moderate", "OBSERVATION_MODIFIER", 93, 101], ["severe", "OBSERVATION_MODIFIER", 102, 108], ["moderate", "OBSERVATION_MODIFIER", 199, 207]]], ["In initially asymptomatic patients, 12% (95% CI 6\u201320%) developed cough during the course of the infection.Symptoms ::: ResultsThe prevalence of dyspnea across all studies is shown in Fig 2.", [["cough", "DISEASE", 65, 70], ["infection", "DISEASE", 96, 105], ["dyspnea", "DISEASE", 144, 151], ["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["CI", "TEST", 45, 47], ["cough", "PROBLEM", 65, 70], ["the infection", "PROBLEM", 92, 105], ["Symptoms", "PROBLEM", 106, 114], ["dyspnea", "PROBLEM", 144, 151], ["all studies", "TEST", 159, 170], ["asymptomatic", "OBSERVATION_MODIFIER", 13, 25], ["cough", "OBSERVATION", 65, 70], ["infection", "OBSERVATION", 96, 105]]], ["Dyspnea was uncommon in all four studies of early disease (pooled prevalence 6%; 95% CI 2\u201311%).", [["Dyspnea", "DISEASE", 0, 7], ["Dyspnea", "PROBLEM", 0, 7], ["early disease", "PROBLEM", 44, 57], ["CI", "TEST", 85, 87], ["early", "OBSERVATION_MODIFIER", 44, 49], ["disease", "OBSERVATION", 50, 57]]], ["Among patients admitted to hospital, there was a wide variation in prevalence (1\u201381%).", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["wide", "OBSERVATION_MODIFIER", 49, 53], ["variation", "OBSERVATION_MODIFIER", 54, 63]]], ["Nevertheless, dyspnea at admission was strongly associated with severity of disease in hospitalized patients, revealing its good predictive power.", [["dyspnea", "DISEASE", 14, 21], ["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108], ["dyspnea", "PROBLEM", 14, 21], ["disease", "PROBLEM", 76, 83], ["disease", "OBSERVATION", 76, 83]]], ["Notably, prevalence of dyspnea increased with severity of patients\u2019 clinical status in: mild/moderate and moderate/severe groups of studies, as well as in severely ill subgroup (Table 3, Source of heterogeneity).", [["dyspnea", "DISEASE", 23, 30], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["dyspnea", "PROBLEM", 23, 30], ["mild/moderate and moderate/severe groups of studies", "PROBLEM", 88, 139], ["dyspnea", "OBSERVATION", 23, 30], ["mild", "OBSERVATION_MODIFIER", 88, 92], ["moderate", "OBSERVATION_MODIFIER", 93, 101], ["moderate", "OBSERVATION_MODIFIER", 106, 114], ["severe", "OBSERVATION_MODIFIER", 115, 121]]], ["However, presence of dyspnea was not exclusive hallmark of severity of disease as even among the 14 studies of moderate/severe patients, there were six studies reporting a prevalence of 15% or less [31\u201335].", [["dyspnea", "DISEASE", 21, 28], ["patients", "ORGANISM", 127, 135], ["patients", "SPECIES", 127, 135], ["dyspnea", "PROBLEM", 21, 28], ["disease", "PROBLEM", 71, 78], ["moderate/severe patients", "PROBLEM", 111, 135], ["six studies", "TEST", 148, 159], ["dyspnea", "OBSERVATION", 21, 28], ["disease", "OBSERVATION", 71, 78], ["moderate", "OBSERVATION_MODIFIER", 111, 119], ["severe", "OBSERVATION_MODIFIER", 120, 126]]], ["Among severely ill patients, the pooled prevalence of dyspnea was 51% (95% 39\u201364%), but there was also a report on zero occurrence of dyspnea among 13 severely ill patients as well [29].Symptoms ::: ResultsAmong hospitalized patients, similar patterns were found for both fatigue and gastrointestinal symptoms, with a trend for increasing prevalence with severity among mild/moderate patients and then decreasing prevalence with severity among moderate/severe, and severely ill patients (Table 3 and forest plots in the Supplementary Appendix in S1 File).", [["gastrointestinal", "ANATOMY", 284, 300], ["dyspnea", "DISEASE", 54, 61], ["dyspnea", "DISEASE", 134, 141], ["fatigue", "DISEASE", 272, 279], ["gastrointestinal symptoms", "DISEASE", 284, 309], ["ill", "DISEASE", 474, 477], ["patients", "ORGANISM", 19, 27], ["patients", "ORGANISM", 164, 172], ["patients", "ORGANISM", 225, 233], ["gastrointestinal", "ORGAN", 284, 300], ["patients", "ORGANISM", 384, 392], ["patients", "ORGANISM", 478, 486], ["patients", "SPECIES", 19, 27], ["patients", "SPECIES", 164, 172], ["patients", "SPECIES", 225, 233], ["patients", "SPECIES", 384, 392], ["patients", "SPECIES", 478, 486], ["dyspnea", "PROBLEM", 54, 61], ["dyspnea", "PROBLEM", 134, 141], ["Symptoms", "PROBLEM", 186, 194], ["both fatigue", "PROBLEM", 267, 279], ["gastrointestinal symptoms", "PROBLEM", 284, 309], ["severity among mild/moderate patients", "PROBLEM", 355, 392], ["severity among moderate/severe", "PROBLEM", 429, 459], ["severely ill patients (Table 3", "PROBLEM", 465, 495], ["forest plots", "TEST", 500, 512], ["severely", "OBSERVATION_MODIFIER", 6, 14], ["ill", "OBSERVATION_MODIFIER", 15, 18], ["gastrointestinal", "ANATOMY", 284, 300], ["mild", "OBSERVATION_MODIFIER", 370, 374], ["moderate", "OBSERVATION_MODIFIER", 375, 383], ["moderate", "OBSERVATION_MODIFIER", 444, 452], ["severe", "OBSERVATION_MODIFIER", 453, 459], ["severely", "OBSERVATION_MODIFIER", 465, 473], ["ill", "OBSERVATION_MODIFIER", 474, 477], ["Appendix", "ANATOMY", 534, 542]]], ["Sore throat was not associated with the severity of disease.", [["Sore throat", "PROBLEM", 0, 11], ["the severity of disease", "PROBLEM", 36, 59], ["disease", "OBSERVATION", 52, 59]]], ["However, except for patients from \u2018initially asymptomatic\u2019 studies who didn\u2019t report any sore throat, this symptom was on average present in 8\u201312% of patients in various settings, from the \u2018early\u2019 studies to the severely ill subgroup.", [["sore throat", "DISEASE", 89, 100], ["ill", "DISEASE", 221, 224], ["patients", "ORGANISM", 20, 28], ["patients", "ORGANISM", 150, 158], ["patients", "SPECIES", 20, 28], ["patients", "SPECIES", 150, 158], ["any sore throat", "PROBLEM", 85, 100], ["this symptom", "PROBLEM", 102, 114]]], ["Similar was found for the headache.", [["headache", "DISEASE", 26, 34], ["the headache", "PROBLEM", 22, 34], ["headache", "OBSERVATION", 26, 34]]], ["We found no association of headache with severity of disease, the symptom was present on average in 10\u201314% of patients from all the analyzed groups.", [["headache", "DISEASE", 27, 35], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 110, 118], ["headache", "PROBLEM", 27, 35], ["severity of disease", "PROBLEM", 41, 60], ["the symptom", "PROBLEM", 62, 73], ["no association of", "UNCERTAINTY", 9, 26], ["headache", "OBSERVATION", 27, 35], ["disease", "OBSERVATION", 53, 60]]], ["The only exception were patients from \u2018initially asymptomatic\u2019 studies in whom the pooled prevalence of headache was significantly lower: 4%; 95 CI 1\u20137%.Symptoms ::: ResultsPrevalence of asymptomatic disease significantly differed between studies in the \u2018early\u2019 group (14%; 95% CI 12\u201317%) and those in the \u2018all-comer\u2019 (2%; 95% CI 2\u20132%) or \u2018admitted to hospital\u2019 (4%; 95% CI 1\u20137%) groups (Table 3).", [["headache", "DISEASE", 104, 112], ["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["headache", "PROBLEM", 104, 112], ["CI", "TEST", 145, 147], ["Symptoms", "PROBLEM", 153, 161], ["asymptomatic disease", "PROBLEM", 187, 207], ["CI", "TEST", 278, 280], ["CI", "TEST", 327, 329], ["CI", "TEST", 371, 373]]], ["In a study of 17 pregnant women with COVID-19 admitted to hospital for a cesarean birth, 9 were asymptomatic or had mild symptoms that did not include fever or cough [36].", [["fever", "DISEASE", 151, 156], ["cough", "DISEASE", 160, 165], ["women", "ORGANISM", 26, 31], ["women", "SPECIES", 26, 31], ["a study", "TEST", 3, 10], ["a cesarean birth", "TREATMENT", 71, 87], ["asymptomatic", "PROBLEM", 96, 108], ["mild symptoms", "PROBLEM", 116, 129], ["fever", "PROBLEM", 151, 156], ["cough", "PROBLEM", 160, 165]]], ["In another study of 13 pregnant women admitted to hospital because of respiratory symptoms or exposure to an infected person, one patient was asymptomatic [37].Symptoms ::: ResultsPneumonia was common, regardless of subgroup: prevalence of at least 50% was reported in all studies except one (Table 3).", [["respiratory", "ANATOMY", 70, 81], ["respiratory symptoms", "DISEASE", 70, 90], ["women", "ORGANISM", 32, 37], ["patient", "ORGANISM", 130, 137], ["women", "SPECIES", 32, 37], ["person", "SPECIES", 118, 124], ["patient", "SPECIES", 130, 137], ["respiratory symptoms", "PROBLEM", 70, 90], ["asymptomatic", "PROBLEM", 142, 154], ["Symptoms", "PROBLEM", 160, 168], ["ResultsPneumonia", "PROBLEM", 173, 189], ["infected", "OBSERVATION", 109, 117]]], ["This outlier, recording an 11% prevalence of pneumonia, was a study of the first recorded patients in Europe [38].", [["pneumonia", "DISEASE", 45, 54], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["pneumonia", "PROBLEM", 45, 54], ["a study", "TEST", 60, 67], ["pneumonia", "OBSERVATION", 45, 54]]], ["Even in two studies of initially asymptomatic patients, the pooled prevalence of pneumonia at some point during follow-up was 62% (95% 45\u201378%) [26, 27].", [["pneumonia", "DISEASE", 81, 90], ["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["pneumonia", "PROBLEM", 81, 90], ["pneumonia", "OBSERVATION", 81, 90]]], ["Among hospitalized patients, the pooled prevalence of pneumonia was 87% (95% CI 82\u201392), increasing to \u226599% in 6 out of 7 studies reporting on the severely ill subgroup.", [["pneumonia", "DISEASE", 54, 63], ["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["pneumonia", "PROBLEM", 54, 63], ["CI", "TEST", 77, 79], ["pneumonia", "OBSERVATION", 54, 63]]], ["The study reporting only 78% of patients with pneumonia in critically ill patients with COVID-19 was a study of the first patients in USA [36].Mortality ::: ResultsPooled mortality estimates were similar among studies in the \u2018early symptoms\u2019 (2.3%; 95% CI 0\u20136%), pregnant (2.6%; 95% CI 0\u20137%) and \u2018all-comer\u2019 (range 0.3% to 2.8%) subgroups (Table 3).", [["pneumonia", "DISEASE", 46, 55], ["critically ill", "DISEASE", 59, 73], ["patients", "ORGANISM", 32, 40], ["patients", "ORGANISM", 74, 82], ["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 32, 40], ["patients", "SPECIES", 74, 82], ["patients", "SPECIES", 122, 130], ["The study", "TEST", 0, 9], ["pneumonia", "PROBLEM", 46, 55], ["COVID", "TEST", 88, 93], ["a study", "TEST", 101, 108], ["early symptoms", "PROBLEM", 226, 240], ["CI", "TEST", 253, 255], ["pregnant", "TEST", 263, 271], ["CI", "TEST", 283, 285], ["\u2018", "TEST", 296, 297], ["pneumonia", "OBSERVATION", 46, 55]]], ["Among studies of hospitalized patients, a distinct pattern emerged.", [["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38]]], ["Most studies enrolling patients with mild/moderate disease reported no deaths (7 out of 10 studies), and the remaining 3 studies reported mortality of 1\u201314%.", [["deaths", "DISEASE", 71, 77], ["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["mild/moderate disease", "PROBLEM", 37, 58], ["the remaining 3 studies", "TEST", 105, 128], ["mortality", "TEST", 138, 147], ["mild", "OBSERVATION_MODIFIER", 37, 41], ["moderate", "OBSERVATION_MODIFIER", 42, 50], ["disease", "OBSERVATION", 51, 58]]], ["However, study sample sizes and follow-up times were usually inadequate to observe those events, and the pooled estimate of 0.1% (95% CI 0.1\u20134.2%) is likely biased.", [["study sample sizes", "TEST", 9, 27], ["the pooled estimate", "TEST", 101, 120], ["CI", "TEST", 134, 136], ["sizes", "OBSERVATION_MODIFIER", 22, 27]]], ["Studies of patients with moderate/severe disease, including subgroup of severely ill patients, reported a wide range of mortality rates, from 0\u201367%, with considerable heterogeneity (I2>90%, p<0.01 for both) stemming from variability in severity of patients\u2019 statuses (Table 3, Source of heterogeneity).", [["patients", "ORGANISM", 11, 19], ["patients", "ORGANISM", 85, 93], ["patients", "ORGANISM", 248, 256], ["patients", "SPECIES", 11, 19], ["patients", "SPECIES", 85, 93], ["patients", "SPECIES", 248, 256], ["Studies", "TEST", 0, 7], ["moderate/severe disease", "PROBLEM", 25, 48], ["mortality rates", "TEST", 120, 135], ["considerable heterogeneity", "PROBLEM", 154, 180], ["I2", "TEST", 182, 184], ["moderate", "OBSERVATION_MODIFIER", 25, 33], ["severe", "OBSERVATION_MODIFIER", 34, 40], ["disease", "OBSERVATION", 41, 48]]], ["In other words, in both moderate/severe, and severely ill patients; mortality was associated with severity of disease.Chest imaging ::: ResultsChest imaging findings are summarized in Table 4 and forest plots are shown in the Supplementary Appendix in S1 File.", [["ill", "DISEASE", 54, 57], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["severity of disease", "PROBLEM", 98, 117], ["Chest imaging", "TEST", 118, 131], ["Chest imaging", "TEST", 143, 156], ["forest plots", "TEST", 196, 208], ["severe", "OBSERVATION_MODIFIER", 33, 39], ["disease", "OBSERVATION", 110, 117], ["Chest", "ANATOMY", 143, 148], ["Supplementary Appendix", "ANATOMY", 226, 248], ["S1", "ANATOMY", 252, 254]]], ["The most common findings were ground glass opacity (GGO), septal thickening and consolidation.", [["septal", "ANATOMY", 58, 64], ["GGO", "DISEASE", 52, 55], ["septal", "TISSUE", 58, 64], ["ground glass opacity (GGO)", "PROBLEM", 30, 56], ["septal thickening", "PROBLEM", 58, 75], ["consolidation", "PROBLEM", 80, 93], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["ground glass opacity", "OBSERVATION", 30, 50], ["GGO", "OBSERVATION_MODIFIER", 52, 55], ["septal", "ANATOMY_MODIFIER", 58, 64], ["thickening", "OBSERVATION", 65, 75], ["consolidation", "OBSERVATION", 80, 93]]], ["The pooled prevalence of any computed tomography (CT) finding across all studies was 89% (95% CI 83\u201393%), but heterogeneity was considerable.", [["any computed tomography (CT)", "TEST", 25, 53], ["all studies", "TEST", 69, 80], ["CI", "TEST", 94, 96]]], ["However, no study reported a prevalence of less than 50%.", [["study", "TEST", 12, 17]]], ["Even in the two studies with initially asymptomatic patients (some of whom went on to become symptomatic) the proportions of patients with any CT finding were 50% (95% CI 30\u201370%) and 78% (95% CI 65\u201389%) [26, 27].", [["patients", "ORGANISM", 52, 60], ["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 52, 60], ["patients", "SPECIES", 125, 133], ["symptomatic", "PROBLEM", 93, 104], ["any CT", "TEST", 139, 145], ["CI", "TEST", 168, 170], ["CI", "TEST", 192, 194]]], ["Studies in the \u2018early\u2019 subgroup reported also a high prevalence of CT findings ranging from 64\u201388%, with the pooled proportion of 74% (95% CI 43\u201397%).", [["CT findings", "TEST", 67, 78], ["CI", "TEST", 139, 141], ["\u2013", "TEST", 144, 145]]], ["Among patients admitted to hospital, probability of positive CT finding increased with disease severity (Table 4, Source of heterogeneity), with all the patients in the severely ill subgroup presenting with CT changes.Chest imaging ::: ResultsGGO changes were commonly reported.", [["patients", "ORGANISM", 6, 14], ["patients", "ORGANISM", 153, 161], ["patients", "SPECIES", 6, 14], ["patients", "SPECIES", 153, 161], ["positive CT", "PROBLEM", 52, 63], ["disease severity", "PROBLEM", 87, 103], ["CT changes", "PROBLEM", 207, 217], ["Chest imaging", "TEST", 218, 231], ["increased", "OBSERVATION_MODIFIER", 72, 81]]], ["Apart from one study of patients with \u2018early\u2019 disease, which reported 8% of patients with any GGO changes [39], other studies declared that at least 40% of patients had GGO changes.", [["GGO", "DISEASE", 94, 97], ["GGO", "DISEASE", 169, 172], ["patients", "ORGANISM", 24, 32], ["patients", "ORGANISM", 76, 84], ["patients", "ORGANISM", 156, 164], ["patients", "SPECIES", 24, 32], ["patients", "SPECIES", 76, 84], ["patients", "SPECIES", 156, 164], ["one study", "TEST", 11, 20], ["\u2018early\u2019 disease", "PROBLEM", 38, 53], ["any GGO changes", "PROBLEM", 90, 105], ["other studies", "TEST", 112, 125], ["GGO changes", "PROBLEM", 169, 180], ["disease", "OBSERVATION", 46, 53], ["GGO", "OBSERVATION", 169, 172]]], ["In the study of 17 parturients (9 asymptomatic), all had GGO [36].", [["GGO", "DISEASE", 57, 60], ["parturients", "ORGANISM", 19, 30], ["the study", "TEST", 3, 12]]], ["Among studies of patients admitted to hospital we found that probability of GGO was decreasing with increasing severity of illness in the mild/moderate (from ~90% to 40\u201347%), moderate/severe (from 98% to 67%), as well as in severely ill subgroup (from 100% to 60%) (Fig 3).", [["GGO", "DISEASE", 76, 79], ["illness", "DISEASE", 123, 130], ["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["GGO", "PROBLEM", 76, 79], ["increasing severity of illness", "PROBLEM", 100, 130], ["moderate/severe", "PROBLEM", 175, 190], ["GGO", "OBSERVATION", 76, 79], ["decreasing", "OBSERVATION_MODIFIER", 84, 94], ["increasing", "OBSERVATION_MODIFIER", 100, 110], ["severity", "OBSERVATION_MODIFIER", 111, 119], ["illness", "OBSERVATION", 123, 130], ["mild", "OBSERVATION_MODIFIER", 138, 142], ["moderate", "OBSERVATION_MODIFIER", 143, 151], ["moderate", "OBSERVATION_MODIFIER", 175, 183], ["severe", "OBSERVATION_MODIFIER", 184, 190]]], ["However, only the associations in severely ill subgroup, and mild/moderate group reached the statistical significance (Table 3, Source of heterogeneity).Chest imaging ::: ResultsParenchymal consolidation was less common than overall GGO changes (range 6\u201368%), and was lowest in a study of 108 patients with early disease [21].", [["Parenchymal", "ANATOMY", 178, 189], ["ill", "DISEASE", 43, 46], ["Parenchymal", "MULTI-TISSUE_STRUCTURE", 178, 189], ["patients", "ORGANISM", 293, 301], ["patients", "SPECIES", 293, 301], ["severely ill subgroup", "PROBLEM", 34, 55], ["mild/moderate group reached the statistical significance", "PROBLEM", 61, 117], ["Chest imaging", "TEST", 153, 166], ["Parenchymal consolidation", "PROBLEM", 178, 203], ["overall GGO changes", "PROBLEM", 225, 244], ["a study", "TEST", 278, 285], ["early disease", "PROBLEM", 307, 320], ["severely", "OBSERVATION_MODIFIER", 34, 42], ["ill subgroup", "OBSERVATION_MODIFIER", 43, 55], ["mild", "OBSERVATION_MODIFIER", 61, 65], ["moderate", "OBSERVATION_MODIFIER", 66, 74], ["Parenchymal", "ANATOMY_MODIFIER", 178, 189], ["consolidation", "OBSERVATION", 190, 203], ["less common", "OBSERVATION_MODIFIER", 208, 219], ["GGO", "OBSERVATION", 233, 236]]], ["Studies on patients admitted to hospital reported highly variable proportions of patients with parenchymal consolidation.", [["parenchymal", "ANATOMY", 95, 106], ["patients", "ORGANISM", 11, 19], ["patients", "ORGANISM", 81, 89], ["parenchymal", "MULTI-TISSUE_STRUCTURE", 95, 106], ["patients", "SPECIES", 11, 19], ["patients", "SPECIES", 81, 89], ["parenchymal consolidation", "PROBLEM", 95, 120], ["parenchymal", "ANATOMY_MODIFIER", 95, 106], ["consolidation", "OBSERVATION", 107, 120]]], ["The source of this heterogeneity was not evident in studies on mild/moderate patients.", [["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["this heterogeneity", "PROBLEM", 14, 32], ["mild/moderate patients", "PROBLEM", 63, 85], ["heterogeneity", "OBSERVATION", 19, 32], ["not evident", "UNCERTAINTY", 37, 48], ["mild", "OBSERVATION_MODIFIER", 63, 67], ["moderate", "OBSERVATION_MODIFIER", 68, 76]]], ["However, in those reporting on patients hospitalized with moderate to severe disease we identified two clusters of studies (subgroup analysis, Supplementary Appendix in S1 File).", [["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["moderate to severe disease", "PROBLEM", 58, 84], ["studies", "TEST", 115, 122], ["subgroup analysis", "TEST", 124, 141], ["moderate", "OBSERVATION_MODIFIER", 58, 66], ["severe", "OBSERVATION_MODIFIER", 70, 76], ["disease", "OBSERVATION", 77, 84], ["Appendix", "ANATOMY", 157, 165]]], ["Four studies reported prevalence of consolidation between 7\u201319% [34, 40\u201342], whereas other three informed on 59\u201364%; with no association with the severity of disease in either cluster [29, 43, 44].", [["Four studies", "TEST", 0, 12], ["consolidation", "PROBLEM", 36, 49], ["disease", "PROBLEM", 158, 165], ["consolidation", "OBSERVATION", 36, 49], ["disease", "OBSERVATION", 158, 165]]], ["We found similar clustering pattern in the severely ill subgroup (Supplementary Appendix in S1 File).", [["ill", "DISEASE", 52, 55], ["similar", "OBSERVATION_MODIFIER", 9, 16], ["clustering", "OBSERVATION_MODIFIER", 17, 27], ["pattern", "OBSERVATION_MODIFIER", 28, 35], ["severely", "OBSERVATION_MODIFIER", 43, 51], ["ill subgroup", "OBSERVATION_MODIFIER", 52, 64], ["Appendix", "ANATOMY", 80, 88]]], ["Likewise, for septal thickening, two clusters were observed among studies of patients admitted to hospital (25\u201337% and 63\u201392%), with no association with disease severity.Laboratory findings ::: ResultsLaboratory findings are summarized in Table 5 and forest plots from the quality effects model are shown in the Supplementary Appendix in S1 File.", [["septal", "ANATOMY", 14, 20], ["septal", "PATHOLOGICAL_FORMATION", 14, 20], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["septal thickening", "PROBLEM", 14, 31], ["disease severity", "PROBLEM", 153, 169], ["forest plots", "TEST", 251, 263], ["septal", "ANATOMY_MODIFIER", 14, 20], ["thickening", "OBSERVATION", 21, 31], ["no association with", "UNCERTAINTY", 133, 152], ["disease", "OBSERVATION", 153, 160], ["Supplementary Appendix", "ANATOMY", 312, 334], ["S1", "ANATOMY", 338, 340]]], ["Low lymphocyte levels were reported in 20% (95% CI 11\u201329%) of patients in the \u2018initially asymptomatic\u2019 studies.", [["lymphocyte", "ANATOMY", 4, 14], ["lymphocyte", "CELL", 4, 14], ["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["Low lymphocyte levels", "PROBLEM", 0, 21], ["CI", "TEST", 48, 50], ["lymphocyte levels", "OBSERVATION", 4, 21]]], ["In the \u2018early\u2019 and pregnant subgroups, pooled percentages were around 50%, although the studies were substantially heterogeneous, most likely due to differences in timing of assessment.", [["pooled percentages", "TEST", 39, 57], ["the studies", "TEST", 84, 95], ["assessment", "TEST", 174, 184], ["substantially", "OBSERVATION_MODIFIER", 101, 114], ["heterogeneous", "OBSERVATION", 115, 128], ["most likely due to", "UNCERTAINTY", 130, 148]]], ["Among studies of patients admitted to hospital, presentation with low number of lymphocytes was strongly associated with the severity of disease.", [["lymphocytes", "ANATOMY", 80, 91], ["patients", "ORGANISM", 17, 25], ["lymphocytes", "CELL", 80, 91], ["lymphocytes", "CELL_TYPE", 80, 91], ["patients", "SPECIES", 17, 25], ["low number of lymphocytes", "PROBLEM", 66, 91], ["the severity of disease", "PROBLEM", 121, 144], ["low number", "OBSERVATION_MODIFIER", 66, 76], ["lymphocytes", "OBSERVATION", 80, 91], ["disease", "OBSERVATION", 137, 144]]], ["Namely, in both the mild/moderate subgroup and the moderate/severe subgroup, there was a trend for increasing prevalence of lymphocytopenia with increasing severity of disease (Table 5, Source of heterogeneity).", [["lymphocytopenia", "DISEASE", 124, 139], ["the mild/moderate subgroup and the moderate/severe subgroup", "PROBLEM", 16, 75], ["lymphocytopenia", "PROBLEM", 124, 139], ["increasing severity of disease", "PROBLEM", 145, 175], ["mild", "OBSERVATION_MODIFIER", 20, 24], ["moderate", "OBSERVATION_MODIFIER", 25, 33], ["moderate", "OBSERVATION_MODIFIER", 51, 59], ["severe", "OBSERVATION_MODIFIER", 60, 66], ["lymphocytopenia", "OBSERVATION", 124, 139], ["increasing", "OBSERVATION_MODIFIER", 145, 155], ["severity", "OBSERVATION_MODIFIER", 156, 164], ["disease", "OBSERVATION", 168, 175]]], ["The pooled prevalence of lymphocytopenia among severely ill patients was high and reached 84% (95% CI 77\u201389%).", [["lymphocytopenia", "DISEASE", 25, 40], ["severely ill", "DISEASE", 47, 59], ["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["lymphocytopenia", "PROBLEM", 25, 40], ["CI", "TEST", 99, 101], ["lymphocytopenia", "OBSERVATION", 25, 40], ["severely", "OBSERVATION_MODIFIER", 47, 55], ["ill", "OBSERVATION_MODIFIER", 56, 59]]], ["Among severely ill patients with lymphocytopenia, the pooled estimate of lymphocyte level was 0.62 (95% CI 0.58\u20130.66) x109 cells/L (heterogeneity, Q = 1.8; p = 0.41; I2 = 0), but among severely ill patients overall there was considerable heterogeneity in lymphocyte count (0.67\u20130.90; Q = 112.56; p = 0.00; I2 = 96%).Laboratory findings ::: ResultsLow white blood cell (WBC) count was described in approximately 20% of patients in the \u2018initially asymptomatic\u2019 studies and the \u2018early\u2019 studies.", [["lymphocyte", "ANATOMY", 73, 83], ["cells", "ANATOMY", 123, 128], ["lymphocyte", "ANATOMY", 255, 265], ["white blood cell", "ANATOMY", 351, 367], ["WBC", "ANATOMY", 369, 372], ["lymphocytopenia", "DISEASE", 33, 48], ["patients", "ORGANISM", 19, 27], ["lymphocyte", "CELL", 73, 83], ["patients", "ORGANISM", 198, 206], ["lymphocyte", "CELL", 255, 265], ["white blood cell", "CELL", 351, 367], ["WBC", "CELL", 369, 372], ["patients", "ORGANISM", 418, 426], ["patients", "SPECIES", 19, 27], ["patients", "SPECIES", 198, 206], ["patients", "SPECIES", 418, 426], ["lymphocytopenia", "PROBLEM", 33, 48], ["lymphocyte level", "TEST", 73, 89], ["CI", "TEST", 104, 106], ["cells", "TEST", 123, 128], ["heterogeneity", "TEST", 132, 145], ["Q", "TEST", 147, 148], ["p", "TEST", 156, 157], ["I2", "TEST", 166, 168], ["considerable heterogeneity", "PROBLEM", 225, 251], ["lymphocyte count", "TEST", 255, 271], ["Q", "TEST", 284, 285], ["p", "TEST", 296, 297], ["I2", "TEST", 306, 308], ["Low white blood cell", "PROBLEM", 347, 367], ["WBC) count", "TEST", 369, 379], ["severely", "OBSERVATION_MODIFIER", 6, 14], ["ill", "OBSERVATION_MODIFIER", 15, 18], ["lymphocytopenia", "OBSERVATION", 33, 48], ["considerable", "OBSERVATION_MODIFIER", 225, 237], ["heterogeneity", "OBSERVATION_MODIFIER", 238, 251], ["lymphocyte count", "OBSERVATION", 255, 271], ["Low", "OBSERVATION_MODIFIER", 347, 350]]], ["Among studies including hospitalized patients, there was a trend for a decrease in prevalence of low WBC count along with increasing severity of disease among all hospitalized (from ~30% to ~10%), as well as moderate/severe hospitalized patients (from ~20% to ~10%) (Fig 4A and Table 5, Source of heterogeneity).", [["WBC", "ANATOMY", 101, 104], ["patients", "ORGANISM", 37, 45], ["patients", "ORGANISM", 237, 245], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 237, 245], ["Among studies", "TEST", 0, 13], ["low WBC count", "PROBLEM", 97, 110], ["increasing severity of disease", "PROBLEM", 122, 152], ["moderate/severe hospitalized patients", "PROBLEM", 208, 245], ["low WBC count", "OBSERVATION_MODIFIER", 97, 110], ["increasing", "OBSERVATION_MODIFIER", 122, 132], ["severity", "OBSERVATION_MODIFIER", 133, 141], ["disease", "OBSERVATION", 145, 152], ["moderate", "OBSERVATION_MODIFIER", 208, 216], ["severe", "OBSERVATION_MODIFIER", 217, 223]]], ["While the initial meta-regression analysis across all studies on hospitalized patients did not reach significance, sensitivity analysis identified the study by Bai et al. as a source of heterogeneity [49].", [["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["the initial meta-regression analysis", "TEST", 6, 42], ["all studies", "TEST", 50, 61], ["sensitivity analysis", "TEST", 115, 135], ["the study", "TEST", 147, 156]]], ["After removal of this study, we found a significant trend across the remaining 20 studies.", [["this study", "TEST", 17, 27], ["significant", "OBSERVATION_MODIFIER", 40, 51], ["trend", "OBSERVATION_MODIFIER", 52, 57]]], ["Complementary data were found for elevated WBC count for which we also found association with the disease severity (Fig 4B and Table 5, Source of heterogeneity), Notably, we observed an increase in prevalence with increasing severity of the disease among moderate/severe hospitalized patients, and also found that probability of elevated WBC was more likely in moderate/severe patients than in mild moderate: 0.17 (95% CI 0.12\u20130.23) vs. 0.03 (95% CI 0.02\u20130.05).", [["WBC", "ANATOMY", 43, 46], ["WBC", "CELL", 43, 46], ["patients", "ORGANISM", 284, 292], ["WBC", "CELL", 338, 341], ["patients", "ORGANISM", 377, 385], ["patients", "SPECIES", 284, 292], ["patients", "SPECIES", 377, 385], ["Complementary data", "TEST", 0, 18], ["elevated WBC count", "PROBLEM", 34, 52], ["the disease severity", "PROBLEM", 94, 114], ["the disease", "PROBLEM", 237, 248], ["elevated WBC", "PROBLEM", 329, 341], ["CI", "TEST", 419, 421], ["CI", "TEST", 447, 449], ["disease", "OBSERVATION", 98, 105], ["increase", "OBSERVATION_MODIFIER", 186, 194], ["increasing", "OBSERVATION_MODIFIER", 214, 224], ["severity", "OBSERVATION_MODIFIER", 225, 233], ["moderate", "OBSERVATION_MODIFIER", 255, 263], ["severe", "OBSERVATION_MODIFIER", 264, 270], ["moderate", "OBSERVATION_MODIFIER", 361, 369], ["severe", "OBSERVATION_MODIFIER", 370, 376], ["mild", "OBSERVATION_MODIFIER", 394, 398], ["moderate", "OBSERVATION_MODIFIER", 399, 407]]], ["Studies in the mild/moderate subgroup initially showed considerable heterogeneity.", [["Studies", "TEST", 0, 7], ["the mild/moderate subgroup", "PROBLEM", 11, 37], ["considerable heterogeneity", "PROBLEM", 55, 81], ["mild", "OBSERVATION_MODIFIER", 15, 19], ["moderate", "OBSERVATION_MODIFIER", 20, 28], ["considerable", "OBSERVATION_MODIFIER", 55, 67], ["heterogeneity", "OBSERVATION", 68, 81]]], ["However, all of this heterogeneity was derived from the study by Bai et al., which reported 29% of patients with elevated WBC [49].", [["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["the study", "TEST", 52, 61], ["elevated WBC", "PROBLEM", 113, 125]]], ["Exclusion of this study mitigated heterogeneity and a pooled prevalence of 3% (95% CI 1.8\u20134.9) was estimated for this subgroup.", [["this study", "TEST", 13, 23], ["a pooled prevalence", "TEST", 52, 71], ["CI", "TEST", 83, 85]]], ["The results from low and elevated WBC analyses suggest that these proportions are interchanged in the Bai et al. paper [42].Laboratory findings ::: ResultsElevated C-reactive protein (CRP) was one of the most common laboratory findings.", [["ResultsElevated C-reactive protein", "GENE_OR_GENE_PRODUCT", 148, 182], ["CRP", "GENE_OR_GENE_PRODUCT", 184, 187], ["C-reactive protein", "PROTEIN", 164, 182], ["CRP", "PROTEIN", 184, 187], ["low and elevated WBC analyses", "PROBLEM", 17, 46], ["Laboratory findings", "TEST", 124, 143], ["C-reactive protein", "TEST", 164, 182], ["CRP", "TEST", 184, 187], ["low", "OBSERVATION_MODIFIER", 17, 20]]], ["The proportion of patients with elevated CRP in the \u2018initially asymptomatic\u2019 studies (pooled prevalence 19%; 95% CI 10\u201328%) was significantly lower than studies in hospitalized patients (63%, 95% CI 0.48\u20130.77).", [["patients", "ORGANISM", 18, 26], ["CRP", "GENE_OR_GENE_PRODUCT", 41, 44], ["patients", "ORGANISM", 177, 185], ["CRP", "PROTEIN", 41, 44], ["patients", "SPECIES", 18, 26], ["patients", "SPECIES", 177, 185], ["elevated CRP", "PROBLEM", 32, 44], ["pooled prevalence", "TEST", 86, 103], ["CI", "TEST", 113, 115], ["CI", "TEST", 196, 198], ["elevated", "OBSERVATION_MODIFIER", 32, 40], ["CRP", "OBSERVATION", 41, 44]]], ["Moreover, in patients admitted to hospital, elevated CRP was further associated with severity of disease as severely ill patients presented with elevated CRP more often than mild/moderate group: 0.88 (95% CI 0.76\u20130.98) vs. 0.63 (95% CI 0.48\u20130.77).", [["patients", "ORGANISM", 13, 21], ["CRP", "GENE_OR_GENE_PRODUCT", 53, 56], ["patients", "ORGANISM", 121, 129], ["CRP", "GENE_OR_GENE_PRODUCT", 154, 157], ["CRP", "PROTEIN", 53, 56], ["CRP", "PROTEIN", 154, 157], ["patients", "SPECIES", 13, 21], ["patients", "SPECIES", 121, 129], ["elevated CRP", "PROBLEM", 44, 56], ["severity of disease", "PROBLEM", 85, 104], ["severely ill", "PROBLEM", 108, 120], ["elevated CRP", "PROBLEM", 145, 157], ["CI", "TEST", 205, 207], ["CI", "TEST", 233, 235], ["disease", "OBSERVATION", 97, 104], ["moderate", "OBSERVATION_MODIFIER", 179, 187]]], ["Finally, in the moderate/severe group of studies we observed an increase in the prevalence of elevated CRP as disease severity increased, from ~60% to 91% (Table 5, Source of heterogeneity).", [["CRP", "GENE_OR_GENE_PRODUCT", 103, 106], ["CRP", "PROTEIN", 103, 106], ["the moderate/severe group of studies", "PROBLEM", 12, 48], ["elevated CRP", "PROBLEM", 94, 106], ["disease severity", "PROBLEM", 110, 126], ["moderate", "OBSERVATION_MODIFIER", 16, 24], ["severe", "OBSERVATION_MODIFIER", 25, 31], ["increase", "OBSERVATION_MODIFIER", 64, 72], ["elevated", "OBSERVATION_MODIFIER", 94, 102], ["CRP", "OBSERVATION", 103, 106], ["severity", "OBSERVATION_MODIFIER", 118, 126], ["increased", "OBSERVATION_MODIFIER", 127, 136]]], ["For interleukin (IL)-6, among patients admitted to hospital, we were able to show that the proportion of patients with interleukin (IL)-6 values above 7 pg/ml appears to increase with the severity of illness, although this only included 5 studies (Fig 5 and Table 5, Source of heterogeneity).", [["illness", "DISEASE", 200, 207], ["interleukin (IL)-6", "GENE_OR_GENE_PRODUCT", 4, 22], ["patients", "ORGANISM", 30, 38], ["patients", "ORGANISM", 105, 113], ["interleukin (IL)-6", "GENE_OR_GENE_PRODUCT", 119, 137], ["interleukin (IL)-6", "PROTEIN", 4, 22], ["interleukin (IL)-6", "PROTEIN", 119, 137], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 105, 113], ["interleukin (IL)", "TREATMENT", 4, 20], ["interleukin (IL)", "TREATMENT", 119, 135], ["illness", "PROBLEM", 200, 207], ["5 studies", "TEST", 237, 246], ["Fig", "TEST", 248, 251]]], ["The single \u2018initially asymptomatic\u2019 subgroup study that reported this variable did not find elevated IL-6 values in any patients (n = 55) [27].", [["IL-6", "GENE_OR_GENE_PRODUCT", 101, 105], ["patients", "ORGANISM", 120, 128], ["IL", "PROTEIN", 101, 103], ["patients", "SPECIES", 120, 128], ["subgroup study", "TEST", 36, 50], ["elevated IL", "PROBLEM", 92, 103]]], ["Among hospitalized patients, elevated D-dimer levels were detected more frequently in the moderate/severe than the mild/moderate group: 0.29 (95% CI 0.18\u20130.42) vs 0.09 (95% CI 0.03\u20130.18).", [["patients", "ORGANISM", 19, 27], ["D-dimer", "GENE_OR_GENE_PRODUCT", 38, 45], ["D-dimer", "PROTEIN", 38, 45], ["patients", "SPECIES", 19, 27], ["elevated D-dimer levels", "PROBLEM", 29, 52], ["CI", "TEST", 146, 148], ["vs", "TEST", 160, 162], ["CI", "TEST", 173, 175], ["moderate", "OBSERVATION_MODIFIER", 90, 98], ["severe", "OBSERVATION", 99, 105], ["mild", "OBSERVATION_MODIFIER", 115, 119], ["moderate", "OBSERVATION_MODIFIER", 120, 128]]], ["In severely ill subgroup, this parameter reached the pooled proportion of 0.60, 95% CI 0.52\u20130.68 after exclusion of severely ill patients from an outlier \u2018all-comers\u2019 study.", [["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 129, 137], ["this parameter", "TEST", 26, 40], ["CI", "TEST", 84, 86], ["severely ill patients", "PROBLEM", 116, 137], ["severely", "OBSERVATION_MODIFIER", 3, 11], ["ill subgroup", "OBSERVATION_MODIFIER", 12, 24]]], ["Low platelet levels were recorded in 12% of hospitalized patients (95% CI 9\u201335%).", [["platelet", "ANATOMY", 4, 12], ["platelet", "CELL", 4, 12], ["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["Low platelet levels", "PROBLEM", 0, 19], ["CI", "TEST", 71, 73], ["platelet levels", "OBSERVATION", 4, 19]]], ["Yet, in moderate/severe group we observed a decreasing prevalence of patients with low platelet count, from ~20% to ~5%, with the increasing severity of COVID19.", [["platelet", "ANATOMY", 87, 95], ["low platelet count", "DISEASE", 83, 101], ["patients", "ORGANISM", 69, 77], ["platelet", "CELL", 87, 95], ["COVID19", "GENE_OR_GENE_PRODUCT", 153, 160], ["COVID19", "PROTEIN", 153, 160], ["patients", "SPECIES", 69, 77], ["low platelet count", "PROBLEM", 83, 101], ["the increasing severity of COVID19", "PROBLEM", 126, 160], ["moderate", "OBSERVATION_MODIFIER", 8, 16], ["severe", "OBSERVATION_MODIFIER", 17, 23], ["decreasing", "OBSERVATION_MODIFIER", 44, 54], ["low platelet count", "OBSERVATION", 83, 101]]], ["Elevated troponin was recorded in 16% (95% CI 11\u201322) of patients in moderate/severe group, but no data were published on other groups.Laboratory findings ::: ResultsAlanine aminotransferase (ALT) was rarely elevated among \u2018initially asymptomatic\u2019 patients (pooled prevalence of 2%; 95% CI 0\u201313%), and in a single \u2018all-comer\u2019 study the prevalence was 21% (95% CI 18\u201324%).", [["ResultsAlanine", "CHEMICAL", 158, 172], ["ResultsAlanine", "CHEMICAL", 158, 172], ["troponin", "GENE_OR_GENE_PRODUCT", 9, 17], ["patients", "ORGANISM", 56, 64], ["ResultsAlanine aminotransferase", "GENE_OR_GENE_PRODUCT", 158, 189], ["ALT", "SIMPLE_CHEMICAL", 191, 194], ["patients", "ORGANISM", 247, 255], ["troponin", "PROTEIN", 9, 17], ["ResultsAlanine aminotransferase", "PROTEIN", 158, 189], ["ALT", "PROTEIN", 191, 194], ["patients", "SPECIES", 56, 64], ["patients", "SPECIES", 247, 255], ["Elevated troponin", "PROBLEM", 0, 17], ["CI", "TEST", 43, 45], ["moderate/severe group", "PROBLEM", 68, 89], ["ResultsAlanine aminotransferase (ALT)", "TEST", 158, 195], ["rarely elevated", "PROBLEM", 200, 215], ["CI", "TEST", 286, 288], ["CI", "TEST", 359, 361], ["moderate", "OBSERVATION_MODIFIER", 68, 76], ["severe", "OBSERVATION", 77, 83]]], ["Among studies of hospitalized patients, prevalence of patients with elevated ALT increased with increasing severity of disease, from 4\u201341% (Table 5, Source of heterogeneity).", [["patients", "ORGANISM", 30, 38], ["patients", "ORGANISM", 54, 62], ["ALT", "SIMPLE_CHEMICAL", 77, 80], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 54, 62], ["elevated ALT", "PROBLEM", 68, 80], ["increasing severity of disease", "PROBLEM", 96, 126], ["increasing", "OBSERVATION_MODIFIER", 96, 106], ["severity", "OBSERVATION_MODIFIER", 107, 115], ["disease", "OBSERVATION", 119, 126]]], ["Moderate/severe group presented with more elevated ALT than mild/moderate 0.31 (95% CI 0.25\u20130.38) vs. 0.11 (95% CI 0.02\u20130.22); while the pooled proportion among severely ill patients without the all-comers study [47] was 40% (95% CI 34\u201346%).", [["ill", "DISEASE", 170, 173], ["patients", "ORGANISM", 174, 182], ["patients", "SPECIES", 174, 182], ["Moderate/severe group", "PROBLEM", 0, 21], ["more elevated ALT", "PROBLEM", 37, 54], ["CI", "TEST", 84, 86], ["CI", "TEST", 112, 114], ["CI", "TEST", 230, 232], ["severe", "OBSERVATION_MODIFIER", 9, 15], ["moderate", "OBSERVATION_MODIFIER", 65, 73], ["severely", "OBSERVATION_MODIFIER", 161, 169], ["ill", "OBSERVATION", 170, 173]]], ["Similarly, across all subgroups there was a clear increase in the occurrence of elevated aspartate aminotransferase (AST) as disease severity increased (Fig 6), with a significant trend detected across the studies of hospitalized patients, from 16\u201361% (R2 = 59%; p<0.001).Hospital admissions and supportive therapy ::: ResultsDuration of hospitalization was reported in 8 studies (n = 1,653) and ranged from 3.7 to 23.2 days.", [["aspartate", "CHEMICAL", 89, 98], ["aspartate", "CHEMICAL", 89, 98], ["aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 89, 115], ["AST", "SIMPLE_CHEMICAL", 117, 120], ["patients", "ORGANISM", 230, 238], ["aspartate aminotransferase", "PROTEIN", 89, 115], ["AST", "PROTEIN", 117, 120], ["patients", "SPECIES", 230, 238], ["elevated aspartate aminotransferase (AST)", "PROBLEM", 80, 121], ["disease severity", "PROBLEM", 125, 141], ["a significant trend", "PROBLEM", 166, 185], ["R2", "TEST", 253, 255], ["p", "TEST", 263, 264], ["supportive therapy", "TREATMENT", 296, 314], ["clear", "OBSERVATION_MODIFIER", 44, 49], ["increase", "OBSERVATION_MODIFIER", 50, 58], ["elevated", "OBSERVATION_MODIFIER", 80, 88], ["aspartate aminotransferase", "OBSERVATION", 89, 115], ["significant", "OBSERVATION_MODIFIER", 168, 179], ["trend", "OBSERVATION_MODIFIER", 180, 185]]], ["Use of supportive therapy is summarized in Table 6.", [["supportive therapy", "TREATMENT", 7, 25]]], ["Overall up to 30% of patients were admitted to an ICU, and the pooled proportion of ICU admissions among the all-comer studies (n = 1439) was 6% (95% 3\u201310%).", [["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29]]], ["Invasive ventilation was used in 0\u201371% of patients overall.", [["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["Invasive ventilation", "TREATMENT", 0, 20]]], ["In the subgroup of severely ill patients 3\u201371% had invasive ventilation and there was a strong trend for increasing use with increased severity (Table 6, Source of heterogeneity).", [["ill", "DISEASE", 28, 31], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["invasive ventilation", "TREATMENT", 51, 71], ["increased severity", "PROBLEM", 125, 143], ["severely", "OBSERVATION_MODIFIER", 19, 27], ["ill", "OBSERVATION_MODIFIER", 28, 31], ["invasive ventilation", "OBSERVATION", 51, 71]]], ["Non-invasive ventilation was used in 0\u201356% of patients (5\u201371% in severely ill patients) and dialysis in 0\u20139% (8%; 95% CI 5\u201312% in severely ill).", [["ill", "DISEASE", 74, 77], ["patients", "ORGANISM", 46, 54], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 46, 54], ["patients", "SPECIES", 78, 86], ["Non-invasive ventilation", "TREATMENT", 0, 24], ["dialysis", "TREATMENT", 92, 100], ["CI", "TEST", 118, 120]]], ["Extracorporeal membrane oxygenation (ECMO) was used in 1% (95% CI 0\u20132%) of patients overall and in 3% of severely ill patients (95% CI 1\u20136%).Pharmacological treatment approaches ::: ResultsMost studies were descriptive, with no control group, and therefore did not assess the efficacy and safety of interventions.", [["Extracorporeal membrane", "ANATOMY", 0, 23], ["ill", "DISEASE", 114, 117], ["Extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 0, 23], ["patients", "ORGANISM", 75, 83], ["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 75, 83], ["patients", "SPECIES", 118, 126], ["Extracorporeal membrane oxygenation", "TREATMENT", 0, 35], ["CI", "TEST", 63, 65], ["CI", "TEST", 132, 134], ["interventions", "TREATMENT", 299, 312], ["membrane oxygenation", "OBSERVATION", 15, 35]]], ["Use of any antiviral was specifically mentioned in 27 studies (n = 3,059), with most of the studies reporting at least 73% of patients receiving at least one antiviral (oseltamivir, ritonavir, lopinavir, ribavirin, peramivir and umifenovir).", [["oseltamivir", "CHEMICAL", 169, 180], ["ritonavir", "CHEMICAL", 182, 191], ["lopinavir", "CHEMICAL", 193, 202], ["ribavirin", "CHEMICAL", 204, 213], ["peramivir", "CHEMICAL", 215, 224], ["umifenovir", "CHEMICAL", 229, 239], ["oseltamivir", "CHEMICAL", 169, 180], ["ritonavir", "CHEMICAL", 182, 191], ["lopinavir", "CHEMICAL", 193, 202], ["ribavirin", "CHEMICAL", 204, 213], ["peramivir", "CHEMICAL", 215, 224], ["umifenovir", "CHEMICAL", 229, 239], ["patients", "ORGANISM", 126, 134], ["oseltamivir", "SIMPLE_CHEMICAL", 169, 180], ["ritonavir", "SIMPLE_CHEMICAL", 182, 191], ["lopinavir", "SIMPLE_CHEMICAL", 193, 202], ["ribavirin", "SIMPLE_CHEMICAL", 204, 213], ["peramivir", "SIMPLE_CHEMICAL", 215, 224], ["umifenovir", "SIMPLE_CHEMICAL", 229, 239], ["patients", "SPECIES", 126, 134], ["any antiviral", "TREATMENT", 7, 20], ["the studies", "TEST", 88, 99], ["oseltamivir", "TREATMENT", 169, 180], ["ritonavir", "TREATMENT", 182, 191], ["lopinavir", "TREATMENT", 193, 202], ["ribavirin", "TREATMENT", 204, 213], ["peramivir", "TREATMENT", 215, 224], ["umifenovir", "TREATMENT", 229, 239]]], ["Six studies reported that 21\u201350% of patients received any antivirals [24, 25, 47, 50\u201352].", [["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["Six studies", "TEST", 0, 11], ["any antivirals", "TREATMENT", 54, 68]]], ["Only one RCT was identified, an open-label trial in 199 Chinese COVID-19 patients in which 99 patients were assigned to the lopinavir\u2013ritonavir group (400 mg and 100 mg orally, for 14 days) plus standard care, and 100 patients to the standard care group [24].", [["lopinavir\u2013ritonavir", "CHEMICAL", 124, 143], ["lopinavir\u2013ritonavir", "CHEMICAL", 124, 143], ["patients", "ORGANISM", 73, 81], ["patients", "ORGANISM", 94, 102], ["lopinavir\u2013ritonavir", "SIMPLE_CHEMICAL", 124, 143], ["patients", "ORGANISM", 218, 226], ["patients", "SPECIES", 73, 81], ["patients", "SPECIES", 94, 102], ["patients", "SPECIES", 218, 226], ["the lopinavir\u2013ritonavir group", "TREATMENT", 120, 149], ["one", "OBSERVATION_MODIFIER", 5, 8], ["RCT", "OBSERVATION", 9, 12]]], ["Standard care comprised, as necessary, supplemental oxygen, noninvasive and invasive ventilation, antibiotic agents, vasopressor support, renal-replacement therapy, and ECMO.", [["renal", "ANATOMY", 138, 143], ["oxygen", "CHEMICAL", 52, 58], ["oxygen", "CHEMICAL", 52, 58], ["oxygen", "SIMPLE_CHEMICAL", 52, 58], ["renal", "ORGAN", 138, 143], ["supplemental oxygen", "TREATMENT", 39, 58], ["noninvasive and invasive ventilation", "TREATMENT", 60, 96], ["antibiotic agents", "TREATMENT", 98, 115], ["vasopressor support", "TREATMENT", 117, 136], ["renal-replacement therapy", "TREATMENT", 138, 163], ["ECMO", "TREATMENT", 169, 173], ["renal", "ANATOMY", 138, 143], ["replacement therapy", "OBSERVATION", 144, 163]]], ["There were no differences between the two groups in terms of time to clinical improvement (hazard ratio for clinical improvement, 1.31; 95% CI 0.95\u20131.80), mortality at 28 days (19.2% vs 25.0%; difference, \u22125.8 percentage points; 95% CI \u221217.3\u20135.7) or proportion of patients with detectable viral RNA.", [["patients", "ORGANISM", 264, 272], ["viral RNA", "RNA", 289, 298], ["patients", "SPECIES", 264, 272], ["CI", "TEST", 140, 142], ["mortality", "TEST", 155, 164], ["CI", "TEST", 233, 235], ["detectable viral RNA", "PROBLEM", 278, 298], ["no", "UNCERTAINTY", 11, 13], ["viral RNA", "OBSERVATION", 289, 298]]], ["Gastro-intestinal adverse events were more common in the intervention group, but serious adverse events were more common in the control group (64.6% vs. 37.9%, mostly respiratory failure, acute kidney damage, and secondary infection).", [["intestinal", "ANATOMY", 7, 17], ["respiratory", "ANATOMY", 167, 178], ["kidney", "ANATOMY", 194, 200], ["respiratory failure", "DISEASE", 167, 186], ["acute kidney damage", "DISEASE", 188, 207], ["infection", "DISEASE", 223, 232], ["intestinal", "ORGAN", 7, 17], ["kidney", "ORGAN", 194, 200], ["Gastro-intestinal adverse events", "PROBLEM", 0, 32], ["serious adverse events", "PROBLEM", 81, 103], ["mostly respiratory failure", "PROBLEM", 160, 186], ["acute kidney damage", "PROBLEM", 188, 207], ["secondary infection", "PROBLEM", 213, 232], ["intestinal", "ANATOMY", 7, 17], ["adverse", "OBSERVATION", 18, 25], ["respiratory failure", "OBSERVATION", 167, 186], ["acute", "OBSERVATION_MODIFIER", 188, 193], ["kidney", "ANATOMY", 194, 200], ["damage", "OBSERVATION", 201, 207], ["secondary", "OBSERVATION_MODIFIER", 213, 222], ["infection", "OBSERVATION", 223, 232]]], ["Among 17 studies that reported antibiotic use (n = 2,471), 4\u201395% of patients received this treatment (including beta-lactams, fluoroquinolones, cephalosporins, piperacillin-tazobactam and meropenem).", [["beta-lactams", "CHEMICAL", 112, 124], ["fluoroquinolones", "CHEMICAL", 126, 142], ["cephalosporins", "CHEMICAL", 144, 158], ["piperacillin-tazobactam", "CHEMICAL", 160, 183], ["meropenem", "CHEMICAL", 188, 197], ["beta-lactams", "CHEMICAL", 112, 124], ["fluoroquinolones", "CHEMICAL", 126, 142], ["cephalosporins", "CHEMICAL", 144, 158], ["piperacillin-tazobactam", "CHEMICAL", 160, 183], ["meropenem", "CHEMICAL", 188, 197], ["patients", "ORGANISM", 68, 76], ["fluoroquinolones", "SIMPLE_CHEMICAL", 126, 142], ["cephalosporins", "SIMPLE_CHEMICAL", 144, 158], ["piperacillin-tazobactam", "SIMPLE_CHEMICAL", 160, 183], ["meropenem", "SIMPLE_CHEMICAL", 188, 197], ["patients", "SPECIES", 68, 76], ["this treatment", "TREATMENT", 86, 100], ["beta-lactams", "TREATMENT", 112, 124], ["fluoroquinolones", "TREATMENT", 126, 142], ["cephalosporins", "TREATMENT", 144, 158], ["piperacillin", "TREATMENT", 160, 172], ["tazobactam", "TREATMENT", 173, 183], ["meropenem", "TREATMENT", 188, 197]]], ["The probability of treatment increased with severity of illness and among hospitalized patients there was an increasing trend, from 23\u2013100% (Table 6, Source of heterogeneity), with 90% (95% CI 80\u201397) of severely ill patients receiving antibiotics.", [["illness", "DISEASE", 56, 63], ["ill", "DISEASE", 212, 215], ["patients", "ORGANISM", 87, 95], ["patients", "ORGANISM", 216, 224], ["patients", "SPECIES", 87, 95], ["patients", "SPECIES", 216, 224], ["treatment", "TREATMENT", 19, 28], ["illness", "PROBLEM", 56, 63], ["an increasing trend", "PROBLEM", 106, 125], ["CI", "TEST", 190, 192], ["antibiotics", "TREATMENT", 235, 246], ["increasing", "OBSERVATION_MODIFIER", 109, 119], ["trend", "OBSERVATION_MODIFIER", 120, 125]]], ["Taking steroids also depended on severity of illness (Table 6, Source of heterogeneity) with 0\u20133% steroids received by least severe hospital patients, followed by 30% that was reported in majority of moderately/severe studies, and finally 58\u201365% taken by most severely ill patients (22 studies; n = 2917).", [["steroids", "CHEMICAL", 7, 15], ["steroids", "CHEMICAL", 98, 106], ["steroids", "CHEMICAL", 7, 15], ["steroids", "CHEMICAL", 98, 106], ["steroids", "SIMPLE_CHEMICAL", 98, 106], ["patients", "ORGANISM", 141, 149], ["patients", "ORGANISM", 273, 281], ["patients", "SPECIES", 141, 149], ["patients", "SPECIES", 273, 281], ["steroids", "TREATMENT", 7, 15], ["0\u20133% steroids", "TREATMENT", 93, 106], ["moderately/severe studies", "PROBLEM", 200, 225]]], ["Four studies reported steroid use that was much higher than anticipated based on the severity of included patients [35, 51, 53, 54].", [["steroid", "CHEMICAL", 22, 29], ["steroid", "CHEMICAL", 22, 29], ["steroid", "SIMPLE_CHEMICAL", 22, 29], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["Four studies", "TEST", 0, 12], ["steroid use", "TREATMENT", 22, 33]]], ["Immunoglobulin usage (18 studies; n = 2,499) also depended on severity of patients with studies on hospitalized patients reporting from 6\u201373% of patients taking it.", [["Immunoglobulin", "GENE_OR_GENE_PRODUCT", 0, 14], ["patients", "ORGANISM", 74, 82], ["patients", "ORGANISM", 112, 120], ["patients", "ORGANISM", 145, 153], ["patients", "SPECIES", 74, 82], ["patients", "SPECIES", 112, 120], ["patients", "SPECIES", 145, 153], ["Immunoglobulin usage", "TEST", 0, 20]]], ["In severely ill, 36% (95% CI, 22\u201351%) received immunoglobulin as a therapy.Incubation time ::: ResultsMeta-analysis of 5,900 patients revealed the range of individual studies\u2019 incubation times of 4\u20138 days (15 studies), and a considerable heterogeneity between, and among subgroups of studies.", [["immunoglobulin", "GENE_OR_GENE_PRODUCT", 47, 61], ["patients", "ORGANISM", 125, 133], ["immunoglobulin", "PROTEIN", 47, 61], ["patients", "SPECIES", 125, 133], ["CI", "TEST", 26, 28], ["immunoglobulin", "TREATMENT", 47, 61], ["a therapy", "TREATMENT", 65, 74], ["individual studies", "TEST", 156, 174], ["severely", "OBSERVATION_MODIFIER", 3, 11], ["ill", "OBSERVATION_MODIFIER", 12, 15], ["considerable", "OBSERVATION_MODIFIER", 225, 237], ["heterogeneity", "OBSERVATION", 238, 251]]], ["The longest time was reported in a single \u2018initially asymptomatic\u2019 study (8 days; 95% CI 7.6\u20138.4) and the shortest for the \u2018all-comer\u2019 studies (4\u20136 days; 4 studies).", [["CI", "TEST", 86, 88]]], ["In severely ill patients, the mean incubation time for one study was 4.0 days (95% CI 3.5\u20134.49), whereas the other two on hospitalized patients reported longer means of 7.4 and 8 days.Features associated with more severe disease states ::: DiscussionOur analysis identified several factors associated with worsening clinical status in adults with COVID-19: fever, cough, dyspnea, pneumonia, any pathological CT findings, any GGO, lymphocytopenia, elevated CRP, elevated ALT and AST, increasing age and male sex.", [["fever", "DISEASE", 357, 362], ["cough", "DISEASE", 364, 369], ["dyspnea", "DISEASE", 371, 378], ["pneumonia", "DISEASE", 380, 389], ["GGO", "DISEASE", 425, 428], ["lymphocytopenia", "DISEASE", 430, 445], ["patients", "ORGANISM", 16, 24], ["patients", "ORGANISM", 135, 143], ["CRP", "GENE_OR_GENE_PRODUCT", 456, 459], ["ALT", "SIMPLE_CHEMICAL", 470, 473], ["AST", "SIMPLE_CHEMICAL", 478, 481], ["CRP", "PROTEIN", 456, 459], ["ALT", "PROTEIN", 470, 473], ["AST", "PROTEIN", 478, 481], ["patients", "SPECIES", 16, 24], ["patients", "SPECIES", 135, 143], ["one study", "TEST", 55, 64], ["CI", "TEST", 83, 85], ["more severe disease states", "PROBLEM", 209, 235], ["DiscussionOur analysis", "TEST", 240, 262], ["worsening clinical status", "PROBLEM", 306, 331], ["COVID", "TEST", 347, 352], ["fever", "PROBLEM", 357, 362], ["cough", "PROBLEM", 364, 369], ["dyspnea", "PROBLEM", 371, 378], ["pneumonia", "PROBLEM", 380, 389], ["any pathological CT findings", "PROBLEM", 391, 419], ["any GGO", "PROBLEM", 421, 428], ["lymphocytopenia", "PROBLEM", 430, 445], ["elevated CRP", "PROBLEM", 447, 459], ["elevated ALT", "PROBLEM", 461, 473], ["AST", "TEST", 478, 481], ["severely", "OBSERVATION_MODIFIER", 3, 11], ["ill", "OBSERVATION_MODIFIER", 12, 15], ["more severe", "OBSERVATION_MODIFIER", 209, 220], ["disease", "OBSERVATION", 221, 228], ["pneumonia", "OBSERVATION", 380, 389], ["lymphocytopenia", "OBSERVATION", 430, 445], ["ALT", "ANATOMY", 470, 473]]], ["Elevated WBC count showed a strong trend for increasing prevalence with more severe disease states in moderate/severely ill patients.", [["WBC", "ANATOMY", 9, 12], ["ill", "DISEASE", 120, 123], ["WBC", "CELL", 9, 12], ["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 124, 132], ["Elevated WBC count", "PROBLEM", 0, 18], ["more severe disease states", "PROBLEM", 72, 98], ["moderate/severely ill patients", "PROBLEM", 102, 132], ["WBC count", "OBSERVATION", 9, 18], ["severe", "OBSERVATION_MODIFIER", 77, 83], ["disease", "OBSERVATION", 84, 91], ["moderate", "OBSERVATION_MODIFIER", 102, 110]]], ["Elevated lymphocytes, low platelets, IL-6, erythrocyte sedimentation rate (ESR) and D-dimers showed borderline associations with worsening clinical status, but because of lack of studies, some analyses were underpowered.", [["lymphocytes", "ANATOMY", 9, 20], ["platelets", "ANATOMY", 26, 35], ["lymphocytes", "CELL", 9, 20], ["platelets", "CELL", 26, 35], ["IL-6", "GENE_OR_GENE_PRODUCT", 37, 41], ["erythrocyte", "CELL", 43, 54], ["D-dimers", "GENE_OR_GENE_PRODUCT", 84, 92], ["lymphocytes", "CELL_TYPE", 9, 20], ["platelets", "CELL_TYPE", 26, 35], ["IL-6", "PROTEIN", 37, 41], ["Elevated lymphocytes", "PROBLEM", 0, 20], ["low platelets", "PROBLEM", 22, 35], ["IL", "TEST", 37, 39], ["erythrocyte sedimentation rate", "TEST", 43, 73], ["ESR", "TEST", 75, 78], ["D-dimers", "TEST", 84, 92], ["borderline associations", "PROBLEM", 100, 123], ["worsening clinical status", "PROBLEM", 129, 154], ["studies", "TEST", 179, 186], ["some analyses", "TEST", 188, 201], ["lymphocytes", "OBSERVATION", 9, 20], ["low platelets", "OBSERVATION_MODIFIER", 22, 35], ["erythrocyte", "ANATOMY", 43, 54], ["worsening", "OBSERVATION_MODIFIER", 129, 138]]], ["Fatigue, gastrointestinal symptoms, consolidation and septal thickening in CT imaging showed non-linear association patterns, suggesting that they do not have high value in clinical assessment of severity.", [["gastrointestinal", "ANATOMY", 9, 25], ["septal", "ANATOMY", 54, 60], ["Fatigue", "DISEASE", 0, 7], ["gastrointestinal symptoms", "DISEASE", 9, 34], ["gastrointestinal", "ORGAN", 9, 25], ["Fatigue", "PROBLEM", 0, 7], ["gastrointestinal symptoms", "PROBLEM", 9, 34], ["consolidation", "PROBLEM", 36, 49], ["septal thickening", "PROBLEM", 54, 71], ["CT imaging", "TEST", 75, 85], ["non-linear association patterns", "PROBLEM", 93, 124], ["clinical assessment", "TEST", 173, 192], ["severity", "PROBLEM", 196, 204], ["gastrointestinal", "ANATOMY", 9, 25], ["consolidation", "OBSERVATION", 36, 49], ["septal", "ANATOMY_MODIFIER", 54, 60], ["thickening", "OBSERVATION", 61, 71]]], ["Headache and sore throat were associated with the presence of disease, but not with worsening clinical status.Features associated with more severe disease states ::: DiscussionLymphocytopenia may be indicative of stronger activation of the immune system even in early stages of COVID, eventually leading to more severe disease and has been suggested as a predictor of poor outcome in COVID-19 [55].", [["immune system", "ANATOMY", 240, 253], ["Headache", "DISEASE", 0, 8], ["sore throat", "DISEASE", 13, 24], ["COVID", "DISEASE", 278, 283], ["Headache", "PROBLEM", 0, 8], ["sore throat", "PROBLEM", 13, 24], ["disease", "PROBLEM", 62, 69], ["worsening clinical status", "PROBLEM", 84, 109], ["more severe disease states", "PROBLEM", 135, 161], ["stronger activation of the immune system", "PROBLEM", 213, 253], ["more severe disease", "PROBLEM", 307, 326], ["COVID", "TEST", 384, 389], ["sore throat", "ANATOMY", 13, 24], ["disease", "OBSERVATION", 62, 69], ["more severe", "OBSERVATION_MODIFIER", 135, 146], ["disease", "OBSERVATION", 147, 154], ["may be indicative of", "UNCERTAINTY", 192, 212], ["stronger", "OBSERVATION_MODIFIER", 213, 221], ["activation", "OBSERVATION", 222, 232], ["severe", "OBSERVATION_MODIFIER", 312, 318], ["disease", "OBSERVATION", 319, 326]]], ["The virus may directly induce T-lymphocyte apoptosis through activating intrinsic and extrinsic mechanisms, e.g. via the ACE2 receptor on lymphocytes [56], or through pro-inflammatory cytokines that negatively influence lymphocyte function [57, 58].", [["T-lymphocyte", "ANATOMY", 30, 42], ["lymphocytes", "ANATOMY", 138, 149], ["lymphocyte", "ANATOMY", 220, 230], ["T-lymphocyte", "CELL", 30, 42], ["ACE2", "GENE_OR_GENE_PRODUCT", 121, 125], ["lymphocytes", "CELL", 138, 149], ["lymphocyte", "CELL", 220, 230], ["ACE2 receptor", "PROTEIN", 121, 134], ["lymphocytes", "CELL_TYPE", 138, 149], ["pro-inflammatory cytokines", "PROTEIN", 167, 193], ["The virus", "PROBLEM", 0, 9], ["lymphocyte apoptosis", "PROBLEM", 32, 52], ["activating intrinsic and extrinsic mechanisms", "PROBLEM", 61, 106], ["the ACE2 receptor", "TEST", 117, 134], ["lymphocytes", "TEST", 138, 149], ["pro-inflammatory cytokines", "TEST", 167, 193], ["lymphocyte function", "TEST", 220, 239], ["virus", "OBSERVATION", 4, 9], ["lymphocyte apoptosis", "OBSERVATION", 32, 52]]], ["Other factors, such as acidosis, might also contribute.", [["acidosis", "DISEASE", 23, 31], ["Other factors", "PROBLEM", 0, 13], ["acidosis", "PROBLEM", 23, 31], ["acidosis", "OBSERVATION", 23, 31]]], ["However, a conclusive pathophysiological explanation regarding replication of the SARS-CoV-2 inside T-lymphocytes or viral induced-apoptosis is not clear at this point [59].", [["T-lymphocytes", "ANATOMY", 100, 113], ["SARS", "DISEASE", 82, 86], ["SARS-CoV-2", "ORGANISM", 82, 92], ["T-lymphocytes", "CELL", 100, 113], ["T-lymphocytes", "CELL_TYPE", 100, 113], ["the SARS", "TEST", 78, 86], ["CoV", "TEST", 87, 90], ["viral induced-apoptosis", "PROBLEM", 117, 140], ["lymphocytes", "ANATOMY", 102, 113]]], ["Our results are also in line with a recent meta-analysis showing raised WBC and lymphocytopenia in COVID-19 patients [60], and overproduction of cytokines, such as IL-6, correlating with disease severity [61].", [["WBC", "ANATOMY", 72, 75], ["lymphocytopenia", "DISEASE", 80, 95], ["WBC", "CELL", 72, 75], ["patients", "ORGANISM", 108, 116], ["IL-6", "GENE_OR_GENE_PRODUCT", 164, 168], ["cytokines", "PROTEIN", 145, 154], ["IL-6", "PROTEIN", 164, 168], ["patients", "SPECIES", 108, 116], ["a recent meta-analysis", "TEST", 34, 56], ["raised WBC", "PROBLEM", 65, 75], ["lymphocytopenia", "PROBLEM", 80, 95], ["COVID", "TEST", 99, 104], ["overproduction of cytokines", "PROBLEM", 127, 154], ["IL", "TEST", 164, 166], ["disease severity", "PROBLEM", 187, 203], ["lymphocytopenia", "OBSERVATION", 80, 95]]], ["Our data on lymphocytopenia, WBC and IL-6 support the hypothesis that severe cytokine release syndrome (\u2018cytokine storm\u2019) causes more profound respiratory disease in COVID-19, which is already established in ARDS generally [62\u201364].", [["WBC", "ANATOMY", 29, 32], ["respiratory", "ANATOMY", 143, 154], ["lymphocytopenia", "DISEASE", 12, 27], ["respiratory disease", "DISEASE", 143, 162], ["ARDS", "DISEASE", 208, 212], ["COVID-19", "CHEMICAL", 166, 174], ["WBC", "CELL", 29, 32], ["IL-6", "GENE_OR_GENE_PRODUCT", 37, 41], ["WBC", "CELL_TYPE", 29, 32], ["IL-6", "PROTEIN", 37, 41], ["cytokine", "PROTEIN", 77, 85], ["cytokine", "PROTEIN", 105, 113], ["Our data", "TEST", 0, 8], ["lymphocytopenia", "PROBLEM", 12, 27], ["WBC", "TEST", 29, 32], ["IL", "TEST", 37, 39], ["the hypothesis", "PROBLEM", 50, 64], ["severe cytokine release syndrome", "PROBLEM", 70, 102], ["cytokine storm\u2019", "TREATMENT", 105, 120], ["profound respiratory disease", "PROBLEM", 134, 162], ["COVID", "TEST", 166, 171], ["ARDS", "PROBLEM", 208, 212], ["lymphocytopenia", "OBSERVATION", 12, 27], ["severe", "OBSERVATION_MODIFIER", 70, 76], ["cytokine release syndrome", "OBSERVATION", 77, 102], ["profound", "OBSERVATION_MODIFIER", 134, 142], ["respiratory disease", "OBSERVATION", 143, 162], ["ARDS", "OBSERVATION", 208, 212]]], ["Cytokine release syndrome may be linked to increased lung injury and T-cell dysfunction [61].", [["lung", "ANATOMY", 53, 57], ["T-cell", "ANATOMY", 69, 75], ["lung injury", "DISEASE", 53, 64], ["Cytokine", "GENE_OR_GENE_PRODUCT", 0, 8], ["lung", "ORGAN", 53, 57], ["T-cell", "CELL", 69, 75], ["Cytokine", "PROTEIN", 0, 8], ["Cytokine release syndrome", "PROBLEM", 0, 25], ["increased lung injury", "PROBLEM", 43, 64], ["T-cell dysfunction", "PROBLEM", 69, 87], ["may be linked to", "UNCERTAINTY", 26, 42], ["increased", "OBSERVATION_MODIFIER", 43, 52], ["lung", "ANATOMY", 53, 57], ["injury", "OBSERVATION", 58, 64], ["cell dysfunction", "OBSERVATION", 71, 87]]], ["Besides a natural inflammatory response to infection (typical of SARS-CoV-2), this elevated WBC count might be associated with pharmacological interventions, such as corticoids, epinephrine and beta-agonists.", [["WBC", "ANATOMY", 92, 95], ["infection", "DISEASE", 43, 52], ["epinephrine", "CHEMICAL", 178, 189], ["epinephrine", "CHEMICAL", 178, 189], ["SARS-CoV-2", "ORGANISM", 65, 75], ["WBC", "CELL", 92, 95], ["corticoids", "SIMPLE_CHEMICAL", 166, 176], ["epinephrine", "SIMPLE_CHEMICAL", 178, 189], ["beta-agonists", "SIMPLE_CHEMICAL", 194, 207], ["SARS-CoV", "SPECIES", 65, 73], ["a natural inflammatory response", "PROBLEM", 8, 39], ["infection", "PROBLEM", 43, 52], ["SARS", "PROBLEM", 65, 69], ["CoV", "TEST", 70, 73], ["this elevated WBC count", "PROBLEM", 78, 101], ["pharmacological interventions", "TREATMENT", 127, 156], ["corticoids", "TREATMENT", 166, 176], ["epinephrine", "TREATMENT", 178, 189], ["beta-agonists", "TREATMENT", 194, 207], ["natural", "OBSERVATION_MODIFIER", 10, 17], ["inflammatory", "OBSERVATION_MODIFIER", 18, 30], ["infection", "OBSERVATION", 43, 52]]], ["However, studies retrieved in this review did not specify medications used in patients with severe disease.", [["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["studies", "TEST", 9, 16], ["medications", "TREATMENT", 58, 69], ["severe disease", "PROBLEM", 92, 106], ["severe", "OBSERVATION_MODIFIER", 92, 98], ["disease", "OBSERVATION", 99, 106]]], ["The clear trend for elevated AST associated with more severe disease accords with other commentary on liver injury in COVID-19 [65].", [["liver", "ANATOMY", 102, 107], ["liver injury", "DISEASE", 102, 114], ["AST", "SIMPLE_CHEMICAL", 29, 32], ["liver", "ORGAN", 102, 107], ["AST", "PROTEIN", 29, 32], ["elevated AST", "PROBLEM", 20, 32], ["more severe disease accords", "PROBLEM", 49, 76], ["liver injury", "PROBLEM", 102, 114], ["COVID", "TEST", 118, 123], ["clear", "OBSERVATION", 4, 9], ["severe", "OBSERVATION_MODIFIER", 54, 60], ["disease", "OBSERVATION", 61, 68], ["liver", "ANATOMY", 102, 107], ["injury", "OBSERVATION", 108, 114]]], ["Therefore, liver function should be closely monitored in patients with COVID-19 and hepatotoxic drugs should be used with caution.Features associated with more severe disease states ::: DiscussionThe most common radiological and CT features found in patients with SARS-CoV-2 pneumonia were GGO, septal thickening and consolidation.", [["liver", "ANATOMY", 11, 16], ["septal", "ANATOMY", 295, 301], ["COVID-19", "CHEMICAL", 71, 79], ["hepatotoxic", "DISEASE", 84, 95], ["SARS", "DISEASE", 264, 268], ["pneumonia", "DISEASE", 275, 284], ["GGO", "DISEASE", 290, 293], ["COVID-19", "CHEMICAL", 71, 79], ["liver", "ORGAN", 11, 16], ["patients", "ORGANISM", 57, 65], ["COVID-19", "SIMPLE_CHEMICAL", 71, 79], ["patients", "ORGANISM", 250, 258], ["SARS-CoV-2", "ORGANISM", 264, 274], ["septal", "TISSUE", 295, 301], ["patients", "SPECIES", 57, 65], ["patients", "SPECIES", 250, 258], ["CoV-", "SPECIES", 269, 273], ["liver function", "TEST", 11, 25], ["COVID", "TEST", 71, 76], ["hepatotoxic drugs", "TREATMENT", 84, 101], ["more severe disease states", "PROBLEM", 155, 181], ["CT features", "TEST", 229, 240], ["SARS", "PROBLEM", 264, 268], ["CoV-2 pneumonia", "PROBLEM", 269, 284], ["GGO", "PROBLEM", 290, 293], ["septal thickening", "PROBLEM", 295, 312], ["consolidation", "PROBLEM", 317, 330], ["liver", "ANATOMY", 11, 16], ["more severe", "OBSERVATION_MODIFIER", 155, 166], ["disease", "OBSERVATION", 167, 174], ["pneumonia", "OBSERVATION", 275, 284], ["GGO", "OBSERVATION", 290, 293], ["septal", "ANATOMY_MODIFIER", 295, 301], ["thickening", "OBSERVATION", 302, 312], ["consolidation", "OBSERVATION", 317, 330]]], ["This is similar to observations reported in other types of viral pneumonia, including those associated with SARS and MERS [66, 67].", [["viral pneumonia", "DISEASE", 59, 74], ["SARS", "DISEASE", 108, 112], ["viral pneumonia", "PROBLEM", 59, 74], ["SARS", "PROBLEM", 108, 112], ["viral", "OBSERVATION_MODIFIER", 59, 64], ["pneumonia", "OBSERVATION", 65, 74]]], ["GGO was strongly associated with severe disease.", [["GGO", "DISEASE", 0, 3], ["GGO", "PROBLEM", 0, 3], ["severe disease", "PROBLEM", 33, 47], ["strongly associated with", "UNCERTAINTY", 8, 32], ["severe", "OBSERVATION_MODIFIER", 33, 39], ["disease", "OBSERVATION", 40, 47]]], ["In COVID-19 patients, middle, lower and posterior lobes, peripherally and symmetrically, are most commonly affected [68].", [["lower", "ANATOMY", 30, 35], ["posterior lobes", "ANATOMY", 40, 55], ["peripherally", "ANATOMY", 57, 69], ["patients", "ORGANISM", 12, 20], ["posterior lobes", "MULTI-TISSUE_STRUCTURE", 40, 55], ["patients", "SPECIES", 12, 20], ["middle", "ANATOMY_MODIFIER", 22, 28], ["lower", "ANATOMY_MODIFIER", 30, 35], ["posterior", "ANATOMY_MODIFIER", 40, 49], ["lobes", "ANATOMY_MODIFIER", 50, 55], ["peripherally", "ANATOMY_MODIFIER", 57, 69], ["symmetrically", "ANATOMY_MODIFIER", 74, 87]]], ["In SARS, GGO is also described predominantly in these regions [69], suggesting that this pattern of GGO might be a hallmark for coronavirus-related pathologies.", [["SARS", "DISEASE", 3, 7], ["GGO", "DISEASE", 100, 103], ["coronavirus", "DISEASE", 128, 139], ["GGO", "CANCER", 100, 103], ["coronavirus", "ORGANISM", 128, 139], ["SARS", "PROBLEM", 3, 7], ["GGO", "PROBLEM", 9, 12], ["GGO", "PROBLEM", 100, 103], ["coronavirus", "PROBLEM", 128, 139], ["pathologies", "PROBLEM", 148, 159], ["SARS", "OBSERVATION", 3, 7], ["GGO", "OBSERVATION", 9, 12], ["predominantly", "OBSERVATION_MODIFIER", 31, 44], ["GGO", "OBSERVATION", 100, 103]]], ["Among studies of patients admitted to hospital we found a pattern of decreasing probability of GGO with increasing severity of illness which occurred separately in the mild/moderate (from ~90% to 40%), and moderate/severe (from 98% to 67%) groups.", [["GGO", "DISEASE", 95, 98], ["illness", "DISEASE", 127, 134], ["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["GGO", "PROBLEM", 95, 98], ["increasing severity of illness", "PROBLEM", 104, 134], ["the mild/moderate", "PROBLEM", 164, 181], ["moderate/severe", "PROBLEM", 206, 221], ["decreasing", "OBSERVATION_MODIFIER", 69, 79], ["GGO", "OBSERVATION", 95, 98], ["increasing", "OBSERVATION_MODIFIER", 104, 114], ["severity", "OBSERVATION_MODIFIER", 115, 123], ["illness", "OBSERVATION", 127, 134], ["mild", "OBSERVATION_MODIFIER", 168, 172], ["moderate", "OBSERVATION_MODIFIER", 173, 181], ["moderate", "OBSERVATION_MODIFIER", 206, 214], ["severe", "OBSERVATION_MODIFIER", 215, 221]]], ["This might be due to the natural evolution of the disease, as consolidation represents a later stage of pulmonary injury.", [["pulmonary", "ANATOMY", 104, 113], ["pulmonary injury", "DISEASE", 104, 120], ["pulmonary", "ORGAN", 104, 113], ["the disease", "PROBLEM", 46, 57], ["consolidation", "PROBLEM", 62, 75], ["pulmonary injury", "PROBLEM", 104, 120], ["might be due to", "UNCERTAINTY", 5, 20], ["disease", "OBSERVATION", 50, 57], ["consolidation", "OBSERVATION", 62, 75], ["pulmonary", "ANATOMY", 104, 113], ["injury", "OBSERVATION", 114, 120]]], ["Therefore, the patients included in our analysis may have already been in a late phase of the disease when radiological imaging was performed, or this might reflect fast disease progression in these patients.Features associated with more severe disease states ::: DiscussionFever, cough and dyspnea were the symptoms most strongly associated with more severe disease states.", [["cough", "DISEASE", 281, 286], ["dyspnea", "DISEASE", 291, 298], ["patients", "ORGANISM", 15, 23], ["patients", "ORGANISM", 199, 207], ["patients", "SPECIES", 15, 23], ["patients", "SPECIES", 199, 207], ["our analysis", "TEST", 36, 48], ["radiological imaging", "TEST", 107, 127], ["fast disease progression", "PROBLEM", 165, 189], ["more severe disease states", "PROBLEM", 233, 259], ["cough", "PROBLEM", 281, 286], ["dyspnea", "PROBLEM", 291, 298], ["the symptoms", "PROBLEM", 304, 316], ["more severe disease states", "PROBLEM", 347, 373], ["fast", "OBSERVATION_MODIFIER", 165, 169], ["disease", "OBSERVATION", 170, 177], ["more severe", "OBSERVATION_MODIFIER", 233, 244], ["disease", "OBSERVATION", 245, 252], ["severe", "OBSERVATION_MODIFIER", 352, 358], ["disease", "OBSERVATION", 359, 366]]], ["This trend was clear for dyspnea and fever even across the studies included in the subgroup analysis of severe patients, suggesting that these are rapidly evolving symptoms with predictive potential in individual treatment plans.", [["dyspnea", "DISEASE", 25, 32], ["fever", "DISEASE", 37, 42], ["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119], ["dyspnea", "PROBLEM", 25, 32], ["fever", "PROBLEM", 37, 42], ["the studies", "TEST", 55, 66], ["rapidly evolving symptoms", "PROBLEM", 147, 172], ["individual treatment plans", "TREATMENT", 202, 228], ["severe", "OBSERVATION_MODIFIER", 104, 110]]], ["Among lab variables, white blood cell count and IL-6 show particular promise as markers of severe disease.", [["white blood cell", "ANATOMY", 21, 37], ["white blood cell", "CELL", 21, 37], ["IL-6", "GENE_OR_GENE_PRODUCT", 48, 52], ["IL-6", "PROTEIN", 48, 52], ["white blood cell count", "TEST", 21, 43], ["IL", "TEST", 48, 50], ["severe disease", "PROBLEM", 91, 105], ["severe", "OBSERVATION_MODIFIER", 91, 97], ["disease", "OBSERVATION", 98, 105]]], ["Elevated white blood cell count showed a striking trend for increasing prevalence with more severe clinical status among hospitalized patients with moderate/severe disease.", [["white blood cell", "ANATOMY", 9, 25], ["white blood cell", "CELL", 9, 25], ["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 134, 142], ["Elevated white blood cell count", "TEST", 0, 31], ["moderate/severe disease", "PROBLEM", 148, 171], ["more severe", "OBSERVATION_MODIFIER", 87, 98], ["moderate", "OBSERVATION_MODIFIER", 148, 156], ["severe", "OBSERVATION_MODIFIER", 157, 163], ["disease", "OBSERVATION", 164, 171]]], ["Although IL-6 was only measured in 6 studies, and therefore more data are needed to increase certainty, an association with severity was clear.", [["IL-6", "GENE_OR_GENE_PRODUCT", 9, 13], ["IL-6", "PROTEIN", 9, 13], ["clear", "OBSERVATION", 137, 142]]], ["Most patients with severe disease had elevated CRP, but this was also common among patients with milder disease.", [["patients", "ORGANISM", 5, 13], ["CRP", "GENE_OR_GENE_PRODUCT", 47, 50], ["patients", "ORGANISM", 83, 91], ["CRP", "PROTEIN", 47, 50], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 83, 91], ["severe disease", "PROBLEM", 19, 33], ["elevated CRP", "PROBLEM", 38, 50], ["milder disease", "PROBLEM", 97, 111], ["severe", "OBSERVATION_MODIFIER", 19, 25], ["disease", "OBSERVATION", 26, 33], ["elevated", "OBSERVATION_MODIFIER", 38, 46], ["CRP", "OBSERVATION", 47, 50], ["milder", "OBSERVATION_MODIFIER", 97, 103], ["disease", "OBSERVATION", 104, 111]]], ["Hence CRP appears to have utility as a marker of clinically manifesting disease, but not related to severity.", [["CRP", "GENE_OR_GENE_PRODUCT", 6, 9], ["CRP", "PROTEIN", 6, 9], ["CRP", "TEST", 6, 9], ["clinically manifesting disease", "PROBLEM", 49, 79], ["not related to", "UNCERTAINTY", 85, 99]]], ["PCT did not show a clear association with the dynamics of COVID-19.", [["COVID-19", "CHEMICAL", 58, 66], ["PCT", "TEST", 0, 3], ["COVID", "TEST", 58, 63], ["clear", "OBSERVATION", 19, 24]]], ["Slightly higher rates of patients with elevated PCT in the severely ill subgroup are likely due to higher rates of bacterial superinfection.", [["ill", "DISEASE", 68, 71], ["superinfection", "DISEASE", 125, 139], ["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["elevated PCT", "PROBLEM", 39, 51], ["bacterial superinfection", "PROBLEM", 115, 139], ["higher", "OBSERVATION_MODIFIER", 9, 15], ["rates", "OBSERVATION_MODIFIER", 16, 21], ["likely due to", "UNCERTAINTY", 85, 98], ["higher", "OBSERVATION_MODIFIER", 99, 105], ["bacterial", "OBSERVATION_MODIFIER", 115, 124], ["superinfection", "OBSERVATION", 125, 139]]], ["This disconnection between PCT and COVID-19 suggests that PCT may have value as a marker of bacterial superinfection to guide rational use of antibiotics in patients with COVID-19.Features associated with early and mild disease ::: DiscussionIn contrast to severe disease, mild disease appears to be more common in women than men.", [["bacterial superinfection", "DISEASE", 92, 116], ["COVID-19", "CHEMICAL", 35, 43], ["PCT", "GENE_OR_GENE_PRODUCT", 58, 61], ["patients", "ORGANISM", 157, 165], ["women", "ORGANISM", 315, 320], ["men", "ORGANISM", 326, 329], ["PCT", "PROTEIN", 58, 61], ["patients", "SPECIES", 157, 165], ["women", "SPECIES", 315, 320], ["men", "SPECIES", 326, 329], ["PCT", "TEST", 27, 30], ["COVID", "TEST", 35, 40], ["PCT", "TEST", 58, 61], ["bacterial superinfection", "PROBLEM", 92, 116], ["antibiotics", "TREATMENT", 142, 153], ["COVID", "TEST", 171, 176], ["early and mild disease", "PROBLEM", 205, 227], ["severe disease", "PROBLEM", 257, 271], ["mild disease", "PROBLEM", 273, 285], ["bacterial", "OBSERVATION_MODIFIER", 92, 101], ["superinfection", "OBSERVATION", 102, 116], ["mild", "OBSERVATION_MODIFIER", 215, 219], ["disease", "OBSERVATION", 220, 227], ["severe", "OBSERVATION_MODIFIER", 257, 263], ["disease", "OBSERVATION", 264, 271], ["mild", "OBSERVATION_MODIFIER", 273, 277], ["disease", "OBSERVATION", 278, 285]]], ["There were more female than male patients in the two \u2018initially asymptomatic\u2019 studies (67% and 60% female), and overall the 11 \u2018early\u2019 studies included higher percentages of women than men, although high heterogeneity limits confidence in these findings.", [["patients", "ORGANISM", 33, 41], ["women", "ORGANISM", 174, 179], ["men", "ORGANISM", 185, 188], ["patients", "SPECIES", 33, 41], ["women", "SPECIES", 174, 179], ["men", "SPECIES", 185, 188], ["high heterogeneity", "PROBLEM", 199, 217]]], ["Potential protective factors for women include immune modulation by sex-specific steroids and the estrogen receptor [70, 71].", [["steroids", "CHEMICAL", 81, 89], ["estrogen", "CHEMICAL", 98, 106], ["steroids", "CHEMICAL", 81, 89], ["estrogen", "CHEMICAL", 98, 106], ["women", "ORGANISM", 33, 38], ["estrogen receptor", "GENE_OR_GENE_PRODUCT", 98, 115], ["estrogen receptor", "PROTEIN", 98, 115], ["women", "SPECIES", 33, 38], ["immune modulation", "TREATMENT", 47, 64], ["specific steroids", "TREATMENT", 72, 89]]], ["The pediatric literature indicates that children are generally unlikely to develop severe disease and suggests no significant differences based on sex [72\u201374].Features associated with early and mild disease ::: DiscussionWe observed a tendency for increasing prevalence of fever and cough with worsening clinical status, with frequencies as low as 13% and 8%, respectively, among studies in the \u2018initially asymptomatic\u2019 and \u2018early\u2019 study subgroups.", [["fever", "DISEASE", 273, 278], ["cough", "DISEASE", 283, 288], ["children", "ORGANISM", 40, 48], ["children", "SPECIES", 40, 48], ["severe disease", "PROBLEM", 83, 97], ["significant differences", "PROBLEM", 114, 137], ["early and mild disease", "PROBLEM", 184, 206], ["fever", "PROBLEM", 273, 278], ["cough", "PROBLEM", 283, 288], ["worsening clinical status", "PROBLEM", 294, 319], ["severe", "OBSERVATION_MODIFIER", 83, 89], ["disease", "OBSERVATION", 90, 97], ["no", "UNCERTAINTY", 111, 113], ["significant", "OBSERVATION_MODIFIER", 114, 125], ["mild", "OBSERVATION_MODIFIER", 194, 198], ["disease", "OBSERVATION", 199, 206], ["fever", "OBSERVATION", 273, 278]]], ["Dyspnea was similarly infrequent in these studies.", [["Dyspnea", "DISEASE", 0, 7], ["Dyspnea", "PROBLEM", 0, 7], ["these studies", "TEST", 36, 49], ["infrequent", "OBSERVATION_MODIFIER", 22, 32]]], ["This supports the idea that these symptoms cannot be relied upon to identify early or mild disease.", [["these symptoms", "PROBLEM", 28, 42], ["mild disease", "PROBLEM", 86, 98], ["mild", "OBSERVATION_MODIFIER", 86, 90], ["disease", "OBSERVATION", 91, 98]]], ["Headache, sore throat and GI symptoms were apparent in the \u2018early\u2019 subgroup in up to 20% of patients, showing association with disease presence but not with worsening clinical status.", [["GI", "ANATOMY", 26, 28], ["Headache", "DISEASE", 0, 8], ["sore throat", "DISEASE", 10, 21], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["Headache", "PROBLEM", 0, 8], ["sore throat", "PROBLEM", 10, 21], ["GI symptoms", "PROBLEM", 26, 37], ["disease presence", "PROBLEM", 127, 143], ["worsening clinical status", "PROBLEM", 157, 182], ["sore throat", "ANATOMY", 10, 21], ["GI", "ANATOMY", 26, 28], ["symptoms", "OBSERVATION", 29, 37]]], ["However, these symptoms are common in other rhino-, echo- and coronaviruses [75], and so do not appear to be helpful in differential diagnosis of COVID-19.Features associated with early and mild disease ::: DiscussionLymphocytopenia and elevated CRP were the most common abnormalities in laboratory markers in early and mild disease, both present in at least 17% of patients in studies of initially asymptomatic individuals.", [["coronaviruses", "ORGANISM", 62, 75], ["CRP", "GENE_OR_GENE_PRODUCT", 246, 249], ["patients", "ORGANISM", 366, 374], ["CRP", "PROTEIN", 246, 249], ["patients", "SPECIES", 366, 374], ["these symptoms", "PROBLEM", 9, 23], ["echo", "TEST", 52, 56], ["coronaviruses", "PROBLEM", 62, 75], ["COVID", "TEST", 146, 151], ["early and mild disease", "PROBLEM", 180, 202], ["DiscussionLymphocytopenia", "PROBLEM", 207, 232], ["elevated CRP", "PROBLEM", 237, 249], ["laboratory markers", "TEST", 288, 306], ["mild disease", "PROBLEM", 320, 332], ["initially asymptomatic individuals", "PROBLEM", 389, 423], ["mild", "OBSERVATION_MODIFIER", 190, 194], ["disease", "OBSERVATION", 195, 202], ["elevated", "OBSERVATION_MODIFIER", 237, 245], ["CRP", "OBSERVATION", 246, 249], ["most common", "OBSERVATION_MODIFIER", 259, 270], ["mild", "OBSERVATION_MODIFIER", 320, 324], ["disease", "OBSERVATION", 325, 332]]], ["Among \u2018early stage\u2019 studies, 20\u201360% of patients had lymphocytopenia, suggesting that this may be an early sign of SARS-CoV-2 infection.", [["lymphocytopenia", "DISEASE", 52, 67], ["SARS-CoV-2 infection", "DISEASE", 114, 134], ["patients", "ORGANISM", 39, 47], ["SARS-CoV-2", "ORGANISM", 114, 124], ["patients", "SPECIES", 39, 47], ["lymphocytopenia", "PROBLEM", 52, 67], ["SARS", "PROBLEM", 114, 118], ["CoV", "PROBLEM", 119, 122], ["2 infection", "PROBLEM", 123, 134], ["lymphocytopenia", "OBSERVATION", 52, 67], ["SARS", "OBSERVATION", 114, 118], ["infection", "OBSERVATION", 125, 134]]], ["Pulmonary abnormalities on CT imaging were common across all patient groups.", [["Pulmonary", "ANATOMY", 0, 9], ["Pulmonary abnormalities", "DISEASE", 0, 23], ["Pulmonary", "ORGAN", 0, 9], ["patient", "ORGANISM", 61, 68], ["patient", "SPECIES", 61, 68], ["Pulmonary abnormalities", "PROBLEM", 0, 23], ["CT imaging", "TEST", 27, 37], ["abnormalities", "OBSERVATION", 10, 23]]], ["CT changes were present in at least 50% of patients in \u2018initially asymptomatic\u2019 studies and 64% of patients in \u2018early\u2019 studies.", [["patients", "ORGANISM", 43, 51], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 43, 51], ["patients", "SPECIES", 99, 107], ["CT changes", "TEST", 0, 10]]], ["This indicates the potential of CT imaging as an early recognition tool of COVID-19.", [["CT imaging", "TEST", 32, 42], ["COVID", "TEST", 75, 80]]], ["Overall, our analysis indicates that symptoms in early and mild disease are non-specific and highly heterogeneous, underlining the need for diagnostic testing to confirm infection.", [["infection", "DISEASE", 170, 179], ["our analysis", "TEST", 9, 21], ["symptoms", "PROBLEM", 37, 45], ["mild disease", "PROBLEM", 59, 71], ["diagnostic testing", "TEST", 140, 158], ["infection", "PROBLEM", 170, 179], ["early", "OBSERVATION_MODIFIER", 49, 54], ["mild", "OBSERVATION_MODIFIER", 59, 63], ["disease", "OBSERVATION", 64, 71], ["non-specific", "OBSERVATION_MODIFIER", 76, 88], ["highly", "OBSERVATION_MODIFIER", 93, 99], ["heterogeneous", "OBSERVATION_MODIFIER", 100, 113], ["infection", "OBSERVATION", 170, 179]]], ["Mild or atypical symptoms should not exclude suspicion of COVID-19.", [["COVID-19", "CHEMICAL", 58, 66], ["Mild or atypical symptoms", "PROBLEM", 0, 25], ["COVID", "TEST", 58, 63], ["atypical", "OBSERVATION_MODIFIER", 8, 16]]], ["In such groups, CT imaging might be helpful in assessing patients for signs of COVID-19 if PCR testing is not available or negative despite high clinical suspicion.Gaps identified in the evidence base ::: DiscussionEvidence to support therapeutic approaches is clearly lacking.", [["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["CT imaging", "TEST", 16, 26], ["COVID", "TEST", 79, 84], ["PCR testing", "TEST", 91, 102], ["therapeutic approaches", "TREATMENT", 235, 257], ["base", "ANATOMY_MODIFIER", 196, 200]]], ["We found only one randomized controlled study of a pharmacological treatment.", [["a pharmacological treatment", "TREATMENT", 49, 76]]], ["As of May 3, 2020, there were 548 ongoing studies registered in ClinicalTrials.gov.", [["ongoing studies", "TEST", 34, 49]]], ["Clinicians should be mindful of the risks of prescribing untested treatments.", [["prescribing untested treatments", "TREATMENT", 45, 76]]], ["Evidence from these ongoing clinical trials and patient registries are clearly of critical importance.", [["patient", "ORGANISM", 48, 55], ["patient", "SPECIES", 48, 55]]], ["More longitudinal studies are needed to help to assess risk factors for severe disease and for poor outcomes.", [["More longitudinal studies", "TEST", 0, 25], ["severe disease", "PROBLEM", 72, 86], ["poor outcomes", "PROBLEM", 95, 108]]], ["Specifically, the available clinical studies were of inappropriate design or of insufficient quality to identify comorbidities associated with severe disease and explore whether factors such as length of hospitalization are linked to laboratory measures or clinical outcomes.Gaps identified in the evidence base ::: DiscussionFour studies (n = 103) described pregnant patients.", [["patients", "ORGANISM", 368, 376], ["patients", "SPECIES", 368, 376], ["the available clinical studies", "TEST", 14, 44], ["comorbidities", "PROBLEM", 113, 126], ["severe disease", "PROBLEM", 143, 157], ["DiscussionFour studies", "TEST", 316, 338], ["severe", "OBSERVATION_MODIFIER", 143, 149], ["disease", "OBSERVATION", 150, 157], ["base", "ANATOMY_MODIFIER", 307, 311]]], ["Compared with other subgroups, pregnant patients may be asymptomatic more often, with potentially lower prevalence of fever compared to other subgroups.", [["fever", "DISEASE", 118, 123], ["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["asymptomatic", "PROBLEM", 56, 68], ["fever", "PROBLEM", 118, 123], ["fever", "OBSERVATION", 118, 123]]], ["One possible explanation is that most studies evaluating pregnant women identified women who presented to hospital to give birth and were diagnosed with SARS-CoV-2 infection upon routine testing.", [["SARS-CoV-2 infection", "DISEASE", 153, 173], ["women", "ORGANISM", 66, 71], ["women", "ORGANISM", 83, 88], ["SARS-CoV-2", "ORGANISM", 153, 163], ["women", "SPECIES", 66, 71], ["women", "SPECIES", 83, 88], ["SARS", "PROBLEM", 153, 157], ["CoV", "PROBLEM", 158, 161], ["2 infection", "PROBLEM", 162, 173], ["routine testing", "TEST", 179, 194], ["infection", "OBSERVATION", 164, 173]]], ["However, the temporary immune suppression seen in pregnancy may play a role in COVID-19 pathogenesis and there are other sparse reports of potential issues in pregnancy.", [["the temporary immune suppression", "TREATMENT", 9, 41], ["potential issues in pregnancy", "PROBLEM", 139, 168]]], ["A recent systematic review of COVID-19 in pregnancy found that 15 of 32 women gave birth prematurely [76].", [["women", "ORGANISM", 72, 77], ["COVID-19", "DNA", 30, 38], ["women", "SPECIES", 72, 77], ["COVID", "TEST", 30, 35]]], ["A study of 10 neonates born to pregnant mothers with confirmed SARS-CoV-2 infection, revealed several adverse outcomes such as premature labor, fetal distress, respiratory distress and even death, but there were no cases of vertical transmission of the infection [77].", [["fetal", "ANATOMY", 144, 149], ["respiratory", "ANATOMY", 160, 171], ["SARS-CoV-2 infection", "DISEASE", 63, 83], ["premature labor", "DISEASE", 127, 142], ["fetal distress", "DISEASE", 144, 158], ["respiratory distress", "DISEASE", 160, 180], ["death", "DISEASE", 190, 195], ["infection", "DISEASE", 253, 262], ["neonates", "ORGANISM", 14, 22], ["mothers", "ORGANISM", 40, 47], ["SARS-CoV-2", "ORGANISM", 63, 73], ["fetal", "ORGANISM_SUBDIVISION", 144, 149], ["CoV-2", "SPECIES", 68, 73], ["SARS-CoV-2", "SPECIES", 63, 73], ["A study", "TEST", 0, 7], ["SARS", "PROBLEM", 63, 67], ["CoV", "PROBLEM", 68, 71], ["2 infection", "PROBLEM", 72, 83], ["several adverse outcomes", "PROBLEM", 94, 118], ["premature labor", "PROBLEM", 127, 142], ["fetal distress", "PROBLEM", 144, 158], ["respiratory distress", "PROBLEM", 160, 180], ["even death", "PROBLEM", 185, 195], ["the infection", "PROBLEM", 249, 262], ["respiratory distress", "OBSERVATION", 160, 180], ["infection", "OBSERVATION", 253, 262]]], ["Overall there is a paucity of evidence on COVID-19 in pregnant women and further research is warranted.Gaps identified in the evidence base ::: DiscussionWe identified a paucity of data on anosmia/hyposmia.", [["anosmia", "DISEASE", 189, 196], ["hyposmia", "DISEASE", 197, 205], ["COVID-19", "GENE_OR_GENE_PRODUCT", 42, 50], ["women", "ORGANISM", 63, 68], ["women", "SPECIES", 63, 68], ["COVID", "TEST", 42, 47], ["anosmia", "PROBLEM", 189, 196], ["hyposmia", "PROBLEM", 197, 205], ["paucity", "OBSERVATION_MODIFIER", 19, 26], ["base", "ANATOMY_MODIFIER", 135, 139], ["hyposmia", "OBSERVATION", 197, 205]]], ["With the media attention given to this potential symptom, the lack of evidence is notable.", [["this potential symptom", "PROBLEM", 34, 56], ["notable", "OBSERVATION_MODIFIER", 82, 89]]], ["Case reports should provide the widest possible range of symptoms since unique features of COVID-19 presentation may be poorly characterized.", [["symptoms", "PROBLEM", 57, 65], ["COVID", "TEST", 91, 96], ["may be", "UNCERTAINTY", 113, 119], ["poorly characterized", "OBSERVATION_MODIFIER", 120, 140]]], ["For laboratory variables, there were too few studies or too little data to indicate any association with COVID-19 or worsening clinical status for neutrophil levels, procalcitonin (PCT) or troponin.", [["neutrophil", "ANATOMY", 147, 157], ["neutrophil", "CELL", 147, 157], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 166, 179], ["troponin", "GENE_OR_GENE_PRODUCT", 189, 197], ["procalcitonin", "PROTEIN", 166, 179], ["PCT", "PROTEIN", 181, 184], ["troponin", "PROTEIN", 189, 197], ["laboratory variables", "TEST", 4, 24], ["COVID", "TEST", 105, 110], ["neutrophil levels", "TEST", 147, 164], ["procalcitonin", "TEST", 166, 179], ["PCT", "TEST", 181, 184], ["troponin", "TEST", 189, 197]]], ["The level of evidence is therefore low and further studies are needed.", [["further studies", "TEST", 43, 58], ["low", "OBSERVATION_MODIFIER", 35, 38]]], ["Markers of myocardial damage such as troponin appear to be of particular interest because of reports of cardiac involvement in COVID-19, potentially related to the ACE2 receptor [78, 79].Gaps identified in the evidence base ::: DiscussionWe were unable to provide strong estimates of mortality or rate of asymptomatic disease from the available clinical data analyzed due to inappropriate study design of included studies to assess this outcome.", [["myocardial", "ANATOMY", 11, 21], ["cardiac", "ANATOMY", 104, 111], ["myocardial damage", "DISEASE", 11, 28], ["myocardial", "MULTI-TISSUE_STRUCTURE", 11, 21], ["troponin", "GENE_OR_GENE_PRODUCT", 37, 45], ["cardiac", "ORGAN", 104, 111], ["ACE2", "GENE_OR_GENE_PRODUCT", 164, 168], ["troponin", "PROTEIN", 37, 45], ["ACE2 receptor", "PROTEIN", 164, 177], ["myocardial damage", "PROBLEM", 11, 28], ["troponin", "TEST", 37, 45], ["cardiac involvement", "PROBLEM", 104, 123], ["COVID", "TEST", 127, 132], ["the ACE2 receptor", "TEST", 160, 177], ["asymptomatic disease", "PROBLEM", 305, 325], ["inappropriate study", "TEST", 375, 394], ["studies", "TEST", 414, 421], ["myocardial", "ANATOMY", 11, 21], ["damage", "OBSERVATION", 22, 28], ["cardiac", "ANATOMY", 104, 111], ["involvement", "OBSERVATION", 112, 123], ["base", "ANATOMY_MODIFIER", 219, 223]]], ["These are likely to represent the closest estimates from our analysis of the true case fatality ratio in the general adult population or slightly overestimate it, and are similar to some modelling estimates based on national statistics [80, 81] and data from the Diamond Princess cruise ship [82].", [["our analysis", "TEST", 57, 69], ["national statistics", "TEST", 216, 235], ["likely to represent", "UNCERTAINTY", 10, 29], ["slightly overestimate", "OBSERVATION_MODIFIER", 137, 158]]], ["Since asymptomatic cases and patients who do not seek medical care are often not tested, and many countries have limited testing resources, the infection fatality rate is likely to be much lower.", [["infection", "DISEASE", 144, 153], ["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37], ["the infection fatality rate", "PROBLEM", 140, 167], ["likely to be", "UNCERTAINTY", 171, 183]]], ["Furthermore, discharged patients may later become positive for SARS-CoV-2 and remain asymptomatic [83], causing challenges for infection control.", [["SARS", "DISEASE", 63, 67], ["infection", "DISEASE", 127, 136], ["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["SARS-CoV", "SPECIES", 63, 71], ["SARS", "PROBLEM", 63, 67], ["CoV", "TEST", 68, 71], ["asymptomatic", "PROBLEM", 85, 97], ["infection control", "TREATMENT", 127, 144], ["infection", "OBSERVATION", 127, 136]]], ["Larger, population-based studies would provide stronger evidence for case-fatality rates and are therefore urgently needed.Strengths and limitations ::: DiscussionAn important strength of our review lies in its rapid assimilation of available data, just weeks after publication of some of the primary studies.", [["based studies", "TEST", 19, 32], ["the primary studies", "TEST", 289, 308]]], ["We also adhered to established strict and systematic methodological criteria, including a clearly defined search strategy, public and transparent protocol and rigorous analysis techniques such as determination of risk of bias.Strengths and limitations ::: DiscussionThe current analysis builds on previous work in an initial scoping review [5].", [["public and transparent protocol", "TREATMENT", 123, 154], ["rigorous analysis techniques", "TEST", 159, 187]]], ["Updating systematic reviews is generally considered to be more efficient than addressing the same question with a fresh protocol [84], and this approach is particularly appropriate in the context of new data emerging on a daily basis.", [["a fresh protocol", "TREATMENT", 112, 128]]], ["We identified 72 new studies for inclusion in this systematic review published after our previous review, between February 24, 2020 and March 22, 2020.", [["new studies", "TEST", 17, 28]]], ["Although our methodology is broadly in line with the previous work, this large number of new studies allowed us to exclude the smallest studies (those with less than 10 patients) and therefore increase confidence in the results.", [["patients", "ORGANISM", 169, 177], ["patients", "SPECIES", 169, 177], ["new studies", "TEST", 89, 100], ["the smallest studies", "TEST", 123, 143]]], ["In contrast to our first scoping review, this new systematic analysis used a quality effects model instead of a random effects model in order to better understand certainty of the signals based on quality and risk of bias of these studies.", [["this new systematic analysis", "TEST", 41, 69], ["a random effects model", "TREATMENT", 110, 132], ["these studies", "TEST", 225, 238]]], ["The quality effects model outperforms random effects where there is considerable heterogeneity.Strengths and limitations ::: DiscussionOur conclusions are constrained by the general low quality of the available studies at this early stage of the pandemic.", [["considerable heterogeneity", "PROBLEM", 68, 94], ["the available studies", "TEST", 197, 218], ["the pandemic", "PROBLEM", 242, 254], ["considerable", "OBSERVATION_MODIFIER", 68, 80], ["heterogeneity", "OBSERVATION", 81, 94]]], ["Studies tended to report the prevalence of symptoms at certain time points in the disease course, for example, in individuals identified through contact tracing, at hospital admission, at the onset of severe disease, or symptoms reported during hospitalization regardless of the time point.", [["Studies", "TEST", 0, 7], ["symptoms", "PROBLEM", 43, 51], ["contact tracing", "TEST", 145, 160], ["severe disease", "PROBLEM", 201, 215], ["symptoms", "PROBLEM", 220, 228], ["disease", "OBSERVATION", 82, 89], ["severe", "OBSERVATION_MODIFIER", 201, 207], ["disease", "OBSERVATION", 208, 215]]], ["Included studies covered a wide range of populations from many countries.", [["Included studies", "TEST", 0, 16], ["wide range", "OBSERVATION_MODIFIER", 27, 37]]], ["There are general concerns about the inclusion of COVID-19 patients in more than one publication [85].", [["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["COVID", "TEST", 50, 55]]], ["We addressed this and sought to mitigate it by close attention to overlapping time frames, study settings and locations.", [["study settings", "TEST", 91, 105]]], ["Our screening process uncovered 19 overlapping studies, which were excluded from the analysis.", [["Our screening process", "TEST", 0, 21], ["overlapping studies", "TEST", 35, 54], ["the analysis", "TEST", 81, 93]]], ["However, we may still have failed to identify some overlapping patients, particularly from studies in the very early phase of reporting the pandemic.", [["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["studies", "TEST", 91, 98], ["the pandemic", "PROBLEM", 136, 148]]], ["Although some studies used consistent methodologies, there may have been constraints on certain healthcare systems that would result in heterogeneous reporting (e.g. a shortage of tests).", [["some studies", "TEST", 9, 21], ["heterogeneous", "OBSERVATION_MODIFIER", 136, 149]]], ["Our subgroup analyses aimed to mitigate this limitation as much as possible.", [["Our subgroup analyses", "TEST", 0, 21]]], ["One potential limitation of our analysis is that we did not consider a specific, well-defined question for analysis.", [["our analysis", "TEST", 28, 40], ["analysis", "TEST", 107, 115]]], ["Rather we chose a broad approach because we judged that at this early stage in the pandemic a search for signals across all the clinical data was necessary, in order to identify areas for future targeted research.ConclusionsIn conclusion, we found worsening clinical status in COVID-19 to be associated with fever, cough, dyspnea, pneumonia, any CT findings, any GGO, lymphocytopenia, elevated WBC, elevated CRP, elevated ALT, elevated AST, increased age and male sex.", [["WBC", "ANATOMY", 394, 397], ["fever", "DISEASE", 308, 313], ["cough", "DISEASE", 315, 320], ["dyspnea", "DISEASE", 322, 329], ["pneumonia", "DISEASE", 331, 340], ["GGO", "DISEASE", 363, 366], ["lymphocytopenia", "DISEASE", 368, 383], ["CRP", "GENE_OR_GENE_PRODUCT", 408, 411], ["ALT", "SIMPLE_CHEMICAL", 422, 425], ["AST", "SIMPLE_CHEMICAL", 436, 439], ["CRP", "PROTEIN", 408, 411], ["ALT", "PROTEIN", 422, 425], ["AST", "PROTEIN", 436, 439], ["a broad approach", "TREATMENT", 16, 32], ["worsening clinical status", "PROBLEM", 248, 273], ["COVID", "TEST", 277, 282], ["fever", "PROBLEM", 308, 313], ["cough", "PROBLEM", 315, 320], ["dyspnea", "PROBLEM", 322, 329], ["pneumonia", "PROBLEM", 331, 340], ["any CT findings", "PROBLEM", 342, 357], ["any GGO", "PROBLEM", 359, 366], ["lymphocytopenia", "PROBLEM", 368, 383], ["elevated WBC", "PROBLEM", 385, 397], ["elevated CRP", "PROBLEM", 399, 411], ["elevated ALT", "PROBLEM", 413, 425], ["elevated AST", "PROBLEM", 427, 439], ["worsening", "OBSERVATION_MODIFIER", 248, 257], ["cough", "OBSERVATION", 315, 320], ["pneumonia", "OBSERVATION", 331, 340], ["lymphocytopenia", "OBSERVATION", 368, 383], ["ALT", "ANATOMY", 422, 425]]], ["Headache and sore throat were associated with the presence of disease, but not with more severe disease.", [["Headache", "DISEASE", 0, 8], ["sore throat", "DISEASE", 13, 24], ["Headache", "PROBLEM", 0, 8], ["sore throat", "PROBLEM", 13, 24], ["disease", "PROBLEM", 62, 69], ["more severe disease", "PROBLEM", 84, 103], ["sore throat", "ANATOMY", 13, 24], ["disease", "OBSERVATION", 62, 69], ["not with", "UNCERTAINTY", 75, 83], ["severe", "OBSERVATION_MODIFIER", 89, 95], ["disease", "OBSERVATION", 96, 103]]], ["Symptoms in early and mild disease are non-specific and highly heterogeneous.", [["Symptoms in early and mild disease", "PROBLEM", 0, 34], ["early", "OBSERVATION_MODIFIER", 12, 17], ["mild", "OBSERVATION_MODIFIER", 22, 26], ["disease", "OBSERVATION", 27, 34], ["non-specific", "OBSERVATION_MODIFIER", 39, 51], ["highly", "OBSERVATION_MODIFIER", 56, 62], ["heterogeneous", "OBSERVATION_MODIFIER", 63, 76]]], ["Although pulmonary abnormalities appear to be common even in mild disease, negative CT imaging cannot exclude suspicion of infection.", [["pulmonary", "ANATOMY", 9, 18], ["pulmonary abnormalities", "DISEASE", 9, 32], ["infection", "DISEASE", 123, 132], ["pulmonary", "ORGAN", 9, 18], ["pulmonary abnormalities", "PROBLEM", 9, 32], ["mild disease", "PROBLEM", 61, 73], ["CT imaging", "TEST", 84, 94], ["infection", "PROBLEM", 123, 132], ["pulmonary", "ANATOMY", 9, 18], ["abnormalities", "OBSERVATION", 19, 32], ["mild", "OBSERVATION_MODIFIER", 61, 65], ["disease", "OBSERVATION", 66, 73], ["infection", "OBSERVATION", 123, 132]]], ["There are urgent evidence gaps in terms of efficacy of treatments, characteristics of disease in severely ill patients, data from longitudinal studies, and evidence is lacking on the prevalence of anosmia and laboratory markers such as troponin, neutrophils and PCT.", [["neutrophils", "ANATOMY", 246, 257], ["severely ill", "DISEASE", 97, 109], ["anosmia", "DISEASE", 197, 204], ["patients", "ORGANISM", 110, 118], ["troponin", "GENE_OR_GENE_PRODUCT", 236, 244], ["neutrophils", "CELL", 246, 257], ["troponin", "PROTEIN", 236, 244], ["neutrophils", "CELL_TYPE", 246, 257], ["PCT", "PROTEIN", 262, 265], ["patients", "SPECIES", 110, 118], ["treatments", "TREATMENT", 55, 65], ["disease in severely ill patients", "PROBLEM", 86, 118], ["longitudinal studies", "TEST", 130, 150], ["anosmia", "PROBLEM", 197, 204], ["laboratory markers", "TEST", 209, 227], ["troponin", "TEST", 236, 244], ["neutrophils", "TEST", 246, 257], ["PCT", "TEST", 262, 265], ["gaps", "OBSERVATION_MODIFIER", 26, 30], ["disease", "OBSERVATION", 86, 93], ["severely", "OBSERVATION_MODIFIER", 97, 105], ["ill", "OBSERVATION_MODIFIER", 106, 109]]], ["Caution must be exercised in interpreting the clinical data on COVID-19 because most studies published in this early stage of the pandemic have a high risk of bias and the overall quality of evidence is low.", [["COVID", "TEST", 63, 68], ["most studies", "TEST", 80, 92], ["low", "OBSERVATION_MODIFIER", 203, 206]]], ["However, the emergency situation demands decision-making based on the available evidence, and hence we offer an analysis of the entirety of the evidence base to date through our broad meta-analysis approach.", [["an analysis", "TEST", 109, 120], ["our broad meta-analysis approach", "TREATMENT", 174, 206]]]]}